PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
15319351-9	2004	We then found that different lines of Chinese hamster ovary TSHR cells, when treated with TSH, showed a time- and dose-dependent increase in TSHR cleavage in addition to ectodomain shedding.	Thyrotropin	60-63	thyrotropin receptor	Cricetulus griseus	141-145
15579752-2	2004	We hypothesized that the basal and TSH-stimulated Tg levels in patients with metastatic thyroid carcinoma would reflect tumor volume, histological subtype, and location of metastatic lesions.	Thyrotropin	35-38	thyroglobulin	Homo sapiens	50-52
15579770-13	2004	In thyroid cancer cell lines, TSH induces VEGF production involving the PKC, rather than the PKA, pathway.	Thyrotropin	30-33	vascular endothelial growth factor A	Rattus norvegicus	42-46
15579770-13	2004	In thyroid cancer cell lines, TSH induces VEGF production involving the PKC, rather than the PKA, pathway.	Thyrotropin	30-33	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	93-96
15579770-0	2004	Thyrotropin (TSH)-induced production of vascular endothelial growth factor in thyroid cancer cells in vitro: evaluation of TSH signal transduction and of angiogenesis-stimulating growth factors.	Thyrotropin	13-16	vascular endothelial growth factor A	Rattus norvegicus	40-74
15579773-2	2004	Recently, RET/PTC1 has been shown to interfere with TSH signaling at multiple levels in thyroid cells.	Thyrotropin	52-55	ret proto-oncogene	Rattus norvegicus	10-13
15579770-4	2004	Therefore, the aim of the current study was to 1) establish the effect of TSH on VEGF as well as 2) evaluate the TSH signal transduction of this effect, and 3) screen other growth factors for the ability to modulate VEGF in thyroid cancer cell lines.	Thyrotropin	74-77	vascular endothelial growth factor A	Rattus norvegicus	81-85
15579770-7	2004	TSHr signal transduction was evaluated by analyzing the effect of stimulators (cholera toxin, 8-bromo-cAMP, forskolin, and 12-O-tetradecanoyl-phorbol-13-acetate) and inhibitors (2",5"-dideoxyadenosine and staurosporine) on VEGF protein levels under basal and TSH-stimulated conditions.	Thyrotropin	0-3	vascular endothelial growth factor A	Rattus norvegicus	223-227
15711028-3	2004	We report a 21-yr-old woman with TSH-secreting pituitary macroadenoma, who was diagnosed based on the symptoms of hyperthyroidism, the lack of inhibition of serum TSH despite an increased serum free thyroxine (FT4), a low response of serum TSH to thyrotropin-releasing hormone, and a pituitary tumor as revealed by magnetic resonance imaging.	Thyrotropin	33-36	thyrotropin releasing hormone	Homo sapiens	247-276
15765025-2	2004	The Tg level becomes a specific and very sensitive marker of DTC recurrence: it is usually evaluated after eradication of thyroid residual tissue (by thyroidectomy and radiometabolic therapy), in presence of high level of TSH (>35 microU/ml) obtained with the suspension of therapy or after rec-TSH administration and in absence of anti-Tg antibodies.	Thyrotropin	222-225	thyroglobulin	Homo sapiens	4-6
15765025-2	2004	The Tg level becomes a specific and very sensitive marker of DTC recurrence: it is usually evaluated after eradication of thyroid residual tissue (by thyroidectomy and radiometabolic therapy), in presence of high level of TSH (>35 microU/ml) obtained with the suspension of therapy or after rec-TSH administration and in absence of anti-Tg antibodies.	Thyrotropin	298-301	thyroglobulin	Homo sapiens	4-6
15765026-14	2004	In low-risk DTC patients serum Tg after TSH stimulation, together with ultrasound of the neck, should be used to monitor persistent disease, avoiding diagnostic TBS which has a poor sensitivity.	Thyrotropin	40-43	thyroglobulin	Homo sapiens	31-33
15550067-9	2004	TSH levels were significantly higher in TPO-Ab-positive women compared with TPO-Ab negative women (median; 1.9 versus 1.1; P = 0.001).	Thyrotropin	0-3	thyroid peroxidase	Homo sapiens	40-43
15550067-9	2004	TSH levels were significantly higher in TPO-Ab-positive women compared with TPO-Ab negative women (median; 1.9 versus 1.1; P = 0.001).	Thyrotropin	0-3	thyroid peroxidase	Homo sapiens	76-79
15550067-10	2004	Elevated TSH levels were found in 13.8% (4 of 29) of the TPO-Ab-positive women compared with only 2.4% (12 of 505) in the TPO-Ab-negative women.	Thyrotropin	9-12	thyroid peroxidase	Homo sapiens	57-60
15231710-8	2004	In fact, acute TSH stimulation (30 and 60 min) induced a decrease in PTEN, but an increase in Egr-1 protein levels.	Thyrotropin	15-18	phosphatase and tensin homolog	Rattus norvegicus	69-73
15231710-8	2004	In fact, acute TSH stimulation (30 and 60 min) induced a decrease in PTEN, but an increase in Egr-1 protein levels.	Thyrotropin	15-18	early growth response 1	Rattus norvegicus	94-99
15231710-10	2004	A chronic TSH treatment (5 d) stimulated PTEN protein expression, whereas Egr-1 protein was down-regulated.	Thyrotropin	10-13	phosphatase and tensin homolog	Rattus norvegicus	41-45
15472201-7	2004	All of the ACTH-deficient subjects were also TSH deficient: eight of nine had a gross abnormality on MRI, and one did not have an MRI report in the medical record.	Thyrotropin	45-48	proopiomelanocortin	Homo sapiens	11-15
15482372-20	2004	The results show that CDP-choline can increase plasma ACTH and produce additional increases in serum levels of TSH, GH and LH stimulated by TRH, clonidine and LHRH, respectively.	Thyrotropin	111-114	gonadotropin releasing hormone 1	Rattus norvegicus	159-163
15472201-1	2004	We sought to determine the prevalence of ACTH deficiency in children with GH deficiency (GHD) of unknown etiology with and without TSH deficiency and to correlate the structural characteristics of the hypothalamic-pituitary region on magnetic resonance imaging (MRI) with TSH and ACTH status.	Thyrotropin	131-134	proopiomelanocortin	Homo sapiens	41-45
15525591-1	2004	We investigated the influence of hypo- and hyperthyroidism on the ability of leptin to modulate TSH secretion.	Thyrotropin	96-99	leptin	Rattus norvegicus	77-83
15364204-14	2004	Human urocortin III (hUCN III), a CRF receptor type 2 (CRF-R2) specific agonist enhanced the release of TSH from the pituitary cells in culture, suggesting the involvement of CRF-R2 in the CRF-induced TSH release in the bullfrogs.	Thyrotropin	104-107	urocortin 3	Homo sapiens	6-19
15542352-15	2004	Decreased serum total T(3), T(4), testosterone, estradiol and increased TSH were observed in PCB-exposed rats.	Thyrotropin	72-75	pyruvate carboxylase	Rattus norvegicus	93-96
15580172-9	2004	TRH serum levels correlated positively with TSH serum levels at 0200 h (r=0.65, p=0.04) and at 0600 h (r=0.64, p=0.04).	Thyrotropin	44-47	thyrotropin releasing hormone	Homo sapiens	0-3
15588378-5	2004	This pituitary TSR-receptor is also recognized by TSHR receptor autoantibodies, which can downregulate TSH secretion independently from thyroid hormone levels, and are therefore thought to be responsible for the frequently observed suppressed TSH levels in patients with Graves" disease who are otherwise euthyroid.	Thyrotropin	103-106	thyroid stimulating hormone receptor	Homo sapiens	50-54
15588379-3	2004	The M22 based assay was more sensitive than a similar ELISA based on inhibition of TSH-biotin binding to TSHR coated wells with 1 U/L of NIBSC 90/672 giving approximately 35% inhibition in the M22-based system compared to approximately 15% inhibition in the TSH-based ELISA.	Thyrotropin	83-86	thyroid stimulating hormone receptor	Homo sapiens	105-109
15364204-14	2004	Human urocortin III (hUCN III), a CRF receptor type 2 (CRF-R2) specific agonist enhanced the release of TSH from the pituitary cells in culture, suggesting the involvement of CRF-R2 in the CRF-induced TSH release in the bullfrogs.	Thyrotropin	104-107	urocortin 3	Homo sapiens	21-29
15364204-14	2004	Human urocortin III (hUCN III), a CRF receptor type 2 (CRF-R2) specific agonist enhanced the release of TSH from the pituitary cells in culture, suggesting the involvement of CRF-R2 in the CRF-induced TSH release in the bullfrogs.	Thyrotropin	104-107	corticotropin releasing hormone receptor 2	Homo sapiens	34-53
15364204-14	2004	Human urocortin III (hUCN III), a CRF receptor type 2 (CRF-R2) specific agonist enhanced the release of TSH from the pituitary cells in culture, suggesting the involvement of CRF-R2 in the CRF-induced TSH release in the bullfrogs.	Thyrotropin	104-107	corticotropin releasing hormone receptor 2	Homo sapiens	55-61
15364204-14	2004	Human urocortin III (hUCN III), a CRF receptor type 2 (CRF-R2) specific agonist enhanced the release of TSH from the pituitary cells in culture, suggesting the involvement of CRF-R2 in the CRF-induced TSH release in the bullfrogs.	Thyrotropin	104-107	corticotropin releasing hormone receptor 2	Homo sapiens	175-181
15364204-14	2004	Human urocortin III (hUCN III), a CRF receptor type 2 (CRF-R2) specific agonist enhanced the release of TSH from the pituitary cells in culture, suggesting the involvement of CRF-R2 in the CRF-induced TSH release in the bullfrogs.	Thyrotropin	201-204	urocortin 3	Homo sapiens	6-19
15364204-14	2004	Human urocortin III (hUCN III), a CRF receptor type 2 (CRF-R2) specific agonist enhanced the release of TSH from the pituitary cells in culture, suggesting the involvement of CRF-R2 in the CRF-induced TSH release in the bullfrogs.	Thyrotropin	201-204	urocortin 3	Homo sapiens	21-29
15364204-14	2004	Human urocortin III (hUCN III), a CRF receptor type 2 (CRF-R2) specific agonist enhanced the release of TSH from the pituitary cells in culture, suggesting the involvement of CRF-R2 in the CRF-induced TSH release in the bullfrogs.	Thyrotropin	201-204	corticotropin releasing hormone receptor 2	Homo sapiens	175-181
15489553-10	2004	INTERPRETATION & CONCLUSION: Our study suggests that it would be beneficial to rule out THBP abnormalities before interpreting results of TFTs, particularly when there is large discrepancy between T4 and TSH levels.	Thyrotropin	208-211	crystallin mu	Homo sapiens	92-96
15362969-7	2004	Co-expression of RGS 2 and TSHR in COS-7 cells reduced the TSHR signaling via inositol-3-phosphate but not via cAMP after stimulation with TSH.	Thyrotropin	27-30	thyroid stimulating hormone receptor	Homo sapiens	59-63
15166254-6	2004	TSH enhanced the effects of serum on retinoblastoma protein hyperphosphorylation, cyclin-dependent kinase 2 activity, and cyclin A expression.	Thyrotropin	0-3	cyclin dependent kinase 2	Rattus norvegicus	82-107
15166254-9	2004	Unexpectedly, TSH enhanced the depletion of nuclear p27 in serum-treated cells.	Thyrotropin	14-17	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	52-55
15497927-10	2004	CONCLUSIONS: Our data suggests that RT-PCR detects Tg mRNA of extrathyroidal origin, from leukocytes or from metastasizing carcinoma cells under basal conditions or after TSH stimulation.	Thyrotropin	171-174	thyroglobulin	Homo sapiens	51-53
15356088-4	2004	TSHR-autoantibody approximate affinities for the holoreceptor assessed indirectly by TSH binding inhibition were 4-27 x 10(-9) m, an underestimate because 100% TSHR autoantibody purity was not attained.	Thyrotropin	0-3	thyroid stimulating hormone receptor	Homo sapiens	160-164
15320966-3	2004	Patient sera containing TSHR autoantibodies with TSH antagonist (blocking) activity inhibited M22 Fab and IgG stimulation in a similar way to their ability to block TSH stimulation.	Thyrotropin	24-27	FA complementation group B	Homo sapiens	98-101
15320966-3	2004	Patient sera containing TSHR autoantibodies with TSH antagonist (blocking) activity inhibited M22 Fab and IgG stimulation in a similar way to their ability to block TSH stimulation.	Thyrotropin	49-52	thyroid stimulating hormone receptor	Homo sapiens	24-28
15320966-3	2004	Patient sera containing TSHR autoantibodies with TSH antagonist (blocking) activity inhibited M22 Fab and IgG stimulation in a similar way to their ability to block TSH stimulation.	Thyrotropin	49-52	FA complementation group B	Homo sapiens	98-101
15320967-8	2004	The longer the cells stay in the stationary phase in 1H (insulin) medium, the higher are cyclic adenosine monophosphate (cAMP) levels after thyrotropin (TSH) stimulation.	Thyrotropin	140-151	insulin	Homo sapiens	57-64
15320967-8	2004	The longer the cells stay in the stationary phase in 1H (insulin) medium, the higher are cyclic adenosine monophosphate (cAMP) levels after thyrotropin (TSH) stimulation.	Thyrotropin	153-156	insulin	Homo sapiens	57-64
15241559-6	2004	Acute stimulation with thyroid-stimulating hormone (TSH) or forskolin prevents all signs of accelerated E-cadherin turnover.	Thyrotropin	23-50	cadherin 1	Sus scrofa	104-114
15185102-11	2004	Our study suggests that cosecretion of GH and/or PRL from TSH-secreting adenoma has no correlation with response of tumor cells to medical treatment.	Thyrotropin	58-61	prolactin	Homo sapiens	49-52
15241559-6	2004	Acute stimulation with thyroid-stimulating hormone (TSH) or forskolin prevents all signs of accelerated E-cadherin turnover.	Thyrotropin	52-55	cadherin 1	Sus scrofa	104-114
15157839-1	2004	Human chorionic gonadotropin (hCG) is a glycoprotein hormone that has structural similarity to TSH.	Thyrotropin	95-98	chorionic gonadotropin subunit beta 5	Homo sapiens	30-33
15181134-1	2004	UNLABELLED: The aim of our study was to evaluate and compare in thyroid cancer patients the predictive value for disease progression of thyroglobulin (Tg) levels measured under thyroid-stimulating hormone (TSH) stimulation, in the postoperative period just before (131)I ablative therapy and at the time of control 6-12 mo later.	Thyrotropin	206-209	thyroglobulin	Homo sapiens	136-149
15181134-1	2004	UNLABELLED: The aim of our study was to evaluate and compare in thyroid cancer patients the predictive value for disease progression of thyroglobulin (Tg) levels measured under thyroid-stimulating hormone (TSH) stimulation, in the postoperative period just before (131)I ablative therapy and at the time of control 6-12 mo later.	Thyrotropin	206-209	thyroglobulin	Homo sapiens	151-153
15118271-6	2004	Postoperative responses of TSH and GH to TRH and GRH, respectively, were two fold higher than the preoperative levels.	Thyrotropin	27-30	thyrotropin releasing hormone	Homo sapiens	41-44
14961213-5	2004	In the hTSHR-transfected CHO cells, the cAMP increase was 3030% in response to 10 U/L TSH and 1240% after 1 U/L TSH.	Thyrotropin	86-89	thyroid stimulating hormone receptor	Homo sapiens	7-12
15118271-6	2004	Postoperative responses of TSH and GH to TRH and GRH, respectively, were two fold higher than the preoperative levels.	Thyrotropin	27-30	gonadotropin releasing hormone 1	Homo sapiens	49-52
15110046-4	2004	The ventral Serrate (Ser), but not fringe (fng) or Lobe (L), is required and sufficient for the tsh ventral function.	Thyrotropin	96-99	Serrate	Drosophila melanogaster	12-19
15080154-7	2004	Similar to D567N, the T449A FSHr mutant shows an increase of its sensitivity to both hCG and TSH, together with an increase in basal activity.	Thyrotropin	93-96	follicle stimulating hormone receptor	Homo sapiens	28-32
15070908-11	2004	The rise in Tg with TSH and the reduction in Tg with L-T(4) provide evidence of target tissue response to TSH and further confirm the TSH rise as physiologically significant.	Thyrotropin	20-23	thyroglobulin	Homo sapiens	12-14
15070908-11	2004	The rise in Tg with TSH and the reduction in Tg with L-T(4) provide evidence of target tissue response to TSH and further confirm the TSH rise as physiologically significant.	Thyrotropin	106-109	thyroglobulin	Homo sapiens	12-14
15070908-11	2004	The rise in Tg with TSH and the reduction in Tg with L-T(4) provide evidence of target tissue response to TSH and further confirm the TSH rise as physiologically significant.	Thyrotropin	106-109	thyroglobulin	Homo sapiens	45-47
15070908-11	2004	The rise in Tg with TSH and the reduction in Tg with L-T(4) provide evidence of target tissue response to TSH and further confirm the TSH rise as physiologically significant.	Thyrotropin	106-109	thyroglobulin	Homo sapiens	12-14
15070908-11	2004	The rise in Tg with TSH and the reduction in Tg with L-T(4) provide evidence of target tissue response to TSH and further confirm the TSH rise as physiologically significant.	Thyrotropin	106-109	thyroglobulin	Homo sapiens	45-47
14985133-4	2004	These data indicated that growth stimulation by TSH+Ins increased the activity of GGPP synthase with its increasing protein expression from G1/S transition, in which both cAMP-PKA and PI3-kinase pathways are involved in the proliferation of FRTL-5 cells.	Thyrotropin	48-51	geranylgeranyl diphosphate synthase 1	Rattus norvegicus	82-95
14985133-4	2004	These data indicated that growth stimulation by TSH+Ins increased the activity of GGPP synthase with its increasing protein expression from G1/S transition, in which both cAMP-PKA and PI3-kinase pathways are involved in the proliferation of FRTL-5 cells.	Thyrotropin	48-51	WAP four-disulfide core domain 15B	Rattus norvegicus	184-187
15001619-7	2004	Similar to D567N, the T449A FSHr mutant shows an increase of its sensitivity to both hCG and TSH, together with an increase in basal activity.	Thyrotropin	93-96	follicle stimulating hormone receptor	Homo sapiens	28-32
14623893-4	2004	This effect takes place at the transcriptional level, as TGF-beta inhibits TSH-induced transcription of a luciferase reporter construct containing a 2.8-kb DNA fragment of the rat NIS promoter.	Thyrotropin	75-78	transforming growth factor, beta 1	Rattus norvegicus	57-65
14630711-5	2004	TSHR antibodies, measured by ELISA, binding to TSHR-expressing eukaryotic cells, and TSH binding inhibition, developed in approximately 60% of TSHR-knockout mice, not significantly different from 80% in the wild-type mice.	Thyrotropin	0-3	thyroid stimulating hormone receptor	Mus musculus	47-51
14630711-5	2004	TSHR antibodies, measured by ELISA, binding to TSHR-expressing eukaryotic cells, and TSH binding inhibition, developed in approximately 60% of TSHR-knockout mice, not significantly different from 80% in the wild-type mice.	Thyrotropin	0-3	thyroid stimulating hormone receptor	Mus musculus	47-51
14660640-5	2004	We now report that Rap1GAP protein levels are dynamically regulated in thyroid-stimulating hormone (TSH)-dependent thyroid cells.	Thyrotropin	71-98	RAP1 GTPase activating protein	Homo sapiens	19-26
14660640-5	2004	We now report that Rap1GAP protein levels are dynamically regulated in thyroid-stimulating hormone (TSH)-dependent thyroid cells.	Thyrotropin	100-103	RAP1 GTPase activating protein	Homo sapiens	19-26
14660640-11	2004	Overexpression of Rap1GAP in thyroid cells impaired TSH/cAMP-stimulated p70S6 kinase activity and cell proliferation.	Thyrotropin	52-55	RAP1 GTPase activating protein	Homo sapiens	18-25
15611817-6	2004	Among those, more consistent data are available on neuromedin B, gastrin-releasing peptide and pituitary leptin, which act as local inhibitors of TSH release.	Thyrotropin	146-149	neuromedin B	Homo sapiens	51-63
15611817-6	2004	Among those, more consistent data are available on neuromedin B, gastrin-releasing peptide and pituitary leptin, which act as local inhibitors of TSH release.	Thyrotropin	146-149	gastrin releasing peptide	Homo sapiens	65-90
15117089-7	2004	TSH levels were correlated with beta2M excretion.	Thyrotropin	0-3	beta-2-microglobulin	Homo sapiens	32-38
14751427-2	2004	TSH responses to TRH showed a tendency to increase from pre- to posttreatment period, while TRH-induced PRL and L-DOPA-induced GH responses did not change with treatment in depressed patients who responded to the treatment.	Thyrotropin	0-3	thyrotropin releasing hormone	Homo sapiens	17-20
14576174-7	2004	On TSH treatment, we observed internalization of human TSHR-YFP and human TSHR, expressed on 293 and CHO cells, respectively.	Thyrotropin	3-6	thyroid stimulating hormone receptor	Homo sapiens	55-59
14576174-7	2004	On TSH treatment, we observed internalization of human TSHR-YFP and human TSHR, expressed on 293 and CHO cells, respectively.	Thyrotropin	3-6	thyroid stimulating hormone receptor	Homo sapiens	74-78
14576174-8	2004	This was further substantiated when we observed colocalization of rhodamine-labeled TSH with TSHR-YFP within the cell and by the uptake of radiolabeled TSH.	Thyrotropin	84-87	thyroid stimulating hormone receptor	Homo sapiens	93-97
12970166-2	2003	In representatives of all nonmammalian vertebrates, CRH has also been shown to induce TSH secretion, acting directly at the level of the pituitary.	Thyrotropin	86-89	corticotropin releasing hormone	Gallus gallus	52-55
15671578-5	2004	Interestingly, by using the Spot method, TSH was also found to interact with peptides bearing amino acids from these two regions, suggesting their involvement in TSH/TSHR interaction.	Thyrotropin	41-44	thyroid stimulating hormone receptor	Homo sapiens	166-170
14580900-8	2003	These results suggest that CLB increases hepatic T4-UDPGT activity leading to acceleration of T4-clearance, which results in decreased plasma thyroidal hormones followed by compensatory increase of TSH biosynthesis and secretion.	Thyrotropin	198-201	UDP glucuronosyltransferase family 1 member A5	Rattus norvegicus	52-57
14637271-7	2003	CysC increased from 0.88+/-0.23 mg/l (reference 0.63-1.33) in the hypothyroid state to 1.01+/-0.21 mg/l when TSH normalized (p<0.001).	Thyrotropin	109-112	cystatin C	Homo sapiens	0-4
14637271-9	2003	CysC declined from 1.04+/-0.29 mg/l at diagnosis of subclinical hyperthyroidism to 0.91+/-0.25 mg/l when TSH normalized (p<0.05).	Thyrotropin	105-108	cystatin C	Homo sapiens	0-4
14970304-1	2004	A patient is described in whom thyroid binding globulin (TBG) excess was found in association with a pituitary macroadenoma containing thyroid stimulating hormone (TSH)-producing cells, and the potential for diagnostic confusion arising from this unusual combination of endocrine disorders is discussed.	Thyrotropin	135-162	serpin family A member 7	Homo sapiens	57-60
14970304-1	2004	A patient is described in whom thyroid binding globulin (TBG) excess was found in association with a pituitary macroadenoma containing thyroid stimulating hormone (TSH)-producing cells, and the potential for diagnostic confusion arising from this unusual combination of endocrine disorders is discussed.	Thyrotropin	164-167	serpin family A member 7	Homo sapiens	57-60
15595273-3	2004	Thyrotropin-releasing hormone (TRH) is located in the hypothalamus and it stimulates TSH, GH and PRL release from the pituitary gland.	Thyrotropin	85-88	thyrotropin releasing hormone	Gallus gallus	0-29
15595273-3	2004	Thyrotropin-releasing hormone (TRH) is located in the hypothalamus and it stimulates TSH, GH and PRL release from the pituitary gland.	Thyrotropin	85-88	thyrotropin releasing hormone	Gallus gallus	31-34
14709141-3	2004	As had been observed earlier with TSH, the cAMP mimetic, dibutyryl cAMP (dbcAMP; 1 mM) induced a significant reduction in CNP-stimulated cGMP generation that was first apparent after 6 h of treatment.	Thyrotropin	34-37	natriuretic peptide C	Rattus norvegicus	122-125
14709141-9	2004	In addition, immunofluorescence staining of FRTL-5 cells with a specific antibody for CNP-22 showed the presence of cytoplasmic CNP that was up-regulated by incubation with either TSH or dbcAMP.	Thyrotropin	180-183	natriuretic peptide C	Rattus norvegicus	86-89
14709141-9	2004	In addition, immunofluorescence staining of FRTL-5 cells with a specific antibody for CNP-22 showed the presence of cytoplasmic CNP that was up-regulated by incubation with either TSH or dbcAMP.	Thyrotropin	180-183	natriuretic peptide C	Rattus norvegicus	128-131
14960028-7	2004	The glycoprotein megalin is expressed on thyroid cells in a TSH-dependent manner and may have a crucial role in the immunopathogenesis of glomerular injury in membranous nephropathy.	Thyrotropin	60-63	LDL receptor related protein 2	Homo sapiens	17-24
12970166-8	2003	The involvement of this CRH receptor in the response of thyrotropes to CRH was further confirmed by the fact that TSH release was stimulated by human urocortin III, a CRH-R2-specific agonist, whereas the TSH response to CRH was completely blocked by the CRH-R blocker astressin and the CRH-R2-specific antagonist antisauvagine-30.	Thyrotropin	114-117	corticotropin releasing hormone	Homo sapiens	24-27
12970166-8	2003	The involvement of this CRH receptor in the response of thyrotropes to CRH was further confirmed by the fact that TSH release was stimulated by human urocortin III, a CRH-R2-specific agonist, whereas the TSH response to CRH was completely blocked by the CRH-R blocker astressin and the CRH-R2-specific antagonist antisauvagine-30.	Thyrotropin	114-117	corticotropin releasing hormone	Homo sapiens	71-74
12970166-8	2003	The involvement of this CRH receptor in the response of thyrotropes to CRH was further confirmed by the fact that TSH release was stimulated by human urocortin III, a CRH-R2-specific agonist, whereas the TSH response to CRH was completely blocked by the CRH-R blocker astressin and the CRH-R2-specific antagonist antisauvagine-30.	Thyrotropin	114-117	urocortin 3	Homo sapiens	150-163
12970166-8	2003	The involvement of this CRH receptor in the response of thyrotropes to CRH was further confirmed by the fact that TSH release was stimulated by human urocortin III, a CRH-R2-specific agonist, whereas the TSH response to CRH was completely blocked by the CRH-R blocker astressin and the CRH-R2-specific antagonist antisauvagine-30.	Thyrotropin	114-117	corticotropin releasing hormone receptor 2	Homo sapiens	167-173
12970166-8	2003	The involvement of this CRH receptor in the response of thyrotropes to CRH was further confirmed by the fact that TSH release was stimulated by human urocortin III, a CRH-R2-specific agonist, whereas the TSH response to CRH was completely blocked by the CRH-R blocker astressin and the CRH-R2-specific antagonist antisauvagine-30.	Thyrotropin	114-117	corticotropin releasing hormone	Homo sapiens	71-74
12970166-8	2003	The involvement of this CRH receptor in the response of thyrotropes to CRH was further confirmed by the fact that TSH release was stimulated by human urocortin III, a CRH-R2-specific agonist, whereas the TSH response to CRH was completely blocked by the CRH-R blocker astressin and the CRH-R2-specific antagonist antisauvagine-30.	Thyrotropin	114-117	corticotropin releasing hormone	Homo sapiens	71-74
12970166-9	2003	We conclude that CRH-induced TSH secretion is mediated by CRH-R2 expressed on thyrotropes.	Thyrotropin	29-32	corticotropin releasing hormone	Gallus gallus	17-20
12970166-9	2003	We conclude that CRH-induced TSH secretion is mediated by CRH-R2 expressed on thyrotropes.	Thyrotropin	29-32	corticotropin releasing hormone receptor 2	Gallus gallus	58-64
14761347-5	2003	The NGF protein expression in rat brain was observed by immunohistochemistry Triiodothyronine (T3), thyroxin (T4), TSH in serum and T3, T4 in brain tissue were determined by radio immunoassays (RIAs).	Thyrotropin	115-118	nerve growth factor	Rattus norvegicus	4-7
14597415-0	2003	The cyclin D3-CDK4-p27kip1 holoenzyme in thyroid epithelial cells: activation by TSH, inhibition by TGFbeta, and phosphorylations of its subunits demonstrated by two-dimensional gel electrophoresis.	Thyrotropin	81-84	cyclin D3	Canis lupus familiaris	4-13
14597415-0	2003	The cyclin D3-CDK4-p27kip1 holoenzyme in thyroid epithelial cells: activation by TSH, inhibition by TGFbeta, and phosphorylations of its subunits demonstrated by two-dimensional gel electrophoresis.	Thyrotropin	81-84	cyclin dependent kinase 4	Canis lupus familiaris	14-18
14597415-0	2003	The cyclin D3-CDK4-p27kip1 holoenzyme in thyroid epithelial cells: activation by TSH, inhibition by TGFbeta, and phosphorylations of its subunits demonstrated by two-dimensional gel electrophoresis.	Thyrotropin	81-84	cyclin dependent kinase inhibitor 1B	Canis lupus familiaris	19-26
14597415-4	2003	p27, like cyclin D3, supported the TSH-stimulated pRb-kinase activity of the CDK4 complex and, as demonstrated using the high-resolution power of the two-dimensional (2D) gel electrophoresis, the phosphorylation of CDK4, presumably by the nuclear CDK-activating kinase.	Thyrotropin	35-38	cyclin dependent kinase inhibitor 1B	Canis lupus familiaris	0-3
14597415-4	2003	p27, like cyclin D3, supported the TSH-stimulated pRb-kinase activity of the CDK4 complex and, as demonstrated using the high-resolution power of the two-dimensional (2D) gel electrophoresis, the phosphorylation of CDK4, presumably by the nuclear CDK-activating kinase.	Thyrotropin	35-38	cyclin D3	Canis lupus familiaris	10-19
12907760-1	2003	Humans expressing one allele of the thyroid transcription factor 1 (TTF1) gene have neurological symptoms and increased serum TSH with variable degrees of hypothyroidism.	Thyrotropin	126-129	NK2 homeobox 1	Mus musculus	36-66
12907760-1	2003	Humans expressing one allele of the thyroid transcription factor 1 (TTF1) gene have neurological symptoms and increased serum TSH with variable degrees of hypothyroidism.	Thyrotropin	126-129	NK2 homeobox 1	Mus musculus	68-72
12907760-2	2003	Ttf1+/- mice have also poor coordination and increased serum TSH concentration (205 +/- 22 vs. 92 +/- 12 mU/liter; P < 0.001) and slightly lower T4 (46 +/- 3 vs. 63 +/- 6 nmol/liter; P < 0.02) as compared with Ttf1+/+ mice.	Thyrotropin	61-64	transcription termination factor, RNA polymerase I	Mus musculus	0-4
14576819-0	2003	Critical role of cyclin D3 in TSH-dependent growth of thyrocytes and in hyperproliferative diseases of the thyroid gland.	Thyrotropin	30-33	cyclin D3	Rattus norvegicus	17-26
14576819-1	2003	We report that cyclin D3 is rate limiting for G1 progression in thyroid follicular cells and that its constitutive upregulation by chronic stimulation of the TSH/cAMP pathway plays a role in human and experimental hyperproliferative diseases of the thyroid gland.	Thyrotropin	158-161	cyclin D3	Homo sapiens	15-24
14576819-3	2003	In rat thyrocytes (PC Cl 3 cells), cyclin D3 expression is enhanced in response to activation of the TSH/cAMP pathway.	Thyrotropin	101-104	cyclin D3	Rattus norvegicus	35-44
14576819-4	2003	Interference with the expression of G1 cyclins (in particular cyclin D3) by the antisense methodology strongly reduced TSH-dependent proliferation of PC Cl 3 cells, indicating that proper progression through G1 requires cyclin D3.	Thyrotropin	119-122	cyclin D3	Rattus norvegicus	62-71
14576819-6	2003	Using an animal experimental model of thyroid stimulation, we demonstrate that cyclin D3 is a key mediator of TSH-dependent proliferation of thyroid follicular cells also in vivo.	Thyrotropin	110-113	cyclin D3	Rattus norvegicus	79-88
14576819-8	2003	The increase in cyclin D3 expression occurred after the propylthiouracil-induced increase in TSH levels and preceded the burst of cell proliferation.	Thyrotropin	93-96	cyclin D3	Rattus norvegicus	16-25
14759077-1	2003	Measurement of serum TSH-stimulated thyroglobulin (Tg) is recognized as a sensitive method for detecting residual/recurrent well-differentiated thyroid carcinoma (WDTC) in patients previously treated by surgery and radioactive iodine (RAI) ablation therapy.	Thyrotropin	21-24	thyroglobulin	Homo sapiens	36-49
14759077-1	2003	Measurement of serum TSH-stimulated thyroglobulin (Tg) is recognized as a sensitive method for detecting residual/recurrent well-differentiated thyroid carcinoma (WDTC) in patients previously treated by surgery and radioactive iodine (RAI) ablation therapy.	Thyrotropin	21-24	thyroglobulin	Homo sapiens	51-53
14654350-1	2003	The thyroid-stimulating hormone (TSH, or thyrotropin) receptor (TSHR) mediates the activating action of TSH to the thyroid gland, resulting in the growth and proliferation of thyrocytes and thyroid hormone production.	Thyrotropin	33-36	thyroid stimulating hormone receptor	Homo sapiens	64-68
14597415-4	2003	p27, like cyclin D3, supported the TSH-stimulated pRb-kinase activity of the CDK4 complex and, as demonstrated using the high-resolution power of the two-dimensional (2D) gel electrophoresis, the phosphorylation of CDK4, presumably by the nuclear CDK-activating kinase.	Thyrotropin	35-38	cyclin dependent kinase 4	Canis lupus familiaris	77-81
14597415-4	2003	p27, like cyclin D3, supported the TSH-stimulated pRb-kinase activity of the CDK4 complex and, as demonstrated using the high-resolution power of the two-dimensional (2D) gel electrophoresis, the phosphorylation of CDK4, presumably by the nuclear CDK-activating kinase.	Thyrotropin	35-38	cyclin dependent kinase 4	Canis lupus familiaris	215-219
12965872-6	2003	The efficacy of GC-1 treatment was verified by a reduction in serum TSH (-52% vs. control, P < 0.05) and cholesterol (-21% vs. control, P < 0.05).	Thyrotropin	68-71	solute carrier family 25 member 22	Rattus norvegicus	16-20
12902333-7	2003	Co-expression of cAMP-dependent protein kinase (PKA) regulatory subunit type II (RIIbeta) inhibited apoptosis and stimulated the growth of cells only in the presence of TSH.	Thyrotropin	169-172	protein kinase, cAMP dependent regulatory, type II beta	Mus musculus	53-89
14567913-3	2003	We provide evidence for direct effects of TSH on both components of skeletal remodeling, osteoblastic bone formation, and osteoclastic bone resorption, mediated via the TSH receptor (TSHR) found on osteoblast and osteoclast precursors.	Thyrotropin	42-45	thyroid stimulating hormone receptor	Homo sapiens	169-181
14567913-3	2003	We provide evidence for direct effects of TSH on both components of skeletal remodeling, osteoblastic bone formation, and osteoclastic bone resorption, mediated via the TSH receptor (TSHR) found on osteoblast and osteoclast precursors.	Thyrotropin	42-45	thyroid stimulating hormone receptor	Homo sapiens	183-187
14530520-6	2003	In conclusion, TRH and leptin rapidly decreased pituitary NB and it is first proposed that the reduction of the inhibitory tonus of NB on TSH release will ultimately contribute to the amplification of TSH secretion elicited by TSH secretagogues.	Thyrotropin	138-141	thyrotropin releasing hormone	Rattus norvegicus	15-18
14530520-6	2003	In conclusion, TRH and leptin rapidly decreased pituitary NB and it is first proposed that the reduction of the inhibitory tonus of NB on TSH release will ultimately contribute to the amplification of TSH secretion elicited by TSH secretagogues.	Thyrotropin	201-204	thyrotropin releasing hormone	Rattus norvegicus	15-18
14530520-6	2003	In conclusion, TRH and leptin rapidly decreased pituitary NB and it is first proposed that the reduction of the inhibitory tonus of NB on TSH release will ultimately contribute to the amplification of TSH secretion elicited by TSH secretagogues.	Thyrotropin	201-204	thyrotropin releasing hormone	Rattus norvegicus	15-18
14557460-1	2003	In this study, we have investigated in vivo the time-dependent effects of TSH on vascular endothelial growth factor (VEGF) production in patients monitored for thyroid carcinoma.	Thyrotropin	74-77	vascular endothelial growth factor A	Homo sapiens	81-115
14557460-1	2003	In this study, we have investigated in vivo the time-dependent effects of TSH on vascular endothelial growth factor (VEGF) production in patients monitored for thyroid carcinoma.	Thyrotropin	74-77	vascular endothelial growth factor A	Homo sapiens	117-121
14557460-7	2003	This result would suggest that TSH may be able in vivo to regulate VEGF production from tissues other than the thyroid gland.	Thyrotropin	31-34	vascular endothelial growth factor A	Homo sapiens	67-71
12969239-3	2003	In addition, as ANXA1 is a substrate for protein kinase C (PKC) and tyrosine kinase, we examined the roles of these kinases in the manifestation of the ANXA1-dependent inhibitory actions of dexamethasone on TSH and LH release.	Thyrotropin	207-210	annexin A1	Homo sapiens	152-157
12970276-3	2003	We postulated that TSH receptor autoantibodies could directly suppress TSH secretion, independently from thyroid hormone levels, via binding to the pituitary TSH receptor.	Thyrotropin	19-22	thyroid stimulating hormone receptor	Homo sapiens	158-170
12970276-9	2003	Our findings suggest that TBII suppress TSH secretion independently of thyroid hormone levels, most likely by binding to the pituitary TSH receptor.	Thyrotropin	40-43	thyroid stimulating hormone receptor	Homo sapiens	135-147
12970307-2	2003	In Albright hereditary osteodystrophy, heterozygous G(s)alpha null mutations only lead to PTH, TSH, and gonadotropin resistance when inherited maternally [pseudohypoparathyroidism type 1A; (PHP1A)].	Thyrotropin	95-98	GNAS complex locus	Homo sapiens	52-61
12970326-3	2003	TSH induced FGF-2 and increased the expression of FGFR1 in FRTL5 cells.	Thyrotropin	0-3	fibroblast growth factor 2	Rattus norvegicus	12-17
12970307-8	2003	This study provides further evidence for tissue-specific imprinting of G(s)alpha in humans and provides a potential mechanism for mild to moderate TSH resistance in PHP1A and borderline resistance in some patients with PHP1B.	Thyrotropin	147-150	GNAS complex locus	Homo sapiens	71-80
12970326-3	2003	TSH induced FGF-2 and increased the expression of FGFR1 in FRTL5 cells.	Thyrotropin	0-3	Fibroblast growth factor receptor 1	Rattus norvegicus	50-55
12812775-7	2003	The perifusion studies show that CRH stimulated the TSH release at all stages tested.	Thyrotropin	52-55	corticotropin releasing hormone	Gallus gallus	33-36
14588100-6	2003	Our results suggest that serial measurements of low levels of Tg by ELISA in treated patients with DTC enable detection of recurrence (without using TSH stimulation) 6-12 months earlier than would have been possible using a conventional Tg immuno-radiometric assay (IRMA).	Thyrotropin	149-152	thyroglobulin	Homo sapiens	62-64
12919165-14	2003	In the euthyroid subjects, TPO antibody titre correlated positively with TSH levels (r = 0.386; P < 0.001).	Thyrotropin	73-76	thyroid peroxidase	Homo sapiens	27-30
12853977-6	2003	Acute expression of RET/PTC3 or RET/PTC3(Y541F), but not PTC2/PDZ, inhibited TSH-induced Tg and NIS expression, suggesting that activation of Shc-Ras, but not PLCgamma, is required for RET/PTC-induced dedifferentiation.	Thyrotropin	77-80	ret proto-oncogene	Rattus norvegicus	20-23
12853977-6	2003	Acute expression of RET/PTC3 or RET/PTC3(Y541F), but not PTC2/PDZ, inhibited TSH-induced Tg and NIS expression, suggesting that activation of Shc-Ras, but not PLCgamma, is required for RET/PTC-induced dedifferentiation.	Thyrotropin	77-80	ret proto-oncogene	Rattus norvegicus	32-35
12853977-6	2003	Acute expression of RET/PTC3 or RET/PTC3(Y541F), but not PTC2/PDZ, inhibited TSH-induced Tg and NIS expression, suggesting that activation of Shc-Ras, but not PLCgamma, is required for RET/PTC-induced dedifferentiation.	Thyrotropin	77-80	ret proto-oncogene	Rattus norvegicus	32-35
12853977-7	2003	Accordingly, acute expression of H-Ras(V12) or of a constitutively active MEK1 also blocked TSH-induced expression of Tg and NIS.	Thyrotropin	92-95	mitogen activated protein kinase kinase 1	Rattus norvegicus	74-78
14594554-13	2003	The number of TRHR-immunoreactive cells increased in parallel with the number of TSH-immunoreactive cells.	Thyrotropin	81-84	thyrotropin releasing hormone receptor	Rattus norvegicus	14-18
12604508-4	2003	A single injection of leptin (8 microg/100 g body wt sc) induced increased thyroid and liver D1 (P < 0.05), but not thyroid D2, activities at 30 and 120 min, independently of the serum TSH rise shown only at 2 h. OCT (1 microg/kg body wt sc) increased D1 and D2 activity significantly 24 h after a single injection, with no changes in serum TSH.	Thyrotropin	188-191	leptin	Rattus norvegicus	22-28
12668683-5	2003	TSH induced a redistribution of PDK1 from the cytoplasm to the plasma membrane in the cells in a PI3K- and protein kinase A-dependent manner.	Thyrotropin	0-3	pyruvate dehydrogenase kinase 1	Homo sapiens	32-36
12668683-6	2003	TSH induced the PDK1-dependent phosphorylation of S6K1 but did not induce Akt/protein kinase B phosphorylation.	Thyrotropin	0-3	pyruvate dehydrogenase kinase 1	Homo sapiens	16-20
12668683-6	2003	TSH induced the PDK1-dependent phosphorylation of S6K1 but did not induce Akt/protein kinase B phosphorylation.	Thyrotropin	0-3	ribosomal protein S6 kinase B1	Homo sapiens	50-54
12668683-8	2003	Rapamycin inhibited the phosphorylation of S6K1 in the cells treated with either TSH or 8-bromo-cAMP.	Thyrotropin	81-84	ribosomal protein S6 kinase B1	Homo sapiens	43-47
12668683-11	2003	These findings suggest an interaction between TSHR and PI3K, which is stimulated by TSH and cAMP and might involve the downstream S6K1 but not Akt/protein kinase B.	Thyrotropin	46-49	ribosomal protein S6 kinase B1	Homo sapiens	130-134
12668683-11	2003	These findings suggest an interaction between TSHR and PI3K, which is stimulated by TSH and cAMP and might involve the downstream S6K1 but not Akt/protein kinase B.	Thyrotropin	46-49	AKT serine/threonine kinase 1	Homo sapiens	143-146
12668683-11	2003	These findings suggest an interaction between TSHR and PI3K, which is stimulated by TSH and cAMP and might involve the downstream S6K1 but not Akt/protein kinase B.	Thyrotropin	46-49	protein tyrosine kinase 2 beta	Homo sapiens	147-163
12668683-12	2003	This pathway may play a role in the TSH/stimulating type TSH receptor antibody-mediated thyrocyte proliferation in vitro and in the response to TSH in vivo.	Thyrotropin	36-39	thyroid stimulating hormone receptor	Homo sapiens	57-69
12899791-1	2003	OBJECTIVE: To investigate the correlation between serum thyroglobulin (Tg) and thyroid stimulating hormone (TSH) in populations with non-toxic goiter.	Thyrotropin	79-106	thyroglobulin	Homo sapiens	56-69
12899791-1	2003	OBJECTIVE: To investigate the correlation between serum thyroglobulin (Tg) and thyroid stimulating hormone (TSH) in populations with non-toxic goiter.	Thyrotropin	79-106	thyroglobulin	Homo sapiens	71-73
12899791-1	2003	OBJECTIVE: To investigate the correlation between serum thyroglobulin (Tg) and thyroid stimulating hormone (TSH) in populations with non-toxic goiter.	Thyrotropin	108-111	thyroglobulin	Homo sapiens	56-69
12899791-1	2003	OBJECTIVE: To investigate the correlation between serum thyroglobulin (Tg) and thyroid stimulating hormone (TSH) in populations with non-toxic goiter.	Thyrotropin	108-111	thyroglobulin	Homo sapiens	71-73
12727856-1	2003	Thyroid-stimulating hormone receptor (TSHR) expression is frequently silenced in epithelial thyroid cancers associated with decreased or absent TSH-promoted iodine uptake.	Thyrotropin	38-41	thyroid stimulating hormone receptor	Homo sapiens	0-36
12780757-9	2003	A previously described heterozygous Arg271Trp mutation in exon 6 of the POU1F1 gene was identified in a female infant who presented with growth failure and was diagnosed with TSH then GH deficiencies.	Thyrotropin	175-178	POU class 1 homeobox 1	Homo sapiens	72-78
12782401-7	2003	Alternatively, a pro-opiomelanocortin (POMC)-derived peptide, secreted by the corticotropes following CRH stimulation, could act as an activator of TSH secretion in a paracrine way.	Thyrotropin	148-151	proopiomelanocortin	Gallus gallus	17-37
12782401-7	2003	Alternatively, a pro-opiomelanocortin (POMC)-derived peptide, secreted by the corticotropes following CRH stimulation, could act as an activator of TSH secretion in a paracrine way.	Thyrotropin	148-151	proopiomelanocortin	Gallus gallus	39-43
12782401-7	2003	Alternatively, a pro-opiomelanocortin (POMC)-derived peptide, secreted by the corticotropes following CRH stimulation, could act as an activator of TSH secretion in a paracrine way.	Thyrotropin	148-151	corticotropin releasing hormone	Gallus gallus	102-105
12699436-1	2003	BACKGROUND: Serum thyroglobulin (Tg) measurement after TSH stimulation, by either thyroid hormone withdrawal or recombinant human TSH (rhTSH) administration, is the most sensitive method for early detection of patients with persistent or recurrent differentiated thyroid cancer (DTC) after total thyroidectomy and 131I ablation.	Thyrotropin	55-58	thyroglobulin	Homo sapiens	18-31
12699436-1	2003	BACKGROUND: Serum thyroglobulin (Tg) measurement after TSH stimulation, by either thyroid hormone withdrawal or recombinant human TSH (rhTSH) administration, is the most sensitive method for early detection of patients with persistent or recurrent differentiated thyroid cancer (DTC) after total thyroidectomy and 131I ablation.	Thyrotropin	130-133	thyroglobulin	Homo sapiens	18-31
12882712-10	2003	CONCLUSION: Serum TG level is affected by gender, amount of iodine intake, serum TSH level and thyroid volume.	Thyrotropin	81-84	thyroglobulin	Homo sapiens	18-20
12679418-4	2003	An undetectable serum Tg measured during thyroid hormone suppression of TSH (THST) is often misleading.	Thyrotropin	72-75	thyroglobulin	Homo sapiens	22-24
12721505-2	2003	SST is synthesized in the hypothalamus and transported to the anterior pituitary gland where it tonicaly inhibits GH and TSH secretion as well as being responsible for GH pulsatile release.	Thyrotropin	121-124	somatostatin	Homo sapiens	0-3
12721508-1	2003	Besides well-known effects in GH-secreting adenomas, somatostatin analogs such as octreotide and lanreotide have been used in TSH-secreting adenomas and in the so-called clinically nonfunctioning adenomas.	Thyrotropin	126-129	somatostatin	Homo sapiens	53-65
12679418-5	2003	Eight studies show that 21% of 784 patients who had no clinical evidence of tumor with baseline serum Tg levels usually below 1 micro g/liter during THST had, in response to recombinant human TSH (rhTSH), a rise in serum Tg to more than 2 micro g/liter.	Thyrotropin	192-195	thyroglobulin	Homo sapiens	102-104
12679418-5	2003	Eight studies show that 21% of 784 patients who had no clinical evidence of tumor with baseline serum Tg levels usually below 1 micro g/liter during THST had, in response to recombinant human TSH (rhTSH), a rise in serum Tg to more than 2 micro g/liter.	Thyrotropin	192-195	thyroglobulin	Homo sapiens	221-223
12679418-8	2003	Ten studies comprising 1599 patients demonstrate that a TSH-stimulated Tg test using a Tg cutoff of 2 micro g/liter (either after thyroid hormone withdrawal or 72 h after rhTSH) is sufficiently sensitive to be used as the principal test in the follow-up management of low-risk patients with DTC and that the routine use of diagnostic whole body scanning in follow-up should be discouraged.	Thyrotropin	56-59	thyroglobulin	Homo sapiens	71-73
12679418-8	2003	Ten studies comprising 1599 patients demonstrate that a TSH-stimulated Tg test using a Tg cutoff of 2 micro g/liter (either after thyroid hormone withdrawal or 72 h after rhTSH) is sufficiently sensitive to be used as the principal test in the follow-up management of low-risk patients with DTC and that the routine use of diagnostic whole body scanning in follow-up should be discouraged.	Thyrotropin	56-59	thyroglobulin	Homo sapiens	87-89
12679418-9	2003	On the basis of the foregoing, we propose a surveillance guideline using TSH-stimulated Tg levels for patients who have undergone total or near-total thyroidectomy and (131)I ablation for DTC and have no clinical evidence of residual tumor with a serum Tg below 1 micro g/liter during THST.	Thyrotropin	73-76	thyroglobulin	Homo sapiens	88-90
12679418-9	2003	On the basis of the foregoing, we propose a surveillance guideline using TSH-stimulated Tg levels for patients who have undergone total or near-total thyroidectomy and (131)I ablation for DTC and have no clinical evidence of residual tumor with a serum Tg below 1 micro g/liter during THST.	Thyrotropin	73-76	thyroglobulin	Homo sapiens	253-255
12624534-8	2003	Both GALP and galanin administration (1 nmol) into the PVN significantly decreased the level of circulating TSH.	Thyrotropin	108-111	galanin-like peptide	Rattus norvegicus	5-9
12741092-8	2003	Endogenous TSH (cTSH) measured parallelly, was elevated in only 60% of the dogs.	Thyrotropin	11-14	cathepsin H	Canis lupus familiaris	16-20
12690093-7	2003	Acute expression of the oncoprotein decreased TSH-mediated growth stimulation due to interference of TSH signaling by RET/PTC at multiple levels.	Thyrotropin	46-49	ret proto-oncogene	Rattus norvegicus	118-121
12538618-7	2003	Insulin increased the levels of both normal and truncated DUOX2 mRNA in FRTL-5 cells grown in TSH-free medium containing a low concentration of serum.	Thyrotropin	94-97	insulin	Sus scrofa	0-7
12538618-7	2003	Insulin increased the levels of both normal and truncated DUOX2 mRNA in FRTL-5 cells grown in TSH-free medium containing a low concentration of serum.	Thyrotropin	94-97	dual oxidase 2	Rattus norvegicus	58-63
12624534-12	2003	These data suggest that in the PVN, GALP may play a role in energy homeostasis by stimulating food intake and suppressing TSH release.	Thyrotropin	122-125	galanin-like peptide	Rattus norvegicus	36-40
12699588-3	2003	Recently, we and others described the expression of two genes participating in thyroid hormone metabolism type I and type II deiodinase (D1 and D2, respectively) that are upregulated by TSH, although the mechanisms responsible for this effect are likely to be different.	Thyrotropin	186-189	leiomodin 1	Homo sapiens	106-146
12488353-6	2003	In contrast, the plasmid DNA vaccination model in female BALB/c (H-2d) mice led to the generation of low levels of anti-TSHR antibodies by flow cytometry, which were undetectable for thyroid-stimulating antibodies, TSH-stimulating blocking antibodies, and TSH-binding inhibiting Ig activity.	Thyrotropin	120-123	histocompatibility 2, D region	Mus musculus	65-69
12393601-3	2003	Conversely, TSH-responsive BM cells defined by expression of TSH receptor (TSHR) using flow cytometry were selectively associated with a nonerythroid CD11b(-) lymphocyte precursor population.	Thyrotropin	12-15	thyroid stimulating hormone receptor	Homo sapiens	61-73
12393601-3	2003	Conversely, TSH-responsive BM cells defined by expression of TSH receptor (TSHR) using flow cytometry were selectively associated with a nonerythroid CD11b(-) lymphocyte precursor population.	Thyrotropin	12-15	thyroid stimulating hormone receptor	Homo sapiens	75-79
12393601-3	2003	Conversely, TSH-responsive BM cells defined by expression of TSH receptor (TSHR) using flow cytometry were selectively associated with a nonerythroid CD11b(-) lymphocyte precursor population.	Thyrotropin	12-15	integrin subunit alpha M	Homo sapiens	150-155
12393601-4	2003	In vitro culture of magnetic-activated cell sorted CD11b(-) and CD11b(+) cells with titrated amounts of purified TSH resulted in significantly higher levels of TNF-alpha secretion from CD11b(-) BM cells compared to non-TSH-treated cells, with no appreciable change in TNF-alpha production from CD11b(+) cells.	Thyrotropin	113-116	integrin subunit alpha M	Homo sapiens	51-56
12393601-4	2003	In vitro culture of magnetic-activated cell sorted CD11b(-) and CD11b(+) cells with titrated amounts of purified TSH resulted in significantly higher levels of TNF-alpha secretion from CD11b(-) BM cells compared to non-TSH-treated cells, with no appreciable change in TNF-alpha production from CD11b(+) cells.	Thyrotropin	113-116	integrin subunit alpha M	Homo sapiens	64-69
12393601-4	2003	In vitro culture of magnetic-activated cell sorted CD11b(-) and CD11b(+) cells with titrated amounts of purified TSH resulted in significantly higher levels of TNF-alpha secretion from CD11b(-) BM cells compared to non-TSH-treated cells, with no appreciable change in TNF-alpha production from CD11b(+) cells.	Thyrotropin	113-116	tumor necrosis factor	Homo sapiens	160-169
12393601-4	2003	In vitro culture of magnetic-activated cell sorted CD11b(-) and CD11b(+) cells with titrated amounts of purified TSH resulted in significantly higher levels of TNF-alpha secretion from CD11b(-) BM cells compared to non-TSH-treated cells, with no appreciable change in TNF-alpha production from CD11b(+) cells.	Thyrotropin	113-116	integrin subunit alpha M	Homo sapiens	64-69
12393601-4	2003	In vitro culture of magnetic-activated cell sorted CD11b(-) and CD11b(+) cells with titrated amounts of purified TSH resulted in significantly higher levels of TNF-alpha secretion from CD11b(-) BM cells compared to non-TSH-treated cells, with no appreciable change in TNF-alpha production from CD11b(+) cells.	Thyrotropin	113-116	tumor necrosis factor	Homo sapiens	268-277
12393601-4	2003	In vitro culture of magnetic-activated cell sorted CD11b(-) and CD11b(+) cells with titrated amounts of purified TSH resulted in significantly higher levels of TNF-alpha secretion from CD11b(-) BM cells compared to non-TSH-treated cells, with no appreciable change in TNF-alpha production from CD11b(+) cells.	Thyrotropin	113-116	integrin subunit alpha M	Homo sapiens	64-69
12393601-4	2003	In vitro culture of magnetic-activated cell sorted CD11b(-) and CD11b(+) cells with titrated amounts of purified TSH resulted in significantly higher levels of TNF-alpha secretion from CD11b(-) BM cells compared to non-TSH-treated cells, with no appreciable change in TNF-alpha production from CD11b(+) cells.	Thyrotropin	219-222	integrin subunit alpha M	Homo sapiens	51-56
12393601-4	2003	In vitro culture of magnetic-activated cell sorted CD11b(-) and CD11b(+) cells with titrated amounts of purified TSH resulted in significantly higher levels of TNF-alpha secretion from CD11b(-) BM cells compared to non-TSH-treated cells, with no appreciable change in TNF-alpha production from CD11b(+) cells.	Thyrotropin	219-222	integrin subunit alpha M	Homo sapiens	64-69
12393601-4	2003	In vitro culture of magnetic-activated cell sorted CD11b(-) and CD11b(+) cells with titrated amounts of purified TSH resulted in significantly higher levels of TNF-alpha secretion from CD11b(-) BM cells compared to non-TSH-treated cells, with no appreciable change in TNF-alpha production from CD11b(+) cells.	Thyrotropin	219-222	tumor necrosis factor	Homo sapiens	160-169
12393601-4	2003	In vitro culture of magnetic-activated cell sorted CD11b(-) and CD11b(+) cells with titrated amounts of purified TSH resulted in significantly higher levels of TNF-alpha secretion from CD11b(-) BM cells compared to non-TSH-treated cells, with no appreciable change in TNF-alpha production from CD11b(+) cells.	Thyrotropin	219-222	integrin subunit alpha M	Homo sapiens	64-69
12393601-4	2003	In vitro culture of magnetic-activated cell sorted CD11b(-) and CD11b(+) cells with titrated amounts of purified TSH resulted in significantly higher levels of TNF-alpha secretion from CD11b(-) BM cells compared to non-TSH-treated cells, with no appreciable change in TNF-alpha production from CD11b(+) cells.	Thyrotropin	219-222	integrin subunit alpha M	Homo sapiens	64-69
12393601-6	2003	They also indicate that TSH-mediated regulation of TNF-alpha secretion within the BM most likely operates through an intrinsic network of TSH production and use between different types of BM cells, and they suggest that local TSH may be an important homeostatic regulator of hematopoiesis mediated by TNF-alpha.	Thyrotropin	24-27	tumor necrosis factor	Homo sapiens	51-60
12393601-6	2003	They also indicate that TSH-mediated regulation of TNF-alpha secretion within the BM most likely operates through an intrinsic network of TSH production and use between different types of BM cells, and they suggest that local TSH may be an important homeostatic regulator of hematopoiesis mediated by TNF-alpha.	Thyrotropin	24-27	tumor necrosis factor	Homo sapiens	301-310
12493572-7	2003	However, glands from hyperestrogenized rats (OVX + EB14) required a higher dose (10(-5) M) of NB to inhibit TSH release (P < 0.05).	Thyrotropin	108-111	neuromedin B	Rattus norvegicus	94-96
12493572-9	2003	In conclusion, estrogen status of female rats modulates the inhibitory effect of NB on TSH release in vitro and hyperestrogenism is required for stimulatory effect of NB on PRL release in vitro.	Thyrotropin	87-90	neuromedin B	Rattus norvegicus	81-83
12534453-1	2002	BACKGROUND: The estimated prevalence of endogenous subclinical hyperthyroidism varies from 4% to 6% and a basal thyroid stimulating hormone (TSH) level < 0.5 mU L-1 may be associated with increased mortality in subjects over 60 years of age who are not on thyroid medication.	Thyrotropin	112-139	immunoglobulin kappa variable 1-16	Homo sapiens	164-167
12525244-4	2003	In order to test a direct action of TSH on in vitro leptin secretion, a systematic study of organ cultures of human omental adipose tIssue was performed in samples obtained at surgery from 34 patients of both sexes during elective abdominal surgery.	Thyrotropin	36-39	leptin	Homo sapiens	52-58
12464672-5	2002	MS-1 also competed for radiolabeled TSH binding to the native TSHR and was able to compete for TSH-induced stimulation.	Thyrotropin	36-39	MS	Homo sapiens	0-4
12464672-5	2002	MS-1 also competed for radiolabeled TSH binding to the native TSHR and was able to compete for TSH-induced stimulation.	Thyrotropin	36-39	thyroid stimulating hormone receptor	Homo sapiens	62-66
12464672-5	2002	MS-1 also competed for radiolabeled TSH binding to the native TSHR and was able to compete for TSH-induced stimulation.	Thyrotropin	62-65	MS	Homo sapiens	0-4
12480497-11	2002	Also, IL-2 increased the TSH concentration.	Thyrotropin	25-28	interleukin 2	Homo sapiens	6-10
12446577-6	2002	NPY, Y1, and Y5 receptor agonist administration suppressed circulating levels of thyroid hormones (T3 and T4) and resulted in inappropriately normal or low TSH levels.	Thyrotropin	156-159	neuropeptide Y	Homo sapiens	0-3
12446577-6	2002	NPY, Y1, and Y5 receptor agonist administration suppressed circulating levels of thyroid hormones (T3 and T4) and resulted in inappropriately normal or low TSH levels.	Thyrotropin	156-159	neuropeptide Y receptor Y5	Homo sapiens	13-24
12486087-0	2002	The mt1 melatonin receptor and RORbeta receptor are co-localized in specific TSH-immunoreactive cells in the pars tuberalis of the rat pituitary.	Thyrotropin	77-80	metallothionein 1	Rattus norvegicus	4-7
12486087-0	2002	The mt1 melatonin receptor and RORbeta receptor are co-localized in specific TSH-immunoreactive cells in the pars tuberalis of the rat pituitary.	Thyrotropin	77-80	RAR-related orphan receptor B	Rattus norvegicus	31-38
12534453-1	2002	BACKGROUND: The estimated prevalence of endogenous subclinical hyperthyroidism varies from 4% to 6% and a basal thyroid stimulating hormone (TSH) level < 0.5 mU L-1 may be associated with increased mortality in subjects over 60 years of age who are not on thyroid medication.	Thyrotropin	141-144	immunoglobulin kappa variable 1-16	Homo sapiens	164-167
12593718-3	2002	mAbs that bound to five different regions of the TSHR (amino acids [aa] 32-41, aa 36-42, aa 246-260, aa 277-296, and aa 381-385) were able to inhibit (125)I-labeled thyrotropin (TSH) binding to solubilized TSHR preparations.	Thyrotropin	165-176	thyroid stimulating hormone receptor	Homo sapiens	49-53
12464461-5	2002	Infusion of SP caused a significant worsening of the mood of the subjects, led to an increase of REM latency and time awake during the SP-infusion intervals, caused increased stage 1 sleep in the first part of the night, and led to increased cortisol and thyroid stimulating hormone levels and a trend for decreased growth hormone levels.	Thyrotropin	255-282	tachykinin precursor 1	Homo sapiens	12-14
12593718-3	2002	mAbs that bound to five different regions of the TSHR (amino acids [aa] 32-41, aa 36-42, aa 246-260, aa 277-296, and aa 381-385) were able to inhibit (125)I-labeled thyrotropin (TSH) binding to solubilized TSHR preparations.	Thyrotropin	49-52	thyroid stimulating hormone receptor	Homo sapiens	206-210
12593718-6	2002	Our studies suggest that three distinct and discontinuous regions of the TSHR (aa 246-260 and 277-296 on the TSHR A subunit) and aa 381-385 (on the TSHR B subunit) fold together to form a complex TSH binding pocket.	Thyrotropin	73-76	thyroid stimulating hormone receptor	Homo sapiens	109-113
12593718-6	2002	Our studies suggest that three distinct and discontinuous regions of the TSHR (aa 246-260 and 277-296 on the TSHR A subunit) and aa 381-385 (on the TSHR B subunit) fold together to form a complex TSH binding pocket.	Thyrotropin	73-76	thyroid stimulating hormone receptor	Homo sapiens	109-113
12223484-9	2002	The TSH-induced decrease in TSHR oligomers was found to be secondary to dissociation of the TSHR complexes as evidenced by an increase in fluorescent intensity of photobleached spots of GFP fluorescence with 10(3) microunits/ml of TSH.	Thyrotropin	4-7	thyroid stimulating hormone receptor	Homo sapiens	28-32
12223484-9	2002	The TSH-induced decrease in TSHR oligomers was found to be secondary to dissociation of the TSHR complexes as evidenced by an increase in fluorescent intensity of photobleached spots of GFP fluorescence with 10(3) microunits/ml of TSH.	Thyrotropin	4-7	thyroid stimulating hormone receptor	Homo sapiens	92-96
12089143-6	2002	In thyroid cells, Akt has been implicated in the stimulation of cell proliferation by TSH and cAMP.	Thyrotropin	86-89	AKT serine/threonine kinase 1	Rattus norvegicus	18-21
12442901-1	2002	We investigated the possible involvement of phosphatidylcholine-specific phospholipase C (PC-PLC) in the thyroid-stimulating hormone (TSH)-induced protein kinase C (PKC)/phospholipase D (PLD) activation in FRTL-5 thyroid cells.	Thyrotropin	105-132	protein kinase C, alpha	Rattus norvegicus	165-168
12442901-1	2002	We investigated the possible involvement of phosphatidylcholine-specific phospholipase C (PC-PLC) in the thyroid-stimulating hormone (TSH)-induced protein kinase C (PKC)/phospholipase D (PLD) activation in FRTL-5 thyroid cells.	Thyrotropin	134-137	protein kinase C, alpha	Rattus norvegicus	165-168
12442901-3	2002	TSH induced translocations of PKCalpha and RhoA from the cytosol to the membrane within 30 min.	Thyrotropin	0-3	protein kinase C, alpha	Rattus norvegicus	30-38
12442901-3	2002	TSH induced translocations of PKCalpha and RhoA from the cytosol to the membrane within 30 min.	Thyrotropin	0-3	ras homolog family member A	Rattus norvegicus	43-47
12442901-6	2002	Moreover, C3 transferase, an inhibitor of RhoA, significantly inhibited PLD activity that was stimulated by TSH, which suggests that RhoA is also involved in TSH-induced PLD activation.	Thyrotropin	108-111	ras homolog family member A	Rattus norvegicus	42-46
12442901-6	2002	Moreover, C3 transferase, an inhibitor of RhoA, significantly inhibited PLD activity that was stimulated by TSH, which suggests that RhoA is also involved in TSH-induced PLD activation.	Thyrotropin	108-111	ras homolog family member A	Rattus norvegicus	133-137
12442901-6	2002	Moreover, C3 transferase, an inhibitor of RhoA, significantly inhibited PLD activity that was stimulated by TSH, which suggests that RhoA is also involved in TSH-induced PLD activation.	Thyrotropin	158-161	ras homolog family member A	Rattus norvegicus	42-46
12442901-6	2002	Moreover, C3 transferase, an inhibitor of RhoA, significantly inhibited PLD activity that was stimulated by TSH, which suggests that RhoA is also involved in TSH-induced PLD activation.	Thyrotropin	158-161	ras homolog family member A	Rattus norvegicus	133-137
12442901-9	2002	Also, RhoA and PKCalpha are involved in the regulation of TSH-induced PLD activation in FRTL-5 thyroid cells.	Thyrotropin	58-61	ras homolog family member A	Rattus norvegicus	6-10
12442901-9	2002	Also, RhoA and PKCalpha are involved in the regulation of TSH-induced PLD activation in FRTL-5 thyroid cells.	Thyrotropin	58-61	protein kinase C, alpha	Rattus norvegicus	15-23
12666446-6	2002	The determinations showed statistically significant lower serum TSH level in psoriatic patients before therapy vs. control and significant, negative correlation with calcitonin concentration in those patients.	Thyrotropin	64-67	calcitonin related polypeptide alpha	Homo sapiens	166-176
12490070-0	2002	Thyroid-stimulating hormone induces interleukin-18 gene expression in FRTL-5 cells: immunohistochemical detection of interleukin-18 in autoimmune thyroid disease.	Thyrotropin	0-27	interleukin 18	Rattus norvegicus	36-50
12490070-0	2002	Thyroid-stimulating hormone induces interleukin-18 gene expression in FRTL-5 cells: immunohistochemical detection of interleukin-18 in autoimmune thyroid disease.	Thyrotropin	0-27	interleukin 18	Rattus norvegicus	117-131
12220730-2	2002	The aim of the present study was to investigate the effects of oxytocin treatment on plasma levels of thyroid-stimulating hormone (TSH), free thyroxine (fT4) and free triiodothyronine (fT3).	Thyrotropin	102-129	oxytocin/neurophysin I prepropeptide	Rattus norvegicus	63-71
12220730-2	2002	The aim of the present study was to investigate the effects of oxytocin treatment on plasma levels of thyroid-stimulating hormone (TSH), free thyroxine (fT4) and free triiodothyronine (fT3).	Thyrotropin	131-134	oxytocin/neurophysin I prepropeptide	Rattus norvegicus	63-71
12220730-9	2002	Thus, the effect seems to have been mediated within the central nervous system, and TSH and the thyroid hormones may be involved in some of the metabolic effects in response to oxytocin.	Thyrotropin	84-87	oxytocin/neurophysin I prepropeptide	Rattus norvegicus	177-185
12225969-10	2002	In the presence of 20 microM TSH, an 88% reduction in terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling (TUNEL)-positive cells was observed in serum-starved (3 h) 3T3-L1 preadipocytes as well as a 93% reduction in the level of cleaved activated caspase 3.	Thyrotropin	29-32	deoxynucleotidyltransferase, terminal	Mus musculus	54-91
12225969-10	2002	In the presence of 20 microM TSH, an 88% reduction in terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling (TUNEL)-positive cells was observed in serum-starved (3 h) 3T3-L1 preadipocytes as well as a 93% reduction in the level of cleaved activated caspase 3.	Thyrotropin	29-32	deoxynucleotidyltransferase, terminal	Mus musculus	93-96
12225969-10	2002	In the presence of 20 microM TSH, an 88% reduction in terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling (TUNEL)-positive cells was observed in serum-starved (3 h) 3T3-L1 preadipocytes as well as a 93% reduction in the level of cleaved activated caspase 3.	Thyrotropin	29-32	caspase 3	Mus musculus	271-280
12242030-3	2002	This study aimed to investigate whether the cAMP/PKA or the PKC system is involved in STAT3 activation in response to TSH.	Thyrotropin	118-121	signal transducer and activator of transcription 3	Homo sapiens	86-91
12210368-4	2002	Bcl-2 expression increased significantly in hypothyroid myopathy, correlating with high serum TSH levels, and not with either triiodothyronine (T3) or thyroxine (T4) serum levels.	Thyrotropin	94-97	BCL2 apoptosis regulator	Homo sapiens	0-5
12210368-5	2002	By contrast, Fas antigen was overexpressed in hyperthyroid myopathy, correlating with low TSH levels.	Thyrotropin	90-93	Fas cell surface death receptor	Homo sapiens	13-24
12242030-5	2002	TSH-induced STAT3 activation was inhibited by a blocking antibody directed against TSHR that was isolated from patients with primary myxoedema.	Thyrotropin	0-3	signal transducer and activator of transcription 3	Homo sapiens	12-17
12242030-5	2002	TSH-induced STAT3 activation was inhibited by a blocking antibody directed against TSHR that was isolated from patients with primary myxoedema.	Thyrotropin	0-3	thyroid stimulating hormone receptor	Homo sapiens	83-87
12147228-0	2002	Paternal imprinting of Galpha(s) in the human thyroid as the basis of TSH resistance in pseudohypoparathyroidism type 1a.	Thyrotropin	70-73	succinate-CoA ligase GDP/ADP-forming subunit alpha	Homo sapiens	23-29
12147228-7	2002	We conclude that Galpha(s) is incompletely imprinted in the thyroid, which provides an explanation for mild TSH resistance in PHP type 1a.	Thyrotropin	108-111	succinate-CoA ligase GDP/ADP-forming subunit alpha	Homo sapiens	17-23
12110538-7	2002	After treatment for 5 days with AGN194204, both wild-type and thyroid hormone receptor beta (TR beta(-/-))-deficient mice demonstrated a nearly 50% decrease in serum TSH and T(4) concentrations.	Thyrotropin	166-169	apoptosis antagonizing transcription factor	Mus musculus	93-100
12099701-6	2002	EGF, phorbol esters or TGF-beta1 predominantly increased PAI-1 protein expression in TSH-treated cells.	Thyrotropin	85-88	transforming growth factor beta 1	Homo sapiens	23-32
12145233-11	2002	Even higher TSH levels were observed in patients with both anti-TPO and anti-TG (4.55 microU/ml, range 0.0-197.0 microU/ml).	Thyrotropin	12-15	thyroid peroxidase	Homo sapiens	64-67
12130551-3	2002	We have studied the impact of a selective RXR agonist (rexinoid), LG100268, on rat thyroid axis hormones and show that the acute phase of hypothyroidism is associated with reduced pituitary TSH secretion.	Thyrotropin	190-193	retinoid X receptor alpha	Homo sapiens	42-45
12099701-6	2002	EGF, phorbol esters or TGF-beta1 predominantly increased PAI-1 protein expression in TSH-treated cells.	Thyrotropin	85-88	serpin family E member 1	Homo sapiens	57-62
12108542-0	2002	Thyroid stimulating hormone upregulates secretion of cathepsin B from thyroid epithelial cells.	Thyrotropin	0-27	cathepsin B	Rattus norvegicus	53-64
12193296-6	2002	Cells produce thyroglobulin constitutively and large amounts of thyroglobulin are easily recovered in TSH-supplemented media, especially in the presence of insulin.	Thyrotropin	102-105	insulin	Homo sapiens	156-163
12193296-10	2002	Addition of TSH to hormone-free cultures or to insulin-, insulin plus hydrocortisone-, or 5H-containing cultures resulted in a clear increase in thyroglobulin production.	Thyrotropin	12-15	insulin	Homo sapiens	57-64
12173070-6	2002	TSH induces both cytoplasm-to-nucleus translocation and neosynthesis of APE/Ref-1 protein.	Thyrotropin	0-3	apurinic/apyrimidinic endodeoxyribonuclease 1	Rattus norvegicus	72-75
12173070-6	2002	TSH induces both cytoplasm-to-nucleus translocation and neosynthesis of APE/Ref-1 protein.	Thyrotropin	0-3	apurinic/apyrimidinic endodeoxyribonuclease 1	Rattus norvegicus	76-81
12098670-2	2002	Here it was investigated in freely fed rats whether leptin modulates thyrotroph function in vivo and whether leptin has direct pituitary effects on TSH release.	Thyrotropin	148-151	leptin	Rattus norvegicus	109-115
12098670-3	2002	Since leptin is produced in the pituitary, the possibility was also investigated that leptin may be a local regulator of TSH release.	Thyrotropin	121-124	leptin	Rattus norvegicus	86-92
12098670-5	2002	Freely fed adult rats 2 h after being injected with a single s.c. injection of 8 microg leptin/100 g body weight showed a 2-fold increase in serum TSH (P<0.05).	Thyrotropin	147-150	leptin	Rattus norvegicus	88-94
12098670-6	2002	Hemi-pituitary explants incubated with 10(-9) and 10(-7) M leptin for 2 h showed a reduced TSH release of 40 and 50% respectively (P<0.05).	Thyrotropin	91-94	leptin	Rattus norvegicus	59-65
12098670-8	2002	In conclusion, also in the fed state, leptin has an acute stimulatory effect on TSH release in vivo, acting probably at the hypothalamus.	Thyrotropin	80-83	leptin	Rattus norvegicus	38-44
12098670-9	2002	However, the direct pituitary effect of leptin is inhibitory and data also provide evidence that in the rat pituitary leptin may act as an autocrine/paracrine inhibitor of TSH release.	Thyrotropin	172-175	leptin	Rattus norvegicus	118-124
12034881-7	2002	In cultures of polarized human thyrocytes from normal patients, thyroid-stimulating hormone or forskolin increased, to a similar extent, Rab5a and Rab7 but not Rab8 expression, apical endocytosis of thyroglobulin and lucifer yellow, and basolateral secretion of T(3) and T(4).	Thyrotropin	64-91	RAB5A, member RAS oncogene family	Homo sapiens	137-142
12034881-7	2002	In cultures of polarized human thyrocytes from normal patients, thyroid-stimulating hormone or forskolin increased, to a similar extent, Rab5a and Rab7 but not Rab8 expression, apical endocytosis of thyroglobulin and lucifer yellow, and basolateral secretion of T(3) and T(4).	Thyrotropin	64-91	RAB7B, member RAS oncogene family	Homo sapiens	147-151
12037720-11	2002	In these subjects, serum TSH levels increased significantly in response to the TRH stimulus from basal values of 2.16 +/- 0.3 to a peak of 10.27 +/- 0.55 microIU/mL (P <.001) during PL treatment and from basal values of 2.10 +/- 0.51 to a peak of 7.82 +/- 1.4 microIU/mL (P <.001) during vit A treatment.	Thyrotropin	25-28	thyrotropin releasing hormone	Homo sapiens	79-82
12037720-12	2002	No significant effects of treatment were found in this group of subjects on TRH-induced TSH levels; however, TSH responses were somewhat lower during vit A treatment with a difference close to statistical significance.	Thyrotropin	88-91	thyrotropin releasing hormone	Homo sapiens	76-79
12108542-5	2002	In this study we have analyzed the secretion of cathepsin B by thyroid follicle cells (primary cells as well as FRTL-5 cells) and its regulation by thyroid stimulating hormone, which stimulated the secretory release of the proenzyme as well as of mature cathepsin B.	Thyrotropin	148-175	cathepsin B	Rattus norvegicus	48-59
12108542-5	2002	In this study we have analyzed the secretion of cathepsin B by thyroid follicle cells (primary cells as well as FRTL-5 cells) and its regulation by thyroid stimulating hormone, which stimulated the secretory release of the proenzyme as well as of mature cathepsin B.	Thyrotropin	148-175	cathepsin B	Rattus norvegicus	254-265
12108542-6	2002	Within one to two hours of stimulation with thyroid stimulating hormone, the cathepsin B activity associated with the plasma membrane increased significantly.	Thyrotropin	44-71	cathepsin B	Rattus norvegicus	77-88
12108542-8	2002	These observations indicate that thyroid stimulating hormone induces the secretion of cathepsin B, which contributes to the extracellular release of thyroxine by thyrocytes.	Thyrotropin	33-60	cathepsin B	Rattus norvegicus	86-97
11959997-4	2002	We have now tested the significance of the mitogenic action of Rap1b in a physiologically relevant model, the differentiated thyroid follicular cells, a system that requires thyroid-stimulating hormone (TSH), acting via cAMP, to mediate a full mitogenic response.	Thyrotropin	203-206	RAP1B, member of RAS oncogene family	Homo sapiens	63-68
12010642-7	2002	Moreover, TGFbeta1 decreases basal and TSH-stimulated cAMP production and TSH receptor expression.	Thyrotropin	39-42	transforming growth factor beta 1	Homo sapiens	10-18
11830278-4	2002	We investigated the effect of orexin A injected intracerebroventricularly (ICV) on thyroid-stimulating hormone (TSH) and thyroid hormones in male rats.	Thyrotropin	83-110	hypocretin neuropeptide precursor	Rattus norvegicus	30-38
11932308-6	2002	Because TSH stimulates both normal and neoplastic thyroid cells, we also proposed that serum VEGF would be further increased by TSH stimulation.	Thyrotropin	8-11	vascular endothelial growth factor A	Homo sapiens	93-97
11932308-6	2002	Because TSH stimulates both normal and neoplastic thyroid cells, we also proposed that serum VEGF would be further increased by TSH stimulation.	Thyrotropin	128-131	vascular endothelial growth factor A	Homo sapiens	93-97
11932308-10	2002	Baseline serum VEGF levels obtained at a time of TSH suppression were significantly higher in patients with known metastatic disease than in those with no evidence of disease (416 +/- 62 pg/ml vs. 185 +/- 25 pg/ml, P = 0.001).	Thyrotropin	49-52	vascular endothelial growth factor A	Homo sapiens	15-19
11932277-5	2002	SCH patients showed significantly higher TC (P < 0.01), LDLc (P = 0.01), and apolipoprotein B (P = 0.001) levels than controls, positively correlated with baseline TSH levels (P = 0.003, P = 0.01, and P = 0.03, respectively).	Thyrotropin	167-170	apolipoprotein B	Homo sapiens	80-96
11830278-4	2002	We investigated the effect of orexin A injected intracerebroventricularly (ICV) on thyroid-stimulating hormone (TSH) and thyroid hormones in male rats.	Thyrotropin	112-115	hypocretin neuropeptide precursor	Rattus norvegicus	30-38
11796836-4	2002	By immunohistochemical analysis, GATA-2 was detected in all of the gonadotropin-subunit (Gn-su)-positive adenomas (n = 8) and in four of five thyroid-stimulating hormone (TSH)-secreting adenomas, but its incidence was low in the other types of adenomas.	Thyrotropin	142-169	GATA binding protein 2	Homo sapiens	33-39
11786384-5	2002	The re-addition of TSH or forskolin to the culture medium is able to restore to wild-type levels the expression of both Pax8 and Tg.	Thyrotropin	19-22	paired box 8	Rattus norvegicus	120-124
11786384-5	2002	The re-addition of TSH or forskolin to the culture medium is able to restore to wild-type levels the expression of both Pax8 and Tg.	Thyrotropin	19-22	thyroglobulin	Rattus norvegicus	129-131
11786384-6	2002	We have determined that the action of TSH/forskolin on Pax8 is at the transcriptional level.	Thyrotropin	38-41	paired box 8	Rattus norvegicus	55-59
11786385-6	2002	Whereas the absence of TRalpha alone does not cause resistance to TH, the absence of TRbeta in the presence of TRalpha results in a 205, 169, 544% increase in serum thyroxine (T(4)), triiodothyronine (T(3)) and TSH concentrations respectively.	Thyrotropin	211-214	apoptosis antagonizing transcription factor	Mus musculus	85-91
11786385-6	2002	Whereas the absence of TRalpha alone does not cause resistance to TH, the absence of TRbeta in the presence of TRalpha results in a 205, 169, 544% increase in serum thyroxine (T(4)), triiodothyronine (T(3)) and TSH concentrations respectively.	Thyrotropin	211-214	guanine nucleotide binding protein, alpha transducing 1	Mus musculus	111-118
11818505-0	2002	PI3K is involved in the IGF-I inhibition of TSH-induced sodium/iodide symporter gene expression.	Thyrotropin	44-47	insulin-like growth factor 1	Rattus norvegicus	24-29
11796836-4	2002	By immunohistochemical analysis, GATA-2 was detected in all of the gonadotropin-subunit (Gn-su)-positive adenomas (n = 8) and in four of five thyroid-stimulating hormone (TSH)-secreting adenomas, but its incidence was low in the other types of adenomas.	Thyrotropin	171-174	GATA binding protein 2	Homo sapiens	33-39
11796836-6	2002	By RT-PCR analysis, GATA-2 was detected in all Gn-su-positive adenomas and TSH-secreting adenomas, and Pit-1 was detected in all TSH-secreting adenomas and GH-secreting adenomas.	Thyrotropin	75-78	GATA binding protein 2	Homo sapiens	20-26
11713206-3	2001	Although the mitogenic action of TSH requires the presence of IGF-I or insulin in primary culture of dog and human thyroid cells, IGF-I has an effect equal to and independent of the effect of TSH on cell proliferation in rat thyroid cell lines and may even be the main growth regulator in this case.	Thyrotropin	33-36	insulin like growth factor 1	Canis lupus familiaris	62-67
11713206-3	2001	Although the mitogenic action of TSH requires the presence of IGF-I or insulin in primary culture of dog and human thyroid cells, IGF-I has an effect equal to and independent of the effect of TSH on cell proliferation in rat thyroid cell lines and may even be the main growth regulator in this case.	Thyrotropin	33-36	insulin	Canis lupus familiaris	71-78
11713206-6	2001	A decreased TSH level together with a slightly increased serum T(4) concentration and increased thyroidal iodine uptake were also observed, suggesting that IGF-I and IGF-I receptor stimulate thyroid function to some extent in vivo.	Thyrotropin	12-15	insulin-like growth factor 1	Mus musculus	156-161
11765049-0	2001	Loss of heterozygosity of the MEN1 gene in a large series of TSH-secreting pituitary adenomas.	Thyrotropin	61-64	menin 1	Homo sapiens	30-34
11694378-4	2001	Moreover, changes in morphological characteristics and production of Tg, T3 and T4 induced by addition of thyroid stimulating hormone (TSH) and epidermal growth factor (EGF) to medium in collagen gel culture were determined.	Thyrotropin	106-133	thyroglobulin	Homo sapiens	69-71
11641751-13	2001	Also mean plasma TSH concentrations 20, 30 and 45 min after the TRH injection increased more with overfeeding among UCP2 A55V (P<0.005) and UCP3 Rsa I CC (P=0.017) subjects.	Thyrotropin	17-20	uncoupling protein 2	Homo sapiens	116-120
11641751-13	2001	Also mean plasma TSH concentrations 20, 30 and 45 min after the TRH injection increased more with overfeeding among UCP2 A55V (P<0.005) and UCP3 Rsa I CC (P=0.017) subjects.	Thyrotropin	17-20	uncoupling protein 3	Homo sapiens	143-147
11641751-15	2001	The association of the UCP2 A55V and UCP3 Rsa I CC genotypes with a greater increase in the TSH response to TRH load could reflect a compensatory mechanism counteracting the effects of overfeeding.	Thyrotropin	92-95	uncoupling protein 2	Homo sapiens	23-27
11641751-15	2001	The association of the UCP2 A55V and UCP3 Rsa I CC genotypes with a greater increase in the TSH response to TRH load could reflect a compensatory mechanism counteracting the effects of overfeeding.	Thyrotropin	92-95	uncoupling protein 3	Homo sapiens	37-41
11800284-0	2001	Influence of type II 5" deiodinase on TSH content in diabetic rats.	Thyrotropin	38-41	iodothyronine deiodinase 2	Rattus norvegicus	13-34
11641420-3	2001	Accordingly, TSH, forskolin (FSK) and 8-bromo-cAMP induced a rapid (3 min) and transient activation of ERK1/2, as assessed by phosphorylation of myelin basic protein and ERK1/2.	Thyrotropin	13-16	mitogen activated protein kinase 3	Rattus norvegicus	103-109
11641420-3	2001	Accordingly, TSH, forskolin (FSK) and 8-bromo-cAMP induced a rapid (3 min) and transient activation of ERK1/2, as assessed by phosphorylation of myelin basic protein and ERK1/2.	Thyrotropin	13-16	myelin basic protein	Rattus norvegicus	145-165
11641420-3	2001	Accordingly, TSH, forskolin (FSK) and 8-bromo-cAMP induced a rapid (3 min) and transient activation of ERK1/2, as assessed by phosphorylation of myelin basic protein and ERK1/2.	Thyrotropin	13-16	mitogen activated protein kinase 3	Rattus norvegicus	170-176
11566956-7	2001	As it has been demonstrated that hypertensive patients have a blunted TSH response to TRH injection, suggesting a defect in the TRHR, we postulate that the TRHR gene is involved in human hypertension.	Thyrotropin	70-73	thyrotropin releasing hormone	Homo sapiens	86-89
11566956-7	2001	As it has been demonstrated that hypertensive patients have a blunted TSH response to TRH injection, suggesting a defect in the TRHR, we postulate that the TRHR gene is involved in human hypertension.	Thyrotropin	70-73	thyrotropin releasing hormone receptor	Homo sapiens	156-160
11549661-5	2001	Peak levels of serum hCG and thyroid hormone concentrations were attained at 12 wk gestation, when serum TSH was fully suppressed.	Thyrotropin	105-108	hypertrichosis 2 (generalised, congenital)	Homo sapiens	21-24
11559906-7	2001	The association between TSH and hCG in unaffected pregnancies was also measured.	Thyrotropin	24-27	hypertrichosis 2 (generalised, congenital)	Homo sapiens	32-35
11769664-11	2001	(5) A significant negative correlation between TSH and hCG levels and a significant positive correlation between hCG and FT4 and TT4/TBG were demonstrated.	Thyrotropin	47-50	hypertrichosis 2 (generalised, congenital)	Homo sapiens	55-58
11514051-8	2001	In conclusion, we succeeded in secreting the ectodomain of TSHR into culture medium, which was capable of binding to TSH and neutralizing anti-TSHR antibody activities.	Thyrotropin	59-62	thyroid stimulating hormone receptor	Homo sapiens	143-147
11559906-8	2001	The Spearman correlation coefficient between TSH and hCG was -0.21 which was statistically significant (p=0.02, 95% confidence interval -0.38 to -0.03).	Thyrotropin	45-48	hypertrichosis 2 (generalised, congenital)	Homo sapiens	53-56
11508827-5	2001	Nuclear TTF-1 staining correlated with the effective serum TSH level (p = 0.02) and patient age (p < 0.05).	Thyrotropin	59-62	NK2 homeobox 1	Homo sapiens	8-13
11476896-5	2001	Stimulation for 24 h by TSH, forskolin or dibutyryl cAMP induced an increase in mRNA levels of PDE4B, PDE4D, and PDE4C.	Thyrotropin	24-27	phosphodiesterase 4B	Rattus norvegicus	95-100
11476896-5	2001	Stimulation for 24 h by TSH, forskolin or dibutyryl cAMP induced an increase in mRNA levels of PDE4B, PDE4D, and PDE4C.	Thyrotropin	24-27	phosphodiesterase 4D	Rattus norvegicus	102-107
11476896-5	2001	Stimulation for 24 h by TSH, forskolin or dibutyryl cAMP induced an increase in mRNA levels of PDE4B, PDE4D, and PDE4C.	Thyrotropin	24-27	phosphodiesterase 4C	Rattus norvegicus	113-118
11579684-8	2001	A marked decrease of p27 expression was noted in ACTH-secreting adenomas, 8/20 (40.0%), compared with other types of pituitary adenomas--GH-secreting adenomas, 35/46 (76.1%); PRL-secreting adenomas, 22/33 (66.7%); TSH-secreting adenomas, 8/11 (72.7%); and nonfunctioning adenomas, 55/69 (79.7%).	Thyrotropin	214-217	zinc ribbon domain containing 2	Homo sapiens	21-24
11416052-5	2001	MCH significantly reduces plasma TSH in vivo at 10 min (0.5 +/- 0.07 ng/ml, p < 0.05, n = 8) and 60 min (0.33 +/- 0.04 ng/ml, p < 0.01, n = 10) compared to saline (0.7 +/- 0.07 ng/ml and 0.69 +/- 0.07 ng/ml respectively) when administered intracerebroventricularly.	Thyrotropin	33-36	pro-melanin concentrating hormone	Homo sapiens	0-3
11416052-7	2001	MCH was also shown to significantly reduce TRH stimulated TSH release from dispersed pituitary cell cultures (basal = 0.5 +/- 0.06 ng/ml, 100 nM TRH = 0.9 +/- 0.2 ng/ml, p < 0.05 0.1 nM MCH = 0.5 +/- 0.1 ng/ml, p < 0.05, 1 nM MCH = 0.3 +/- 0.03 ng/ml, p < 0.01, 10 nM MCH = 0.4 +/- 0.02 ng/ml, p < 0.01, 1000 nM MCH = 0.4 +/- 0.05 ng/ml, P < 0.01, n = 4), although basal release of TSH from these cultures was unaffected.	Thyrotropin	58-61	pro-melanin concentrating hormone	Homo sapiens	0-3
11416052-7	2001	MCH was also shown to significantly reduce TRH stimulated TSH release from dispersed pituitary cell cultures (basal = 0.5 +/- 0.06 ng/ml, 100 nM TRH = 0.9 +/- 0.2 ng/ml, p < 0.05 0.1 nM MCH = 0.5 +/- 0.1 ng/ml, p < 0.05, 1 nM MCH = 0.3 +/- 0.03 ng/ml, p < 0.01, 10 nM MCH = 0.4 +/- 0.02 ng/ml, p < 0.01, 1000 nM MCH = 0.4 +/- 0.05 ng/ml, P < 0.01, n = 4), although basal release of TSH from these cultures was unaffected.	Thyrotropin	58-61	thyrotropin releasing hormone	Homo sapiens	43-46
11416052-7	2001	MCH was also shown to significantly reduce TRH stimulated TSH release from dispersed pituitary cell cultures (basal = 0.5 +/- 0.06 ng/ml, 100 nM TRH = 0.9 +/- 0.2 ng/ml, p < 0.05 0.1 nM MCH = 0.5 +/- 0.1 ng/ml, p < 0.05, 1 nM MCH = 0.3 +/- 0.03 ng/ml, p < 0.01, 10 nM MCH = 0.4 +/- 0.02 ng/ml, p < 0.01, 1000 nM MCH = 0.4 +/- 0.05 ng/ml, P < 0.01, n = 4), although basal release of TSH from these cultures was unaffected.	Thyrotropin	397-400	pro-melanin concentrating hormone	Homo sapiens	0-3
11478409-8	2001	In both groups II and III, TRH-induced TSH increments were above the normal range (maximal increment> 15 mU/L) and were significantly higher than in group I.	Thyrotropin	39-42	thyrotropin releasing hormone	Homo sapiens	27-30
11478409-9	2001	After the second treatment with TRH, pretreatment with dex significantly decreased both basal TSH levels and peak TSH responses to TRH in all groups.	Thyrotropin	94-97	thyrotropin releasing hormone	Homo sapiens	32-35
11478409-9	2001	After the second treatment with TRH, pretreatment with dex significantly decreased both basal TSH levels and peak TSH responses to TRH in all groups.	Thyrotropin	114-117	thyrotropin releasing hormone	Homo sapiens	32-35
11478409-9	2001	After the second treatment with TRH, pretreatment with dex significantly decreased both basal TSH levels and peak TSH responses to TRH in all groups.	Thyrotropin	114-117	thyrotropin releasing hormone	Homo sapiens	131-134
11478409-11	2001	CONCLUSIONS: The sensitivity of the TSH secretory system to glucocorticoid inhibitory action is preserved in obese subjects with abnormally elevated TSH response to TRH, but not in subclinically hypothyroid obese patients.	Thyrotropin	36-39	thyrotropin releasing hormone	Homo sapiens	165-168
11478409-11	2001	CONCLUSIONS: The sensitivity of the TSH secretory system to glucocorticoid inhibitory action is preserved in obese subjects with abnormally elevated TSH response to TRH, but not in subclinically hypothyroid obese patients.	Thyrotropin	149-152	thyrotropin releasing hormone	Homo sapiens	165-168
11313862-3	2001	Recent evidence indicates that p21 Ras is required for TSH-induced mitogenesis, but the molecular mechanism(s) is not known.	Thyrotropin	55-58	H3 histone pseudogene 16	Homo sapiens	31-34
11290744-8	2001	Here we show that TSH induces de novo NIS biosynthesis and modulates the long NIS half-life ( approximately 5 days).	Thyrotropin	18-21	solute carrier family 5 member 5	Homo sapiens	38-41
11290744-8	2001	Here we show that TSH induces de novo NIS biosynthesis and modulates the long NIS half-life ( approximately 5 days).	Thyrotropin	18-21	solute carrier family 5 member 5	Homo sapiens	78-81
11290744-9	2001	In addition, we demonstrate that TSH is required for NIS targeting to or retention in the plasma membrane.	Thyrotropin	33-36	solute carrier family 5 member 5	Homo sapiens	53-56
11397875-10	2001	In conclusion, we have demonstrated the expression of Tie-2 and Ang-1 in thyroid epithelial and endothelial cells, and have shown the regulation of Tie-2 by TSH and cAMP in follicular cells.	Thyrotropin	157-160	TEK receptor tyrosine kinase	Homo sapiens	148-153
11237861-4	2001	In contrast, two distinct protein-DNA complexes were activated in the presence of TSH: the faster-migrating complex contained only p50 subunit; the slower-migrating complex consisted of p65-p50 heterodimer.	Thyrotropin	82-85	synaptotagmin 1	Rattus norvegicus	186-189
11237861-8	2001	Although the expression of the p105 gene, another known target for NF-kappaB, was increased by TNF-alpha in the absence of TSH, the presence of TSH further increased the mRNA level.	Thyrotropin	123-126	nucleoporin 107	Rattus norvegicus	31-35
11237861-8	2001	Although the expression of the p105 gene, another known target for NF-kappaB, was increased by TNF-alpha in the absence of TSH, the presence of TSH further increased the mRNA level.	Thyrotropin	144-147	nucleoporin 107	Rattus norvegicus	31-35
11237861-9	2001	Taken together, these observations indicate that the presence of TSH is crucial for the NF-kappaB-mediated actions of TNF-alpha on thyroid follicular cells.	Thyrotropin	65-68	tumor necrosis factor	Rattus norvegicus	118-127
11292067-1	2001	We had previously shown that GRP acts directly at the pituitary gland inhibiting basal and TRH-stimulated TSH secretion in adult male rats.	Thyrotropin	106-109	gastrin releasing peptide	Rattus norvegicus	29-32
11292067-3	2001	In both female and male young adult animals, GRP-incubated pituitaries showed approximately 50% less basal and TRH-stimulated TSH secretion to the medium, without affecting the pituitary content of TSH.	Thyrotropin	126-129	gastrin releasing peptide	Rattus norvegicus	45-48
11292067-5	2001	Our data suggest a loss of thyrotrope responsiveness to GRP in aged male rats that could contribute to the decrease in TSH pituitary stores leading to lower basal and TRH-stimulated TSH secretion.	Thyrotropin	119-122	gastrin releasing peptide	Rattus norvegicus	56-59
11484895-14	2001	The increase of TSH suggests a central stimulation directed by the action of IL-2 as the major mechanism.	Thyrotropin	16-19	interleukin 2	Homo sapiens	77-81
11422113-12	2001	In vitro leptin stimulation of pituitary tumours caused stimulation of FSH and alpha-subunit secretion from a non-functioning adenoma and TSH secretion from a somatotroph adenoma.	Thyrotropin	138-141	leptin	Homo sapiens	9-15
11374913-2	2001	However, little is known about the Ames dwarf mouse, which has a Prop-1 gene mutation resulting in deficiencies in growth hormone, thyroid-stimulating hormone, and prolactin.	Thyrotropin	131-158	paired like homeodomain factor 1	Mus musculus	65-71
11442000-0	2001	Thyroid stimulating hormone downregulates vascular endothelial growth factor expression in FRTL-5 cells.	Thyrotropin	0-27	vascular endothelial growth factor A	Rattus norvegicus	42-76
11442000-1	2001	We studied the regulation of the expression of vascular endothelial growth factor (VEGF) by TSH in monolayer cultures of rat thyroid FRTL-5 cell lines.	Thyrotropin	92-95	vascular endothelial growth factor A	Rattus norvegicus	47-81
11442000-1	2001	We studied the regulation of the expression of vascular endothelial growth factor (VEGF) by TSH in monolayer cultures of rat thyroid FRTL-5 cell lines.	Thyrotropin	92-95	vascular endothelial growth factor A	Rattus norvegicus	83-87
11442000-4	2001	Our results suggest that the direct effect of TSH/cAMP is to inhibit the VEGF synthesis in monolayer cells.	Thyrotropin	46-49	vascular endothelial growth factor A	Rattus norvegicus	73-77
11517924-5	2001	We propose that thyroid stimulating hormone regulates extracellular proteolysis of thyroglobulin in that it enhances the rate of exocytosis of lysosomal proteins at the apical plasma membrane.	Thyrotropin	16-43	thyroglobulin	Homo sapiens	83-96
11250652-6	2001	per day) recovered liver mRNA expression of IGF-I and ensured euthyroid status as shown by the normalized levels of plasma TSH.	Thyrotropin	123-126	insulin-like growth factor 1	Rattus norvegicus	44-49
11241164-7	2001	It is possible that the mechanism of PIPKIIgamma gene expression is involved in the permissive effect of the TSH-cAMP cascade proper.	Thyrotropin	109-112	phosphatidylinositol-5-phosphate 4-kinase type 2 beta	Rattus norvegicus	37-48
11313862-5	2001	We show that PI3K inhibitors block TSH-induced DNA synthesis, cAMP-PKA stimulate the formation of the complex PI3K-p21 Ras and reduce the complex Ras-Raf1 in thyroid and other cells types.	Thyrotropin	35-38	HRas proto-oncogene, GTPase	Homo sapiens	115-122
11313862-5	2001	We show that PI3K inhibitors block TSH-induced DNA synthesis, cAMP-PKA stimulate the formation of the complex PI3K-p21 Ras and reduce the complex Ras-Raf1 in thyroid and other cells types.	Thyrotropin	35-38	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	150-154
11181535-7	2001	Type II iodothyronine deiodinase mRNA, its activity, and uncoupling protein-1 mRNA in cultured rat brown adipocytes were significantly increased by incubation with TSH in a dose-dependent manner.	Thyrotropin	164-167	iodothyronine deiodinase 2	Rattus norvegicus	0-32
11171111-9	2001	In conclusion, the results show that inhibition of complex-type structure formation leads to (i) an incapacity for TSHR to bind TSH, without affecting its intracellular transport and (ii) an increase of TSHR susceptibility to proteases that remove the C peptide.	Thyrotropin	115-118	thyroid stimulating hormone receptor	Homo sapiens	203-207
11181535-7	2001	Type II iodothyronine deiodinase mRNA, its activity, and uncoupling protein-1 mRNA in cultured rat brown adipocytes were significantly increased by incubation with TSH in a dose-dependent manner.	Thyrotropin	164-167	uncoupling protein 1	Rattus norvegicus	57-77
11181542-1	2001	The stimulation of thyroid cell proliferation by TSH through cAMP depends on permissive comitogenic factors, generally the insulin-like growth factors and insulin.	Thyrotropin	49-52	insulin	Canis lupus familiaris	123-130
11181542-1	2001	The stimulation of thyroid cell proliferation by TSH through cAMP depends on permissive comitogenic factors, generally the insulin-like growth factors and insulin.	Thyrotropin	49-52	insulin	Canis lupus familiaris	155-162
11145590-6	2001	When the nuclear extracts prepared from TGF-beta1-treated FRTL-5 cells were used in gel mobility shift assays, the amount of protein-DNA complex formed by Pax-8 was reduced, both in the presence and in the absence of TSH, but protein-DNA complexes formed by thyroid transcription factor-1 (TTF-1) and TTF-2 were not.	Thyrotropin	217-220	transforming growth factor, beta 1	Rattus norvegicus	40-49
11238928-12	2001	The ability of TSH to phosphorylate Akt was impaired in cells expressing a Rap1A mutant that could be activated but not phosphorylated.	Thyrotropin	15-18	AKT serine/threonine kinase 1	Rattus norvegicus	36-39
11238928-12	2001	The ability of TSH to phosphorylate Akt was impaired in cells expressing a Rap1A mutant that could be activated but not phosphorylated.	Thyrotropin	15-18	RAP1A, member of RAS oncogene family	Rattus norvegicus	75-80
11238928-15	2001	TSH effects on thyroid-specific gene expression, but not its effects on proliferation, were markedly enhanced in cells expressing activated Rap1A and repressed in cells expressing a dominant-negative Rap1A mutant.	Thyrotropin	0-3	RAP1A, member of RAS oncogene family	Rattus norvegicus	140-145
11238928-15	2001	TSH effects on thyroid-specific gene expression, but not its effects on proliferation, were markedly enhanced in cells expressing activated Rap1A and repressed in cells expressing a dominant-negative Rap1A mutant.	Thyrotropin	0-3	RAP1A, member of RAS oncogene family	Rattus norvegicus	200-205
11437473-6	2001	On day 1 only, a statistically significant increase in AUC (0--5 h) was found for prolactin at 1.71 and 6.86 mg/kg (P< 0.05), for thyroid-stimulating hormone (TSH) at 3.0 mg/kg (P< 0.01) and for adrenocorticotrophic hormone (ACTH) at 4.5 mg/kg (P< 0.05); however, no dose--response relationship was observed for TSH or ACTH.	Thyrotropin	162-165	proopiomelanocortin	Homo sapiens	231-235
11437473-6	2001	On day 1 only, a statistically significant increase in AUC (0--5 h) was found for prolactin at 1.71 and 6.86 mg/kg (P< 0.05), for thyroid-stimulating hormone (TSH) at 3.0 mg/kg (P< 0.01) and for adrenocorticotrophic hormone (ACTH) at 4.5 mg/kg (P< 0.05); however, no dose--response relationship was observed for TSH or ACTH.	Thyrotropin	162-165	proopiomelanocortin	Homo sapiens	328-332
11158019-5	2001	Two hundred and eighty-nine patients were examined by both DxWBS and by measurement of the serum thyroglobulin (Tg) response to elevated TSH levels.	Thyrotropin	137-140	thyroglobulin	Homo sapiens	97-110
11158019-5	2001	Two hundred and eighty-nine patients were examined by both DxWBS and by measurement of the serum thyroglobulin (Tg) response to elevated TSH levels.	Thyrotropin	137-140	thyroglobulin	Homo sapiens	112-114
11288978-3	2001	TSH dose-dependently increased T3 and Tg but not IL-6 levels in the conditioned medium.	Thyrotropin	0-3	thyroglobulin	Homo sapiens	38-40
11275680-6	2001	Incubation with NF-H antibodies produced a significant inhibition of calcium-induced TSH release in digitonin-permeabilized adenohypophysial cells.	Thyrotropin	85-88	neurofilament heavy chain	Rattus norvegicus	16-20
11145590-6	2001	When the nuclear extracts prepared from TGF-beta1-treated FRTL-5 cells were used in gel mobility shift assays, the amount of protein-DNA complex formed by Pax-8 was reduced, both in the presence and in the absence of TSH, but protein-DNA complexes formed by thyroid transcription factor-1 (TTF-1) and TTF-2 were not.	Thyrotropin	217-220	paired box 8	Rattus norvegicus	155-160
11824507-10	2001	In vitro leptin stimulation of pituitary tumors caused stimulation of FSH and a-subunit secretion from a non-functioning adenoma and TSH secretion from a somatotroph adenoma.	Thyrotropin	133-136	leptin	Homo sapiens	9-15
11179600-7	2001	Topical application of TRH and M-TRH induced an increase in TSH serum concentration from 0.32 +/- 0.09 ng/ml to 32.6 +/- 5.0 and 22.9 +/- 7.6 ng/ml, respectively, after 30 min.	Thyrotropin	60-63	thyrotropin releasing hormone	Rattus norvegicus	23-26
11179600-7	2001	Topical application of TRH and M-TRH induced an increase in TSH serum concentration from 0.32 +/- 0.09 ng/ml to 32.6 +/- 5.0 and 22.9 +/- 7.6 ng/ml, respectively, after 30 min.	Thyrotropin	60-63	thyrotropin releasing hormone	Rattus norvegicus	33-36
11179600-8	2001	The addition of terpene and ethanol in combination with TRH or M-TRH, increased the TSH release to 43.0 +/- 3.8 and 48.4 +/- 4.0 ng/ml, respectively.	Thyrotropin	84-87	thyrotropin releasing hormone	Rattus norvegicus	56-59
11179600-8	2001	The addition of terpene and ethanol in combination with TRH or M-TRH, increased the TSH release to 43.0 +/- 3.8 and 48.4 +/- 4.0 ng/ml, respectively.	Thyrotropin	84-87	thyrotropin releasing hormone	Rattus norvegicus	65-68
11215682-6	2001	We have also shown that those microsomal enzyme inducers that increase serum TSH increase T3 UDP-glucuronosyltransferase (UGT) activity, whereas those microsomal enzyme inducers that do not increase serum TSH do not increase T3 UGT activity.	Thyrotropin	77-80	UDP glycosyltransferase 2 family, polypeptide B	Rattus norvegicus	93-120
11215682-6	2001	We have also shown that those microsomal enzyme inducers that increase serum TSH increase T3 UDP-glucuronosyltransferase (UGT) activity, whereas those microsomal enzyme inducers that do not increase serum TSH do not increase T3 UGT activity.	Thyrotropin	77-80	UDP glycosyltransferase 2 family, polypeptide B	Rattus norvegicus	122-125
11272097-2	2001	Studies in vivo and with cultured thyroid cells have provided evidence that megalin expression on thyroid cells is TSH-dependent.	Thyrotropin	115-118	LDL receptor related protein 2	Homo sapiens	76-83
11006268-0	2000	Thyroid-stimulating hormone and cyclic AMP activate p38 mitogen-activated protein kinase cascade.	Thyrotropin	0-27	mitogen activated protein kinase 14	Rattus norvegicus	52-55
12182045-0	2001	[Prospective analysis of criteria for interpreting measurements of thyroglobulin serum concentration during conditions of endogenous TSH stimulation in serum of patients with differentiated thyroid carcinoma].	Thyrotropin	133-136	thyroglobulin	Homo sapiens	67-80
12182045-1	2001	The aim of this study was the assessment of diagnostic value of thyroglobulin serum measurement in patients with DTC during endogenous TSH stimulation.	Thyrotropin	135-138	thyroglobulin	Homo sapiens	64-77
11006268-3	2000	We show here that p38-MAPKs are activated upon stimulation by thyroid-stimulating hormone (TSH) or cAMP.	Thyrotropin	62-89	mitogen activated protein kinase 14	Rattus norvegicus	18-21
11006268-3	2000	We show here that p38-MAPKs are activated upon stimulation by thyroid-stimulating hormone (TSH) or cAMP.	Thyrotropin	91-94	mitogen activated protein kinase 14	Rattus norvegicus	18-21
11006268-4	2000	TSH caused the phosphorylation of p38-MAPK in Chinese hamster ovary cells stably transfected with the human TSH receptor but not in wild-type Chinese hamster ovary cells.	Thyrotropin	0-3	mitogen activated protein kinase 14	Rattus norvegicus	34-37
11006268-4	2000	TSH caused the phosphorylation of p38-MAPK in Chinese hamster ovary cells stably transfected with the human TSH receptor but not in wild-type Chinese hamster ovary cells.	Thyrotropin	0-3	thyroid stimulating hormone receptor	Homo sapiens	108-120
11006268-8	2000	TSH and forskolin stimulated the activity of the alpha-isoform of p38-MAPK assayed by phosphorylation of the transcription factor ATF2.	Thyrotropin	0-3	mitogen activated protein kinase 14	Rattus norvegicus	66-69
11006268-8	2000	TSH and forskolin stimulated the activity of the alpha-isoform of p38-MAPK assayed by phosphorylation of the transcription factor ATF2.	Thyrotropin	0-3	activating transcription factor 2	Rattus norvegicus	130-134
11006268-13	2000	Diphenylene iodonium, a potent inhibitor of NADPH oxidase(s), and ascorbic acid, an effective free radical scavenger, suppressed TSH- or forskolin-stimulated p38-MAPK phosphorylation, indicating that the generation of reactive oxygen species plays a key role in signaling from cAMP to p38-MAPKs.	Thyrotropin	129-132	mitogen activated protein kinase 14	Rattus norvegicus	158-161
11006268-13	2000	Diphenylene iodonium, a potent inhibitor of NADPH oxidase(s), and ascorbic acid, an effective free radical scavenger, suppressed TSH- or forskolin-stimulated p38-MAPK phosphorylation, indicating that the generation of reactive oxygen species plays a key role in signaling from cAMP to p38-MAPKs.	Thyrotropin	129-132	mitogen activated protein kinase 14	Rattus norvegicus	285-294
11006268-14	2000	Inhibition of the p38-MAPK pathway with SB203580 partially but significantly, attenuates cAMP- and TSH-induced expression of the sodium iodide symporter in FRTL-5 cells.	Thyrotropin	99-102	mitogen activated protein kinase 14	Rattus norvegicus	18-21
11112439-0	2000	TSH induces insulin receptors that mediate insulin costimulation of growth in normal human thyroid cells.	Thyrotropin	0-3	insulin	Homo sapiens	12-19
11112439-0	2000	TSH induces insulin receptors that mediate insulin costimulation of growth in normal human thyroid cells.	Thyrotropin	0-3	insulin	Homo sapiens	43-50
11112439-2	2000	Contrary to general assumption, we show here that very low concentrations of insulin, acting through insulin receptors but not IGF-I receptors, can also support the stimulation of DNA synthesis by TSH in primary cultures of normal human thyrocytes.	Thyrotropin	197-200	insulin	Homo sapiens	77-84
11112439-2	2000	Contrary to general assumption, we show here that very low concentrations of insulin, acting through insulin receptors but not IGF-I receptors, can also support the stimulation of DNA synthesis by TSH in primary cultures of normal human thyrocytes.	Thyrotropin	197-200	insulin	Homo sapiens	101-108
11112439-4	2000	These observations provide the first in vitro evidence in normal human thyroid cells of a functional interaction between TSH and insulin acting through its own receptor.	Thyrotropin	121-124	insulin	Homo sapiens	129-136
11201849-9	2000	Four of the mAbs inhibited 125I-labeled TSH binding to solubilized full-length TSHR.	Thyrotropin	40-43	thyroid stimulating hormone receptor	Homo sapiens	79-83
11122302-2	2000	We have investigated the role of TSH in the expression of FGF-2, FGFR-1 and Tie-2 in FRTL-5 cells, which are a functional rat thyroid cell line.	Thyrotropin	33-36	fibroblast growth factor 2	Rattus norvegicus	58-63
11122302-2	2000	We have investigated the role of TSH in the expression of FGF-2, FGFR-1 and Tie-2 in FRTL-5 cells, which are a functional rat thyroid cell line.	Thyrotropin	33-36	Fibroblast growth factor receptor 1	Rattus norvegicus	65-71
11122302-2	2000	We have investigated the role of TSH in the expression of FGF-2, FGFR-1 and Tie-2 in FRTL-5 cells, which are a functional rat thyroid cell line.	Thyrotropin	33-36	TEK receptor tyrosine kinase	Rattus norvegicus	76-81
11122302-6	2000	A dominant fragment of its receptor (FGFR-1) at >> 57 kDa was dose-dependently increased by TSH.	Thyrotropin	98-101	Fibroblast growth factor receptor 1	Rattus norvegicus	37-43
11122302-9	2000	CONCLUSION: Both FGF-2 and its receptor, as well as Tie-2 are increased in rat thyroid cells by elevated TSH.	Thyrotropin	105-108	fibroblast growth factor 2	Rattus norvegicus	17-22
11122302-9	2000	CONCLUSION: Both FGF-2 and its receptor, as well as Tie-2 are increased in rat thyroid cells by elevated TSH.	Thyrotropin	105-108	TEK receptor tyrosine kinase	Rattus norvegicus	52-57
11201849-11	2000	These results together with previous studies on the direct binding of TSH to the TSHR A subunit suggest that at least two distinct regions of the TSHR sequence, including one region on the A subunit and one region on the B subunit, fold together to form part of a complex TSH binding site.	Thyrotropin	70-73	thyrotropin receptor	Cricetulus griseus	81-85
11201849-11	2000	These results together with previous studies on the direct binding of TSH to the TSHR A subunit suggest that at least two distinct regions of the TSHR sequence, including one region on the A subunit and one region on the B subunit, fold together to form part of a complex TSH binding site.	Thyrotropin	70-73	thyroid stimulating hormone receptor	Homo sapiens	146-150
11095478-1	2000	TSH secretion from the anterior pituitary is mainly regulated by TRH and thyroid hormones.	Thyrotropin	0-3	thyrotropin releasing hormone	Homo sapiens	65-68
11084395-10	2000	By contrast, mice TRalpha(-/-) exhibited thyroid gland atrophy along with decreased thyroid hormones and TSH levels.	Thyrotropin	105-108	guanine nucleotide binding protein, alpha transducing 1	Mus musculus	18-25
11084395-13	2000	Finally, transgenic overexpression of a mutant TRB gene reproduced the dominant form of RTH and confirmed the major role of dominant negative activity in the occurrence of some phenotypic key-features such as high circulating hormone levels despite high TSH levels, hyperactivity and lack of severe hearing loss.	Thyrotropin	254-257	apoptosis antagonizing transcription factor	Mus musculus	47-50
11089547-4	2000	Two hours after insulin treatment, TSH or cAMP analog (Bu)2cAMP stimulation, glucose transport was increased and most of the intracellular Glut-1 pool was translocated to plasma membranes.	Thyrotropin	35-38	solute carrier family 2 member 1	Rattus norvegicus	139-145
11089547-5	2000	Wortmannin or LY294002 blocked the insulin, (Bu)2cAMP, and the TSH-induced translocation of Glut-1.	Thyrotropin	63-66	solute carrier family 2 member 1	Rattus norvegicus	92-98
11041314-9	2000	Baseline TSH levels were significantly lower after acute hydrocortisone compared with placebo, suggesting an increase in somatostatin levels.	Thyrotropin	9-12	somatostatin	Homo sapiens	121-133
10965874-7	2000	Additional dose-response studies in hypercholesteremic rats confirmed the preferential effect of GC-1 on TRbeta-mediated parameters by showing a much higher potency to influence cholesterol and TSH than heart rate.	Thyrotropin	194-197	solute carrier family 25 member 22	Rattus norvegicus	97-101
11041451-2	2000	We show that p42/p44 MAPK phosphorylation was induced by both TSH preparations at similar levels in CHO-hTSHR cells and in wild-type CHO cells.	Thyrotropin	62-65	cyclin dependent kinase 20	Homo sapiens	13-16
11041451-2	2000	We show that p42/p44 MAPK phosphorylation was induced by both TSH preparations at similar levels in CHO-hTSHR cells and in wild-type CHO cells.	Thyrotropin	62-65	interferon induced protein 44	Homo sapiens	17-20
11024561-7	2000	Administration of leptin to food-deprived euthyroid rats led to a reversal of the inhibitory effect exerted by fasting on spontaneous TSH secretion.	Thyrotropin	134-137	leptin	Rattus norvegicus	18-24
11000525-12	2000	To establish the dependence of PLD-1 on small molecular weight G-proteins, the translocations of ARF and RhoA to the membrane fractions was determined after stimulation by TSH.	Thyrotropin	172-175	ras homolog family member A	Rattus norvegicus	105-109
11000525-13	2000	Both ARF and RhoA were maximally translocated to the membrane fraction after 10 min incubation with 100 microU/ml TSH by approximately 1.7- and 2.3-fold over control values, respectively (P<0.02 and P<0.03, ANOVA).	Thyrotropin	114-117	ras homolog family member A	Rattus norvegicus	13-17
10996429-1	2000	In this study the regulation of GH-receptor gene (GHR/GHBP) transcription by different concentrations of GH (0, 12.5, 25, 50, 150, 500 ng/ml) with and without variable TSH concentrations (0.5, 2, 20 mU/l) in primary human thyroid cells cultured in serum-free hormonally-defined medium was studied.	Thyrotropin	168-171	growth hormone receptor	Homo sapiens	32-43
10996429-1	2000	In this study the regulation of GH-receptor gene (GHR/GHBP) transcription by different concentrations of GH (0, 12.5, 25, 50, 150, 500 ng/ml) with and without variable TSH concentrations (0.5, 2, 20 mU/l) in primary human thyroid cells cultured in serum-free hormonally-defined medium was studied.	Thyrotropin	168-171	growth hormone receptor	Homo sapiens	50-53
10830295-10	2000	In conclusion, we have identified a novel mechanism in which TSH modulates the IFNgamma-mediated Jak/STAT signaling pathway through the inhibition of Jak1 and STAT1.	Thyrotropin	61-64	signal transducer and activator of transcription 1	Rattus norvegicus	159-164
11075731-7	2000	Serum TSH decreased not only after administration of CRH, octreotide, or L-DOPA, but also after administration of LH-RH.	Thyrotropin	6-9	corticotropin releasing hormone	Homo sapiens	53-56
11075731-7	2000	Serum TSH decreased not only after administration of CRH, octreotide, or L-DOPA, but also after administration of LH-RH.	Thyrotropin	6-9	gonadotropin releasing hormone 1	Homo sapiens	114-119
10940722-5	2000	Furthermore, human kidney cells responded to TSH with a 2.5- fold increase in intracellular cyclic adenosine monophosphate, suggesting the presence of functional TSHR protein.	Thyrotropin	45-48	thyroid stimulating hormone receptor	Homo sapiens	162-166
10854851-2	2000	Although ERp29 mRNA was constantly expressed, its expression began to increase remarkably from 10(-9) M TSH.	Thyrotropin	104-107	endoplasmic reticulum protein 29	Rattus norvegicus	9-14
10854851-3	2000	On the other hand, the effect of TSH on the abundance of ERp29 mRNA started within 6 h and peaked at 8 h. Actinomycin D strongly blocked this effect while cycloheximide did not.	Thyrotropin	33-36	endoplasmic reticulum protein 29	Rattus norvegicus	57-62
10854851-4	2000	The half-life of ERp29 mRNA was about 4-4.5 h in the presence or absence of TSH that was not affected by the stability of ERp29 mRNA.	Thyrotropin	76-79	endoplasmic reticulum protein 29	Rattus norvegicus	17-22
10848877-6	2000	RESULTS: The TSH response to TRH stimulation correlated directly with basal plasma TSH but not basal plasma total T4.	Thyrotropin	13-16	thyrotropin releasing hormone	Homo sapiens	29-32
10830295-9	2000	Furthermore, our results showed that the inhibitory effect of TSH on IFNgamma signaling is caused by inhibition of tyrosine phosphorylation on STAT1, Janus kinase-1 (Jak1), and IFNgamma receptor a, but not Jak2.	Thyrotropin	62-65	interferon gamma	Rattus norvegicus	69-77
10830295-9	2000	Furthermore, our results showed that the inhibitory effect of TSH on IFNgamma signaling is caused by inhibition of tyrosine phosphorylation on STAT1, Janus kinase-1 (Jak1), and IFNgamma receptor a, but not Jak2.	Thyrotropin	62-65	signal transducer and activator of transcription 1	Rattus norvegicus	143-148
10830295-9	2000	Furthermore, our results showed that the inhibitory effect of TSH on IFNgamma signaling is caused by inhibition of tyrosine phosphorylation on STAT1, Janus kinase-1 (Jak1), and IFNgamma receptor a, but not Jak2.	Thyrotropin	62-65	Janus kinase 1	Rattus norvegicus	150-164
10830295-9	2000	Furthermore, our results showed that the inhibitory effect of TSH on IFNgamma signaling is caused by inhibition of tyrosine phosphorylation on STAT1, Janus kinase-1 (Jak1), and IFNgamma receptor a, but not Jak2.	Thyrotropin	62-65	Janus kinase 1	Rattus norvegicus	166-170
10830295-9	2000	Furthermore, our results showed that the inhibitory effect of TSH on IFNgamma signaling is caused by inhibition of tyrosine phosphorylation on STAT1, Janus kinase-1 (Jak1), and IFNgamma receptor a, but not Jak2.	Thyrotropin	62-65	interferon gamma	Rattus norvegicus	177-185
10830295-9	2000	Furthermore, our results showed that the inhibitory effect of TSH on IFNgamma signaling is caused by inhibition of tyrosine phosphorylation on STAT1, Janus kinase-1 (Jak1), and IFNgamma receptor a, but not Jak2.	Thyrotropin	62-65	Janus kinase 2	Rattus norvegicus	206-210
10830295-10	2000	In conclusion, we have identified a novel mechanism in which TSH modulates the IFNgamma-mediated Jak/STAT signaling pathway through the inhibition of Jak1 and STAT1.	Thyrotropin	61-64	interferon gamma	Rattus norvegicus	79-87
10830295-10	2000	In conclusion, we have identified a novel mechanism in which TSH modulates the IFNgamma-mediated Jak/STAT signaling pathway through the inhibition of Jak1 and STAT1.	Thyrotropin	61-64	signal transducer and activator of transcription 1	Rattus norvegicus	101-105
10875243-1	2000	In previous studies, we showed that pretreatment of rat FRTL-5 thyroid cells with TSH, or other agents that increased intracellular cAMP, markedly potentiated DNA synthesis in response to insulin-like growth factor-I (IGF-I).	Thyrotropin	82-85	insulin-like growth factor 1	Rattus norvegicus	188-216
10875243-1	2000	In previous studies, we showed that pretreatment of rat FRTL-5 thyroid cells with TSH, or other agents that increased intracellular cAMP, markedly potentiated DNA synthesis in response to insulin-like growth factor-I (IGF-I).	Thyrotropin	82-85	insulin-like growth factor 1	Rattus norvegicus	218-223
10875243-2	2000	In addition, we found that TSH pretreatment caused an increase in tyrosine phosphorylation of intracellular proteins including an unidentified 125-kDa protein that was well correlated with the TSH-potentiating effect on DNA synthesis induced by IGF-I.	Thyrotropin	27-30	insulin-like growth factor 1	Rattus norvegicus	245-250
10875243-2	2000	In addition, we found that TSH pretreatment caused an increase in tyrosine phosphorylation of intracellular proteins including an unidentified 125-kDa protein that was well correlated with the TSH-potentiating effect on DNA synthesis induced by IGF-I.	Thyrotropin	193-196	insulin-like growth factor 1	Rattus norvegicus	245-250
10849441-7	2000	Overexpression of Prx I and Prx II enhances the elimination of H(2)O(2) produced by TSH in FRTL-5 cells.	Thyrotropin	84-87	periaxin	Rattus norvegicus	18-21
10849441-7	2000	Overexpression of Prx I and Prx II enhances the elimination of H(2)O(2) produced by TSH in FRTL-5 cells.	Thyrotropin	84-87	periaxin	Rattus norvegicus	28-31
10816429-9	2000	In contrast, phosphatidylinositol 3-kinase (PI 3-kinase) and protein kinase B (PKB) activation by insulin and HGF is strong and sustained, whereas it is weak and transient with EGF and absent in the presence of TSH or PMA.	Thyrotropin	211-214	AKT serine/threonine kinase 2	Canis lupus familiaris	61-77
10816429-9	2000	In contrast, phosphatidylinositol 3-kinase (PI 3-kinase) and protein kinase B (PKB) activation by insulin and HGF is strong and sustained, whereas it is weak and transient with EGF and absent in the presence of TSH or PMA.	Thyrotropin	211-214	AKT serine/threonine kinase 2	Canis lupus familiaris	79-82
10816429-9	2000	In contrast, phosphatidylinositol 3-kinase (PI 3-kinase) and protein kinase B (PKB) activation by insulin and HGF is strong and sustained, whereas it is weak and transient with EGF and absent in the presence of TSH or PMA.	Thyrotropin	211-214	insulin	Canis lupus familiaris	98-105
10816429-9	2000	In contrast, phosphatidylinositol 3-kinase (PI 3-kinase) and protein kinase B (PKB) activation by insulin and HGF is strong and sustained, whereas it is weak and transient with EGF and absent in the presence of TSH or PMA.	Thyrotropin	211-214	hepatocyte growth factor	Canis lupus familiaris	110-113
28796353-6	2000	RESULTS: The TSH response to TRH stimulation correlated directly with basal plasma TSH but not basal plasma total T4.	Thyrotropin	13-16	thyrotropin releasing hormone	Homo sapiens	29-32
10830295-10	2000	In conclusion, we have identified a novel mechanism in which TSH modulates the IFNgamma-mediated Jak/STAT signaling pathway through the inhibition of Jak1 and STAT1.	Thyrotropin	61-64	Janus kinase 1	Rattus norvegicus	150-154
10809230-3	2000	We show here that TSH induces the phosphorylation of tyrosine in the intracellular kinases Janus kinase 1 (JAK1) and -2 (JAK2) in rat thyroid cells and in Chinese hamster ovary (CHO) cells transfected with human TSH receptor (TSHR).	Thyrotropin	18-21	Janus kinase 1	Rattus norvegicus	91-119
10881589-9	2000	In the older children group, serum leptin concentrations significantly correlated with T4 (r = 0.510, P < 0.05) and BMI (n = 16, r = 0.647, P < 0.01), but not with TSH or FT4.	Thyrotropin	170-173	leptin	Homo sapiens	35-41
10809788-7	2000	Thus, PKA is responsible for the TSH-induction of 3-hydroxy-3-methylglutaryl-CoA reductase mRNA levels, RhoA activation, and down-regulation of p27(kip1).	Thyrotropin	33-36	ras homolog family member A	Rattus norvegicus	104-108
10809788-7	2000	Thus, PKA is responsible for the TSH-induction of 3-hydroxy-3-methylglutaryl-CoA reductase mRNA levels, RhoA activation, and down-regulation of p27(kip1).	Thyrotropin	33-36	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	144-147
10809788-7	2000	Thus, PKA is responsible for the TSH-induction of 3-hydroxy-3-methylglutaryl-CoA reductase mRNA levels, RhoA activation, and down-regulation of p27(kip1).	Thyrotropin	33-36	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	148-152
10809230-3	2000	We show here that TSH induces the phosphorylation of tyrosine in the intracellular kinases Janus kinase 1 (JAK1) and -2 (JAK2) in rat thyroid cells and in Chinese hamster ovary (CHO) cells transfected with human TSH receptor (TSHR).	Thyrotropin	18-21	Janus kinase 2	Rattus norvegicus	121-125
10809230-3	2000	We show here that TSH induces the phosphorylation of tyrosine in the intracellular kinases Janus kinase 1 (JAK1) and -2 (JAK2) in rat thyroid cells and in Chinese hamster ovary (CHO) cells transfected with human TSH receptor (TSHR).	Thyrotropin	18-21	thyroid stimulating hormone receptor	Homo sapiens	212-224
10809230-3	2000	We show here that TSH induces the phosphorylation of tyrosine in the intracellular kinases Janus kinase 1 (JAK1) and -2 (JAK2) in rat thyroid cells and in Chinese hamster ovary (CHO) cells transfected with human TSH receptor (TSHR).	Thyrotropin	18-21	thyroid stimulating hormone receptor	Homo sapiens	226-230
10809230-4	2000	The JAK family substrates STAT3 (signal transducers and activators of transcription) are rapidly tyrosine phosphorylated in response to TSH.	Thyrotropin	136-139	signal transducer and activator of transcription 3	Cricetulus griseus	26-31
10809808-3	2000	The response of the serum TSH concentration to exogenously administered thyrotropin-releasing hormone (TRH) and circadian variation in serum TSH were also studied in the two groups.	Thyrotropin	26-29	thyrotropin releasing hormone	Homo sapiens	72-101
10809808-3	2000	The response of the serum TSH concentration to exogenously administered thyrotropin-releasing hormone (TRH) and circadian variation in serum TSH were also studied in the two groups.	Thyrotropin	26-29	thyrotropin releasing hormone	Homo sapiens	103-106
10809808-6	2000	The response of serum TSH concentration to TRH was basically the same.	Thyrotropin	22-25	thyrotropin releasing hormone	Homo sapiens	43-46
10720070-1	2000	In the thyroid, active transport of iodide is under control of the TSH-dependent Na+/I- symporter (NIS), whereas in the breast such control is less well understood.	Thyrotropin	67-70	solute carrier family 5 member 5	Homo sapiens	81-97
10788562-4	2000	We have shown that serum TSH is increased the most in rats treated with the microsomal enzyme inducers phenobarbital (PB) or pregnenolone-16alpha-carbonitrile (PCN), whereas TSH is affected less in rats treated with 3-methylcholanthrene (3MC) and Aroclor 1254 (PCB).	Thyrotropin	25-28	pyruvate carboxylase	Rattus norvegicus	261-264
11370541-4	2000	Thyroglobulin, being organ-specific, plays a major role as tumor marker and it is used essentially in the monitoring and follow-up of patients with differentiated thyroid carcinoma, both during L-thyroxine suppressive therapy and when it is discontinued or after recombinant TSH administration.	Thyrotropin	275-278	thyroglobulin	Homo sapiens	0-13
10845190-9	2000	These results indicate that the effect of SF is similar to those of PB and thyroid hypertrophy seen in the oral 2-week treatment with SF, and may be caused by indirectly elevated TSH levels which resulted from the induction of hepatic UDPGT activity.	Thyrotropin	179-182	UDP glucuronosyltransferase family 1 member A1	Rattus norvegicus	235-240
10770186-17	2000	SR-L appears to be able to suppress clinical signs of hyperthyroidism in our series of patients with TSH-secreting pituitary adenomas.	Thyrotropin	101-104	sarcalumenin	Homo sapiens	0-4
10736973-3	2000	We measured the TSH response to TRH and serum-free T4 and T3 levels.	Thyrotropin	16-19	thyrotropin releasing hormone	Homo sapiens	32-35
10727449-2	2000	All mice produced antibodies capable of recognizing the recombinant receptor expressed at the surface of stably transfected Chinese hamster ovary (CHO) cells, and sera from most of the immunized mice blocked TSH-dependent stimulation of cAMP accumulation in cells expressing the TSHr.	Thyrotropin	208-211	thyroid stimulating hormone receptor	Mus musculus	279-283
10736973-10	2000	RESULTS: In all subjects from groups 1, 2, and 3, TRH-induced TSH rise was significantly lower after dex than after placebo treatment.	Thyrotropin	62-65	thyrotropin releasing hormone	Homo sapiens	50-53
10707961-12	2000	TSH induced phosphorylation of both Y705 and S727 in STAT3, while IFN-gamma phosphorylated only the Y705.	Thyrotropin	0-3	signal transducer and activator of transcription 3	Rattus norvegicus	53-58
10736973-12	2000	In contrast, the concomitant administration of MCP and pyridostigmine significantly enhanced the TRH-induced TSH rise in dex-treated subjects and made the TSH response to TRH similar to that observed in the TRH plus placebo test.	Thyrotropin	109-112	thyrotropin releasing hormone	Homo sapiens	97-100
10736973-13	2000	CONCLUSIONS: These data indicate that enhanced-hypothalamic somatostatinergic and dopaminergic inhibitory activities are involved in the mechanism underlying the reduced TSH response to TRH induced by glucocorticoid treatment.	Thyrotropin	170-173	thyrotropin releasing hormone	Homo sapiens	186-189
10707961-2	2000	This report demonstrates that TSH induces the expression of suppressor of cytokine signaling (SOCS)-1 and -3 proteins and alters the phosphorylation state of signal transducer and activator of transcription (STAT) proteins STAT1 and STAT3.	Thyrotropin	30-33	suppressor of cytokine signaling 1	Rattus norvegicus	60-108
10707961-13	2000	In addition, we found that SOCS-3 was associated with JAK1 and JAK2 and that these associations were stimulated by TSH.	Thyrotropin	115-118	suppressor of cytokine signaling 3	Rattus norvegicus	27-33
10707961-2	2000	This report demonstrates that TSH induces the expression of suppressor of cytokine signaling (SOCS)-1 and -3 proteins and alters the phosphorylation state of signal transducer and activator of transcription (STAT) proteins STAT1 and STAT3.	Thyrotropin	30-33	signal transducer and activator of transcription 1	Rattus norvegicus	223-228
10707961-2	2000	This report demonstrates that TSH induces the expression of suppressor of cytokine signaling (SOCS)-1 and -3 proteins and alters the phosphorylation state of signal transducer and activator of transcription (STAT) proteins STAT1 and STAT3.	Thyrotropin	30-33	signal transducer and activator of transcription 3	Rattus norvegicus	233-238
10707961-10	2000	The phosphorylation of Y701 in STAT1, which is responsible for homodimer formation, nuclear translocation, and DNA binding, was specifically stimulated by IFN-gamma, but not by TSH or forskolin.	Thyrotropin	177-180	signal transducer and activator of transcription 1	Rattus norvegicus	31-36
10707961-13	2000	In addition, we found that SOCS-3 was associated with JAK1 and JAK2 and that these associations were stimulated by TSH.	Thyrotropin	115-118	Janus kinase 1	Rattus norvegicus	54-58
10707961-11	2000	However, the phosphorylation of S727 in STAT1 was induced by IFN-gamma, TSH, and forskolin.	Thyrotropin	72-75	signal transducer and activator of transcription 1	Rattus norvegicus	40-45
10707961-13	2000	In addition, we found that SOCS-3 was associated with JAK1 and JAK2 and that these associations were stimulated by TSH.	Thyrotropin	115-118	Janus kinase 2	Rattus norvegicus	63-67
10779136-4	2000	Intracellular cyclic adenosine monophosphate (cAMP) accumulation was determined by radioimmunoassay after exposure to increasing doses of bovine TSH.	Thyrotropin	145-148	cathelicidin-7	Bos taurus	14-44
10650941-3	2000	We examined the effects of IFNgamma on acute responses to TSH in rat thyroid cells.	Thyrotropin	58-61	interferon gamma	Rattus norvegicus	27-35
10720030-18	2000	This is the first time that a loss of function mutation of the TSH receptor is described in a patient with severe congenital hypothyroidism and absent circulating thyroglobulin due to TSH unresponsiveness and the first time that an inactivating mutation of the TSH receptor is described in the first extracellular loop.	Thyrotropin	63-66	thyroid stimulating hormone receptor	Homo sapiens	261-273
10650967-7	2000	Using a cultured rat thyroid cell line (FRTL-5), PDS expression was found to be significantly induced by low concentrations of thyroglobulin (TG), but not by TSH, sodium iodide, or insulin.	Thyrotropin	158-161	solute carrier family 26 member 4	Rattus norvegicus	49-52
10650957-2	2000	The finding that intracerebroventricular GLP-1 stimulates LH, TSH, corticosterone, and vasopressin secretion in rats prompted us to assess the neuroendocrine consequences of disrupting GLP-1 signaling in mice in vivo.	Thyrotropin	62-65	glucagon	Rattus norvegicus	41-46
10690866-9	2000	The association between iodine supplementation and high serum TSH in the neonates was further substantiated by an inverse correlation between thyroglobulin and TSH in cord blood (P < 0.001), whereas no specific pattern was observed in the mothers.	Thyrotropin	62-65	thyroglobulin	Homo sapiens	142-155
10665997-1	2000	Since cross-reactivity of TSH with the human FSH receptor has been reported, in this study we tested the effect of thyroid-stimulating antibody (TSAb) and thyroid stimulation-blocking antibody (TSBAb) on Chinese hamster ovary cells expressing human FSH receptor (CHO-hFSH-R cells).	Thyrotropin	26-29	follicle stimulating hormone receptor	Homo sapiens	45-57
10614633-10	2000	These results suggest that PKCzeta stimulates TSH-independent mitogenesis through a p42/p44 MAPK-dependent pathway.	Thyrotropin	46-49	mitogen activated protein kinase 3	Rattus norvegicus	88-96
10702801-9	2000	Unlike the inhibitory effects of TSH on the proliferation of RasV12S35-expressing cells, TSH enhanced RasV12C40-stimulated proliferation by further increasing the activity of p70s6k, an important mediator of the mitogenic effects of TSH and RasV12C40.	Thyrotropin	89-92	ribosomal protein S6 kinase B1	Homo sapiens	175-181
10625876-4	2000	We found a good correlation between TSH and serum IL-2 levels (r = 0.56; P<0.01).	Thyrotropin	36-39	interleukin 2	Homo sapiens	50-54
11215051-4	2000	The plasma levels of PRL were increased in most patients (11/18), and the plasma levels of TSH in gsp-positive patients were higher than those in gsp-negative patients (P < 0.05).	Thyrotropin	91-94	GSM1	Homo sapiens	98-101
10579323-2	1999	In the pituitary, somatostatin inhibits TSH release from thyrotropes and GH release from somatotropes.	Thyrotropin	40-43	somatostatin	Mus musculus	18-30
10628749-2	2000	Here we show that protein kinase A (PKA), a downstream effector of the TSH/cAMP pathway, reproduces the effects of TSH in repressing class I transcription.	Thyrotropin	71-74	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	18-34
10628749-2	2000	Here we show that protein kinase A (PKA), a downstream effector of the TSH/cAMP pathway, reproduces the effects of TSH in repressing class I transcription.	Thyrotropin	71-74	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	36-39
10628749-4	2000	ICER (inducible cAMP early response), a transcriptional repressor induced by TSH/cAMP can decrease class I promoter activity when introduced into FRTL-5 thyroid cells in the absence of TSH/cAMP.	Thyrotropin	77-80	cAMP responsive element modulator	Rattus norvegicus	0-4
10628749-4	2000	ICER (inducible cAMP early response), a transcriptional repressor induced by TSH/cAMP can decrease class I promoter activity when introduced into FRTL-5 thyroid cells in the absence of TSH/cAMP.	Thyrotropin	77-80	cAMP responsive element modulator	Rattus norvegicus	6-35
10628749-4	2000	ICER (inducible cAMP early response), a transcriptional repressor induced by TSH/cAMP can decrease class I promoter activity when introduced into FRTL-5 thyroid cells in the absence of TSH/cAMP.	Thyrotropin	185-188	cAMP responsive element modulator	Rattus norvegicus	0-4
10628749-4	2000	ICER (inducible cAMP early response), a transcriptional repressor induced by TSH/cAMP can decrease class I promoter activity when introduced into FRTL-5 thyroid cells in the absence of TSH/cAMP.	Thyrotropin	185-188	cAMP responsive element modulator	Rattus norvegicus	6-35
10628749-5	2000	ICER binds to both the CRE-like element and the upstream 30-bp segment, generating a novel TSH-induced ternary complex.	Thyrotropin	91-94	cAMP responsive element modulator	Rattus norvegicus	0-4
10628753-3	2000	Immunohistochemical analysis revealed a number of TSH-immunopositive cells in the TRH-/- pituitary on embryonic day 17.5 and at birth.	Thyrotropin	50-53	thyrotropin releasing hormone	Mus musculus	82-85
10628753-8	2000	As expected, TSH content in the TRH-/- pituitary showed a marked reduction to only 40% of that in the wild type.	Thyrotropin	13-16	thyrotropin releasing hormone	Mus musculus	32-35
10599990-3	1999	We examined the effects of TSH on leptin production and lipolysis in rat epididymal adipocytes.	Thyrotropin	27-30	leptin	Rattus norvegicus	34-40
10602491-2	1999	We have addressed the question of the requirement for insulin/IGF-1 also observed in many cell culture systems in the physiologically relevant system of primary cultures of dog thyroid epithelial cells stimulated by TSH, which exerts its mitogenic activity only via cAMP.	Thyrotropin	216-219	insulin	Canis lupus familiaris	54-61
10602491-2	1999	We have addressed the question of the requirement for insulin/IGF-1 also observed in many cell culture systems in the physiologically relevant system of primary cultures of dog thyroid epithelial cells stimulated by TSH, which exerts its mitogenic activity only via cAMP.	Thyrotropin	216-219	insulin like growth factor 1	Canis lupus familiaris	62-67
10599990-8	1999	This TSH-induced glycerol release was further enhanced by adenosine deaminase (ADA).	Thyrotropin	5-8	adenosine deaminase	Rattus norvegicus	58-77
10566623-2	1999	The objectives of this study were to compare the effect of administered recombinant human TSH with thyroid hormone withdrawal on the results of radioiodine whole body scanning (WBS) and serum thyroglobulin (Tg) levels.	Thyrotropin	90-93	thyroglobulin	Homo sapiens	192-205
10534758-6	1999	Our results support the existence in porcine thyroid cells of the GPI/IPG system, which can take part in TSH-dependent signal transduction processes.	Thyrotropin	105-108	glucose-6-phosphate isomerase	Homo sapiens	66-69
10576759-2	1999	Several studies, at both the mRNA and the protein expression levels, have demonstrated that TSH, the primary regulator of iodide uptake, upregulates NIS gene expression and NIS protein abundance, both in vitro and in vivo.	Thyrotropin	92-95	solute carrier family 5 member 5	Homo sapiens	149-152
10576759-2	1999	Several studies, at both the mRNA and the protein expression levels, have demonstrated that TSH, the primary regulator of iodide uptake, upregulates NIS gene expression and NIS protein abundance, both in vitro and in vivo.	Thyrotropin	92-95	solute carrier family 5 member 5	Homo sapiens	173-176
10566646-13	1999	Eight of the nine patients studied with low and high TSH concentrations displayed greater amounts of circulating Tg mRNA after T4 withdrawal.	Thyrotropin	53-56	thyroglobulin	Homo sapiens	113-115
10497313-1	1999	In dog thyroid cells, insulin or IGF-1 induces cell growth and is required for the mitogenic action of TSH through cyclic AMP, of EGF, and of phorbol esters.	Thyrotropin	103-106	insulin	Canis lupus familiaris	22-29
10497313-1	1999	In dog thyroid cells, insulin or IGF-1 induces cell growth and is required for the mitogenic action of TSH through cyclic AMP, of EGF, and of phorbol esters.	Thyrotropin	103-106	insulin like growth factor 1	Canis lupus familiaris	33-38
10497313-5	1999	TSH or forskolin increased the levels of c-myc, jun B, jun D, c-fos, and fos B while decreasing those of c-jun and egr1.	Thyrotropin	0-3	MYC proto-oncogene, bHLH transcription factor	Canis lupus familiaris	41-46
10566623-9	1999	In conclusion, recombinant human TSH administration is a safe and effective means of stimulating radioiodine uptake and serum Tg levels in patients undergoing evaluation for thyroid cancer persistence and recurrence.	Thyrotropin	33-36	thyroglobulin	Homo sapiens	126-128
10568704-7	1999	Both strains of rats responded to intravenous TRH by releasing TSH into their blood in a dose-responsive fashion.	Thyrotropin	63-66	thyrotropin releasing hormone	Rattus norvegicus	46-49
10497313-5	1999	TSH or forskolin increased the levels of c-myc, jun B, jun D, c-fos, and fos B while decreasing those of c-jun and egr1.	Thyrotropin	0-3	JUNB	Canis lupus familiaris	48-53
10497313-5	1999	TSH or forskolin increased the levels of c-myc, jun B, jun D, c-fos, and fos B while decreasing those of c-jun and egr1.	Thyrotropin	0-3	JunD proto-oncogene, AP-1 transcription factor subunit	Canis lupus familiaris	55-60
10497313-5	1999	TSH or forskolin increased the levels of c-myc, jun B, jun D, c-fos, and fos B while decreasing those of c-jun and egr1.	Thyrotropin	0-3	Fos proto-oncogene, AP-1 transcription factor subunit	Canis lupus familiaris	64-67
10497313-5	1999	TSH or forskolin increased the levels of c-myc, jun B, jun D, c-fos, and fos B while decreasing those of c-jun and egr1.	Thyrotropin	0-3	Fos proto-oncogene, AP-1 transcription factor subunit	Canis lupus familiaris	73-76
10497313-5	1999	TSH or forskolin increased the levels of c-myc, jun B, jun D, c-fos, and fos B while decreasing those of c-jun and egr1.	Thyrotropin	0-3	Jun proto-oncogene, AP-1 transcription factor subunit	Canis lupus familiaris	105-110
10497313-5	1999	TSH or forskolin increased the levels of c-myc, jun B, jun D, c-fos, and fos B while decreasing those of c-jun and egr1.	Thyrotropin	0-3	early growth response 1	Canis lupus familiaris	115-119
10497313-14	1999	On the other hand, insulin clearly enhances the effects of TSH, phorbol ester, and EGF on c-myc, junB, and c-fos expression.	Thyrotropin	59-62	insulin	Canis lupus familiaris	19-26
10497313-14	1999	On the other hand, insulin clearly enhances the effects of TSH, phorbol ester, and EGF on c-myc, junB, and c-fos expression.	Thyrotropin	59-62	MYC proto-oncogene, bHLH transcription factor	Canis lupus familiaris	90-95
10497313-14	1999	On the other hand, insulin clearly enhances the effects of TSH, phorbol ester, and EGF on c-myc, junB, and c-fos expression.	Thyrotropin	59-62	JUNB	Canis lupus familiaris	97-101
10497313-14	1999	On the other hand, insulin clearly enhances the effects of TSH, phorbol ester, and EGF on c-myc, junB, and c-fos expression.	Thyrotropin	59-62	Fos proto-oncogene, AP-1 transcription factor subunit	Canis lupus familiaris	109-112
10497313-19	1999	(5) fos B, which is induced by TSH, forskolin, phorbol ester, and HGF but not by insulin, could be involved in the mitogenic action of the former factors.	Thyrotropin	31-34	Fos proto-oncogene, AP-1 transcription factor subunit	Canis lupus familiaris	4-7
10568704-10	1999	The effective dose 50 (ED50) of TRH (that dose causing release of half maximal TSH concentrations) was 61 ng in F344 rats and 78 ng in SD rats.	Thyrotropin	79-82	thyrotropin releasing hormone	Rattus norvegicus	32-35
10523032-5	1999	Preincubation of labeled TSHR with unlabeled TSH before reaction with test sera inhibited the immunoprecipitation reaction, providing further evidence for a close relationship between the TSHR autoantibody binding site(s) and the TSH binding site.	Thyrotropin	25-28	thyroid stimulating hormone receptor	Homo sapiens	188-192
10670752-8	1999	In euthyroid obese subjects there was a positive relationship between serum leptin levels and serum TSH levels (r=0.37, P<0.01).	Thyrotropin	100-103	leptin	Homo sapiens	76-82
10618734-4	1999	This is the second reported case of such adverse reactions to TRH alone and the first in which the patient had prior elevation of TSH.	Thyrotropin	130-133	thyrotropin releasing hormone	Homo sapiens	62-65
10504153-7	1999	We found a statistically significant positive association between the mono-ortho congener PCB 118 and TSH as well as statistically significant negative relationships of PCBs 138, 153, 180, 183, and 187 to FT(3).	Thyrotropin	102-105	pyruvate carboxylase	Homo sapiens	90-93
10523032-5	1999	Preincubation of labeled TSHR with unlabeled TSH before reaction with test sera inhibited the immunoprecipitation reaction, providing further evidence for a close relationship between the TSHR autoantibody binding site(s) and the TSH binding site.	Thyrotropin	45-48	thyroid stimulating hormone receptor	Homo sapiens	25-29
10523032-5	1999	Preincubation of labeled TSHR with unlabeled TSH before reaction with test sera inhibited the immunoprecipitation reaction, providing further evidence for a close relationship between the TSHR autoantibody binding site(s) and the TSH binding site.	Thyrotropin	45-48	thyroid stimulating hormone receptor	Homo sapiens	188-192
10523032-9	1999	Overall, our results indicate that TSHR autoantibodies bind principally to a region on the TSHR closely related to the TSH binding site, and this seems to be the case whether the autoantibodies act as TSH agonists or antagonists.	Thyrotropin	35-38	thyroid stimulating hormone receptor	Homo sapiens	91-95
10464393-8	1999	Pituitary TSH content decreased in the SP-treated group compared to controls (0.75 +/- 0.03 microg/hemipituitary) at the same proportion as the increase in TSH secretion, and this effect was also blocked when GRP and SP were co-incubated.	Thyrotropin	10-13	gastrin releasing peptide	Rattus norvegicus	209-212
10544750-17	1999	For thyroid morphology diseases, the problem is generally one of differentiated thyroid cancer, particular as the frequency is probably higher during pregnancy, the course being aggravated by the TSH-like effect of hCG, and curative treatment with radioactive iodine which cannot be started unless there is no risk of pregnancy.	Thyrotropin	196-199	hypertrichosis 2 (generalised, congenital)	Homo sapiens	215-218
10596724-4	1999	We previously reported the presence of nerve growth factor (NGF) and brain derived neurotrophic factor (BDNF) proteins in association with the thyroid stimulating hormone (TSH) and the corresponding mRNAs in the anterior lobe (AL) of the pituitary of adult rats (1).	Thyrotropin	143-170	nerve growth factor	Rattus norvegicus	39-58
10487707-11	1999	Expression of the D727E hTSHR variant in eukaryotic cells (COS-7) resulted in an exaggerated cAMP response to TSH stimulation compared to that of the wild-type hTSHR.	Thyrotropin	25-28	thyroid stimulating hormone receptor	Homo sapiens	160-165
10465304-8	1999	Both TGF-beta1 and activin A, but not BMP-7, increased the phosphorylation of Smad2, induced nuclear translocation of Smad2, Smad3, and Smad4, and inhibited thyrocyte cell growth as well as TSH-stimulated cAMP response.	Thyrotropin	190-193	transforming growth factor beta 1	Homo sapiens	5-14
10465304-8	1999	Both TGF-beta1 and activin A, but not BMP-7, increased the phosphorylation of Smad2, induced nuclear translocation of Smad2, Smad3, and Smad4, and inhibited thyrocyte cell growth as well as TSH-stimulated cAMP response.	Thyrotropin	190-193	SMAD family member 2	Homo sapiens	78-83
10524567-4	1999	The high serum TSH and ACTH levels in the presence of normal or hypoplastic thyroid glands and low glucocorticoid, but not mineralocorticoid concentrations, are characteristic of resistance to TSH and ACTH.	Thyrotropin	15-18	proopiomelanocortin	Homo sapiens	201-205
10524567-4	1999	The high serum TSH and ACTH levels in the presence of normal or hypoplastic thyroid glands and low glucocorticoid, but not mineralocorticoid concentrations, are characteristic of resistance to TSH and ACTH.	Thyrotropin	193-196	proopiomelanocortin	Homo sapiens	23-27
10596724-4	1999	We previously reported the presence of nerve growth factor (NGF) and brain derived neurotrophic factor (BDNF) proteins in association with the thyroid stimulating hormone (TSH) and the corresponding mRNAs in the anterior lobe (AL) of the pituitary of adult rats (1).	Thyrotropin	143-170	nerve growth factor	Rattus norvegicus	60-63
10596724-4	1999	We previously reported the presence of nerve growth factor (NGF) and brain derived neurotrophic factor (BDNF) proteins in association with the thyroid stimulating hormone (TSH) and the corresponding mRNAs in the anterior lobe (AL) of the pituitary of adult rats (1).	Thyrotropin	143-170	brain-derived neurotrophic factor	Rattus norvegicus	69-102
10596724-4	1999	We previously reported the presence of nerve growth factor (NGF) and brain derived neurotrophic factor (BDNF) proteins in association with the thyroid stimulating hormone (TSH) and the corresponding mRNAs in the anterior lobe (AL) of the pituitary of adult rats (1).	Thyrotropin	143-170	brain-derived neurotrophic factor	Rattus norvegicus	104-108
10596724-4	1999	We previously reported the presence of nerve growth factor (NGF) and brain derived neurotrophic factor (BDNF) proteins in association with the thyroid stimulating hormone (TSH) and the corresponding mRNAs in the anterior lobe (AL) of the pituitary of adult rats (1).	Thyrotropin	172-175	nerve growth factor	Rattus norvegicus	39-58
10596724-4	1999	We previously reported the presence of nerve growth factor (NGF) and brain derived neurotrophic factor (BDNF) proteins in association with the thyroid stimulating hormone (TSH) and the corresponding mRNAs in the anterior lobe (AL) of the pituitary of adult rats (1).	Thyrotropin	172-175	nerve growth factor	Rattus norvegicus	60-63
10596724-4	1999	We previously reported the presence of nerve growth factor (NGF) and brain derived neurotrophic factor (BDNF) proteins in association with the thyroid stimulating hormone (TSH) and the corresponding mRNAs in the anterior lobe (AL) of the pituitary of adult rats (1).	Thyrotropin	172-175	brain-derived neurotrophic factor	Rattus norvegicus	69-102
10596724-4	1999	We previously reported the presence of nerve growth factor (NGF) and brain derived neurotrophic factor (BDNF) proteins in association with the thyroid stimulating hormone (TSH) and the corresponding mRNAs in the anterior lobe (AL) of the pituitary of adult rats (1).	Thyrotropin	172-175	brain-derived neurotrophic factor	Rattus norvegicus	104-108
10394027-12	1999	RESULTS: The results indicate that enteral TRH (125 and 500 microg) produced the same TSH response as intravenous TRH.	Thyrotropin	86-89	thyrotropin releasing hormone	Rattus norvegicus	43-46
10419550-5	1999	Consistently, FRTL-5 cells overexpressing GRK2-K220R show increased TSH-induced cyclic AMP response, demonstrating that this receptor is under tonic control by GRK.	Thyrotropin	68-71	G protein-coupled receptor kinase 2	Rattus norvegicus	42-46
10443695-4	1999	Serum LIF concentrations linearly correlated with serum TSH in the 40 samples (r = 0.58, P < 0.001).	Thyrotropin	56-59	LIF interleukin 6 family cytokine	Homo sapiens	6-9
10418587-14	1999	Serum thyroglobulin levels are most precise when patients are hypothyroid (high TSH) and may be unreliable in patients with antithyroglobulin antibodies.	Thyrotropin	80-83	thyroglobulin	Homo sapiens	6-19
10475145-5	1999	When insulin concentration was kept constant, increasing amounts of TSH, from 0.5 to 10 U/l), also caused a synergic stimulation of DOG uptake.	Thyrotropin	68-71	insulin	Canis lupus familiaris	5-12
10475145-7	1999	Timecourse studies showed that TSH had a peak at 3 h of incubation, while insulin caused a progressive increase for up to 72 h. At short incubation times, up to 6 h, an additive effect of TSH and insulin was observed, while at longer times the interaction was synergic.	Thyrotropin	31-34	insulin	Canis lupus familiaris	196-203
10475145-7	1999	Timecourse studies showed that TSH had a peak at 3 h of incubation, while insulin caused a progressive increase for up to 72 h. At short incubation times, up to 6 h, an additive effect of TSH and insulin was observed, while at longer times the interaction was synergic.	Thyrotropin	188-191	insulin	Canis lupus familiaris	74-81
10418587-15	1999	We recommend TSH-stimulated thyroglobulin testing for all patients after total thyroidectomy for differentiated thyroid cancer of follicular cell origin regardless of patient age or risk group.	Thyrotropin	13-16	thyroglobulin	Homo sapiens	28-41
10411124-6	1999	The effect of TSH/forskolin, as well as TNF-alpha and IFN-gamma, on ICAM-1 RNA levels is transcriptional.	Thyrotropin	14-17	intercellular adhesion molecule 1	Rattus norvegicus	68-74
10468944-9	1999	CONCLUSION: Coding mutations of the putative tumour suppressor gene MEN1 are unlikely to contribute to pituitary tumorigenesis in sporadic nonfunctioning, GH-secreting and TSH-secreting adenomas.	Thyrotropin	172-175	menin 1	Homo sapiens	68-72
10364699-9	1999	Changes in SSTR gene expression may contribute to the increase in circulating TSH levels in hypothyroidism.	Thyrotropin	78-81	somatostatin receptor 3	Rattus norvegicus	11-15
10447009-6	1999	In normal pregnancy, when hCG levels are highest at 10 to 12 weeks gestation, there is suppression of serum TSH levels, presumably due to slight increases in free thyroxine (T4) concentration.	Thyrotropin	108-111	chorionic gonadotropin subunit beta 5	Homo sapiens	26-29
10411124-8	1999	TSH or forskolin, in contrast, halved the activity of the full length chimera within 24 hours and significantly suppressed the TNF-alpha and IFN-gamma-induced increase (>50%; p < 0.02).	Thyrotropin	0-3	tumor necrosis factor	Rattus norvegicus	127-136
10411124-8	1999	TSH or forskolin, in contrast, halved the activity of the full length chimera within 24 hours and significantly suppressed the TNF-alpha and IFN-gamma-induced increase (>50%; p < 0.02).	Thyrotropin	0-3	interferon gamma	Rattus norvegicus	141-150
10411124-15	1999	We thus show that TSH/cAMP can downregulate ICAM-1 gene expression and inhibit the activity of cytokines (TNF-alpha and IFN-gamma) to increase ICAM-1 gene expression in FRTL-5 thyroid cells.	Thyrotropin	18-21	intercellular adhesion molecule 1	Rattus norvegicus	44-50
10411124-15	1999	We thus show that TSH/cAMP can downregulate ICAM-1 gene expression and inhibit the activity of cytokines (TNF-alpha and IFN-gamma) to increase ICAM-1 gene expression in FRTL-5 thyroid cells.	Thyrotropin	18-21	tumor necrosis factor	Rattus norvegicus	106-115
10411124-15	1999	We thus show that TSH/cAMP can downregulate ICAM-1 gene expression and inhibit the activity of cytokines (TNF-alpha and IFN-gamma) to increase ICAM-1 gene expression in FRTL-5 thyroid cells.	Thyrotropin	18-21	interferon gamma	Rattus norvegicus	120-129
10411124-15	1999	We thus show that TSH/cAMP can downregulate ICAM-1 gene expression and inhibit the activity of cytokines (TNF-alpha and IFN-gamma) to increase ICAM-1 gene expression in FRTL-5 thyroid cells.	Thyrotropin	18-21	intercellular adhesion molecule 1	Rattus norvegicus	143-149
10468928-9	1999	Mean serum TSH levels were significantly lower in hyperemetics than in controls (0.33 mIU/l vs. 1.19 mIU/l, P < 0.001) and correlated with the hCG concentration between pH 4.6 and 2.8, while serum FT4 correlated with the hCG concentration below pH 4.0.	Thyrotropin	11-14	chorionic gonadotropin subunit beta 5	Homo sapiens	146-149
10468928-9	1999	Mean serum TSH levels were significantly lower in hyperemetics than in controls (0.33 mIU/l vs. 1.19 mIU/l, P < 0.001) and correlated with the hCG concentration between pH 4.6 and 2.8, while serum FT4 correlated with the hCG concentration below pH 4.0.	Thyrotropin	11-14	chorionic gonadotropin subunit beta 5	Homo sapiens	224-227
10370862-7	1999	A 75% (TRH) and 50% (oCRH) increase in plasma TSH was recorded in fasted animals, whereas both secretagogues did not evoke any response in their fed counterparts.	Thyrotropin	46-49	thyrotropin releasing hormone	Gallus gallus	7-10
10218995-13	1999	Peripheral serum TSH concentration was less (P < 0.05) HST compared with SOC calves.	Thyrotropin	17-20	fibroblast growth factor 4	Bos taurus	58-61
10218995-17	1999	Coronal sections of the gland stained with performic acid-Alcian blue-periodic acid-Schiff-orange G, revealed GH and TSH secreting cells in HST calves similar to controls.	Thyrotropin	117-120	fibroblast growth factor 4	Bos taurus	140-143
10229912-4	1999	RESULTS: NIS gene expression was up-regulated by TSH in a dose-dependent and time-dependent way in normal PC Cl 3 cells.	Thyrotropin	49-52	solute carrier family 5 member 5	Rattus norvegicus	9-12
10235418-1	1999	Concomitantly we observed an increase of FT4 and FT3 with a totally depressed TSH level 80 days after starting INF-alpha administration.	Thyrotropin	78-81	interferon alpha 17	Homo sapiens	111-120
10361382-12	1999	In contrast, the concomitant administration of naloxone and pyridostigmine significantly enhanced the TRH-induced TSH rise.	Thyrotropin	114-117	thyrotropin releasing hormone	Homo sapiens	102-105
10361382-16	1999	This suggests that an enhanced hypothalamic somatostatinergic activity is involved in the mechanism underlying the reduced TSH response to TRH.	Thyrotropin	123-126	thyrotropin releasing hormone	Homo sapiens	139-142
11081207-2	1999	In the human pituitary adenomas, Pit-1 is highly expressed in GH secreting and TSH secreting adenomas as it can well be anticipated.	Thyrotropin	79-82	POU class 1 homeobox 1	Homo sapiens	33-38
10365673-5	1999	The Tg fold response to rhTSH (rhTSH-stimulated Tg/basal Tg) is an index of the tumor"s sensitivity to TSH.	Thyrotropin	26-29	thyroglobulin	Homo sapiens	4-6
10365673-5	1999	The Tg fold response to rhTSH (rhTSH-stimulated Tg/basal Tg) is an index of the tumor"s sensitivity to TSH.	Thyrotropin	26-29	thyroglobulin	Homo sapiens	48-50
10365673-5	1999	The Tg fold response to rhTSH (rhTSH-stimulated Tg/basal Tg) is an index of the tumor"s sensitivity to TSH.	Thyrotropin	26-29	thyroglobulin	Homo sapiens	48-50
10365673-6	1999	Normal thyroid remnant and well-differentiated thyroid tumors display a greater (>10-fold) serum Tg response to TSH stimulation compared with less well-differentiated tumors (<3-fold).	Thyrotropin	115-118	thyroglobulin	Homo sapiens	100-102
10365673-13	1999	The development of a low (<1 ng/mL) serum Tg (on LT4 therapy) by the second postoperative year signifies a low 5-year recurrence risk whereas a rising serum Tg in the face of TSH suppression is an abnormal response consistent with recurrence.	Thyrotropin	178-181	thyroglobulin	Homo sapiens	45-47
10365676-8	1999	In a few studies, TRH was also tested as an adjuvant to increase endogenous TSH and thus help to stimulate function in thyroid cancer, but this attracted little interest.	Thyrotropin	76-79	thyrotropin releasing hormone	Homo sapiens	18-21
10365684-7	1999	The presence of cyclic adenosine monophosphate (cAMP)-generating system (forskolin) in TSH-free medium increased MMI-mediated TPO activity.	Thyrotropin	87-90	thyroid peroxidase	Homo sapiens	126-129
10098509-2	1999	We investigated whether and how TSH, which promotes the proliferation and differentiation of thyroid cells, regulates JNK activity in primary cultured human thyroid cells.	Thyrotropin	32-35	mitogen-activated protein kinase 8	Homo sapiens	118-121
10098509-3	1999	TSH stimulated JNK activity in cytosolic fractions of thyroid cells measured by in vitro kinase assay.	Thyrotropin	0-3	mitogen-activated protein kinase 8	Homo sapiens	15-18
10098509-4	1999	A low concentration of TSH (10(-11) M) stimulated JNK activity but at a higher dose (10(-8)-10(-7) M), TSH suppressed JNK activity without any change of JNK protein level.	Thyrotropin	23-26	mitogen-activated protein kinase 8	Homo sapiens	50-53
10098509-4	1999	A low concentration of TSH (10(-11) M) stimulated JNK activity but at a higher dose (10(-8)-10(-7) M), TSH suppressed JNK activity without any change of JNK protein level.	Thyrotropin	23-26	mitogen-activated protein kinase 8	Homo sapiens	118-121
10098509-4	1999	A low concentration of TSH (10(-11) M) stimulated JNK activity but at a higher dose (10(-8)-10(-7) M), TSH suppressed JNK activity without any change of JNK protein level.	Thyrotropin	23-26	mitogen-activated protein kinase 8	Homo sapiens	118-121
10098509-4	1999	A low concentration of TSH (10(-11) M) stimulated JNK activity but at a higher dose (10(-8)-10(-7) M), TSH suppressed JNK activity without any change of JNK protein level.	Thyrotropin	103-106	mitogen-activated protein kinase 8	Homo sapiens	118-121
10098509-4	1999	A low concentration of TSH (10(-11) M) stimulated JNK activity but at a higher dose (10(-8)-10(-7) M), TSH suppressed JNK activity without any change of JNK protein level.	Thyrotropin	103-106	mitogen-activated protein kinase 8	Homo sapiens	118-121
10098509-7	1999	We next elucidated the signal transduction pathways in TSH-induced JNK activation by examining the involvement of four distinct intracellular signal molecules; protein kinase C (PKC), cAMP, Ca2+, and PI3-kinase.	Thyrotropin	55-58	mitogen-activated protein kinase 8	Homo sapiens	67-70
10411119-1	1999	Cathepsin B (CB) is involved in the hydrolysis of thyroglobulin (Tg) and thought to be regulated by thyroid stimulating hormone (TSH) in the normal thyroid.	Thyrotropin	100-127	cathepsin B	Homo sapiens	0-11
10411119-1	1999	Cathepsin B (CB) is involved in the hydrolysis of thyroglobulin (Tg) and thought to be regulated by thyroid stimulating hormone (TSH) in the normal thyroid.	Thyrotropin	100-127	cathepsin B	Homo sapiens	13-15
10411119-1	1999	Cathepsin B (CB) is involved in the hydrolysis of thyroglobulin (Tg) and thought to be regulated by thyroid stimulating hormone (TSH) in the normal thyroid.	Thyrotropin	129-132	cathepsin B	Homo sapiens	0-11
10411119-1	1999	Cathepsin B (CB) is involved in the hydrolysis of thyroglobulin (Tg) and thought to be regulated by thyroid stimulating hormone (TSH) in the normal thyroid.	Thyrotropin	129-132	cathepsin B	Homo sapiens	13-15
10411124-4	1999	TSH/forskolin downregulate ICAM-1 RNA levels independent of the presence or absence of hydrocortisone or insulin.	Thyrotropin	0-3	intercellular adhesion molecule 1	Rattus norvegicus	27-33
10411124-5	1999	Moreover, TSH/forskolin decrease ICAM-1 RNA levels that are maximally induced by two cytokines: 100 ng/mL tumor necrosis factor-alpha (TNF-alpha) or 100 U/ml interferon-gamma (IFN-gamma).	Thyrotropin	10-13	intercellular adhesion molecule 1	Rattus norvegicus	33-39
10411124-5	1999	Moreover, TSH/forskolin decrease ICAM-1 RNA levels that are maximally induced by two cytokines: 100 ng/mL tumor necrosis factor-alpha (TNF-alpha) or 100 U/ml interferon-gamma (IFN-gamma).	Thyrotropin	10-13	tumor necrosis factor	Rattus norvegicus	135-144
10411124-5	1999	Moreover, TSH/forskolin decrease ICAM-1 RNA levels that are maximally induced by two cytokines: 100 ng/mL tumor necrosis factor-alpha (TNF-alpha) or 100 U/ml interferon-gamma (IFN-gamma).	Thyrotropin	10-13	interferon gamma	Rattus norvegicus	158-174
10411124-5	1999	Moreover, TSH/forskolin decrease ICAM-1 RNA levels that are maximally induced by two cytokines: 100 ng/mL tumor necrosis factor-alpha (TNF-alpha) or 100 U/ml interferon-gamma (IFN-gamma).	Thyrotropin	10-13	interferon gamma	Rattus norvegicus	176-185
10401666-6	1999	We now show that follicular TG, 27S > 19S > 12S, counter-regulates TSH-increased thyroid-specific gene transcription by suppressing the expression of the TTF-1, TTF-2, and Pax-8 genes.	Thyrotropin	73-76	thyroglobulin	Homo sapiens	28-30
10401666-6	1999	We now show that follicular TG, 27S > 19S > 12S, counter-regulates TSH-increased thyroid-specific gene transcription by suppressing the expression of the TTF-1, TTF-2, and Pax-8 genes.	Thyrotropin	73-76	transcription termination factor 1	Homo sapiens	160-165
10401666-6	1999	We now show that follicular TG, 27S > 19S > 12S, counter-regulates TSH-increased thyroid-specific gene transcription by suppressing the expression of the TTF-1, TTF-2, and Pax-8 genes.	Thyrotropin	73-76	transcription termination factor 2	Homo sapiens	167-172
10401666-6	1999	We now show that follicular TG, 27S > 19S > 12S, counter-regulates TSH-increased thyroid-specific gene transcription by suppressing the expression of the TTF-1, TTF-2, and Pax-8 genes.	Thyrotropin	73-76	paired box 8	Homo sapiens	178-183
10401667-7	1999	In concert with our previous finding that PIA in a similar concentration range inhibited TSH-induced cAMP production through the adenosine A1 receptor, the present results strongly support the idea that the major pathway of adenosine signaling for the inhibition of the TSH-induced cell proliferation is through the A1 adenosine receptor-Gi system.	Thyrotropin	89-92	adenosine A1 receptor	Rattus norvegicus	129-150
10199772-13	1999	In conclusion, 5-day infusion of GHRP-2 plus TRH in protracted critical illness reactivates blunted GH and TSH secretion, with preserved pulsatility, peripheral responsiveness, and feedback inhibition and without affecting serum cortisol, and induces a shift toward anabolic metabolism.	Thyrotropin	107-110	thyrotropin releasing hormone	Homo sapiens	45-48
10066375-3	1999	Transforming growth factor beta-1 (TGFbeta1) induced a rapid spreading of the TSH-treated cells only.	Thyrotropin	78-81	transforming growth factor beta 1	Homo sapiens	0-33
10202153-4	1999	At baseline, SRC-1(-/-) mice display resistance to TH (RTH) as evidenced by a 2.5-fold elevation of serum TSH levels, despite a 50% increase in serum free TH levels as compared with wild-type (SRC-1(+/+)) mice.	Thyrotropin	106-109	nuclear receptor coactivator 1	Mus musculus	13-18
10202153-5	1999	When mice were made hypothyroid, TSH levels increased, obliterating the difference between SRC-1(+/+) and SRC-1(-/-) mice observed at baseline.	Thyrotropin	33-36	nuclear receptor coactivator 1	Mus musculus	91-96
10202153-5	1999	When mice were made hypothyroid, TSH levels increased, obliterating the difference between SRC-1(+/+) and SRC-1(-/-) mice observed at baseline.	Thyrotropin	33-36	nuclear receptor coactivator 1	Mus musculus	106-111
10202153-6	1999	In contrast, the decline of TSH by treatment with L-triiodothyronine was severely blunted in SRC-1(-/-) mice.	Thyrotropin	28-31	nuclear receptor coactivator 1	Mus musculus	93-98
10202153-8	1999	However, SRC-1 enhances the sensitivity of TSH downregulation by TH.	Thyrotropin	43-46	nuclear receptor coactivator 1	Mus musculus	9-14
10319936-6	1999	As one possibility, this suggested there might be a hitherto unrecognized suppressor of TTF-1 RNA levels and TSH-induced Tg synthesis in individual follicles.	Thyrotropin	109-112	thyroglobulin	Rattus norvegicus	121-123
10319936-8	1999	Supporting this possibility, we show that physiological concentrations of highly purified 19S follicular Tg decrease TTF-1 RNA levels in rat FRTL-5 thyroid cells and inhibit the action of TSH to increase Tg synthesis.	Thyrotropin	188-191	thyroglobulin	Rattus norvegicus	105-107
10319936-8	1999	Supporting this possibility, we show that physiological concentrations of highly purified 19S follicular Tg decrease TTF-1 RNA levels in rat FRTL-5 thyroid cells and inhibit the action of TSH to increase Tg synthesis.	Thyrotropin	188-191	thyroglobulin	Rattus norvegicus	204-206
10319936-9	1999	We therefore suggest that follicular Tg is a feedback autoregulator of thyroid function that can counterregulate TSH actions on thyroid function in vivo and in thyroid cells in culture.	Thyrotropin	113-116	thyroglobulin	Rattus norvegicus	37-39
10066375-3	1999	Transforming growth factor beta-1 (TGFbeta1) induced a rapid spreading of the TSH-treated cells only.	Thyrotropin	78-81	transforming growth factor beta 1	Homo sapiens	35-43
15251689-7	1999	Basal TSH was higher in both patients with type I pseudohypoparathyroidism than in normal subjects, but TSH responses after administration of TRH, although not significantly different from normal, were blunted in relationship to the basal concentrations, as expressed as a percentage increase in TSH as well as a cumulative TSH response.	Thyrotropin	104-107	thyrotropin releasing hormone	Homo sapiens	142-145
10067864-2	1999	The purpose of the present study was to determine whether TSH treatment, therefore, results in higher levels of ANF-induced intracellular cGMP, and whether TSH elicits similar effects on cGMP signaling through the NPR-B receptor.	Thyrotropin	58-61	natriuretic peptide A	Rattus norvegicus	112-115
15251689-7	1999	Basal TSH was higher in both patients with type I pseudohypoparathyroidism than in normal subjects, but TSH responses after administration of TRH, although not significantly different from normal, were blunted in relationship to the basal concentrations, as expressed as a percentage increase in TSH as well as a cumulative TSH response.	Thyrotropin	104-107	thyrotropin releasing hormone	Homo sapiens	142-145
15251689-7	1999	Basal TSH was higher in both patients with type I pseudohypoparathyroidism than in normal subjects, but TSH responses after administration of TRH, although not significantly different from normal, were blunted in relationship to the basal concentrations, as expressed as a percentage increase in TSH as well as a cumulative TSH response.	Thyrotropin	104-107	thyrotropin releasing hormone	Homo sapiens	142-145
10067831-3	1999	TSH promoted follicle formation and inhibited TSP1 production.	Thyrotropin	0-3	thrombospondin 1	Homo sapiens	46-50
10067831-6	1999	Transforming growth factor-beta, like 12-O-tetradecanoyl-phorbol 13-acetate, increased TSP1 synthesis and prevented TSH-induced follicle formation.	Thyrotropin	116-119	transforming growth factor beta 1	Homo sapiens	0-31
10067867-5	1999	The murine serum demonstrated the presence of antibodies to the TSHR, as evidenced by inhibition of labeled TSH binding to the hTSHR, and these sera had in vitro thyroid stimulating activity.	Thyrotropin	64-67	thyroid stimulating hormone receptor	Homo sapiens	127-132
10067864-6	1999	Scatchard analysis of [125I]ANF binding in TSH-treated (6H) FRTL-5 cultures indicated a 5.6-fold increase in high affinity ANF-binding sites compared with TSH-deficient (5H) cultures [binding capacity (Bmax) of 6H cells, 227.2 +/- 33.7 fmol/mg protein; Bmax of 5H cells, 40.2 +/- 4.7 fmol/mg protein].	Thyrotropin	43-46	natriuretic peptide A	Rattus norvegicus	28-31
10067864-6	1999	Scatchard analysis of [125I]ANF binding in TSH-treated (6H) FRTL-5 cultures indicated a 5.6-fold increase in high affinity ANF-binding sites compared with TSH-deficient (5H) cultures [binding capacity (Bmax) of 6H cells, 227.2 +/- 33.7 fmol/mg protein; Bmax of 5H cells, 40.2 +/- 4.7 fmol/mg protein].	Thyrotropin	43-46	natriuretic peptide A	Rattus norvegicus	123-126
10067864-7	1999	The effect of TSH on [125I]ANF binding was mimicked by forskolin and (Bu)2cAMP, indicating receptor up-regulation via a cAMP pathway.	Thyrotropin	14-17	natriuretic peptide A	Rattus norvegicus	27-30
10526632-4	1999	Blunted TSH levels were found in healthy elderly subjects and, probably due to overactivity of corticotropin-releasing hormone in patients with depression in comparison to young normal controls.	Thyrotropin	8-11	corticotropin releasing hormone	Homo sapiens	95-126
9927422-4	1999	We show by this method that the TRbeta receptors are the most potent regulators of the production of thyroid stimulating hormone (TSH).	Thyrotropin	101-128	apoptosis antagonizing transcription factor	Mus musculus	32-38
9927422-4	1999	We show by this method that the TRbeta receptors are the most potent regulators of the production of thyroid stimulating hormone (TSH).	Thyrotropin	130-133	apoptosis antagonizing transcription factor	Mus musculus	32-38
9927422-5	1999	However, in the absence of TRbeta, the products of the TRalpha gene can fulfill this function as, in the absence of any receptors, TSH and thyroid hormone concentrations reach very high levels.	Thyrotropin	131-134	guanine nucleotide binding protein, alpha transducing 1	Mus musculus	55-62
10426581-2	1999	The administration of GHRH induced significant increases in GH, PRL and TSH.	Thyrotropin	72-75	growth hormone releasing hormone	Homo sapiens	22-26
10066009-5	1999	There was a significant inverse correlation between plasma TSH concentrations 20 min after TRH administration (deltaTSH) and seizure duration.	Thyrotropin	59-62	thyrotropin releasing hormone	Homo sapiens	91-94
9988700-5	1999	We also demonstrate that calreticulin mRNA levels in thyroid cells are under strict control by the thyroid-stimulating hormone, thus implicating calreticulin in the modulation of thyroid gene expression by thyroid-stimulating hormone.	Thyrotropin	99-126	calreticulin	Homo sapiens	25-37
9988700-5	1999	We also demonstrate that calreticulin mRNA levels in thyroid cells are under strict control by the thyroid-stimulating hormone, thus implicating calreticulin in the modulation of thyroid gene expression by thyroid-stimulating hormone.	Thyrotropin	99-126	calreticulin	Homo sapiens	145-157
10022397-8	1999	Thyroid carcinoma patients on TSH suppressive therapy also had significantly raised levels of IL-6 (2.5 +/- 0.42 ng/L) and IL-8 (4.4 +/- 0.63 ng/L).	Thyrotropin	30-33	interleukin 6	Homo sapiens	94-98
10022397-8	1999	Thyroid carcinoma patients on TSH suppressive therapy also had significantly raised levels of IL-6 (2.5 +/- 0.42 ng/L) and IL-8 (4.4 +/- 0.63 ng/L).	Thyrotropin	30-33	C-X-C motif chemokine ligand 8	Homo sapiens	123-127
10101724-6	1999	CONCLUSIONS: These results confirm the findings from earlier reports that patients with PD show blunted TSH response to TRH which is similar to that seen in depressed patients.	Thyrotropin	104-107	thyrotropin releasing hormone	Homo sapiens	120-123
10066009-7	1999	Finally, the seizure duration in the group with blunted TSH responses was reduced significantly when TRH was co-administered, while it remained unchanged in the group with non-blunted TSH responses.	Thyrotropin	56-59	thyrotropin releasing hormone	Homo sapiens	101-104
10052682-6	1999	These data demonstrate that rabbit antibodies that bind to amino acids 367-386 mediate their TSBAb activity by inhibiting the binding of TSH to TSHR; whereas, antibodies to regions 352-415, excluding aa 367-386, exert their TSBAb activity by affecting a step subsequent to TSH binding.	Thyrotropin	137-140	thyroid stimulating hormone receptor	Homo sapiens	144-148
10433088-1	1999	To get some insight on the in vitro effect of TSH on the expression of two thyroid specific antigens (thyroglobulin (Tg) and thyroid peroxidase (TPO)) on the cell surface of cultured human thyroid cells an indirect immunofluorescence-activated cell sorter (FACStar IV, Becton-Dickinson) was used.	Thyrotropin	46-49	thyroid peroxidase	Homo sapiens	145-148
9886811-4	1999	Blockage of somatostatin by specific antibodies resulted in an increased capacity of TSH-induced FRTL-5 cell-conditioned medium to promote cell proliferation, demonstrating that under physiological conditions, somatostatin exerts a cytostatic effect on FRTL-5 cells growth.	Thyrotropin	85-88	somatostatin	Rattus norvegicus	12-24
9886811-4	1999	Blockage of somatostatin by specific antibodies resulted in an increased capacity of TSH-induced FRTL-5 cell-conditioned medium to promote cell proliferation, demonstrating that under physiological conditions, somatostatin exerts a cytostatic effect on FRTL-5 cells growth.	Thyrotropin	85-88	somatostatin	Rattus norvegicus	210-222
9851791-4	1998	Thyroglobulin mRNA was amplified from peripheral blood of 77 patients who had undergone thyroidectomy for well differentiated thyroid cancer, 68 of whom while taking thyroid hormone for TSH suppression.	Thyrotropin	186-189	thyroglobulin	Homo sapiens	0-13
9935112-11	1999	The TSH level was abnormal (<0.2 microIU/mL) in only one of the TPO antibody-positive women who miscarried.	Thyrotropin	4-7	thyroid peroxidase	Homo sapiens	67-70
9920067-2	1999	We report in this study on a second generation TSH binding inhibitory assay using the human recombinant TSH-R with two major improvements: 1) superior diagnostic sensitivity for Graves" disease, and 2) for the first time, nonradioactive and radioactive coated tube (CT) technology.	Thyrotropin	47-50	thyroid stimulating hormone receptor	Homo sapiens	104-109
9920067-6	1999	The binding of TSH to the TSH-R could be demonstrated by the addition of 125I- or acridinium ester-labeled bovine TSH, and this binding could be inhibited by sera from patients with Graves" disease up to 95%.	Thyrotropin	15-18	thyroid stimulating hormone receptor	Bos taurus	26-31
10099868-14	1998	These results suggest that the greater secretion of TSH in pregnant rats is in part due to an increase of spontaneous release of TRH by MBH and a decrease of plasma thyroid hormones.	Thyrotropin	52-55	thyrotropin releasing hormone	Rattus norvegicus	129-132
9837919-5	1998	In contrast, all of the TSHRs synthesized in mutant CHO-Lec1, 2, and 8 cells (mannose-rich, sialic acid-deficient, and galactose-deficient oligosaccharides, respectively) bound TSH and produced cAMP in response to TSH with an affinity and an EC50 similar to those in TSHR expressed in parental CHO cells (CHO-TSHR; sialylated oligosaccharides).	Thyrotropin	24-27	thyrotropin receptor	Cricetulus griseus	267-271
9894580-8	1999	While basal TSH secretion was significantly increased by both compounds, TRH-stimulated TSH secretion was elevated only in patients treated with amisulpride.	Thyrotropin	88-91	thyrotropin releasing hormone	Homo sapiens	73-76
10543413-4	1999	In a highly differentiated thyroid carcinoma cell line of Hurthle cell origin (XTC), we tested the hypothesis that TSH would stimulate thyroglobulin secretion (a differentiated function) more than EGF, and EGF would stimulate invasion (a de-differentiated function) more than TSH.	Thyrotropin	115-118	thyroglobulin	Homo sapiens	135-148
10727004-3	1999	The Roundtable included a panel discussion centering on three major topics: 1) rationale for use of exogenous versus endogenous TSH stimulation of radioiodine uptake and thyroglobulin (Tg) production; 2) impact and use of rhTSH in diagnostic follow-up; and 3) role of rhTSH in radioablation.	Thyrotropin	128-131	thyroglobulin	Homo sapiens	170-183
9837919-5	1998	In contrast, all of the TSHRs synthesized in mutant CHO-Lec1, 2, and 8 cells (mannose-rich, sialic acid-deficient, and galactose-deficient oligosaccharides, respectively) bound TSH and produced cAMP in response to TSH with an affinity and an EC50 similar to those in TSHR expressed in parental CHO cells (CHO-TSHR; sialylated oligosaccharides).	Thyrotropin	177-180	thyrotropin receptor	Cricetulus griseus	24-28
9814467-7	1998	There was also a significant correlation between serum VEGF and TSH levels in patients with HT who were hypothyroid and had a goiter.	Thyrotropin	64-67	vascular endothelial growth factor A	Homo sapiens	55-59
9828939-8	1998	Median percentage change in TSH concentration after TRH administration was 207% (range, 25 to 2,200%) in healthy dogs, 24% (-21 to 134%) in hypothyroid dogs, and 167% (69 to 1,800%) in euthyroid dogs with concurrent diseases.	Thyrotropin	28-31	TRH	Canis lupus familiaris	52-55
9828939-9	1998	Overall accuracy of using the TRH-induced change in TSH concentration to identify hypothyroid dogs was 90%.	Thyrotropin	52-55	TRH	Canis lupus familiaris	30-33
9828939-10	1998	CLINICAL IMPLICATIONS: Although percentage change in TSH concentration in response to TRH administration can be used to differentiate euthyroid from hypothyroid dogs, the test has little advantage over measurement of baseline TSH and total or free T4 concentration.	Thyrotropin	53-56	TRH	Canis lupus familiaris	86-89
9827657-2	1998	The recent introduction of an ultrasensitive TSH assay, able to clearly distinguish suppressed from unsuppressed TSH levels, has rendered the use of the TRH test obsolete in the diagnosis of classic hyperthyroidism.	Thyrotropin	45-48	thyrotropin releasing hormone	Homo sapiens	153-156
9803444-6	1998	TSH at birth was approximately 3.5-fold greater for infants delivered at 0-6 h after the last TRH dose compared with the control group and was suppressed in infants delivering at 7-36 h. T3 and TSH levels were not different between control and TRH-treated groups at 3-28 d of age.	Thyrotropin	0-3	thyrotropin releasing hormone	Homo sapiens	94-97
9803444-6	1998	TSH at birth was approximately 3.5-fold greater for infants delivered at 0-6 h after the last TRH dose compared with the control group and was suppressed in infants delivering at 7-36 h. T3 and TSH levels were not different between control and TRH-treated groups at 3-28 d of age.	Thyrotropin	0-3	thyrotropin releasing hormone	Homo sapiens	244-247
9803444-7	1998	In TRH stimulation tests on d 28, control and TRH-treated groups had similar peak levels of TSH and incidence of exaggerated response (TSH > or = 35 mU/L).	Thyrotropin	92-95	thyrotropin releasing hormone	Homo sapiens	46-49
9928666-3	1998	While induction of UDP-GT activity decreases thyroid hormone levels by enhancing biotransformation and subsequent biliary secretion, only certain UDP-GT inducers exhibit the ability to increase serum TSH levels.	Thyrotropin	200-203	UDP glycosyltransferase 2 family, polypeptide B	Rattus norvegicus	146-152
9928666-4	1998	For example, phenobarbital (PB) and pregnenolone-16alpha-carbonitrile (PCN) increase serum levels of TSH, while 3-methylcholanthrene (3MC) and Aroclor 1254 (PCB) do not.	Thyrotropin	101-104	pyruvate carboxylase	Rattus norvegicus	157-160
9928666-5	1998	Increased serum TSH concentration also enhances thyroid gland expression of TGF-beta1, an anti-proliferative, pro-apoptotic protein.	Thyrotropin	16-19	transforming growth factor, beta 1	Rattus norvegicus	76-85
9928666-7	1998	The present study was designed to examine the dose-response effect of TSH-increasing (PB and PCN) and nonincreasing (3MC and PCB) UDP-GT inducers on apoptosis and TGF-beta1.	Thyrotropin	70-73	transforming growth factor, beta 1	Rattus norvegicus	163-172
9876351-8	1998	IL-1 alpha, TNF alpha and IFN gamma at concentrations of 10(5) U/l all inhibited TSH-induced NIS gene expression and iodide uptake.	Thyrotropin	81-84	interleukin 1 alpha	Homo sapiens	0-10
9876351-8	1998	IL-1 alpha, TNF alpha and IFN gamma at concentrations of 10(5) U/l all inhibited TSH-induced NIS gene expression and iodide uptake.	Thyrotropin	81-84	tumor necrosis factor	Homo sapiens	12-21
9876351-8	1998	IL-1 alpha, TNF alpha and IFN gamma at concentrations of 10(5) U/l all inhibited TSH-induced NIS gene expression and iodide uptake.	Thyrotropin	81-84	interferon gamma	Homo sapiens	26-35
9876351-8	1998	IL-1 alpha, TNF alpha and IFN gamma at concentrations of 10(5) U/l all inhibited TSH-induced NIS gene expression and iodide uptake.	Thyrotropin	81-84	solute carrier family 5 member 5	Homo sapiens	93-96
9827660-11	1998	In order to establish whether decreased activity of TRH cells in the PVN contributes to the persistence of low TSH levels in nonthyroidal illness (NTI), hypothalamic TRH gene expression was investigated in patients whose plasma concentrations of thyroid hormones had been measured just before death.	Thyrotropin	111-114	thyrotropin releasing hormone	Homo sapiens	52-55
9827660-12	1998	Quantitative in situ hybridization showed a positive correlation of total TRH mRNA in the PVN and serum concentrations of TSH and triiodothyronine (T3) less than 24 hours before death, supporting our hypothesis.	Thyrotropin	122-125	thyrotropin releasing hormone	Homo sapiens	74-77
9827657-3	1998	On the contrary, the TRH test is still extremely useful in hyperthyroid patients with inappropriate secretion of thyrotropin, allowing the distinction between TSH-secreting pituitary tumors (usually unresponsive) and the pituitary variant of resistance to thyroid hormone (PRTH) syndrome (always responsive).	Thyrotropin	159-162	thyrotropin releasing hormone	Homo sapiens	21-24
9827657-4	1998	In hypothyroidism, the TRH test is still of value in patients with preclinical primary hypothyroidism, as they show exaggerated TSH response, and in those with central hypothyroidism, allowing the differentiation between pituitary (secondary) and hypothalamic (tertiary) hypothyroidism.	Thyrotropin	128-131	thyrotropin releasing hormone	Homo sapiens	23-26
9827660-6	1998	Dense TRH-containing fiber networks were present not only in the median eminence but also in a number of other hypothalamic areas, suggesting a physiological function of TRH as a neuromodulator or neurotransmitter in the human brain, in addition to its neuroendocrine role in pituitary secretion of thyroid-stimulating hormone (TSH).	Thyrotropin	299-326	thyrotropin releasing hormone	Homo sapiens	6-9
9827660-6	1998	Dense TRH-containing fiber networks were present not only in the median eminence but also in a number of other hypothalamic areas, suggesting a physiological function of TRH as a neuromodulator or neurotransmitter in the human brain, in addition to its neuroendocrine role in pituitary secretion of thyroid-stimulating hormone (TSH).	Thyrotropin	299-326	thyrotropin releasing hormone	Homo sapiens	170-173
9827660-6	1998	Dense TRH-containing fiber networks were present not only in the median eminence but also in a number of other hypothalamic areas, suggesting a physiological function of TRH as a neuromodulator or neurotransmitter in the human brain, in addition to its neuroendocrine role in pituitary secretion of thyroid-stimulating hormone (TSH).	Thyrotropin	328-331	thyrotropin releasing hormone	Homo sapiens	6-9
9827660-6	1998	Dense TRH-containing fiber networks were present not only in the median eminence but also in a number of other hypothalamic areas, suggesting a physiological function of TRH as a neuromodulator or neurotransmitter in the human brain, in addition to its neuroendocrine role in pituitary secretion of thyroid-stimulating hormone (TSH).	Thyrotropin	328-331	thyrotropin releasing hormone	Homo sapiens	170-173
9804293-5	1998	TRbeta-/-mice also over-produce thyroid hormones and thyroid stimulating hormone; however, levels of these hormones were unaltered by RXR mutations.	Thyrotropin	53-80	thyroid hormone receptor beta	Mus musculus	0-6
9781636-6	1998	Plasma TSH levels were 27% lower 240 minutes after IL-6 relative to control levels (0.93 +/- 0.10 v 1.28 +/- 0.18 mIU/mL, P = .001), but recovered by 24 hours.	Thyrotropin	7-10	interleukin 6	Homo sapiens	51-55
9781636-14	1998	Alternatively, IL-6 may have suppressed TSH secretion via a direct suprapituitary action.	Thyrotropin	40-43	interleukin 6	Homo sapiens	15-19
9722570-4	1998	We have cloned cDNA for rat AKAP121 and show that AKAP121 protein expression is regulated by thyroid stimulating hormone (TSH) and cAMP.	Thyrotropin	93-120	A-kinase anchoring protein 1	Rattus norvegicus	28-35
9722570-4	1998	We have cloned cDNA for rat AKAP121 and show that AKAP121 protein expression is regulated by thyroid stimulating hormone (TSH) and cAMP.	Thyrotropin	93-120	A-kinase anchoring protein 1	Rattus norvegicus	50-57
9722570-4	1998	We have cloned cDNA for rat AKAP121 and show that AKAP121 protein expression is regulated by thyroid stimulating hormone (TSH) and cAMP.	Thyrotropin	122-125	A-kinase anchoring protein 1	Rattus norvegicus	28-35
9722570-4	1998	We have cloned cDNA for rat AKAP121 and show that AKAP121 protein expression is regulated by thyroid stimulating hormone (TSH) and cAMP.	Thyrotropin	122-125	A-kinase anchoring protein 1	Rattus norvegicus	50-57
9722570-5	1998	Differentiated thyroid cells (TL5) accumulate AKAP121 upon incubation with TSH or a cAMP analog.	Thyrotropin	75-78	A-kinase anchoring protein 1	Rattus norvegicus	46-53
9846164-5	1998	TSH enhanced NIS mRNA expression in a dose-dependent manner, with induction evident at 0.1 mU/l, reaching a peak at 50 mU/l, an effect detected after 6 h of stimulation, but not in the first 2 h. Both TNF alpha and, to a lesser extent, IL-1 alpha inhibited basal and TSH-induced NIS expression.	Thyrotropin	0-3	solute carrier family 5 member 5	Rattus norvegicus	13-16
9758449-0	1998	Heterogeneous signal pathways through TSH receptors in porcine thyroid cells following stimulation with Graves" immunoglobulin G. OBJECTIVE: We compared different signal transduction pathways through thyroid stimulating hormone receptor (TSH-R) in porcine thyroid cells (PTC) following stimulation with thyroid stimulating hormone (TSH) and 11 thyroid stimulating immunoglobulin samples (TSI) obtained from patients with Graves" disease.	Thyrotropin	200-227	thyroid stimulating hormone receptor	Homo sapiens	238-243
9846164-5	1998	TSH enhanced NIS mRNA expression in a dose-dependent manner, with induction evident at 0.1 mU/l, reaching a peak at 50 mU/l, an effect detected after 6 h of stimulation, but not in the first 2 h. Both TNF alpha and, to a lesser extent, IL-1 alpha inhibited basal and TSH-induced NIS expression.	Thyrotropin	0-3	tumor necrosis factor	Rattus norvegicus	201-210
9846164-5	1998	TSH enhanced NIS mRNA expression in a dose-dependent manner, with induction evident at 0.1 mU/l, reaching a peak at 50 mU/l, an effect detected after 6 h of stimulation, but not in the first 2 h. Both TNF alpha and, to a lesser extent, IL-1 alpha inhibited basal and TSH-induced NIS expression.	Thyrotropin	0-3	interleukin 1 alpha	Rattus norvegicus	236-246
9846164-5	1998	TSH enhanced NIS mRNA expression in a dose-dependent manner, with induction evident at 0.1 mU/l, reaching a peak at 50 mU/l, an effect detected after 6 h of stimulation, but not in the first 2 h. Both TNF alpha and, to a lesser extent, IL-1 alpha inhibited basal and TSH-induced NIS expression.	Thyrotropin	0-3	solute carrier family 5 member 5	Rattus norvegicus	279-282
9846164-5	1998	TSH enhanced NIS mRNA expression in a dose-dependent manner, with induction evident at 0.1 mU/l, reaching a peak at 50 mU/l, an effect detected after 6 h of stimulation, but not in the first 2 h. Both TNF alpha and, to a lesser extent, IL-1 alpha inhibited basal and TSH-induced NIS expression.	Thyrotropin	267-270	solute carrier family 5 member 5	Rattus norvegicus	13-16
9846164-9	1998	In summary, we have shown that TSH upregulates rat NIS gene expression in vitro, and this induction can be modulated by cytokines.	Thyrotropin	31-34	solute carrier family 5 member 5	Rattus norvegicus	51-54
9846165-14	1998	Pharmacological doses of TRH cause an increased quantity of TSH to be released, but do not significantly alter the proportion of sialylated or terminally galactosylated TSH isoforms.	Thyrotropin	60-63	thyrotropin releasing hormone	Homo sapiens	25-28
10335025-10	1998	Administration of SC with TRH causes significantly smaller growth of TSH concentration than observed after infusion of TRH alone.	Thyrotropin	69-72	thyrotropin releasing hormone	Homo sapiens	26-29
9737366-7	1998	Five Mabs (M3, M4, M5, M6, and M9) inhibited the binding of 125I-TSH to functional hTSHR expressed on Chinese hamster ovary (CHO) cells, and four (M1, M3, M5, and M9) blocked the TSH-stimulated generation of cyclic adenosine monophosphate (cAMP), using the same cells.	Thyrotropin	65-68	thyroid stimulating hormone receptor	Homo sapiens	83-88
9681491-10	1998	Thus, TRH synthesized by cultured AP cells not only stimulates TSH release through a paracrine effect, but has a negative feedback on its own biosynthesis by an autocrine mechanism.	Thyrotropin	63-66	thyrotropin releasing hormone	Homo sapiens	6-9
9675095-2	1998	After TSHR solubilization with 1% dodecylpolyethy-leneglycoether, TSH binding affinity was increased, from Kd = 1.15 nM to 0.45 nM, and TSH binding capacity was slightly increased, from 0.15 nM to 0.19 nM.	Thyrotropin	66-69	thyroid stimulating hormone receptor	Homo sapiens	6-10
9653173-7	1998	In this report we show that follicular TG counter-regulates TSH-increased, thyroid-specific gene transcription by suppressing expression of the TTF-1, TTF-2, and Pax-8 genes.	Thyrotropin	60-63	thyroglobulin	Homo sapiens	39-41
9675095-3	1998	With a particulate membrane suspension from thyroid cells, blocking of TSH binding to the membrane suspension by anti-thyrotropin receptor antibody was observed only for thyroid stimulation blocking antibody (TSBAb), not for thyroid-stimulating antibody (TSAb).	Thyrotropin	71-74	thyroid stimulating hormone receptor	Homo sapiens	118-138
9653173-7	1998	In this report we show that follicular TG counter-regulates TSH-increased, thyroid-specific gene transcription by suppressing expression of the TTF-1, TTF-2, and Pax-8 genes.	Thyrotropin	60-63	transcription termination factor 1	Homo sapiens	144-149
9675095-4	1998	After the solubilization of TSHR, both TSBAb and TSAb blocked TSH-binding to the solubilized TSHR.	Thyrotropin	28-31	thyroid stimulating hormone receptor	Homo sapiens	93-97
9691974-4	1998	Previous work from this laboratory has shown TSH to cause acute transient increases in intracellular calcium in pig, human and FR TL-5 rat thyroid cells as well as in cell transfected with the human TSH receptor (JPO9 cells) in some (but not all) experiments.	Thyrotropin	45-48	thyroid stimulating hormone receptor	Homo sapiens	199-211
9653173-7	1998	In this report we show that follicular TG counter-regulates TSH-increased, thyroid-specific gene transcription by suppressing expression of the TTF-1, TTF-2, and Pax-8 genes.	Thyrotropin	60-63	transcription termination factor 2	Homo sapiens	151-156
9653173-7	1998	In this report we show that follicular TG counter-regulates TSH-increased, thyroid-specific gene transcription by suppressing expression of the TTF-1, TTF-2, and Pax-8 genes.	Thyrotropin	60-63	paired box 8	Homo sapiens	162-167
9645688-10	1998	The DC-induced inhibition of thyroid follicle growth was totally abrogated after addition of anti-IL-1beta antibodies; anti-IL-6 only had effect on the DC inhibition of non-TSH-stimulated thyrocytes, whereas anti-TNF-alpha demonstrated no effect at all.	Thyrotropin	173-176	interleukin 6	Rattus norvegicus	124-128
9697993-9	1998	We showed that these TSHR antibodies acted, in vitro, as TSH blocking antibodies, inhibiting TSH-induced generation of cyclic AMP in chinese hamster ovary (CHO) cells transfected with the hTSHR.	Thyrotropin	21-24	thyroid stimulating hormone receptor	Homo sapiens	188-193
9661632-5	1998	Nighttime TSH isoforms have an increased degree of sialylation compared to daytime TSH (35.8 +/- 9.7% vs. 23.8 +/- 5.8%; P < 0.03), thus accounting for the lower bioactivity [biological/immunological TSH ratio (TSH B/I), 1.3 +/- 0.4 vs. 2.0 +/- 0.2; P < 0.0007].	Thyrotropin	10-13	thyroid stimulating hormone subunit beta	Homo sapiens	214-219
9702065-1	1998	Since 1993, a number of mutations of the thyrotropin receptor(TSHR) gene causing human diseases have been reported; activating TSHR somatic mutations causing autonomously functioning thyroid nodules, activating TSHR germ-line mutations causing familial non-autoimmune hyperthyroidism, and inactivating TSHR germ-line mutations causing hypothyroidism due to TSH unresponsiveness.	Thyrotropin	62-65	thyroid stimulating hormone receptor	Homo sapiens	41-61
9702065-1	1998	Since 1993, a number of mutations of the thyrotropin receptor(TSHR) gene causing human diseases have been reported; activating TSHR somatic mutations causing autonomously functioning thyroid nodules, activating TSHR germ-line mutations causing familial non-autoimmune hyperthyroidism, and inactivating TSHR germ-line mutations causing hypothyroidism due to TSH unresponsiveness.	Thyrotropin	62-65	thyroid stimulating hormone receptor	Homo sapiens	127-131
9702065-1	1998	Since 1993, a number of mutations of the thyrotropin receptor(TSHR) gene causing human diseases have been reported; activating TSHR somatic mutations causing autonomously functioning thyroid nodules, activating TSHR germ-line mutations causing familial non-autoimmune hyperthyroidism, and inactivating TSHR germ-line mutations causing hypothyroidism due to TSH unresponsiveness.	Thyrotropin	62-65	thyroid stimulating hormone receptor	Homo sapiens	127-131
9702065-1	1998	Since 1993, a number of mutations of the thyrotropin receptor(TSHR) gene causing human diseases have been reported; activating TSHR somatic mutations causing autonomously functioning thyroid nodules, activating TSHR germ-line mutations causing familial non-autoimmune hyperthyroidism, and inactivating TSHR germ-line mutations causing hypothyroidism due to TSH unresponsiveness.	Thyrotropin	62-65	thyroid stimulating hormone receptor	Homo sapiens	127-131
9675566-6	1998	TRH stimulation evoked a TSH response with a peak of 14.1 +/- 1.2 mIU/ml at 30 min.	Thyrotropin	25-28	thyrotropin releasing hormone	Homo sapiens	0-3
9675566-9	1998	The most striking finding was the enhanced responsiveness of TSH to TRH stimulation while the thyroid hormones, free triiodothyronine (fT3) and free thyroxine (fT4), remained in the normal range.	Thyrotropin	61-64	thyrotropin releasing hormone	Homo sapiens	68-71
9528987-5	1998	Longer T/EBP mRNAs are more abundant in rat FRTL-5 thyroid cells maintained in the absence of TSH (-TSH) than in cells maintained in the presence of TSH (+TSH).	Thyrotropin	94-97	NK2 homeobox 1	Homo sapiens	7-12
9626138-2	1998	After the addition of A23187 with PMA, a significant induction in TR expression was observed after 6 h, with maximal induction occurring by 24 h. The addition of 8-bromo-cAMP (10(-4) mol/L) or TSH (10 U/L) alone had no effect on TR expression, nor did these agents influence the induction of TR brought about by the addition of A23187 and PMA.	Thyrotropin	193-196	peroxiredoxin 5	Homo sapiens	66-68
9528975-1	1998	Immunization of AKR/N mice with murine fibroblasts, transfected with the TSH receptor (TSHR) and a murine major histocompatibility complex class II molecule having the same H-2k haplotype (but not either alone), induces immune thyroid disease with the humoral and histological features of human Graves", including the presence of two different TSHR antibodies (TSHRAbs): stimulating TSHRAbs, which cause hyperthyroidism; and TSH-binding-inhibiting immunoglobulins.	Thyrotropin	73-76	thyroid stimulating hormone receptor	Mus musculus	87-91
9687151-5	1998	Stimulation with TSH (10 mIU/l) and IFNgamma (500 IU/l) resulted in a twofold increase and a 60% reduction in the luciferase activity respectively, similar to the effect observed with the endogenous Tg gene.	Thyrotropin	17-20	thyroglobulin	Homo sapiens	199-201
9564838-5	1998	This is evidenced by increased exogenous promoter activity, increased endogenous RNA levels, and increased endogenous antigen expression after transfecting full-length SSBP-1 complementary DNA together with a HLA-DR alpha promoter-reporter gene chimera into TSH-treated FRTL-5 thyroid cells whose endogenous SSBP-1 levels are low.	Thyrotropin	258-261	single stranded DNA binding protein 1	Rattus norvegicus	168-174
9589658-2	1998	In this context, the present study aimed to specify the contributions of IL-6 to the regulation of pituitary-adrenal secretory activity and GH and TSH secretion, as well as to the regulation of central nervous sleep and mood in healthy men.	Thyrotropin	147-150	interleukin 6	Homo sapiens	73-77
9585008-5	1998	In the perfusion experiments, at physiologic concentrations the slow decline of TSH in the maternal circulation was associated with a small linear increase in fetal levels to 0.11 +/- 0.04% of initial dose at 2 h. The placental transfer rate was 0.08 microIU min(-1).	Thyrotropin	80-83	CD59 molecule (CD59 blood group)	Homo sapiens	259-265
9585008-7	1998	The placental permeability of TSH was 2.4 x 10(-4) mL min(-1) g(-1) and was proportional to its coefficients of diffusion in water and molecular size.	Thyrotropin	30-33	CD59 molecule (CD59 blood group)	Homo sapiens	54-60
9528987-5	1998	Longer T/EBP mRNAs are more abundant in rat FRTL-5 thyroid cells maintained in the absence of TSH (-TSH) than in cells maintained in the presence of TSH (+TSH).	Thyrotropin	100-103	NK2 homeobox 1	Homo sapiens	7-12
9528987-5	1998	Longer T/EBP mRNAs are more abundant in rat FRTL-5 thyroid cells maintained in the absence of TSH (-TSH) than in cells maintained in the presence of TSH (+TSH).	Thyrotropin	100-103	NK2 homeobox 1	Homo sapiens	7-12
9528987-5	1998	Longer T/EBP mRNAs are more abundant in rat FRTL-5 thyroid cells maintained in the absence of TSH (-TSH) than in cells maintained in the presence of TSH (+TSH).	Thyrotropin	100-103	NK2 homeobox 1	Homo sapiens	7-12
9614352-10	1998	Incubation with TSH (1 mU/ml) caused a fourfold increase in [3H]thymidine incorporation that was diminished by co-incubation with 10 ng/ml or greater VEGF.	Thyrotropin	16-19	vascular endothelial growth factor A	Rattus norvegicus	150-154
9700468-7	1998	We have shown that priming with TSH potentiated DNA synthesis induced by IGF-I, whereas pretreatment with IGF-I enhanced protein synthesis induced by TSH.	Thyrotropin	32-35	insulin-like growth factor 1	Rattus norvegicus	73-78
9700468-7	1998	We have shown that priming with TSH potentiated DNA synthesis induced by IGF-I, whereas pretreatment with IGF-I enhanced protein synthesis induced by TSH.	Thyrotropin	150-153	insulin-like growth factor 1	Rattus norvegicus	106-111
9700468-10	1998	On the other hand, IGF-I and TSH stimulated (alpha-aminoisobutyric acid (AIB) uptake synergistically, but RNA synthesis induced by IGF-I was depressed by TSH.	Thyrotropin	154-157	insulin-like growth factor 1	Rattus norvegicus	19-24
9700468-10	1998	On the other hand, IGF-I and TSH stimulated (alpha-aminoisobutyric acid (AIB) uptake synergistically, but RNA synthesis induced by IGF-I was depressed by TSH.	Thyrotropin	154-157	insulin-like growth factor 1	Rattus norvegicus	131-136
9700468-11	1998	From these results, we concluded that in FRTL-5 cells, IGF-I potentiated protein synthesis induced by TSH by means of complex mechanisms and the interaction between IGF-I and cAMP-dependent pathways may also have a physiological meaning in regulating protein anabolism.	Thyrotropin	102-105	insulin-like growth factor 1	Rattus norvegicus	55-60
9623636-0	1998	Insulin-like growth factor-binding protein-3 (IGFBP-3) but not insulin-like growth factor-I (IGF-I) remains elevated in euthyroid TSH-suppressed Graves" disease.	Thyrotropin	130-133	insulin like growth factor binding protein 3	Homo sapiens	0-44
9623636-8	1998	The IGF-I levels of the thyroid patients aged 20-40 showed significant negative correlation to TSH and positive correlations to the thyroid hormones.	Thyrotropin	95-98	insulin like growth factor 1	Homo sapiens	4-9
9584838-3	1998	The reactivity of these antibodies with the TSHR was assessed by Western blotting with both native and recombinant human TSHR expressed in CHO cells, immunoprecipitation of 35S-labelled full-length TSHR produced in an in vitro transcription/ translation system, immunoprecipitation of 125I-TSH/TSHR complexes, inhibition of 125I-TSH binding to the TSHR and fluorescence activated cell sorter (FACS) analysis of binding to CHO-K1 cells expressing the TSHR on their cell surface.	Thyrotropin	44-47	thyroid stimulating hormone receptor	Homo sapiens	121-125
9584838-3	1998	The reactivity of these antibodies with the TSHR was assessed by Western blotting with both native and recombinant human TSHR expressed in CHO cells, immunoprecipitation of 35S-labelled full-length TSHR produced in an in vitro transcription/ translation system, immunoprecipitation of 125I-TSH/TSHR complexes, inhibition of 125I-TSH binding to the TSHR and fluorescence activated cell sorter (FACS) analysis of binding to CHO-K1 cells expressing the TSHR on their cell surface.	Thyrotropin	44-47	thyrotropin receptor	Cricetulus griseus	121-125
9584838-3	1998	The reactivity of these antibodies with the TSHR was assessed by Western blotting with both native and recombinant human TSHR expressed in CHO cells, immunoprecipitation of 35S-labelled full-length TSHR produced in an in vitro transcription/ translation system, immunoprecipitation of 125I-TSH/TSHR complexes, inhibition of 125I-TSH binding to the TSHR and fluorescence activated cell sorter (FACS) analysis of binding to CHO-K1 cells expressing the TSHR on their cell surface.	Thyrotropin	44-47	thyrotropin receptor	Cricetulus griseus	121-125
9584838-3	1998	The reactivity of these antibodies with the TSHR was assessed by Western blotting with both native and recombinant human TSHR expressed in CHO cells, immunoprecipitation of 35S-labelled full-length TSHR produced in an in vitro transcription/ translation system, immunoprecipitation of 125I-TSH/TSHR complexes, inhibition of 125I-TSH binding to the TSHR and fluorescence activated cell sorter (FACS) analysis of binding to CHO-K1 cells expressing the TSHR on their cell surface.	Thyrotropin	44-47	thyrotropin receptor	Cricetulus griseus	121-125
9584838-3	1998	The reactivity of these antibodies with the TSHR was assessed by Western blotting with both native and recombinant human TSHR expressed in CHO cells, immunoprecipitation of 35S-labelled full-length TSHR produced in an in vitro transcription/ translation system, immunoprecipitation of 125I-TSH/TSHR complexes, inhibition of 125I-TSH binding to the TSHR and fluorescence activated cell sorter (FACS) analysis of binding to CHO-K1 cells expressing the TSHR on their cell surface.	Thyrotropin	44-47	thyrotropin receptor	Cricetulus griseus	121-125
9614352-11	1998	Similarly, 10 ng/ml or greater VEGF significantly reduced the ability of TSH to increase [125I] uptake.	Thyrotropin	73-76	vascular endothelial growth factor A	Rattus norvegicus	31-35
9614352-12	1998	The antagonistic effects of VEGF on TSH-stimulated [3H]thymidine incorporation or [125I] uptake were significantly reduced in the presence of an anti-VEGF antiserum.	Thyrotropin	36-39	vascular endothelial growth factor A	Rattus norvegicus	28-32
9614352-12	1998	The antagonistic effects of VEGF on TSH-stimulated [3H]thymidine incorporation or [125I] uptake were significantly reduced in the presence of an anti-VEGF antiserum.	Thyrotropin	36-39	vascular endothelial growth factor A	Rattus norvegicus	150-154
9508775-5	1998	Unlike epidermal growth factor (EGF)+serum and other cAMP-independent mitogens, TSH did not induce the accumulation of cyclins D1 and D2 and partially inhibited the basal expression of the most abundant cyclin D3.	Thyrotropin	80-83	cyclin D3	Canis lupus familiaris	203-212
9588495-6	1998	In the TTF-1 gene, we detected a transition (guanine to adenine) in the intron at the minus four position of cryptic 3" splice site in one allele, but absence of linkage suggested that the transition was not responsible for the TSH unresponsiveness.	Thyrotropin	228-231	NK2 homeobox 1	Homo sapiens	7-12
18406250-2	1998	TRbeta knockout mice have goiter, elevated thyroid hormone and TSH levels, and a functional auditory defect.	Thyrotropin	63-66	apoptosis antagonizing transcription factor	Mus musculus	0-6
10052168-4	1998	The progressive decrease T4/TBG molar ratio implies the reduction of serum FT4 and the consequently increase of serum TSH.	Thyrotropin	118-121	serpin family A member 7	Homo sapiens	28-31
9579292-7	1998	Similarly, the time-course of TRH-induced TSH release was not modified by the treatment.	Thyrotropin	42-45	thyrotropin releasing hormone	Homo sapiens	30-33
9500485-11	1998	CONCLUSION: Although maternally administered thyrotropin-releasing hormone crosses the placenta sparingly, it still elicits a thyroid-stimulating hormone but not a prolactin response in the human fetus.	Thyrotropin	126-153	thyrotropin releasing hormone	Homo sapiens	45-74
9428802-13	1998	TSH modified the intracellular distribution of the enzyme, increasing the TPO pool from the perinuclear area to apical membrane.	Thyrotropin	0-3	thyroid peroxidase	Homo sapiens	74-77
9440477-2	1998	Both endogenous depression and subclinical thyrotoxicosis are frequently associated with low basal TSH levels and a blunted (<5 mIU/L) TSH response to TRH despite thyroid hormone levels within the normal range.	Thyrotropin	138-141	thyrotropin releasing hormone	Homo sapiens	154-157
9421422-1	1998	TRH, an amidated tripeptide secreted by certain hypothalamic neurons, is a principal regulator of TSH secretion and thyroid hormone release.	Thyrotropin	98-101	thyrotropin releasing hormone	Rattus norvegicus	0-3
9440477-9	1998	Pyridostigmine did not change basal TSH levels in any group, but significantly enhanced the TRH-induced TSH increase in normal controls and in depressed subjects (TSH increment became >7 mIU/L in all depressed subjects).	Thyrotropin	104-107	thyrotropin releasing hormone	Homo sapiens	92-95
9440477-11	1998	Basal and TRH- and pyridostigmine + TRH-induced TSH levels were significantly higher in the normal controls than in the other groups.	Thyrotropin	48-51	thyrotropin releasing hormone	Homo sapiens	10-13
9440477-11	1998	Basal and TRH- and pyridostigmine + TRH-induced TSH levels were significantly higher in the normal controls than in the other groups.	Thyrotropin	48-51	thyrotropin releasing hormone	Homo sapiens	36-39
9460173-12	1998	The hyt/hyt mouse has a mutation in the thyroid stimulating hormone receptor (TSHr) gene which renders it incapable of transducing the TSH signal in the thyrocyte to produce thyroid hormone.	Thyrotropin	78-81	thyroid stimulating hormone receptor	Mus musculus	40-76
10027006-3	1998	Thyroid tumors in these RET/PTC1 transgenic mice are characterized by a slow growth rate, thyroid-stimulating hormone (TSH)-responsive tumor progression, and loss of radioiodide-concentrating activity despite continued expression of thyroglobulin (Tg).	Thyrotropin	90-117	ret proto-oncogene	Mus musculus	24-27
10027006-3	1998	Thyroid tumors in these RET/PTC1 transgenic mice are characterized by a slow growth rate, thyroid-stimulating hormone (TSH)-responsive tumor progression, and loss of radioiodide-concentrating activity despite continued expression of thyroglobulin (Tg).	Thyrotropin	90-117	patched 1	Mus musculus	28-32
10027006-3	1998	Thyroid tumors in these RET/PTC1 transgenic mice are characterized by a slow growth rate, thyroid-stimulating hormone (TSH)-responsive tumor progression, and loss of radioiodide-concentrating activity despite continued expression of thyroglobulin (Tg).	Thyrotropin	119-122	ret proto-oncogene	Mus musculus	24-27
9551251-6	1997	The spontaneous and TRH-induced release of TSH in vitro from rat APs, and pituitary TSH content were increased by T3, or T3 plus P as compared with the animals injected with vehicle, or P alone.	Thyrotropin	43-46	thyrotropin releasing hormone	Rattus norvegicus	20-23
9677668-5	1998	The functional sensitivity for TSH, TNT and PSA was met by low concentrations: < 0.02 microIU/ml TSH, < 0.05 ng/ml TNT and < 0.07 ng/ml PSA.	Thyrotropin	31-34	chromosome 16 open reading frame 82	Homo sapiens	121-124
9677668-5	1998	The functional sensitivity for TSH, TNT and PSA was met by low concentrations: < 0.02 microIU/ml TSH, < 0.05 ng/ml TNT and < 0.07 ng/ml PSA.	Thyrotropin	31-34	aminopeptidase puromycin sensitive	Homo sapiens	145-148
9551251-6	1997	The spontaneous and TRH-induced release of TSH in vitro from rat APs, and pituitary TSH content were increased by T3, or T3 plus P as compared with the animals injected with vehicle, or P alone.	Thyrotropin	84-87	thyrotropin releasing hormone	Rattus norvegicus	20-23
9551251-8	1997	Application of T3 in vitro prevented the release of TSH in response to TRH.	Thyrotropin	52-55	thyrotropin releasing hormone	Rattus norvegicus	71-74
9444627-6	1997	It may be concluded that vasopressin modulate the pituitary-thyroid system function; AVP is probably a physiological stimulator of TSH and thyroid hormones secretion.	Thyrotropin	131-134	arginine vasopressin	Rattus norvegicus	85-88
9389545-12	1997	These results indicate that TGFbeta1 induces a mesenchyme-like cell shape accompanied by cytoskeletal molecular change and the loss of both epithelial polarization and a function in thyrocytes, and that it results in inhibiting thyroid folliculogenesis with or without TSH.	Thyrotropin	269-272	transforming growth factor beta 1	Homo sapiens	28-36
9349585-9	1997	hCG, and to a greater extent ds-hCG and dg-hCG, inhibited, as did TSH, gamma-interferon-induced human leukocyte antigen-DR (HLA-DR) expression in human thyrocytes, again reflecting the intrinsic thyrotropic activity of native hCG and its variants depleted of sialic acid or carbohydrate residues.	Thyrotropin	66-69	chorionic gonadotropin subunit beta 5	Homo sapiens	0-3
9400995-0	1997	Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization.	Thyrotropin	92-95	placental growth factor	Rattus norvegicus	39-43
9400995-0	1997	Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization.	Thyrotropin	92-95	vascular endothelial growth factor A	Rattus norvegicus	45-49
9400995-0	1997	Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization.	Thyrotropin	92-95	Fms related receptor tyrosine kinase 1	Rattus norvegicus	71-76
9400995-0	1997	Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization.	Thyrotropin	92-95	kinase insert domain receptor	Rattus norvegicus	78-83
9400995-0	1997	Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization.	Thyrotropin	92-95	kinase insert domain receptor	Rattus norvegicus	84-87
9400995-4	1997	In vivo studies demonstrated that in the thyroid gland of thiouracil-fed rats, increased mRNA and protein expression of PIGF, VEGF, Flt-1 and Flk-1/KDR occurred subsequent to the rise in the serum thyroid stimulating hormone (TSH) levels and in parallel with thyroid capillary proliferation.	Thyrotropin	226-229	phosphatidylinositol glycan anchor biosynthesis, class F	Rattus norvegicus	120-124
9430820-9	1997	These data demonstrate that thyroid hormone resistance at the level of TRH gene regulation, due to reduced inhibitory actions of mutant TR-T3 complexes, as well as dominant negative effects upon WT hTR beta 1 mediated inhibition, likely contribute to elevated TSH values observed in the syndrome of thyroid hormone resistance.	Thyrotropin	260-263	thyrotropin releasing hormone	Homo sapiens	71-74
9430820-9	1997	These data demonstrate that thyroid hormone resistance at the level of TRH gene regulation, due to reduced inhibitory actions of mutant TR-T3 complexes, as well as dominant negative effects upon WT hTR beta 1 mediated inhibition, likely contribute to elevated TSH values observed in the syndrome of thyroid hormone resistance.	Thyrotropin	260-263	tRNA-Thr (AGT) 7-1	Homo sapiens	136-141
9361690-3	1997	Pretreatment with PZP induced a significant reduction of GH secretion (3.17 +/- 1.1 v 13.4 +/- 1.1 ng/mL, P < .001) and TSH secretion (1.61 +/- 0.21 microU/mL, P < .05) in the first phase of the night, accounting for a 64% and 11% reduction in the GH and TSH nocturnal peak, respectively.	Thyrotropin	123-126	PZP alpha-2-macroglobulin like	Homo sapiens	18-21
18372514-4	1997	Antagonism of PKC reversed TSH-mediated stimulation, whereas it had no effect on EGF-stimulation.	Thyrotropin	27-30	proline rich transmembrane protein 2	Homo sapiens	14-17
9369235-2	1997	In this study, the Mn-SOD content was found to increase in thyroid tissues of rats administered thyroid stimulating hormone (TSH) and in thyrocytes cultured in medium supplemented with TSH.	Thyrotropin	96-123	superoxide dismutase 2	Rattus norvegicus	19-25
9369235-2	1997	In this study, the Mn-SOD content was found to increase in thyroid tissues of rats administered thyroid stimulating hormone (TSH) and in thyrocytes cultured in medium supplemented with TSH.	Thyrotropin	125-128	superoxide dismutase 2	Rattus norvegicus	19-25
9369235-2	1997	In this study, the Mn-SOD content was found to increase in thyroid tissues of rats administered thyroid stimulating hormone (TSH) and in thyrocytes cultured in medium supplemented with TSH.	Thyrotropin	185-188	superoxide dismutase 2	Rattus norvegicus	19-25
9369235-3	1997	Furthermore, in the thyroid glands of rats whose serum TSH level was elevated by inhibiting the synthesis of T3 and T4 by 6-methyl-2-thiouracil, the Mn-SOD increased as the TSH concentration increased.	Thyrotropin	55-58	superoxide dismutase 2	Rattus norvegicus	149-155
9369235-3	1997	Furthermore, in the thyroid glands of rats whose serum TSH level was elevated by inhibiting the synthesis of T3 and T4 by 6-methyl-2-thiouracil, the Mn-SOD increased as the TSH concentration increased.	Thyrotropin	173-176	superoxide dismutase 2	Rattus norvegicus	149-155
9369235-4	1997	In the cultured thyrocytes, the increase in Mn-SOD induced by TSH was inhibited by the C-kinase inhibitor H7.	Thyrotropin	62-65	superoxide dismutase 2	Rattus norvegicus	44-50
9369235-5	1997	These findings suggest the induction of Mn-SOD by TSH in thyroid cells and point to a role of C-kinase in this process, thereby indicating that a close relationship exists between the serum TSH level and the change in Mn-SOD content in thyrocytes with thyroid dysfunction.	Thyrotropin	50-53	superoxide dismutase 2	Rattus norvegicus	40-46
9369235-5	1997	These findings suggest the induction of Mn-SOD by TSH in thyroid cells and point to a role of C-kinase in this process, thereby indicating that a close relationship exists between the serum TSH level and the change in Mn-SOD content in thyrocytes with thyroid dysfunction.	Thyrotropin	50-53	superoxide dismutase 2	Rattus norvegicus	218-224
9329373-10	1997	TSH induced cath D synthesis and secretion in extracellular fluid of normal human thyroid cells in primary culture; TSH had little effect on intracellular cath D level.	Thyrotropin	0-3	cathepsin D	Homo sapiens	12-18
9329373-11	1997	In conclusion, TSH-induced cath D synthesis may explain high cath D levels in Graves" disease tissues and toxic adenomas, because these tissues possess a permanently stimulated cAMP transduction pathway.	Thyrotropin	15-18	cathepsin D	Homo sapiens	27-33
9329373-11	1997	In conclusion, TSH-induced cath D synthesis may explain high cath D levels in Graves" disease tissues and toxic adenomas, because these tissues possess a permanently stimulated cAMP transduction pathway.	Thyrotropin	15-18	cathepsin D	Homo sapiens	61-67
9349586-6	1997	Western blot analysis demonstrated that TGFbeta1 suppressed TSH-stimulated NIS protein levels.	Thyrotropin	60-63	transforming growth factor, beta 1	Rattus norvegicus	40-48
9349586-8	1997	As predicted, TGFbeta1 inhibited TSH-stimulated iodide uptake activity.	Thyrotropin	33-36	transforming growth factor, beta 1	Rattus norvegicus	14-22
9349586-9	1997	These results suggest that the inhibitory effect of TGFbeta1 on TSH-stimulated iodide uptake is at least in part due to a suppression of NIS specific transcription.	Thyrotropin	64-67	transforming growth factor, beta 1	Rattus norvegicus	52-60
9426438-2	1997	Specifically, TSH induces fibronectin secretion by FTC-133, possibly as a result of increased cyclic adenosine monophosphate (cAMP), yet induces in vitro invasion through a protein kinase C-dependent mechanism.	Thyrotropin	14-17	fibronectin 1	Homo sapiens	26-37
9345297-3	1997	The superoxide radical generated was completely scavenged by SOD during the late phase of TSH-treatment, presumably as an adaptive measure to check the oxygen burst.	Thyrotropin	90-93	superoxide dismutase 1	Homo sapiens	61-64
9349585-9	1997	hCG, and to a greater extent ds-hCG and dg-hCG, inhibited, as did TSH, gamma-interferon-induced human leukocyte antigen-DR (HLA-DR) expression in human thyrocytes, again reflecting the intrinsic thyrotropic activity of native hCG and its variants depleted of sialic acid or carbohydrate residues.	Thyrotropin	66-69	chorionic gonadotropin subunit beta 5	Homo sapiens	32-35
9349585-9	1997	hCG, and to a greater extent ds-hCG and dg-hCG, inhibited, as did TSH, gamma-interferon-induced human leukocyte antigen-DR (HLA-DR) expression in human thyrocytes, again reflecting the intrinsic thyrotropic activity of native hCG and its variants depleted of sialic acid or carbohydrate residues.	Thyrotropin	66-69	chorionic gonadotropin subunit beta 5	Homo sapiens	32-35
9349585-9	1997	hCG, and to a greater extent ds-hCG and dg-hCG, inhibited, as did TSH, gamma-interferon-induced human leukocyte antigen-DR (HLA-DR) expression in human thyrocytes, again reflecting the intrinsic thyrotropic activity of native hCG and its variants depleted of sialic acid or carbohydrate residues.	Thyrotropin	66-69	chorionic gonadotropin subunit beta 5	Homo sapiens	32-35
9349586-3	1997	Although transforming growth factor-beta1 (TGFbeta1) is known to affect thyroid cell function, it is still unclear how TGFbeta1 regulates TSH-stimulated iodide accumulation.	Thyrotropin	138-141	transforming growth factor, beta 1	Rattus norvegicus	119-127
9349586-4	1997	Therefore, the effects of TGFbeta1 on TSH-stimulated NIS mRNA and protein levels were examined in FRTL-5 rat thyroid cells by Northern and Western blot analyses, and iodide uptake was assessed.	Thyrotropin	38-41	transforming growth factor, beta 1	Rattus norvegicus	26-34
9316456-6	1997	We conclude that TNF-alpha, through a sphingomyelinase-ceramide pathway, regulates TSH-induced H2O2 production at steps beyond the Ca2+ mobilization step in the PLC-Ca2+ signaling pathway coupled to TSH.	Thyrotropin	83-86	tumor necrosis factor	Rattus norvegicus	17-26
9316456-0	1997	Inhibition of TSH-induced hydrogen peroxide production by TNF-alpha through a sphingomyelinase signaling pathway.	Thyrotropin	14-17	tumor necrosis factor	Rattus norvegicus	58-67
9316456-6	1997	We conclude that TNF-alpha, through a sphingomyelinase-ceramide pathway, regulates TSH-induced H2O2 production at steps beyond the Ca2+ mobilization step in the PLC-Ca2+ signaling pathway coupled to TSH.	Thyrotropin	199-202	tumor necrosis factor	Rattus norvegicus	17-26
9316456-3	1997	In the present study, we found that TNF-alpha inhibits TSH-induced H2O2 production, which is an inevitable process for iodide organification, and hence thyroid hormone synthesis, in FRTL-5 thyroid cells.	Thyrotropin	55-58	tumor necrosis factor	Rattus norvegicus	36-45
9275045-7	1997	Thyroid hormone deprivation rapidly increased the serum TSH level in both TR beta+/+ and TR beta-/- mice, reaching a similar level in the absence of thyroid hormone.	Thyrotropin	56-59	apoptosis antagonizing transcription factor	Mus musculus	74-81
9299474-4	1997	Not all TSH effects, especially in neurological and psychiatric disease states, can readily be explained by the action of the hormone on the thyroid gland and/or TRH levels.	Thyrotropin	8-11	thyrotropin releasing hormone	Homo sapiens	162-165
9275045-7	1997	Thyroid hormone deprivation rapidly increased the serum TSH level in both TR beta+/+ and TR beta-/- mice, reaching a similar level in the absence of thyroid hormone.	Thyrotropin	56-59	apoptosis antagonizing transcription factor	Mus musculus	89-96
9275048-1	1997	We demonstrated previously that TSH activates phospholipase D (PLD) via stimulation of protein kinase C (PKC) in Fischer rat thyroid line (FRTL)-5 thyroid cells.	Thyrotropin	32-35	protein kinase C, gamma	Rattus norvegicus	87-103
9275048-1	1997	We demonstrated previously that TSH activates phospholipase D (PLD) via stimulation of protein kinase C (PKC) in Fischer rat thyroid line (FRTL)-5 thyroid cells.	Thyrotropin	32-35	protein kinase C, gamma	Rattus norvegicus	105-108
9442572-4	1997	On the other hand, subchronic cadmium chloride administration for 14 days, increased plasma levels of GH (13.39 +/- 2.74 vs. 6.71 +/- 1.3 ng/mL, p < 0.05), TSH (27.8 +/- 4.42 vs. 6.65 +/- 1.15 ng/mL, p < 0.001), LH (11.1 +/- 1.3 vs. 5.18 +/- 0.28 ng/mL, p < 0.001) and FSH (53.16 +/- 3.66 vs. 12.51 +/- 1.45, p < 0.001), whereas plasma prolactin levels decreased (6.86 +/- 1.38 vs. 16.2 +/- 2.7 ng/mL, p < 0.01).	Thyrotropin	159-162	gonadotropin releasing hormone receptor	Rattus norvegicus	102-104
9373451-0	1997	Influence of residual C-peptide secretion on nocturnal serum TSH peak in well-controlled diabetic patients.	Thyrotropin	61-64	insulin	Homo sapiens	22-31
9342543-7	1997	TSH levels were abnormal in only one relative of the group without endocrinopathy but occurred in 6 relatives of the proband with overt endocrinopathy-associated diabetes (p < 0.02) in marked association with TPO antibodies (p < 10(-4).	Thyrotropin	0-3	thyroid peroxidase	Homo sapiens	212-215
9447286-11	1997	Prior to adrenalectomy, TSH, GH or LH showed a low response to TRH, GHRH or LHRH, respectively.	Thyrotropin	24-27	growth hormone releasing hormone	Homo sapiens	68-72
9242683-5	1997	TSH/cAMP decreases TTF-1 complex formation with the silencer, thereby decreasing maximal class I expression; TSH/cAMP enhance TSEP-1 and Pax-8 complex formation in association with their repressive actions.	Thyrotropin	0-3	NK2 homeobox 1	Homo sapiens	19-24
9242683-5	1997	TSH/cAMP decreases TTF-1 complex formation with the silencer, thereby decreasing maximal class I expression; TSH/cAMP enhance TSEP-1 and Pax-8 complex formation in association with their repressive actions.	Thyrotropin	0-3	paired box 8	Homo sapiens	137-142
9242683-7	1997	TSEP-1, TTF-1, and/or Pax-8 are involved in TSH/cAMP-induced negative regulation of the TSH receptor gene in thyrocytes, suppression of MHC class II, and up-regulation of thyroglobulin.	Thyrotropin	44-47	NK2 homeobox 1	Homo sapiens	8-13
9242683-7	1997	TSEP-1, TTF-1, and/or Pax-8 are involved in TSH/cAMP-induced negative regulation of the TSH receptor gene in thyrocytes, suppression of MHC class II, and up-regulation of thyroglobulin.	Thyrotropin	44-47	paired box 8	Homo sapiens	22-27
9242683-7	1997	TSEP-1, TTF-1, and/or Pax-8 are involved in TSH/cAMP-induced negative regulation of the TSH receptor gene in thyrocytes, suppression of MHC class II, and up-regulation of thyroglobulin.	Thyrotropin	44-47	thyroid stimulating hormone receptor	Homo sapiens	88-100
9260746-1	1997	Previous studies revealed that NGF-like immunoreactivity is present in cells from the adult rat anterior pituitary lobe, both in vivo and in vitro, and that in both situations NGF colocalizes with the thyroid-stimulating hormone (TSH).	Thyrotropin	230-233	nerve growth factor	Rattus norvegicus	176-179
9260746-2	1997	More recently, brain-derived neurotrophic factor (BDNF) was similarly found to occur in the anterior pituitary tissue, again with a general colocalization with TSH.	Thyrotropin	160-163	brain-derived neurotrophic factor	Rattus norvegicus	15-48
9260746-2	1997	More recently, brain-derived neurotrophic factor (BDNF) was similarly found to occur in the anterior pituitary tissue, again with a general colocalization with TSH.	Thyrotropin	160-163	brain-derived neurotrophic factor	Rattus norvegicus	50-54
9447286-11	1997	Prior to adrenalectomy, TSH, GH or LH showed a low response to TRH, GHRH or LHRH, respectively.	Thyrotropin	24-27	gonadotropin releasing hormone 1	Homo sapiens	76-80
9274703-14	1997	Both the amplitude and duration of hCG production (i.e. the global exposure of the thyroid gland to hCG) are responsible for increased thyroidal stimulation, leading more frequently to increased free T4 and suppressed TSH levels.	Thyrotropin	218-221	chorionic gonadotropin subunit beta 5	Homo sapiens	35-38
9292955-9	1997	In contrast, both TSH (1 mU/mL) and forskolin (16 microM) decreased TGF beta 1 mRNA expression to about 70%, and this effect was abolished when follicles were pretreated with iodide (40 microM KI) in a concentration known to inhibit TSH action on cyclic adenosine monophosphate (cAMP) formation and proliferation.	Thyrotropin	18-21	transforming growth factor beta 1	Homo sapiens	68-78
9215283-0	1997	The human thyrotropin (TSH) receptor in a TSH binding inhibition assay for TSH receptor autoantibodies.	Thyrotropin	23-26	thyroid stimulating hormone receptor	Homo sapiens	75-87
9215283-1	1997	Seven years after the molecular cloning of the human TSH receptor (TSHR), the porcine TSHR remains in general use in the TSH binding inhibition (TBI) assay for autoantibodies to the TSHR.	Thyrotropin	53-56	thyroid stimulating hormone receptor	Homo sapiens	67-71
9274703-14	1997	Both the amplitude and duration of hCG production (i.e. the global exposure of the thyroid gland to hCG) are responsible for increased thyroidal stimulation, leading more frequently to increased free T4 and suppressed TSH levels.	Thyrotropin	218-221	chorionic gonadotropin subunit beta 5	Homo sapiens	100-103
9177393-1	1997	We have previously demonstrated antagonistic interactions between the major signal transduction pathways in human thyroid follicles: TSH acting via protein kinase A (PKA) attenuated phorbol ester [acting via protein kinase C (PKC)] as well as epidermal growth factor (EGF)-protein tyrosine kinase (PTK)-mediated cell proliferation, whereas the PKC and PTK pathways inhibited PKA-mediated cell differentiation.	Thyrotropin	133-136	epidermal growth factor	Homo sapiens	268-271
9165005-1	1997	To investigate the mechanism of I- transport stimulation by TSH, we studied the effects of TSH on Na+/I- symporter (NIS) messenger RNA (mRNA) and protein levels in FRTL-5 cells and correlated these with I- transport activity.	Thyrotropin	91-94	solute carrier family 5 member 5	Rattus norvegicus	98-114
9177393-1	1997	We have previously demonstrated antagonistic interactions between the major signal transduction pathways in human thyroid follicles: TSH acting via protein kinase A (PKA) attenuated phorbol ester [acting via protein kinase C (PKC)] as well as epidermal growth factor (EGF)-protein tyrosine kinase (PTK)-mediated cell proliferation, whereas the PKC and PTK pathways inhibited PKA-mediated cell differentiation.	Thyrotropin	133-136	protein tyrosine kinase 2 beta	Homo sapiens	298-301
9165005-1	1997	To investigate the mechanism of I- transport stimulation by TSH, we studied the effects of TSH on Na+/I- symporter (NIS) messenger RNA (mRNA) and protein levels in FRTL-5 cells and correlated these with I- transport activity.	Thyrotropin	91-94	solute carrier family 5 member 5	Rattus norvegicus	116-119
9165005-4	1997	D-ribofranosylbenzimidazole, a transcription inhibitor, almost completely blocked TSH-induced stimulation of I- transport and NIS mRNA levels.	Thyrotropin	82-85	solute carrier family 5 member 5	Rattus norvegicus	126-129
9177393-7	1997	TSH induced an increase in c-jun and c-fos mRNA, which, though significant, was small compared to that elicited by TPA or EGF.	Thyrotropin	0-3	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	27-32
9177393-7	1997	TSH induced an increase in c-jun and c-fos mRNA, which, though significant, was small compared to that elicited by TPA or EGF.	Thyrotropin	0-3	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	37-42
9165005-5	1997	Western blot analysis demonstrated that TSH increased NIS protein levels at 36 h, reaching a maximum at 72 h, in parallel with the kinetics of TSH-induced I- transport activity.	Thyrotropin	40-43	solute carrier family 5 member 5	Rattus norvegicus	54-57
9165005-6	1997	However, it also showed that the amount of NIS protein already present in FRTL-5 cell membranes before the addition of TSH was about one third of the maximum level induced by TSH.	Thyrotropin	119-122	solute carrier family 5 member 5	Rattus norvegicus	43-46
9165005-7	1997	These results indicate that stimulation of I- transport activity by TSH in thyrocytes is partly due to a rapid increase in NIS gene expression, followed by a relatively slow NIS protein synthesis.	Thyrotropin	68-71	solute carrier family 5 member 5	Rattus norvegicus	123-126
9165005-7	1997	These results indicate that stimulation of I- transport activity by TSH in thyrocytes is partly due to a rapid increase in NIS gene expression, followed by a relatively slow NIS protein synthesis.	Thyrotropin	68-71	solute carrier family 5 member 5	Rattus norvegicus	174-177
9177393-1	1997	We have previously demonstrated antagonistic interactions between the major signal transduction pathways in human thyroid follicles: TSH acting via protein kinase A (PKA) attenuated phorbol ester [acting via protein kinase C (PKC)] as well as epidermal growth factor (EGF)-protein tyrosine kinase (PTK)-mediated cell proliferation, whereas the PKC and PTK pathways inhibited PKA-mediated cell differentiation.	Thyrotropin	133-136	protein tyrosine kinase 2 beta	Homo sapiens	352-355
9112403-4	1997	TSH-stimulated cultured human thyroid cells exposed for 72 h to IL-1beta (0.0002-20 microg/liter = 1-105 IU/liter) exhibited a dose-dependent and reversible inhibition of thyroglobulin and cAMP release and a dose-dependent stimulation of cGMP and IL-6 release.	Thyrotropin	0-3	interleukin 1 beta	Homo sapiens	64-72
9228893-0	1997	Exaggerated TSH responses to TRH in depressed patients with "normal" baseline TSH.	Thyrotropin	12-15	thyrotropin releasing hormone	Homo sapiens	29-32
9228893-5	1997	A rise in TSH after TRH (peak value minus baseline) of > 25 mIU/L represented an exaggerated TSH response.	Thyrotropin	10-13	thyrotropin releasing hormone	Homo sapiens	20-23
9228893-5	1997	A rise in TSH after TRH (peak value minus baseline) of > 25 mIU/L represented an exaggerated TSH response.	Thyrotropin	96-99	thyrotropin releasing hormone	Homo sapiens	20-23
9112403-4	1997	TSH-stimulated cultured human thyroid cells exposed for 72 h to IL-1beta (0.0002-20 microg/liter = 1-105 IU/liter) exhibited a dose-dependent and reversible inhibition of thyroglobulin and cAMP release and a dose-dependent stimulation of cGMP and IL-6 release.	Thyrotropin	0-3	thyroglobulin	Homo sapiens	171-184
9112403-4	1997	TSH-stimulated cultured human thyroid cells exposed for 72 h to IL-1beta (0.0002-20 microg/liter = 1-105 IU/liter) exhibited a dose-dependent and reversible inhibition of thyroglobulin and cAMP release and a dose-dependent stimulation of cGMP and IL-6 release.	Thyrotropin	0-3	interleukin 6	Homo sapiens	247-251
9100579-2	1997	We report here that a child with features of TSH resistance, including markedly increased serum TSH concentrations and low normal thyroid hormone levels, is a compound heterozygote for two novel mutations in the TSH receptor gene.	Thyrotropin	45-48	thyroid stimulating hormone receptor	Homo sapiens	212-224
9100579-2	1997	We report here that a child with features of TSH resistance, including markedly increased serum TSH concentrations and low normal thyroid hormone levels, is a compound heterozygote for two novel mutations in the TSH receptor gene.	Thyrotropin	96-99	thyroid stimulating hormone receptor	Homo sapiens	212-224
9002992-0	1997	Thyroid-stimulating hormone-induced down-regulation of thyroid transcription factor 1 in rat thyroid FRTL-5 cells.	Thyrotropin	0-27	transcription termination factor 1	Rattus norvegicus	55-85
9121114-0	1997	Thyroid-stimulating hormone promotes growth of thyroid carcinomas in transgenic mice with targeted expression of the ret/PTC1 oncogene.	Thyrotropin	0-27	ret proto-oncogene	Mus musculus	117-120
9121114-0	1997	Thyroid-stimulating hormone promotes growth of thyroid carcinomas in transgenic mice with targeted expression of the ret/PTC1 oncogene.	Thyrotropin	0-27	patched 1	Mus musculus	121-125
9121114-10	1997	Our results show that ret/PTC1-induced thyroid follicular cell carcinomas retain TSH responsiveness and maintain a benign biologic behavior despite histologic evidence of anaplasia.	Thyrotropin	81-84	ret proto-oncogene	Mus musculus	22-25
9121114-10	1997	Our results show that ret/PTC1-induced thyroid follicular cell carcinomas retain TSH responsiveness and maintain a benign biologic behavior despite histologic evidence of anaplasia.	Thyrotropin	81-84	patched 1	Mus musculus	26-30
9142647-2	1997	TNF-alpha is only cytotoxic to aged (> 40 passages) FRTL-5 cells grown in TSH-containing medium, whereas TGF-beta induces programmed cell death (apoptosis) in epithelial cells but not in FRTL-5 cells, which otherwise retain many properties of normal thyroid follicular cells.	Thyrotropin	77-80	tumor necrosis factor	Rattus norvegicus	0-9
9142647-4	1997	One prominent effect of TNF-alpha (and TGF-beta 1) on FRTL-5 cell function is suppression of iodide uptake, which is markedly stimulated by TSH.	Thyrotropin	140-143	tumor necrosis factor	Rattus norvegicus	24-33
9142647-4	1997	One prominent effect of TNF-alpha (and TGF-beta 1) on FRTL-5 cell function is suppression of iodide uptake, which is markedly stimulated by TSH.	Thyrotropin	140-143	transforming growth factor, beta 1	Rattus norvegicus	39-49
9002992-2	1997	The role of TSH in the regulation of TTF-1 messenger RNA (mRNA) and protein abundance was investigated in rat thyroid FRTL-5 cells.	Thyrotropin	12-15	transcription termination factor 1	Rattus norvegicus	37-42
9030820-2	1997	Neuromedin B is a bombesin-like peptide highly concentrated in the pituitary gland that has been shown to have inhibitory action on TSH secretion, acting as an autocrine/paracrine factor.	Thyrotropin	132-135	neuromedin B	Rattus norvegicus	0-12
9161839-5	1997	Logarithmically transformed values of U-EGF were inversely correlated with TSH serum levels (p = 0.0000), but positively associated with T4 levels (p = 0.0005).	Thyrotropin	75-78	epidermal growth factor	Homo sapiens	40-43
9189008-9	1997	However, Fab expressed by individual clones or from enriched libraries were not specific as determined by (i) binding to purified, radio-labeled antigen, (ii) FACS analysis of TSHR on intact CHO cells and, (iii) inhibition of radiolabeled TSH binding.	Thyrotropin	176-179	FA complementation group B	Homo sapiens	9-12
9007042-8	1997	Increased thyroid T4 elimination, primarily via increased hepatic conjugation by T4-UDPGT, resulting in decreased serum T4, appeared to be responsible for the increased TSH levels.	Thyrotropin	169-172	UDP glucuronosyltransferase family 1 member A1	Rattus norvegicus	84-89
8940336-11	1996	Essentially all TRH-responsive cells stained for either PRL or TSH.	Thyrotropin	63-66	thyrotropin releasing hormone	Rattus norvegicus	16-19
9396064-1	1997	Thyrotropin-releasing hormone (TRH) from the hypothalamus is the major regulator of TSH synthesis and secretion.	Thyrotropin	84-87	thyrotropin releasing hormone	Rattus norvegicus	0-29
9396064-1	1997	Thyrotropin-releasing hormone (TRH) from the hypothalamus is the major regulator of TSH synthesis and secretion.	Thyrotropin	84-87	thyrotropin releasing hormone	Rattus norvegicus	31-34
9001192-17	1996	We conclude that augmentation of TSH-R expression levels, and thus potential ligand binding sites, may indicate an important regulatory principle in the pathogenesis of autoimmune hyperthyroidism in vivo: the responsiveness of the TSH-R to TSH and TSAb induced negative regulation is lost.	Thyrotropin	33-36	thyroid stimulating hormone receptor	Homo sapiens	231-236
8957478-0	1996	Thyroid-stimulating hormone promotes the secretion of vascular endothelial growth factor in thyroid cancer cell lines.	Thyrotropin	0-27	vascular endothelial growth factor A	Homo sapiens	54-88
8957478-2	1996	Because thyroid-stimulating hormone (TSH) promotes growth and progression of thyroid cancers, we postulated that TSH may increase the production and secretion of VEGF by thyroid cancer cells.	Thyrotropin	37-40	vascular endothelial growth factor A	Homo sapiens	162-166
8957478-7	1996	All thyroid cancer cells secrete significantly more VEGF than normal thyroid cells after TSH (10 mIU/ml) stimulation (p < 0.05).	Thyrotropin	89-92	vascular endothelial growth factor A	Homo sapiens	52-56
8957478-9	1996	CONCLUSIONS: These results suggest that VEGF secretion is constitutively activated in some thyroid cancers and that VEGF secretion is stimulated by TSH; thus TSH may promote growth in some thyroid cancers by stimulating VEGF secretion and angiogenesis.	Thyrotropin	148-151	vascular endothelial growth factor A	Homo sapiens	116-120
8910605-3	1996	In the present study, in TSH-treated cells, IGF-I receptors and insulin receptors were paradoxically equivalent in their capacity to elicit the comitogenic pathway, which, however, was mediated only by IGF-I receptors in dog thyroid cells stimulated by cAMP-independent mitogens.	Thyrotropin	25-28	insulin like growth factor 1	Canis lupus familiaris	44-49
8957478-9	1996	CONCLUSIONS: These results suggest that VEGF secretion is constitutively activated in some thyroid cancers and that VEGF secretion is stimulated by TSH; thus TSH may promote growth in some thyroid cancers by stimulating VEGF secretion and angiogenesis.	Thyrotropin	148-151	vascular endothelial growth factor A	Homo sapiens	116-120
8957478-9	1996	CONCLUSIONS: These results suggest that VEGF secretion is constitutively activated in some thyroid cancers and that VEGF secretion is stimulated by TSH; thus TSH may promote growth in some thyroid cancers by stimulating VEGF secretion and angiogenesis.	Thyrotropin	158-161	vascular endothelial growth factor A	Homo sapiens	40-44
8957478-9	1996	CONCLUSIONS: These results suggest that VEGF secretion is constitutively activated in some thyroid cancers and that VEGF secretion is stimulated by TSH; thus TSH may promote growth in some thyroid cancers by stimulating VEGF secretion and angiogenesis.	Thyrotropin	158-161	vascular endothelial growth factor A	Homo sapiens	116-120
8957478-9	1996	CONCLUSIONS: These results suggest that VEGF secretion is constitutively activated in some thyroid cancers and that VEGF secretion is stimulated by TSH; thus TSH may promote growth in some thyroid cancers by stimulating VEGF secretion and angiogenesis.	Thyrotropin	158-161	vascular endothelial growth factor A	Homo sapiens	116-120
8910605-3	1996	In the present study, in TSH-treated cells, IGF-I receptors and insulin receptors were paradoxically equivalent in their capacity to elicit the comitogenic pathway, which, however, was mediated only by IGF-I receptors in dog thyroid cells stimulated by cAMP-independent mitogens.	Thyrotropin	25-28	insulin	Canis lupus familiaris	64-71
8910605-3	1996	In the present study, in TSH-treated cells, IGF-I receptors and insulin receptors were paradoxically equivalent in their capacity to elicit the comitogenic pathway, which, however, was mediated only by IGF-I receptors in dog thyroid cells stimulated by cAMP-independent mitogens.	Thyrotropin	25-28	insulin like growth factor 1	Canis lupus familiaris	202-207
8910605-4	1996	Moreover, prior cell exposure to TSH or forskolin increased their responsiveness to insulin, IGF-I, and IGF-II, as seen on DNA synthesis and activation of a common insulin/IGF signaling pathway.	Thyrotropin	33-36	insulin	Canis lupus familiaris	84-91
8910605-4	1996	Moreover, prior cell exposure to TSH or forskolin increased their responsiveness to insulin, IGF-I, and IGF-II, as seen on DNA synthesis and activation of a common insulin/IGF signaling pathway.	Thyrotropin	33-36	insulin like growth factor 1	Canis lupus familiaris	93-98
8910605-4	1996	Moreover, prior cell exposure to TSH or forskolin increased their responsiveness to insulin, IGF-I, and IGF-II, as seen on DNA synthesis and activation of a common insulin/IGF signaling pathway.	Thyrotropin	33-36	insulin	Canis lupus familiaris	164-171
8895321-3	1996	Similarly, [125I]TSH cross-linking to the surface of intact CHO cells revealed a progressive increase in TSH-binding sites with dihydrofolate reductase minigene amplification, with a 12.8-fold increase in TSHR in TSHR-10,000 vs. TSHR-0 cells.	Thyrotropin	17-20	thyrotropin receptor	Cricetulus griseus	205-209
8952005-9	1996	This rapid and marked effect on pituitary neuromedin B content, associated in time with TSH suppression, is in agreement with the hypothesis that neuromedin B may mediate at least in part, the acute suppression of TSH release by thyroid hormone, a hypothesis that still needs further verification.	Thyrotropin	214-217	neuromedin B	Rattus norvegicus	146-158
8895321-3	1996	Similarly, [125I]TSH cross-linking to the surface of intact CHO cells revealed a progressive increase in TSH-binding sites with dihydrofolate reductase minigene amplification, with a 12.8-fold increase in TSHR in TSHR-10,000 vs. TSHR-0 cells.	Thyrotropin	17-20	thyroid stimulating hormone receptor	Homo sapiens	213-217
8895321-7	1996	We assessed the kinetics of TSH binding to CHO cells overexpressing the TSHR using [125I]TSH in the presence of increasing concentrations of unlabeled TSH as well as by attempted saturation with labeled ligand.	Thyrotropin	28-31	thyrotropin receptor	Cricetulus griseus	72-76
8895321-3	1996	Similarly, [125I]TSH cross-linking to the surface of intact CHO cells revealed a progressive increase in TSH-binding sites with dihydrofolate reductase minigene amplification, with a 12.8-fold increase in TSHR in TSHR-10,000 vs. TSHR-0 cells.	Thyrotropin	17-20	thyrotropin receptor	Cricetulus griseus	213-217
8895335-3	1996	We have shown that TSH and forskolin, which both induce proliferation and differentiation of the thyroid cells by activation of the protein kinase A pathway, lead to a strong and transient expression of two NGFI-B mRNA species, which differ in the length of the poly(A) tail.	Thyrotropin	19-22	nuclear receptor subfamily 4 group A member 1	Canis lupus familiaris	207-213
8934215-0	1996	Suppression of TRH-stimulated TSH secretion by glucose-induced hypothalamic somatostatin release.	Thyrotropin	30-33	thyrotropin releasing hormone	Homo sapiens	15-18
8923467-2	1996	Mutation analyses indicate that it is functionally distinct from the TTF-1 element and is important for the constitutive expression and TSH/cAMP-induced negative autoregulation of the TSHR in thyroid cells but only constitutive expression in nonthyroid cells.	Thyrotropin	136-139	transcription termination factor 1	Rattus norvegicus	69-74
8923467-2	1996	Mutation analyses indicate that it is functionally distinct from the TTF-1 element and is important for the constitutive expression and TSH/cAMP-induced negative autoregulation of the TSHR in thyroid cells but only constitutive expression in nonthyroid cells.	Thyrotropin	136-139	thyroid stimulating hormone receptor	Rattus norvegicus	184-188
8923467-8	1996	This reverses TSH-induced negative regulation of the TSHR.	Thyrotropin	14-17	thyroid stimulating hormone receptor	Rattus norvegicus	53-57
8980894-4	1996	On the other hand, serum TSH increased significantly from a baseline of 1.70 +/- 0.82 to 3.34 +/- 1.98 microU/ml during IFN-beta administration (P < 0.005).	Thyrotropin	25-28	interferon beta 1	Homo sapiens	120-128
8930604-8	1996	The proposed TSH-mediated effect of CRF on thyroid function was further confirmed in two in vitro experiments in which oCRF did not directly influence the thyroidal T4 secretion but, when applied to pituitaries, clearly increased the alpha-subunit release.	Thyrotropin	13-16	ovomucin, alpha subunit	Gallus gallus	234-247
8959237-10	1996	hypothyroidism may be present in a substantial amount of psychogeriatric patients, as we found an adequate TSH response to exogenous thyrotropin-releasing hormone (TRH) also in patients with decreased fT3/fT4 and no signs of non thyroid diseases.	Thyrotropin	107-110	thyrotropin releasing hormone	Homo sapiens	133-162
8828468-5	1996	Chemical cross-linking of [125I]GLP-1-receptor complexes revealed a single band of 64,300 +/- 100 Mr in alpha-TSH membranes.	Thyrotropin	110-113	glucagon-like peptide 1 receptor	Mus musculus	32-46
8828468-9	1996	Furthermore, GLP-1 stimulates basal TSH release from dispersed anterior pituitary cells in a concentration-dependent manner (100 nM GLP-1, 63 +/- 3 fmol/10(6) cells.h; control, 35 +/- 1 fmol/10(6) cells.h; P < 0.0005), but had no effect on basal PRL, GH, or LH release.	Thyrotropin	36-39	glucagon	Mus musculus	13-18
8855796-4	1996	TSH (10 U/L) stimulated 3H-CMP-PA accumulation in an LiCl-and propranolol-insensitive way, as well as 2H-fatty acids incorporation into PA, diacylglycerol, and phosphatidylcholine (PtdCho) with on evidence of dose-dependent effects and had no detectable action on PLD activity.	Thyrotropin	0-3	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	264-267
8934215-10	1996	The oral glucose administration also significantly suppressed TRH-stimulated TSH response by 27-35% between 40 min and 80 min in Test 4.	Thyrotropin	77-80	thyrotropin releasing hormone	Homo sapiens	62-65
8934215-11	1996	In contrast, the pretreatment with PST completely reverted the suppressive effect of glucose on TRH-stimulated TSH response in Test 5.	Thyrotropin	111-114	thyrotropin releasing hormone	Homo sapiens	96-99
8934215-12	1996	These data suggest that the increased hypothalamic SRIH secretion induced by oral glucose administration can suppress TRH-stimulated TSH response in normal men, and the combined glucose-TRH test can be a useful method to evaluate the hypothalamic somatostatinergic activity.	Thyrotropin	133-136	thyrotropin releasing hormone	Homo sapiens	118-121
8949573-15	1996	The addition of TRH further increased this TSH response > ninefold (P = 0.005), elicited a 60% rise in serum T3 (P = 0.01) and an 18% increase in T4 (P = 0.005) levels, without altering rT3 or TBG levels.	Thyrotropin	43-46	thyrotropin releasing hormone	Homo sapiens	16-19
8949573-15	1996	The addition of TRH further increased this TSH response > ninefold (P = 0.005), elicited a 60% rise in serum T3 (P = 0.01) and an 18% increase in T4 (P = 0.005) levels, without altering rT3 or TBG levels.	Thyrotropin	43-46	serpin family A member 7	Homo sapiens	196-199
8754734-4	1996	Treatment of thyrocytes with 8-bromo-cAMP mimicked the effect of TSH, suggesting that the inhibitory effect of TSH on Fas antigen expression was mediated by activating protein kinase A.	Thyrotropin	65-68	Fas cell surface death receptor	Homo sapiens	118-129
8812207-13	1996	Increased metabolism of T4 via hepatic enzymatic conjugation (i.e., T4-UDPGT) appeared to be responsible for the increased TSH levels.	Thyrotropin	123-126	UDP glucuronosyltransferase family 1 member A1	Rattus norvegicus	71-76
8915692-3	1996	The gammaglobulin from each of the 3 patients with PGA and an isolated failure of secretion of adrenocorticotropic hormone (ACTH), thyroid stimulating hormone (TSH) or gonadotropin inhibited the secretion of ACTH, TSH or gonadotropin in cultures of rat anterior pituitary cells.	Thyrotropin	131-158	proopiomelanocortin	Homo sapiens	208-212
8915692-3	1996	The gammaglobulin from each of the 3 patients with PGA and an isolated failure of secretion of adrenocorticotropic hormone (ACTH), thyroid stimulating hormone (TSH) or gonadotropin inhibited the secretion of ACTH, TSH or gonadotropin in cultures of rat anterior pituitary cells.	Thyrotropin	214-217	proopiomelanocortin	Homo sapiens	95-122
8915692-3	1996	The gammaglobulin from each of the 3 patients with PGA and an isolated failure of secretion of adrenocorticotropic hormone (ACTH), thyroid stimulating hormone (TSH) or gonadotropin inhibited the secretion of ACTH, TSH or gonadotropin in cultures of rat anterior pituitary cells.	Thyrotropin	214-217	proopiomelanocortin	Homo sapiens	208-212
8905697-4	1996	In the anterior lobe, varying degrees of BDNF immunoreactivity were observed exclusively in cells shown by double-labeling techniques to contain thyroid stimulating hormone (TSH), although not all TSH-positive cells contained detectable BDNF labeling.	Thyrotropin	145-172	brain-derived neurotrophic factor	Rattus norvegicus	41-45
8905697-4	1996	In the anterior lobe, varying degrees of BDNF immunoreactivity were observed exclusively in cells shown by double-labeling techniques to contain thyroid stimulating hormone (TSH), although not all TSH-positive cells contained detectable BDNF labeling.	Thyrotropin	174-177	brain-derived neurotrophic factor	Rattus norvegicus	41-45
8886857-8	1996	IL-1 reduced the TPO content and inhibited the TSH-induced increase in TPO in a concentration-dependent manner.	Thyrotropin	47-50	interleukin 1 beta	Homo sapiens	0-4
8886857-8	1996	IL-1 reduced the TPO content and inhibited the TSH-induced increase in TPO in a concentration-dependent manner.	Thyrotropin	47-50	thyroid peroxidase	Homo sapiens	71-74
8784084-7	1996	At baseline and after 6 and 18 months, TSH receptor antibodies were measured both by the ability of patients" sera to stimulate cAMP production by FRTL-5 cells (thyroid-stimulating Ig) and by the ability of patients" sera to inhibit binding of radiolabeled TSH to solubilized porcine thyroid membranes (TSH-binding, inhibiting Ig).	Thyrotropin	257-260	thyroid stimulating hormone receptor	Homo sapiens	39-51
8892315-4	1996	Incorporation of [3H]thymidine and increase in cell number was slightly inhibited by TSH in TSHR-expressing cells in vitro.	Thyrotropin	85-88	thyroid stimulating hormone receptor	Homo sapiens	92-96
8892315-8	1996	The present results suggest a TSH-mediated growth inhibition in the TSHR-transfected C 643 anaplastic thyroid carcinoma cells.	Thyrotropin	30-33	thyroid stimulating hormone receptor	Homo sapiens	68-72
8754734-5	1996	In contrast, treatment of thyrocytes with either interleukin-1 beta (IL-1 beta) or interferon- gamma (IFN gamma) markedly increased Fas antigen expression on thyrocytes, and these effects were inhibited in the presence of TSH.	Thyrotropin	222-225	interleukin 1 beta	Homo sapiens	49-67
8754734-5	1996	In contrast, treatment of thyrocytes with either interleukin-1 beta (IL-1 beta) or interferon- gamma (IFN gamma) markedly increased Fas antigen expression on thyrocytes, and these effects were inhibited in the presence of TSH.	Thyrotropin	222-225	interleukin 1 beta	Homo sapiens	69-78
8754734-5	1996	In contrast, treatment of thyrocytes with either interleukin-1 beta (IL-1 beta) or interferon- gamma (IFN gamma) markedly increased Fas antigen expression on thyrocytes, and these effects were inhibited in the presence of TSH.	Thyrotropin	222-225	interferon gamma	Homo sapiens	83-100
8754734-5	1996	In contrast, treatment of thyrocytes with either interleukin-1 beta (IL-1 beta) or interferon- gamma (IFN gamma) markedly increased Fas antigen expression on thyrocytes, and these effects were inhibited in the presence of TSH.	Thyrotropin	222-225	interferon gamma	Homo sapiens	102-111
8754734-5	1996	In contrast, treatment of thyrocytes with either interleukin-1 beta (IL-1 beta) or interferon- gamma (IFN gamma) markedly increased Fas antigen expression on thyrocytes, and these effects were inhibited in the presence of TSH.	Thyrotropin	222-225	Fas cell surface death receptor	Homo sapiens	132-143
8754734-7	1996	When thyrocytes stimulated with either IL-1 beta or IFN gamma were treated with anti-Fas IgM mAb, the cells were committed to apoptosis, whereas this apoptotic process was significantly inhibited by the addition of TSH.	Thyrotropin	215-218	interleukin 1 beta	Homo sapiens	39-48
8754734-7	1996	When thyrocytes stimulated with either IL-1 beta or IFN gamma were treated with anti-Fas IgM mAb, the cells were committed to apoptosis, whereas this apoptotic process was significantly inhibited by the addition of TSH.	Thyrotropin	215-218	interferon gamma	Homo sapiens	52-61
8768874-12	1996	This Study shows that enhanced production of IGFBPs is correlated with inhibition of thyroid function and that TSH, through cAMP, is one factor capable of inhibiting IGFBP production.	Thyrotropin	111-114	insulin like growth factor binding protein 3	Homo sapiens	45-50
8813721-11	1996	Pax-8 and TTF-1 binding activities were gradually increased during the initial 6 h after TSH.	Thyrotropin	89-92	paired box 8	Rattus norvegicus	0-5
8768874-10	1996	In contrast, protein kinase C activation with phorbol esters and transforming growth factor beta, and high TSH concentrations enhanced IGFBP secretion.	Thyrotropin	107-110	insulin like growth factor binding protein 3	Homo sapiens	135-140
8768874-11	1996	Steady-state levels of IGFBP-3 and IGFBP-5 messenger RNAs were elevated after treatment with transforming growth factor-beta and high TSH concentrations.	Thyrotropin	134-137	insulin like growth factor binding protein 3	Homo sapiens	23-30
8768874-11	1996	Steady-state levels of IGFBP-3 and IGFBP-5 messenger RNAs were elevated after treatment with transforming growth factor-beta and high TSH concentrations.	Thyrotropin	134-137	insulin like growth factor binding protein 5	Homo sapiens	35-42
8832398-6	1996	Nevertheless, in the case of stimulation by TSH alone, the cAMP-dependent cell cycle progression was fully compatible with the enhanced expression of p27kip1.	Thyrotropin	44-47	cyclin dependent kinase inhibitor 1B	Canis lupus familiaris	150-157
8875754-10	1996	The present results show an inhibitory effect of excess iodide on TSH-stimulated thyroglobulin biosynthesis in FRTL-5 cells.	Thyrotropin	66-69	thyroglobulin	Rattus norvegicus	81-94
8765983-14	1996	During these conditions, the mitogenic effect of IGF-I is partially inhibited by TSH, which has no growth-promoting action on its own.	Thyrotropin	81-84	insulin like growth factor 1	Sus scrofa	49-54
8813721-11	1996	Pax-8 and TTF-1 binding activities were gradually increased during the initial 6 h after TSH.	Thyrotropin	89-92	transcription termination factor 1	Rattus norvegicus	10-15
8612490-1	1996	The effects of interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF alpha) on basal and TRH-induced TSH release, and the effects of IL-1 beta on the uptake of [125I]T3 and [125I]T4 and on nuclear binding of [125I]T3 were examined.	Thyrotropin	115-118	tumor necrosis factor	Rattus norvegicus	79-88
8828910-4	1996	Addition of purified PP-1 and PP-2A to crude membranes from cells preincubated with OA, reversed OA-induced adenylyl cyclase inhibition, confirming that these protein phosphatases regulate TSH-mediated cAMP production.	Thyrotropin	189-192	inorganic pyrophosphatase 1	Homo sapiens	21-25
8828910-4	1996	Addition of purified PP-1 and PP-2A to crude membranes from cells preincubated with OA, reversed OA-induced adenylyl cyclase inhibition, confirming that these protein phosphatases regulate TSH-mediated cAMP production.	Thyrotropin	189-192	protein phosphatase 2 phosphatase activator	Homo sapiens	30-35
8828910-7	1996	H-7, an inhibitor of nucleotide- and calcium/phospholipid-dependent protein kinase (PKC), increased by 197% the stimulation of cAMP accumulation by TSH in thyroid cells.	Thyrotropin	148-151	proline rich transmembrane protein 2	Homo sapiens	84-87
8807635-10	1996	The effect mimics the action of TSH as it activates Gs alpha and enhances the action of forskolin.	Thyrotropin	32-35	GNAS complex locus	Homo sapiens	52-60
8612490-5	1996	Exposure to IL-1 beta (1 pM-1 nM) or TNF alpha (100 pM) for 2-4 h resulted in a significant decline in TSH release, which was almost 50% (P < 0.05) for 1 nM IL-1 beta and 24% (P < 0.05) for 100 pM TNF alpha.	Thyrotropin	103-106	interleukin 1 beta	Rattus norvegicus	12-21
8612545-1	1996	We have investigated the mechanism by which TSH pretreatment potentiates insulin-like growth factor I (IGF-I)-induced DNA synthesis in FRTL-5 cells.	Thyrotropin	44-47	insulin-like growth factor 1	Rattus norvegicus	73-101
8612490-5	1996	Exposure to IL-1 beta (1 pM-1 nM) or TNF alpha (100 pM) for 2-4 h resulted in a significant decline in TSH release, which was almost 50% (P < 0.05) for 1 nM IL-1 beta and 24% (P < 0.05) for 100 pM TNF alpha.	Thyrotropin	103-106	tumor necrosis factor	Rattus norvegicus	37-46
8612545-1	1996	We have investigated the mechanism by which TSH pretreatment potentiates insulin-like growth factor I (IGF-I)-induced DNA synthesis in FRTL-5 cells.	Thyrotropin	44-47	insulin-like growth factor 1	Rattus norvegicus	103-108
8612545-5	1996	When the time course of thymidine uptake after IGF-I addition was studied, TSH pretreatment increased the maximum DNA incorporation and shortened the G1 phase interval.	Thyrotropin	75-78	insulin-like growth factor 1	Rattus norvegicus	47-52
8612490-5	1996	Exposure to IL-1 beta (1 pM-1 nM) or TNF alpha (100 pM) for 2-4 h resulted in a significant decline in TSH release, which was almost 50% (P < 0.05) for 1 nM IL-1 beta and 24% (P < 0.05) for 100 pM TNF alpha.	Thyrotropin	103-106	interleukin 1 beta	Rattus norvegicus	160-169
8612490-5	1996	Exposure to IL-1 beta (1 pM-1 nM) or TNF alpha (100 pM) for 2-4 h resulted in a significant decline in TSH release, which was almost 50% (P < 0.05) for 1 nM IL-1 beta and 24% (P < 0.05) for 100 pM TNF alpha.	Thyrotropin	103-106	tumor necrosis factor	Rattus norvegicus	203-212
8612545-7	1996	Cyclins are key regulators of the cell cycle; therefore, we investigated the expression of cyclins D1 and E after TSH stimulation.	Thyrotropin	114-117	cyclin D1	Rattus norvegicus	91-107
8612490-7	1996	When the effects of IL-1 beta (1 pM-1 nM) and TNF alpha (100 pM) on TRH-induced TSH release were measured in short term experiments, the inhibitory effects had disappeared.	Thyrotropin	80-83	interleukin 1 beta	Rattus norvegicus	20-29
8612545-8	1996	TSH- and A kinase-activating agents increased the expression of cyclins D1 and E after 24 h. The same amounts of cyclins D1 and E induced by IGF-I were increased after TSH pretreatment.	Thyrotropin	0-3	cyclin D1	Rattus norvegicus	64-80
8612490-7	1996	When the effects of IL-1 beta (1 pM-1 nM) and TNF alpha (100 pM) on TRH-induced TSH release were measured in short term experiments, the inhibitory effects had disappeared.	Thyrotropin	80-83	tumor necrosis factor	Rattus norvegicus	46-55
8612545-8	1996	TSH- and A kinase-activating agents increased the expression of cyclins D1 and E after 24 h. The same amounts of cyclins D1 and E induced by IGF-I were increased after TSH pretreatment.	Thyrotropin	0-3	cyclin D1	Rattus norvegicus	113-129
8612490-11	1996	When IL-1 beta (100 pM) was present during 3 days of culture, TSH release was reduced to 88 +/- 2% of the control value (P < 0.05).	Thyrotropin	62-65	interleukin 1 beta	Rattus norvegicus	5-14
8612545-8	1996	TSH- and A kinase-activating agents increased the expression of cyclins D1 and E after 24 h. The same amounts of cyclins D1 and E induced by IGF-I were increased after TSH pretreatment.	Thyrotropin	0-3	insulin-like growth factor 1	Rattus norvegicus	141-146
8612545-9	1996	TSH pretreatment induced the expression of G1 cyclin in FRTL-5 cells, and IGF-I caused the accumulation of enough G1 cyclins to drive the cell cycle from G1 to S phase in a short time, which accounts for the effect of TSH on IGF-I induced DNA synthesis.	Thyrotropin	0-3	insulin-like growth factor 1	Rattus norvegicus	225-230
8612490-13	1996	We conclude that 1) IL-1 beta decreases TSH release by a direct action on the pituitary; 2) this effect is not due to elevated thyroid hormone uptake or increase T3 nuclear occupancy; 3) IL-1 beta does not affect TRH-induced TSH release or the release of other anterior pituitary hormones; and 4) TNF alpha affects basal and TRH-induced TSH release in the same way as IL-1 beta.	Thyrotropin	40-43	interleukin 1 beta	Rattus norvegicus	20-29
8612545-9	1996	TSH pretreatment induced the expression of G1 cyclin in FRTL-5 cells, and IGF-I caused the accumulation of enough G1 cyclins to drive the cell cycle from G1 to S phase in a short time, which accounts for the effect of TSH on IGF-I induced DNA synthesis.	Thyrotropin	218-221	insulin-like growth factor 1	Rattus norvegicus	74-79
8612408-8	1996	MEASUREMENTS AND MAIN RESULTS: There was a > 100-fold interindividual variation in the baseline TSH concentration and in the TSH peak value after TRH administration.	Thyrotropin	99-102	thyrotropin releasing hormone	Homo sapiens	149-152
8626871-9	1996	There was a statistically significant difference between the TRH-stimulated TSH response in test 4 compared to that in test 5.	Thyrotropin	76-79	thyrotropin releasing hormone	Homo sapiens	61-64
8612408-8	1996	MEASUREMENTS AND MAIN RESULTS: There was a > 100-fold interindividual variation in the baseline TSH concentration and in the TSH peak value after TRH administration.	Thyrotropin	128-131	thyrotropin releasing hormone	Homo sapiens	149-152
8733883-12	1996	The differential induction of fos and jun family genes suggests an important role of their gene products on the regulation of thyroid cell function by TSH.	Thyrotropin	151-154	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	30-33
8733883-10	1996	TSH induced similar changes in the levels of c-jun and junB mRNAs.	Thyrotropin	0-3	JunB proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	55-59
8603567-7	1996	But cells grown in the presence of TSH (0.1 mU/ml) had a CA2+- and NADPH-dependent H2O2-generating activity that increased up to the third day in culture, as did the cell iodide organification capacity.	Thyrotropin	35-38	carbonic anhydrase 2	Canis lupus familiaris	57-62
8618941-4	1996	As expected, in euthyroid rats NB decreased basal and TRH-stimulated TSH release, but only at the highest concentration tested (10(-7) M).	Thyrotropin	69-72	neuromedin B	Rattus norvegicus	31-33
8618941-4	1996	As expected, in euthyroid rats NB decreased basal and TRH-stimulated TSH release, but only at the highest concentration tested (10(-7) M).	Thyrotropin	69-72	thyrotropin releasing hormone	Rattus norvegicus	54-57
8618941-5	1996	Incubation of the pituitaries from euthyroid rats with the antiserum against NB increased basal TSH release above that from glands of normal rabbit serum-incubated controls, as anticipated based on the concept that NB inhibits TSH release from the pituitary glands of euthyroid animals.	Thyrotropin	96-99	neuromedin B	Rattus norvegicus	77-79
8618941-5	1996	Incubation of the pituitaries from euthyroid rats with the antiserum against NB increased basal TSH release above that from glands of normal rabbit serum-incubated controls, as anticipated based on the concept that NB inhibits TSH release from the pituitary glands of euthyroid animals.	Thyrotropin	96-99	neuromedin B	Rattus norvegicus	215-217
8618941-5	1996	Incubation of the pituitaries from euthyroid rats with the antiserum against NB increased basal TSH release above that from glands of normal rabbit serum-incubated controls, as anticipated based on the concept that NB inhibits TSH release from the pituitary glands of euthyroid animals.	Thyrotropin	227-230	neuromedin B	Rattus norvegicus	77-79
8618941-5	1996	Incubation of the pituitaries from euthyroid rats with the antiserum against NB increased basal TSH release above that from glands of normal rabbit serum-incubated controls, as anticipated based on the concept that NB inhibits TSH release from the pituitary glands of euthyroid animals.	Thyrotropin	227-230	neuromedin B	Rattus norvegicus	215-217
8618941-9	1996	Surprisingly, pituitaries from hypothyroid rats showed a paradoxical increased release of TSH in response to the lowest concentration of NB (10(-11) M), which decreased with increasing concentrations and was not distinguishable from control release in the presence of TRH at the highest concentration of NB (10(-7) M).	Thyrotropin	90-93	neuromedin B	Rattus norvegicus	137-139
8618941-9	1996	Surprisingly, pituitaries from hypothyroid rats showed a paradoxical increased release of TSH in response to the lowest concentration of NB (10(-11) M), which decreased with increasing concentrations and was not distinguishable from control release in the presence of TRH at the highest concentration of NB (10(-7) M).	Thyrotropin	90-93	thyrotropin releasing hormone	Rattus norvegicus	268-271
8618941-9	1996	Surprisingly, pituitaries from hypothyroid rats showed a paradoxical increased release of TSH in response to the lowest concentration of NB (10(-11) M), which decreased with increasing concentrations and was not distinguishable from control release in the presence of TRH at the highest concentration of NB (10(-7) M).	Thyrotropin	90-93	neuromedin B	Rattus norvegicus	304-306
8618941-10	1996	We hypothesize that the increased responsiveness to the inhibition of basal TSH release by NB in the hypothyroid pituitaries may be related to an upregulation of NB receptors in this situation, in which the release of NB is diminished because of loss of feedback via thyroid hormones.	Thyrotropin	76-79	neuromedin B	Rattus norvegicus	91-93
8618941-14	1996	That NB was probably being secreted in vitro from the hyperthyroid pituitaries was indicated by an increased basal TSH release as well as a higher TSH medium concentration after TRH in the presence of the aNB.	Thyrotropin	115-118	neuromedin B	Rattus norvegicus	5-7
8618941-14	1996	That NB was probably being secreted in vitro from the hyperthyroid pituitaries was indicated by an increased basal TSH release as well as a higher TSH medium concentration after TRH in the presence of the aNB.	Thyrotropin	147-150	neuromedin B	Rattus norvegicus	5-7
8618941-16	1996	This downregulation of receptors in some manner reverses the inhibitory action of NB on basal and TRH-stimulated TSH release.	Thyrotropin	113-116	neuromedin B	Rattus norvegicus	82-84
8618941-16	1996	This downregulation of receptors in some manner reverses the inhibitory action of NB on basal and TRH-stimulated TSH release.	Thyrotropin	113-116	thyrotropin releasing hormone	Rattus norvegicus	98-101
8618941-17	1996	In conclusion, the results provide further evidence for an important role of NB as an autocrine regulator of TSH release, which is modulated by increased release of NB induced by thyroid hormones.	Thyrotropin	109-112	neuromedin B	Rattus norvegicus	77-79
8618941-17	1996	In conclusion, the results provide further evidence for an important role of NB as an autocrine regulator of TSH release, which is modulated by increased release of NB induced by thyroid hormones.	Thyrotropin	109-112	neuromedin B	Rattus norvegicus	165-167
8616533-17	1996	We show that the serum TG/TSH ratio may be used as a predictive index of thyroid reserve and of positive response to iodine administration.	Thyrotropin	26-29	thyroglobulin	Homo sapiens	23-25
8603567-12	1996	On the other hand, the Ca2+- and NADPH-dependent H2O2 generator, so-called thyroid NADPH- oxidase, is induced by TSH through the cAMP cascade.	Thyrotropin	113-116	carbonic anhydrase 2	Canis lupus familiaris	23-28
8616538-10	1996	Gene expression of TGF-beta1 was induced in TSH- and PTU-treated rats.	Thyrotropin	44-47	transforming growth factor, beta 1	Rattus norvegicus	19-28
8636437-3	1996	Thyrotropin-releasing hormone-stimulated TSH secretion did not increase thyroid hormone production in these patients as compared to their unaffected siblings, suggesting that the mutant TSH was biologically inactive in vivo.	Thyrotropin	41-44	thyrotropin releasing hormone	Homo sapiens	0-29
8616538-11	1996	In TSH-treated rats TGF-beta1 gene expression was less detectable than in PTU-treated rats, where it became evident after 2 weeks and remained through weeks 4-8.	Thyrotropin	3-6	transforming growth factor, beta 1	Rattus norvegicus	20-29
8616538-14	1996	In conclusion, TGF-beta1 is produced in response to both a direct (TSH by itself) and indirect (TSH induced by PTU-induced hypothyroidism) cellular proliferative stimulus and is not linked to an adaptative phenomenon secondary to hypothyroidism.	Thyrotropin	67-70	transforming growth factor, beta 1	Rattus norvegicus	15-24
8616538-14	1996	In conclusion, TGF-beta1 is produced in response to both a direct (TSH by itself) and indirect (TSH induced by PTU-induced hypothyroidism) cellular proliferative stimulus and is not linked to an adaptative phenomenon secondary to hypothyroidism.	Thyrotropin	96-99	transforming growth factor, beta 1	Rattus norvegicus	15-24
8772590-8	1996	Neonates with TSH receptor-blocking activity greater than 132 U/L had a significantly lower T4 level (P < 0.05) and higher TSH (P < 0.005) than those in whom TSH binding-inhibitory activity was less than 132 U/L.	Thyrotropin	126-129	thyroid stimulating hormone receptor	Homo sapiens	14-26
8772593-6	1996	In both groups of women with suppressed TSH values, hCG and hCG beta levels were higher than in the women with normal TSH levels.	Thyrotropin	40-43	chorionic gonadotropin subunit beta 3	Homo sapiens	60-68
8772597-11	1996	From these data we conclude that in vivo, IGF-I does not independently stimulate thyroid growth, but promotes thyroid cell proliferation by potentiating the mitogenic action of TSH.	Thyrotropin	177-180	insulin like growth factor 1	Homo sapiens	42-47
8636448-7	1996	The nocturnal rise in leptin observed in the present study resembles those reported for prolactin, thyroid-stimulating hormone, and free fatty acids.	Thyrotropin	99-126	leptin	Homo sapiens	22-28
8647316-9	1996	In the secondary culture the TSH-stimulated Tg production decreased from 253 ng/micrograms DNA (205-263) after 3 weeks to 18 ng/micrograms DNA (6-81), P < 0.001, n = 6 after 12 weeks and TSH-stimulated cAMP production from 660 pmol/micrograms DNA (500-840) to 60 (40-200), P < 0.001, n = 6.	Thyrotropin	29-32	thyroglobulin	Homo sapiens	44-46
8647316-9	1996	In the secondary culture the TSH-stimulated Tg production decreased from 253 ng/micrograms DNA (205-263) after 3 weeks to 18 ng/micrograms DNA (6-81), P < 0.001, n = 6 after 12 weeks and TSH-stimulated cAMP production from 660 pmol/micrograms DNA (500-840) to 60 (40-200), P < 0.001, n = 6.	Thyrotropin	190-193	thyroglobulin	Homo sapiens	44-46
8550781-7	1996	In this case and in control subjects, Nothern gel analysis of TPO messenger RNA from unstimulated and TSH-stimulated thyroid cells revealed a 3.2 kilobase species in the former and four distinct messenger RNA species of 4.0, 3.2, 2.1, and 1.7 kilobases in the latter.	Thyrotropin	102-105	thyroid peroxidase	Homo sapiens	62-65
8647316-7	1996	Furthermore, a preserved ability of TSH-stimulated production of Tg and cAMP in 12-week-old secondary and tertiary cultures was found.	Thyrotropin	36-39	thyroglobulin	Homo sapiens	65-67
8834538-6	1996	The highest incidence was observed in 15 GH-secreting adenomas and 8 TSH-secreting adenomas, in which Pit-1 mRNA was detected in all cases.	Thyrotropin	69-72	POU class 1 homeobox 1	Homo sapiens	102-107
8612966-2	1995	Mutations in the Pit-1 gene, as first described in Snell and Jackson dwarf (dw) mice, led to pituitary hypoplasia due to lack of these three cell types, as well as hypothyroidism and dwarfism because of deficiency of thyroid-stimulating hormone and growth hormone, respectively.	Thyrotropin	217-244	POU domain, class 1, transcription factor 1	Mus musculus	17-22
8568475-4	1996	In TFC cultures exposed to TSH, the level of [methyl-3H]thymidine incorporation attained at a dose of 1 U TSH/1 was enhanced in the presence of TGF-beta 1 antiserum, although the similar stimulatory effect of 8-bromo cAMP was unaffected.	Thyrotropin	27-30	threonine synthase like 1	Homo sapiens	106-111
8568475-4	1996	In TFC cultures exposed to TSH, the level of [methyl-3H]thymidine incorporation attained at a dose of 1 U TSH/1 was enhanced in the presence of TGF-beta 1 antiserum, although the similar stimulatory effect of 8-bromo cAMP was unaffected.	Thyrotropin	27-30	transforming growth factor beta 1	Homo sapiens	144-154
8750573-5	1996	On the contrary, a significant inhibition of the TSH response was observed in the group of TRH-responder patients (delta TSH after TRH 4.76 +/- 1.11 microU/ml, after NAL + TRH 2.81 +/- 0.99 microU/ml, p < 0.05).	Thyrotropin	49-52	ceramide synthase 5	Homo sapiens	131-136
8561281-4	1995	To test further the hypothesis that the TRH-induced TSH response is a vulnerability marker for alcoholism, we tested 25 young men with an alcoholic father [family history-positive (FHP)] and matched them, on alcohol consumption, to 25 young men with no identified first- or second-degree relatives with alcoholism [family history-negative (FHN)].	Thyrotropin	52-55	thyrotropin releasing hormone	Homo sapiens	40-43
8543924-0	1995	Dexamethasone inhibits the release of TSH from the rat anterior pituitary gland in vitro by mechanisms dependent on de novo protein synthesis and lipocortin 1.	Thyrotropin	38-41	annexin A1	Rattus norvegicus	146-158
8543924-3	1995	In addition, we have investigated the potential role of lipocortin 1 (LC1), a protein shown previously to contribute to glucocorticoid action in several systems, as a mediator of the glucocorticoid-induced suppression of TSH release in our in vitro preparation.	Thyrotropin	221-224	annexin A1	Rattus norvegicus	56-68
7491516-11	1995	CONCLUSIONS: These findings show that TSH-stimulated invasion may be due to PKC-induced activation of uPA and 94 kd type IV collagenase.	Thyrotropin	38-41	plasminogen activator, urokinase	Homo sapiens	102-105
8804472-9	1995	Both TSH and melatonin decreased after G-CSF, without, however, significant differences with respect to the values seen on saline alone.	Thyrotropin	5-8	colony stimulating factor 3	Homo sapiens	39-44
7493654-4	1995	It is proposed that insulin induces the increase of cell mass that is a prerequisite for the mitogenic effect of TSH.	Thyrotropin	113-116	insulin	Canis lupus familiaris	20-27
8781630-1	1995	Oral thyrotrophin-releasing hormone (TRH) and lithium were given to patients on follow-up for well-differentiated thyroid carcinoma to see their effect on serum thyrotrophin level (TSH) and radioiodine (I-131) uptake (RAIU).	Thyrotropin	5-17	thyrotropin releasing hormone	Homo sapiens	37-40
8781630-7	1995	We conclude that while oral TRH will increase endogenous serum TSH significantly, there is no significant increase in I-131 uptake.	Thyrotropin	63-66	thyrotropin releasing hormone	Homo sapiens	28-31
7501234-7	1995	These data indicate that at high concentration, TRH-Gly interacts directly with TRH-R to activate signal transduction pathway, and that release of prolactin and TSH induced by TRH-Gly in vitro may be due, at least in part, to the direct effect of TRH-Gly on the TRH-R.	Thyrotropin	161-164	thyrotropin releasing hormone	Rattus norvegicus	48-51
8542475-6	1995	Correlation analysis showed a direct relationship between serum T4 and hCG and an inverse relationship between serum TSH and hCG in pregnancy with morning sickness.	Thyrotropin	117-120	chorionic gonadotropin subunit beta 5	Homo sapiens	125-128
7568187-5	1995	Here we show that TSH drives the induction of the inducible cAMP early repressor (ICER) isoform of the cAMP response element (CRE) modulator gene both in rat thyroid gland and in the differentiated thyroid cell line FRTL-5.	Thyrotropin	18-21	cAMP responsive element modulator	Rattus norvegicus	50-80
7568187-5	1995	Here we show that TSH drives the induction of the inducible cAMP early repressor (ICER) isoform of the cAMP response element (CRE) modulator gene both in rat thyroid gland and in the differentiated thyroid cell line FRTL-5.	Thyrotropin	18-21	cAMP responsive element modulator	Rattus norvegicus	82-86
7568187-5	1995	Here we show that TSH drives the induction of the inducible cAMP early repressor (ICER) isoform of the cAMP response element (CRE) modulator gene both in rat thyroid gland and in the differentiated thyroid cell line FRTL-5.	Thyrotropin	18-21	cAMP responsive element modulator	Rattus norvegicus	103-140
7568187-8	1995	Thus, ICER induction by TSH in the thyroid gland represents a paradigm of the molecular mechanism by which pituitary hormones elicit homologous long-term desensitization.	Thyrotropin	24-27	cAMP responsive element modulator	Rattus norvegicus	6-10
7581975-7	1995	In contrast, DEA significantly potentiates the TSH response to TRH and the DHP nifedipine reverses that potentiation.	Thyrotropin	47-50	thyrotropin releasing hormone	Rattus norvegicus	63-66
8563478-7	1995	Furthermore, TSH response to iv TRH administration was significantly blunted during glucagon infusion alone as expressed by both the absolute rise (delta TSH, post-TRH, 1.1 +/- 0.5 vs 5.9 +/- 1.7 ng/ml for normal saline, p < 0.01) as well as an integrated response over a 2-h period (sigma TSH, post-TRH, 4.0 +/- 1.1 vs 11.7 +/- 3.5 ng/min/mL, p < 0.001).	Thyrotropin	13-16	TRH	Canis lupus familiaris	32-35
8563478-7	1995	Furthermore, TSH response to iv TRH administration was significantly blunted during glucagon infusion alone as expressed by both the absolute rise (delta TSH, post-TRH, 1.1 +/- 0.5 vs 5.9 +/- 1.7 ng/ml for normal saline, p < 0.01) as well as an integrated response over a 2-h period (sigma TSH, post-TRH, 4.0 +/- 1.1 vs 11.7 +/- 3.5 ng/min/mL, p < 0.001).	Thyrotropin	13-16	TRH	Canis lupus familiaris	164-167
8563478-7	1995	Furthermore, TSH response to iv TRH administration was significantly blunted during glucagon infusion alone as expressed by both the absolute rise (delta TSH, post-TRH, 1.1 +/- 0.5 vs 5.9 +/- 1.7 ng/ml for normal saline, p < 0.01) as well as an integrated response over a 2-h period (sigma TSH, post-TRH, 4.0 +/- 1.1 vs 11.7 +/- 3.5 ng/min/mL, p < 0.001).	Thyrotropin	13-16	TRH	Canis lupus familiaris	164-167
8563478-7	1995	Furthermore, TSH response to iv TRH administration was significantly blunted during glucagon infusion alone as expressed by both the absolute rise (delta TSH, post-TRH, 1.1 +/- 0.5 vs 5.9 +/- 1.7 ng/ml for normal saline, p < 0.01) as well as an integrated response over a 2-h period (sigma TSH, post-TRH, 4.0 +/- 1.1 vs 11.7 +/- 3.5 ng/min/mL, p < 0.001).	Thyrotropin	154-157	TRH	Canis lupus familiaris	32-35
8563483-2	1995	In these cases, greatly increased human chorionic gonadotropin (hCG) levels and suppressed TSH levels suggest that hCG has thyrotropic activity.	Thyrotropin	91-94	chorionic gonadotropin subunit beta 5	Homo sapiens	115-118
7673415-7	1995	In normal subjects, the daytime ratio of TSH bioactivity to immunoreactivity (TSH B/I) was higher than the nocturnal one [1.4 +/- 0.6 (+/- SD) vs. 1.1 +/- 0.6; P < 0.02].	Thyrotropin	41-44	thyroid stimulating hormone subunit beta	Homo sapiens	78-85
7501234-7	1995	These data indicate that at high concentration, TRH-Gly interacts directly with TRH-R to activate signal transduction pathway, and that release of prolactin and TSH induced by TRH-Gly in vitro may be due, at least in part, to the direct effect of TRH-Gly on the TRH-R.	Thyrotropin	161-164	thyrotropin releasing hormone receptor	Homo sapiens	80-85
7501234-7	1995	These data indicate that at high concentration, TRH-Gly interacts directly with TRH-R to activate signal transduction pathway, and that release of prolactin and TSH induced by TRH-Gly in vitro may be due, at least in part, to the direct effect of TRH-Gly on the TRH-R.	Thyrotropin	161-164	thyrotropin releasing hormone	Homo sapiens	80-83
7501234-7	1995	These data indicate that at high concentration, TRH-Gly interacts directly with TRH-R to activate signal transduction pathway, and that release of prolactin and TSH induced by TRH-Gly in vitro may be due, at least in part, to the direct effect of TRH-Gly on the TRH-R.	Thyrotropin	161-164	thyrotropin releasing hormone	Rattus norvegicus	80-83
8562313-3	1995	Insulin-like growth factor-I (IGF-I) or phorbol 12-myristate 13-acetate (PMA) only showed an attenuated reaction compared with that of TSH or Bt2cAMP.	Thyrotropin	135-138	insulin-like growth factor 1	Rattus norvegicus	30-35
8546810-9	1995	Addition of TSH (1 mU/ml) produced an increase in the level of IL-1 alpha mRNA in primary TFC and HTori3 cells, at 12 and 24 h. TSH had no significant effect on the expression of IL-6 or IL-8 mRNA.	Thyrotropin	12-15	interleukin 1 alpha	Homo sapiens	63-73
8546810-9	1995	Addition of TSH (1 mU/ml) produced an increase in the level of IL-1 alpha mRNA in primary TFC and HTori3 cells, at 12 and 24 h. TSH had no significant effect on the expression of IL-6 or IL-8 mRNA.	Thyrotropin	12-15	interleukin 6	Homo sapiens	179-183
8546810-9	1995	Addition of TSH (1 mU/ml) produced an increase in the level of IL-1 alpha mRNA in primary TFC and HTori3 cells, at 12 and 24 h. TSH had no significant effect on the expression of IL-6 or IL-8 mRNA.	Thyrotropin	12-15	C-X-C motif chemokine ligand 8	Homo sapiens	187-191
8562313-2	1995	TSH and N6-2"-O-dibutyryladenosine 3"-5"-cyclic monophosphate (Bt2cAMP) decreased the phosphotyrosine content of 110,000-130,000 M(r) substrate (p120) in parallel with a morphological change in FRTL-5 cells.	Thyrotropin	0-3	bromodomain containing 8	Rattus norvegicus	145-149
7614740-1	1995	We have studied the influence of triiodothyronine (T3), thyroxine (T4), thyrotropin (TSH), and methimazole (MMI) on the expression of major histocompatibility (MHC) Class II antigen expression in human thyroid cells.	Thyrotropin	85-88	major histocompatibility complex, class II, DR beta 6 (pseudogene)	Homo sapiens	134-181
7614740-8	1995	At a concentration of 100 microU/ml, TSH enhanced IFN-gamma-induced HLA-DR expression.	Thyrotropin	37-40	interferon gamma	Homo sapiens	50-59
7626034-7	1995	In TSH-treated cells, however, up-regulation of myo-inositol transport was linked with increased myo-inositol cycling across the cell membrane, increased phospholipase A2-mediated turnover of phosphatidylinositol and a concomitant increase in arachidonic acid turnover.	Thyrotropin	3-6	phospholipase A2 group IB	Homo sapiens	154-170
7542953-8	1995	IGFBP-3 production is increased by dedifferentiation factors such as EGF and TPA and inhibited by TSH and forskolin, which enhance differentiated function.	Thyrotropin	98-101	insulin like growth factor binding protein 3	Homo sapiens	0-7
7789339-5	1995	Stimulation of the cells by TSH (1 mU/ml) or forskolin (10 microM) induced an increase in E-cadherin mRNA levels with a maximal effect after 20 h. An up-regulation of E-cadherin protein levels are also observed by immunostaining with anti-E-cadherin antibodies.	Thyrotropin	28-31	cadherin 1	Homo sapiens	90-100
7789339-5	1995	Stimulation of the cells by TSH (1 mU/ml) or forskolin (10 microM) induced an increase in E-cadherin mRNA levels with a maximal effect after 20 h. An up-regulation of E-cadherin protein levels are also observed by immunostaining with anti-E-cadherin antibodies.	Thyrotropin	28-31	cadherin 1	Homo sapiens	167-177
7789339-5	1995	Stimulation of the cells by TSH (1 mU/ml) or forskolin (10 microM) induced an increase in E-cadherin mRNA levels with a maximal effect after 20 h. An up-regulation of E-cadherin protein levels are also observed by immunostaining with anti-E-cadherin antibodies.	Thyrotropin	28-31	cadherin 1	Homo sapiens	167-177
7789339-10	1995	These results suggest that the cell-cell adhesion protein E-cadherin is under the control of the TSH-cAMP-dependent pathway and may play an important physiological role on the action of this pathway in proliferation and differentiation.	Thyrotropin	97-100	cadherin 1	Homo sapiens	58-68
7608274-2	1995	TRH administration in the healthy subjects resulted in a significant increase in serum T3 and T4 levels after 2 h. However, in the patients with untreated hyperthyroid Graves" disease, a significant decrease in serum T3 and T4 levels with undetectable TSH was found 2 h after TRH administration.	Thyrotropin	252-255	thyrotropin releasing hormone	Homo sapiens	0-3
7496087-7	1995	The GC replacement in combination with daily s.c. injection of recombinant human GH (rhGH) not only normalized plasma IGF-I and IGFBP-3 levels, but also further lowered the plasma TSH level, possibly due to an increased T4/T3 conversion, which resulted in a beneficial change in body composition.	Thyrotropin	180-183	growth hormone 1	Homo sapiens	81-83
8547858-0	1995	Acute effect of thyroxine on pituitary neuromedin B content of hypothyroid rats and its correlation with TSH secretion.	Thyrotropin	105-108	neuromedin B	Rattus norvegicus	39-51
7542953-4	1995	In both cell lines, EGF or TPA stimulated IGFBP-3 production while TSH or forskolin inhibited IGFBP-3 production and reduced the stimulation of IGFBP-3 seen with EGF or TPA.	Thyrotropin	67-70	insulin like growth factor binding protein 3	Homo sapiens	94-101
7542953-4	1995	In both cell lines, EGF or TPA stimulated IGFBP-3 production while TSH or forskolin inhibited IGFBP-3 production and reduced the stimulation of IGFBP-3 seen with EGF or TPA.	Thyrotropin	67-70	insulin like growth factor binding protein 3	Homo sapiens	94-101
7542953-4	1995	In both cell lines, EGF or TPA stimulated IGFBP-3 production while TSH or forskolin inhibited IGFBP-3 production and reduced the stimulation of IGFBP-3 seen with EGF or TPA.	Thyrotropin	67-70	plasminogen activator, tissue type	Homo sapiens	169-172
7542953-5	1995	IGFBP-4 production was increased in the presence of TSH, forskolin, and EGF and was reduced by TPA.	Thyrotropin	52-55	insulin like growth factor binding protein 4	Homo sapiens	0-7
7636435-8	1995	In two wild type FRTL-5 cell lines EGF stimulates growth, an effect that is enhanced by the presence of TSH, and partially inhibits iodide uptake.	Thyrotropin	104-107	epidermal growth factor like 1	Rattus norvegicus	35-38
7554585-0	1995	Increased membrane-bound protein kinase C in porcine thyroid cells following TSH exposure.	Thyrotropin	77-80	proline rich transmembrane protein 2	Homo sapiens	25-41
7554585-3	1995	Measuring PKC by Western blotting, we assessed whether physiological concentrations of human TSH could translocate PKC in porcine thyroid cells.	Thyrotropin	93-96	proline rich transmembrane protein 2	Homo sapiens	115-118
7554585-5	1995	Although TSH did not affect cytosolic PKC, human TSH at 1, 10 and 100 microU/ml produced increases compared to control values in membrane-bound PKC of 80.3 +/- 15.8, 66.8 +/- 9.7 and 74.0 +/- 19.8%, respectively (mean +/- SE, p < 0.01 at all TSH concentrations used).	Thyrotropin	49-52	proline rich transmembrane protein 2	Homo sapiens	144-147
7554585-7	1995	In addition, we observed qualitative differences in phorbol ester and TSH-mediated PKC activation.	Thyrotropin	70-73	proline rich transmembrane protein 2	Homo sapiens	83-86
7745024-2	1995	Crude immunoglobulin fractions from sera of patients with Graves" disease, containing stimulatory TSH receptor (TSHR) autoantibodies, significantly increased lipolysis in fat cells from infants, whereas immunoglobulin fraction from a patient with inhibitory TSHR autoantibodies (TBab) blocked TSH-induced lipolysis in a dose-dependent manner.	Thyrotropin	98-101	thyroid stimulating hormone receptor	Homo sapiens	112-116
7720677-13	1995	The increase in EGF receptor-labeled cells among thyrotropes may point to an important autocrine role for EGF in maintaining TSH responses to cold.	Thyrotropin	125-128	epidermal growth factor like 1	Rattus norvegicus	16-19
7720677-13	1995	The increase in EGF receptor-labeled cells among thyrotropes may point to an important autocrine role for EGF in maintaining TSH responses to cold.	Thyrotropin	125-128	epidermal growth factor like 1	Rattus norvegicus	106-109
7749503-6	1995	Preincubation of the porcine follicles with KI decreased dose dependently the TSH-induced IGF-I mRNA expression, with complete inhibition at 10 mumol/l KI.	Thyrotropin	78-81	insulin like growth factor 1	Homo sapiens	90-95
7745026-3	1995	With this antibody, a strong cytoplasmic Gs alpha-immunostaining was detectable in cultured human thyroid cells and in TSH-stimulated rat thyroids, in contrast to normal human thyroids and to T4-treated rat thyroids, which showed only weak immunoreactivity.	Thyrotropin	119-122	GNAS complex locus	Homo sapiens	41-49
7565801-1	1995	An element, -186 to -176 base pairs (bp), in the minimal TSH receptor (TSHR) promoter binds thyroid transcription factor-1 (TTF-1) and is important for both constitutive expression and TSH/cAMP-induced negative autoregulation of the TSHR in thyroid cells.	Thyrotropin	57-60	thyroid stimulating hormone receptor	Rattus norvegicus	71-75
7565801-1	1995	An element, -186 to -176 base pairs (bp), in the minimal TSH receptor (TSHR) promoter binds thyroid transcription factor-1 (TTF-1) and is important for both constitutive expression and TSH/cAMP-induced negative autoregulation of the TSHR in thyroid cells.	Thyrotropin	57-60	transcription termination factor 1	Rattus norvegicus	92-122
7565801-1	1995	An element, -186 to -176 base pairs (bp), in the minimal TSH receptor (TSHR) promoter binds thyroid transcription factor-1 (TTF-1) and is important for both constitutive expression and TSH/cAMP-induced negative autoregulation of the TSHR in thyroid cells.	Thyrotropin	57-60	transcription termination factor 1	Rattus norvegicus	124-129
7617131-10	1995	These above results indicated that the increase in plasma PRL and TSH levels is associated with a rise in hypophysial portal plasma dopamine and TRH following injection of both progesterone and estradiol benzoate.	Thyrotropin	66-69	thyrotropin releasing hormone	Rattus norvegicus	145-148
7565801-1	1995	An element, -186 to -176 base pairs (bp), in the minimal TSH receptor (TSHR) promoter binds thyroid transcription factor-1 (TTF-1) and is important for both constitutive expression and TSH/cAMP-induced negative autoregulation of the TSHR in thyroid cells.	Thyrotropin	57-60	thyroid stimulating hormone receptor	Rattus norvegicus	233-237
7565801-7	1995	The SSBPs function conjointly with TTF-1 in thyroid-specific, TSH/cAMP-induced negative autoregulation of the TSHR.	Thyrotropin	62-65	transcription termination factor 1	Rattus norvegicus	35-40
7565801-7	1995	The SSBPs function conjointly with TTF-1 in thyroid-specific, TSH/cAMP-induced negative autoregulation of the TSHR.	Thyrotropin	62-65	thyroid stimulating hormone receptor	Rattus norvegicus	110-114
7565801-9	1995	The TSH-induced effect in each case is inhibited by cycloheximide; the TSH-induced decrease in SSBP/DNA complex formation requires the presence of insulin or calf serum, exactly as does TSH-induced down-regulation of TSHR RNA levels.	Thyrotropin	4-7	single stranded DNA binding protein 1	Rattus norvegicus	95-99
7565801-9	1995	The TSH-induced effect in each case is inhibited by cycloheximide; the TSH-induced decrease in SSBP/DNA complex formation requires the presence of insulin or calf serum, exactly as does TSH-induced down-regulation of TSHR RNA levels.	Thyrotropin	4-7	thyroid stimulating hormone receptor	Rattus norvegicus	217-221
7565801-9	1995	The TSH-induced effect in each case is inhibited by cycloheximide; the TSH-induced decrease in SSBP/DNA complex formation requires the presence of insulin or calf serum, exactly as does TSH-induced down-regulation of TSHR RNA levels.	Thyrotropin	71-74	single stranded DNA binding protein 1	Rattus norvegicus	95-99
7565801-9	1995	The TSH-induced effect in each case is inhibited by cycloheximide; the TSH-induced decrease in SSBP/DNA complex formation requires the presence of insulin or calf serum, exactly as does TSH-induced down-regulation of TSHR RNA levels.	Thyrotropin	71-74	thyroid stimulating hormone receptor	Rattus norvegicus	217-221
7565801-9	1995	The TSH-induced effect in each case is inhibited by cycloheximide; the TSH-induced decrease in SSBP/DNA complex formation requires the presence of insulin or calf serum, exactly as does TSH-induced down-regulation of TSHR RNA levels.	Thyrotropin	71-74	single stranded DNA binding protein 1	Rattus norvegicus	95-99
7565801-9	1995	The TSH-induced effect in each case is inhibited by cycloheximide; the TSH-induced decrease in SSBP/DNA complex formation requires the presence of insulin or calf serum, exactly as does TSH-induced down-regulation of TSHR RNA levels.	Thyrotropin	71-74	thyroid stimulating hormone receptor	Rattus norvegicus	217-221
7621893-0	1995	Triiodo-L-thyronine enhances TRH-induced TSH release from perifused rat pituitaries and intracellular Ca2+ levels from dispersed pituitary cells.	Thyrotropin	41-44	thyrotropin releasing hormone	Rattus norvegicus	29-32
7627812-5	1995	Basal and TSH-induced I-5"-deiodination were significantly inhibited by 100 ng/liter of IL-1 beta and IL-6, and the inhibitory effect of TNF-alpha was seen over 1 microgram/liter.	Thyrotropin	10-13	interleukin 1 beta	Rattus norvegicus	88-97
7647568-5	1995	We have used immunoprecipitation to isolate the previously characterized 95-100 kDa TSH-holoreceptor, 187 kDa intermediate, and 230 kDa precursor forms of the TSHR from plasma membrane prepared from transfected COS-7 cells and human thyroid tissue.	Thyrotropin	84-87	thyroid stimulating hormone receptor	Homo sapiens	159-163
7627812-5	1995	Basal and TSH-induced I-5"-deiodination were significantly inhibited by 100 ng/liter of IL-1 beta and IL-6, and the inhibitory effect of TNF-alpha was seen over 1 microgram/liter.	Thyrotropin	10-13	interleukin 6	Rattus norvegicus	102-106
7627812-5	1995	Basal and TSH-induced I-5"-deiodination were significantly inhibited by 100 ng/liter of IL-1 beta and IL-6, and the inhibitory effect of TNF-alpha was seen over 1 microgram/liter.	Thyrotropin	10-13	tumor necrosis factor	Rattus norvegicus	137-146
7867606-1	1995	The dog thyrocyte I- trapping activity and the expression of the genes coding for dog thyrocyte thyroglobulin or thyroid peroxidase are enhanced by TSH through the cAMP cascade and reduced by mitogens such as epidermal growth factor (EGF) or 12-O-tetradecanoylphorbol 13-acetate (TPA).	Thyrotropin	148-151	thyroglobulin	Canis lupus familiaris	96-109
7615907-3	1995	In the intact rats, GHRH(1-29)NH2 potentiated TRH-stimulated TSH release in the evening, but potentiation was not observed in the morning and in dispersed pituitary cells.	Thyrotropin	61-64	growth hormone releasing hormone	Rattus norvegicus	20-24
7883846-1	1995	Basic fibroblast growth factor (bFGF) is a potent mitogenic and angiogenic factor that is known to regulate GH, PRL, and TSH secretion.	Thyrotropin	121-124	fibroblast growth factor 2	Homo sapiens	0-30
7883846-1	1995	Basic fibroblast growth factor (bFGF) is a potent mitogenic and angiogenic factor that is known to regulate GH, PRL, and TSH secretion.	Thyrotropin	121-124	fibroblast growth factor 2	Homo sapiens	32-36
8591810-9	1995	In addition, our findings suggest that Prl and GH may be physiological modulators of mammary SOD activity, and that TSH can possibly influence the activity of both CAT and SOD in liver via a thyroid-independent pathway.	Thyrotropin	116-119	catalase	Rattus norvegicus	164-167
7615907-0	1995	The effect of GHRH on TSH release in rats in vivo and in vitro.	Thyrotropin	22-25	growth hormone releasing hormone	Rattus norvegicus	14-18
7615907-2	1995	To study the way by which GHRH affects TRH-stimulated TSH release, we examined the effect of GHRH (1-29)NH2 on basal and stimulated TSH secretion in intact male rats and superfused dispersed rat pituitary cells.	Thyrotropin	54-57	growth hormone releasing hormone	Rattus norvegicus	26-30
7738480-5	1995	We found that basal TSH in subclinical hypothyroidism, and TRH-released TSH in euthyroidism and in subclinical hypothyroidism is distributed in a similar neutral to acidic pattern, which significantly differs from the more alkaline to neutral isoform pattern of intrapituitary TSH (P < 0.05).	Thyrotropin	72-75	thyrotropin releasing hormone	Homo sapiens	59-62
7738480-7	1995	Lentil lectin affinity chromatography revealed that TRH-released TSH in euthyroid subjects has more core fucose residues than TSH from patients with subclinical hypothyroidism (64.6 +/- 6.7 vs 12.5 +/- 2.7%, P < 0.0001).	Thyrotropin	65-68	thyrotropin releasing hormone	Homo sapiens	52-55
7858746-5	1995	When thyroid cells were cultured for 3 days with thyrotropin (TSH) in the presence of TGF-alpha, TSH-induced iodide uptake was inhibited in a dose-dependent manner.	Thyrotropin	62-65	transforming growth factor alpha	Homo sapiens	86-95
7862110-5	1995	Here we report that serum-stimulated hyperphosphorylation of Raf-1 was inhibited by TSH treatment of Wistar rat thyroid cells, indicating that in this cell line, as in other cell types, increases in intracellular cAMP levels inhibit activation of downstream kinases targeted by Ras.	Thyrotropin	84-87	Raf-1 proto-oncogene, serine/threonine kinase	Rattus norvegicus	61-66
7882998-5	1995	This stimulation of MAP kinase by TSH was specifically inhibited by incubation of astrocytes in the presence of human blocking anti-(TSH receptor) IgG, and by immunoprecipitation of TSH with monoclonal anti-TSH IgG.	Thyrotropin	34-37	thyroid stimulating hormone receptor	Homo sapiens	133-145
7858746-9	1995	Thus, we conclude that TGF-alpha inhibits TSH-induced iodine metabolism largely by acting at the steps distal to cAMP production.	Thyrotropin	42-45	transforming growth factor alpha	Homo sapiens	23-32
7876108-4	1995	Maximal activity was reached after 20 min and remained sustained for 1-3 h, TSH being as potent as EGF; EC50 was 1.5 nM TSH.	Thyrotropin	120-123	epidermal growth factor	Homo sapiens	99-102
7876108-6	1995	p42 was phosphorylated on tyrosine residues and showed a reduced electrophoretic mobility in follicles stimulated by TSH.	Thyrotropin	117-120	cyclin dependent kinase 20	Homo sapiens	0-3
7835292-7	1995	EGF exhibited a time- and dose-dependent (0.02-8 nM) restraining influence on the above TSH-stimulated differentiated functions, except for cAMP, which was enhanced.	Thyrotropin	88-91	epidermal growth factor	Homo sapiens	0-3
7835292-12	1995	TSH (0.5 U/liter) inhibited both the mitogenic and antimitogenic actions of TPA as well as the cell-proliferative influence of EGF.	Thyrotropin	0-3	epidermal growth factor	Homo sapiens	127-130
7835292-13	1995	In conclusion, the data demonstrate mutual antagonistic interactions between the signal transduction pathways: the PKC and EGF (tyrosine kinase) pathways seem to inhibit TSH (cAMP)-mediated human thyroid cell differentiation, whereas TSH attenuates PKC-mediated thyroid cell mitogenesis and antimitogenesis as well as EGF-mediated cell proliferation.	Thyrotropin	170-173	proline rich transmembrane protein 2	Homo sapiens	115-126
7835292-13	1995	In conclusion, the data demonstrate mutual antagonistic interactions between the signal transduction pathways: the PKC and EGF (tyrosine kinase) pathways seem to inhibit TSH (cAMP)-mediated human thyroid cell differentiation, whereas TSH attenuates PKC-mediated thyroid cell mitogenesis and antimitogenesis as well as EGF-mediated cell proliferation.	Thyrotropin	170-173	proline rich transmembrane protein 2	Homo sapiens	115-118
7835292-13	1995	In conclusion, the data demonstrate mutual antagonistic interactions between the signal transduction pathways: the PKC and EGF (tyrosine kinase) pathways seem to inhibit TSH (cAMP)-mediated human thyroid cell differentiation, whereas TSH attenuates PKC-mediated thyroid cell mitogenesis and antimitogenesis as well as EGF-mediated cell proliferation.	Thyrotropin	170-173	epidermal growth factor	Homo sapiens	123-126
7828520-12	1995	In conclusion, in FRTL-5 cells, TSH-induced H2O2 production is mediated not by cAMP, but by the phospholipase-C/Ca2+ cascade, possibly followed by the Ca(2+)-dependent phospholipase-A2/arachidonate cascade.	Thyrotropin	32-35	phospholipase A2 group IB	Rattus norvegicus	168-184
7852536-9	1995	Consequently, the current description of Pit-1 gene mutations leading to complete GH, PRL, and TSH deficiencies needs to be expanded to GH and PRL deficiencies associated with a compromise of the thyrotroph"s ability to synthesize TSH.	Thyrotropin	95-98	POU class 1 homeobox 1	Homo sapiens	41-46
7604150-6	1995	TSH levels decreased insignificantly to 57.5% of baseline levels, while TRH-induced TSH release was not affected by subchronic roxindole.	Thyrotropin	84-87	thyrotropin releasing hormone	Homo sapiens	72-75
7487672-2	1995	Changes in morphological characteristics and production of Tg, T3, and T4 induced by addition of thyroid stimulating hormone (TSH) to medium in collagen gel culture were also determined.	Thyrotropin	97-124	thyroglobulin	Homo sapiens	59-61
7487672-2	1995	Changes in morphological characteristics and production of Tg, T3, and T4 induced by addition of thyroid stimulating hormone (TSH) to medium in collagen gel culture were also determined.	Thyrotropin	126-129	thyroglobulin	Homo sapiens	59-61
7487672-6	1995	Only for normal thyroid cells did addition of TSH to medium induce increase the percentage of colonies producing Tg or T4 and morphological changes including an enlarged follicular lumen and increase in the height of columnar epithelium.	Thyrotropin	46-49	thyroglobulin	Homo sapiens	113-115
7828540-1	1995	A thyroid transcription factor-1 (TTF-1)-binding element in the rat TSH receptor (TSHR) promoter, between -189 and -175 basepairs (bp), is important for both thyroid-specific expression and thyroid-specific TSH/cAMP autoregulation of the TSHR.	Thyrotropin	68-71	transcription termination factor 1	Rattus norvegicus	2-32
7828540-1	1995	A thyroid transcription factor-1 (TTF-1)-binding element in the rat TSH receptor (TSHR) promoter, between -189 and -175 basepairs (bp), is important for both thyroid-specific expression and thyroid-specific TSH/cAMP autoregulation of the TSHR.	Thyrotropin	68-71	transcription termination factor 1	Rattus norvegicus	34-39
7852507-7	1995	Asialo-hCG purified from a patient with choriocarcinoma had very potent TSH-like activity (468 microU hTSH/mg).	Thyrotropin	72-75	hypertrichosis 2 (generalised, congenital)	Homo sapiens	7-10
7828540-1	1995	A thyroid transcription factor-1 (TTF-1)-binding element in the rat TSH receptor (TSHR) promoter, between -189 and -175 basepairs (bp), is important for both thyroid-specific expression and thyroid-specific TSH/cAMP autoregulation of the TSHR.	Thyrotropin	68-71	thyroid stimulating hormone receptor	Rattus norvegicus	82-86
7828540-1	1995	A thyroid transcription factor-1 (TTF-1)-binding element in the rat TSH receptor (TSHR) promoter, between -189 and -175 basepairs (bp), is important for both thyroid-specific expression and thyroid-specific TSH/cAMP autoregulation of the TSHR.	Thyrotropin	68-71	thyroid stimulating hormone receptor	Rattus norvegicus	238-242
21153235-5	1995	Animals given a single intraperitoneal injection of ethanol (3 g/kg) that produced a blood alcohol concentration of nearly 300 mg/100 mL exhibited the same increase in circulating levels of TSH following an intravenous infusion of TRH.	Thyrotropin	190-193	thyrotropin releasing hormone	Homo sapiens	231-234
7750518-1	1995	In thyrocytes, the beta-amyloid precursor protein (beta-APP) is expressed, proteolytically cleaved and released into the extracellular space in a TSH-dependent fashion.	Thyrotropin	146-149	amyloid beta precursor protein	Rattus norvegicus	19-49
7750518-1	1995	In thyrocytes, the beta-amyloid precursor protein (beta-APP) is expressed, proteolytically cleaved and released into the extracellular space in a TSH-dependent fashion.	Thyrotropin	146-149	amyloid beta precursor protein	Rattus norvegicus	51-59
7750518-7	1995	Upon stimulation with TSH, O-glycosylation as measured by the degree of sialylation increased by a factor of approximately 1.7 thereby raising the molecular mass of mature beta-APP by 4 to 5 kDa above that from control cells.	Thyrotropin	22-25	amyloid beta precursor protein	Rattus norvegicus	172-180
7750518-9	1995	When cells were stimulated with TSH in the presence of cycloheximide, the Golgi cisternae lost their predominant immunoreactivity for beta-APP and were rapidly emptied (within 30 min).	Thyrotropin	32-35	amyloid beta precursor protein	Rattus norvegicus	134-142
7828520-13	1995	PIA amplifies TSH-induced H2O2 production at the steps of phospholipase-C and phospholipase-A2 activation in a pertussis toxin-sensitive manner.	Thyrotropin	14-17	phospholipase A2 group IB	Rattus norvegicus	78-94
7829625-2	1995	Interaction of TSH with the human FSH receptor (hFSH-R) is a possible pathophysiological mechanism for this syndrome that has not been explored due to the lack of hFSH-free TSH preparations and the scarcity of a suitable hFSH-R-based assay system.	Thyrotropin	15-18	follicle stimulating hormone receptor	Homo sapiens	34-46
7829625-2	1995	Interaction of TSH with the human FSH receptor (hFSH-R) is a possible pathophysiological mechanism for this syndrome that has not been explored due to the lack of hFSH-free TSH preparations and the scarcity of a suitable hFSH-R-based assay system.	Thyrotropin	15-18	follicle stimulating hormone receptor	Homo sapiens	48-54
7829625-2	1995	Interaction of TSH with the human FSH receptor (hFSH-R) is a possible pathophysiological mechanism for this syndrome that has not been explored due to the lack of hFSH-free TSH preparations and the scarcity of a suitable hFSH-R-based assay system.	Thyrotropin	15-18	follicle stimulating hormone receptor	Homo sapiens	221-227
7630321-0	1995	Effect of gastrin-releasing peptide (GRP) and GRP antagonists on TSH secretion from rat isolated pituitaries.	Thyrotropin	65-68	gastrin releasing peptide	Rattus norvegicus	37-40
7623615-2	1995	20 hours exposure to recombinant murine TNF-alpha (10(-11) to 10(-10) mol/l) enhanced the basal and the TRH-stimulated release of TSH by cultured rat anterior pituitary cells, but 4 hours exposure increased only basal TSH secretion.	Thyrotropin	130-133	tumor necrosis factor	Mus musculus	40-49
7623615-2	1995	20 hours exposure to recombinant murine TNF-alpha (10(-11) to 10(-10) mol/l) enhanced the basal and the TRH-stimulated release of TSH by cultured rat anterior pituitary cells, but 4 hours exposure increased only basal TSH secretion.	Thyrotropin	218-221	tumor necrosis factor	Mus musculus	40-49
7630321-0	1995	Effect of gastrin-releasing peptide (GRP) and GRP antagonists on TSH secretion from rat isolated pituitaries.	Thyrotropin	65-68	gastrin releasing peptide	Rattus norvegicus	46-49
7623615-3	1995	Recombinant human (rh) IL-1 beta, at a dose of 10(-11) mol/l only, produced a very small increase in basal TSH secretion after 4h, but not 20h, exposure.	Thyrotropin	107-110	interleukin 1 beta	Homo sapiens	23-32
7630321-2	1995	In this study, we have shown that GRP acts directly at the pituitary gland, inhibiting basal and TRH-stimulated TSH release from incubated rat anterior pituitary glands.	Thyrotropin	112-115	gastrin releasing peptide	Rattus norvegicus	34-37
7746348-2	1995	The subcutaneous (s.c.) administration of caerulein and CCK-8s suppressed dose-dependently TSH and GH levels.	Thyrotropin	91-94	cholecystokinin	Rattus norvegicus	56-59
7479297-5	1995	TNF-alpha did not affect the concanavalin A and lentil lectin binding of TSH accumulated in the medium during the 4-day culture, but significantly decreased the lentil lectin binding of TSH released in response to acute TRH stimulation.	Thyrotropin	186-189	tumor necrosis factor	Rattus norvegicus	0-9
7709602-13	1995	TTF-1 is implicated as a critical autoregulatory component in both positive and negative regulation of the TSHR and appears to be the link between TSH, the TSHR, TSHR-mediated signals, TG and TPO biosynthesis, and thyroid hormone formation.	Thyrotropin	107-110	transcription termination factor 1	Homo sapiens	0-5
7479297-5	1995	TNF-alpha did not affect the concanavalin A and lentil lectin binding of TSH accumulated in the medium during the 4-day culture, but significantly decreased the lentil lectin binding of TSH released in response to acute TRH stimulation.	Thyrotropin	186-189	thyrotropin releasing hormone	Rattus norvegicus	220-223
7892156-13	1994	From our investigations, the role of Pit-1 in multidirectional differentiation during the development of TSH-secreting adenoma was suggested.	Thyrotropin	105-108	POU class 1 homeobox 1	Homo sapiens	37-42
7839517-1	1994	Peripheral thyroid hormone resistance (PTHR) was first described by Refetoff in 1967, and was characterized by raised serum hormone values of T4 and T3 and in appropriately elevated values of TSH.	Thyrotropin	192-195	parathyroid hormone 1 receptor	Homo sapiens	0-37
7839517-1	1994	Peripheral thyroid hormone resistance (PTHR) was first described by Refetoff in 1967, and was characterized by raised serum hormone values of T4 and T3 and in appropriately elevated values of TSH.	Thyrotropin	192-195	parathyroid hormone 1 receptor	Homo sapiens	39-43
7894262-6	1994	The TSH responses to TRH were unaltered by the treatment (means 8.25 and 7.74 mIU/l).	Thyrotropin	4-7	thyrotropin releasing hormone	Homo sapiens	21-24
7892156-0	1994	Clinical and immunohistochemical studies on TSH-secreting pituitary adenoma: its multihormonality and expression of Pit-1.	Thyrotropin	44-47	POU class 1 homeobox 1	Homo sapiens	116-121
7999049-0	1994	Western blot analysis of thyrotropin receptor expression in human thyroid tumours and correlation with TSH-binding.	Thyrotropin	103-106	thyroid stimulating hormone receptor	Homo sapiens	25-45
7952156-6	1994	In 28 patients with subnormal TSH, a normal TG value had a predictive value of 0.6 to exclude autonomous thyroid function.	Thyrotropin	30-33	thyroglobulin	Homo sapiens	44-46
7925105-6	1994	EGF reduced the basal rate and inhibited the TSH-induced long term up-regulation of FTE 125I- across the cell layer in the basoapical direction.	Thyrotropin	45-48	epidermal growth factor	Homo sapiens	0-3
7956924-5	1994	EGFR was detected in only 5-10% of the cells in all of the normal pituitary sections and was almost undetectable in all (34/34) of the hormone-secreting tumors (19 GH-, 9 ACTH-, 4 PRL- and 2 TSH-secreting tumors).	Thyrotropin	191-194	epidermal growth factor receptor	Homo sapiens	0-4
7925133-8	1994	We found NGF immunoreactivity in 10% of cells containing ACTH, 64% of cells with TSH, 75% of cells with LH, 51% of cells containing GH, and 42% of cells with PRL antigens.	Thyrotropin	81-84	nerve growth factor	Homo sapiens	9-12
7525632-1	1994	Recently we identified a unique region, residues 9-30 in the extracellular domain of the FSH receptor, capable of binding FSH but not LH or TSH.	Thyrotropin	140-143	follicle stimulating hormone receptor	Homo sapiens	89-101
7607071-10	1994	In the central midgut mesoderm Ubx, abd-A, dpp, and wg are required for proper tsh expression.	Thyrotropin	79-82	Ultrabithorax	Drosophila melanogaster	31-34
7607071-10	1994	In the central midgut mesoderm Ubx, abd-A, dpp, and wg are required for proper tsh expression.	Thyrotropin	79-82	abdominal A	Drosophila melanogaster	36-41
7607071-10	1994	In the central midgut mesoderm Ubx, abd-A, dpp, and wg are required for proper tsh expression.	Thyrotropin	79-82	decapentaplegic	Drosophila melanogaster	43-46
7607071-11	1994	The control of tsh by Ubx and abd-A, and probably also by Antp, is mediated by secreted signaling molecules.	Thyrotropin	15-18	Ultrabithorax	Drosophila melanogaster	22-25
7607071-11	1994	The control of tsh by Ubx and abd-A, and probably also by Antp, is mediated by secreted signaling molecules.	Thyrotropin	15-18	abdominal A	Drosophila melanogaster	30-35
7607071-11	1994	The control of tsh by Ubx and abd-A, and probably also by Antp, is mediated by secreted signaling molecules.	Thyrotropin	15-18	Antennapedia	Drosophila melanogaster	58-62
7925105-9	1994	Acute stimulation of EGF-treated cultures with TSH (10 mU/ml) or forskolin (50 microM) caused, as in controls, an increase in apical, but not basal, 125I- efflux within minutes; the peak value of stimulated apical efflux was 10-fold over the prestimulatory level of basoapical FTE 125I- in the same culture.	Thyrotropin	47-50	epidermal growth factor	Homo sapiens	21-24
7964297-9	1994	Although ET-1 did not affect DNA synthesis stimulated by either EGF or IGF-I, it dose-dependently inhibited TSH-induced iodide uptake and also inhibited iodide uptake stimulated by forskolin and 8-bromo-cAMP.	Thyrotropin	108-111	endothelin 1	Homo sapiens	9-13
7827627-10	1994	TSH concentration in the culture medium was increased by TRH treatment on 6, 12 and 24 h after the treatment on day 2, on 12 h and 24 h on day 3, and 24 h on day 6.	Thyrotropin	0-3	thyrotropin releasing hormone	Rattus norvegicus	57-60
7934981-3	1994	Exposure of the pituitary cells to TRH (0.1 mumol/L) for 2 hours stimulated TSH secretion by 176%.	Thyrotropin	76-79	thyrotropin releasing hormone	Rattus norvegicus	35-38
7826822-17	1994	Plasma TSH concentrations were significantly (P < 0.01) reduced from 2 h to day 4 following SR-L injection.2+ "	Thyrotropin	7-10	sarcalumenin	Homo sapiens	95-99
7925094-13	1994	The TSH-suppressive effect of IL-6, either administered as such or induced by IL-1 infusion, may be due to a direct effect on the thyrotroph, whereas additional effects of IL-1 may involve changes in the hypothalamic release of somatostatin or TRH.	Thyrotropin	4-7	interleukin 6	Rattus norvegicus	30-34
7833660-2	1994	To elucidate whether structural abnormalities in the TSH receptor (TSHR) could be a primary underlying mechanism of this disorder, we analyzed nucleotide sequence of the entire coding region of the TSHR gene in three patients diagnosed with congenital primary hypothyroidism associated with TSH unresponsiveness.	Thyrotropin	53-56	thyroid stimulating hormone receptor	Homo sapiens	67-71
7833660-2	1994	To elucidate whether structural abnormalities in the TSH receptor (TSHR) could be a primary underlying mechanism of this disorder, we analyzed nucleotide sequence of the entire coding region of the TSHR gene in three patients diagnosed with congenital primary hypothyroidism associated with TSH unresponsiveness.	Thyrotropin	53-56	thyroid stimulating hormone receptor	Homo sapiens	198-202
7946276-6	1994	Testing of TPO antibodies from samples with abnormal TSH levels is discussed.	Thyrotropin	53-56	thyroid peroxidase	Homo sapiens	11-14
7835824-4	1994	IL-1 beta (10 U/ml) decreased basal and TSH-stimulated iodide uptake and organification after an incubation time of 45 min to 6 h without any influence on cAMP-formation.	Thyrotropin	40-43	interleukin 1 beta	Homo sapiens	0-9
7835824-5	1994	In addition, after 40 h of incubation IL-1 beta dose-dependently increased T3-secretion, followed by a decrease during simultaneous TSH-stimulation, whereas there was no effect on T4-secretion.	Thyrotropin	132-135	interleukin 1 beta	Homo sapiens	38-47
7964297-13	1994	Antibody to ET-1 was found to increase TSH-induced iodide uptake.	Thyrotropin	39-42	endothelin 1	Homo sapiens	12-16
8033808-9	1994	The TSH receptor mRNA level correlated to the beta-actin mRNA was 2-fold higher in control cells compared to that in 1,25-(OH)2D3-treated cells 12 h after TSH removal.	Thyrotropin	4-7	actin, beta	Rattus norvegicus	46-56
7804136-4	1994	TSH and retinoic acid did not significantly modify RAR alpha mRNA levels, whereas RA caused a significant decrease in basal and TSH-induced thyroid peroxidase (TPO) mRNA levels, and a decrease in DNA synthesis.	Thyrotropin	128-131	thyroid peroxidase	Homo sapiens	160-163
8033821-16	1994	When thyrocytes were cultured with TSH, but at a low density (< 0.2 x 10(6) cells/cm2) to prevent follicle formation, a TSH-dependent increase in Cx43 was observed in monolayer cells.	Thyrotropin	35-38	gap junction protein alpha 1	Homo sapiens	149-153
8033821-16	1994	When thyrocytes were cultured with TSH, but at a low density (< 0.2 x 10(6) cells/cm2) to prevent follicle formation, a TSH-dependent increase in Cx43 was observed in monolayer cells.	Thyrotropin	123-126	gap junction protein alpha 1	Homo sapiens	149-153
7525909-1	1994	Insulin-like growth factor 1 (IGF1) has emerged as an essential factor in the follicular cell growth response in vitro to TSH, although its source within the thyroid in vivo is not clear.	Thyrotropin	122-125	insulin-like growth factor 1	Mus musculus	0-28
8045981-11	1994	Acting as a partial agonist, hCG was also capable of dose-dependently inhibiting TSH-stimulated cAMP formation.	Thyrotropin	81-84	chorionic gonadotropin subunit beta 5	Homo sapiens	29-32
7913937-8	1994	The appearance of HLA-DR induced by IFN gamma was accompanied by a progressive reduction of TPO despite stimulation by TSH or TSab.	Thyrotropin	119-122	interferon gamma	Homo sapiens	36-45
7525909-1	1994	Insulin-like growth factor 1 (IGF1) has emerged as an essential factor in the follicular cell growth response in vitro to TSH, although its source within the thyroid in vivo is not clear.	Thyrotropin	122-125	insulin-like growth factor 1	Mus musculus	30-34
8013345-4	1994	HGF inhibited both TSH- and forskolin-stimulated iodide uptake (a thyroid-specific differentiation marker) in the same way as EGF.	Thyrotropin	19-22	hepatocyte growth factor	Canis lupus familiaris	0-3
8021301-11	1994	In contrast, when cells were cultured in the presence of TSH alone at concentrations higher than 0.1 mU/ml, collagen and thrombospondin in the medium were decreased by a factor 2.0 and 1.9, respectively, and TSH preferentially activated Tg synthesis.	Thyrotropin	57-60	transcription termination factor 2	Homo sapiens	170-178
8080892-2	1994	Depressed patients exhibited elevated circulating concentrations of thyroid hormones, which were associated with and may have contributed to the blunted TSH response to TRH.	Thyrotropin	153-156	thyrotropin releasing hormone	Homo sapiens	169-172
7725746-12	1994	Furthermore, TSH treatment may promote FN secretion by FTC-133, although it does not seem to affect FnR or absolute FN expression.	Thyrotropin	13-16	fibronectin 1	Homo sapiens	39-41
7949641-4	1994	Lipid values in patients with basal serum TSH levels below 10 mU/l were not affected by L-T4 therapy, whereas serum levels of TC and LDL-C decreases significantly (P < 0.01) in patients with serum TSH levels above 10 mU/l.	Thyrotropin	200-203	component of oligomeric golgi complex 2	Homo sapiens	133-138
7970152-1	1994	Prepro-TRH-(160-169) (Ps4), one of the predicted connecting peptides of pro-TRH, potentiates TRH-induced TSH release in vivo and in vitro.	Thyrotropin	105-108	thyrotropin releasing hormone	Rattus norvegicus	7-10
7970152-1	1994	Prepro-TRH-(160-169) (Ps4), one of the predicted connecting peptides of pro-TRH, potentiates TRH-induced TSH release in vivo and in vitro.	Thyrotropin	105-108	thyrotropin releasing hormone	Rattus norvegicus	3-10
7970152-1	1994	Prepro-TRH-(160-169) (Ps4), one of the predicted connecting peptides of pro-TRH, potentiates TRH-induced TSH release in vivo and in vitro.	Thyrotropin	105-108	thyrotropin releasing hormone	Rattus norvegicus	76-79
8194638-3	1994	Patients with menstrual disturbances, galactorrhea, and confirmed elevations in serum PRL should have a screening TSH to rule out primary hypothyroidism (5).	Thyrotropin	114-117	prolactin	Homo sapiens	86-89
7515390-8	1994	ER expression in normal pituitary paralleled that in macroadenomas (GH, 2.3%; PRL, 50%; FSH, 70%; LH, 83%; TSH, 4%; ACTH, 1%).	Thyrotropin	107-110	estrogen receptor 1	Homo sapiens	0-2
7951579-7	1994	Human growth hormone releasing hormone (GRH) together with thyrotropin releasing hormone (TRH) elicited a normal response of TSH and low responses of GH and PRL.	Thyrotropin	125-128	growth hormone releasing hormone	Homo sapiens	6-38
7951579-7	1994	Human growth hormone releasing hormone (GRH) together with thyrotropin releasing hormone (TRH) elicited a normal response of TSH and low responses of GH and PRL.	Thyrotropin	125-128	growth hormone releasing hormone	Homo sapiens	40-43
7951579-7	1994	Human growth hormone releasing hormone (GRH) together with thyrotropin releasing hormone (TRH) elicited a normal response of TSH and low responses of GH and PRL.	Thyrotropin	125-128	thyrotropin releasing hormone	Homo sapiens	59-88
8055833-4	1994	IL-6 induced DNA synthesis when it was added to TSH-pretreated cells.	Thyrotropin	48-51	interleukin 6	Rattus norvegicus	0-4
8174642-13	1994	We propose that the dephosphorylation of destrin and cofilin could be involved in the TSH-stimulated macropinocytic activity, a key process in thyroid hormone secretion.	Thyrotropin	86-89	destrin, actin depolymerizing factor	Canis lupus familiaris	41-48
8156904-1	1994	TSH-induced desensitization was studied in nonthyroidal cells expressing functionally active TSH receptors (TSHR).	Thyrotropin	0-3	thyroid stimulating hormone receptor	Homo sapiens	93-106
8156904-1	1994	TSH-induced desensitization was studied in nonthyroidal cells expressing functionally active TSH receptors (TSHR).	Thyrotropin	0-3	thyroid stimulating hormone receptor	Homo sapiens	108-112
7749040-2	1994	She had 3 different antibodies (Ab) to the thyrotropin receptor (TSHR) in her serum, viz., TSH binding-inhibiting (TBIAb), thyroid-stimulating (TSAb) and an additional stimulating Ab (SAb).	Thyrotropin	65-68	thyroid stimulating hormone receptor	Homo sapiens	43-63
8137731-3	1994	The incorporation of 3H-mannose per molecule of Tg was increased 1.5-fold by a 50 microU/ml minimal concentration of TSH.	Thyrotropin	117-120	thyroglobulin	Homo sapiens	48-50
8196187-8	1994	Third, a binding site for the thyroid-specific transcription factor TTF-1, which dictates thyroid-specific expression and negative regulation by TSH/cAMP of the gene.	Thyrotropin	145-148	transcription termination factor 1	Rattus norvegicus	68-73
7519916-1	1994	We examined the effects of thyroid-stimulating hormone (TSH) on basic fibroblast growth factor (basic FGF) expression in isolated ovine thyroid follicles in vitro, and the effects of exogenous basic FGF on thyroid growth and function, to elucidate the significance of increased basic FGF expression during TSH-induced rat thyroid hyperplasia in vivo.	Thyrotropin	56-59	fibroblast growth factor 2	Rattus norvegicus	64-94
7519916-1	1994	We examined the effects of thyroid-stimulating hormone (TSH) on basic fibroblast growth factor (basic FGF) expression in isolated ovine thyroid follicles in vitro, and the effects of exogenous basic FGF on thyroid growth and function, to elucidate the significance of increased basic FGF expression during TSH-induced rat thyroid hyperplasia in vivo.	Thyrotropin	56-59	fibroblast growth factor 2	Rattus norvegicus	96-105
7519916-5	1994	Basic FGF mRNA transcripts of 3.7, 3.0, and 2.2 kb, respectively, were found in thyroid follicles cultured in 3H medium, and the abundance of each increased between 2- and 3-fold following incubation with 10-50 microU/mL TSH, although higher concentrations of TSH were less effective.	Thyrotropin	221-224	fibroblast growth factor 2	Rattus norvegicus	0-9
7519916-5	1994	Basic FGF mRNA transcripts of 3.7, 3.0, and 2.2 kb, respectively, were found in thyroid follicles cultured in 3H medium, and the abundance of each increased between 2- and 3-fold following incubation with 10-50 microU/mL TSH, although higher concentrations of TSH were less effective.	Thyrotropin	260-263	fibroblast growth factor 2	Rattus norvegicus	0-9
8119184-3	1994	Sera were also tested for their ability to block TSH binding to native TSHr.	Thyrotropin	49-52	thyrotropin receptor	Oryctolagus cuniculus	71-75
7514548-1	1994	This study examines the mechanism of TSH action on the cAMP-dependent protein kinases (PKA) by measuring the catalytic activity of the two PKA isozymes (PKA I and PKA II) and their capacity to bind cAMP to the regulatory subunits (RI and RII) in thyroid cell cultures exposed for two days to different doses of TSH.	Thyrotropin	37-40	protein kinase cAMP-activated catalytic subunit alpha	Sus scrofa	87-90
7514548-1	1994	This study examines the mechanism of TSH action on the cAMP-dependent protein kinases (PKA) by measuring the catalytic activity of the two PKA isozymes (PKA I and PKA II) and their capacity to bind cAMP to the regulatory subunits (RI and RII) in thyroid cell cultures exposed for two days to different doses of TSH.	Thyrotropin	37-40	protein kinase cAMP-activated catalytic subunit alpha	Sus scrofa	139-142
7514548-1	1994	This study examines the mechanism of TSH action on the cAMP-dependent protein kinases (PKA) by measuring the catalytic activity of the two PKA isozymes (PKA I and PKA II) and their capacity to bind cAMP to the regulatory subunits (RI and RII) in thyroid cell cultures exposed for two days to different doses of TSH.	Thyrotropin	37-40	protein kinase cAMP-activated catalytic subunit alpha	Sus scrofa	139-142
7514548-1	1994	This study examines the mechanism of TSH action on the cAMP-dependent protein kinases (PKA) by measuring the catalytic activity of the two PKA isozymes (PKA I and PKA II) and their capacity to bind cAMP to the regulatory subunits (RI and RII) in thyroid cell cultures exposed for two days to different doses of TSH.	Thyrotropin	37-40	protein kinase cAMP-activated catalytic subunit alpha	Sus scrofa	139-142
7514548-1	1994	This study examines the mechanism of TSH action on the cAMP-dependent protein kinases (PKA) by measuring the catalytic activity of the two PKA isozymes (PKA I and PKA II) and their capacity to bind cAMP to the regulatory subunits (RI and RII) in thyroid cell cultures exposed for two days to different doses of TSH.	Thyrotropin	311-314	protein kinase cAMP-activated catalytic subunit alpha	Sus scrofa	87-90
7514548-2	1994	In TSH-treated cell cultures a selective down regulation (up to 60%) of the catalytic activity was found; the PKA I was down regulated at lower TSH doses (0.1 mU/ml and even 0.05 mU/ml) than was the PKA II (1.0 mU/ml TSH).	Thyrotropin	3-6	protein kinase cAMP-activated catalytic subunit alpha	Sus scrofa	110-113
7514548-2	1994	In TSH-treated cell cultures a selective down regulation (up to 60%) of the catalytic activity was found; the PKA I was down regulated at lower TSH doses (0.1 mU/ml and even 0.05 mU/ml) than was the PKA II (1.0 mU/ml TSH).	Thyrotropin	3-6	protein kinase cAMP-activated catalytic subunit alpha	Sus scrofa	199-202
7514548-2	1994	In TSH-treated cell cultures a selective down regulation (up to 60%) of the catalytic activity was found; the PKA I was down regulated at lower TSH doses (0.1 mU/ml and even 0.05 mU/ml) than was the PKA II (1.0 mU/ml TSH).	Thyrotropin	144-147	protein kinase cAMP-activated catalytic subunit alpha	Sus scrofa	110-113
7514548-2	1994	In TSH-treated cell cultures a selective down regulation (up to 60%) of the catalytic activity was found; the PKA I was down regulated at lower TSH doses (0.1 mU/ml and even 0.05 mU/ml) than was the PKA II (1.0 mU/ml TSH).	Thyrotropin	144-147	protein kinase cAMP-activated catalytic subunit alpha	Sus scrofa	110-113
8077615-4	1994	In contrast, plasma membrane Glut-1 increased (300-400% over control) after 2 hours of stimulation with TSH (10 mU/ml), dibutyryl-cAMP (1mM), IGF-1 (10 ng/ml) and insulin (10 nM).	Thyrotropin	104-107	solute carrier family 2 member 1	Rattus norvegicus	29-35
8054860-1	1994	Our previous study of chimeric TSH-LH/CG receptors showed that substituting amino acid residues 268-304 of the TSH receptor with homologous residues from the LH/CG receptor markedly decreased high affinity TSH binding as evidenced by ligand displacement assays [Akamizu et al.	Thyrotropin	31-34	luteinizing hormone/choriogonadotropin receptor	Rattus norvegicus	35-49
8054860-7	1994	A single point mutation of cysteine-301 to glutamate resulted in a mutant receptor that exhibited the same receptor bioactivity as the chimeric receptor with amino acids 268-304 substituted by LH/CG receptor residues: apparent low affinity TSH binding in ligand displacement assays but significant retention of the cAMP response to TSH.	Thyrotropin	240-243	luteinizing hormone/choriogonadotropin receptor	Rattus norvegicus	193-207
7509736-12	1994	When the inhibitory effect of TSH and cortisol was removed, IGFBP-2 mRNA increased within 3 h and was 7-fold greater within 12 h. IGFBP-2 did not appear in the conditioned medium until 12 h after TSH removal, along with the other IGFBP species.	Thyrotropin	30-33	insulin like growth factor binding protein 2	Homo sapiens	60-67
8051338-10	1994	A low affinity TSH-binding site is present in orbital connective tissue, and is recognized by IgG"s from patients with ophthalmopathy which suggests that TSH receptor antibodies may target the orbit.	Thyrotropin	15-18	thyroid stimulating hormone receptor	Homo sapiens	154-166
8170469-1	1994	The hyt/hyt hypothyroid mouse has an autosomal recessive, fetal-onset, severe hypothyroidism related to TSH hyporesponsiveness and associated with elevated TSH.	Thyrotropin	104-107	thyroid stimulating hormone receptor	Mus musculus	4-7
8170469-1	1994	The hyt/hyt hypothyroid mouse has an autosomal recessive, fetal-onset, severe hypothyroidism related to TSH hyporesponsiveness and associated with elevated TSH.	Thyrotropin	104-107	thyroid stimulating hormone receptor	Mus musculus	8-11
7578850-2	1994	IL-1 inhibits the function of cultured human thyroid cells too, and in this study human thyroid cell production of NO in response to the TSH-stimulated influence of IL-1 beta (10(5) U/l) and TNF-alpha (10(6) U/l), alone or in combination was measured.	Thyrotropin	137-140	interleukin 1 beta	Homo sapiens	0-4
7578850-2	1994	IL-1 inhibits the function of cultured human thyroid cells too, and in this study human thyroid cell production of NO in response to the TSH-stimulated influence of IL-1 beta (10(5) U/l) and TNF-alpha (10(6) U/l), alone or in combination was measured.	Thyrotropin	137-140	interleukin 1 beta	Homo sapiens	165-174
7578850-2	1994	IL-1 inhibits the function of cultured human thyroid cells too, and in this study human thyroid cell production of NO in response to the TSH-stimulated influence of IL-1 beta (10(5) U/l) and TNF-alpha (10(6) U/l), alone or in combination was measured.	Thyrotropin	137-140	tumor necrosis factor	Homo sapiens	191-200
7998484-12	1994	A mild elevation of the activity of hepatic enzymes (glutathione-S-transferase, gamma glutamyltransferase, alanine amino-transferase, angiotensin-converting enzyme) has been observed in patients under T4 treatment in TSH-suppressive doses.	Thyrotropin	217-220	glutathione S-transferase kappa 1	Homo sapiens	53-78
7924634-9	1994	We conclude that in Graves" disease, patients are rendered hyperthyroid by continued, non-pulsatile and non-chaotic binding of stimulatory antibodies to the TSH binding site of the TSH-R.	Thyrotropin	157-160	thyroid stimulating hormone receptor	Homo sapiens	181-186
7998484-12	1994	A mild elevation of the activity of hepatic enzymes (glutathione-S-transferase, gamma glutamyltransferase, alanine amino-transferase, angiotensin-converting enzyme) has been observed in patients under T4 treatment in TSH-suppressive doses.	Thyrotropin	217-220	angiotensin I converting enzyme	Homo sapiens	134-163
8124749-1	1994	Clinical observations and experimental studies indicate that administration of growth hormone (GH) affects thyroid parameters either via inhibited TSH secretion or via activation of the peripheral conversion of T4 to T3.	Thyrotropin	147-150	growth hormone 1	Homo sapiens	79-93
7648793-2	1994	The aim of this study was to investigate the prevalence of abnormal TSH concentrations, using a sensitive immunometric assay, in patients with type 2 (non-insulin-dependent) diabetes mellitus.	Thyrotropin	68-71	insulin	Homo sapiens	155-162
7736768-5	1994	NPY (10(-10) M) used together with TSH, produced an increase of 3H-thymidine incorporation into DNA, when compared with controls and the TSH-exposed group.	Thyrotropin	137-140	neuropeptide Y	Rattus norvegicus	0-3
7774286-10	1994	In all groups and at all times an increase of 3H-thymidine incorporation occurred; the stimulatory effect of VIP (in all doses) was stronger than that of TSH; the rate of 3H-thymidine incorporation after injections of both VIP and TSH (group 6), was higher than the rates following injections of VIP alone (group 5) or TSH alone (group 2).	Thyrotropin	231-234	vasoactive intestinal peptide	Rattus norvegicus	109-112
7774286-10	1994	In all groups and at all times an increase of 3H-thymidine incorporation occurred; the stimulatory effect of VIP (in all doses) was stronger than that of TSH; the rate of 3H-thymidine incorporation after injections of both VIP and TSH (group 6), was higher than the rates following injections of VIP alone (group 5) or TSH alone (group 2).	Thyrotropin	231-234	vasoactive intestinal peptide	Rattus norvegicus	109-112
7736768-5	1994	NPY (10(-10) M) used together with TSH, produced an increase of 3H-thymidine incorporation into DNA, when compared with controls and the TSH-exposed group.	Thyrotropin	35-38	neuropeptide Y	Rattus norvegicus	0-3
8136736-2	1993	We now report the effect of NB, thyroxin (T4) and NB + thyroxin on basal and THR (50 nM)-stimulated TSH release from isolated hemipituitaries of hyperthyroid rats.	Thyrotropin	100-103	neuromedin B	Rattus norvegicus	28-30
7937323-9	1994	These findings suggest that the ANF-R1 receptor, preferentially expressed in FRTL-5 cells and regulated by TSH, might play a role in regulating thyroid hormone production.	Thyrotropin	107-110	natriuretic peptide A	Rattus norvegicus	32-35
32138434-1	1993	Pit-1, the pituitary-specific transcriptional factor, has been known as a gene that regulates the functional differentiation of the anterior pituitary gland, especially in GH, PRL, and TSH production.	Thyrotropin	185-188	POU class 1 homeobox 1	Homo sapiens	0-5
8136736-2	1993	We now report the effect of NB, thyroxin (T4) and NB + thyroxin on basal and THR (50 nM)-stimulated TSH release from isolated hemipituitaries of hyperthyroid rats.	Thyrotropin	100-103	neuromedin B	Rattus norvegicus	50-52
8136736-6	1993	Basal TSH release was paradoxically increased in the presence of 0.1 microM T4 or 0.1 microM NB and even two times higher in the presence of both (Control: 30.0 +/- 4.2 ng/ml; T4: 58.6 +/- 5.6 ng/ml; NB: 53.4 +/- 6.1 ng/ml; T4 + NB: 90.4 +/- 8.5 ng/ml).	Thyrotropin	6-9	neuromedin B	Rattus norvegicus	93-95
8136736-6	1993	Basal TSH release was paradoxically increased in the presence of 0.1 microM T4 or 0.1 microM NB and even two times higher in the presence of both (Control: 30.0 +/- 4.2 ng/ml; T4: 58.6 +/- 5.6 ng/ml; NB: 53.4 +/- 6.1 ng/ml; T4 + NB: 90.4 +/- 8.5 ng/ml).	Thyrotropin	6-9	neuromedin B	Rattus norvegicus	200-202
8136736-6	1993	Basal TSH release was paradoxically increased in the presence of 0.1 microM T4 or 0.1 microM NB and even two times higher in the presence of both (Control: 30.0 +/- 4.2 ng/ml; T4: 58.6 +/- 5.6 ng/ml; NB: 53.4 +/- 6.1 ng/ml; T4 + NB: 90.4 +/- 8.5 ng/ml).	Thyrotropin	6-9	neuromedin B	Rattus norvegicus	200-202
8136736-7	1993	The percent increment above basal TSH levels after TRH was higher only in the presence of NB (Control: 44.5 +/- 8.2%, NB: 105.3 +/- 18.8%; P < 0.05).	Thyrotropin	34-37	neuromedin B	Rattus norvegicus	90-92
8077321-12	1993	These data demonstrate selective expression of the human pit-1 gene in adenohypophysial cell types responsible for GH, PRL, and/or TSH synthesis and are consistent with a predominantly pretranslational regulatory mechanism for Pit-1 expression in the human.	Thyrotropin	131-134	POU class 1 homeobox 1	Homo sapiens	57-62
8308468-8	1993	Specific TSH binding was unmasked by serum in the human cell lines, as observed for the human thyroid TSH receptor, whereas serum hindered TSH binding in the murine cell lines.	Thyrotropin	9-12	thyroid stimulating hormone receptor	Homo sapiens	102-114
8256209-1	1993	BACKGROUND: Thyroid-stimulating hormone (TSH) stimulates thyroid growth through two signal transduction pathways: the G protein-adenylate cyclase system and the G protein-phospholipase C (PLC) system.	Thyrotropin	12-39	heparan sulfate proteoglycan 2	Homo sapiens	188-191
8256209-1	1993	BACKGROUND: Thyroid-stimulating hormone (TSH) stimulates thyroid growth through two signal transduction pathways: the G protein-adenylate cyclase system and the G protein-phospholipase C (PLC) system.	Thyrotropin	41-44	heparan sulfate proteoglycan 2	Homo sapiens	188-191
8256209-7	1993	Although there were no differences in basal or TSH-stimulated PLC activity between the groups of normal thyroid, multinodular goiter, follicular adenoma, or the cancers, one half of the high-risk cancers had an aberrant PLC response.	Thyrotropin	47-50	heparan sulfate proteoglycan 2	Homo sapiens	62-65
8256209-9	1993	Aberrant TSH-stimulated PLC activity was present in half of the aggressive thyroid neoplasms.	Thyrotropin	9-12	heparan sulfate proteoglycan 2	Homo sapiens	24-27
8077347-1	1993	When interferons (IFN-alpha-2a, IFN-alpha-2b, natural IFN-alpha and IFN-beta) were cultured with human thyroid follicles, each IFN inhibited TSH-induced thyroid function (125I incorporation and release of 125I-T4) in a concentration-dependent manner.	Thyrotropin	141-144	interferon alpha 1	Homo sapiens	18-27
8077347-1	1993	When interferons (IFN-alpha-2a, IFN-alpha-2b, natural IFN-alpha and IFN-beta) were cultured with human thyroid follicles, each IFN inhibited TSH-induced thyroid function (125I incorporation and release of 125I-T4) in a concentration-dependent manner.	Thyrotropin	141-144	interferon alpha 1	Homo sapiens	32-41
8077347-1	1993	When interferons (IFN-alpha-2a, IFN-alpha-2b, natural IFN-alpha and IFN-beta) were cultured with human thyroid follicles, each IFN inhibited TSH-induced thyroid function (125I incorporation and release of 125I-T4) in a concentration-dependent manner.	Thyrotropin	141-144	interferon alpha 1	Homo sapiens	32-41
8077347-1	1993	When interferons (IFN-alpha-2a, IFN-alpha-2b, natural IFN-alpha and IFN-beta) were cultured with human thyroid follicles, each IFN inhibited TSH-induced thyroid function (125I incorporation and release of 125I-T4) in a concentration-dependent manner.	Thyrotropin	141-144	interferon beta 1	Homo sapiens	68-76
8238336-5	1993	The ET-1-to-ET-3 potency ratio was three orders of magnitude higher on PRL or TSH secretion than on LH and FSH secretion, whereas SRTX-b-to-ET-3 potency ratios were similar on all four hormones.	Thyrotropin	78-81	endothelin 1	Rattus norvegicus	4-8
8216292-3	1993	Thus, in cells with TSHR, about 3 x 10(-11) and 3 x 10(-10) M TSH cause half maximal increases in cAMP and inositol phosphate (IP) levels, respectively, whereas 10(-6) M hCG has no effect on either.	Thyrotropin	20-23	chorionic gonadotropin subunit beta 5	Homo sapiens	170-173
8216292-7	1993	Thus, TSH binds with high affinity (Kd = 7 x 10(-11) M) to the human TSHR; hCG (up to 10(-7) M) does not displace TSH binding.	Thyrotropin	6-9	thyroid stimulating hormone receptor	Homo sapiens	69-73
8216292-10	1993	The unusual agonist action of TSH with recombinant CGR is consistent with TSHR models describing separate agonist and antagonist determinants; it may be a factor in the precocious puberty of juvenile hypothyroidism with high TSH levels	Thyrotropin	30-33	thyroid stimulating hormone receptor	Homo sapiens	74-78
8238336-5	1993	The ET-1-to-ET-3 potency ratio was three orders of magnitude higher on PRL or TSH secretion than on LH and FSH secretion, whereas SRTX-b-to-ET-3 potency ratios were similar on all four hormones.	Thyrotropin	78-81	endothelin 3	Rattus norvegicus	12-16
7691861-6	1993	These results demonstrate that hLH is a more potent TSH than hCG and that the C-terminal extension of the hCG beta-subunit can interfere with hCG interaction with the hTSH receptor.	Thyrotropin	52-55	thyroid stimulating hormone receptor	Homo sapiens	167-180
8104224-4	1993	We hypothesized that anti-Gal may bind in vitro to alpha-galactosyl epitopes on xenogeneic TSH receptors (TSHR) and mimic the effect of TSH on xenogeneic thyrocytes.	Thyrotropin	91-94	galanin and GMAP prepropeptide	Homo sapiens	26-29
8104224-4	1993	We hypothesized that anti-Gal may bind in vitro to alpha-galactosyl epitopes on xenogeneic TSH receptors (TSHR) and mimic the effect of TSH on xenogeneic thyrocytes.	Thyrotropin	91-94	thyroid stimulating hormone receptor	Homo sapiens	106-110
8257866-5	1993	The amount of immunoreactive (ir)-ET-1 secreted from the cells was also increased by TPA and was decreased by TSH.	Thyrotropin	110-113	endothelin 1	Homo sapiens	34-38
8408457-1	1993	To evaluate the role of interferon-gamma (IFN gamma) on human thyroid-specific gene expression, the effect of IFN gamma on TSH- and cAMP-induced TSH receptor gene expression was studied using cultured thyroid cells obtained from normal thyroid glands and those from patients with Graves" disease.	Thyrotropin	123-126	interferon gamma	Homo sapiens	110-119
8264661-8	1993	Protein-DNA binding studies show that the thyroid-specific nuclear protein TTF-2, which binds to the rTPO promoter, is induced by TSH and forskolin, and this effect is clearly observable as early as 5 h post induction.	Thyrotropin	130-133	transcription termination factor 2	Rattus norvegicus	75-80
8264661-10	1993	Heterologous promoter constructs containing four, eight, or 12 tandem repeats of an oligonucleotide that includes the TTF-2 binding site increase their activity in response to TSH, forskolin, and insulin, while the the presence of A23187 or TPA inhibits their activity.	Thyrotropin	176-179	transcription termination factor 2	Rattus norvegicus	118-123
7902304-2	1993	In normal human thyroid cells in primary culture, TGF beta 1 inhibited inconstantly the low basal DNA synthesis and strongly the stimulation of DNA synthesis by epidermal growth factor (EGF) and serum, and by thyroid-stimulating hormone (TSH) acting through cAMP.	Thyrotropin	209-236	transforming growth factor beta 1	Homo sapiens	50-60
8191112-5	1993	A positive correlation between TPO antigen and TSH levels was observed (r = 0.69, p < 0.001).	Thyrotropin	47-50	thyroid peroxidase	Homo sapiens	31-34
8103769-4	1993	The antigen frequency of HLA-DR8 was significantly increased in 23 atrophic autoimmune thyroiditis patients that were positive for TSH binding inhibitor immunoglobulin (TBII) compared to 136 controls [52% vs. 16%; chi 2 = 13.1; Pc (corrected P value) = 0.003].	Thyrotropin	131-134	major histocompatibility complex, class II, DQ beta 1	Homo sapiens	25-28
7902304-2	1993	In normal human thyroid cells in primary culture, TGF beta 1 inhibited inconstantly the low basal DNA synthesis and strongly the stimulation of DNA synthesis by epidermal growth factor (EGF) and serum, and by thyroid-stimulating hormone (TSH) acting through cAMP.	Thyrotropin	238-241	transforming growth factor beta 1	Homo sapiens	50-60
7920881-0	1993	TSH secretory responses to prolonged infusion of TRH in hypothyroid rats.	Thyrotropin	0-3	thyrotropin releasing hormone	Rattus norvegicus	49-52
8399820-3	1993	Further, TSH responses to TRH among 11 healthy male nonpsychiatric controls were not significantly different from those in patients with personality disorders.	Thyrotropin	9-12	thyrotropin releasing hormone	Homo sapiens	26-29
7920902-7	1993	A review of the literature on 103 cases disclosed that more than half the cases with isolated ACTH deficiency had a high plasma level of TSH, basal and/or TRH-induced, while the antithyroid antibodies were reported to be positive in only 13 cases.	Thyrotropin	137-140	proopiomelanocortin	Homo sapiens	94-98
8413850-3	1993	The stimulatory effect of TRH on TSH release from monocytes is totally blocked by triiodothyronine (T3) administrations.	Thyrotropin	33-36	thyrotropin releasing hormone	Homo sapiens	26-29
7901757-0	1993	Substitutions of different regions of the third cytoplasmic loop of the thyrotropin (TSH) receptor have selective effects on constitutive, TSH-, and TSH receptor autoantibody-stimulated phosphoinositide and 3",5"-cyclic adenosine monophosphate signal generation.	Thyrotropin	85-88	thyroid stimulating hormone receptor	Rattus norvegicus	149-161
8217398-11	1993	The effect of TRH on serum TSH secretion was not evident in this patient.	Thyrotropin	27-30	thyrotropin releasing hormone	Homo sapiens	14-17
8327473-3	1993	Similar interaction between the thyrotropin (TSH) receptor and ABP in endocrine cells might explain the rapid and profound disruption of actin microfilaments induced by TSH in cultured thyroid follicular cells.	Thyrotropin	45-48	sex hormone binding globulin	Homo sapiens	63-66
8327473-10	1993	We suggest, therefore, that signal transduction by TSH in the thyroid involves direct linkage of the TSH receptor to actin microfilaments by ABP and that TABP may interact with ABP to mediate TSH-induced actin microfilament disruption.	Thyrotropin	51-54	sex hormone binding globulin	Homo sapiens	141-144
8327473-10	1993	We suggest, therefore, that signal transduction by TSH in the thyroid involves direct linkage of the TSH receptor to actin microfilaments by ABP and that TABP may interact with ABP to mediate TSH-induced actin microfilament disruption.	Thyrotropin	101-104	sex hormone binding globulin	Homo sapiens	141-144
7920881-3	1993	Infusion of a constant concentration of TRH induced a peak in the plasma TSH concentration within 5-15 min which declined to the baseline within 1 h. The refractory period lasted 20-40 min after stopping the continuous TRH infusion.	Thyrotropin	73-76	thyrotropin releasing hormone	Rattus norvegicus	40-43
7920881-4	1993	A second burst of TSH secretion was induced by increasing the TRH concentration during the refractory period while TRH was being continuously infused.	Thyrotropin	18-21	thyrotropin releasing hormone	Rattus norvegicus	62-65
7920881-4	1993	A second burst of TSH secretion was induced by increasing the TRH concentration during the refractory period while TRH was being continuously infused.	Thyrotropin	18-21	thyrotropin releasing hormone	Rattus norvegicus	115-118
7920881-5	1993	These data indicate that in hypothyroid rats TSH secretion rapidly becomes refractory to continuous exposure to the same concentration of TRH but is stimulated by a higher TRH concentration.	Thyrotropin	45-48	thyrotropin releasing hormone	Rattus norvegicus	138-141
7920881-5	1993	These data indicate that in hypothyroid rats TSH secretion rapidly becomes refractory to continuous exposure to the same concentration of TRH but is stimulated by a higher TRH concentration.	Thyrotropin	45-48	thyrotropin releasing hormone	Rattus norvegicus	172-175
8516785-4	1993	In a histological evaluation of thyroids, the PCB 118 pups revealed changes suggestive of sustained TSH stimulation, including increased follicular cell vacuolization and height, increased nuclear vesiculation, and decreased colloid area.	Thyrotropin	100-103	pyruvate carboxylase	Rattus norvegicus	46-49
8349030-9	1993	The data thus support a model of TSH-induced splicing and regulation of the two Tg mRNAs in the rat.	Thyrotropin	33-36	thyroglobulin	Rattus norvegicus	80-82
8344646-1	1993	Thyrotropin releasing hormone (TRH) administration is known to induce a greater TSH response in normal subjects than in obese subjects.	Thyrotropin	80-83	thyrotropin releasing hormone	Homo sapiens	0-29
8344646-1	1993	Thyrotropin releasing hormone (TRH) administration is known to induce a greater TSH response in normal subjects than in obese subjects.	Thyrotropin	80-83	thyrotropin releasing hormone	Homo sapiens	31-34
8344646-4	1993	In order to evaluate the possible interference of an increased somatostatinergic tone on TSH secretion, we studied the TSH response to a TRH bolus in 5 obese children with or without a pyr pretreatment.	Thyrotropin	119-122	thyrotropin releasing hormone	Homo sapiens	137-140
8492709-5	1993	Mean 24-hour TSH levels were increased in HIV patients (2.39 +/- 0.33 v 1.44 +/- 0.16 mU/L, P < .05), associated with increased mean TSH pulse amplitude and TSH responsiveness to TRH.	Thyrotropin	13-16	thyrotropin releasing hormone	Homo sapiens	182-185
8350517-7	1993	Sequence comparisons using PCR amplified PIT1 gene sequences revealed only one nonsense mutation in the patient, and established that this alteration caused the combined deficiencies of TSH, GH and PRL.	Thyrotropin	186-189	POU class 1 homeobox 1	Homo sapiens	41-45
8386510-3	1993	By contrast, IL-6 stimulated DNA synthesis in a dose dependent manner when TSH was added concomitantly.	Thyrotropin	75-78	interleukin 6	Rattus norvegicus	13-17
8367024-8	1993	The prompt parallel rate of rise of plasma TSH in Sham and PVN groups following thyroidectomy indicates that a primary physiologic action of TRH in the thyrotroph is to control the set-point for thyroid hormone negative feedback on TSH secretion.	Thyrotropin	43-46	thyrotropin releasing hormone	Rattus norvegicus	141-144
8462478-1	1993	We and others have previously shown that 12-O-tetracanoylphorbol-13-acetate (TPA), a protein kinase-C (PKC) activator, inhibits TSH-stimulated iodide organification in porcine thyroid cells.	Thyrotropin	128-131	proline rich transmembrane protein 2	Homo sapiens	85-101
8462478-1	1993	We and others have previously shown that 12-O-tetracanoylphorbol-13-acetate (TPA), a protein kinase-C (PKC) activator, inhibits TSH-stimulated iodide organification in porcine thyroid cells.	Thyrotropin	128-131	proline rich transmembrane protein 2	Homo sapiens	103-106
8462478-10	1993	In summary, these studies indicate that in porcine thyroid cells, three distinct PKC inhibitors all enhanced TSH-stimulated iodide organification and that staurosporine reversed the effects of TPA on TSH-stimulated iodide organification.	Thyrotropin	109-112	proline rich transmembrane protein 2	Homo sapiens	81-84
7682563-7	1993	IR IGF-I levels correlated positively with free T3 and free T4 and negatively with TSH levels.	Thyrotropin	83-86	insulin like growth factor 1	Homo sapiens	3-8
8385451-4	1993	Transfected cells, designated HTC-TSHr, expressed the TSH receptor mRNA and synthesized a functional TSH receptor with a TSH binding affinity in the order of magnitude of normal thyroid cells.	Thyrotropin	34-37	thyroid stimulating hormone receptor	Homo sapiens	54-66
8385451-4	1993	Transfected cells, designated HTC-TSHr, expressed the TSH receptor mRNA and synthesized a functional TSH receptor with a TSH binding affinity in the order of magnitude of normal thyroid cells.	Thyrotropin	34-37	thyroid stimulating hormone receptor	Homo sapiens	101-113
8469246-6	1993	An elevated serum TSH was associated with the presence of hTPO-Ab in varying concentrations.	Thyrotropin	18-21	thyroid peroxidase	Homo sapiens	58-62
8471682-4	1993	A blunted response of TSH to TRH was found without a significant effect on a PRL response to TRH after long-term treatment with TRH in four patients in whom a TRH test was performed.	Thyrotropin	22-25	thyrotropin releasing hormone	Homo sapiens	29-32
8426735-4	1993	The E1A transfected cells, PC E1A, partially lost the dependency on TSH for growth and completely lost the ability to trap iodide and synthesize thyroglobulin; however they did not acquire the typical markers of the neoplastic phenotype.	Thyrotropin	68-71	branched chain keto acid dehydrogenase E1 subunit alpha	Rattus norvegicus	4-7
8426735-4	1993	The E1A transfected cells, PC E1A, partially lost the dependency on TSH for growth and completely lost the ability to trap iodide and synthesize thyroglobulin; however they did not acquire the typical markers of the neoplastic phenotype.	Thyrotropin	68-71	branched chain keto acid dehydrogenase E1 subunit alpha	Rattus norvegicus	30-33
8102255-0	1993	Induction of TSH binding inhibitory immunoglobulins with the extracellular domain of human thyrotropin receptor produced using baculovirus expression system.	Thyrotropin	13-16	thyroid stimulating hormone receptor	Homo sapiens	91-111
8406344-6	1993	Plasma TRH and TSH level responses to cold as well as plasma TSH level response to TRH were enhanced with treatment of antisera to these peptides.	Thyrotropin	61-64	thyrotropin releasing hormone	Rattus norvegicus	83-86
8421082-4	1993	Although TSH alone did not significantly modulate ET release into medium, TSH enhanced the stimulatory effect of TGF-beta.	Thyrotropin	74-77	transforming growth factor beta 1	Homo sapiens	113-121
8095322-5	1993	Since the latter have been shown to interact with high affinity TSH-binding sites on the C-terminal portion of the external domain of the TSHR, stimulating TSHRAbs and blocking TSHRAbs react with different receptor determinants, which can be presumed to have different roles in receptor function.	Thyrotropin	64-67	thyroid stimulating hormone receptor	Rattus norvegicus	138-142
8479613-7	1993	In another experiment, EGF 10(-8) M or TRH 10(-8) M significantly elevated TSH secretion (p < 0.01).	Thyrotropin	75-78	epidermal growth factor like 1	Rattus norvegicus	23-26
8479613-7	1993	In another experiment, EGF 10(-8) M or TRH 10(-8) M significantly elevated TSH secretion (p < 0.01).	Thyrotropin	75-78	thyrotropin releasing hormone	Rattus norvegicus	39-42
8479613-9	1993	In the in vivo studies, the intravenous administration of EGF 10(-5) M or TRH 10(-5) M both induced significant elevation of TSH release at 10 min after the injection (p < 0.02 for EGF and p < 0.01 for TRH).	Thyrotropin	125-128	epidermal growth factor like 1	Rattus norvegicus	58-61
8479613-9	1993	In the in vivo studies, the intravenous administration of EGF 10(-5) M or TRH 10(-5) M both induced significant elevation of TSH release at 10 min after the injection (p < 0.02 for EGF and p < 0.01 for TRH).	Thyrotropin	125-128	thyrotropin releasing hormone	Rattus norvegicus	74-77
1333981-5	1992	These findings suggest that the unresponsiveness to TSH in these cells may be due to an abnormality of TSH receptor-G protein coupling rather than to a decreased level of TSH-receptor expression or a Gs protein abnormality.	Thyrotropin	52-55	thyroid stimulating hormone receptor	Homo sapiens	103-115
1446603-7	1992	This alpha 2-adrenergic agonist caused a significant (P < 0.01) 12.7-fold rise in plasma TSH levels in normal rabbit serum-treated animals, which was completely abolished by TRH-AS pretreatment, indicating that clonidine stimulates TSH secretion via activation of hypothalamic TRH release.	Thyrotropin	92-95	thyrotropin releasing hormone	Rattus norvegicus	177-180
1446603-7	1992	This alpha 2-adrenergic agonist caused a significant (P < 0.01) 12.7-fold rise in plasma TSH levels in normal rabbit serum-treated animals, which was completely abolished by TRH-AS pretreatment, indicating that clonidine stimulates TSH secretion via activation of hypothalamic TRH release.	Thyrotropin	92-95	thyrotropin releasing hormone	Rattus norvegicus	280-283
1446603-7	1992	This alpha 2-adrenergic agonist caused a significant (P < 0.01) 12.7-fold rise in plasma TSH levels in normal rabbit serum-treated animals, which was completely abolished by TRH-AS pretreatment, indicating that clonidine stimulates TSH secretion via activation of hypothalamic TRH release.	Thyrotropin	235-238	thyrotropin releasing hormone	Rattus norvegicus	177-180
1446603-8	1992	When TRH-AS was slowly infused into hypothyroid rats that were sampled frequently for the detection of TSH pulsatility, it caused a significant (60.3%; P < 0.01) decrease in mean TSH levels, with TSH titers approaching euthyroid concentrations 1 h after the infusion of TRH-AS.	Thyrotropin	103-106	thyrotropin releasing hormone	Rattus norvegicus	5-8
1446603-8	1992	When TRH-AS was slowly infused into hypothyroid rats that were sampled frequently for the detection of TSH pulsatility, it caused a significant (60.3%; P < 0.01) decrease in mean TSH levels, with TSH titers approaching euthyroid concentrations 1 h after the infusion of TRH-AS.	Thyrotropin	182-185	thyrotropin releasing hormone	Rattus norvegicus	5-8
1446603-8	1992	When TRH-AS was slowly infused into hypothyroid rats that were sampled frequently for the detection of TSH pulsatility, it caused a significant (60.3%; P < 0.01) decrease in mean TSH levels, with TSH titers approaching euthyroid concentrations 1 h after the infusion of TRH-AS.	Thyrotropin	182-185	thyrotropin releasing hormone	Rattus norvegicus	5-8
1446629-2	1992	The long-term iodination of thyroglobulin secreted into the apical medium of thyroid cells cultured as monolayers on porous bottom chambers reached 5.87 +/- 1.66 atoms of iodine/mol thyroglobulin after 11 days incubation in the presence of TSH (0.1 mU/ml) and iodide (0.5 microM) in the basal medium.	Thyrotropin	240-243	thyroglobulin	Homo sapiens	28-41
1490587-2	1992	Preincubation of the pituitaries with 50 ng/ml (64 nM) thyroxine (T4) for 6 hr suppressed the TRH- and oCRH-induced (268 nM) secretion of bioactive TSH, but did not affect the response of the pituitaries to 268 nM mGnRH.	Thyrotropin	148-151	thyrotropin releasing hormone	Homo sapiens	94-97
1490587-3	1992	Triiodothyronine (T3) (64 nM) reduced both the TRH- and mGnRH-stimulated release of bioactive TSH; the response of TSH to TRH even decreased toward basal levels while a significant TSH response to mGnRH remained.	Thyrotropin	94-97	thyrotropin releasing hormone	Homo sapiens	47-50
1490587-3	1992	Triiodothyronine (T3) (64 nM) reduced both the TRH- and mGnRH-stimulated release of bioactive TSH; the response of TSH to TRH even decreased toward basal levels while a significant TSH response to mGnRH remained.	Thyrotropin	115-118	thyrotropin releasing hormone	Homo sapiens	122-125
1490587-3	1992	Triiodothyronine (T3) (64 nM) reduced both the TRH- and mGnRH-stimulated release of bioactive TSH; the response of TSH to TRH even decreased toward basal levels while a significant TSH response to mGnRH remained.	Thyrotropin	115-118	thyrotropin releasing hormone	Homo sapiens	122-125
1490587-6	1992	The inhibitory effects of thyroid hormones on the TRH-induced release of bioactive TSH was present for at least 4 hr after their removal from the incubation medium.	Thyrotropin	83-86	thyrotropin releasing hormone	Homo sapiens	50-53
1475033-5	1992	Also CCK-8 decreased TSH levels at the doses of 20 and 50 micrograms/kg at 15 min.	Thyrotropin	21-24	cholecystokinin	Rattus norvegicus	5-8
1425414-5	1992	During the infusion of 2.0 micrograms IL-1/day, the decrease in plasma free T4 levels was paralleled by a significant decline in plasma TSH values and an impaired TSH responsiveness to TRH administration on the second day of infusion.	Thyrotropin	136-139	interleukin 1 beta	Homo sapiens	38-42
1425414-5	1992	During the infusion of 2.0 micrograms IL-1/day, the decrease in plasma free T4 levels was paralleled by a significant decline in plasma TSH values and an impaired TSH responsiveness to TRH administration on the second day of infusion.	Thyrotropin	163-166	interleukin 1 beta	Homo sapiens	38-42
1425414-10	1992	Restriction of food consumption to the level observed in the 2.0 micrograms IL-1 experiment caused small decreases in T3, total and free T4, and TSH levels compared to those in ad libitum fed rats, but had no effects on T4 binding.	Thyrotropin	145-148	interleukin 1 beta	Homo sapiens	76-80
1452118-6	1992	In conclusion, a weak but not significant decrease in the TSH response to TRH in postmenopausal women may be explained by the lower endogenous estradiol level.	Thyrotropin	58-61	thyrotropin releasing hormone	Homo sapiens	74-77
1279944-6	1992	Thyroid stimulating hormone, phorbol 12, 13-dibutyrate and thyroid stimulating autoantibody enhanced the MACIF and DAF expression.	Thyrotropin	0-27	CD59 molecule (CD59 blood group)	Homo sapiens	105-110
1279944-6	1992	Thyroid stimulating hormone, phorbol 12, 13-dibutyrate and thyroid stimulating autoantibody enhanced the MACIF and DAF expression.	Thyrotropin	0-27	CD55 molecule (Cromer blood group)	Homo sapiens	115-118
1422229-1	1992	Previous studies had shown that epidermal growth factor (EGF) will stimulate growth of cultured thyroid cells in vitro, and TSH will stimulate total assayable EGF receptor in cultured porcine thyroid cells.	Thyrotropin	124-127	epidermal growth factor	Homo sapiens	159-162
1422229-2	1992	In this study, we report the effect of TSH on EGF binding to human thyroid cells.	Thyrotropin	39-42	epidermal growth factor	Homo sapiens	46-49
1643752-1	1992	We have used the mouse model of experimental autoimmune thyroiditis (EAT) to examine the hypothesis that the strengthening of self-tolerance to thyroglobulin by exogenous mouse thyroglobulin (MTg) or stimulation of endogenous MTg secretion by thyroid-stimulating hormone (TSH) is correlated with the length of time MTg rises above the normal range.	Thyrotropin	243-270	thyroglobulin	Mus musculus	144-157
1643752-1	1992	We have used the mouse model of experimental autoimmune thyroiditis (EAT) to examine the hypothesis that the strengthening of self-tolerance to thyroglobulin by exogenous mouse thyroglobulin (MTg) or stimulation of endogenous MTg secretion by thyroid-stimulating hormone (TSH) is correlated with the length of time MTg rises above the normal range.	Thyrotropin	272-275	thyroglobulin	Mus musculus	144-157
1520303-4	1992	TGF beta inhibits the TSH induced transition of quiescent thyroid cell from the G0 to the S phase.	Thyrotropin	22-25	transforming growth factor, beta 1	Rattus norvegicus	0-8
1379163-2	1992	Interestingly, measurement of serum TSH and thyroid hormones in rats treated with 6 micrograms/kg.day acidic FGF for 30 days revealed only a slight increase in serum T4 and reverse T3 concentrations.	Thyrotropin	36-39	fibroblast growth factor 1	Rattus norvegicus	102-112
1379163-4	1992	There was a small increase in the serum TSH concentrations at 2, 4, 8, and 24 h after a single high dose iv injection of acidic FGF (60 micrograms/kg).	Thyrotropin	40-43	fibroblast growth factor 1	Rattus norvegicus	121-131
1612026-4	1992	TGF beta (10 ng/ml) inhibited TSH-induced DNA synthesis and iodide uptake.	Thyrotropin	30-33	transforming growth factor, beta 1	Rattus norvegicus	0-8
1319454-4	1992	IL-6 release over 24 h was stimulated by TSH (5000 microU/ml), by forskolin (0.01 mmol/l), by fetal calf serum (1-20%) and by epidermal growth factor (20 ng/ml).	Thyrotropin	41-44	interleukin 6	Homo sapiens	0-4
1635932-0	1992	TSH responses to TRH as a function of basal serum TSH: relevance for unipolar depression in females--a multivariate study.	Thyrotropin	0-3	thyrotropin releasing hormone	Homo sapiens	17-20
1635932-2	1992	It was found that TRH-induced TSH responses were linearly and positively related to basal TSH-IRMA; lower TRH-stimulated TSH secretion in melancholic patients was attributable to lowered basal TSH-IRMA values.	Thyrotropin	30-33	thyrotropin releasing hormone	Homo sapiens	18-21
1635932-2	1992	It was found that TRH-induced TSH responses were linearly and positively related to basal TSH-IRMA; lower TRH-stimulated TSH secretion in melancholic patients was attributable to lowered basal TSH-IRMA values.	Thyrotropin	90-93	thyrotropin releasing hormone	Homo sapiens	18-21
1635932-2	1992	It was found that TRH-induced TSH responses were linearly and positively related to basal TSH-IRMA; lower TRH-stimulated TSH secretion in melancholic patients was attributable to lowered basal TSH-IRMA values.	Thyrotropin	90-93	thyrotropin releasing hormone	Homo sapiens	18-21
1589596-2	1992	We hypothesized that the inappropriately high TSH secretion in SHR may be the result of an impaired thyroid hormone negative feedback regulation of hypothalamic thyrotropin-releasing hormone (TRH) and/or pituitary TSH production.	Thyrotropin	46-49	thyrotropin releasing hormone	Rattus norvegicus	161-190
1589596-2	1992	We hypothesized that the inappropriately high TSH secretion in SHR may be the result of an impaired thyroid hormone negative feedback regulation of hypothalamic thyrotropin-releasing hormone (TRH) and/or pituitary TSH production.	Thyrotropin	46-49	thyrotropin releasing hormone	Rattus norvegicus	192-195
1589596-15	1992	Since the overproduction of hypothalamic TRH and hypophysial TSH should lead to an increased thyroid hormone biosynthesis other defects in the hypothalamus-pituitary-thyroid-axis may contribute to the abnormal regulation of TSH secretion in SHR rats.	Thyrotropin	224-227	thyrotropin releasing hormone	Rattus norvegicus	41-44
1424168-8	1992	The response of TSH to TRH correlated inversely with the serum level of total and free T4, and also with the plasma level of IGF-I (r = -0.74, P less than 0.05, n = 9).	Thyrotropin	16-19	insulin like growth factor 1	Homo sapiens	125-130
1424168-10	1992	CONCLUSION: GH may have a direct stimulatory action on the thyroid secretion of T4 possibly via increased IGF-I, despite suppressed TSH secretion.	Thyrotropin	132-135	growth hormone 1	Homo sapiens	12-14
1557409-5	1992	In euthyroid rats, NB suppressed TSH release from hemipituitaries in vitro.	Thyrotropin	33-36	neuromedin B	Rattus norvegicus	19-21
1557409-6	1992	Incubation of these pituitaries with highly specific antiserum against NB produced a stimulation of TSH release, whereas normal rabbit serum had no effect on the output of TSH.	Thyrotropin	100-103	neuromedin B	Rattus norvegicus	71-73
1557409-7	1992	Thus, in euthyroid animals NB is a physiologically significant inhibitor of TSH release from the pituitary.	Thyrotropin	76-79	neuromedin B	Rattus norvegicus	27-29
1557409-9	1992	TSH release from hemipituitaries of hypothyroid animals was also suppressed by NB as in euthyroid animals.	Thyrotropin	0-3	neuromedin B	Rattus norvegicus	79-81
1557409-12	1992	When antiserum to NB was microinjected twice into the 3V, there was a delayed increase in plasma TSH manifest 24 hr after the initial injection.	Thyrotropin	97-100	neuromedin B	Rattus norvegicus	18-20
1557409-13	1992	TSH release from pituitaries of these animals was markedly increased in the presence of NB antiserum.	Thyrotropin	0-3	neuromedin B	Rattus norvegicus	88-90
1557409-14	1992	Thus, NB has a physiologically significant TSH release-inhibiting action at the pituitary in the hyperthyroid as well as in the euthyroid rat.	Thyrotropin	43-46	neuromedin B	Rattus norvegicus	6-8
1557409-15	1992	We conclude that in the euthyroid animal NB acts in an autocrine fashion to suppress TSH release from the thyrotropes directly.	Thyrotropin	85-88	neuromedin B	Rattus norvegicus	41-43
1557409-17	1992	In hyperthyroidism, the concentration of NB in thyrotropes and presumably its release is increased so that it has a physiologically significant TSH release-inhibiting action.	Thyrotropin	144-147	neuromedin B	Rattus norvegicus	41-43
1537308-2	1992	We now present evidence that the effects of TSH on 1,2-DG content are associated with commensurate changes in PKC activity.	Thyrotropin	44-47	protein kinase C, gamma	Rattus norvegicus	110-113
1537308-6	1992	In cells growing under the influence of TSH in medium containing a high dose of insulin, we found that PKC activity varied during growth.	Thyrotropin	40-43	protein kinase C, gamma	Rattus norvegicus	103-106
1311244-8	1992	Incubation of in vivo labeled insulin and IGF-I receptors with extracts from TSH-treated cells also decreased receptor phosphoserine and phosphothreonine content.	Thyrotropin	77-80	insulin-like growth factor 1	Rattus norvegicus	42-47
1311244-9	1992	Furthermore, preincubation of insulin and IGF-I receptors with extracts from TSH-treated cells enhanced in vitro autophosphorylation.	Thyrotropin	77-80	insulin-like growth factor 1	Rattus norvegicus	42-47
1311244-11	1992	The data suggest that in FRTL5 cells, TSH induces the activity of a Ser/Thr protein phosphatase, which dephosphorylates insulin and IGF-I receptors and enhances their endogenous kinases.	Thyrotropin	38-41	insulin-like growth factor 1	Rattus norvegicus	132-137
1310679-6	1992	Treatment of the cells with TSH or forskolin transiently increased the TSHr mRNA level after 20 h, an effect inhibited by cycloheximide.	Thyrotropin	28-31	thyroid stimulating hormone receptor	Canis lupus familiaris	71-75
1310679-8	1992	Long term TSH treatment led to a slight down-regulation of TSHr mRNA in dog thyrocytes, but in human thyroid cells no marked down-regulation was observed.	Thyrotropin	10-13	thyroid stimulating hormone receptor	Canis lupus familiaris	59-63
1733738-7	1992	The 34A mAb, which fully competes with [125I]TSH for binding to hTSH-R, was able to induce both functions.	Thyrotropin	45-48	thyroid stimulating hormone receptor	Homo sapiens	64-70
1572595-5	1992	An injection of 250 ng of TRH increased plasma concentrations of TSH in all groups, but this increase was more pronounced in fasted rats injected with pimozide during 3 consecutive days.	Thyrotropin	65-68	thyrotropin releasing hormone	Rattus norvegicus	26-29
1370485-1	1992	Thyroglobulin secreted in the medium by Fisher rat thyroid line-5 (FRTL-5) cells cultured in the presence of thyroid stimulating hormone (TSH) shows a slower electrophoretic mobility in sodium dodecyl sulfate-polyacrylamide gel electrophoresis and a higher density position in a CsCl gradient than thyroglobulin secreted by FRTL-5 cells cultured in the absence of TSH for 5-7 days.	Thyrotropin	109-136	thyroglobulin	Homo sapiens	0-13
1370485-1	1992	Thyroglobulin secreted in the medium by Fisher rat thyroid line-5 (FRTL-5) cells cultured in the presence of thyroid stimulating hormone (TSH) shows a slower electrophoretic mobility in sodium dodecyl sulfate-polyacrylamide gel electrophoresis and a higher density position in a CsCl gradient than thyroglobulin secreted by FRTL-5 cells cultured in the absence of TSH for 5-7 days.	Thyrotropin	109-136	thyroglobulin	Rattus norvegicus	298-311
1370485-1	1992	Thyroglobulin secreted in the medium by Fisher rat thyroid line-5 (FRTL-5) cells cultured in the presence of thyroid stimulating hormone (TSH) shows a slower electrophoretic mobility in sodium dodecyl sulfate-polyacrylamide gel electrophoresis and a higher density position in a CsCl gradient than thyroglobulin secreted by FRTL-5 cells cultured in the absence of TSH for 5-7 days.	Thyrotropin	138-141	thyroglobulin	Homo sapiens	0-13
1370485-1	1992	Thyroglobulin secreted in the medium by Fisher rat thyroid line-5 (FRTL-5) cells cultured in the presence of thyroid stimulating hormone (TSH) shows a slower electrophoretic mobility in sodium dodecyl sulfate-polyacrylamide gel electrophoresis and a higher density position in a CsCl gradient than thyroglobulin secreted by FRTL-5 cells cultured in the absence of TSH for 5-7 days.	Thyrotropin	138-141	thyroglobulin	Rattus norvegicus	298-311
1370485-1	1992	Thyroglobulin secreted in the medium by Fisher rat thyroid line-5 (FRTL-5) cells cultured in the presence of thyroid stimulating hormone (TSH) shows a slower electrophoretic mobility in sodium dodecyl sulfate-polyacrylamide gel electrophoresis and a higher density position in a CsCl gradient than thyroglobulin secreted by FRTL-5 cells cultured in the absence of TSH for 5-7 days.	Thyrotropin	364-367	thyroglobulin	Homo sapiens	0-13
1370485-3	1992	Intracellular thyroglobulin migrates faster than thyroglobulin secreted either in the presence or in the absence of TSH.	Thyrotropin	116-119	thyroglobulin	Rattus norvegicus	14-27
1370485-5	1992	Bio-Gel P6 chromatography shows that TSH increases the complex type carbohydrate chains while decreasing the high mannose chains in the secreted thyroglobulin.	Thyrotropin	37-40	thyroglobulin	Rattus norvegicus	145-158
1519463-12	1992	TRH stimulated TSH and PRL response in group B was declined.	Thyrotropin	15-18	thyrotropin releasing hormone	Homo sapiens	0-3
1530781-10	1992	In conclusion, STZ-induced diabetes in the rat is associated with reduced hypothalamic secretion of TRH, which, in turn, may be responsible for the reduced plasma TSH and thyroid hormone levels.	Thyrotropin	163-166	thyrotropin releasing hormone	Rattus norvegicus	100-103
1309347-6	1992	Moreover, insulin, IGF-I, and/or calf serum are required for the autoregulatory negative transcriptional regulation of the TSH receptor by TSH/cAMP, as is the case for thyroglobulin.	Thyrotropin	123-126	insulin-like growth factor 1	Rattus norvegicus	19-24
1504113-8	1992	Symptoms in patients with subclinical hyperthyroidism probably result from central changes which lead to attenuated TSH responses to TRH, or from elevated but still normal thyroxine levels, which possibly enhance the effect of catecholamines.	Thyrotropin	116-119	thyrotropin releasing hormone	Homo sapiens	133-136
1356902-2	1992	In controls, TSH responsiveness to TRH was enhanced by ATT (p less than 0.001).	Thyrotropin	13-16	thyrotropin releasing hormone	Homo sapiens	35-38
1769134-10	1991	Moderate elevation of serum Tg may be due to inadequate thyroxine suppression therapy, assessed by detectable TSH values measured in a sensitive assay.	Thyrotropin	110-113	thyroglobulin	Homo sapiens	28-30
1745985-8	1991	TNF caused small inhibition of both basal RAI uptake and T3 release but greatly decreased TSH-stimulated RAI uptake and T3 secretion.	Thyrotropin	90-93	tumor necrosis factor-like	Rattus norvegicus	0-3
1752338-10	1991	The expression of both TPO and Tg mRNA was greatly decreased in BB/W rats compared with that in Wistar rats despite the high serum TSH levels in BB/W rats.	Thyrotropin	131-134	thyroid peroxidase	Rattus norvegicus	23-26
1752338-10	1991	The expression of both TPO and Tg mRNA was greatly decreased in BB/W rats compared with that in Wistar rats despite the high serum TSH levels in BB/W rats.	Thyrotropin	131-134	thyroglobulin	Rattus norvegicus	31-33
1957553-4	1991	These findings suggest that in acromegaly, like in healthy individuals, GHRH potentiates the TSH response to TRH and that the effects of GHRH and TRH on PRL secretion are additive.	Thyrotropin	93-96	growth hormone releasing hormone	Homo sapiens	72-76
1957553-4	1991	These findings suggest that in acromegaly, like in healthy individuals, GHRH potentiates the TSH response to TRH and that the effects of GHRH and TRH on PRL secretion are additive.	Thyrotropin	93-96	thyrotropin releasing hormone	Homo sapiens	109-112
1914236-2	1991	Autoantibodies to the thyrotropin (TSH) receptor from these patients, which had been initially characterized by their ability to stimulate adenylate cyclase and inhibit the binding of radiolabelled TSH to thyroid membrane preparations, were studied for their effects on thyroglobulin and thyroid peroxidase mRNA levels.	Thyrotropin	35-38	thyroglobulin	Homo sapiens	270-283
1654270-6	1991	Increasing intracellular concentrations of cyclic-AMP by forskolin or TSH was followed by an inhibition of the expression of c-jun.	Thyrotropin	70-73	Jun proto-oncogene, AP-1 transcription factor subunit	Canis lupus familiaris	125-130
1654270-8	1991	Similarly, the TPA or EGF stimulation of c-jun expression was also inhibited by TSH or forskolin, as in fibroblasts in which cyclic-AMP inhibits proliferation.	Thyrotropin	80-83	Jun proto-oncogene, AP-1 transcription factor subunit	Canis lupus familiaris	41-46
1915099-6	1991	TSH given for 12 h after 4 days of exposure to EGF was able to induce luminal dilation of mother follicles, but caused no change in the appearance of microlumina.	Thyrotropin	0-3	epidermal growth factor	Homo sapiens	47-50
1915100-4	1991	Basal or TSH-activated Tg internalization, i.e. transfer from IL to cells, was assessed by measuring [125I]Tg in the cells and the IL; the IL fraction was collected after selective opening of lumina by a short treatment of RTF in a calcium-free medium.	Thyrotropin	9-12	thyroglobulin	Homo sapiens	23-25
1915100-6	1991	TSH caused a very rapid increase in the cellular uptake of labeled Tg; the endocytic index increased by a factor of 4-8.	Thyrotropin	0-3	thyroglobulin	Homo sapiens	67-69
1915100-9	1991	At 20 as well as 37 C, the action of TSH on Tg endocytosis was concentration dependent in the range of 0.05-10 mU/ml.	Thyrotropin	37-40	thyroglobulin	Homo sapiens	44-46
1915100-11	1991	The labeled Tg content of purified coated vesicles varied with the temperature of the chase-incubation and was increased in TSH-treated RTF.	Thyrotropin	124-127	thyroglobulin	Homo sapiens	12-14
1759034-5	1991	The TSH response to TRH exhibited no difference between AD and VD patients (9.18 +/- 4.93 mU/ml vs. 10.35 +/- 8.81).	Thyrotropin	4-7	thyrotropin releasing hormone	Homo sapiens	20-23
1651314-1	1991	Our previous studies involving chimeric thyrotropin-lutropin/choriogonadotropin (TSH-LH/CG) receptors suggest that multiple segments spanning the entire extracellular domain of the human TSH receptor contribute to the TSH binding site.	Thyrotropin	81-84	thyroid stimulating hormone receptor	Homo sapiens	187-199
1648085-8	1991	When adenosine deaminase is added to the reaction medium, TSH-induced cAMP accumulation is significantly enhanced, suggesting an autocrine action of adenosine.	Thyrotropin	58-61	adenosine deaminase	Rattus norvegicus	5-24
1711544-7	1991	IgG with TSH binding-inhibitory activity when tested with the wild-type TSH receptor also inhibited TSH binding to the chimera with TSH receptor domains DE.	Thyrotropin	9-12	thyroid stimulating hormone receptor	Homo sapiens	72-84
1711544-7	1991	IgG with TSH binding-inhibitory activity when tested with the wild-type TSH receptor also inhibited TSH binding to the chimera with TSH receptor domains DE.	Thyrotropin	9-12	thyroid stimulating hormone receptor	Homo sapiens	132-144
1711544-10	1991	Nonstimulatory IgG with TSH binding-inhibitory activity inhibited the action of stimulatory IgG on the wild-type TSH receptor, but not with the chimera containing TSH receptor domains ABC.	Thyrotropin	24-27	thyroid stimulating hormone receptor	Homo sapiens	113-125
1688101-7	1991	However, there were significantly more patients with TBII activity who had elevated TSH levels (3 of 4 vs 1 of 24, p less than 0.05), suggesting a potential physiologic response to TSH receptor blockade.	Thyrotropin	84-87	thyroid stimulating hormone receptor	Homo sapiens	181-193
1851180-1	1991	TSH secretion was evaluated in 10 patients with ACTH-dependent (pituitary microadenoma, n = 5) or ACTH-independent [adrenal adenoma (n = 4) or carcinoma (n = 1)] Cushing"s syndrome, and in 12 normal controls matched for age and sex.	Thyrotropin	0-3	proopiomelanocortin	Homo sapiens	48-52
1851180-1	1991	TSH secretion was evaluated in 10 patients with ACTH-dependent (pituitary microadenoma, n = 5) or ACTH-independent [adrenal adenoma (n = 4) or carcinoma (n = 1)] Cushing"s syndrome, and in 12 normal controls matched for age and sex.	Thyrotropin	0-3	proopiomelanocortin	Homo sapiens	98-102
1712434-0	1991	[Behavior of serum angiotensin converting enzyme in hyperthyroidism correlated to that of TSH].	Thyrotropin	90-93	angiotensin I converting enzyme	Homo sapiens	19-48
1903012-6	1991	When TRH (500 micrograms, iv) was administered 120 min after the 3rd sulpiride injection, TSH and PRL increments were not different from those before the sulpiride injection in both patients with prolactinoma (N = 6) and normal subjects (N = 6).	Thyrotropin	90-93	thyrotropin releasing hormone	Homo sapiens	5-8
1903012-7	1991	Further, combined administration of sulpiride and TRH in 5 patients with prolactinoma clearly enhanced the TSH and PRL responses compared with the single administration of each agent.	Thyrotropin	107-110	thyrotropin releasing hormone	Homo sapiens	50-53
2022709-1	1991	We studied the suitability of using the recombinant human TSH receptor expressed in Chinese hamster ovary cells in a TSH binding inhibition (TBI) assay for autoantibodies against the TSH receptor.	Thyrotropin	58-61	thyroid stimulating hormone receptor	Homo sapiens	183-195
2022709-2	1991	Purified immunoglobulin G (IgG) containing potent thyroid-stimulating immunoglobulin bioactivity competed for radiolabeled TSH binding to recombinant TSH receptor in parallel to inhibition by unlabeled TSH.	Thyrotropin	123-126	thyroid stimulating hormone receptor	Homo sapiens	150-162
1646352-2	1991	One hypothesis proposed to explain the reduced TSH response is down-regulation of pituitary TRH receptors.	Thyrotropin	47-50	thyrotropin releasing hormone	Homo sapiens	92-95
1646352-8	1991	The present study confirms the observation of a lower TSH response to TRH in abstinent alcoholics and indicates that the lower response cannot be overcome by increasing TRH dosage.	Thyrotropin	54-57	thyrotropin releasing hormone	Homo sapiens	70-73
1726900-5	1991	The basal and delta max rise of TSH to TRH (200 micrograms i.v.)	Thyrotropin	32-35	thyrotropin releasing hormone	Homo sapiens	39-42
1850422-8	1991	Pretreatment for 6-12 h with either TSH or other agents that elevate intracellular cAMP potentiated the IGF-I-dependent tyrosine phosphorylation of the 175-kDa substrate by 3-5-fold.	Thyrotropin	36-39	insulin-like growth factor 1	Rattus norvegicus	104-109
1850422-10	1991	Surprisingly, IGF-I-independent tyrosine phosphorylation was also increased by pretreatment with TSH.	Thyrotropin	97-100	insulin-like growth factor 1	Rattus norvegicus	14-19
1726489-7	1991	In contrast, only 20% of TSH-treated cells reacted with vimentin antibody and we observed a marked decrease in vimentin synthesis in response to TSH.	Thyrotropin	25-28	vimentin	Canis lupus familiaris	56-64
1726489-7	1991	In contrast, only 20% of TSH-treated cells reacted with vimentin antibody and we observed a marked decrease in vimentin synthesis in response to TSH.	Thyrotropin	145-148	vimentin	Canis lupus familiaris	111-119
1726489-8	1991	Therefore, vimentin synthesis, which should occur in at least some normal thyroid follicles in vivo, was inhibited in vitro by TSH which promotes differentiation expression.	Thyrotropin	127-130	vimentin	Canis lupus familiaris	11-19
1849283-10	1991	IL-2 stimulated ACTH and TSH release at 1 hr and the MEDs were 10(-12) and 10(-15) M, respectively.	Thyrotropin	25-28	interleukin 2	Homo sapiens	0-4
2011918-6	1991	Interleukin 6 (10(4)-10(5) U/l) inhibited TSH-induced thyroid peroxidase mRNA in a dose-dependent manner, although the basal level of thyroid peroxidase mRNA expression was not suppressed by interleukin 6.	Thyrotropin	42-45	interleukin 6	Homo sapiens	0-13
2011918-6	1991	Interleukin 6 (10(4)-10(5) U/l) inhibited TSH-induced thyroid peroxidase mRNA in a dose-dependent manner, although the basal level of thyroid peroxidase mRNA expression was not suppressed by interleukin 6.	Thyrotropin	42-45	interleukin 6	Homo sapiens	191-204
2011918-9	1991	Subsequently, interleukin 6 inhibited TSH-induced T3 secretion in a dose-dependent manner after 72 h treatment.	Thyrotropin	38-41	interleukin 6	Homo sapiens	14-27
1900229-7	1991	On the other hand, the follicles cultured with IFN gamma showed poor response to TSH.	Thyrotropin	81-84	interferon gamma	Homo sapiens	47-56
1900229-8	1991	Thus, IFN gamma induced the expression of MHC class II antigens of cultured thyroid follicles and inhibited TSH-induced morphological changes in the cells.	Thyrotropin	108-111	interferon gamma	Homo sapiens	6-15
1847707-8	1991	In chase studies employing cells pretreated with chloroquine, TSH stimulated the internalization rate of ANP-receptor complex.	Thyrotropin	62-65	natriuretic peptide A	Homo sapiens	105-108
1847707-9	1991	By 30 min, TSH significantly reduced the membrane-bound ANP, and the decrease was inversely correlated to the increase in internalized radioactivity.	Thyrotropin	11-14	natriuretic peptide A	Homo sapiens	56-59
1848384-5	1991	Binding studies of TSH in FRTL-5 cells also indicated the dose-dependent displacements of [125I]TSH by hCG.	Thyrotropin	19-22	hypertrichosis 2 (generalised, congenital)	Homo sapiens	103-106
1848384-6	1991	Although half-maximal inhibitory concentration of hCG was about 20 times as high as that of TSH on a molar basis, displacement of [125I]TSH was observed at a concentration of hCG of 10(5)IU/l or more, which could be a physiological concentration of hCG in sera of normal pregnant women.	Thyrotropin	136-139	hypertrichosis 2 (generalised, congenital)	Homo sapiens	175-178
1848384-6	1991	Although half-maximal inhibitory concentration of hCG was about 20 times as high as that of TSH on a molar basis, displacement of [125I]TSH was observed at a concentration of hCG of 10(5)IU/l or more, which could be a physiological concentration of hCG in sera of normal pregnant women.	Thyrotropin	136-139	hypertrichosis 2 (generalised, congenital)	Homo sapiens	175-178
1846578-5	1991	The inhibitory action of insulin/IGF-I is not additive with hydrocortisone, which, under the same conditions, also inhibits TSH- or cAMP-induced iodide porter activity.	Thyrotropin	124-127	insulin-like growth factor 1	Rattus norvegicus	33-38
2005412-2	1991	This action of TSH was antagonized by low concentrations of epidermal growth factor (EGF; 0.1-5 nmol/l).	Thyrotropin	15-18	epidermal growth factor	Homo sapiens	60-83
2005412-2	1991	This action of TSH was antagonized by low concentrations of epidermal growth factor (EGF; 0.1-5 nmol/l).	Thyrotropin	15-18	epidermal growth factor	Homo sapiens	85-88
2005412-6	1991	The effect of TSH in low-calcium media was to inhibit the increased release of radioiodine, and EGF (0.5 nmol/l) antagonized this inhibitory effect of TSH.	Thyrotropin	151-154	epidermal growth factor	Homo sapiens	96-99
1845972-4	1991	TSH increased cyclooxygenase activity in homogenates only if the cells were also exposed to insulin, IGF-I, and/or 5% calf serum; TSH alone had no apparent effect on the activity.	Thyrotropin	0-3	insulin-like growth factor 1	Rattus norvegicus	101-106
1936193-3	1991	The TRH-induced TSH release elicited by pituitary fragments from the old rats was decreased in comparison to that found in young animals.	Thyrotropin	16-19	thyrotropin releasing hormone	Rattus norvegicus	4-7
1936193-4	1991	Addition of T3 to the superfusion medium did not alter basal TSH release but significantly decreased the TSH secretory response to TRH in the young rats.	Thyrotropin	105-108	thyrotropin releasing hormone	Rattus norvegicus	131-134
1936193-6	1991	Our results suggest that aging induces not only a TSH hyporesponsiveness to TRH stimulation but also a decrease of this responsiveness to the inhibitory effect of T3 which could be related to a decreased TSH synthesis and to an age-related impairment of T3 action on the thyrotrophs.	Thyrotropin	50-53	thyrotropin releasing hormone	Rattus norvegicus	76-79
1832134-6	1991	The TRH-test is based on feedback mechanisms between the hypothalamic TRH which stimulates hypophyseal TSH and PRL release.	Thyrotropin	103-106	thyrotropin releasing hormone	Homo sapiens	4-7
1832134-6	1991	The TRH-test is based on feedback mechanisms between the hypothalamic TRH which stimulates hypophyseal TSH and PRL release.	Thyrotropin	103-106	thyrotropin releasing hormone	Homo sapiens	70-73
1832134-11	1991	Significantly elevated TSH levels prior to and after TRH stimulation in the hairloss group indicate that hypothyroidism may be an important hormonal disturbance in androgenic hairloss.	Thyrotropin	23-26	thyrotropin releasing hormone	Homo sapiens	53-56
1999676-6	1991	TSH increased the amount of thyroglobulin secreted into the apical medium by five- to sixfold, whereas high basal iodide concentrations (greater than 5 mumol/l) inhibited thyroglobulin secretion by TSH-stimulated cells.	Thyrotropin	0-3	thyroglobulin	Homo sapiens	28-41
1770328-9	1991	The present case provided evidence that starvation elicits lowered TSH response and GH hypersecretion to intravenously administered TRH, and distorts diurnal rhythmicity of adrenal cortisol secretion in a healthy subject without any psychogenic disorders.	Thyrotropin	67-70	thyrotropin releasing hormone	Homo sapiens	132-135
2128053-6	1990	Significant differences in sensitivity to TSH in T3 nonsuppressible patients were found compared to suppressible patients regardless of their TSH responses to TRH or modality of therapy.	Thyrotropin	42-45	thyrotropin releasing hormone	Homo sapiens	159-162
2128932-6	1990	Ir-pro-TRH concentrations in the hypothalamus decreased significantly after T4 and T3 injection and tended to decrease after TRH and TSH injection, but not significantly.	Thyrotropin	133-136	thyrotropin releasing hormone	Rattus norvegicus	7-10
2229314-4	1990	Compared with the control experiment, TNF induced significant decreases in T3 (-36 +/- 2%; saline, -20 +/- 3%; P less than 0.05) and TSH levels (-68 +/- 3%; saline, -44 +/- 8%; P less than 0.05) and a significant increase in rT3 values (+48 +/- 11%; saline, -12 +/- 7%; P less than 0.05).	Thyrotropin	133-136	tumor necrosis factor	Homo sapiens	38-41
1980023-10	1990	As expected however, plasma TSH and T3 levels were increased at 20 min and 2 h, respectively, following TRH infusions.	Thyrotropin	28-31	thyrotropin releasing hormone	Rattus norvegicus	104-107
2256433-9	1990	Approximately 50% of those with serum TSH overlapping the hyperthyroid range had serum SHBG% levels above reference range.	Thyrotropin	38-41	sex hormone binding globulin	Homo sapiens	87-91
2226318-4	1990	In addition, the IL-1-treated mouse thyroid showed an in vitro unresponsiveness to TSH, with an increase of pituitary TSH (2.24-fold by 15 micrograms IL-1).	Thyrotropin	83-86	interleukin 1 complex	Mus musculus	17-21
2226318-4	1990	In addition, the IL-1-treated mouse thyroid showed an in vitro unresponsiveness to TSH, with an increase of pituitary TSH (2.24-fold by 15 micrograms IL-1).	Thyrotropin	118-121	interleukin 1 complex	Mus musculus	17-21
2226318-4	1990	In addition, the IL-1-treated mouse thyroid showed an in vitro unresponsiveness to TSH, with an increase of pituitary TSH (2.24-fold by 15 micrograms IL-1).	Thyrotropin	118-121	interleukin 1 complex	Mus musculus	150-154
1700796-2	1990	IGF-I stimulated an approximately 3.5-fold increase in the rate of Ca2+ influx sustained for at least 6 h in TSH-pretreated cells but not in quiescent cells.	Thyrotropin	109-112	insulin-like growth factor 1	Rattus norvegicus	0-5
1700796-5	1990	In addition, the stimulations of Ca2+ influx and DNA synthesis by IGF-I were dependent on extracellular Ca2+ in TSH-pretreated cells.	Thyrotropin	112-115	insulin-like growth factor 1	Rattus norvegicus	66-71
2174456-6	1990	Exogenous recombinant IL-6 reduced cyclic AMP production in response to TSH when added to thyroid cell cultures.	Thyrotropin	72-75	interleukin 6	Homo sapiens	22-26
2239085-0	1990	Intravenous administration of recombinant IGF-I lowers serum GHRH and TSH.	Thyrotropin	70-73	insulin like growth factor 1	Homo sapiens	42-47
2167217-6	1990	IL-1 beta had no effect on basal TG release but modulates the TSH-stimulated TG secretion.	Thyrotropin	62-65	interleukin 1 beta	Homo sapiens	0-9
2167217-7	1990	At low dose (10(-5) to 10(-3) U/ml) IL-1 beta increased the TSH-stimulated TG secretion while higher doses (1-100 U/ml) of IL-1 beta had an inhibitory effect.	Thyrotropin	60-63	interleukin 1 beta	Homo sapiens	36-45
2167217-7	1990	At low dose (10(-5) to 10(-3) U/ml) IL-1 beta increased the TSH-stimulated TG secretion while higher doses (1-100 U/ml) of IL-1 beta had an inhibitory effect.	Thyrotropin	60-63	interleukin 1 beta	Homo sapiens	123-132
2167217-11	1990	This biphasic effect of IL-1 beta on TG synthesis is paralleled by a similar change in TSH-stimulated cAMP secretion.	Thyrotropin	87-90	interleukin 1 beta	Homo sapiens	24-33
2167218-7	1990	The increased responsiveness of aged cells to insulin or IGF-I is inhibited by indomethacin or hydrocortisone and is associated with insulin or IGF-I, but not TSH, stimulation of cyclooxygenase and prostaglandin E2 (PGE2) isomerase-like activity.	Thyrotropin	159-162	insulin-like growth factor 1	Rattus norvegicus	57-62
2129364-2	1990	The aim of this study was to examine the correlation between the increased TSH levels and Tg, and thyroid hormones in the serum in dependence of pathomorphological thyroid status and the patients" ages.	Thyrotropin	75-78	thyroglobulin	Homo sapiens	90-92
2199463-6	1990	EGF and 12-0-tetradecanoyl phorbol-13-acetate (TPA) inhibited the Tg mRNA accumulation induced by TSH (and/or insulin).	Thyrotropin	98-101	epidermal growth factor	Canis lupus familiaris	0-3
2199463-6	1990	EGF and 12-0-tetradecanoyl phorbol-13-acetate (TPA) inhibited the Tg mRNA accumulation induced by TSH (and/or insulin).	Thyrotropin	98-101	thyroglobulin	Canis lupus familiaris	66-68
2199463-11	1990	Indeed, the same cell distribution of Tg mRNA content was observed in quiescent cells stimulated by TSH alone, or in cells approximately 50% of which had performed one mitotic cycle in response to TSH + insulin.	Thyrotropin	100-103	thyroglobulin	Canis lupus familiaris	38-40
2199463-11	1990	Indeed, the same cell distribution of Tg mRNA content was observed in quiescent cells stimulated by TSH alone, or in cells approximately 50% of which had performed one mitotic cycle in response to TSH + insulin.	Thyrotropin	197-200	thyroglobulin	Canis lupus familiaris	38-40
19215369-5	1990	There are some data to suggest that somatostatin inhibits TRH-stimulated TSH release.	Thyrotropin	73-76	thyrotropin releasing hormone	Homo sapiens	58-61
2372949-4	1990	In contrast, alkaline phosphatase (ALP) was significantly positively correlated with differences in Stratus and RIA TSH concentrations (P less than 0.001).	Thyrotropin	116-119	alkaline phosphatase, placental	Homo sapiens	13-33
2372949-4	1990	In contrast, alkaline phosphatase (ALP) was significantly positively correlated with differences in Stratus and RIA TSH concentrations (P less than 0.001).	Thyrotropin	116-119	alkaline phosphatase, placental	Homo sapiens	35-38
1694494-0	1990	Interferon-gamma reduces actin filaments and inhibits thyroid-stimulating hormone-induced formation of microvilli and pseudopods in mouse monolayer thyrocytes.	Thyrotropin	54-81	interferon gamma	Mus musculus	0-16
1694494-4	1990	Coculture of thyrocytes with IFN gamma for more than 24 h inhibited TSH-induced morphological changes in the thyrocytes; IFN gamma inhibited the increase in the number of and elongation of microvilli and the appearance of pseudopods.	Thyrotropin	68-71	interferon gamma	Mus musculus	29-38
2110573-13	1990	Without previous ablative therapy, serum TSH in patients with GRTH is usually normal or mildly elevated.	Thyrotropin	41-44	thyroid hormone receptor beta	Homo sapiens	62-66
2159204-2	1990	A stimulatory effect on [125I] iodide incorporation into protein (iodination) was seen in cultures exposed to human recombinant interleukin 1 alpha (20 micrograms/l) for 1 h and (0.1 or 10 micrograms/l) for 18 h, whereas an inhibitory effect on iodination of interleukin 1 (10 micrograms/l) was registered after pre-incubation for 42 h and significant upon stimulation with TSH (200 mU/l).	Thyrotropin	374-377	interleukin 1 alpha	Homo sapiens	128-147
2159204-2	1990	A stimulatory effect on [125I] iodide incorporation into protein (iodination) was seen in cultures exposed to human recombinant interleukin 1 alpha (20 micrograms/l) for 1 h and (0.1 or 10 micrograms/l) for 18 h, whereas an inhibitory effect on iodination of interleukin 1 (10 micrograms/l) was registered after pre-incubation for 42 h and significant upon stimulation with TSH (200 mU/l).	Thyrotropin	374-377	interleukin 1 alpha	Homo sapiens	128-141
2159204-3	1990	Cyclic AMP levels were stimulated in cells exposed to interleukin 1, however, significantly only after 42 h of pre-incubation, whereas TSH-stimulated cAMP response was inhibited by interleukin 1 already after 18 h of pre-incubation.	Thyrotropin	135-138	interleukin 1 alpha	Homo sapiens	181-194
2318952-2	1990	These changes are characterized by 1) increased pituitary release of TSH in response to iv TRH, 2) increased serum clearance of orally administered T3, and 3) normal serum total, free T4, and unstimulated TSH levels.	Thyrotropin	69-72	thyrotropin releasing hormone	Homo sapiens	91-94
2164546-1	1990	The content of epidermal-growth-factor receptor (EGFr) and its relation to TSH-response were examined in 27 malignant thyroid tumors (5 follicular, 6 papillary, 5 medullary, 11 anaplastic carcinomas) and in 30 tumor-like lesions (21 hyperplastic goiters and 9 toxic adenomatous goiters).	Thyrotropin	75-78	epidermal growth factor receptor	Homo sapiens	15-47
2164546-1	1990	The content of epidermal-growth-factor receptor (EGFr) and its relation to TSH-response were examined in 27 malignant thyroid tumors (5 follicular, 6 papillary, 5 medullary, 11 anaplastic carcinomas) and in 30 tumor-like lesions (21 hyperplastic goiters and 9 toxic adenomatous goiters).	Thyrotropin	75-78	epidermal growth factor receptor	Homo sapiens	49-53
2164546-7	1990	An inverse correlation between EGFr content and TSH-response was found when anaplastic thyroid tumors were compared to tumor-like lesions.	Thyrotropin	48-51	epidermal growth factor receptor	Homo sapiens	31-35
2360457-4	1990	Addition of TSH (10 mU/ml/day) to the culture medium increased the synthesis and release of TG.	Thyrotropin	12-15	thyroglobulin	Homo sapiens	92-94
2306241-0	1990	Thyroid peroxidase gene promoter confers TSH responsiveness to heterologous reporter genes in transfection experiments.	Thyrotropin	41-44	thyroid peroxidase	Homo sapiens	0-18
2109772-2	1990	Two patients had previously undetected hypothyroidism while 7 additional patients had normal serum thyroid hormone levels but an exaggerated TSH response to thyrotropin-releasing hormone (TRH) administration, consistent with subclinical hypothyroidism.	Thyrotropin	141-144	thyrotropin releasing hormone	Homo sapiens	157-186
2109772-2	1990	Two patients had previously undetected hypothyroidism while 7 additional patients had normal serum thyroid hormone levels but an exaggerated TSH response to thyrotropin-releasing hormone (TRH) administration, consistent with subclinical hypothyroidism.	Thyrotropin	141-144	thyrotropin releasing hormone	Homo sapiens	188-191
1967241-8	1990	TSH responses to 25 nM oCRH and rGHRH and GH responses to rGHRH were significantly reduced by preincubation with 60 nM SRIH.	Thyrotropin	0-3	growth hormone 1	Homo sapiens	33-35
2125573-10	1990	In these experiments, 25 X 10(3) U/l of hCG produced equivalent stimulation to 1 mU/l of TSH.	Thyrotropin	89-92	chorionic gonadotropin subunit beta 5	Homo sapiens	40-43
2112565-5	1990	In the patients who died the TSH response after stimulation with TRH was also absent.	Thyrotropin	29-32	thyrotropin releasing hormone	Homo sapiens	65-68
2294139-5	1990	Serum TSH levels correlated negatively to serum BGP levels (r = -0.60; P less than 0.001).	Thyrotropin	6-9	bone gamma-carboxyglutamate protein	Homo sapiens	48-51
2294139-8	1990	Six patients had serum BGP levels above the normal range, and patients with reduced serum TSH levels (less than 0.45 mU/L; n = 12) had significantly enhanced serum BGP levels [median, 1.53 nmol/L (range, 1.02-4.24) vs. 1.23 nmol/L (0.62-3.71); P less than 0.05].	Thyrotropin	90-93	bone gamma-carboxyglutamate protein	Homo sapiens	164-167
2294139-9	1990	Serum TSH also correlated negatively to serum SHBG levels (r = -0.56; P less than 0.001; women alone: r = -0.58; P less than 0.001).	Thyrotropin	6-9	sex hormone binding globulin	Homo sapiens	46-50
2294139-10	1990	Eight patients had serum SHBG levels above the normal range, and patients with reduced serum TSH levels had significantly enhanced serum SHBG levels, expressed as a percentage of the mean control value for the relevant sex [203% (range, 75-288) vs. 120% (42-317); P less than 0.01].	Thyrotropin	93-96	sex hormone binding globulin	Homo sapiens	137-141
2294139-11	1990	It is concluded that the lower serum TSH levels in patients with nontoxic goiter, the higher are serum BGP and SHBG levels.	Thyrotropin	37-40	bone gamma-carboxyglutamate protein	Homo sapiens	103-106
2294139-11	1990	It is concluded that the lower serum TSH levels in patients with nontoxic goiter, the higher are serum BGP and SHBG levels.	Thyrotropin	37-40	sex hormone binding globulin	Homo sapiens	111-115
2148362-4	1990	ANF (3 nmol/animal) was found to inhibit the increase in blood radioiodine levels that was induced by TSH or vasoactive intestinal polypeptide (VIP).	Thyrotropin	102-105	natriuretic peptide type A	Mus musculus	0-3
2148362-5	1990	Furthermore, ANF and norepinephrine additively inhibited the TSH-induced increase in blood radioiodine levels.	Thyrotropin	61-64	natriuretic peptide type A	Mus musculus	13-16
33236107-8	2021	Duration of symptoms, AM and PM F, ACTH, and UFC were inversely related to TSH, FT4 and/or T3 levels (r -0.24 to -0.52, P <0.0001 to 0.02).	Thyrotropin	75-78	proopiomelanocortin	Homo sapiens	35-39
31149253-8	2018	Serum HDL and T4 concentrations were lower and serum IL-23 was higher among patients with higher TSH concentrations.	Thyrotropin	97-100	interleukin 37	Homo sapiens	53-58
31149253-9	2018	BMI, WC and serum HDL were negative predictors of serum TSH while IL-23 was positively associated with TSH concentrations.	Thyrotropin	103-106	interleukin 37	Homo sapiens	66-71
1730805-11	1992	Stimulation of iodide uptake by TSH was inhibited by the simultaneous presence of low concentrations of hCG while activity was restored with high concentrations.	Thyrotropin	32-35	chorionic gonadotropin subunit beta 5	Homo sapiens	104-107
34896620-0	2022	TSH stimulation of human thyroglobulin and thyroid peroxidase gene transcription is partially dependent on internalization.	Thyrotropin	0-3	thyroglobulin	Homo sapiens	25-38
34896620-11	2022	We showed that dynamin 2 knockdown inhibited TSHR internalization and decreased the TSH-stimulated levels of TG and TPO mRNAs and proteins.	Thyrotropin	84-87	dynamin 2	Homo sapiens	15-24
34896620-11	2022	We showed that dynamin 2 knockdown inhibited TSHR internalization and decreased the TSH-stimulated levels of TG and TPO mRNAs and proteins.	Thyrotropin	84-87	thyroid peroxidase	Homo sapiens	116-119
34435365-8	2022	Additionally, we detected functional TSHR in PCs; blocking TSHR significantly restricted TSH-induced apoptosis.	Thyrotropin	89-92	thyroid stimulating hormone receptor	Bos taurus	59-63
34801870-10	2022	We also found that either TSH or NAC enhanced PKA, Akt, mTORC, AMPK, Sirtuins, PGC1alpha, NRF-2, mitofusin-2, TFAM and catalase in the N-TSHR-mAb stressed cells.	Thyrotropin	26-29	NFE2 like bZIP transcription factor 2	Rattus norvegicus	90-95
34801870-10	2022	We also found that either TSH or NAC enhanced PKA, Akt, mTORC, AMPK, Sirtuins, PGC1alpha, NRF-2, mitofusin-2, TFAM and catalase in the N-TSHR-mAb stressed cells.	Thyrotropin	26-29	mitofusin 2	Rattus norvegicus	97-108
34801870-10	2022	We also found that either TSH or NAC enhanced PKA, Akt, mTORC, AMPK, Sirtuins, PGC1alpha, NRF-2, mitofusin-2, TFAM and catalase in the N-TSHR-mAb stressed cells.	Thyrotropin	26-29	transcription factor A, mitochondrial	Rattus norvegicus	110-114
34801870-10	2022	We also found that either TSH or NAC enhanced PKA, Akt, mTORC, AMPK, Sirtuins, PGC1alpha, NRF-2, mitofusin-2, TFAM and catalase in the N-TSHR-mAb stressed cells.	Thyrotropin	26-29	catalase	Rattus norvegicus	119-127
34801870-10	2022	We also found that either TSH or NAC enhanced PKA, Akt, mTORC, AMPK, Sirtuins, PGC1alpha, NRF-2, mitofusin-2, TFAM and catalase in the N-TSHR-mAb stressed cells.	Thyrotropin	26-29	thyroid stimulating hormone receptor	Rattus norvegicus	137-141
34801870-13	2022	CONCLUSIONS: These findings indicated that TSH or antioxidant can rescue thyroid cells from N-TSHR-mAb induced apoptosis via enhanced autophagy.	Thyrotropin	43-46	thyroid stimulating hormone receptor	Rattus norvegicus	94-98
34801870-14	2022	These observations signify that N-TSHR-mAb in GD under low TSH conditions caused by the hyperthyroidism could be detrimental for thyrocyte survival which would be another factor able to precipitate ongoing autoinflammation.	Thyrotropin	59-62	thyroid stimulating hormone receptor	Rattus norvegicus	34-38
34970803-9	2022	These data indicate that when endocannabinoid release of tanycytes is decreased, the disinhibition of the TRH release induces increased TSH synthesis and higher circulating T4 levels.	Thyrotropin	136-139	thyrotropin releasing hormone	Mus musculus	106-109
34392245-7	2022	The function of TSHR in NK cells was investigated by measuring the TSH-stimulated cAMP levels.	Thyrotropin	67-70	thyroid stimulating hormone receptor	Homo sapiens	16-20
34392245-11	2022	CONCLUSIONS: Our findings confirm that TSHR is present and functional in NK cells and provide key clues for the potential regulatory effects of TSH on TSHR in NK cells in the immune system.	Thyrotropin	144-147	thyroid stimulating hormone receptor	Homo sapiens	39-43
34392245-11	2022	CONCLUSIONS: Our findings confirm that TSHR is present and functional in NK cells and provide key clues for the potential regulatory effects of TSH on TSHR in NK cells in the immune system.	Thyrotropin	144-147	thyroid stimulating hormone receptor	Homo sapiens	151-155
8319364-10	1993	Serum free T4 and free T3 were higher in the hyperemesis group (P &lt; 0.01) and the emesis group (P &lt; 0.01), and serum TSH was suppressed to less than 0.1 mU/l in both groups, while serum hCG was not significantly different among these three groups.	Thyrotropin	123-126	hypertrichosis 2 (generalised, congenital)	Homo sapiens	192-195
7690117-6	1993	Lastly, pretreatment with the 5-HT synthesis inhibitor p-chlorophenylalanine prevented the immediate inhibitory effect of the selective 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) upon cold-induced TSH release, but it amplified the late release of TSH in cold-exposed 8-OH-DPAT-injected rats.	Thyrotropin	229-232	5-hydroxytryptamine receptor 1A	Rattus norvegicus	136-142
7690117-6	1993	Lastly, pretreatment with the 5-HT synthesis inhibitor p-chlorophenylalanine prevented the immediate inhibitory effect of the selective 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) upon cold-induced TSH release, but it amplified the late release of TSH in cold-exposed 8-OH-DPAT-injected rats.	Thyrotropin	279-282	5-hydroxytryptamine receptor 1A	Rattus norvegicus	136-142
7690117-7	1993	These results suggest that presynaptic 5-HT1A receptors mediate ipsapirone-induced inhibition of cold-elicited TSH release, an effect which may be partially opposed by postsynaptic 5-HT1A receptor stimulation.	Thyrotropin	111-114	5-hydroxytryptamine receptor 1A	Rattus norvegicus	39-45
8387868-1	1993	The purpose of this study is to characterize the adenyl cyclase (AC) activity in Fisher rat thyroid cell line when stimulated with several agonists, such as: forskolin, sodium fluoride, Gpp(NH)p (guanosine-5"-(beta, gamma -imino) triphosphate or thyrotropin.	Thyrotropin	246-257	adenylate cyclase 1	Homo sapiens	49-63
8387868-1	1993	The purpose of this study is to characterize the adenyl cyclase (AC) activity in Fisher rat thyroid cell line when stimulated with several agonists, such as: forskolin, sodium fluoride, Gpp(NH)p (guanosine-5"-(beta, gamma -imino) triphosphate or thyrotropin.	Thyrotropin	246-257	adenylate cyclase 1	Homo sapiens	65-67
7951489-4	1993	The development of microvilli containing TPO activity on the cell surface facing the culture medium was observed when normal thyroid tissue or Graves" thyroid tissue was incubated with TSH but in the TSH-free group the development of microvilli was poor and TPO activity was very much decreased.	Thyrotropin	185-188	thyroid peroxidase	Homo sapiens	41-44
7951489-4	1993	The development of microvilli containing TPO activity on the cell surface facing the culture medium was observed when normal thyroid tissue or Graves" thyroid tissue was incubated with TSH but in the TSH-free group the development of microvilli was poor and TPO activity was very much decreased.	Thyrotropin	200-203	thyroid peroxidase	Homo sapiens	41-44
7951489-6	1993	Our findings suggested that thyroid peroxidase activity is regulated by thyroid stimulating substances such as TSH and by TPO in tissue.	Thyrotropin	111-114	thyroid peroxidase	Homo sapiens	28-46
8459200-4	1993	Preincubation of cells with up to 100 micrograms bFGF/l potentiated TSH-stimulated cAMP release from the transfected cells but inhibited release from primary human thyroid cultures.	Thyrotropin	68-71	fibroblast growth factor 2	Homo sapiens	49-53
8118227-2	1993	In FRTL-5 rat thyroid cells, both human and murine TNF-alpha inhibited basal and TSH-stimulated [125I]iodide transport.	Thyrotropin	81-84	tumor necrosis factor	Mus musculus	51-60
8118227-6	1993	Inhibition of protein kinase A and protein kinase C by H7 or HA inhibited TSH-stimulated iodide transport, but did not block the TNF-alpha action, suggesting that the mechanism of TNF-alpha action on thyroid cells is independent of protein kinase A and C.	Thyrotropin	74-77	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	14-30
8118227-6	1993	Inhibition of protein kinase A and protein kinase C by H7 or HA inhibited TSH-stimulated iodide transport, but did not block the TNF-alpha action, suggesting that the mechanism of TNF-alpha action on thyroid cells is independent of protein kinase A and C.	Thyrotropin	74-77	tumor necrosis factor	Rattus norvegicus	180-189
8118227-7	1993	In pituitary cells, both human and murine TNF-alpha did not affect basal TSH secretion, but TNF-alpha reduced TRH-stimulated TSH secretion.	Thyrotropin	125-128	tumor necrosis factor	Mus musculus	92-101
1281481-8	1992	Northern blot analysis for rat cathepsin S revealed tissue-specific expression distinct from the distribution of cathepsin B and L. The regulation of expression of rat cathepsin S mRNA in response to thyroid-stimulating hormone was studied in a rat thyroid cell line FRTL-5.	Thyrotropin	200-227	cathepsin S	Rattus norvegicus	168-179
1362849-6	1992	Single injections of IGF-I caused significant decreases of serum TSH in LTD patients (iv: 1.7 +/- 0.2 to 1.1 +/- 0.1 mU/l; sc: from 2.1 +/- 0.4 to 1.1 +/- 0.2; p &lt; 0.0005).	Thyrotropin	65-68	insulin like growth factor 1	Homo sapiens	21-26
1362849-10	1992	TSH stimulation by TRH was significantly augmented after four months of IGF-I treatment (p &lt; 0.005).	Thyrotropin	0-3	insulin like growth factor 1	Homo sapiens	72-77
1290333-9	1992	A thyrotropin-releasing hormone (TRH) test was performed in 10 women having the highest TSH levels.	Thyrotropin	88-91	thyrotropin releasing hormone	Homo sapiens	2-31
1290333-9	1992	A thyrotropin-releasing hormone (TRH) test was performed in 10 women having the highest TSH levels.	Thyrotropin	88-91	thyrotropin releasing hormone	Homo sapiens	33-36
1363083-4	1992	MEASUREMENTS: The 3H-cAMP produced in cells incubated with either bovine TSH (bTSH) or polyethylene glycol-precipitated serum immunoglobulins, was separated by sequential chromatography on Dowex and alumina columns, and counted.	Thyrotropin	73-76	cathelicidin-7	Bos taurus	21-25
1332847-3	1992	Other agents that increase c-fos mRNA levels and DNA synthesis in FRTL-5 cells include TSH, insulin, insulin-like growth factor-I, phorbol esters, A23187, and alpha 1-adrenergic agents; the last two agents also act by increasing cytosolic Ca2+ levels.	Thyrotropin	87-90	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	27-32
1332847-4	1992	Despite its enhancement of DNA synthesis, however, bFGF decreases TSH-induced cAMP-mediated iodide uptake.	Thyrotropin	66-69	fibroblast growth factor 2	Rattus norvegicus	51-55
1332847-10	1992	Both effects are, presumably, associated with the ability of bFGF to counteract TSH/cAMP-induced increases in thyroid peroxidase mRNA levels, which we demonstrate.	Thyrotropin	80-83	fibroblast growth factor 2	Rattus norvegicus	61-65
1442032-3	1992	Exaggerated thyrotropin (TSH) responses to thyrotropin-releasing hormone increased basal TSH levels, and low free thyroxine levels were also found in all three.	Thyrotropin	25-28	thyrotropin releasing hormone	Homo sapiens	43-72
1443425-6	1992	The present findings indicate that noncirrhotic, abstinent alcoholic men exhibit normal suppression of the TSH response to TRH following T3.	Thyrotropin	107-110	thyrotropin releasing hormone	Homo sapiens	123-126
1333055-8	1992	However, cells expressing KCREB showed an 18-40% reduction in TSH-stimulated thymidine incorporation, a 31% increase in the length of the cell cycle, and a 4-fold reduction in TSH-stimulated iodide uptake in comparison with wild type cells or cells tranfected with wild type CREB.	Thyrotropin	62-65	cAMP responsive element binding protein 1	Rattus norvegicus	27-31
1333055-8	1992	However, cells expressing KCREB showed an 18-40% reduction in TSH-stimulated thymidine incorporation, a 31% increase in the length of the cell cycle, and a 4-fold reduction in TSH-stimulated iodide uptake in comparison with wild type cells or cells tranfected with wild type CREB.	Thyrotropin	176-179	cAMP responsive element binding protein 1	Rattus norvegicus	27-31
1422229-7	1992	The rate at which prebound [125I]EGF was released into medium was not affected by the presence of TSH, indicating that TSH-enhanced binding may not be attributed to a reduction in EGF degradation.	Thyrotropin	119-122	epidermal growth factor	Homo sapiens	33-36
1422229-8	1992	Coincubation of thyroid cells with EGF at 0 and 1 ng/mL and increasing concentrations of TSH (0-10 mU/mL) indicated that EGF stimulated thymidine incorporation, although TSH failed to synergistically enhance EGF-stimulated cell growth.	Thyrotropin	89-92	epidermal growth factor	Homo sapiens	121-124
1422229-8	1992	Coincubation of thyroid cells with EGF at 0 and 1 ng/mL and increasing concentrations of TSH (0-10 mU/mL) indicated that EGF stimulated thymidine incorporation, although TSH failed to synergistically enhance EGF-stimulated cell growth.	Thyrotropin	89-92	epidermal growth factor	Homo sapiens	121-124
1422233-7	1992	The maternal administration of TRH from at least 25 weeks gestation stimulates the fetal pituitary gland to produce TSH.	Thyrotropin	116-119	thyrotropin releasing hormone	Homo sapiens	31-34
1414153-3	1992	We have compared the effect of CRH on ACTH, GH, PRL and TSH secretion during inferior petrosal sinus sampling with its effect on the in vitro secretion of the corticotropic adenoma after excision in one case of Cushing"s disease.	Thyrotropin	56-59	corticotropin releasing hormone	Homo sapiens	31-34
1414153-5	1992	After CRH administration, the petrosal concentrations of all hormones increased preferentially on the side of the adenoma resulting in significant intersinus gradients: 8.1 for ACTH, 2.0 for GH, 1.8 for PRL and 1.5 for TSH.	Thyrotropin	219-222	corticotropin releasing hormone	Homo sapiens	6-9
1529659-2	1992	Consequently, the unstimulated episodic and thyrotropin-releasing hormone (TRH) stimulated TSH secretion was evaluated in postmenopausal women before and during sequential ovarian sex steroid replacements.	Thyrotropin	91-94	thyrotropin releasing hormone	Homo sapiens	44-73
1529659-2	1992	Consequently, the unstimulated episodic and thyrotropin-releasing hormone (TRH) stimulated TSH secretion was evaluated in postmenopausal women before and during sequential ovarian sex steroid replacements.	Thyrotropin	91-94	thyrotropin releasing hormone	Homo sapiens	75-78
1322286-5	1992	TNF alpha markedly stimulated [3H]thymidine incorporation into DNA, inhibited TSH-stimulated 125I uptake per micrograms DNA, but dramatically decreased the total DNA content and cell number.	Thyrotropin	78-81	tumor necrosis factor	Rattus norvegicus	0-9
1446262-5	1992	A major polarized secretion of thyroglobulin into the apical compartment was observed; it was increased in the presence of TSH as well as the thyroglobulin synthesis and mRNA level.	Thyrotropin	123-126	thyroglobulin	Homo sapiens	31-44
1512078-6	1992	It was observed that there was a great increase in IL-2-induced lymphocyte proliferation by TSH.	Thyrotropin	92-95	interleukin 2	Mus musculus	51-55
1512078-8	1992	The studies carried out on the cytotoxic activity of NK cells showed that TSH was able to significantly increase the IL-2-induced NK cell activity without modifying the basal levels of cytotoxicity.	Thyrotropin	74-77	interleukin 2	Mus musculus	117-121
1322918-7	1992	Moreover, TSH potentiated the mitogenic effect of insulin only in low density cultures.	Thyrotropin	10-13	insulin	Homo sapiens	50-57
1623331-3	1992	The HBP as well as the biochemical indices of bone remodeling were significantly negatively correlated with serum TSH levels.	Thyrotropin	114-117	heme binding protein 1	Homo sapiens	4-7
1375893-10	1992	TSH-stimulated DNA synthesis was blocked in IGF-I-expressing FRTL-5 cell by a monoclonal antibody to IGF (Sm 1.2).	Thyrotropin	0-3	insulin-like growth factor 1	Rattus norvegicus	44-49
1592894-7	1992	Together with the increased SHBG levels observed in both thyrotoxic and euthyroid subjects with suppressed serum TSH concentrations, these data support the concept that the TSH-suppressed euthyroid subjects have generalized increased thyroid hormone effects on peripheral tissues.	Thyrotropin	113-116	sex hormone binding globulin	Homo sapiens	28-32
1592894-7	1992	Together with the increased SHBG levels observed in both thyrotoxic and euthyroid subjects with suppressed serum TSH concentrations, these data support the concept that the TSH-suppressed euthyroid subjects have generalized increased thyroid hormone effects on peripheral tissues.	Thyrotropin	173-176	sex hormone binding globulin	Homo sapiens	28-32
1630587-5	1992	However, a few NT-IR cells did not stain for beta-LH nor FSH, but for TSH.	Thyrotropin	70-73	neurotensin	Rattus norvegicus	15-20
1315258-4	1992	TSH (100 microU/ml) alone modestly stimulated iodine uptake and organification, which was further potentiated by pharmacological or physiological concentrations of insulin and by physiological concentrations of IGF-I or IGF-II.	Thyrotropin	0-3	LOC105613195	Ovis aries	164-171
1315258-4	1992	TSH (100 microU/ml) alone modestly stimulated iodine uptake and organification, which was further potentiated by pharmacological or physiological concentrations of insulin and by physiological concentrations of IGF-I or IGF-II.	Thyrotropin	0-3	insulin-like growth factor I	Ovis aries	211-216
1315258-4	1992	TSH (100 microU/ml) alone modestly stimulated iodine uptake and organification, which was further potentiated by pharmacological or physiological concentrations of insulin and by physiological concentrations of IGF-I or IGF-II.	Thyrotropin	0-3	insulin-like growth factor II	Ovis aries	220-226
1315258-9	1992	IGF-I and IGF-II were equipotent in their stimulation of thyroid hormonogenesis in the presence of TSH.	Thyrotropin	99-102	insulin-like growth factor I	Ovis aries	0-5
1315258-9	1992	IGF-I and IGF-II were equipotent in their stimulation of thyroid hormonogenesis in the presence of TSH.	Thyrotropin	99-102	insulin-like growth factor II	Ovis aries	10-16
1506619-5	1992	In the presence of TSH, TRH did not stimulate radioiodine uptake, whereas incorporation of [3H]thymidine into DNA was not antagonized by TSH.	Thyrotropin	19-22	thyrotropin releasing hormone	Homo sapiens	24-27
1316588-0	1992	Okadaic acid inhibits the release of TSH in response to TRH and K+ from rat anterior pituitaries.	Thyrotropin	37-40	thyrotropin releasing hormone	Rattus norvegicus	56-59
1311244-5	1992	In vitro, insulin as well as IGF-I receptors purified from cells treated with 10 pM TSH also exhibited 2-fold enhanced receptor autophosphorylation and kinase activity toward the exogenous substrate poly(Glu,Tyr) (4:1).	Thyrotropin	84-87	insulin-like growth factor 1	Rattus norvegicus	29-34
1740495-2	1992	Furthermore, it has been reported that interferon-gamma-induced DR-positive thyrocytes in vitro secrete less thyroid hormone in response to TSH stimulation compared with DR-negative ones.	Thyrotropin	140-143	interferon gamma	Homo sapiens	39-55
1349294-1	1992	Two studies were performed to determine the importance of endogenous somatostatin (SS) in regulating human TSH secretion.	Thyrotropin	107-110	somatostatin	Homo sapiens	69-81
1349156-6	1992	This is confirmed by the demonstration that these TSBAbs interact with high affinity TSH-binding sites previously identified at tyrosine-385 or at residues 295-306 of the extracellular domain of the TSH receptor.	Thyrotropin	85-88	thyroid stimulating hormone receptor	Homo sapiens	199-211
1376959-5	1992	These results point towards a facilitatory role of HA on TSH secretion both at the hypothalamic level where it may interfere with TRH synthesis, as well as at the pituitary level where it may modify TSH response to TRH.	Thyrotropin	57-60	thyrotropin releasing hormone	Rattus norvegicus	130-133
1376959-5	1992	These results point towards a facilitatory role of HA on TSH secretion both at the hypothalamic level where it may interfere with TRH synthesis, as well as at the pituitary level where it may modify TSH response to TRH.	Thyrotropin	57-60	thyrotropin releasing hormone	Rattus norvegicus	215-218
1370597-6	1992	However, TSH levels were increased 2.1 fold after chronic treatment with calcitonin in both male and female rats (P less than 0.001).	Thyrotropin	9-12	calcitonin-related polypeptide alpha	Rattus norvegicus	73-83
1294362-5	1992	Calcitonin (10(-7) M), as well as CGRP (10(-8) M), suppressed the stimulatory effect of TSH on 3H-thymidine incorporation.	Thyrotropin	88-91	calcitonin-related polypeptide alpha	Rattus norvegicus	0-10
1294362-5	1992	Calcitonin (10(-7) M), as well as CGRP (10(-8) M), suppressed the stimulatory effect of TSH on 3H-thymidine incorporation.	Thyrotropin	88-91	calcitonin-related polypeptide alpha	Rattus norvegicus	34-38
1468512-2	1992	Whereas in nearly all cell culture systems using thyroid cell monolayers TSH enhances cell proliferation, TSH inhibits cell growth induced by EGF in intact thyroid follicles.	Thyrotropin	106-109	epidermal growth factor	Homo sapiens	142-145
1468512-4	1992	In addition there is some evidence that IGF I is necessary for the growth stimulating effect of TSH and IGF I seems to be an autocrine growth factor, which is under the control of TSH and/or iodine deficiency within the thyroid cell.	Thyrotropin	96-99	insulin like growth factor 1	Homo sapiens	40-45
1306520-1	1992	Pituitary thyroid hormone resistance (PRTH) refers to a particular form of thyroid hormone refractoriness that is accompanied by peripheral hyperthyroidism, as only the TSH-secreting pituitary cells appear to be resistant to the effects of thyroid hormones.	Thyrotropin	169-172	thyroid hormone receptor beta	Homo sapiens	38-42
1306520-2	1992	The presence of PRTH is suspected and diagnosed on the basis of the finding of high free thyroid hormone levels along with unsuppressed TSH, clinical signs and symptoms of hyperthyroidism and values of at least one of the parameters evaluating peripheral thyroid hormone action in the hyperthyroid range.	Thyrotropin	136-139	thyroid hormone receptor beta	Homo sapiens	16-20
1518372-5	1992	Thyroid peroxidase (TPO) activity in the cultured follicles with TSH for 96 h was dose-dependently inhibited by NaI.	Thyrotropin	65-68	thyroid peroxidase	Homo sapiens	0-18
1518372-5	1992	Thyroid peroxidase (TPO) activity in the cultured follicles with TSH for 96 h was dose-dependently inhibited by NaI.	Thyrotropin	65-68	thyroid peroxidase	Homo sapiens	20-23
1518372-6	1992	One hundred microM of NaI completely inhibited TSH-induced TPO activity.	Thyrotropin	47-50	thyroid peroxidase	Homo sapiens	59-62
1738433-4	1992	Furthermore, in vitro pre-treatment of anterior pituitaries with triiodothyronine (T3) produced a dose-dependent decrease in both TSH secretion and the formation of [3H]IP in response to TRH.	Thyrotropin	130-133	thyrotropin releasing hormone	Rattus norvegicus	187-190
1738433-5	1992	These results indicate that thyroid hormones regulate TRH receptor-linked inositol phospholipid hydrolysis in the rat anterior pituitary, suggesting that negative feedback action of thyroid hormone occurs at post receptor event in the rat anterior pituitary, which may, to a certain extent, be responsible for the underlying mechanism of T3 inhibition of TSH secretion.	Thyrotropin	355-358	thyrotropin releasing hormone	Rattus norvegicus	54-57
1954900-11	1991	The time course for the effect of thyroidectomy on Fos expression in the pPVN paralleled increased plasma TSH concentration.	Thyrotropin	106-109	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	51-54
1687598-0	1991	The effect of intracerebroventricular administration of somatostatin on prolactin and TSH release in rats.	Thyrotropin	86-89	somatostatin	Rattus norvegicus	56-68
1664499-1	1991	The stimulation of TSH secretion by TRH involves the phosphatidylinositol second messenger pathway via activation of phospholipase C. This effect is mediated by a GTP-binding protein and leads to a mobilization of intracellular Ca2+ stores and an activation of protein kinase C. However, TRH stimulation also results in an influx of extracellular Ca2+.	Thyrotropin	19-22	thyrotropin releasing hormone	Rattus norvegicus	36-39
1664499-1	1991	The stimulation of TSH secretion by TRH involves the phosphatidylinositol second messenger pathway via activation of phospholipase C. This effect is mediated by a GTP-binding protein and leads to a mobilization of intracellular Ca2+ stores and an activation of protein kinase C. However, TRH stimulation also results in an influx of extracellular Ca2+.	Thyrotropin	19-22	thyrotropin releasing hormone	Rattus norvegicus	288-291
1656797-0	1991	Inverse relationship between CSF TRH concentrations and the TSH response to TRH in abstinent alcohol-dependent patients.	Thyrotropin	60-63	thyrotropin releasing hormone	Homo sapiens	33-36
1656797-0	1991	Inverse relationship between CSF TRH concentrations and the TSH response to TRH in abstinent alcohol-dependent patients.	Thyrotropin	60-63	thyrotropin releasing hormone	Homo sapiens	76-79
1656797-3	1991	This finding supports the hypothesis that as the concentration of CSF TRH increases, anterior pituitary TRH receptor density decreases, resulting in a blunted TSH response to TRH stimulation.	Thyrotropin	159-162	thyrotropin releasing hormone	Homo sapiens	70-73
1656797-3	1991	This finding supports the hypothesis that as the concentration of CSF TRH increases, anterior pituitary TRH receptor density decreases, resulting in a blunted TSH response to TRH stimulation.	Thyrotropin	159-162	thyrotropin releasing hormone	Homo sapiens	104-107
1656797-3	1991	This finding supports the hypothesis that as the concentration of CSF TRH increases, anterior pituitary TRH receptor density decreases, resulting in a blunted TSH response to TRH stimulation.	Thyrotropin	159-162	thyrotropin releasing hormone	Homo sapiens	104-107
1779967-2	1991	We reexamined this model by covalently cross-linking radiolabeled TSH to the recombinant human TSH receptor stably expressed in Chinese hamster ovary (CHO) cells.	Thyrotropin	66-69	thyroid stimulating hormone receptor	Homo sapiens	95-107
1779967-4	1991	In contrast, however, cross-linking of TSH to the TSH receptor in intact CHO cells before membrane preparation revealed, even under reducing conditions, an approximately 100-kDa receptor as well as an approximately 54-kDa hormone-binding subunit.	Thyrotropin	39-42	thyroid stimulating hormone receptor	Homo sapiens	50-62
1957553-2	1991	The combination of GHRH(1-29)NH2 with TRH resulted in a larger increment of peak and of integrated plasma TSH and PRL levels than after TRH alone.	Thyrotropin	106-109	growth hormone releasing hormone	Homo sapiens	19-23
1957553-2	1991	The combination of GHRH(1-29)NH2 with TRH resulted in a larger increment of peak and of integrated plasma TSH and PRL levels than after TRH alone.	Thyrotropin	106-109	thyrotropin releasing hormone	Homo sapiens	38-41
1654270-0	1991	Differential regulation of protooncogenes c-jun and jun D expressions by protein tyrosine kinase, protein kinase C, and cyclic-AMP mitogenic pathways in dog primary thyrocytes: TSH and cyclic-AMP induce proliferation but downregulate C-jun expression.	Thyrotropin	177-180	JunD proto-oncogene, AP-1 transcription factor subunit	Canis lupus familiaris	52-57
1654270-0	1991	Differential regulation of protooncogenes c-jun and jun D expressions by protein tyrosine kinase, protein kinase C, and cyclic-AMP mitogenic pathways in dog primary thyrocytes: TSH and cyclic-AMP induce proliferation but downregulate C-jun expression.	Thyrotropin	177-180	Jun proto-oncogene, AP-1 transcription factor subunit	Canis lupus familiaris	234-239
1660515-9	1991	Increased TSH levels, induced either by exogenous TSH or methimazole administration, resulted in a significant increase in thyroid MAO activity.	Thyrotropin	10-13	monoamine oxidase A	Rattus norvegicus	131-134
1660515-9	1991	Increased TSH levels, induced either by exogenous TSH or methimazole administration, resulted in a significant increase in thyroid MAO activity.	Thyrotropin	50-53	monoamine oxidase A	Rattus norvegicus	131-134
1656957-3	1991	A Graves" IgG with TSH-binding inhibitor immunoglobulin (TBII) activity (89%) markedly stimulated cAMP formation in both CHO-K1 cells transfected with TSH-R cDNA (340 microU/ml of TSH equivalent) and rat thyroid cells, FRTL-5, (410 microU/ml of TSH equivalent).	Thyrotropin	19-22	thyrotropin receptor	Cricetulus griseus	151-156
1658674-5	1991	Plasma TSH levels were significantly lowered by a dose of 0.25 pmol IL-6, but neither the lower dose of 0.05 pmol nor the higher dose of 1.25 pmol altered plasma TSH levels throughout the 180 min of the experiment.	Thyrotropin	7-10	interleukin 6	Rattus norvegicus	68-72
1680265-0	1991	The role of somatostatin and/or dopamine in basal and TRH-stimulated TSH release in food-restricted rats.	Thyrotropin	69-72	thyrotropin releasing hormone	Rattus norvegicus	54-57
1680265-3	1991	Restricted feeding by 50% or 75% was associated with a decrease in the pituitary and circulating levels of TSH and GH in both untreated and TRH-treated groups (p less than 0.001), the changes being proportional to the feeding level.	Thyrotropin	107-110	thyrotropin releasing hormone	Rattus norvegicus	140-143
1648698-9	1991	In early pregnancy, when hCG concentrations are highest, free thyroid hormones are increased and serum TSH concentration is decreased.	Thyrotropin	103-106	hypertrichosis 2 (generalised, congenital)	Homo sapiens	25-28
1648698-10	1991	An inverse correlation exists between serum hCG and TSH concentrations, but hCG generally correlates poorly with individual thyroid tests.	Thyrotropin	52-55	hypertrichosis 2 (generalised, congenital)	Homo sapiens	44-47
1872130-0	1991	Human recombinant interleukin 1 inhibits TSH-stimulated morphological changes in thyroid follicles cultured as semi-organs.	Thyrotropin	41-44	interleukin 1 alpha	Homo sapiens	18-31
1872130-6	1991	On the other hand, both IL-1 alpha and beta inhibited these TSH-stimulated changes.	Thyrotropin	60-63	interleukin 1 alpha	Homo sapiens	24-34
1872130-8	1991	We conclude that IL-1 inhibits TSH-stimulated morphological changes in thyroid follicles cultured as semi-organs, depending on the concentration of IL-1.	Thyrotropin	31-34	interleukin 1 alpha	Homo sapiens	17-21
1872130-8	1991	We conclude that IL-1 inhibits TSH-stimulated morphological changes in thyroid follicles cultured as semi-organs, depending on the concentration of IL-1.	Thyrotropin	31-34	interleukin 1 alpha	Homo sapiens	148-152
1889138-7	1991	Six women with elevated TSH concentrations (range 6.9-54 mU/l) had both a FT4 concentration and a T4/TBG ratio and/or a T4 concentration more than two standard deviations below the respective control means, meeting the study criteria for thyroid deficiency, and thus giving a prevalence of 0.3%.	Thyrotropin	24-27	serpin family A member 7	Homo sapiens	101-104
1873483-2	1991	In addition, 10 ng/mL of IL-1 beta in combination with 10 to 1,000 microU/mL of thyroid-stimulating hormone (TSH) synergistically enhanced IL-6 production.	Thyrotropin	80-107	interleukin 6	Rattus norvegicus	139-143
1873483-2	1991	In addition, 10 ng/mL of IL-1 beta in combination with 10 to 1,000 microU/mL of thyroid-stimulating hormone (TSH) synergistically enhanced IL-6 production.	Thyrotropin	109-112	interleukin 6	Rattus norvegicus	139-143
1715378-12	1991	The addition of TSH, or TSH plus cortisol to OH or 3H medium significantly decreased the 125I-labelled IGF-II associated with the 34- and 28-kDa IGFBP species.	Thyrotropin	16-19	insulin-like growth factor II	Ovis aries	103-109
1715378-12	1991	The addition of TSH, or TSH plus cortisol to OH or 3H medium significantly decreased the 125I-labelled IGF-II associated with the 34- and 28-kDa IGFBP species.	Thyrotropin	24-27	insulin-like growth factor II	Ovis aries	103-109
1880476-4	1991	Exposure of porcine thyroid follicular cells in subconfluent monolayer culture to TGF-beta over a 7-day period reduced both IGF-I release and the incorporation of [methyl-3H]thymidine into trichloroacetic acid-precipitable cellular material, while preincubation of cells with NaI (0.1 mmol/l) for 24 h prior to the addition of TSH reduced the stimulatory effect of the latter on IGF-I release over the following 7 days.	Thyrotropin	327-330	transforming growth factor beta 1	Homo sapiens	82-90
1668616-6	1991	TNF had no effect on either basal or TSH-stimulated cAMP generation, but significantly blunted TSH-stimulated Tg secretion.	Thyrotropin	95-98	tumor necrosis factor	Homo sapiens	0-3
1668616-6	1991	TNF had no effect on either basal or TSH-stimulated cAMP generation, but significantly blunted TSH-stimulated Tg secretion.	Thyrotropin	95-98	thyroglobulin	Homo sapiens	110-112
1668617-13	1991	The specificity of this effect on adenylyl cyclase-cAMP is shown by the reduction of TSH-cAMP regulated thyroid peroxidase (TPO) and thyroglobulin mRNAs in the hyt/hyt thyroid gland.	Thyrotropin	85-88	thyroid peroxidase	Mus musculus	124-127
2026761-3	1991	At high TSH concentrations (greater than 1000 mU/L), this increase in TSHR-specific mRNA was markedly reduced.	Thyrotropin	8-11	thyroid stimulating hormone receptor	Homo sapiens	70-74
2046691-8	1991	The sequence of the cell biological changes involved is not fully understood, but it has been shown that IGF-1 is a necessary co-factor for the growth-stimulating effect of TSH in the normal cell, and that autocrine production of IGF-1 is a feature of spontaneous thyroid adenomas.	Thyrotropin	173-176	insulin like growth factor 1	Homo sapiens	105-110
1645766-7	1991	TSH, but not forskolin, produced a significant increase in intracellular calmodulin after 3 days of culture of cells with TSH.	Thyrotropin	0-3	calmodulin-3	Sus scrofa	73-83
1645766-7	1991	TSH, but not forskolin, produced a significant increase in intracellular calmodulin after 3 days of culture of cells with TSH.	Thyrotropin	122-125	calmodulin-3	Sus scrofa	73-83
1903197-1	1991	The presence of gsp mutations at codons 201 and 227 in the gene coding for the alpha subunit of the GTP-binding Gs protein which stimulates adenylyl cyclase (AC) has been investigated in 31 samples of differentiated thyroid tumours, which had been previously characterized with respect to their adenylyl cyclase activity (ACA) before and after stimulation by thyroid-stimulating hormone (TSH).	Thyrotropin	359-386	GSM1	Homo sapiens	16-19
1903197-1	1991	The presence of gsp mutations at codons 201 and 227 in the gene coding for the alpha subunit of the GTP-binding Gs protein which stimulates adenylyl cyclase (AC) has been investigated in 31 samples of differentiated thyroid tumours, which had been previously characterized with respect to their adenylyl cyclase activity (ACA) before and after stimulation by thyroid-stimulating hormone (TSH).	Thyrotropin	388-391	GSM1	Homo sapiens	16-19
1826401-6	1991	In contrast, vasoactive intestinal peptide has convincingly been demonstrated to stimulate thyroid hormone secretion, and neuropeptide Y to potentiate the inhibitory action of noradrenaline on TSH-induced thyroid hormone secretion.	Thyrotropin	193-196	neuropeptide Y	Homo sapiens	122-136
1907564-7	1991	In the hypophysectomized rats, ir-pro-TRH concentrations in the hypothalamus decreased significantly after T4 or T3 injection and tended to decrease after TRH or TSH injection.	Thyrotropin	162-165	thyrotropin releasing hormone	Rattus norvegicus	34-41
1917429-3	1991	hCG can cross-react with TSH in older TSH radioimmunoassays causing falsely elevated TSH levels.	Thyrotropin	25-28	chorionic gonadotropin subunit beta 5	Homo sapiens	0-3
1917429-3	1991	hCG can cross-react with TSH in older TSH radioimmunoassays causing falsely elevated TSH levels.	Thyrotropin	38-41	chorionic gonadotropin subunit beta 5	Homo sapiens	0-3
1917429-3	1991	hCG can cross-react with TSH in older TSH radioimmunoassays causing falsely elevated TSH levels.	Thyrotropin	38-41	chorionic gonadotropin subunit beta 5	Homo sapiens	0-3
1901077-3	1991	By contrast, TRH-induced TSH stimulation occurred after repeated injection of TRH for 4 consecutive days (basal level, 1.5 microU ml-1 vs. 5.6 microU ml-1 30 min after injection).	Thyrotropin	25-28	thyrotropin releasing hormone	Homo sapiens	13-16
1901077-3	1991	By contrast, TRH-induced TSH stimulation occurred after repeated injection of TRH for 4 consecutive days (basal level, 1.5 microU ml-1 vs. 5.6 microU ml-1 30 min after injection).	Thyrotropin	25-28	thyrotropin releasing hormone	Homo sapiens	78-81
1915116-5	1991	Six hours after TSH was injected into the thyroxine-treated rats, localization of TPO staining in the apical region was observed.	Thyrotropin	16-19	thyroid peroxidase	Rattus norvegicus	82-85
1915116-6	1991	These results suggest that TSH may play a role in the translocation of preexisting TPO to the apical region before TSH-induced biosynthesis becomes evident.	Thyrotropin	27-30	thyroid peroxidase	Rattus norvegicus	83-86
1992482-6	1991	With respect to hormone binding, substitution of the entire extracellular domain of the LH/CG receptor for the corresponding region of the TSH receptor resulted in high-affinity human CG binding with complete loss of TSH binding.	Thyrotropin	139-142	luteinizing hormone/choriogonadotropin receptor	Rattus norvegicus	88-102
1992482-8	1991	Substitution of residues 1-170 of the TSH receptor with the corresponding region of the LH/CG receptor was associated with the retention of high-affinity TSH binding but ligand specificity was lost in that TSH and human CG could interact functionally with the receptor.	Thyrotropin	38-41	luteinizing hormone/choriogonadotropin receptor	Rattus norvegicus	88-102
1663395-1	1991	Evidence has accumulated in the last few years that the expression of the microsomal/peroxidase antigen (M/TPO-Ag) in thyroid cells is induced by TSH, through pathways which involve intracellular cAMP accumulation and protein synthesis.	Thyrotropin	146-149	thyroid peroxidase	Homo sapiens	107-110
1663395-9	1991	Cytokines, such as gamma-interferon, interleukin-1, and interleukin-6 have been shown to inhibit the TSH-induced increase of TPO mRNA, but further investigations are required to elucidate the exact role of cytokines in the regulation of M/TPO-Ag expression.	Thyrotropin	101-104	interleukin 6	Homo sapiens	56-69
1663395-9	1991	Cytokines, such as gamma-interferon, interleukin-1, and interleukin-6 have been shown to inhibit the TSH-induced increase of TPO mRNA, but further investigations are required to elucidate the exact role of cytokines in the regulation of M/TPO-Ag expression.	Thyrotropin	101-104	thyroid peroxidase	Homo sapiens	125-128
1663395-9	1991	Cytokines, such as gamma-interferon, interleukin-1, and interleukin-6 have been shown to inhibit the TSH-induced increase of TPO mRNA, but further investigations are required to elucidate the exact role of cytokines in the regulation of M/TPO-Ag expression.	Thyrotropin	101-104	thyroid peroxidase	Homo sapiens	239-242
1851642-7	1991	This soluble glycosyl inositol-phosphate which acts as insulin on adipocyte, modulates the cAMP accumulation and iodine metabolism in thyrocytes and could be held responsible for the cAMP independent effects of TSH.	Thyrotropin	211-214	insulin	Sus scrofa	55-62
1901540-12	1991	TRF induced TSH release only on the first day of injection.	Thyrotropin	12-15	interleukin 5	Bos taurus	0-3
1821922-7	1991	Addition of EGF 10(-8) M increased TSH secretion from a mean basal value of 68.9 +/- 5.6 ng/ml to 201 +/- 44.3 ng/ml (P less than 0.02) and a return to normal value at 20 min.	Thyrotropin	35-38	epidermal growth factor like 1	Rattus norvegicus	12-15
1850110-2	1991	In the thyroid, HMG 14 displays TSH-dependent phosphorylation that is mediated by cAMP-dependent protein kinase (A-kinase).	Thyrotropin	32-35	high mobility group nucleosome binding domain 1	Homo sapiens	16-22
2027875-4	1991	A group of patients with a low level of STH in response to TRH-stimulation demonstrated more pronounced changes of the hypothalamo-hypophyseal-thyroid system, characterized by a rise of a TSH level in response to stimulation up to 27.59 +/- 3.7 microU and a slightly reduced level of thyroid hormones.	Thyrotropin	188-191	saitohin	Homo sapiens	40-43
1907379-2	1991	TSH response to TRH was assessed in 25 patients meeting operationalized criteria for the post-psychotic depression syndrome and in an age and sex matched control group of 34 primary depressed patients.	Thyrotropin	0-3	thyrotropin releasing hormone	Homo sapiens	16-19
1981767-0	1990	Effect of Somatostatin on TSH levels in non-toxic sporadic goiter.	Thyrotropin	26-29	somatostatin	Homo sapiens	10-22
1981767-3	1990	Somatostatin did not lower the basal TSH levels as compared to the pre-infusion levels in this type of goiter, but produced a decrease in the TSH response to TRH during and after the infusion.	Thyrotropin	142-145	somatostatin	Homo sapiens	0-12
2177478-3	1990	While IGF-I is able to stimulate the proliferation of the hybrid cells (TxL) TSH fails to induce their growth.	Thyrotropin	77-80	insulin-like growth factor 1	Rattus norvegicus	6-11
1706271-0	1990	Involvement of dihydropyridine-sensitive calcium channels in the GABAA potentiation of TRH-induced TSH release.	Thyrotropin	99-102	thyrotropin releasing hormone	Rattus norvegicus	87-90
1706271-2	1990	At nanomolar concentrations the two agonists induced potentiation of the TRH-induced TSH release.	Thyrotropin	85-88	thyrotropin releasing hormone	Rattus norvegicus	73-76
1706271-4	1990	The isoguvacine potentiation of the TSH response to TRH failed to occur when cobalt (Co2+) was added to the perifused medium.	Thyrotropin	36-39	thyrotropin releasing hormone	Rattus norvegicus	52-55
1699744-15	1990	In contrast, GAL-AS reduced TSH concentrations by 50% compared to control values.	Thyrotropin	28-31	galanin and GMAP prepropeptide	Rattus norvegicus	13-16
2096156-15	1990	The increase in TPO mRNA can be explained as a compensatory mechanism vis a vis an increase in serum TSH caused by decreased serum T3 and T4 due to the impairment in Tg mRNA.	Thyrotropin	101-104	thyroid peroxidase	Homo sapiens	16-19
2176629-7	1990	(4) EGF alone had no effect on protein synthesis in monolayer cells but it inhibited both the morphological changes induced by TSH and dibutyryl cAMP and the effect of these agents on the synthesis of 23 proteins including thyroperoxidase.	Thyrotropin	127-130	epidermal growth factor	Homo sapiens	4-7
1976464-5	1990	The incremental increase in IFN-gamma values from Graves" disease PBMC correlated with the serum TSH values (r = 0.622, P less than 0.01), but not with thyroid autoantibodies (anti-thyroid microsomal antibodies, anti-thyroid microsomal antibodies, nor TSH-binding inhibitory immunoglobulin activities).	Thyrotropin	97-100	interferon gamma	Homo sapiens	28-37
1976464-5	1990	The incremental increase in IFN-gamma values from Graves" disease PBMC correlated with the serum TSH values (r = 0.622, P less than 0.01), but not with thyroid autoantibodies (anti-thyroid microsomal antibodies, anti-thyroid microsomal antibodies, nor TSH-binding inhibitory immunoglobulin activities).	Thyrotropin	252-255	interferon gamma	Homo sapiens	28-37
2124532-4	1990	TRF increased (P less than .01) prolactin (Prl), thyrotropin (TSH), triiodothyronine (T3) and thyroxine (T4) concentrations similarly at the 1.1 and 3.3 micrograms.kg-1 doses and GRF did not interact (P greater than .40) with TRF on the release of these hormones.	Thyrotropin	62-65	interleukin 5	Bos taurus	0-3
2124532-7	1990	The TRF and GRF-TRF treatments were equipotent (P greater than .05) in increasing Prl and TSH concentrations.	Thyrotropin	90-93	interleukin 5	Bos taurus	4-7
2124532-7	1990	The TRF and GRF-TRF treatments were equipotent (P greater than .05) in increasing Prl and TSH concentrations.	Thyrotropin	90-93	growth hormone releasing hormone	Bos taurus	12-15
2124532-7	1990	The TRF and GRF-TRF treatments were equipotent (P greater than .05) in increasing Prl and TSH concentrations.	Thyrotropin	90-93	interleukin 5	Bos taurus	16-19
2178251-9	1990	To induce a significant release of TSH several hundred times more of 4(5)-I-Im-TRH and over 1000 times more of 2,4(5)-I2-Im-TRH were needed as compared to TRH.	Thyrotropin	35-38	thyrotropin releasing hormone	Rattus norvegicus	79-82
2373049-6	1990	In general, both low-dose and high-dose TSH promoted DNA synthesis under low EGF conditions but were ineffective in the presence of higher levels of EGF.	Thyrotropin	40-43	epidermal growth factor like 1	Rattus norvegicus	77-80
2373049-6	1990	In general, both low-dose and high-dose TSH promoted DNA synthesis under low EGF conditions but were ineffective in the presence of higher levels of EGF.	Thyrotropin	40-43	epidermal growth factor like 1	Rattus norvegicus	149-152
1974263-3	1990	There is one report of the existence of 2.1- and 1.7-kb transcripts (hTPO mRNA species I and II), representing up to half of the hTPO mRNA in TSH-stimulated human thyroid cells.	Thyrotropin	142-145	thyroid peroxidase	Homo sapiens	69-73
1974263-10	1990	hTPO mRNA transcripts I and II are present in TSH-stimulated and TSH-deprived human thyroid cells in culture as well as in intact thyroid tissue.	Thyrotropin	46-49	thyroid peroxidase	Homo sapiens	0-4
1974263-10	1990	hTPO mRNA transcripts I and II are present in TSH-stimulated and TSH-deprived human thyroid cells in culture as well as in intact thyroid tissue.	Thyrotropin	65-68	thyroid peroxidase	Homo sapiens	0-4
19215378-20	1990	The inhibition of TSH secretion may result from the inhibition of thyrotropin-releasing hormone release from more caudal periventricular structures of the hypothalamus.	Thyrotropin	18-21	thyrotropin releasing hormone	Rattus norvegicus	66-95
1963470-6	1990	Exposure of transfected NIH-3T3 cells to dBcAMP mimicked in all respects the effects of TSH and dBcAMP on ferritin-H promoter activity in FRTL5 cells.	Thyrotropin	88-91	ferritin mitochondrial	Mus musculus	106-116
2215827-4	1990	Osteocalcin was statistically significantly correlated with serum free thyroxine (FT4), both in the total population and in the subpopulation of patients with TSH greater than or equal to 0.1 mU/l (r = 0.61; P less than 0.001, resp. r = 0.51; P less than 0.05).	Thyrotropin	159-162	bone gamma-carboxyglutamate protein	Homo sapiens	0-11
1695481-4	1990	Furthermore, thyrotropin-releasing hormone (TRH)-induced TSH release was decreased about 30% and the intracellular TSH content was also reduced 45% in diabetic rat thyrotrophs compared with controls.	Thyrotropin	57-60	thyrotropin releasing hormone	Rattus norvegicus	13-42
1695481-4	1990	Furthermore, thyrotropin-releasing hormone (TRH)-induced TSH release was decreased about 30% and the intracellular TSH content was also reduced 45% in diabetic rat thyrotrophs compared with controls.	Thyrotropin	57-60	thyrotropin releasing hormone	Rattus norvegicus	44-47
1695481-8	1990	Preincubation of thyrotrophs with 10, 100, or 1000 nM of T4 for 48 h decreased basal TSH release by 27%, 45%, and 48%, respectively, and reduced TRH-induced TSH release by 46%, 48%, and 55%; 100 nM T4 also reduced TRH-induced TSH release from diabetic thyrotrophs.	Thyrotropin	157-160	thyrotropin releasing hormone	Rattus norvegicus	145-148
1695481-8	1990	Preincubation of thyrotrophs with 10, 100, or 1000 nM of T4 for 48 h decreased basal TSH release by 27%, 45%, and 48%, respectively, and reduced TRH-induced TSH release by 46%, 48%, and 55%; 100 nM T4 also reduced TRH-induced TSH release from diabetic thyrotrophs.	Thyrotropin	157-160	thyrotropin releasing hormone	Rattus norvegicus	145-148
2361484-1	1990	A cDNA clone (G18) was selected from an FRTL5 rat thyroid cell cDNA library by a differential screening procedure designed to identify TSH-responsive genes in thyroid cells.	Thyrotropin	135-138	G-protein signaling modulator 3	Rattus norvegicus	14-17
2361484-3	1990	On Northern blot analysis, TSH increased GAPD mRNA levels in FRTL5 cells, reaching a maximum (4- to 10-fold above basal in different experiments) after approximately 24 h of TSH stimulation.	Thyrotropin	27-30	glyceraldehyde-3-phosphate dehydrogenase	Rattus norvegicus	41-45
2164529-3	1990	TSH-BAb were measured in immunoglobulin G prepared by DEAE-Sephadex A-50 by determining their ability to inhibit TSH-dependent cAMP production in a differentiated strain of cultured rat thyroid cells (FRTL-5).	Thyrotropin	0-3	cathelicidin antimicrobial peptide	Rattus norvegicus	127-131
2190803-1	1990	Using a specific antiserum recognizing recombinant rat interleukin-1 beta (IL-1 beta), immunoreactive material was localized to cytoplasmic granules in anterior pituitary endocrine cells and colocalized with TSH in thyrotropes.	Thyrotropin	208-211	interleukin 1 beta	Rattus norvegicus	55-73
2190803-1	1990	Using a specific antiserum recognizing recombinant rat interleukin-1 beta (IL-1 beta), immunoreactive material was localized to cytoplasmic granules in anterior pituitary endocrine cells and colocalized with TSH in thyrotropes.	Thyrotropin	208-211	interleukin 1 beta	Rattus norvegicus	75-84
2335576-10	1990	Determination of TSH binding inhibitory IgGs, but not antimicrosomal antibodies, is a sensitive screening test for the presence of TSH receptor-blocking antibodies.	Thyrotropin	17-20	thyroid stimulating hormone receptor	Homo sapiens	131-143
2336036-9	1990	Serum TSH response to 500 micrograms intravenous (IV) thyrotropin-releasing hormone (TRH) was normal (serum TSH post-TRH, 8 to 28 microU/mL) in two patients with elevated TSH and T4, one patient with normal TSH and high T4, and one patient with normal TSH and T4.	Thyrotropin	6-9	thyrotropin releasing hormone	Homo sapiens	54-83
2110411-8	1990	In the cord blood of newborns whose mothers received TRH, serum TSH, T4 and T3 concentrations were significantly higher than in cord blood of newborns whose mothers received saline.	Thyrotropin	64-67	thyrotropin releasing hormone	Homo sapiens	53-56
2338527-1	1990	Calmodulin inhibited 125I-labelled TSH binding to the membranes of various target tissues for TSH (thyroid, epididymal fat and testis) of the guinea-pig.	Thyrotropin	35-38	calmodulin-3	Cavia porcellus	0-10
2338527-1	1990	Calmodulin inhibited 125I-labelled TSH binding to the membranes of various target tissues for TSH (thyroid, epididymal fat and testis) of the guinea-pig.	Thyrotropin	94-97	calmodulin-3	Cavia porcellus	0-10
2338527-7	1990	It was not inhibited by a pure preparation of TSH, but it was inhibited by contaminated calmodulin in a crude TSH preparation.	Thyrotropin	110-113	calmodulin-3	Cavia porcellus	88-98
2159046-8	1990	The results suggest that FRTL cells contain mostly the alpha 1b-adrenergic receptor subtype; that the alpha 1b receptors mediate cytosolic free Ca2+ and iodide efflux responses, and that TSH enhances these responses by increasing the alpha 1b receptor density without affecting the post-receptor mechanism.	Thyrotropin	187-190	adrenoceptor alpha 1B	Rattus norvegicus	55-83
2330843-3	1990	Microvillar TPO reaction products were positive in all thyroid follicular cells in patients with increased TSH levels, but no TPO activity was observed on the microvilli of patients with normal or low TSH levels, irrespective of their histological type or serum anti-microsomal antibody titer.	Thyrotropin	107-110	thyroid peroxidase	Homo sapiens	12-15
2339765-7	1990	The patients with microprolactinomas had a low prolactin response (increments less than 300-400%) and delayed TSH response.	Thyrotropin	110-113	prolactin	Homo sapiens	23-32
2189602-2	1990	Selective pituitary resistance to thyroid hormone (PRTH) is responsible for thyrotoxicosis due to inappropriate secretion of TSH.	Thyrotropin	125-128	thyroid hormone receptor beta	Homo sapiens	51-55
2153526-18	1990	In summary, our observation indicates that 1) the converting phenomenon is induced via IgG-TSH receptor complexes; 2) the mechanism aside from receptor aggregation, i.e. the recognition of a critical domain in TSH receptor molecule, seems necessary for promoting converting phenomenon; and 3) the addition of antihuman IgG Ab affects a postreceptor step via TSH receptor structures that differ from the TSH-binding site.	Thyrotropin	91-94	thyroid stimulating hormone receptor	Homo sapiens	210-222
2153526-18	1990	In summary, our observation indicates that 1) the converting phenomenon is induced via IgG-TSH receptor complexes; 2) the mechanism aside from receptor aggregation, i.e. the recognition of a critical domain in TSH receptor molecule, seems necessary for promoting converting phenomenon; and 3) the addition of antihuman IgG Ab affects a postreceptor step via TSH receptor structures that differ from the TSH-binding site.	Thyrotropin	91-94	thyroid stimulating hormone receptor	Homo sapiens	210-222
2239430-5	1990	In our experiments we showed that IL-1 at low but not higher doses appears to act intrahypothalamically to stimulate GH and PRL release and to inhibit TSH release.	Thyrotropin	151-154	interleukin 1 alpha	Homo sapiens	34-38
2279259-9	1990	Taken together, our results provide circumstantial evidence that c-fos, at least in part, may play a role in TSH-mediated thyroid cell growth.	Thyrotropin	109-112	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	65-70
25839128-8	2015	The percentage of CD4+CD28- T cells correlated positively with serum levels of FT3 (r=0.354, P&lt;0.01) and TRAb (r=0.304, P&lt;0.05), but did not correlate with serum FT4 or TSH.	Thyrotropin	175-178	CD4 molecule	Homo sapiens	18-21
25839128-8	2015	The percentage of CD4+CD28- T cells correlated positively with serum levels of FT3 (r=0.354, P&lt;0.01) and TRAb (r=0.304, P&lt;0.05), but did not correlate with serum FT4 or TSH.	Thyrotropin	175-178	CD28 molecule	Homo sapiens	22-26
34801870-4	2022	Furthermore, the addition of TSH, or the antioxidant N-acetyl-l-cysteine (NAC), rescued N-TSHR-mAb-induced apoptotic death.	Thyrotropin	29-32	thyroid stimulating hormone receptor	Rattus norvegicus	90-94
34801870-7	2022	RESULTS: Under starvation conditions with N-TSHR-mAb the addition of TSH or NAC prevented thyroid cell death by enhancing autophagy.	Thyrotropin	69-72	thyroid stimulating hormone receptor	Rattus norvegicus	44-48
34801870-10	2022	We also found that either TSH or NAC enhanced PKA, Akt, mTORC, AMPK, Sirtuins, PGC1alpha, NRF-2, mitofusin-2, TFAM and catalase in the N-TSHR-mAb stressed cells.	Thyrotropin	26-29	AKT serine/threonine kinase 1	Rattus norvegicus	51-54
34801870-10	2022	We also found that either TSH or NAC enhanced PKA, Akt, mTORC, AMPK, Sirtuins, PGC1alpha, NRF-2, mitofusin-2, TFAM and catalase in the N-TSHR-mAb stressed cells.	Thyrotropin	26-29	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	63-67
34801870-10	2022	We also found that either TSH or NAC enhanced PKA, Akt, mTORC, AMPK, Sirtuins, PGC1alpha, NRF-2, mitofusin-2, TFAM and catalase in the N-TSHR-mAb stressed cells.	Thyrotropin	26-29	PPARG coactivator 1 alpha	Rattus norvegicus	79-88
34726504-11	2022	TSH via cAMP activated Hippo signaling pathway and, consequently, TAZ was excluded from the nucleus.	Thyrotropin	0-3	tafazzin, phospholipid-lysophospholipid transacylase	Mus musculus	66-69
34975767-9	2021	Correlation analyses showed that I-FABP, LPS, and D-lactate were positively associated with FT4 and negatively associated with TSH.	Thyrotropin	127-130	fatty acid binding protein 2	Homo sapiens	33-39
34524974-11	2021	Interestingly, the fasting blood glucose, fasting insulin, adipo-IR and TSH in the higher TSH group decreased more remarkably than in the lower TSH group.	Thyrotropin	90-93	insulin	Homo sapiens	50-57
34892205-3	2021	Using appropriate assumptions on the behavior of the hormones, along with relevant boundary conditions, we modeled an output of TSH using constant TRH input over the course of a six-hour period.	Thyrotropin	128-131	thyrotropin releasing hormone	Homo sapiens	147-150
34831012-8	2021	In a previous work, we have shown that the activity of the small GTPase RAC1 has a positive impact on TSH-induced NIS expression and iodide uptake in thyroid cells.	Thyrotropin	102-105	Rac family small GTPase 1	Homo sapiens	72-76
34804362-5	2021	More importantly, TSHR knockout or inhibition of PA-induced TSHR palmitoylation could alleviate the apoptosis induced by TSH.	Thyrotropin	121-124	thyroid stimulating hormone receptor	Rattus norvegicus	18-22
34804362-5	2021	More importantly, TSHR knockout or inhibition of PA-induced TSHR palmitoylation could alleviate the apoptosis induced by TSH.	Thyrotropin	121-124	thyroid stimulating hormone receptor	Rattus norvegicus	60-64
34524974-11	2021	Interestingly, the fasting blood glucose, fasting insulin, adipo-IR and TSH in the higher TSH group decreased more remarkably than in the lower TSH group.	Thyrotropin	144-147	insulin	Homo sapiens	50-57
34650915-8	2021	We observed that signaling pathways downstream of Galpha12/13 signaling were increased, while that of Galphas signaling was decreased in thyroid cancer cells undergoing dedifferentiation compared to control cells following stimulation with different levels of TSH.	Thyrotropin	260-263	PAXIP1 associated glutamate rich protein 1	Homo sapiens	102-109
34468398-9	2021	TSH levels were inversely correlated with IL-8 (r = -0.248), IL-10 (r = -0.253), IL-15 (r = -0.213), IP-10 (r = -0.334) and GM-CSF (r = -0.254).	Thyrotropin	0-3	C-X-C motif chemokine ligand 8	Homo sapiens	42-46
34468398-9	2021	TSH levels were inversely correlated with IL-8 (r = -0.248), IL-10 (r = -0.253), IL-15 (r = -0.213), IP-10 (r = -0.334) and GM-CSF (r = -0.254).	Thyrotropin	0-3	interleukin 10	Homo sapiens	61-66
34468398-9	2021	TSH levels were inversely correlated with IL-8 (r = -0.248), IL-10 (r = -0.253), IL-15 (r = -0.213), IP-10 (r = -0.334) and GM-CSF (r = -0.254).	Thyrotropin	0-3	interleukin 15	Homo sapiens	81-86
34468398-9	2021	TSH levels were inversely correlated with IL-8 (r = -0.248), IL-10 (r = -0.253), IL-15 (r = -0.213), IP-10 (r = -0.334) and GM-CSF (r = -0.254).	Thyrotropin	0-3	C-X-C motif chemokine ligand 10	Homo sapiens	101-106
34468398-9	2021	TSH levels were inversely correlated with IL-8 (r = -0.248), IL-10 (r = -0.253), IL-15 (r = -0.213), IP-10 (r = -0.334) and GM-CSF (r = -0.254).	Thyrotropin	0-3	colony stimulating factor 2	Homo sapiens	124-130
34335902-8	2021	The TSH receptor is stimulated by TSH and HCG which has a similar structure.	Thyrotropin	34-37	thyroid stimulating hormone receptor	Homo sapiens	4-16
34533693-12	2021	Moreover, rs6083269 (CST1-CST2, p = 3.36 x 10- 06) was a significant locus for circulating TSH level.	Thyrotropin	91-94	cystatin SN	Homo sapiens	21-25
34533693-12	2021	Moreover, rs6083269 (CST1-CST2, p = 3.36 x 10- 06) was a significant locus for circulating TSH level.	Thyrotropin	91-94	cystatin SA	Homo sapiens	26-30
34552555-13	2021	Our results strongly suggest that primary cilia harbors LRP2/megalin, and are involved in TSH-mediated endocytosis of Tg in murine thyroid follicles.	Thyrotropin	90-93	thyroglobulin	Mus musculus	118-120
34650915-3	2021	However, non-iodide-avid metastases of DTC which is dedifferentiated do not respond to stimulation by high levels of TSH, suggesting abnormal TSH-TSHR signal transduction in cancer cells.	Thyrotropin	142-145	thyroid stimulating hormone receptor	Homo sapiens	146-150
34650915-5	2021	Therefore, in this study, we aimed to explore the role of abnormal TSH-TSHR signaling activation in regulating iodide uptake and cell mobility in thyroid cancer and its relationship with PI3K/AKT/mTOR signaling.	Thyrotropin	67-70	thyroid stimulating hormone receptor	Homo sapiens	71-75
34650915-5	2021	Therefore, in this study, we aimed to explore the role of abnormal TSH-TSHR signaling activation in regulating iodide uptake and cell mobility in thyroid cancer and its relationship with PI3K/AKT/mTOR signaling.	Thyrotropin	67-70	AKT serine/threonine kinase 1	Homo sapiens	192-195
34650915-5	2021	Therefore, in this study, we aimed to explore the role of abnormal TSH-TSHR signaling activation in regulating iodide uptake and cell mobility in thyroid cancer and its relationship with PI3K/AKT/mTOR signaling.	Thyrotropin	67-70	mechanistic target of rapamycin kinase	Homo sapiens	196-200
34650915-6	2021	We found that in thyroid cancer cells, TSH binds TSHR coupled to the Galpha12/13 protein and then activates RhoA through interacting with leukemia associated RhoA guanine exchange factor (LARG).	Thyrotropin	39-42	thyroid stimulating hormone receptor	Homo sapiens	49-53
34650915-6	2021	We found that in thyroid cancer cells, TSH binds TSHR coupled to the Galpha12/13 protein and then activates RhoA through interacting with leukemia associated RhoA guanine exchange factor (LARG).	Thyrotropin	39-42	G protein subunit alpha 12	Homo sapiens	69-80
34650915-6	2021	We found that in thyroid cancer cells, TSH binds TSHR coupled to the Galpha12/13 protein and then activates RhoA through interacting with leukemia associated RhoA guanine exchange factor (LARG).	Thyrotropin	39-42	ras homolog family member A	Homo sapiens	108-112
34650915-6	2021	We found that in thyroid cancer cells, TSH binds TSHR coupled to the Galpha12/13 protein and then activates RhoA through interacting with leukemia associated RhoA guanine exchange factor (LARG).	Thyrotropin	39-42	Rho guanine nucleotide exchange factor 12	Homo sapiens	138-186
34650915-6	2021	We found that in thyroid cancer cells, TSH binds TSHR coupled to the Galpha12/13 protein and then activates RhoA through interacting with leukemia associated RhoA guanine exchange factor (LARG).	Thyrotropin	39-42	Rho guanine nucleotide exchange factor 12	Homo sapiens	188-192
34650915-8	2021	We observed that signaling pathways downstream of Galpha12/13 signaling were increased, while that of Galphas signaling was decreased in thyroid cancer cells undergoing dedifferentiation compared to control cells following stimulation with different levels of TSH.	Thyrotropin	260-263	G protein subunit alpha 12	Homo sapiens	50-61
34319904-8	2021	Using HTR-8/SVneo cells, we demonstrated that elevated TSH inhibited miR-17-5p expression, as well as trophoblast migration and invasion.	Thyrotropin	55-58	microRNA 17	Homo sapiens	69-78
34237030-9	2021	We conclude that THRB sumoylation at K146 is required for normal TSH feedback regulation and TH synthesis in the thyroid gland, by a TSH-independent pathway.	Thyrotropin	65-68	thyroid hormone receptor beta	Mus musculus	17-21
34237030-9	2021	We conclude that THRB sumoylation at K146 is required for normal TSH feedback regulation and TH synthesis in the thyroid gland, by a TSH-independent pathway.	Thyrotropin	133-136	thyroid hormone receptor beta	Mus musculus	17-21
35138554-8	2022	The findings of this study suggest that E2 may bind to ERalpha to trigger TSH release and provide novel information on the differential regulation of multiple estrogen receptors in the pituitary.	Thyrotropin	74-77	estrogen receptor 1 (alpha)	Mus musculus	55-62
34258276-7	2021	TSH levels were significantly different between T2DM patients with different FTO genotypes, rs8050136 (P = 0.008) and rs9939609 (P = 0.003), with TSH levels in rs8050136 CC genotype carriers showing a significant increase compared to those in the AA genotype carriers (P = 0.005).	Thyrotropin	146-149	FTO alpha-ketoglutarate dependent dioxygenase	Homo sapiens	77-80
35611323-1	2022	Context: The thyrotropin (TSH) receptor (TSH-R) autoantibody activity is clinically measured by inhibition of labeled ligand (TSH or M22) binding to the TSH-R (TSH-binding inhibitory immunoglobulin (TBII)) or by stimulation (TSH-R stimulating antibody (TSAb)) or inhibition (TSH-R blocking antibody (TSBAb)) of 3",5"-cyclic adenosine 5"-monophosphate (cAMP) production in isolated cells.	Thyrotropin	126-129	thyroid stimulating hormone receptor	Homo sapiens	0-39
35611323-1	2022	Context: The thyrotropin (TSH) receptor (TSH-R) autoantibody activity is clinically measured by inhibition of labeled ligand (TSH or M22) binding to the TSH-R (TSH-binding inhibitory immunoglobulin (TBII)) or by stimulation (TSH-R stimulating antibody (TSAb)) or inhibition (TSH-R blocking antibody (TSBAb)) of 3",5"-cyclic adenosine 5"-monophosphate (cAMP) production in isolated cells.	Thyrotropin	126-129	thyroid stimulating hormone receptor	Homo sapiens	41-46
35611323-1	2022	Context: The thyrotropin (TSH) receptor (TSH-R) autoantibody activity is clinically measured by inhibition of labeled ligand (TSH or M22) binding to the TSH-R (TSH-binding inhibitory immunoglobulin (TBII)) or by stimulation (TSH-R stimulating antibody (TSAb)) or inhibition (TSH-R blocking antibody (TSBAb)) of 3",5"-cyclic adenosine 5"-monophosphate (cAMP) production in isolated cells.	Thyrotropin	126-129	thyroid stimulating hormone receptor	Homo sapiens	153-158
35611323-1	2022	Context: The thyrotropin (TSH) receptor (TSH-R) autoantibody activity is clinically measured by inhibition of labeled ligand (TSH or M22) binding to the TSH-R (TSH-binding inhibitory immunoglobulin (TBII)) or by stimulation (TSH-R stimulating antibody (TSAb)) or inhibition (TSH-R blocking antibody (TSBAb)) of 3",5"-cyclic adenosine 5"-monophosphate (cAMP) production in isolated cells.	Thyrotropin	126-129	thyroid stimulating hormone receptor	Homo sapiens	225-230
35611323-1	2022	Context: The thyrotropin (TSH) receptor (TSH-R) autoantibody activity is clinically measured by inhibition of labeled ligand (TSH or M22) binding to the TSH-R (TSH-binding inhibitory immunoglobulin (TBII)) or by stimulation (TSH-R stimulating antibody (TSAb)) or inhibition (TSH-R blocking antibody (TSBAb)) of 3",5"-cyclic adenosine 5"-monophosphate (cAMP) production in isolated cells.	Thyrotropin	126-129	thyroid stimulating hormone receptor	Homo sapiens	275-280
35611323-7	2022	Conclusion: We present here the TBIIs with neutral bioactivities found in the patient with autoimmune thyroid disease, which strongly inhibit TSH binding to the TSH-R but exerts neither TSAb nor TSBAb activity.	Thyrotropin	142-145	thyroid stimulating hormone receptor	Homo sapiens	161-166
35510203-2	2022	A sufficient level of leptin signalling is needed for the normal production of TSH and thyroid hormones by the thyroid gland.	Thyrotropin	79-82	leptin	Homo sapiens	22-28
35317605-7	2022	RESULTS: In the total population, women with high-normal TSH levels had significantly decreased AMH concentrations (p<0.001), a lower bilateral AFC (p<0.001), and a higher prevalence of diminished ovarian reserve (DOR) (p=0.018) than women with low-normal TSH levels.	Thyrotropin	57-60	anti-Mullerian hormone	Homo sapiens	96-99
35455992-8	2022	Furthermore, CREB3L1 knockdown hampers the increase the TSH-induced NIS expression levels.	Thyrotropin	56-59	cAMP responsive element binding protein 3-like 1	Rattus norvegicus	13-20
35455992-8	2022	Furthermore, CREB3L1 knockdown hampers the increase the TSH-induced NIS expression levels.	Thyrotropin	56-59	solute carrier family 5 member 5	Rattus norvegicus	68-71
35455992-10	2022	Taken together, our findings highlight the role of CREB3L1 in maintaining the homeostasis of thyroid follicular cells, regulating the adaptation of the secretory pathway as well as the synthesis of thyroid-specific proteins in response to TSH stimulation.	Thyrotropin	239-242	cAMP responsive element binding protein 3-like 1	Rattus norvegicus	51-58
35320949-3	2022	The objective of this study was to determine the potential role of TSH in the suppression of insulin receptor substrate-1 (IRS-1) expression and IRS-1 tyrosyl phosphorylation, which might contribute to insulin resistance.	Thyrotropin	67-70	insulin receptor substrate 1	Mus musculus	93-121
35399935-15	2022	This may be related to a disruption of the effect of leptin on TSH production and could indicate wide ranging disturbances of hypothalamic signals, and consequently be the cause of inappropriate GH secretion.	Thyrotropin	63-66	leptin	Homo sapiens	53-59
35387426-1	2022	In animal studies, both in basic science and in toxicological assessment of potential endocrine disruptors, the state of the thyroid hormone (TH) axis is often described and defined exclusively by the concentrations of circulating THs and TSH.	Thyrotropin	239-242	tyrosine hydroxylase	Mus musculus	125-140
35387426-1	2022	In animal studies, both in basic science and in toxicological assessment of potential endocrine disruptors, the state of the thyroid hormone (TH) axis is often described and defined exclusively by the concentrations of circulating THs and TSH.	Thyrotropin	239-242	tyrosine hydroxylase	Mus musculus	142-144
35320949-8	2022	Results: TSH induced TNF-alpha secretion in a dose-dependent manner.	Thyrotropin	9-12	tumor necrosis factor	Bos taurus	21-30
35320949-3	2022	The objective of this study was to determine the potential role of TSH in the suppression of insulin receptor substrate-1 (IRS-1) expression and IRS-1 tyrosyl phosphorylation, which might contribute to insulin resistance.	Thyrotropin	67-70	insulin receptor substrate 1	Mus musculus	123-128
35320949-11	2022	Treatment of cultured adipocytes with TSH inhibited insulin-stimulated IRS-1 tyrosyl phosphorylation but promoted TSH-dependent secretion of TNF-alpha and activation of NF-kappaB DNA-binding activity.	Thyrotropin	38-41	insulin receptor substrate 1	Mus musculus	71-76
35320949-11	2022	Treatment of cultured adipocytes with TSH inhibited insulin-stimulated IRS-1 tyrosyl phosphorylation but promoted TSH-dependent secretion of TNF-alpha and activation of NF-kappaB DNA-binding activity.	Thyrotropin	38-41	tumor necrosis factor	Bos taurus	141-150
35320949-3	2022	The objective of this study was to determine the potential role of TSH in the suppression of insulin receptor substrate-1 (IRS-1) expression and IRS-1 tyrosyl phosphorylation, which might contribute to insulin resistance.	Thyrotropin	67-70	insulin receptor substrate 1	Mus musculus	145-150
35320949-11	2022	Treatment of cultured adipocytes with TSH inhibited insulin-stimulated IRS-1 tyrosyl phosphorylation but promoted TSH-dependent secretion of TNF-alpha and activation of NF-kappaB DNA-binding activity.	Thyrotropin	38-41	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	169-178
35151725-4	2022	PCBs and OH-PCBs decreased the TSH-stimulated TSHR expression.	Thyrotropin	31-34	thyroid stimulating hormone receptor	Gallus gallus	46-50
35320949-11	2022	Treatment of cultured adipocytes with TSH inhibited insulin-stimulated IRS-1 tyrosyl phosphorylation but promoted TSH-dependent secretion of TNF-alpha and activation of NF-kappaB DNA-binding activity.	Thyrotropin	114-117	tumor necrosis factor	Bos taurus	141-150
35320949-13	2022	Conclusion: TSH inhibited IRS-1 protein expression and tyrosyl phosphorylation in 3T3-L1 adipocytes by stimulating TNF-alpha production via promotion of NF-kappaB DNA-binding activity.	Thyrotropin	12-15	insulin receptor substrate 1	Mus musculus	26-31
35320949-13	2022	Conclusion: TSH inhibited IRS-1 protein expression and tyrosyl phosphorylation in 3T3-L1 adipocytes by stimulating TNF-alpha production via promotion of NF-kappaB DNA-binding activity.	Thyrotropin	12-15	tumor necrosis factor	Bos taurus	115-124
35320949-13	2022	Conclusion: TSH inhibited IRS-1 protein expression and tyrosyl phosphorylation in 3T3-L1 adipocytes by stimulating TNF-alpha production via promotion of NF-kappaB DNA-binding activity.	Thyrotropin	12-15	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	153-162
35140269-4	2022	Specifically, TSH stimulates the cAMP/PKA pathway to transcriptionally upregulate Sox9 mRNA and protein expression, a mechanism that is mediated by the binding of CREB to a CRE site within the Sox9 promoter.	Thyrotropin	14-17	SRY-box transcription factor 9	Homo sapiens	82-86
35140269-4	2022	Specifically, TSH stimulates the cAMP/PKA pathway to transcriptionally upregulate Sox9 mRNA and protein expression, a mechanism that is mediated by the binding of CREB to a CRE site within the Sox9 promoter.	Thyrotropin	14-17	cAMP responsive element binding protein 1	Homo sapiens	163-167
35140269-4	2022	Specifically, TSH stimulates the cAMP/PKA pathway to transcriptionally upregulate Sox9 mRNA and protein expression, a mechanism that is mediated by the binding of CREB to a CRE site within the Sox9 promoter.	Thyrotropin	14-17	SRY-box transcription factor 9	Homo sapiens	193-197
35140269-5	2022	Contrastingly, TGFbeta signals through Smad proteins to inhibit TSH-induced Sox9 transcription.	Thyrotropin	64-67	transforming growth factor alpha	Homo sapiens	15-22
35140269-5	2022	Contrastingly, TGFbeta signals through Smad proteins to inhibit TSH-induced Sox9 transcription.	Thyrotropin	64-67	SRY-box transcription factor 9	Homo sapiens	76-80
34751390-0	2022	Capsaicin restores sodium iodine symporter-mediated radioiodine uptake through bypassing canonical TSH-TSHR pathway in anaplastic thyroid carcinoma cells.	Thyrotropin	99-102	thyroid stimulating hormone receptor	Homo sapiens	103-107
35054977-11	2022	Increased expression of nuclear VDR (p < 0.05) points to direct, TSH independent action of Vit.	Thyrotropin	65-68	vitamin D receptor	Rattus norvegicus	32-35
35163879-4	2022	Current study examined the role of TSH on human osteoblastic Runx2 expression and their functional genes by in vitro and in slico analysis.	Thyrotropin	35-38	RUNX family transcription factor 2	Homo sapiens	61-66
35163879-7	2022	TSH treatment induced osteoblastic essential transcriptional factor, Runx2 in HOS and SaOS2 cells on 48 h duration and elevated the expression of IGF-IR beta gene and Protein in SaoS-2 cells.	Thyrotropin	0-3	RUNX family transcription factor 2	Homo sapiens	69-74
35054977-11	2022	Increased expression of nuclear VDR (p < 0.05) points to direct, TSH independent action of Vit.	Thyrotropin	65-68	vitrin	Rattus norvegicus	91-94
35101946-8	2022	TSH released by moDCs promoted proliferation and invasion of tumors with high TSHR expressions, such as thyroid cancers and glioma.	Thyrotropin	0-3	thyroid stimulating hormone receptor	Mus musculus	78-82
35101946-9	2022	TSH also induced tumor programmed death-ligand 1 (PD-L1) expression through the TSHR-AC-PKA-JNK-c-JUN pathway.	Thyrotropin	0-3	CD274 antigen	Mus musculus	23-48
35101946-9	2022	TSH also induced tumor programmed death-ligand 1 (PD-L1) expression through the TSHR-AC-PKA-JNK-c-JUN pathway.	Thyrotropin	0-3	CD274 antigen	Mus musculus	50-55
35101946-9	2022	TSH also induced tumor programmed death-ligand 1 (PD-L1) expression through the TSHR-AC-PKA-JNK-c-JUN pathway.	Thyrotropin	0-3	thyroid stimulating hormone receptor	Mus musculus	80-84
35101946-9	2022	TSH also induced tumor programmed death-ligand 1 (PD-L1) expression through the TSHR-AC-PKA-JNK-c-JUN pathway.	Thyrotropin	0-3	jun proto-oncogene	Mus musculus	96-101
2692373-6	1989	When human thyroid cell cultures were used, a significant increase of labelled amino acid transport was induced by TSH, i.e. from 0.1 pmol/l to 10 pmol/l; IGF-I stimulated amino acid transport in a range from 0.13 pmol/l to 13 pmol/l, under the same conditions.	Thyrotropin	115-118	insulin like growth factor 1	Homo sapiens	155-160
2584351-15	1989	However, small amounts of functionally active Tg could be synthesized, iodinated, and immediately hydrolized, yielding mostly T3, owing to the intense tissue stimulation by TSH.	Thyrotropin	173-176	thyroglobulin	Homo sapiens	46-48
2532008-2	1989	1-deoxynojirimycin and N-methyl-1-deoxynojirimycin, both inhibitors of glucosidases I and II, decreased intracellular TSH (to 60-76% of control) and secreted TSH (to 60-63% of control) after a 1-hour incubation (pulse) with [35S]methionine and an 8-hour incubation (chase) in isotope-free media.	Thyrotropin	118-121	mannosyl-oligosaccharide glucosidase	Homo sapiens	71-92
2484871-10	1989	Furthermore, pretreatment with the inhibitor of GABA-degrading enzyme GABA transaminase (gamma-vinyl GABA) impaired the stimulatory effect of TSH on blood radioiodine levels.	Thyrotropin	142-145	4-aminobutyrate aminotransferase	Mus musculus	70-87
2607258-3	1989	In only one out of the six was IGF-I release increased in the presence of physiological mitogenic concentrations of TSH (0.1-100 microU/ml).	Thyrotropin	116-119	insulin like growth factor 1	Homo sapiens	31-36
2511713-5	1989	The increase in TSH (delta TSH) 30 min after the iv injection of TRH was also significantly blunted in patients with primary hyperparathyroidism; delta TSH was highly correlated with basal TSH in hypercalcemic patients.	Thyrotropin	16-19	thyrotropin releasing hormone	Homo sapiens	65-68
2484872-2	1989	The thyrotropin receptor antibodies were assessed by parallel measurements of thyrotropin binding inhibitor immunoglobulin (TBII), thyroid stimulating antibody (TSAb), and thyroid stimulation blocking antibody (TSBAb) in serum by radioreceptor assay, stimulation of adenylate cyclase and inhibition of TSH-stimulated adenylate cyclase activation in FRTL-5 cells, respectively.	Thyrotropin	302-305	thyroid stimulating hormone receptor	Rattus norvegicus	4-24
2484874-4	1989	Serum TSH response to TRH (400 micrograms I.V.)	Thyrotropin	6-9	thyrotropin releasing hormone	Homo sapiens	22-25
2516787-7	1989	A significant positive correlation was present between TT4 and TBG, TT4 and TSH, and TBG and TSH levels; on the contrary, no correlation was demonstrated between FT4 and TSH levels.	Thyrotropin	93-96	serpin family A member 7	Homo sapiens	85-88
2793998-7	1989	The increase in ricin binding induced by neuraminidase treatment was significantly higher for TSH from patients with primary hypothyroidism than in that from euthyroid subjects (42.3 +/- 7.6% vs. 22.3 +/- 4.4%; P less than 0.01) and was greater for long term than for short term hypothyroid patients (49.5 +/- 5.0% vs. 36.5 +/- 6.5%; P less than 0.01).	Thyrotropin	94-97	neuraminidase 1	Homo sapiens	41-54
2516787-7	1989	A significant positive correlation was present between TT4 and TBG, TT4 and TSH, and TBG and TSH levels; on the contrary, no correlation was demonstrated between FT4 and TSH levels.	Thyrotropin	93-96	serpin family A member 7	Homo sapiens	85-88
2551628-1	1989	Administration of recombinant human tumor necrosis factor-alpha (TNF) to rats and mice produces a model of nonthyroid illness in which there is impairment of hypothalamic-pituitary thyroid function, including reduced serum concentrations of T4 and T3, reduced thyroid radioiodine uptake, and reduced response to TSH.	Thyrotropin	312-315	tumor necrosis factor	Homo sapiens	36-63
2514392-3	1989	Anterior pituitary in the presence of TRH showed heterogeneous components of [3H]glucosamine-labeled TSH with 6 different isoelectric points (components I-VI).	Thyrotropin	101-104	thyrotropin releasing hormone	Rattus norvegicus	38-41
2800921-6	1989	Both interleukin 1 alpha and beta inhibited TSH-induced thyroid peroxidase mRNA in a dose responsive manner; 10(3) U/1 interleukin 1 caused maximal suppression of TSH-induced thyroid peroxidase mRNA level to nearly basal levels.	Thyrotropin	44-47	interleukin 1 alpha	Homo sapiens	5-24
2800921-6	1989	Both interleukin 1 alpha and beta inhibited TSH-induced thyroid peroxidase mRNA in a dose responsive manner; 10(3) U/1 interleukin 1 caused maximal suppression of TSH-induced thyroid peroxidase mRNA level to nearly basal levels.	Thyrotropin	44-47	interleukin 1 alpha	Homo sapiens	5-18
2800921-6	1989	Both interleukin 1 alpha and beta inhibited TSH-induced thyroid peroxidase mRNA in a dose responsive manner; 10(3) U/1 interleukin 1 caused maximal suppression of TSH-induced thyroid peroxidase mRNA level to nearly basal levels.	Thyrotropin	163-166	interleukin 1 alpha	Homo sapiens	5-24
2800921-6	1989	Both interleukin 1 alpha and beta inhibited TSH-induced thyroid peroxidase mRNA in a dose responsive manner; 10(3) U/1 interleukin 1 caused maximal suppression of TSH-induced thyroid peroxidase mRNA level to nearly basal levels.	Thyrotropin	163-166	interleukin 1 alpha	Homo sapiens	5-18
2800921-9	1989	These results demonstrate that interleukin 1 directly inhibits TSH-induced thyroid peroxidase gene expression and provide further evidence for a paracrine role of interleukin 1 as a local inhibitor of thyroid hormone synthesis.	Thyrotropin	63-66	interleukin 1 alpha	Homo sapiens	31-44
2800921-9	1989	These results demonstrate that interleukin 1 directly inhibits TSH-induced thyroid peroxidase gene expression and provide further evidence for a paracrine role of interleukin 1 as a local inhibitor of thyroid hormone synthesis.	Thyrotropin	63-66	interleukin 1 alpha	Homo sapiens	163-176
2507289-9	1989	TRH administration in vivo normalized the Concanavalin-A binding pattern of secreted TSH glycopeptides in the PVN lesioned group but had no significant effect in the sham lesioned group.	Thyrotropin	85-88	thyrotropin releasing hormone	Rattus norvegicus	0-3
2691880-6	1989	Despite the fact TSH action in both cases is duplicated, and presumably mediated, by cAMP, TSH-induced increases in thyroid peroxidase and thyroglobulin mRNA levels differ.	Thyrotropin	17-20	thyroid peroxidase	Rattus norvegicus	116-134
2691880-6	1989	Despite the fact TSH action in both cases is duplicated, and presumably mediated, by cAMP, TSH-induced increases in thyroid peroxidase and thyroglobulin mRNA levels differ.	Thyrotropin	17-20	thyroglobulin	Rattus norvegicus	139-152
2691880-6	1989	Despite the fact TSH action in both cases is duplicated, and presumably mediated, by cAMP, TSH-induced increases in thyroid peroxidase and thyroglobulin mRNA levels differ.	Thyrotropin	91-94	thyroid peroxidase	Rattus norvegicus	116-134
2691880-6	1989	Despite the fact TSH action in both cases is duplicated, and presumably mediated, by cAMP, TSH-induced increases in thyroid peroxidase and thyroglobulin mRNA levels differ.	Thyrotropin	91-94	thyroglobulin	Rattus norvegicus	139-152
2691880-12	1989	Finally, methimazole and phorbol 12-myristate 13-acetate show different effects on TSH-induced increases in thyroglobulin and thyroid peroxidase mRNA levels.	Thyrotropin	83-86	thyroglobulin	Rattus norvegicus	108-121
2691880-12	1989	Finally, methimazole and phorbol 12-myristate 13-acetate show different effects on TSH-induced increases in thyroglobulin and thyroid peroxidase mRNA levels.	Thyrotropin	83-86	thyroid peroxidase	Rattus norvegicus	126-144
2693820-7	1989	We conclude from these findings, first, that TSH appears to be a growth factor for human thyroid cells under the conditions described, and, second, the effects of TSH on thyroid cell proliferation are under the control of cofactors like insulin and IGF I.	Thyrotropin	45-48	insulin	Homo sapiens	237-244
2693820-7	1989	We conclude from these findings, first, that TSH appears to be a growth factor for human thyroid cells under the conditions described, and, second, the effects of TSH on thyroid cell proliferation are under the control of cofactors like insulin and IGF I.	Thyrotropin	45-48	insulin like growth factor 1	Homo sapiens	249-254
2551628-1	1989	Administration of recombinant human tumor necrosis factor-alpha (TNF) to rats and mice produces a model of nonthyroid illness in which there is impairment of hypothalamic-pituitary thyroid function, including reduced serum concentrations of T4 and T3, reduced thyroid radioiodine uptake, and reduced response to TSH.	Thyrotropin	312-315	tumor necrosis factor	Homo sapiens	65-68
2551628-3	1989	The TSH-stimulated [125I]iodide uptake by FRTL-5 cells was inhibited by TNF in a dose-dependent manner.	Thyrotropin	4-7	tumor necrosis factor	Rattus norvegicus	72-75
2612732-4	1989	Thyroglobulin was the only protein in the culture medium, that was iodinated with high specificity and in a TSH-dependent fashion.	Thyrotropin	108-111	thyroglobulin	Rattus norvegicus	0-13
2515928-9	1989	The TSH responses to TRH in IGD males and females were similar to each other and similar to normal.	Thyrotropin	4-7	thyrotropin releasing hormone	Homo sapiens	21-24
2474435-4	1989	IFN gamma stimulated the 30-min I- uptake and enhanced the effect of TSH.	Thyrotropin	69-72	interferon gamma	Rattus norvegicus	0-9
2559822-6	1989	Nine pregnant women with serum TSH concentrations less than the lower limit of the normal range (less than 0.25 mU/l) displayed significantly higher values for both thyroid stimulating activities and serum hCG concentrations (P less than 0.001, respectively) compared with those who had normal TSH levels in serum.	Thyrotropin	31-34	hypertrichosis 2 (generalised, congenital)	Homo sapiens	206-209
2474435-11	1989	Stimulation of I- uptake by TSH was enhanced by IFN gamma, reduced by TNF alpha, and, when serum was present, increased to a degree that was greater than additive by the combined cytokines.	Thyrotropin	28-31	interferon gamma	Rattus norvegicus	48-57
2474435-5	1989	TNF alpha had minimal effects on growth indices (slight increase in [3H]Tdr incorporation) and had no influence on I- uptake; it inhibited TSH stimulation of both growth and I- uptake.	Thyrotropin	139-142	tumor necrosis factor	Rattus norvegicus	0-9
2474435-11	1989	Stimulation of I- uptake by TSH was enhanced by IFN gamma, reduced by TNF alpha, and, when serum was present, increased to a degree that was greater than additive by the combined cytokines.	Thyrotropin	28-31	tumor necrosis factor	Rattus norvegicus	70-79
2474435-6	1989	When combined, IFN gamma and TNF alpha synergized in inhibiting TSH-stimulated growth.	Thyrotropin	64-67	interferon gamma	Rattus norvegicus	15-24
2474435-14	1989	Simultaneous with inhibition of TSH-stimulated growth, both IFN gamma and TNF alpha enhanced cAMP accumulation.	Thyrotropin	32-35	interferon gamma	Rattus norvegicus	60-69
2474435-6	1989	When combined, IFN gamma and TNF alpha synergized in inhibiting TSH-stimulated growth.	Thyrotropin	64-67	tumor necrosis factor	Rattus norvegicus	29-38
2474435-14	1989	Simultaneous with inhibition of TSH-stimulated growth, both IFN gamma and TNF alpha enhanced cAMP accumulation.	Thyrotropin	32-35	tumor necrosis factor	Rattus norvegicus	74-83
2474435-7	1989	By itself TNF alpha inhibited stimulation of I- uptake by TSH, but augmented the enhancement seen with IFN gamma.	Thyrotropin	58-61	tumor necrosis factor	Rattus norvegicus	10-19
2546966-1	1989	We have previously demonstrated that interferon-gamma (IFN-gamma) induced HLA-DR antigen and also inhibited thyrotropin (TSH)-induced triiodothyronine (T3) and thyroglobulin (Tg) secretion from cultured human thyrocytes.	Thyrotropin	121-124	interferon gamma	Homo sapiens	55-64
2760176-5	1989	In addition, several patients with undetectable basal and detectable TRH-stimulated TSH values in the immunoradiometric assay had detectable basal TSH values in the chemiluminescent assay.	Thyrotropin	84-87	thyrotropin releasing hormone	Homo sapiens	69-72
2505466-7	1989	Before treatment a diminished or absent TSH response to TRH was exhibited by 64% of the goitre patients and 34% of the non-goitre groups (p less than 0.05).	Thyrotropin	40-43	thyrotropin releasing hormone	Homo sapiens	56-59
2505466-10	1989	There was, however, a negative correlation (r = -0.765, p less than 0.05) between the incremental TSH response to TRH and somatomedin-C levels for females with goitre.	Thyrotropin	98-101	thyrotropin releasing hormone	Homo sapiens	114-117
2505466-10	1989	There was, however, a negative correlation (r = -0.765, p less than 0.05) between the incremental TSH response to TRH and somatomedin-C levels for females with goitre.	Thyrotropin	98-101	insulin like growth factor 1	Homo sapiens	122-135
2506089-2	1989	N-acetyl-beta-glucosaminidase (NAG) activity was increased by 14% after 10 min TSH stimulation and NAG and beta-galactosidase activities were increased by 24% and 25% respectively (P less than 0.05) after 20 min stimulation and by 40% and 45% (P less than 0.05) respectively after 30 min stimulation with TSH, indicating an early processing of these carbohydrate residues in thyroglobulin.	Thyrotropin	79-82	O-GlcNAcase	Homo sapiens	0-29
2506089-2	1989	N-acetyl-beta-glucosaminidase (NAG) activity was increased by 14% after 10 min TSH stimulation and NAG and beta-galactosidase activities were increased by 24% and 25% respectively (P less than 0.05) after 20 min stimulation and by 40% and 45% (P less than 0.05) respectively after 30 min stimulation with TSH, indicating an early processing of these carbohydrate residues in thyroglobulin.	Thyrotropin	79-82	O-GlcNAcase	Homo sapiens	31-34
2506089-2	1989	N-acetyl-beta-glucosaminidase (NAG) activity was increased by 14% after 10 min TSH stimulation and NAG and beta-galactosidase activities were increased by 24% and 25% respectively (P less than 0.05) after 20 min stimulation and by 40% and 45% (P less than 0.05) respectively after 30 min stimulation with TSH, indicating an early processing of these carbohydrate residues in thyroglobulin.	Thyrotropin	305-308	O-GlcNAcase	Homo sapiens	0-29
2667954-5	1989	Insulin and IGF-I had effects comparable to each other, but much smaller concentrations of IGF-I were required; they both augmented growth and enhanced growth stimulation by TSH.	Thyrotropin	174-177	insulin-like growth factor 1	Rattus norvegicus	12-17
2667954-5	1989	Insulin and IGF-I had effects comparable to each other, but much smaller concentrations of IGF-I were required; they both augmented growth and enhanced growth stimulation by TSH.	Thyrotropin	174-177	insulin-like growth factor 1	Rattus norvegicus	91-96
2512341-4	1989	Pretreatment with atropine (0.01 mg/kg IM 30 min prior to the TRH administration) abolished the TRH induced GH rise (peak GH after TRH of 1.5 +/- 1.0 ng/ml, p less than 0.01) but did not modify the TSH response (peak TSH after TRH: basal conditions 8.7 +/- 0.8 microU/ml, post atropine: 9.5 +/- 1.4 microU/ml, p greater than 0.05).	Thyrotropin	198-201	thyrotropin releasing hormone	Homo sapiens	96-99
2512341-4	1989	Pretreatment with atropine (0.01 mg/kg IM 30 min prior to the TRH administration) abolished the TRH induced GH rise (peak GH after TRH of 1.5 +/- 1.0 ng/ml, p less than 0.01) but did not modify the TSH response (peak TSH after TRH: basal conditions 8.7 +/- 0.8 microU/ml, post atropine: 9.5 +/- 1.4 microU/ml, p greater than 0.05).	Thyrotropin	198-201	thyrotropin releasing hormone	Homo sapiens	96-99
2512341-4	1989	Pretreatment with atropine (0.01 mg/kg IM 30 min prior to the TRH administration) abolished the TRH induced GH rise (peak GH after TRH of 1.5 +/- 1.0 ng/ml, p less than 0.01) but did not modify the TSH response (peak TSH after TRH: basal conditions 8.7 +/- 0.8 microU/ml, post atropine: 9.5 +/- 1.4 microU/ml, p greater than 0.05).	Thyrotropin	198-201	thyrotropin releasing hormone	Homo sapiens	96-99
2483473-10	1989	Difluoromethylornithine, a specific inhibitor of ornithine decarboxylase, inhibited growth induced by both TPA and TSH in putrescine-free medium.	Thyrotropin	115-118	ornithine decarboxylase 1	Rattus norvegicus	49-72
2546742-6	1989	TSH, acting within 5 min, induced a modest increase in transferrin binding, due to a cycloheximide-resistant increase in binding sites.	Thyrotropin	0-3	transferrin	Rattus norvegicus	55-66
2546966-2	1989	In order to further clarify the inhibitory effect of IFN-gamma on TSH-stimulated thyroid hormone secretion, we have examined human thyroid peroxidase (TPO) gene expression.	Thyrotropin	66-69	interferon gamma	Homo sapiens	53-62
2546425-3	1989	They used 125I-ANP to study the effect of TSH on ANP binding to human thyroid cells in primary culture.	Thyrotropin	42-45	natriuretic peptide A	Homo sapiens	49-52
2677534-11	1989	The present results suggest that HTH, whose production by the thymus is known to be stimulated by TSH and GH, is involved in an inhibitory feedback loop regulating plasma TSH and GH in young rats.	Thyrotropin	98-101	gonadotropin releasing hormone receptor	Rattus norvegicus	179-181
2677534-11	1989	The present results suggest that HTH, whose production by the thymus is known to be stimulated by TSH and GH, is involved in an inhibitory feedback loop regulating plasma TSH and GH in young rats.	Thyrotropin	171-174	gonadotropin releasing hormone receptor	Rattus norvegicus	106-108
2546425-9	1989	Thus, human thyroid cells possess a single class of high-affinity, specific receptors for ANP with binding activity that is temperature dependent and modulated by TSH at physiologic temperature.	Thyrotropin	163-166	natriuretic peptide A	Homo sapiens	90-93
2546425-10	1989	TSH-mediated reduction of binding at 37 degrees C but not at 4 degrees C suggests an energy-dependent process that acts possibly by activating an ANP degradative enzyme or by changing the rate of receptor internalization and subsequent degradation.	Thyrotropin	0-3	natriuretic peptide A	Homo sapiens	146-149
2544413-22	1989	These studies demonstrate that AVP target cells include thyrotropes, corticotropes, and unique cells that store both ACTH and TSH.	Thyrotropin	126-129	arginine vasopressin	Homo sapiens	31-34
2506120-4	1989	Apart from 1 patient with pituitary apoplexy all had normal basal TSH levels and 9 showed a significant TSH response to TRH.	Thyrotropin	104-107	thyrotropin releasing hormone	Homo sapiens	120-123
2571629-6	1989	It was significant that TSH receptor antibodies could also be detected in both groups, namely, thyroid stimulating antibody and long acting thyroid stimulator (LATS) in 4 of 9 patients in the high TSH Ab group and TBII in 55 of 104 in the low TSH Ab group, respectively.	Thyrotropin	197-200	thyroid stimulating hormone receptor	Homo sapiens	24-36
2500334-5	1989	The single injection of 200 micrograms TNF/kg significantly reduced (all P less than 0.05) serum TSH, T4, free T4, T3, and hypothalamic TRH compared to the corresponding hormone levels in saline-injected control rats.	Thyrotropin	97-100	tumor necrosis factor	Rattus norvegicus	39-42
2500334-10	1989	TNF treatment also reduced thyroid 125I uptake and reduced thyroidal release of T4 and T3 in response to bovine TSH, but did not change the TSH response to TRH.	Thyrotropin	112-115	tumor necrosis factor	Bos taurus	0-3
2500334-11	1989	TNF treatment reduced the binding of pituitary TSH to Concanavalin-A, indicating that it alters the glycosylation of TSH.	Thyrotropin	47-50	tumor necrosis factor	Rattus norvegicus	0-3
2742742-0	1989	Activation of the thyroid peroxidase gene in human thyroid cells: effect of thyrotrophin, forskolin and phorbol ester.	Thyrotropin	76-88	thyroid peroxidase	Homo sapiens	18-36
2788696-5	1989	Both IL-1 alpha and beta inhibited TSH-induced Tg release at concentrations ranging from 0.01 to 10 U/ml.	Thyrotropin	35-38	interleukin 1 alpha	Homo sapiens	5-15
2788696-5	1989	Both IL-1 alpha and beta inhibited TSH-induced Tg release at concentrations ranging from 0.01 to 10 U/ml.	Thyrotropin	35-38	thyroglobulin	Homo sapiens	47-49
2788696-9	1989	Both IL-1 alpha and beta inhibited TSH-induced Tg mRNA in a dose-responsive manner.	Thyrotropin	35-38	interleukin 1 alpha	Homo sapiens	5-15
2788696-9	1989	Both IL-1 alpha and beta inhibited TSH-induced Tg mRNA in a dose-responsive manner.	Thyrotropin	35-38	thyroglobulin	Homo sapiens	47-49
2788696-13	1989	These results demonstrate that IL-1 directly inhibits TSH-induced Tg gene expression and provide further support for a functional role of IL-1 as a local modulator of thyroid hormone synthesis.	Thyrotropin	54-57	interleukin 1 alpha	Homo sapiens	31-35
2788696-13	1989	These results demonstrate that IL-1 directly inhibits TSH-induced Tg gene expression and provide further support for a functional role of IL-1 as a local modulator of thyroid hormone synthesis.	Thyrotropin	54-57	thyroglobulin	Homo sapiens	66-68
2788696-13	1989	These results demonstrate that IL-1 directly inhibits TSH-induced Tg gene expression and provide further support for a functional role of IL-1 as a local modulator of thyroid hormone synthesis.	Thyrotropin	54-57	interleukin 1 alpha	Homo sapiens	138-142
2742742-4	1989	Addition of TSH (10 mU/ml) to primary thyroid cultures for 4 h led to increased TPO mRNA levels which were maximal after 48 h and significantly higher than basal even after 7 days of co-culture.	Thyrotropin	12-15	thyroid peroxidase	Homo sapiens	80-83
2742742-6	1989	The adenylate cyclase activator forskolin (1-100 microM) mimicked TSH in increasing TPO mRNA levels whilst, in contrast, the phorbol ester 12-O-tetradecanoyl phorbol 13-acetate (TPA; 0.01-1 microM) led to levels of TPO mRNA that were lower than basal.	Thyrotropin	66-69	thyroid peroxidase	Homo sapiens	84-87
2742742-6	1989	The adenylate cyclase activator forskolin (1-100 microM) mimicked TSH in increasing TPO mRNA levels whilst, in contrast, the phorbol ester 12-O-tetradecanoyl phorbol 13-acetate (TPA; 0.01-1 microM) led to levels of TPO mRNA that were lower than basal.	Thyrotropin	66-69	thyroid peroxidase	Homo sapiens	215-218
2498332-3	1989	In mouse thyrotropic tumor (TtT) cells, maximally effective doses of TRH caused biphasic stimulation of thyroid-stimulating hormone (TSH) secretion, whereas CCH stimulated monophasic sustained TSH secretion without a burst phase.	Thyrotropin	104-131	thyrotropin releasing hormone	Mus musculus	69-72
2507375-3	1989	Using an in vitro system, we screened T cell lines for the production of TSH in response to thyrotropin-releasing hormone (TRH).	Thyrotropin	73-76	thyrotropin releasing hormone	Homo sapiens	92-121
2498332-3	1989	In mouse thyrotropic tumor (TtT) cells, maximally effective doses of TRH caused biphasic stimulation of thyroid-stimulating hormone (TSH) secretion, whereas CCH stimulated monophasic sustained TSH secretion without a burst phase.	Thyrotropin	133-136	thyrotropin releasing hormone	Mus musculus	69-72
2474048-7	1989	At an extracellular Ca2+ concentration of less than 500 nmol/l, TRH-induced TSH release was observed only after treatment with 1,25-(OH)2D3 (P less than 0.01).	Thyrotropin	76-79	thyrotropin releasing hormone	Rattus norvegicus	64-67
2497169-4	1989	Men revealed significantly diminished TSH responses to TRH injection relative to women.	Thyrotropin	38-41	thyrotropin releasing hormone	Homo sapiens	55-58
2548370-4	1989	ACTH secretion following CRH and TRH-induced TSH release were positively correlated across depressed patients and controls but no significant correlations between GH responses to GHRH and TRH-induced TSH release or ACTH and cortisol secretion following CRH administration were demonstrated.	Thyrotropin	45-48	thyrotropin releasing hormone	Homo sapiens	33-36
2474048-8	1989	As the extracellular Ca2+ concentration was increased, greater increments of TRH-induced TSH release were observed following pretreatment with 1,25-(OH)2D3 (P less than 0.01).	Thyrotropin	89-92	thyrotropin releasing hormone	Rattus norvegicus	77-80
2502597-3	1989	TRH (1 nmol/l)-induced TSH release over 1 h was enhanced by 70% (P less than 0.01) following exposure to 10 nmol 1,25-(OH)2D3/l for 24 h. Pretreatment with T3 (1 pmol/l-1 mumol/l) for 24 h caused a dose-dependent inhibition of TRH-induced TSH release.	Thyrotropin	23-26	thyrotropin releasing hormone	Rattus norvegicus	0-3
2502597-3	1989	TRH (1 nmol/l)-induced TSH release over 1 h was enhanced by 70% (P less than 0.01) following exposure to 10 nmol 1,25-(OH)2D3/l for 24 h. Pretreatment with T3 (1 pmol/l-1 mumol/l) for 24 h caused a dose-dependent inhibition of TRH-induced TSH release.	Thyrotropin	239-242	thyrotropin releasing hormone	Rattus norvegicus	0-3
2500677-3	1989	Eight alcoholics (seven with cerebral atrophy) had blunted TSH and PRL responses to TRH and a TRH-induced paradoxical increase of GH.	Thyrotropin	59-62	thyrotropin releasing hormone	Homo sapiens	84-87
2502597-4	1989	Net TRH-induced TSH release was inhibited by 85% at T3 concentrations of 3 nmol/l or greater.	Thyrotropin	16-19	thyrotropin releasing hormone	Rattus norvegicus	4-7
2502597-5	1989	Co-incubation with 1,25-(OH)2D3 resulted in enhanced TRH-induced TSH release at all T3 concentrations tested (P less than 0.001).	Thyrotropin	65-68	thyrotropin releasing hormone	Rattus norvegicus	53-56
2502597-6	1989	The increment of TRH-induced TSH release resulting from 1,25-(OH)2D3 pretreatment was equivalent in the presence or absence of maximal inhibitory T3 concentrations.	Thyrotropin	29-32	thyrotropin releasing hormone	Rattus norvegicus	17-20
2502597-7	1989	At 1 nmol T3/l, there was a two- to threefold relative increase in 1,25-(OH)2D3-enhanced TRH-induced TSH release.	Thyrotropin	101-104	thyrotropin releasing hormone	Rattus norvegicus	89-92
2502597-8	1989	Incubation with cortisol (100 pmol/l-100 nmol/l) had no effect on basal or TRH-induced TSH release, nor did it alter 1,25-(OH)2D3-enhanced TRH-induced TSH release when added 24 h before, or at the time of addition of 1,25-(OH)2D3.	Thyrotropin	151-154	thyrotropin releasing hormone	Rattus norvegicus	139-142
2723027-8	1989	These results suggest that human thyroid cells contain four distinct TPO mRNAs and a single species of Tg mRNA, and the levels of all mRNAs are increased by TSH/cAMP stimulation.	Thyrotropin	157-160	thyroid peroxidase	Homo sapiens	69-72
2723027-8	1989	These results suggest that human thyroid cells contain four distinct TPO mRNAs and a single species of Tg mRNA, and the levels of all mRNAs are increased by TSH/cAMP stimulation.	Thyrotropin	157-160	thyroglobulin	Homo sapiens	103-105
2471981-3	1989	In this study, we demonstrate that the activation of the beta 2-adrenergic receptor, transfected into a thyroid epithelial cell, elicits a program of growth and differentiation normally observed with TSH.	Thyrotropin	200-203	adrenoceptor beta 2	Homo sapiens	57-83
2471981-4	1989	In thyroid cells expressing beta 2 receptors, the beta 2 agonist isoproterenol activates adenylate cyclase, induces the expression of a thyroid-specific iodide carrier system, and can substitute for TSH to promote growth.	Thyrotropin	199-202	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	28-34
2471981-4	1989	In thyroid cells expressing beta 2 receptors, the beta 2 agonist isoproterenol activates adenylate cyclase, induces the expression of a thyroid-specific iodide carrier system, and can substitute for TSH to promote growth.	Thyrotropin	199-202	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	50-56
2471981-5	1989	Thus, in thyroid cells expressing beta 2-adrenergic receptors, isoproterenol elicits the entire array of thyroid-specific functions normally activated by TSH.	Thyrotropin	154-157	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	34-40
2498473-3	1989	Iron-deficient anemic rats had lower basal TSH values and blunted TSH responses to intravenous TRH injection at three different doses (10, 25 and 50 ng TRH/100 g body wt).	Thyrotropin	66-69	thyrotropin releasing hormone	Rattus norvegicus	95-98
2551602-3	1989	The preoperative abnormal serum TSH response to TRH was found in 8/20 patients with prolactinoma, 9/16 with GH tumour, and 2/2 with Cushing"s disease due to ACTH microadenoma.	Thyrotropin	32-35	proopiomelanocortin	Homo sapiens	157-161
2564328-0	1989	Resistance to experimental autoimmune thyroiditis: L3T4+ cells as mediators of both thyroglobulin-activated and TSH-induced suppression.	Thyrotropin	112-115	CD4 antigen	Mus musculus	51-55
2564328-6	1989	Similarly, the suppressor state evoked by TSH infusion could only be abrogated by anti-L3T4 treatment.	Thyrotropin	42-45	CD4 antigen	Mus musculus	87-91
2564328-7	1989	These findings indicate that both MTg-activated and TSH-induced suppression are mediated by L3T4+ cells.	Thyrotropin	52-55	CD4 antigen	Mus musculus	92-96
2542780-1	1989	Thyroid hormones suppress the synthesis of TSH in part by decreasing the rate of alpha and TSH beta gene transcription.	Thyrotropin	43-46	thyroid stimulating hormone subunit beta	Rattus norvegicus	91-99
2542003-3	1989	TSH withdrawal from the culture medium led to a decline in TPO mRNA levels over 24 h. In contrast, no decline in beta-actin mRNA levels occurred after 24 h of incubation in TSH-free medium.	Thyrotropin	0-3	thyroid peroxidase	Rattus norvegicus	59-62
2542003-9	1989	This TSH effect may represent a primary site of TSH action in regulating TPO bioactivity.	Thyrotropin	5-8	thyroid peroxidase	Rattus norvegicus	73-76
2542003-9	1989	This TSH effect may represent a primary site of TSH action in regulating TPO bioactivity.	Thyrotropin	48-51	thyroid peroxidase	Rattus norvegicus	73-76
2540196-2	1989	In contrast to the c-fos gene, induction of the thyroglobulin gene by TSH or cAMP is slow (10 h) and sensitive to cycloheximide treatment.	Thyrotropin	70-73	thyroglobulin	Rattus norvegicus	48-61
2654128-3	1989	Data are presented supporting the hypothesis that TSH blunting may be secondary to central nervous system (CNS) hypersecretion of TRH, and that the enhanced TSH response may be secondary to subclinical hypothyroidism associated with autoimmune thyroiditis.	Thyrotropin	50-53	thyrotropin releasing hormone	Homo sapiens	130-133
2473935-5	1989	TSH induced a significant increase of [3H]thy incorporation and c-myc expression only in adenoma cultures and a significant increase of tgb RNA levels in both normal and adenomatous samples.	Thyrotropin	0-3	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	64-69
2473935-5	1989	TSH induced a significant increase of [3H]thy incorporation and c-myc expression only in adenoma cultures and a significant increase of tgb RNA levels in both normal and adenomatous samples.	Thyrotropin	0-3	pro-platelet basic protein	Homo sapiens	136-139
2473935-7	1989	The results show that E, like TSH, stimulates in vitro the expression of the tgb gene in differentiated cells, without stimulating the expression of the c-myc proto-oncogene, suggesting a possible action of E on normal thyroid function and perhaps growth, even if not associated with increased c-myc expression.	Thyrotropin	30-33	pro-platelet basic protein	Homo sapiens	77-80
2725843-6	1989	Through their lifetime, the hyt/hyt mice had reduced serum thyroxine (T4), triiodothyronine (T3), reduced thyroid gland intralumenal colloid on electron microscopy and a 100-fold elevation of TSH-like activity compared to hyt/+ littermates.	Thyrotropin	192-195	thyroid stimulating hormone receptor	Mus musculus	28-31
2725843-6	1989	Through their lifetime, the hyt/hyt mice had reduced serum thyroxine (T4), triiodothyronine (T3), reduced thyroid gland intralumenal colloid on electron microscopy and a 100-fold elevation of TSH-like activity compared to hyt/+ littermates.	Thyrotropin	192-195	thyroid stimulating hormone receptor	Mus musculus	32-35
2725843-6	1989	Through their lifetime, the hyt/hyt mice had reduced serum thyroxine (T4), triiodothyronine (T3), reduced thyroid gland intralumenal colloid on electron microscopy and a 100-fold elevation of TSH-like activity compared to hyt/+ littermates.	Thyrotropin	192-195	thyroid stimulating hormone receptor	Mus musculus	32-35
2705461-10	1989	When TRH (500 ng/kg body weight, IV) was given, the increment in serum TSH at 10 minutes was significantly lower in the PB group (PB, 53 +/- 26 microU/ml vs. control, 131 +/- 18 microU/ml, p less than .05).	Thyrotropin	71-74	thyrotropin releasing hormone	Rattus norvegicus	5-8
2661062-7	1989	Readdition of TSH (0.1-100 mU/ml) to cells lacking M/TPO-Ag elicited its reappearance within 48-72 h. This effect of TSH was prevented by 10 microM cycloheximide but not by methimazole (0.1-2 mM).	Thyrotropin	14-17	thyroid peroxidase	Homo sapiens	53-56
2661062-7	1989	Readdition of TSH (0.1-100 mU/ml) to cells lacking M/TPO-Ag elicited its reappearance within 48-72 h. This effect of TSH was prevented by 10 microM cycloheximide but not by methimazole (0.1-2 mM).	Thyrotropin	117-120	thyroid peroxidase	Homo sapiens	53-56
2564680-11	1989	The cyclooxygenase inhibitor indomethacin nearly completely blocked the stimulatory effect of cachectin on release of GH and TSH from dispersed pituitary cells but had only a slight and nonsignificant attenuating effect on its ACTH-releasing action.	Thyrotropin	125-128	tumor necrosis factor	Homo sapiens	94-103
2494827-7	1989	TSH secretion, assessed in only 4 patients, was stimulated after each TRH dose, though a minimal but significant reduction of nAUC of TSH after repeated TRH challenge occurred.	Thyrotropin	0-3	thyrotropin releasing hormone	Homo sapiens	70-73
2494827-7	1989	TSH secretion, assessed in only 4 patients, was stimulated after each TRH dose, though a minimal but significant reduction of nAUC of TSH after repeated TRH challenge occurred.	Thyrotropin	134-137	thyrotropin releasing hormone	Homo sapiens	153-156
2784248-0	1989	Effects of calcitonin, katacalcin, and calcitonin gene-related peptide on basal and TSH-stimulated thyroid hormone secretion in the mouse.	Thyrotropin	84-87	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	39-70
2541597-0	1989	Induction of peroxidase and thyroglobulin by TSH in cultured thyroid cells from patients with Basedow"s disease and its inhibition by actinomycin D.	Thyrotropin	45-48	thyroglobulin	Homo sapiens	28-41
2518225-4	1989	A few minutes (1.89 +/- 1.30 min) after the administration of TRH, the secretion of TSH (0.025 +/- 0.016 microU/min ml) was stimulated, and the total release over about 1 h was 12.5 +/- 5.6 microU/ml.	Thyrotropin	84-87	thyrotropin releasing hormone	Homo sapiens	62-65
2518225-7	1989	These data confirm that the stimulated secretion continues for more than 30 min, and that the pituitary releases 43.2 +/- 22.9 mU of TSH (assuming the distribution volume of TSH is 5.8% of body weight) in response to TRH, an amount which correlates closely (r = 0.91) with TSH before TRH administration.	Thyrotropin	133-136	thyrotropin releasing hormone	Homo sapiens	217-220
2518225-7	1989	These data confirm that the stimulated secretion continues for more than 30 min, and that the pituitary releases 43.2 +/- 22.9 mU of TSH (assuming the distribution volume of TSH is 5.8% of body weight) in response to TRH, an amount which correlates closely (r = 0.91) with TSH before TRH administration.	Thyrotropin	133-136	thyrotropin releasing hormone	Homo sapiens	284-287
2537339-7	1989	These data suggest that the stimulatory effect of TSH on thyroid cell proliferation could be mediated through IGF-I action and suggest that an increase in IGF-I production could sustain the goitrogenic process.	Thyrotropin	50-53	insulin like growth factor 1	Homo sapiens	110-115
2776353-5	1989	Hyperprolactinaemia (greater than 350 mIU/l) was present in hypothyroid cretins only (13 of 26; 50%) and serum PRL showed a curvilinear relation with serum TSH levels (r = 0.7, P less than 0.0001).	Thyrotropin	156-159	prolactin	Homo sapiens	111-114
2916386-6	1989	GRP seemed to exert additive effects on thyroid hormone secretion with vasoactive intestinal peptide and with TSH at a threshold dose level.	Thyrotropin	110-113	gastrin releasing peptide	Mus musculus	0-3
2492328-3	1989	Our studies demonstrate that TRH at very low concentrations (pM) enhances the in vitro plaque-forming cell response to BA-TNP and also induces splenocyte production of TSH.	Thyrotropin	168-171	thyrotropin releasing hormone	Oryctolagus cuniculus	29-32
2495823-3	1989	The optimum TSH concentration for Tg mRNA production was between 0.1-1.0 mU/ml.	Thyrotropin	12-15	thyroglobulin	Ovis aries	34-36
2510123-5	1989	After TRH administration 7 patients produced normal TSH response, none of them became hyperthyroid in the subsequent 2-4 years follow-up period.	Thyrotropin	52-55	thyrotropin releasing hormone	Homo sapiens	6-9
2562827-2	1989	Previous reports that GH and TSH secretion are decreased following injection of endotoxin or IL-1 led us to test the hypothesis that IL-1 acts by releasing increased amounts of somatostatin (SS), a hypothalamic factor inhibitory of both GH and TSH release.	Thyrotropin	244-247	somatostatin	Rattus norvegicus	177-189
2517858-15	1989	These data suggest that the release of TSH from APs in response to TRH is decreased by aging in female but not in male rats.	Thyrotropin	39-42	thyrotropin releasing hormone	Rattus norvegicus	67-70
2731222-2	1989	The size and location of cytoplasmic granules showing immunoreactivity for cathepsin B and T4 in the cells varied over 24 h, corresponding to a change in plasma TSH concentrations.	Thyrotropin	161-164	cathepsin B	Rattus norvegicus	75-86
2562827-2	1989	Previous reports that GH and TSH secretion are decreased following injection of endotoxin or IL-1 led us to test the hypothesis that IL-1 acts by releasing increased amounts of somatostatin (SS), a hypothalamic factor inhibitory of both GH and TSH release.	Thyrotropin	244-247	somatostatin	Rattus norvegicus	191-193
2630310-5	1989	Conversely, in the latter group, the thyroidal T4/T3 ratio in paranodular tissue, but not in the nodule, was found to be dependent on the serum T4/T3 ratio, suggesting that paranodular thyroid tissue more readily responds to 1-thyroxine-inhibited TSH secretion.	Thyrotropin	247-250	solute carrier family 25 member 5	Homo sapiens	47-52
2783307-6	1989	Furthermore, the T3 and T4 responses to TSH were greatly diminished in IL-1-treated mice.	Thyrotropin	40-43	interleukin 1 complex	Mus musculus	71-75
2630310-6	1989	The results demonstrate that 1. the serum thyroid hormone pattern under physiological conditions is dependent on the intrathyroidal T4/T3 ratio, and 2. minor alterations in the serum thyroid hormones may secondarily change the thyroidal T4/T3 ratio, presumably by their effect on TSH secretion.	Thyrotropin	280-283	solute carrier family 25 member 5	Homo sapiens	237-242
2663567-8	1989	Moreover, only a partial restoration of this expression was achieved after addition of TSH or forskolin to well spread-out cells that had proliferated in response to EGF or serum.	Thyrotropin	87-90	LOC521832	Bos taurus	166-169
2542521-5	1989	Unexpectedly, melatonin (at a concentration of 10(-7) M) added to the incubation medium with TSH (60 mU/ml), decreased the cAMP concentration in the thyroid compared with the group exposed to melatonin (10(-7) M) alone.	Thyrotropin	93-96	cathelicidin antimicrobial peptide	Rattus norvegicus	123-127
2811602-2	1989	On the other hand, the activity in those cultured with 5H + TSH (6H) was several times higher than that cultured with 5H after 96 h, although an initial decrease of TPO activity during the first 24 h of culture was observed in both conditions.	Thyrotropin	60-63	thyroid peroxidase	Homo sapiens	165-168
2811602-4	1989	The half-maximal dose of TSH for stimulation of TPO activity and iodide metabolism was 0.03-0.04 mU/ml and the effect was mediated by cAMP.	Thyrotropin	25-28	thyroid peroxidase	Homo sapiens	48-51
2811602-5	1989	These results indicate that in porcine thyroid follicles in primary suspension culture, TPO activity as well as the ability of iodide metabolism is induced by chronic TSH stimulation.	Thyrotropin	167-170	thyroid peroxidase	Homo sapiens	88-91
2811602-6	1989	In addition, epidermal growth factor (EGF, 10(-9)M) and phorbol 12-myristate 13-acetate (PMA, 10(-8) M) completely inhibited TSH stimulation on both activities and also basal (5H) activity of iodide metabolism.	Thyrotropin	125-128	epidermal growth factor	Homo sapiens	13-36
2501768-4	1989	Highly significant positive correlations between whole blood TRH-Gly-IR levels and the corresponding serum TSH values (p less than 0.01), whole blood TRH-IR versus serum TSH (p less than 0.01) and whole blood TRH-Gly-IR versus whole blood TRH-IR (p less than 0.01) are consistent with cosecretion of TRH and TRH precursor peptides into the circulation.	Thyrotropin	107-110	thyrotropin releasing hormone	Rattus norvegicus	61-64
2663567-9	1989	The results show that in calf thyroid cells, iodide transport and Tg gene expression are regulated by TSH through cyclic AMP; hydrocortisone potentiates this effect on Tg gene expression, while all growth promoting factors inhibit the expression of these differentiated functions.	Thyrotropin	102-105	thyroglobulin	Bos taurus	66-68
2663567-9	1989	The results show that in calf thyroid cells, iodide transport and Tg gene expression are regulated by TSH through cyclic AMP; hydrocortisone potentiates this effect on Tg gene expression, while all growth promoting factors inhibit the expression of these differentiated functions.	Thyrotropin	102-105	thyroglobulin	Bos taurus	168-170
3243203-4	1988	After insulin injection a significant decrease (P less than 0.05 to less than 0.001) of TSH level was found at 45 to 120 min irrespectively of the ambient temperature.	Thyrotropin	88-91	insulin	Homo sapiens	6-13
2570483-10	1989	The basal release of immunodetectable Tg, as measured in a perifusion system, increased in response to thyroid stimulating hormone (TSH) (P less than 0.025) or TSH combined with theophylline (P less than 0.001).	Thyrotropin	103-130	thyroglobulin	Homo sapiens	38-40
2570483-10	1989	The basal release of immunodetectable Tg, as measured in a perifusion system, increased in response to thyroid stimulating hormone (TSH) (P less than 0.025) or TSH combined with theophylline (P less than 0.001).	Thyrotropin	132-135	thyroglobulin	Homo sapiens	38-40
2570483-10	1989	The basal release of immunodetectable Tg, as measured in a perifusion system, increased in response to thyroid stimulating hormone (TSH) (P less than 0.025) or TSH combined with theophylline (P less than 0.001).	Thyrotropin	160-163	thyroglobulin	Homo sapiens	38-40
3262503-0	1988	Human recombinant interleukin-1 beta decreases plasma thyroid hormone and thyroid stimulating hormone levels in rats.	Thyrotropin	74-101	interleukin 1 beta	Homo sapiens	18-36
3146541-7	1988	Positive correlation (P less than 0.05, R = 0.59) was found between the TSH and GH responses, but not between these two parameters and the PRL response to TRH.	Thyrotropin	72-75	growth hormone 1	Homo sapiens	80-82
2903866-7	1988	After GHRH-Arg-TRH, the maximal serum GH level was significantly higher (72.7 +/- 13.4 micrograms/L) than that after Arg-TRH alone, whereas serum TSH and PRL increased to comparable levels (TSH, 10.2 +/- 3.0 mU/L; PRL, 64.4 +/- 13.6 micrograms/L).	Thyrotropin	190-193	growth hormone releasing hormone	Rattus norvegicus	6-10
3143866-4	1988	A thyrotropin releasing hormone (TRH) test may be needed to diagnose hyperthyroidism in a hospitalized patient with a basal sensitive TSH level of less than 0.1 microU/ml because a detectable TRH response contraindicates hyperthyroidism whereas hyperthyroid patients with nonthyroidal illness have the expected absent response.	Thyrotropin	134-137	thyrotropin releasing hormone	Homo sapiens	2-31
3150823-4	1988	The TSH response in the TRH test did not correlate with the direct measurements of prevailing thyroid hormone levels (Total T4 or Free T4).	Thyrotropin	4-7	thyrotropin releasing hormone	Homo sapiens	24-27
3199062-7	1988	Furthermore, stimulation of the thyroid by excess TSH induced by the administration of 1-methyl-2-mercaptoimidazole resulted in an increase of all forms of thyroid DNA polymerase-beta.	Thyrotropin	50-53	DNA polymerase beta	Rattus norvegicus	164-183
2464492-5	1988	The urinary TSH excretion correlated significantly with both urinary protein excretion and urinary beta 2-microglobulin excretion.	Thyrotropin	12-15	beta-2-microglobulin	Homo sapiens	99-119
3416995-0	1988	Release of 3,5,3"-triiodothyronine, thyroxine and thyroglobulin from TSH-stimulated mouse thyroids in the perifusion system.	Thyrotropin	69-72	thyroglobulin	Mus musculus	50-63
2458377-6	1988	These results suggest that TSI interact with the TSH receptor at the site that recognizes the portion of the TSH alpha-subunit represented by the synthetic peptide alpha 26-46 and, thus, support the concept that the TSH-binding site of the TSH receptor is the site of antigen binding between TSI and the thyroid cell.	Thyrotropin	49-52	thyroid stimulating hormone receptor	Homo sapiens	240-252
3251664-0	1988	TSH dependent elevation of serum thyroglobulin in reversible primary hypothyroidism.	Thyrotropin	0-3	thyroglobulin	Homo sapiens	33-46
3143225-0	1988	Relationship of age to TSH response to TRH in depressed men.	Thyrotropin	23-26	thyrotropin releasing hormone	Homo sapiens	39-42
3251664-3	1988	In all of these 12 patients, thyroid function recovered spontaneously with only iodide restriction and the serum Tg levels declined concomitantly with the decrease in serum TSH concentrations, events suggesting the TSH dependency of this Tg elevation.	Thyrotropin	173-176	thyroglobulin	Homo sapiens	238-240
3251666-5	1988	Concentrations of the liver-specific form of glutathione S-transferase (GST) in serum decreased (P less than 0.01) after the reduction in thyroxine dose; abnormally high GST levels, found in eight patients when TSH was suppressed, returned to normal in six of these patients when normal basal and TRH-stimulated TSH concentrations had been restored.	Thyrotropin	312-315	glutathione S-transferase kappa 1	Homo sapiens	72-75
3251664-3	1988	In all of these 12 patients, thyroid function recovered spontaneously with only iodide restriction and the serum Tg levels declined concomitantly with the decrease in serum TSH concentrations, events suggesting the TSH dependency of this Tg elevation.	Thyrotropin	215-218	thyroglobulin	Homo sapiens	113-115
3251664-3	1988	In all of these 12 patients, thyroid function recovered spontaneously with only iodide restriction and the serum Tg levels declined concomitantly with the decrease in serum TSH concentrations, events suggesting the TSH dependency of this Tg elevation.	Thyrotropin	215-218	thyroglobulin	Homo sapiens	238-240
3251666-5	1988	Concentrations of the liver-specific form of glutathione S-transferase (GST) in serum decreased (P less than 0.01) after the reduction in thyroxine dose; abnormally high GST levels, found in eight patients when TSH was suppressed, returned to normal in six of these patients when normal basal and TRH-stimulated TSH concentrations had been restored.	Thyrotropin	211-214	glutathione S-transferase kappa 1	Homo sapiens	45-70
3251666-5	1988	Concentrations of the liver-specific form of glutathione S-transferase (GST) in serum decreased (P less than 0.01) after the reduction in thyroxine dose; abnormally high GST levels, found in eight patients when TSH was suppressed, returned to normal in six of these patients when normal basal and TRH-stimulated TSH concentrations had been restored.	Thyrotropin	211-214	glutathione S-transferase kappa 1	Homo sapiens	72-75
3251666-5	1988	Concentrations of the liver-specific form of glutathione S-transferase (GST) in serum decreased (P less than 0.01) after the reduction in thyroxine dose; abnormally high GST levels, found in eight patients when TSH was suppressed, returned to normal in six of these patients when normal basal and TRH-stimulated TSH concentrations had been restored.	Thyrotropin	211-214	glutathione S-transferase kappa 1	Homo sapiens	170-173
3251666-5	1988	Concentrations of the liver-specific form of glutathione S-transferase (GST) in serum decreased (P less than 0.01) after the reduction in thyroxine dose; abnormally high GST levels, found in eight patients when TSH was suppressed, returned to normal in six of these patients when normal basal and TRH-stimulated TSH concentrations had been restored.	Thyrotropin	312-315	glutathione S-transferase kappa 1	Homo sapiens	45-70
3165340-6	1988	To further investigate the possible mechanisms of the effects of TGF beta on the cells, we measured the influence of the growth factor on [125I]TSH binding.	Thyrotropin	144-147	myotrophin	Rattus norvegicus	121-134
3402396-10	1988	Preparations of hCGv were also capable of inhibiting the adenylate cyclase response to TSH in human thyroid membranes, and Lineweaver-Burk analysis revealed this inhibition to be competitive in nature.	Thyrotropin	87-90	protein phosphatase 1 regulatory inhibitor subunit 11	Homo sapiens	16-20
3165340-7	1988	TGF beta did not compete for specific TSH-binding sites; however, exposure of the cells to TGF beta for 12 or more h resulted in a dose-dependent down-regulation of TSH receptors that was fully reversible.	Thyrotropin	38-41	transforming growth factor, beta 1	Rattus norvegicus	91-99
3165340-11	1988	These studies suggest that TGF beta may represent an autocrine mechanism of controlling the growth response to TSH in thyroid follicular cells, while allowing the continuance of differentiated function.	Thyrotropin	111-114	transforming growth factor, beta 1	Rattus norvegicus	27-35
3136807-0	1988	TSH response to TRH and haloperidol response latency in psychoses.	Thyrotropin	0-3	thyrotropin releasing hormone	Homo sapiens	16-19
2840263-4	1988	When porcine thyroid cells were cultured with TSH for 3 days in the presence of TGF-beta, TSH-induced iodide uptake and organification were reduced at rates that were dependent on the TGF-beta concentrations.	Thyrotropin	46-49	transforming growth factor beta 1	Homo sapiens	80-88
2456200-7	1988	Readdition of TSH (250 microU/ml) to the culture medium of cells lacking the M/TPO antigen elicited its reappearance within 24-48 h. This effect of TSH was prevented by 10 microM cycloheximide or 0.5-5 micrograms/ml actinomycin D.	Thyrotropin	14-17	thyroid peroxidase	Rattus norvegicus	79-82
2456200-7	1988	Readdition of TSH (250 microU/ml) to the culture medium of cells lacking the M/TPO antigen elicited its reappearance within 24-48 h. This effect of TSH was prevented by 10 microM cycloheximide or 0.5-5 micrograms/ml actinomycin D.	Thyrotropin	148-151	thyroid peroxidase	Rattus norvegicus	79-82
2456200-8	1988	Two well known stimulators of the adenylate cyclase-cAMP system, cholera toxin and forskolin, mimicked TSH in inducing the reappearance of the M/TPO antigen.	Thyrotropin	103-106	thyroid peroxidase	Rattus norvegicus	145-148
2840263-10	1988	These results strongly suggest that TGF-beta inhibits TSH-stimulated iodine metabolism, at least in part, by affecting events subsequent to cAMP production.	Thyrotropin	54-57	transforming growth factor beta 1	Homo sapiens	36-44
2840263-4	1988	When porcine thyroid cells were cultured with TSH for 3 days in the presence of TGF-beta, TSH-induced iodide uptake and organification were reduced at rates that were dependent on the TGF-beta concentrations.	Thyrotropin	46-49	transforming growth factor beta 1	Homo sapiens	184-192
2840263-4	1988	When porcine thyroid cells were cultured with TSH for 3 days in the presence of TGF-beta, TSH-induced iodide uptake and organification were reduced at rates that were dependent on the TGF-beta concentrations.	Thyrotropin	90-93	transforming growth factor beta 1	Homo sapiens	80-88
2840263-4	1988	When porcine thyroid cells were cultured with TSH for 3 days in the presence of TGF-beta, TSH-induced iodide uptake and organification were reduced at rates that were dependent on the TGF-beta concentrations.	Thyrotropin	90-93	transforming growth factor beta 1	Homo sapiens	184-192
2840263-6	1988	Only 6 h of exposure to TGF-beta resulted in a significant inhibition of TSH-induced iodine metabolism.	Thyrotropin	73-76	transforming growth factor beta 1	Homo sapiens	24-32
3134778-1	1988	In order to test the reactivity of TSH to TRH during amiodarone treatment we investigated 7 hypothyroid subjects treated with 50 micrograms T3/day.	Thyrotropin	35-38	thyrotropin releasing hormone	Homo sapiens	42-45
3138157-4	1988	Incubation in 10 or 100 ng/ml TRH for 2 or 3 hr significantly augmented release of TSH bioactivity in a dose-dependent manner.	Thyrotropin	83-86	thyrotropin releasing hormone	Anolis carolinensis	30-33
3197656-1	1988	It has been observed that basal and/or TRH-stimulated serum TSH levels occasionally conflict with the actual values of circulating thyroid hormones in patients with anorexia nervosa.	Thyrotropin	60-63	thyrotropin releasing hormone	Homo sapiens	39-42
2968566-6	1988	In a control series of 50 age- and sex- matched subjects without thyroid disorders or dysrhythmia, TSH level was low in only one case with insufficient response to TRH, but the scintigraphic image did not suggest nodular hyperthyroidism.	Thyrotropin	99-102	thyrotropin releasing hormone	Homo sapiens	164-167
3138170-0	1988	Assessment of the clinically significant TSH response to TRH in patients with nodular goitre.	Thyrotropin	41-44	thyrotropin releasing hormone	Homo sapiens	57-60
3138170-6	1988	A TSH response to TRH of 0.10 mU/l provided a better discrimination allowing a correct diagnosis in 92% of the patients.	Thyrotropin	2-5	thyrotropin releasing hormone	Homo sapiens	18-21
3138170-8	1988	However, patients with basal serum TSH levels below 0.10 mU/l need further investigation with a TRH-test.	Thyrotropin	35-38	thyrotropin releasing hormone	Homo sapiens	96-99
3138170-9	1988	A TSH response to TRH above 0.10 mU/l seems to secure euthyroidism, whereas lower responses almost always are associated with hyperthyroidism.	Thyrotropin	2-5	thyrotropin releasing hormone	Homo sapiens	18-21
2836470-9	1988	The mitogenic effect of TSH required a high insulin concentration (8.3 X 10(-7) mol/L) or a low insulin-like growth factor I concentration.	Thyrotropin	24-27	insulin like growth factor 1	Homo sapiens	96-124
3346361-2	1988	The high serum hCG levels in early pregnancy were accompanied by an increase in serum thyroid hormone and a decrease in serum TSH levels.	Thyrotropin	126-129	chorionic gonadotropin subunit beta 5	Homo sapiens	15-18
3346361-7	1988	In individual women serum hCG correlated negatively with TSH (r = 0.322; P = 0.005) and positively with free T3 (r = 0.388; P less than 0.001).	Thyrotropin	57-60	chorionic gonadotropin subunit beta 5	Homo sapiens	26-29
3346361-8	1988	These results suggest that hCG has thyrotropic activity, which, through rises in thyroid hormone levels, suppresses TSH secretion.	Thyrotropin	116-119	chorionic gonadotropin subunit beta 5	Homo sapiens	27-30
3127831-2	1988	Pretreatment with iopanoic acid blocked the ability of T4 but not of T3 to suppress TRH-induced TSH secretion 2 hr after administration of the respective thyroid hormone.	Thyrotropin	96-99	thyrotropin releasing hormone	Rattus norvegicus	84-87
2833549-1	1988	Thyrotrophin (TSH) and prostaglandin E2 (PGE2) increased cellular cyclic AMP (cAMP), calmodulin levels and cAMP phosphodiesterase activity in cultured porcine thyroid cells.	Thyrotropin	0-12	calmodulin 1	Homo sapiens	85-95
2833549-1	1988	Thyrotrophin (TSH) and prostaglandin E2 (PGE2) increased cellular cyclic AMP (cAMP), calmodulin levels and cAMP phosphodiesterase activity in cultured porcine thyroid cells.	Thyrotropin	14-17	calmodulin 1	Homo sapiens	85-95
3127831-5	1988	Our data support the concept that although equivalent physiologic doses of T4 or T3 inhibit basal or TRH-induced TSH secretion equally rapidly, TSH inhibition produced by T4 is probably dependent on its rapid conversion to T3, either within the pituitary or peripherally.	Thyrotropin	113-116	thyrotropin releasing hormone	Rattus norvegicus	101-104
3362301-3	1988	Naloxone administration produced a significant increase in the basal concentration of TSH response to TRH (5 micrograms i.v.)	Thyrotropin	86-89	thyrotropin releasing hormone	Rattus norvegicus	102-105
3276396-3	1988	Sensitivity of TG for the detection of metastases amounted to 83% under TSH stimulation and 50% under thyroxine (T4) treatment.	Thyrotropin	72-75	thyroglobulin	Homo sapiens	15-17
2836225-5	1988	These data imply that the reduction in the blood TRH level may contribute in part to the decrease in the blood TSH level after food deprivation, but the origin of the blood TRH has remained to be determined.	Thyrotropin	111-114	thyrotropin releasing hormone	Rattus norvegicus	49-52
3286744-8	1988	This exaggerated TSH-response to TRH was demonstrated to be entirely due to simultaneous administration of GRF, whereas CRF and LHRH in combination with TRH had no additional effect on TSH release.	Thyrotropin	17-20	growth hormone releasing hormone	Homo sapiens	107-110
3286231-12	1988	Recent studies using affinity labeling with 125I-labeled TSH have enabled elucidation of the structure of the TSH receptor.	Thyrotropin	57-60	thyroid stimulating hormone receptor	Homo sapiens	110-122
3286455-4	1988	The presence of insulin is also required to observe hydrocortisone and TSH stimulations.	Thyrotropin	71-74	LOC105613195	Ovis aries	16-23
3123200-1	1988	Small amounts of TRH are present in the thyroid, and TRH has been shown in several studies to have a moderate direct inhibitory effect on TSH-stimulated thyroid hormone secretion.	Thyrotropin	138-141	TRH	Canis lupus familiaris	17-20
3123200-1	1988	Small amounts of TRH are present in the thyroid, and TRH has been shown in several studies to have a moderate direct inhibitory effect on TSH-stimulated thyroid hormone secretion.	Thyrotropin	138-141	TRH	Canis lupus familiaris	53-56
3340004-2	1988	The administration of pharmacologic quantities of iodine (10 to 1,000 mg daily) to euthyroid subjects results in small decreases in the serum T4 and T3 concentrations and a compensatory increase in the basal and TRH-stimulated serum TSH concentrations.	Thyrotropin	233-236	thyrotropin releasing hormone	Homo sapiens	212-215
3368333-1	1988	Basal and TRH-stimulated TSH levels were determined in 72 patients with differentiated thyroid cancer on hormonal treatment, using a highly sensitive immunoradiometric assay (IRMAclon, Henning).	Thyrotropin	25-28	thyrotropin releasing hormone	Homo sapiens	10-13
3368333-6	1988	In 2 patients with elevated basal TSH levels (0.23 and 0.60 mU/l, resp.) in the IRMAclon, total suppression of TSH secretion was suggested by a failure of TSH to rise after TRH.	Thyrotropin	34-37	thyrotropin releasing hormone	Homo sapiens	173-176
3368333-8	1988	In conclusion, basal and TRH-stimulated TSH levels are well correlated in most patients with thyroid cancer under hormonal treatment.	Thyrotropin	40-43	thyrotropin releasing hormone	Homo sapiens	25-28
3340004-5	1988	Following the administration of 1500 micrograms iodine daily, there were small but significant decreases in the serum T4 and T3 concentrations and a small compensatory increase in the serum TSH concentration and the serum TSH response to TRH.	Thyrotropin	222-225	thyrotropin releasing hormone	Homo sapiens	238-241
3140559-4	1988	Thyroid hormones exert other effects on the pituitary such as increased synthesis of substance P, increased synthesis of GH, and decreased TRH receptors, TRH also modifies its own receptors in the pituitary and exerts modulatory effects on TSH molecule.	Thyrotropin	240-243	thyrotropin releasing hormone	Homo sapiens	154-157
3410280-0	1988	The effect of indomethacin, ibuprofen and paracetamol on the TRH induced TSH secretion in the rat.	Thyrotropin	73-76	thyrotropin releasing hormone	Rattus norvegicus	61-64
3129486-4	1988	TRH injection induced significant TSH elevations but no changes in serum vitamin D metabolites, calcium and phosphorus.	Thyrotropin	34-37	thyrotropin releasing hormone	Homo sapiens	0-3
3136487-0	1988	TSH responses to two TRH doses in men with Alzheimer"s disease.	Thyrotropin	0-3	thyrotropin releasing hormone	Homo sapiens	21-24
3124121-5	1988	In 1-day-old rats the only alteration present, in addition to elevated plasma TSH levels, was a clear-cut decrease in plasma GH levels.	Thyrotropin	78-81	gonadotropin releasing hormone receptor	Rattus norvegicus	125-127
2484719-1	1987	We have examined the effect of TSH on thyroid peroxidase (TPO) mRNA levels in dog thyroid cell primary cultures.	Thyrotropin	31-34	thyroid peroxidase	Canis lupus familiaris	38-56
3130594-0	1987	Non-linear correlation of basal serum TSH and TRH-stimulated TSH response: new aspects in pituitary-thyroid regulation.	Thyrotropin	38-41	thyrotropin releasing hormone	Homo sapiens	46-49
3130594-0	1987	Non-linear correlation of basal serum TSH and TRH-stimulated TSH response: new aspects in pituitary-thyroid regulation.	Thyrotropin	61-64	thyrotropin releasing hormone	Homo sapiens	46-49
3130594-1	1987	The relationship between basal and TRH-induced TSH in the 200 micrograms i.v.	Thyrotropin	47-50	thyrotropin releasing hormone	Homo sapiens	35-38
3130594-6	1987	The resulting correlation curve revealed three points of inflection, one located in the subnormal, one in the normal and one in the high-normal range of the basal as well as the TRH-induced TSH concentrations.	Thyrotropin	190-193	thyrotropin releasing hormone	Homo sapiens	178-181
2484719-1	1987	We have examined the effect of TSH on thyroid peroxidase (TPO) mRNA levels in dog thyroid cell primary cultures.	Thyrotropin	31-34	thyroid peroxidase	Canis lupus familiaris	58-61
3122525-4	1987	The TSH response to TRH stimulation in these 18 patients who committed suicide was lower than in the patients who did not commit suicide.	Thyrotropin	4-7	thyrotropin releasing hormone	Homo sapiens	20-23
3127251-2	1987	TSH secretion from the rat anterior pituitaries progressively increased in the presence of TRH in doses between 0.2-20 ng/ml.	Thyrotropin	0-3	thyrotropin releasing hormone	Rattus norvegicus	91-94
3127251-3	1987	In contrast, administration of TRH in a dose of 200 ng/ml decreased TSH secretion as compared to TRH in a dose of 20 ng/ml.	Thyrotropin	68-71	thyrotropin releasing hormone	Rattus norvegicus	31-34
3127251-6	1987	These data indicate that in vitro refractoriness of TSH response to TRH did not depend on the significant change in TRH disappearance rate.	Thyrotropin	52-55	thyrotropin releasing hormone	Rattus norvegicus	68-71
3312242-11	1987	It was stimulated threefold by TSH, increasing the Tg concentration in the apical compartment of the stimulated cell layer.	Thyrotropin	31-34	thyroglobulin	Homo sapiens	51-53
3113918-4	1987	1 X 10(-9) M 1,25-(OH)2D3 increased TRH (10(-9) M)-induced TSH release by 20% (P less than 0.05) but 10(-7) M and 10(-6) M 25-hydroxyvitamin D3 (25-OH D3) had no effect.	Thyrotropin	59-62	thyrotropin releasing hormone	Rattus norvegicus	36-39
3123103-10	1987	In addition, the secretory capacity of the pituitary to exogeneous TRH is significantly enhanced in those patients with low basal TSH.	Thyrotropin	130-133	thyrotropin releasing hormone	Homo sapiens	67-70
3113918-5	1987	The effect of 1,25-(OH)2D3 on TRH (10(-9) M)-induced TSH release was evident within 8 h and was maximal by 16 h. There was no effect on basal TSH release, TSH accumulation in the medium in the preceding 24 h nor on cell-associated TSH.	Thyrotropin	53-56	thyrotropin releasing hormone	Rattus norvegicus	30-33
3329719-4	1987	In contrast, in v-ras-transformed rat thyroid cells, which express very high levels of p21, treatment with either TSH, forskolin or TPA does not induce c-fos gene expression, while c-myc expression was constitutive.	Thyrotropin	114-117	KRAS proto-oncogene, GTPase	Rattus norvegicus	87-90
3114594-0	1987	Comparison of the effects of pulsatile and continuous TRH infusion on TSH release in men.	Thyrotropin	70-73	thyrotropin releasing hormone	Homo sapiens	54-57
3119746-0	1987	[Study on serum TSH and its response to TRH measured by a high sensitive immunoradiometric assay during and after pregnancy].	Thyrotropin	16-19	thyrotropin releasing hormone	Homo sapiens	40-43
3116883-10	1987	Older pituitaries (19- to 21-day) apparently can release an amount of TSH in the presence of TRH that is greater than their own spontaneous TSH secretion.	Thyrotropin	70-73	thyrotropin releasing hormone	Rattus norvegicus	93-96
3315639-4	1987	However, a positive correlation was observed between serum concentrations of Tg and thyroid stimulating hormone (TSH).	Thyrotropin	84-111	thyroglobulin	Homo sapiens	77-79
3315639-4	1987	However, a positive correlation was observed between serum concentrations of Tg and thyroid stimulating hormone (TSH).	Thyrotropin	113-116	thyroglobulin	Homo sapiens	77-79
3114044-6	1987	These data provide the first direct evidence for the stimulation of TSH secretion by TRH in a reptile and confirm earlier reports that TRH stimulates the release of PRL in the turtle.	Thyrotropin	68-71	thyrotropin releasing hormone	Homo sapiens	85-88
3118642-3	1987	When compared to controls, patients demonstrated a significantly lower free T3 value (but not free T4), a blunted TSH response to TRH, slightly elevated basal PRL and GH values and a small GH response to TRH.	Thyrotropin	114-117	thyrotropin releasing hormone	Homo sapiens	130-133
2443593-3	1987	An involvement of intracellular cAMP as a positive intermediate in cell division was further suggested by the finding that a low dose of forskolin (0.1 mumol/l) potentiated TSH stimulation of mitosis.	Thyrotropin	173-176	cathelicidin antimicrobial peptide	Rattus norvegicus	32-36
3107620-2	1987	Prior to antidepressant therapy, the sensitivity for nonsuppression to the DST was 36.0%, whereas that for blunted thyroid-stimulating hormone (TSH) response to TRH was 28.0%.	Thyrotropin	115-142	thyrotropin releasing hormone	Homo sapiens	161-164
2885177-2	1987	The effects of electrical stimulation of the hypothalamic periventricular nucleus (PE) on vasoactive intestinal polypeptide (VIP)-induced PRL and TRH-stimulated TSH secretion were studied using pentobarbital-anesthetized male rats bearing indwelling cannulae in the right atria.	Thyrotropin	161-164	vasoactive intestinal peptide	Rattus norvegicus	90-123
2885177-2	1987	The effects of electrical stimulation of the hypothalamic periventricular nucleus (PE) on vasoactive intestinal polypeptide (VIP)-induced PRL and TRH-stimulated TSH secretion were studied using pentobarbital-anesthetized male rats bearing indwelling cannulae in the right atria.	Thyrotropin	161-164	vasoactive intestinal peptide	Rattus norvegicus	125-128
3498156-5	1987	However, the radioiodine secretion stimulated by both TSH (120 microU/animal) and vasoactive intestinal peptide (VIP; 5 micrograms/animal) were inhibited by EGF (5 micrograms/animal).	Thyrotropin	54-57	epidermal growth factor	Mus musculus	157-160
3114358-0	1987	Low TSH-response to TRH in a former endemic goiter area.	Thyrotropin	4-7	thyrotropin releasing hormone	Homo sapiens	20-23
3114358-7	1987	The mean age was significantly higher (60.3 yr) as compared to that in the group which had a TSH-response to TRH of greater than 20 mU/l, smaller glands and less thyroid nodules (45.1 yr).	Thyrotropin	93-96	thyrotropin releasing hormone	Homo sapiens	109-112
3114404-1	1987	The effects of a physiological replacement dose of thyroxine (T4) on the response of plasma TSH to TRH in hypothyroid rats were studied.	Thyrotropin	92-95	thyrotropin releasing hormone	Rattus norvegicus	99-102
3114404-7	1987	The plasma concentration of TSH 10 min after injection of TRH increased to 167 +/- 14% of the mean basal value (P less than 0.001).	Thyrotropin	28-31	thyrotropin releasing hormone	Rattus norvegicus	58-61
3114404-8	1987	The injection of T4 significantly (P less than 0.005) reduced the TSH response to TRH in both IOP-treated (118 +/- 15%) and vehicle-treated (108 +/- 15%) rats compared with untreated controls.	Thyrotropin	66-69	thyrotropin releasing hormone	Rattus norvegicus	82-85
3107620-2	1987	Prior to antidepressant therapy, the sensitivity for nonsuppression to the DST was 36.0%, whereas that for blunted thyroid-stimulating hormone (TSH) response to TRH was 28.0%.	Thyrotropin	144-147	thyrotropin releasing hormone	Homo sapiens	161-164
2952962-0	1987	[Ultrasensitive assay of TSH response to TRH in thyroid pathology].	Thyrotropin	25-28	thyrotropin releasing hormone	Homo sapiens	41-44
3104329-3	1987	We have used serial lectin affinity analysis to explore whether TRH, in addition to promoting TSH secretion, alters the carbohydrate structure of secreted TSH.	Thyrotropin	94-97	thyrotropin releasing hormone	Mus musculus	64-67
3104329-3	1987	We have used serial lectin affinity analysis to explore whether TRH, in addition to promoting TSH secretion, alters the carbohydrate structure of secreted TSH.	Thyrotropin	155-158	thyrotropin releasing hormone	Mus musculus	64-67
3104329-8	1987	TRH caused a 2-fold increase in secretion of [3H]mannose-labeled TSH glycopeptides due almost exclusively to a specific increase in structures that bound to ConA-Sepharose and eluted with 10mM alpha-methylglucoside, corresponding to biantennary complex or unusual hybrid species.	Thyrotropin	65-68	thyrotropin releasing hormone	Mus musculus	0-3
3104329-11	1987	Moreover, ConA-Sepharose chromatography of secreted [3H]glucosamine- and [3H]fucose-labeled TSH glycopeptides showed similar increases in ConA-Sepharose binding with TRH as noted with [3H]mannose labeling.	Thyrotropin	92-95	thyrotropin releasing hormone	Mus musculus	166-169
3104329-14	1987	In addition, TRH in vitro promotes the secretion of specific TSH molecules apparently enriched in biantennary complex or unusual hybrid oligosaccharides.	Thyrotropin	61-64	thyrotropin releasing hormone	Mus musculus	13-16
3107297-6	1987	Regression analysis showed that FT4, T4/TBG ratio, T4, and FT3 had a significant inverse correlation with TSH in hypothyroid patients.	Thyrotropin	106-109	serpin family A member 7	Homo sapiens	40-43
3105334-0	1987	TRH-induced TSH response in healthy volunteers: relationship to psychiatric history.	Thyrotropin	12-15	thyrotropin releasing hormone	Homo sapiens	0-3
3100285-1	1987	Ca2+-dependent and TSH-, norepinephrine (NE)-, and A23187-induced iodide (I-) efflux from FRTL-5 rat thyroid cells is inhibited by quinacrine and trifluoroperazine, agents that inhibit phospholipase A2 activity.	Thyrotropin	19-22	phospholipase A2 group IB	Rattus norvegicus	185-201
3106028-8	1987	After incubation of pituitary cells with 0.1-10 microM Pb2+ for 2 hr, followed by the addition of TRH, there was a dose-dependent inhibition of TSH release.	Thyrotropin	144-147	thyrotropin releasing hormone	Homo sapiens	98-101
3100285-6	1987	The data thus suggest that TSH- and NE-induced I- efflux from FRTL-5 thyroid cells involves lipoxygenase and/or epoxygenase metabolites of arachidonic acid, released from phospholipids upon Ca2+-dependent activation of phospholipase A2.	Thyrotropin	27-30	phospholipase A2 group IB	Rattus norvegicus	219-235
3108918-5	1987	At the end of the therapeutic course, TSH responses increased in both groups of depressed patients, and the elevation was more relevant in depressed patients with normal TSH/TRH.	Thyrotropin	38-41	thyrotropin releasing hormone	Homo sapiens	174-177
3102657-3	1987	Serum TSH responses to TRH are altered by even smaller decreases and increases in serum thyroid hormone concentrations.	Thyrotropin	6-9	thyrotropin releasing hormone	Homo sapiens	23-26
3102657-4	1987	This sensitivity explains the value of measurements of basal serum TSH concentrations and serum TSH responses to TRH in the diagnosis of hypothyroidism and hyperthyroidism, respectively.	Thyrotropin	96-99	thyrotropin releasing hormone	Homo sapiens	113-116
3589002-6	1987	NPY (250-750 pmol) reduced the serum levels of thyreotropine (TSH), prolactin (PRL) and growth hormone (GH) but increased CORTICO, adrenocorticotropin (ACTH) and ALDO serum levels.	Thyrotropin	62-65	neuropeptide Y	Rattus norvegicus	0-3
3589002-7	1987	In conclusion, it is suggested that the NPY induced changes in DA utilization in the tuberoinfundibular DA neurons may contribute to the NPY induced changes in PRL and TSH secretion.	Thyrotropin	168-171	neuropeptide Y	Rattus norvegicus	40-43
3589002-7	1987	In conclusion, it is suggested that the NPY induced changes in DA utilization in the tuberoinfundibular DA neurons may contribute to the NPY induced changes in PRL and TSH secretion.	Thyrotropin	168-171	neuropeptide Y	Rattus norvegicus	137-140
3038506-0	1987	The inhibitory effects of calmodulin antagonists on TSH-stimulated thyroid hormone release by mouse thyroid lobes.	Thyrotropin	52-55	calmodulin 2	Mus musculus	26-36
3103364-3	1987	A similar order of potency in increasing plasma TSH (Analogue I greater than TRH greater than Analogue II) was found in vivo, as shown by dose-response curves.	Thyrotropin	48-51	thyrotropin releasing hormone	Rattus norvegicus	77-80
3103364-4	1987	After a 4-day pre-treatment with TRH (2 X 100 micrograms/day) a similar TSH response to TRH and Analogue I (500 nmol/kg body weight) was observed.	Thyrotropin	72-75	thyrotropin releasing hormone	Rattus norvegicus	33-36
3105251-0	1987	Unaltered 24 h serum PRL levels and PRL response to TRH in contrast to decreased 24 h serum TSH levels and TSH response to TRH in major depressive disorder.	Thyrotropin	107-110	thyrotropin releasing hormone	Homo sapiens	123-126
3038506-3	1987	So we examined the effects of several types of calmodulin antagonists on TSH-stimulated thyroid hormone release in vitro.	Thyrotropin	73-76	calmodulin 2	Mus musculus	47-57
3039776-2	1987	EGF inhibited TSH-induced cAMP-formation maximally by 40%, this effect remained up to 1 h of pre-incubation.	Thyrotropin	14-17	epidermal growth factor	Homo sapiens	0-3
2878935-0	1987	Evidence for thyrotropin (TSH)-blocking activity in goitrous Hashimoto"s thyroiditis with assays measuring inhibition of TSH receptor binding and TSH-stimulated thyroid adenosine 3",5"-monophosphate responses/cell growth by immunoglobulins.	Thyrotropin	26-29	thyroid stimulating hormone receptor	Homo sapiens	121-133
3475905-7	1987	In contrast, TSH-conditioned medium inhibited IGF I production in fibroblasts.	Thyrotropin	13-16	insulin like growth factor 1	Homo sapiens	46-51
3475922-7	1987	The identity between TPO and M is further supported by four-layer immunofluorescence analysis showing a complete overlap of the two antigens both in the surface and in the cytoplasm of thyroid cells and by the observation that the expression of M and TPO is similarly modulated by TSH, possibly through a cAMP-dependent mechanism.	Thyrotropin	281-284	thyroid peroxidase	Homo sapiens	21-24
3101338-0	1987	The pituitary TSH response to TRH is inversely related to the plasma TSH concentration and directly related to the pituitary TSH content during hypothyroidism in the rat.	Thyrotropin	14-17	thyrotropin releasing hormone	Rattus norvegicus	30-33
3497508-5	1987	EGF-binding and sensitization to the mitotic activity of EGF, however, is increased by TSH.	Thyrotropin	87-90	epidermal growth factor	Homo sapiens	0-3
3101338-0	1987	The pituitary TSH response to TRH is inversely related to the plasma TSH concentration and directly related to the pituitary TSH content during hypothyroidism in the rat.	Thyrotropin	69-72	thyrotropin releasing hormone	Rattus norvegicus	30-33
3497508-5	1987	EGF-binding and sensitization to the mitotic activity of EGF, however, is increased by TSH.	Thyrotropin	87-90	epidermal growth factor	Homo sapiens	57-60
3101338-4	1987	After 7 or 14 days of severe hypothyroidism (nonreplaced THYREX rats) the pituitary TSH secretory response to TRH (250 ng/100 g body weight, iv) was found to be decreased when compared to that of euthyroid rats.	Thyrotropin	84-87	thyrotropin releasing hormone	Rattus norvegicus	110-113
3101341-0	1987	The effect of 1,25-dihydroxy-cholecalciferol on the TRH induced TSH release in rats.	Thyrotropin	64-67	thyrotropin releasing hormone	Rattus norvegicus	52-55
3101341-1	1987	The effect of 1,25-dihydroxy-vitamin D3 (1,25-(OH)2-D3) on the TRH induced TSH release was investigated.	Thyrotropin	75-78	thyrotropin releasing hormone	Rattus norvegicus	63-66
2829507-9	1987	e) Central NPY administration leads to alterations in serum levels of corticosterone, aldosterone, angiotensin II, vasopressin, PRL, LH, GH and TSH which are parallel to changes in discrete hypothalamic catecholamine neuronal systems.	Thyrotropin	144-147	neuropeptide Y	Homo sapiens	11-14
3128159-1	1987	The binding capacity of serum TeBG (testosterone-estradiol binding globulin), the plasma concentrations of thyroid hormones and the TSH response to TRF (200 micrograms i.v.)	Thyrotropin	132-135	telomeric repeat binding factor 1	Homo sapiens	148-151
3128159-5	1987	In patients with a cold nodule, the administration of dl-Thyroxine (200-300 micrograms/daily) suppressed the response of TSH to TRF and increased slightly TeBG from 0.97 +/- 0.08 to 1.29 +/- 0.10 micrograms/dl (p less than 0.05) with a value higher than 1.77 micrograms/dl in 5.	Thyrotropin	121-124	telomeric repeat binding factor 1	Homo sapiens	128-131
3111805-0	1987	Theophylline treatment in the neonate with apnea: effect on growth hormone, thyroid hormone and TRH induced TSH secretion.	Thyrotropin	108-111	thyrotropin releasing hormone	Homo sapiens	96-99
2842125-2	1987	Effect of long-term administration of corticoliberin on serum levels of ACTH, TSH and thyroxine in male rats].	Thyrotropin	78-81	corticotropin releasing hormone	Rattus norvegicus	38-52
2832304-0	1987	Control of thyroglobulin gene transcription by TSH and cAMP.	Thyrotropin	47-50	thyroglobulin	Homo sapiens	11-24
3582274-3	1987	Newly synthesized rat TPO was observed in the presence of TSH (10 mU/ml), an effect which was completely blocked by co-incubation with cycloheximide.	Thyrotropin	58-61	thyroid peroxidase	Rattus norvegicus	22-25
3582274-4	1987	TPO biosynthesis was detected within 6 h of incubation, consistent within a rapid effect of TSH on thyroidal protein biosynthesis.	Thyrotropin	92-95	thyroid peroxidase	Rattus norvegicus	0-3
3596465-2	1987	In hyperthyroidism, including 3,3",5-triiodothyronine (T3) toxicosis, thyrotrophin (TSH) response to thyrotrophin-releasing hormone (TRH) is blunted.	Thyrotropin	70-82	thyrotropin releasing hormone	Homo sapiens	101-131
3596465-2	1987	In hyperthyroidism, including 3,3",5-triiodothyronine (T3) toxicosis, thyrotrophin (TSH) response to thyrotrophin-releasing hormone (TRH) is blunted.	Thyrotropin	70-82	thyrotropin releasing hormone	Homo sapiens	133-136
3596465-2	1987	In hyperthyroidism, including 3,3",5-triiodothyronine (T3) toxicosis, thyrotrophin (TSH) response to thyrotrophin-releasing hormone (TRH) is blunted.	Thyrotropin	84-87	thyrotropin releasing hormone	Homo sapiens	101-131
3596465-2	1987	In hyperthyroidism, including 3,3",5-triiodothyronine (T3) toxicosis, thyrotrophin (TSH) response to thyrotrophin-releasing hormone (TRH) is blunted.	Thyrotropin	84-87	thyrotropin releasing hormone	Homo sapiens	133-136
3596465-6	1987	Reverse T3 increases and serum T3 decreases when the patients become more ill. Serum TSH response to TRH is often blunted.	Thyrotropin	85-88	thyrotropin releasing hormone	Homo sapiens	101-104
2435587-0	1987	Intralysosomal hydrolysis of thyroglobulin: specific and cAMP-mediated activation by TSH.	Thyrotropin	85-88	thyroglobulin	Sus scrofa	29-42
3108134-0	1987	TSH and PRL responses to domperidone and TRH in men with insulin-dependent diabetes mellitus of different duration.	Thyrotropin	0-3	thyrotropin releasing hormone	Homo sapiens	41-44
3027108-9	1987	Insulin stimulated the progression in the prereplicative phase initiated by TSH or forskolin.	Thyrotropin	76-79	insulin	Canis lupus familiaris	0-7
2435587-3	1987	TSH stimulated the intralysosomal Tg hydrolysis.	Thyrotropin	0-3	thyroglobulin	Sus scrofa	34-36
2893409-8	1987	Some abnormal responses of GH to TRH and of TSH to GHRH were observed in chronically stressed rats.	Thyrotropin	44-47	growth hormone releasing hormone	Rattus norvegicus	51-55
3817231-3	1986	Mouse monoclonal antibodies to TSH receptor were derived from spleen cells of mice immunized with partially purified human TSH receptor, which was prepared by TSH-coupled affinity chromatography of thyroid membrane solubilized with Triton X-100.	Thyrotropin	31-34	thyroid stimulating hormone receptor	Homo sapiens	123-135
3108919-5	1987	The maximum increase in TSH concentrations following TRH administration in the group I patients with vomiting (4.0 +/- 0.90 microU/ml, mean +/- S.E.)	Thyrotropin	24-27	thyrotropin releasing hormone	Homo sapiens	53-56
3114838-4	1987	After intravenous TRH administration in 2-week old lambs, the maximal increase in plasma TSH levels occurred after the injection of 0.25 microgram/kg.	Thyrotropin	89-92	LOW QUALITY PROTEIN: thyrotropin-releasing hormone	Ovis aries	18-21
3817230-0	1986	[Regulation of epidermal growth factor receptors by TSH, and effects of EGF, TSH and phorbol ester on DNA synthesis in cultured porcine thyroid cells].	Thyrotropin	52-55	epidermal growth factor	Homo sapiens	15-38
2884095-5	1986	7-oxa-13-prostynoic acid (PY1), a prostaglandin antagonist, which can act as an agonist in some systems, itself exhibited agonistic properties of PGEs with respect to basal and TRH induced TSH release.	Thyrotropin	189-192	prostaglandin E synthase	Rattus norvegicus	146-150
3817230-4	1986	When thyroid cells were cultured in the presence of various concentrations of TSH (0 approximately 50 mU/ml) and for various times (0 approximately 96 h) with TSH (10 mU/ml), specific EGF binding to the cells increased dose- and time-dependently.	Thyrotropin	78-81	epidermal growth factor	Homo sapiens	184-187
3817230-5	1986	On TSH (10 mU/ml)-treated cells for 4 days, two kinds of EGF receptors, i.e. high affinity and low capacity (K1 = 5.39 +/- 1.75 X 10(-9) M and 17,200 +/- 2,500 sites/cell) and low affinity and high capacity (K2 = 1.70 +/- 1.40 X 10(-7)M and 76,300 +/- 17,900 sites/cells), were resolved.	Thyrotropin	3-6	epidermal growth factor	Homo sapiens	57-60
3817230-9	1986	Maximal responses were obtained with EGF ranging from 10(-9) to 10(-7)M and with PMA from 10(-9) to 10(-7)M. In contrast, TSH inhibits [Me-3H] thymidine incorporation dose-dependently.	Thyrotropin	122-125	epidermal growth factor	Homo sapiens	37-40
2884095-2	1986	PGEs and Fs induced significant increases in basal TSH release of the order of 30% at 10(-9) or 10(-8) to 10(-5) or 10(-4) M. Only PGEs accentuated the TSH release induced by a half maximal dose of TRH (10(-9) M) of the order of 60% in a dose dependent manner (10(-9) to 10(-6) M of PGEs), whereas PGFs did not.	Thyrotropin	51-54	prostaglandin E synthase	Rattus norvegicus	0-4
3023014-1	1986	The perifusion technique was used to investigate the action of diazepam (DZ), a benzodiazepine molecule known to compete for TRH receptor binding in rat pituitary, on TRH-induced TSH and GH release.	Thyrotropin	179-182	thyrotropin releasing hormone	Rattus norvegicus	167-170
3492364-8	1986	The plasma TSH response to TRH was also enhanced by PG A1 and A2.	Thyrotropin	11-14	thyrotropin releasing hormone	Rattus norvegicus	27-30
3023014-3	1986	The dynamic patterns of TSH and GH release in response to TRH were characterized by a rapid increase in hormone release, declining slowly over the next 20 min.	Thyrotropin	24-27	thyrotropin releasing hormone	Rattus norvegicus	58-61
3023014-5	1986	Addition of increasing doses of DZ suppressed the stimulatory effect of TRH in a dose-related manner, with an ID50 of 3 nM for both TSH and GH.	Thyrotropin	132-135	thyrotropin releasing hormone	Rattus norvegicus	72-75
3097618-7	1986	The five individuals who were given thyrotropin-releasing hormone showed exaggerated TSH responses, which normalized on L-thyroxine therapy.	Thyrotropin	85-88	thyrotropin releasing hormone	Homo sapiens	36-65
3021438-1	1986	The effect of calmodulin inhibitors, N-(6-aminohexyl)-5-chloro-1-naphthalene sulfonamide (W-7) and trifluoperazine, on TSH-induced thyroid hormone secretion from rat thyroid was examined in vivo and in vitro.	Thyrotropin	119-122	calmodulin 1	Rattus norvegicus	14-24
3097230-5	1986	These results suggest that TRH exerts a direct effect on the pretranslational events involved in TSH synthesis and further that the adenylate cyclase system may be involved in the regulation of synthesis.	Thyrotropin	97-100	thyrotropin releasing hormone	Rattus norvegicus	27-30
3096145-3	1986	In hypophysectomized rats, TRH infusion led to the appearance of substantial amounts of biologically active serum TSH and prevented the hypothyroidism that occurred in the control group.	Thyrotropin	114-117	thyrotropin releasing hormone	Rattus norvegicus	27-30
3096145-6	1986	TRH infusion depleted only 63% of the TSH content of sellar thyrotrophs.	Thyrotropin	38-41	thyrotropin releasing hormone	Rattus norvegicus	0-3
3099318-4	1986	Second, approximately 30% of euthyroid patients with major depression show a blunted, i.e., attenuated TSH response after TRH administration.	Thyrotropin	103-106	thyrotropin releasing hormone	Homo sapiens	122-125
3096035-3	1986	In contrast, the TRH-elicited TSH responses did not differ significantly after the two pre-treatments.	Thyrotropin	30-33	thyrotropin releasing hormone	Homo sapiens	17-20
3830075-3	1986	In group I, TSH level rose from 1.96 +/- 0.42 mu u/ml (mean +/- SEM) to 2.52 +/- 0.30 mu u/ml (p less than 0.01), and PRL levels rose from 11.0 +/- 2.0 ng/ml to 19.0 +/- 5.2 ng/ml (p less than 0.01).	Thyrotropin	12-15	prolactin	Homo sapiens	118-121
3091628-10	1986	These results provide direct evidence in man that chronic TRH administration can cause modest sustained increases in serum TSH and thyroid hormones, though the metabolic consequences of these changes are uncertain, and appears to raise the set-point of the pituitary-thyroid axis, i.e. the serum T4 and T3 concentrations needed for a given degree of suppression of basal TSH secretion.	Thyrotropin	123-126	thyrotropin releasing hormone	Homo sapiens	58-61
3095783-4	1986	Administration of 400 micrograms of TRH resulted in significant elevations of maternal TSH (15.7 +/- 2.9 versus 3.2 +/- 0.4 microU/ml, p less than 0.01) and prolactin (416 +/- 94 versus 223 +/- 41 ng/ml, p less than 0.05) 2 h later.	Thyrotropin	87-90	thyrotropin releasing hormone	Homo sapiens	36-39
2426082-10	1986	TSH secreted in the presence of TRH had a lower sulfate to mannose ratio [28 +/- (+/- SE) 4% of control; P less than 0.05] and a lower sialic acid to mannose ratio (63 +/- 8% of control; P less than 0.05).	Thyrotropin	0-3	thyrotropin releasing hormone	Mus musculus	32-35
2427524-3	1986	Hypothalamic hormones such as thyrotropin-releasing hormone (TRH) and dopamine have profound effects on TSH secretion and may also modulate TSH synthesis.	Thyrotropin	104-107	thyrotropin releasing hormone	Rattus norvegicus	30-59
2427524-3	1986	Hypothalamic hormones such as thyrotropin-releasing hormone (TRH) and dopamine have profound effects on TSH secretion and may also modulate TSH synthesis.	Thyrotropin	104-107	thyrotropin releasing hormone	Rattus norvegicus	61-64
2427524-3	1986	Hypothalamic hormones such as thyrotropin-releasing hormone (TRH) and dopamine have profound effects on TSH secretion and may also modulate TSH synthesis.	Thyrotropin	140-143	thyrotropin releasing hormone	Rattus norvegicus	30-59
2427524-3	1986	Hypothalamic hormones such as thyrotropin-releasing hormone (TRH) and dopamine have profound effects on TSH secretion and may also modulate TSH synthesis.	Thyrotropin	140-143	thyrotropin releasing hormone	Rattus norvegicus	61-64
3791670-8	1986	The expected inverse relation between TSH concentration and the thyroid hormones was seen, the three closest correlations being between the logarithm of the TSH concentration and FT3, the ratio T4/TBG and FT4 (r = 0.927, -0.917 and -0.900 respectively).	Thyrotropin	38-41	serpin family A member 7	Homo sapiens	197-200
3758168-5	1986	Noradrenaline inhibited the TSH-induced thyroid hormone secretion to 168 +/- 6% (P less than 0.01), and NPY potentiated this inhibitory action of noradrenaline (P less than 0.01): the TSH-induced thyroid hormone secretion was only 19 +/- 6% after administration of both noradrenaline and NPY.	Thyrotropin	28-31	neuropeptide Y	Mus musculus	288-291
3758168-5	1986	Noradrenaline inhibited the TSH-induced thyroid hormone secretion to 168 +/- 6% (P less than 0.01), and NPY potentiated this inhibitory action of noradrenaline (P less than 0.01): the TSH-induced thyroid hormone secretion was only 19 +/- 6% after administration of both noradrenaline and NPY.	Thyrotropin	184-187	neuropeptide Y	Mus musculus	104-107
3758168-6	1986	Furthermore, alpha-adrenoceptor blockade by phentolamine abolished the effect of noradrenaline on TSH-induced thyroid hormone secretion and, during alpha-adrenoceptor blockade, NPY potentiated the secretory response to TSH.	Thyrotropin	219-222	neuropeptide Y	Mus musculus	177-180
3087736-1	1986	To investigate whether TRH regulates TSH production through a pre- or posttranslational mechanism, we determined the pituitary levels of mRNAs for alpha-subunit and TSH beta in male Sprague-Dawley rats given TRH in the presence or absence of thyroid hormones, with or without hypothalamic influence.	Thyrotropin	37-40	thyrotropin releasing hormone	Rattus norvegicus	23-26
3087736-3	1986	Infusion of TRH, achieved by osmotic minipumps that were implanted sc, increased serum TSH for 3 days.	Thyrotropin	87-90	thyrotropin releasing hormone	Rattus norvegicus	12-15
3087736-9	1986	These pituitaries responded to TRH infusion by releasing TSH.	Thyrotropin	57-60	thyrotropin releasing hormone	Rattus norvegicus	31-34
3087736-14	1986	Although a translational regulation cannot be completely excluded, the present data, in conjunction with previous findings, support the hypothesis that TRH regulates TSH production primarily by stimulating both posttranslational carbohydrate processing and secretion of this hormone.	Thyrotropin	166-169	thyrotropin releasing hormone	Rattus norvegicus	152-155
3084213-1	1986	The regulation of TSH biological activity by thyroid hormone and TRH was studied by comparison of pituitary and in vitro secreted TSH from normal and thyroidectomized rats that were alternatively treated with TRH either in vivo or in vitro.	Thyrotropin	18-21	thyrotropin releasing hormone	Rattus norvegicus	65-68
2426166-8	1986	Treatment with TRH caused small increases in serum TSH and in both alpha and TSH-beta mRNA levels.	Thyrotropin	51-54	thyrotropin releasing hormone	Mus musculus	15-18
2428859-4	1986	The present study indicates that cytoplasmic calcium ion derived from the extracellular and intracellular sources plays a pivotal role in the controlling of TRH-stimulated TSH secretion in human subjects.	Thyrotropin	172-175	thyrotropin releasing hormone	Homo sapiens	157-160
3084213-5	1986	TRH, both in vivo and in vitro, when compared to the corresponding untreated groups, produced a significant increase in bioactive TSH in media from both normal (TRH in vivo, 131%; TRH in vitro, 139%) and thyroidectomized samples after TRH in vivo (158%).	Thyrotropin	130-133	thyrotropin releasing hormone	Rattus norvegicus	0-3
3084213-5	1986	TRH, both in vivo and in vitro, when compared to the corresponding untreated groups, produced a significant increase in bioactive TSH in media from both normal (TRH in vivo, 131%; TRH in vitro, 139%) and thyroidectomized samples after TRH in vivo (158%).	Thyrotropin	130-133	thyrotropin releasing hormone	Rattus norvegicus	161-164
3084213-5	1986	TRH, both in vivo and in vitro, when compared to the corresponding untreated groups, produced a significant increase in bioactive TSH in media from both normal (TRH in vivo, 131%; TRH in vitro, 139%) and thyroidectomized samples after TRH in vivo (158%).	Thyrotropin	130-133	thyrotropin releasing hormone	Rattus norvegicus	161-164
3084213-5	1986	TRH, both in vivo and in vitro, when compared to the corresponding untreated groups, produced a significant increase in bioactive TSH in media from both normal (TRH in vivo, 131%; TRH in vitro, 139%) and thyroidectomized samples after TRH in vivo (158%).	Thyrotropin	130-133	thyrotropin releasing hormone	Rattus norvegicus	161-164
3084213-6	1986	The TRH effect in the pituitary showed a significant increase in TSH bioactivity from normal samples treated with TRH in vivo (137%), whereas in thyroidectomized pituitary samples with TRH in vitro, TSH bioactivity was decreased (69%).	Thyrotropin	65-68	thyrotropin releasing hormone	Rattus norvegicus	4-7
3084213-6	1986	The TRH effect in the pituitary showed a significant increase in TSH bioactivity from normal samples treated with TRH in vivo (137%), whereas in thyroidectomized pituitary samples with TRH in vitro, TSH bioactivity was decreased (69%).	Thyrotropin	65-68	thyrotropin releasing hormone	Rattus norvegicus	114-117
3084213-6	1986	The TRH effect in the pituitary showed a significant increase in TSH bioactivity from normal samples treated with TRH in vivo (137%), whereas in thyroidectomized pituitary samples with TRH in vitro, TSH bioactivity was decreased (69%).	Thyrotropin	65-68	thyrotropin releasing hormone	Rattus norvegicus	114-117
3084213-6	1986	The TRH effect in the pituitary showed a significant increase in TSH bioactivity from normal samples treated with TRH in vivo (137%), whereas in thyroidectomized pituitary samples with TRH in vitro, TSH bioactivity was decreased (69%).	Thyrotropin	199-202	thyrotropin releasing hormone	Rattus norvegicus	4-7
3084213-7	1986	These results indicate that thyroid hormone deficiency and TRH differentially regulate TSH bioactivity.	Thyrotropin	87-90	thyrotropin releasing hormone	Rattus norvegicus	59-62
3707578-0	1986	TSH-stimulated increases in calcium uptake and calmodulin levels in thyroid cells.	Thyrotropin	0-3	calmodulin 1	Homo sapiens	47-57
3086478-1	1986	We have investigated the effect of TRH on the accumulation of glycosylated TSH in the rat anterior pituitary gland.	Thyrotropin	75-78	thyrotropin releasing hormone	Rattus norvegicus	35-38
3086478-5	1986	Although the release of [3H]glucosamine-labelled and unlabelled TSH into media was stimulated by the addition of TRH in a time- and dose-dependent manner, TRH administration did not alter the amounts of labelled or unlabelled TSH in the anterior pituitary lobes.	Thyrotropin	64-67	thyrotropin releasing hormone	Rattus norvegicus	113-116
3086478-8	1986	The present data provide evidence that TRH significantly changes the heterogeneity of glycosylated TSH in the anterior pituitary without altering the amount of the glycosylated form.	Thyrotropin	99-102	thyrotropin releasing hormone	Rattus norvegicus	39-42
3707578-2	1986	In cultured porcine thyroid cells, 6 days" exposure to TSH (above 0.02 mU/ml) increased cellular calmodulin contents.	Thyrotropin	55-58	calmodulin 1	Homo sapiens	97-107
3707578-4	1986	This TSH-stimulated increase in calcium uptake was partly due to the increase in cellular calmodulin contents.	Thyrotropin	5-8	calmodulin 1	Homo sapiens	90-100
3757917-5	1986	These results suggest that episodic degenerative discharge of thyroid hormone from nodular goiters may be a cause of impaired or blunted TSH response to TRH, frequently observed in patients with common nontoxic nodular goiters.	Thyrotropin	137-140	thyrotropin releasing hormone	Homo sapiens	153-156
3007124-5	1986	The specific effect of TSH on one protein labeling (protein 7; Mr approximately equal to 39 000) was potentiated by EGF and serum while the specific effect of EGF and serum on another protein labeling (protein 1) was potentiated by TSH.	Thyrotropin	23-26	epidermal growth factor	Canis lupus familiaris	116-119
2871684-8	1986	Pretreatment with 50 and 100 micrograms of SMS 202-995 sc (n = 9) inhibited (P less than 0.001) the stimulatory effect of TRH (200 micrograms iv) on TSH without modifying basal levels.	Thyrotropin	149-152	thyrotropin releasing hormone	Homo sapiens	122-125
3014823-0	1986	Twenty-four-hour serum levels of T4 and T3 in relation to decreased TSH serum levels and decreased TSH response to TRH in affective disorders.	Thyrotropin	99-102	thyrotropin releasing hormone	Homo sapiens	115-118
3014823-3	1986	The results show that there was no significant difference in T4 or T3 levels during the 24 h period between depressed patients and 32 healthy controls despite significantly decreased TSH levels and TSH response to TRH administration (delta TSH) in the patient group.	Thyrotropin	198-201	thyrotropin releasing hormone	Homo sapiens	214-217
3014823-3	1986	The results show that there was no significant difference in T4 or T3 levels during the 24 h period between depressed patients and 32 healthy controls despite significantly decreased TSH levels and TSH response to TRH administration (delta TSH) in the patient group.	Thyrotropin	198-201	thyrotropin releasing hormone	Homo sapiens	214-217
3007124-5	1986	The specific effect of TSH on one protein labeling (protein 7; Mr approximately equal to 39 000) was potentiated by EGF and serum while the specific effect of EGF and serum on another protein labeling (protein 1) was potentiated by TSH.	Thyrotropin	232-235	epidermal growth factor	Canis lupus familiaris	159-162
3716844-6	1986	A significant positive correlation was found between the DBH activity and the TSH levels, estimated by several parameters during the 24 h period, in the acutely ill patients, whereas no significant correlation was found in patients in remission or in the normal subjects.	Thyrotropin	78-81	dopamine beta-hydroxylase	Homo sapiens	57-60
3082177-7	1986	It is concluded 1) there is reduced binding of T4 and T3 to TBG in untreated PEM which takes 2-3 wk to recover; 2) there are methodological differences in evaluating free T4 levels in PEM; 3) increased TSH secretion appears to be an integral part of the recovery from PEM.	Thyrotropin	202-205	serpin family A member 7	Homo sapiens	60-63
3716844-8	1986	The mechanism behind the significant correlation between the DBH activity and TSH levels remains to be clarified.	Thyrotropin	78-81	dopamine beta-hydroxylase	Homo sapiens	61-64
2871949-6	1986	The combination of GHRH(1-29)NH2 with LHRH plus TRH caused a larger increment of peak and integrated plasma TSH levels than LHRH plus TRH alone.	Thyrotropin	108-111	growth hormone releasing hormone	Homo sapiens	19-23
3008042-3	1986	The data indicate that the contractions produced by TRH in these gut tissues are mediated by TRH receptors with similar characteristics as the pituitary TRH receptors responsible for TSH release.	Thyrotropin	183-186	thyrotropin releasing hormone	Cavia porcellus	52-55
3000588-2	1986	We have shown previously that EGF stimulates DNA synthesis and proliferation and inhibits TSH-induced markers of differentiation in dog thyroid follicle-derived primary cultures.	Thyrotropin	90-93	epidermal growth factor	Canis lupus familiaris	30-33
2871949-6	1986	The combination of GHRH(1-29)NH2 with LHRH plus TRH caused a larger increment of peak and integrated plasma TSH levels than LHRH plus TRH alone.	Thyrotropin	108-111	gonadotropin releasing hormone 1	Homo sapiens	38-42
2871949-8	1986	Because of the finding of potentiation of the TSH-releasing activity of LHRH plus TRH by GHRH(1-29)NH2, the study was extended to the investigation of TSH release after infusion of TRH in combination with either GHRH(1-29)NH2 or GHRH(1-40).	Thyrotropin	46-49	gonadotropin releasing hormone 1	Homo sapiens	72-76
3000588-7	1986	Moreover like EGF, phorbol esters strongly inhibited in 2 days the morphological effects of TSH and basal and TSH-stimulated iodide transport capacity and thyroglobulin messenger RNA accumulation, two markers of thyroid differentiation.	Thyrotropin	92-95	epidermal growth factor	Canis lupus familiaris	14-17
3000588-7	1986	Moreover like EGF, phorbol esters strongly inhibited in 2 days the morphological effects of TSH and basal and TSH-stimulated iodide transport capacity and thyroglobulin messenger RNA accumulation, two markers of thyroid differentiation.	Thyrotropin	110-113	epidermal growth factor	Canis lupus familiaris	14-17
2871949-8	1986	Because of the finding of potentiation of the TSH-releasing activity of LHRH plus TRH by GHRH(1-29)NH2, the study was extended to the investigation of TSH release after infusion of TRH in combination with either GHRH(1-29)NH2 or GHRH(1-40).	Thyrotropin	46-49	growth hormone releasing hormone	Homo sapiens	89-93
2871949-9	1986	In this study the combination of TRH with both GHRH preparations also caused a larger increment of the peak and integrated plasma TSH levels than TRH alone.	Thyrotropin	130-133	growth hormone releasing hormone	Homo sapiens	47-51
3941162-5	1986	The higher serum Tg level at birth was not entirely due to increased cord serum TSH levels, since newborns from the iodine-deficient areas with serum TSH levels at birth similar to those in infants from the control area had higher serum Tg levels.	Thyrotropin	150-153	thyroglobulin	Homo sapiens	17-19
2831684-3	1986	Combination of TSH with dibutyryl cAMP reduced the intensity of imprinting, whereas theophylline or lithium ions not only reduced the efficacy of normal imprinting, but also gave rise to faulty imprinting (for insulin instead of TSH).	Thyrotropin	15-18	insulin	Homo sapiens	210-217
3005459-4	1986	Pretreatment with TRH (20 nmol/l) for 8 h reduced subsequent TSH release: basal release fell to 64% of the control value (1.01 +/- 0.10 micrograms/l pretreated, 1.58 +/- 0.16 control) and release in response to TRH (100 nmol/l) to 69% of the control (2.7 +/- 0.19 micrograms/l vs 3.98 +/- 0.22); K+ response was reduced to 86% of the control (3.77 +/- 0.21 micrograms/l vs 4.39 +/- 0.20), significantly less than the other reductions.	Thyrotropin	61-64	thyrotropin releasing hormone	Rattus norvegicus	18-21
3005459-7	1986	After 6-h pretreatment with dbcAMP, subsequent TSH responses were augmented: basal release was 130% of the control, response to TRH (100 nmol/l) was 137% and to K+ it was 132% of the control, with a parallel upward shift of the TRH dose-response curve but no change in cellular TSH content.	Thyrotropin	47-50	thyrotropin releasing hormone	Rattus norvegicus	128-131
3005459-7	1986	After 6-h pretreatment with dbcAMP, subsequent TSH responses were augmented: basal release was 130% of the control, response to TRH (100 nmol/l) was 137% and to K+ it was 132% of the control, with a parallel upward shift of the TRH dose-response curve but no change in cellular TSH content.	Thyrotropin	47-50	thyrotropin releasing hormone	Rattus norvegicus	228-231
3788719-4	1986	Neuroendocrine factors, such as thyrotropin-releasing hormone, appear to modulate the carbohydrate structure of secreted TSH, which results in a change in the relative bioactivity of the circulating hormone.	Thyrotropin	121-124	thyrotropin releasing hormone	Homo sapiens	32-61
3753950-3	1986	The intracellular concentration of TSH after the TRH test showed a slight decreasing tendency after a 24 h incubation with increasing amounts of 1,25(OH)2D3.	Thyrotropin	35-38	thyrotropin releasing hormone	Rattus norvegicus	49-52
2819929-5	1986	Variable TSH responses to TRH were observed in the study but there was no correlation with the occurrence of GH or cortisol responses.	Thyrotropin	9-12	thyrotropin releasing hormone	Homo sapiens	26-29
3512397-0	1986	Insulin hypoglycemia suppresses TSH secretion in man: studies with an immunoradiometric TSH assay.	Thyrotropin	32-35	insulin	Homo sapiens	0-7
3080358-9	1986	The plasma TSH response to TRH was inhibited by histidine or HA and enhanced by FA.	Thyrotropin	11-14	thyrotropin releasing hormone	Rattus norvegicus	27-30
3005895-5	1986	Blockade of CNS EPI synthesis resulted in inhibition of basal and cold and thyrotropin-releasing hormone induced TSH release, suppression of serum T4, and increased corticosterone release.	Thyrotropin	113-116	thyrotropin releasing hormone	Rattus norvegicus	75-104
3009595-8	1985	We conclude that HF treatment of bTSH results in partially deglycosylated TSH derivatives that exhibit enhanced ability to bind to the TSH receptor and markedly diminished adenylate cyclase-stimulating activity.	Thyrotropin	34-37	thyroid stimulating hormone receptor	Homo sapiens	135-147
2998390-2	1985	The phospholipid turnover, evaluated after a 2 hr incorporation of 32P-phosphate into phospholipids, is markedly modified by the presence of TPA (1.5 microM, 2 hr) in the incubation medium of control and TSH treated cells.	Thyrotropin	204-207	plasminogen activator, tissue type	Homo sapiens	141-144
2999511-3	1985	Because of compensatory thyroid hypertrophy the concentration of TSH binding sites in the thyroid glands from hemithyroidectomized and control rats was related to particulate protein concentration, to the degree of thyroid cellularity as indicated by DNA concentration, and to the concentration of the plasma membrane markers, 5"-nucleotidase and magnesium-dependent ATPase.	Thyrotropin	65-68	5' nucleotidase, ecto	Rattus norvegicus	327-342
3005061-8	1985	When TSH and hCG were added together, the secretion of thyroid hormone was the same as that obtained by TSH single administration.	Thyrotropin	104-107	glycoprotein hormones, alpha polypeptide	Homo sapiens	13-16
2998390-9	1985	TPA inhibits by about 50-80% the stimulation evoked by TSH and only by 10% that evoked by forskolin (0.1 mM).	Thyrotropin	55-58	plasminogen activator, tissue type	Homo sapiens	0-3
2995010-0	1985	TSH and cAMP enhance expression of the myc proto-oncogene in cultured thyroid cells.	Thyrotropin	0-3	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	39-42
2995010-1	1985	The effect of TSH stimulation on cellular (c)-myc mRNA content in cultured thyroid cells was examined by Northern blot analysis.	Thyrotropin	14-17	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	46-49
3877650-4	1985	Epidermal growth factor (EGF) markedly inhibited differentiation when added together with TSH.	Thyrotropin	90-93	epidermal growth factor	Homo sapiens	0-23
3877650-4	1985	Epidermal growth factor (EGF) markedly inhibited differentiation when added together with TSH.	Thyrotropin	90-93	epidermal growth factor	Homo sapiens	25-28
3877650-6	1985	Morphological changes in response to TSH were also diminished by EGF.	Thyrotropin	37-40	epidermal growth factor	Homo sapiens	65-68
3926471-6	1985	The change in the plasma TSH concentration (delta plasma TSH) was significantly greater 15, 30, and 45 min after iv bolus injection of TRH in food-deprived rats than in control rats.	Thyrotropin	25-28	thyrotropin releasing hormone	Rattus norvegicus	135-138
2998424-4	1985	Elevated serum Tg (patient taking T4 in suppressive dose) was generally associated with tumours which had 131I concentrating function when stimulated by excess TSH.	Thyrotropin	160-163	thyroglobulin	Homo sapiens	15-17
4092675-8	1985	TRH induced TSH increase in the chronic administration group was similar to or greater than that of control subjects with matched basal TSH.	Thyrotropin	12-15	thyrotropin releasing hormone	Homo sapiens	0-3
4092675-8	1985	TRH induced TSH increase in the chronic administration group was similar to or greater than that of control subjects with matched basal TSH.	Thyrotropin	136-139	thyrotropin releasing hormone	Homo sapiens	0-3
3935346-1	1985	We have studied the effects of the TRH related dipeptide histidyl-proline diketopiperazine [cyclo (His-Pro)] on basal and stimulated TSH and PRL secretion in normal volunteers, in patients with microprolactinomas and in patients with primary hypothyroidism.	Thyrotropin	133-136	thyrotropin releasing hormone	Homo sapiens	35-38
3926471-6	1985	The change in the plasma TSH concentration (delta plasma TSH) was significantly greater 15, 30, and 45 min after iv bolus injection of TRH in food-deprived rats than in control rats.	Thyrotropin	57-60	thyrotropin releasing hormone	Rattus norvegicus	135-138
2990855-7	1985	In contrast, TRH (and the Ca+2 channel ionophore A23187) released twice as much TSH from the hypothyroid cells as in the euthyroid cultures.	Thyrotropin	80-83	thyrotropin releasing hormone	Rattus norvegicus	13-16
4053410-3	1985	Discrepant results, however, were found when serum Tg concentrations were correlated either with serum TSH or with goitre size.	Thyrotropin	103-106	thyroglobulin	Homo sapiens	51-53
2990855-9	1985	In contrast, TRH-induced TSH release was enhanced (P less than 0.001) in the euthyroid cultures.	Thyrotropin	25-28	thyrotropin releasing hormone	Rattus norvegicus	13-16
3926927-3	1985	Injection of sheep anti-TRH serum blocked the rise in plasma TSH concentration in response to stimulation of either brain area, but did not block the increase in plasma prolactin concentration.	Thyrotropin	61-64	thyrotropin releasing hormone	Rattus norvegicus	24-27
4005279-5	1985	125I-labeled apolipoprotein A-I binds TSH in the solid-phase assay and titration of DNS-TSH with apolipoprotein A-I causes perturbations nearly identical to those observed with intact HDL.	Thyrotropin	38-41	apolipoprotein A1	Homo sapiens	13-31
3923032-3	1985	The increment of TSH levels in the obese group [mean maximum change (delta max), 19.3 +/- 3.0 (+/-SEM) mIU/liter] was significantly higher (P less than 0.025) than that in the control group (delta max, 11.3 +/- 1.3 mIU/liter), whereas PRL levels rose significantly less (P less than 0.025) in these obese women than in the control group (delta max, 738 +/- 132 and 1311 +/- 133 mIU/liter, respectively).	Thyrotropin	17-20	prolactin	Homo sapiens	235-238
3926927-5	1985	Injection of anti-TRH serum, but not control non-immune or anti-bovine serum albumin, significantly decreased the basal release of TSH but did not abolish the prolactin response to suckling.	Thyrotropin	131-134	thyrotropin releasing hormone	Rattus norvegicus	18-21
3926927-6	1985	These results show that TRH is the principal mediator of the neural control of TSH release in the rat, but is not crucial for the release of prolactin in response to either hypothalamic stimulation or suckling.	Thyrotropin	79-82	thyrotropin releasing hormone	Rattus norvegicus	24-27
2988512-4	1985	The material released by dithiothreitol treatment could be crosslinked to 125I-labelled TSH coupled to N-hydroxysuccinimidyl 4-azidobenzoate (125I-HSAB-TSH), suggesting that it contained a component of the TSH receptor.	Thyrotropin	88-91	thyroid stimulating hormone receptor	Homo sapiens	206-218
3927182-0	1985	Comparison of the ability of thyroxine and triiodothyronine to suppress TRH-induced TSH secretion by perfused rat anterior pituitary fragments.	Thyrotropin	84-87	thyrotropin releasing hormone	Rattus norvegicus	72-75
3927182-3	1985	A similar temporal course of inhibition of TRH-induced TSH secretion was produced by both iodothyronines, suggesting but not proving that T4 may inhibit the TSH secretion by a direct effect not dependent on its prior intra- or extrapituitary conversion to T3.	Thyrotropin	55-58	thyrotropin releasing hormone	Rattus norvegicus	43-46
3925674-3	1985	TRH-treated sham-operated animals showed significantly reduced serum and pituitary TSH levels and increased serum T3 levels at most of the times studied (1, 6, 10, 18 and 34 days of oral TRH or DW administration), and a transient elevation in serum T4 between day 1 and 6.	Thyrotropin	83-86	thyrotropin releasing hormone	Rattus norvegicus	0-3
3925674-5	1985	TSH response to iv TRH administration on the 10th day of oral TRH administration was reduced in controls chronically treated with oral TRH as compared to non-treated controls, and was increased in thyroidectomized-L-T4-treated animals on chronic TRH vs the same group on oral DW.	Thyrotropin	0-3	thyrotropin releasing hormone	Rattus norvegicus	19-22
3925674-5	1985	TSH response to iv TRH administration on the 10th day of oral TRH administration was reduced in controls chronically treated with oral TRH as compared to non-treated controls, and was increased in thyroidectomized-L-T4-treated animals on chronic TRH vs the same group on oral DW.	Thyrotropin	0-3	thyrotropin releasing hormone	Rattus norvegicus	62-65
3925674-5	1985	TSH response to iv TRH administration on the 10th day of oral TRH administration was reduced in controls chronically treated with oral TRH as compared to non-treated controls, and was increased in thyroidectomized-L-T4-treated animals on chronic TRH vs the same group on oral DW.	Thyrotropin	0-3	thyrotropin releasing hormone	Rattus norvegicus	62-65
3925674-5	1985	TSH response to iv TRH administration on the 10th day of oral TRH administration was reduced in controls chronically treated with oral TRH as compared to non-treated controls, and was increased in thyroidectomized-L-T4-treated animals on chronic TRH vs the same group on oral DW.	Thyrotropin	0-3	thyrotropin releasing hormone	Rattus norvegicus	62-65
3987898-1	1985	ACAT activity measured in microsomes of thyroid cells cultured for 4 days in the presence of TSH (1 mU/ml) was two or three times lower than that of the control cells cultured for the same period in the absence of TSH.	Thyrotropin	93-96	sterol O-acyltransferase 1	Homo sapiens	0-4
3987898-1	1985	ACAT activity measured in microsomes of thyroid cells cultured for 4 days in the presence of TSH (1 mU/ml) was two or three times lower than that of the control cells cultured for the same period in the absence of TSH.	Thyrotropin	214-217	sterol O-acyltransferase 1	Homo sapiens	0-4
3921349-8	1985	The specificity of GRF for GH control, whether stimulatory or inhibitory, was seen by the failure of GRF to modify PRL, TSH, or LH release.	Thyrotropin	120-123	growth hormone releasing hormone	Homo sapiens	19-22
3160737-3	1985	No significant difference was found between these two subtypes of depression with respect to mean basal hormonal levels or magnitude of the TSH response to TRH.	Thyrotropin	140-143	thyrotropin releasing hormone	Homo sapiens	156-159
3921296-6	1985	administration its stimulatory effect is prolonged, lasting over 3 h. At the dose used in this study the peak TSH response after intranasal TRH administration was 14.7 +/- 1.6 mU/l compared to 8.4 +/- 1.4 and 23.1 +/- 4.4 mU/l after i.v.	Thyrotropin	110-113	thyrotropin releasing hormone	Homo sapiens	140-143
3971912-2	1985	Thyroiditis of sufficient severity to result in elevation of TSH levels is seen in Buffalo rats (RT1b).	Thyrotropin	61-64	RT1 class II, locus B	Rattus norvegicus	97-101
2985304-4	1985	After crosslinking, the crosslinked TSH-TSH receptor complexes were separated from aggregates and free TSH on Sephacryl S-300, incubated with test sera followed by immunoprecipitation using anti-IgG or Protein A.	Thyrotropin	36-39	thyroid stimulating hormone receptor	Homo sapiens	40-52
3920752-3	1985	Intranasal administration of TRH leads to excellent stimulation of pituitary TSH secretion.	Thyrotropin	77-80	thyrotropin releasing hormone	Homo sapiens	29-32
2982588-2	1985	Whether cultures were initiated in the absence or presence of 50 mU/ml TSH, TPO activity fell in the first 24 h of culture to approximately 10% of the activity in freshly isolated follicles.	Thyrotropin	71-74	thyroid peroxidase	Canis lupus familiaris	76-79
2982588-3	1985	After 5 days in culture, TPO activity almost completely disappeared in the absence of TSH, whereas in the presence of TSH, TPO activity rebounded to approximately 30% of that in freshly isolated follicles.	Thyrotropin	118-121	thyroid peroxidase	Canis lupus familiaris	123-126
2982588-4	1985	TSH similarly induced TPO activity in cells that had lost this activity during a 1- to 6-day preincubation period in the absence of hormone.	Thyrotropin	0-3	thyroid peroxidase	Canis lupus familiaris	22-25
2982588-6	1985	Whether TSH was present from the start of culture or added after 5 days of culture without TSH, the half-maximal dose for reinduction of TPO activity was 0.3-0.4 mU TSH/ml.	Thyrotropin	8-11	thyroid peroxidase	Canis lupus familiaris	137-140
2982588-7	1985	(Bu)2cAMP, 8-bromo-cAMP, forskolin, and cholera toxin all mimicked, either completely or in part, the ability of TSH to induce TPO activity in cells preincubated without hormone.	Thyrotropin	113-116	thyroid peroxidase	Canis lupus familiaris	127-130
3920752-5	1985	As with intravenous TRH, peak TSH response is reached at 20-30 minutes, but the stimulatory effect is prolonged and elevated TSH levels can be measured for up to 3 hours.	Thyrotropin	30-33	thyrotropin releasing hormone	Homo sapiens	20-23
3920752-5	1985	As with intravenous TRH, peak TSH response is reached at 20-30 minutes, but the stimulatory effect is prolonged and elevated TSH levels can be measured for up to 3 hours.	Thyrotropin	125-128	thyrotropin releasing hormone	Homo sapiens	20-23
3977849-11	1985	In particulate preparations from which endogenous calmodulin had been removed by La3+ treatment, the addition of pure calmodulin caused an increase (73 +/- 22%; mean +/- S.E.M., n = 8) in TSH-stimulated thyroid adenylate cyclase activity.	Thyrotropin	188-191	calmodulin 1	Homo sapiens	118-128
3922262-6	1985	Although mean concentrations of TSH in serum were higher (P less than 0.05) in euthyroid dogs after TRH administration, the response was too variable among individual animals for accurate evaluation of pituitary gland function.	Thyrotropin	32-35	TRH	Canis lupus familiaris	100-103
3964748-10	1985	We conclude that acute TSH suppression slows intraluminal diffusion of thyroglobulin molecules and acute TSH injection accelerates the mixing process, whereas, in contrast, chronic TSH suppression improves and acute TSH action on chronically suppressed follicles impairs diffusion.	Thyrotropin	23-26	thyroglobulin	Rattus norvegicus	71-84
2578386-13	1985	Incubation with forskolin or TSH and IBMX for 2-3 h resulted in arborization of 30-60% of the cells that contained bundles of microtubules, myosin fibers, or microfilaments into dendrite-like processes and increased staining near the nucleus.	Thyrotropin	29-32	myosin heavy chain 14	Homo sapiens	140-146
2578386-17	1985	These studies are consistent with effects of cAMP on microtubules, myosin-containing fibrils, and microfilaments and may provide a basis for the morphological response to TSH.	Thyrotropin	171-174	myosin heavy chain 14	Homo sapiens	67-73
3930704-1	1985	TSH responsiveness to 500 micrograms TRH given intravenously was examined in ten bulimic outpatients, nine anorexic in-patients and a group of age matched healthy subjects.	Thyrotropin	0-3	thyrotropin releasing hormone	Homo sapiens	37-40
2418468-5	1985	In all subjects the TSH response correlated positively with pre- and post-TRH urinary MHPG.	Thyrotropin	20-23	thyrotropin releasing hormone	Homo sapiens	74-77
3936054-3	1985	The measurement of serum TSH after administration of TRH, however, has revealed that approximately 25% of depressed patients show a blunted TSH response after TRH.	Thyrotropin	25-28	thyrotropin releasing hormone	Homo sapiens	53-56
3936054-3	1985	The measurement of serum TSH after administration of TRH, however, has revealed that approximately 25% of depressed patients show a blunted TSH response after TRH.	Thyrotropin	25-28	thyrotropin releasing hormone	Homo sapiens	159-162
2865765-1	1985	The finding of a diminished TSH response to exogenously administered TRH in a significant proportion of depressed patients has now been established as one of the most reproducible findings in biological psychiatry.	Thyrotropin	28-31	thyrotropin releasing hormone	Homo sapiens	69-72
6532799-9	1984	Nine of 86 (10.5%) subjects with AAT had apparently increased basal TSH level.	Thyrotropin	68-71	serpin family A member 1	Homo sapiens	33-36
6209123-4	1984	The effects of TSH (50 mU/ml) on the 32P labeling of group I proteins were partially reproduced by (Bu)2cAMP (1 mM), 8-bromo-cAMP (1 mM), and butyrate (2 mM), and closely mimicked by 8-(4-chlorophenylthio)cAMP (1 mM), forskolin (25 microM), and butyrate (10 mM).	Thyrotropin	15-18	cathelicidin-7	Bos taurus	104-108
6209123-4	1984	The effects of TSH (50 mU/ml) on the 32P labeling of group I proteins were partially reproduced by (Bu)2cAMP (1 mM), 8-bromo-cAMP (1 mM), and butyrate (2 mM), and closely mimicked by 8-(4-chlorophenylthio)cAMP (1 mM), forskolin (25 microM), and butyrate (10 mM).	Thyrotropin	15-18	cathelicidin-7	Bos taurus	125-129
6209123-8	1984	Our results provide strong support for the hypothesis that TSH-dependent phosphorylation of group I proteins is mediated by cAMP, but they provide little evidence of cGMP regulation of histone or HMG protein phosphorylation.	Thyrotropin	59-62	cathelicidin-7	Bos taurus	124-128
6434589-2	1984	Increasing TSH rises were elicited by TRH administration as follows: 1) 500 micrograms iv as a single bolus in 10 subjects [mean peak serum TSH, 14.3 +/- 1.8 (SE) microU/ml]; 2) 1000 micrograms infused iv in 2 h in 10 subjects (mean peak TSH, 25.5 +/- 2.6 microU/ml); 3) 40 mg orally in 10 subjects (mean peak TSH, 27.5 +/- 3.0 microU/ml, with a delayed and more prolonged rise).	Thyrotropin	11-14	thyrotropin releasing hormone	Homo sapiens	38-41
6436423-7	1984	Addition of TRH increased incorporation of [14C]alanine into TSH in each of the components to a greater extent than that of [3H]glucosamine.	Thyrotropin	61-64	thyrotropin releasing hormone	Rattus norvegicus	12-15
6436423-8	1984	In addition, new components with pI 7.2, 6.5 and 6.2, each component corresponding to each unlabelled TSH component, were demonstrated in the presence of TRH.	Thyrotropin	102-105	thyrotropin releasing hormone	Rattus norvegicus	154-157
6092768-4	1984	Unexpected combinations were observed in 3 tumors (5.4%); a GH-LH-containing adenoma, a PRL-ACTH-containing adenoma, and a PRL-LH-TSH-containing adenoma were noted.	Thyrotropin	130-133	prolactin	Rattus norvegicus	123-126
6437538-3	1984	In all except one patient the basal TSH concentration by immunoradiometric assay predicted the response of TSH by radioimmunoassay to TRH, an undetectable value being recorded in patients with a subnormal response and a measurable value in those with a normal test result.	Thyrotropin	36-39	thyrotropin releasing hormone	Homo sapiens	134-137
6437538-3	1984	In all except one patient the basal TSH concentration by immunoradiometric assay predicted the response of TSH by radioimmunoassay to TRH, an undetectable value being recorded in patients with a subnormal response and a measurable value in those with a normal test result.	Thyrotropin	107-110	thyrotropin releasing hormone	Homo sapiens	134-137
6437538-5	1984	In a series of 39 hospital inpatients with acute or chronic non-thyroidal illness, of whom 11 had low concentrations of total thyroxine or triiodothyronine, or both, basal TSH concentrations were detectable by both radioimmunoassay and immunoradiometric assay in all cases and were associated with normal responses to TRH.	Thyrotropin	172-175	thyrotropin releasing hormone	Homo sapiens	318-321
6437538-6	1984	The immunoradiometric assay for TSH, which is commercially available, may therefore obviate the need for the more time consuming TRH test and simplify the approach to thyroid function testing in patients with suspected hyperthyroidism.	Thyrotropin	32-35	thyrotropin releasing hormone	Homo sapiens	129-132
6437105-4	1984	These findings suggest that TRH administered intranasally or rectally enters the blood stream and stimulates TSH, prolactin and thyroid hormone release in man.	Thyrotropin	109-112	thyrotropin releasing hormone	Homo sapiens	28-31
6548182-5	1984	As tested in mice in vivo, NPY did not affect basal or norepinephrine-stimulated thyroid hormone secretion, but enhanced isoprenaline-, TSH-, and vasoactive intestinal polypeptide-induced iodothyronine release.	Thyrotropin	136-139	neuropeptide Y	Mus musculus	27-30
6495989-4	1984	However, ET/PEP was unequivocally elevated in about 40% of treated hypothyroid patients with normal serum T3, T4 and TSH levels which had been maintained over 48-54 months.	Thyrotropin	117-120	progestagen associated endometrial protein	Homo sapiens	12-15
6434573-3	1984	Twenty five micrograms of TRH, injected iv in six alcoholic men during acute withdrawal, raised TSH by 1.6 +/- 0.8 (SEM) microU/ml and PRL by 18 +/- 7 ng/ml.	Thyrotropin	96-99	thyrotropin releasing hormone	Homo sapiens	26-29
6434573-8	1984	Furthermore, TRH, injected 90 min after oral priming with metoclopramide in six additional alcoholics, elicited TSH and PRL increments in the acute withdrawal state which did not differ significantly from those obtained in the late withdrawal state (TSH, 3.5 +/- 0.9 vs. 4.1 +/- 1.2 microU/ml; PRL, 27 +/- 3 vs. 24 +/- 6 ng/ml).	Thyrotropin	112-115	thyrotropin releasing hormone	Homo sapiens	13-16
6434573-8	1984	Furthermore, TRH, injected 90 min after oral priming with metoclopramide in six additional alcoholics, elicited TSH and PRL increments in the acute withdrawal state which did not differ significantly from those obtained in the late withdrawal state (TSH, 3.5 +/- 0.9 vs. 4.1 +/- 1.2 microU/ml; PRL, 27 +/- 3 vs. 24 +/- 6 ng/ml).	Thyrotropin	250-253	thyrotropin releasing hormone	Homo sapiens	13-16
6094284-2	1984	In the serum-free culture, in which TSH was administered to well-reformed follicles, this increase in 5"-nucleotidase activity concerns both the ecto-enzymic and intracellular forms of the enzyme and it coincides with the period of several days during which several glycosyltransferase activities are elevated and thyroglobulin production increased.	Thyrotropin	36-39	5'-nucleotidase ecto	Homo sapiens	102-117
6094205-3	1984	At concentrations ranging from 0.5 to 2.5 microM, PAF-acether inhibited significantly the accumulation of cyclic AMP resulting from a 5 min incubation of the cells with TSH (40 mU/ml) or forskolin (0.1 mM).	Thyrotropin	169-172	PCNA clamp associated factor	Homo sapiens	50-53
6094205-8	1984	When PAF-acether was incubated for 2 h with [32P]phosphate, it mimicked the effects of TSH, i.e. it increased phosphatidylinositol (PI) labelling on 1 day control cells (expected effect) and decreased it with 1 day TSH cells (reverse effects).	Thyrotropin	87-90	PCNA clamp associated factor	Homo sapiens	5-8
6094205-8	1984	When PAF-acether was incubated for 2 h with [32P]phosphate, it mimicked the effects of TSH, i.e. it increased phosphatidylinositol (PI) labelling on 1 day control cells (expected effect) and decreased it with 1 day TSH cells (reverse effects).	Thyrotropin	215-218	PCNA clamp associated factor	Homo sapiens	5-8
6094205-10	1984	After cell prelabelling for 2 h in the presence of TSH, PAF-acether added for 15 min completely counteracted the hormone effects on PI and phosphatidylcholine (PC) but increased the phosphatidic acid (PA) labelling.	Thyrotropin	51-54	PCNA clamp associated factor	Homo sapiens	56-59
6086714-7	1984	In a TSH receptor binding assay, the anti-idiotype could inhibit TSH receptor binding in Graves" sera at a 1,000-fold lower concentration than could anti-kappa/lambda antiserum; the anti-idiotypic antiserum also inhibited in vitro TSH-mediated adenylate cyclase stimulation at an IgG concentration of 5 micrograms/ml, while heterologous anti-TSH antisera and normal IgG at similar concentrations had no effect.	Thyrotropin	5-8	thyroid stimulating hormone receptor	Homo sapiens	65-77
6432670-6	1984	The plasma TSH response to TRH was also significantly inhibited.	Thyrotropin	11-14	thyrotropin releasing hormone	Rattus norvegicus	27-30
6432605-10	1984	Basal secretion of TSH and PRL was rapidly and significantly inhibited by DA in a dose-dependent manner (ED50 20 +/- 25 nM for TSH and 70 +/- 40 nM for PRL).	Thyrotropin	19-22	prolactin	Rattus norvegicus	152-155
6432605-12	1984	Simultaneous administration of 10(-6) M DA with 10(-8) M TRH prevented the release of TSH and PRL.	Thyrotropin	86-89	thyrotropin releasing hormone	Rattus norvegicus	57-60
6427264-7	1984	The basal levels of PRL in the first patient were elevated at both T4 doses; also, her PRL responses to TRH and metoclopramide were exaggerated and, compared to normal values, disproportionate to her TSH responses to these provocative agents.	Thyrotropin	200-203	prolactin	Homo sapiens	20-23
6329654-5	1984	In contrast, exogenous TRH caused a 9-fold increase in plasma TSH levels during suckling without further increasing the PRL response.	Thyrotropin	62-65	thyrotropin releasing hormone	Rattus norvegicus	23-26
6430673-10	1984	In 5-hydroxytryptophan pretreated group the stimulatory effect of VIP on TSH release was prevented, but not in that pretreated with para-chlorophenylalanine, L-DOPA or haloperidol.	Thyrotropin	73-76	vasoactive intestinal peptide	Rattus norvegicus	66-69
6430673-13	1984	These findings suggest that VIP acts on the hypothalamus, pituitary and thyroid gland to stimulate TRH, TSH and thyroid hormone release, respectively, and that its effect may be at least partially modified by the serotonergic system and opioid peptides.	Thyrotropin	104-107	vasoactive intestinal peptide	Rattus norvegicus	28-31
6086426-6	1984	Moreover, chronic exposure to EGF induced a striking fibroblast-like morphology and inhibited all the studied characteristics of morphological and biochemical differentiation stimulated by TSH.	Thyrotropin	189-192	epidermal growth factor	Canis lupus familiaris	30-33
6475061-6	1984	TG was highest in metastatic disease and practically uninfluenced by T4, i.e. by the endogenous TSH level.	Thyrotropin	96-99	thyroglobulin	Homo sapiens	0-2
6428117-6	1984	In the superfusion study, a biphasic profile of TSH release was observed during a continuous exposure (100 min) to maximal doses of either the analogue or TRH.	Thyrotropin	48-51	thyrotropin releasing hormone	Rattus norvegicus	155-158
6428436-0	1984	[Evaluation of TSH secretion after GnRh in patients with primary hypothyroidism].	Thyrotropin	15-18	gonadotropin releasing hormone 1	Homo sapiens	35-39
6428117-1	1984	Using dispersed and primarily cultured cells of rat pituitary glands, thyrotrophin (TSH) release by TSH-releasing hormone (TRH) and an analogue, gamma-butyrolactone-gamma-carbonyl-L-histidyl-L- prolinamide (DN-1417) which is more potent than TRH on central nervous system behavioural paradigms, was examined under conditions of static incubation and superfusion.	Thyrotropin	70-82	thyrotropin releasing hormone	Rattus norvegicus	100-121
6428117-1	1984	Using dispersed and primarily cultured cells of rat pituitary glands, thyrotrophin (TSH) release by TSH-releasing hormone (TRH) and an analogue, gamma-butyrolactone-gamma-carbonyl-L-histidyl-L- prolinamide (DN-1417) which is more potent than TRH on central nervous system behavioural paradigms, was examined under conditions of static incubation and superfusion.	Thyrotropin	70-82	thyrotropin releasing hormone	Rattus norvegicus	123-126
6428117-1	1984	Using dispersed and primarily cultured cells of rat pituitary glands, thyrotrophin (TSH) release by TSH-releasing hormone (TRH) and an analogue, gamma-butyrolactone-gamma-carbonyl-L-histidyl-L- prolinamide (DN-1417) which is more potent than TRH on central nervous system behavioural paradigms, was examined under conditions of static incubation and superfusion.	Thyrotropin	84-87	thyrotropin releasing hormone	Rattus norvegicus	100-121
6428117-1	1984	Using dispersed and primarily cultured cells of rat pituitary glands, thyrotrophin (TSH) release by TSH-releasing hormone (TRH) and an analogue, gamma-butyrolactone-gamma-carbonyl-L-histidyl-L- prolinamide (DN-1417) which is more potent than TRH on central nervous system behavioural paradigms, was examined under conditions of static incubation and superfusion.	Thyrotropin	84-87	thyrotropin releasing hormone	Rattus norvegicus	123-126
6430600-2	1984	Subjects in the high TSH group all fell within the normal range for measurements of total T4, total T3 and T4/TBG ratio.	Thyrotropin	21-24	serpin family A member 7	Homo sapiens	110-113
6432565-4	1984	Finally, under the above dose of infused apomorphine, the effect of TRH on the increase of TSH level was depressed at the 30th min as compared to that 0 and 120th min of infusion.	Thyrotropin	91-94	thyrotropin releasing hormone	Rattus norvegicus	68-71
6428436-6	1984	TSH is unresponsive to GnRH in normal condition, while shows a clear decrease (-78%) 30 minutes after GnRH in primary hypothyroidism.	Thyrotropin	0-3	gonadotropin releasing hormone 1	Homo sapiens	102-106
6423373-2	1984	TRH (10(-9) and 10(-8)M) consistently stimulated the release of TSH and PRL, but not GH, in pituitary cell cultures of euthyroid male rats.	Thyrotropin	64-67	thyrotropin releasing hormone	Rattus norvegicus	0-3
6200315-1	1984	It has been previously shown that carbamylcholine (10(-5) M) decreases TSH-induced cAMP accumulation and hormone secretion in dog thyroid slices.	Thyrotropin	71-74	cathelicidin antimicrobial peptide	Canis lupus familiaris	83-87
6430687-2	1984	Release of TSH in response to continuous exposure to TRH exhibited a biphasic pattern; the first phase was characterized by a rapid, transient and high-rate release (phase I) and the second phase by a chronic and low-rate release (phase II).	Thyrotropin	11-14	thyrotropin releasing hormone	Rattus norvegicus	53-56
6423373-3	1984	Basal and TRH-stimulated TSH secretion were significantly increased in cells from thyroidectomized rats cultured in medium supplemented with hypothyroid serum, and a dose-related stimulation of GH release by 10(-9)-10(-8) M TRH was observed.	Thyrotropin	25-28	thyrotropin releasing hormone	Rattus norvegicus	10-13
6430687-9	1984	The decreased phase I release in response to TRH was observed with the cells which were previously stimulated by high K+ instead of TRH, suggesting that the decrease in the response of phase I reflects the depletion of a releasable pool of TSH rather than homologous desensitization of thyrotrophs with TRH.	Thyrotropin	240-243	thyrotropin releasing hormone	Rattus norvegicus	45-48
6423373-3	1984	Basal and TRH-stimulated TSH secretion were significantly increased in cells from thyroidectomized rats cultured in medium supplemented with hypothyroid serum, and a dose-related stimulation of GH release by 10(-9)-10(-8) M TRH was observed.	Thyrotropin	25-28	thyrotropin releasing hormone	Rattus norvegicus	224-227
6423373-4	1984	The minimum duration of hypothyroidism required to demonstrate the onset of this GH stimulatory effect of TRH was 4 weeks, a period significantly longer than that required to cause intracellular GH depletion, decreased basal secretion of GH, elevated serum TSH, or increased basal secretion of TSH by cultured cells.	Thyrotropin	257-260	thyrotropin releasing hormone	Rattus norvegicus	106-109
6423373-4	1984	The minimum duration of hypothyroidism required to demonstrate the onset of this GH stimulatory effect of TRH was 4 weeks, a period significantly longer than that required to cause intracellular GH depletion, decreased basal secretion of GH, elevated serum TSH, or increased basal secretion of TSH by cultured cells.	Thyrotropin	294-297	thyrotropin releasing hormone	Rattus norvegicus	106-109
6710532-5	1984	When a single dose of nitrofen was administered to euthyroid female rats, a trend toward reduction (p = 0.058) in the release of TSH after a thyrotropin-releasing hormone (TRH) challenge was observed 4 and 5 hr after exposure.	Thyrotropin	129-132	thyrotropin releasing hormone	Rattus norvegicus	141-170
6321134-7	1984	The bTSH preparation (Thytropar) showed a 10-fold greater binding inhibition potency at these sites than either the as-hCG or the as-hCG beta preparation, in keeping with the inference that as-hCG beta interacts with the low affinity class of TSH-binding sites.	Thyrotropin	5-8	chorionic gonadotropin subunit beta 3	Homo sapiens	193-201
6322495-4	1984	Analysis of the TSH-TSH receptor interaction in the presence of TSH alone yielded curvilinear Scatchard plots, indicating the existence of two independent classes of binding sites (high affinity Ka: 8.5 +/- 4.8 X 10(8) M-1; low affinity Ka: 5.3 +/- 2.7 X 10(6) M-1).	Thyrotropin	16-19	thyroid stimulating hormone receptor	Homo sapiens	20-32
6322495-8	1984	This marked change in the kinetic behaviour of the TSH binding sites provided evidence that there is a direct interaction between anti-TSH receptor antibodies and autologous TSH receptors.	Thyrotropin	51-54	thyroid stimulating hormone receptor	Homo sapiens	135-147
6322495-9	1984	Divalency of Graves" IgG or linkage of Fab fragments by anti-Fab antiserum proved to be necessary to produce this specific change in the kinetic behaviour of TSH binding sites.	Thyrotropin	158-161	FA complementation group B	Homo sapiens	39-42
6322495-9	1984	Divalency of Graves" IgG or linkage of Fab fragments by anti-Fab antiserum proved to be necessary to produce this specific change in the kinetic behaviour of TSH binding sites.	Thyrotropin	158-161	FA complementation group B	Homo sapiens	61-64
6321134-2	1984	To assess the relevance of the class of TSH-binding sites characterized by low affinity and high capacity to the stimulation of adenylate cyclase, we studied the interactions of desialylated hCG (as-hCG) and its beta-subunit (as-hCG beta) with human thyroid membranes.	Thyrotropin	40-43	chorionic gonadotropin subunit beta 5	Homo sapiens	191-194
6321134-2	1984	To assess the relevance of the class of TSH-binding sites characterized by low affinity and high capacity to the stimulation of adenylate cyclase, we studied the interactions of desialylated hCG (as-hCG) and its beta-subunit (as-hCG beta) with human thyroid membranes.	Thyrotropin	40-43	chorionic gonadotropin subunit beta 5	Homo sapiens	199-202
6321134-9	1984	In contrast, the as-hCG molecule, which interacts with both classes of TSH-binding sites, fully inhibited TSH stimulation of adenylate cyclase.	Thyrotropin	71-74	chorionic gonadotropin subunit beta 5	Homo sapiens	20-23
6321134-3	1984	In low ionic strength buffer, pH 7.8, where both classes of sites are operant, as-hCG fully inhibited and as-hCG beta partially inhibited [125I] bovine (b) TSH binding.	Thyrotropin	156-159	chorionic gonadotropin subunit beta 5	Homo sapiens	109-112
6321134-9	1984	In contrast, the as-hCG molecule, which interacts with both classes of TSH-binding sites, fully inhibited TSH stimulation of adenylate cyclase.	Thyrotropin	106-109	chorionic gonadotropin subunit beta 5	Homo sapiens	20-23
6202655-3	1984	Patients with cystinosis appear to have pituitary resistance to thyroid hormones, and the increase in serum TSH is often associated with high levels of TSHalpha .	Thyrotropin	108-111	glycoprotein hormones, alpha polypeptide	Homo sapiens	152-160
6425038-8	1984	The plasma TSH response to TRH was also significantly enhanced by PG I2.	Thyrotropin	11-14	thyrotropin releasing hormone	Rattus norvegicus	27-30
6693543-3	1984	In 24 patients who had a PRL-secreting pituitary adenoma, diagnosed by pituitary dynamic function tests and CT scan, and confirmed at surgery, the TSH response to a dopamine (DA)-antagonist drug, metoclopramide (MCP), was studied pre- and postoperatively to elucidate whether altered DA tone was present and related to hyperprolactinemia.	Thyrotropin	147-150	prolactin	Homo sapiens	25-28
6425068-2	1984	Phospholipase A2 and 4 beta-phorbol 12 beta-myristate 13 alpha-acetate (PMA), which increase the intracellular availability of arachidonic acid, potently stimulated TSH release from anterior pituitary cells continuously perifused in columns and from hemipituitary glands in vitro.	Thyrotropin	165-168	phospholipase A2 group IB	Homo sapiens	0-16
6322686-3	1984	Deglycosylated hCG (dghCG) bound to the high affinity-low capacity TSH-binding sites of thyroid membranes; its equilibrium dissociation constant was lower than that of asialo-hCG (ashCG) (ED50: 2.6 and 6 microM, respectively).	Thyrotropin	67-70	chorionic gonadotropin subunit beta 5	Homo sapiens	15-18
6322686-3	1984	Deglycosylated hCG (dghCG) bound to the high affinity-low capacity TSH-binding sites of thyroid membranes; its equilibrium dissociation constant was lower than that of asialo-hCG (ashCG) (ED50: 2.6 and 6 microM, respectively).	Thyrotropin	67-70	chorionic gonadotropin subunit beta 5	Homo sapiens	22-25
6425068-4	1984	Conversely, quinacrine (50 microM), an inhibitor of phospholipase A2 activity, inhibited basal and stimulated TSH release from pituitary cells perifused in columns.	Thyrotropin	110-113	phospholipase A2 group IB	Homo sapiens	52-68
6425068-8	1984	BW755c, another lipoxygenase inhibitor, also inhibited TRH-stimulated TSH secretion.	Thyrotropin	70-73	thyrotropin releasing hormone	Homo sapiens	55-58
6695544-12	1984	It is suggested that a discernible degree of heterogeneity of TSH, particularly of TSH beta, is dependent upon the increased rate of TSH biosynthesis at the pituitary level.	Thyrotropin	62-65	thyroid stimulating hormone subunit beta	Rattus norvegicus	83-91
6439618-5	1984	An increase in the dose of TRH (112 pmol), administered to euthyroid tissue, resulted in increased TSH and PRL response, but no decline in response to sequential stimuli was observed.	Thyrotropin	99-102	thyrotropin releasing hormone	Rattus norvegicus	27-30
6486614-3	1984	False negative results are rare but have been reported and therefore, it is useful to repeat Tg measurement after TSH stimulation in patients with undetectable Tg levels during T4 treatment.	Thyrotropin	114-117	thyroglobulin	Homo sapiens	160-162
6439618-6	1984	Three consecutive stimuli by TRH (28 pmol) of hypothyroid tissue resulted in a consistent decline in TSH response.	Thyrotropin	101-104	thyrotropin releasing hormone	Rattus norvegicus	29-32
6232157-6	1983	Plasma TSH increased following the beginning of a continuous infusion with TRH and reached a peak at approximately 180 min, maintaining a plateau until the infusion was withheld.	Thyrotropin	7-10	thyrotropin releasing hormone	Homo sapiens	75-78
6201427-6	1984	The plasma TSH levels were significantly increased by angiotensin II and significantly decreased by oxotremorine, SP or PG D2 in a dose-related manner.	Thyrotropin	11-14	angiotensinogen	Rattus norvegicus	54-68
6201427-8	1984	The plasma TSH response to TRH was inhibited by SP, but enhanced by angiotensin II.	Thyrotropin	11-14	thyrotropin releasing hormone	Rattus norvegicus	27-30
6201427-8	1984	The plasma TSH response to TRH was inhibited by SP, but enhanced by angiotensin II.	Thyrotropin	11-14	angiotensinogen	Rattus norvegicus	68-82
6429690-6	1984	However, three of the four autistic children showed hyperresponse of TSH to TRH before treatment, whereas only one also showed a hyperresponse during treatment.	Thyrotropin	69-72	thyrotropin releasing hormone	Homo sapiens	76-79
6232157-8	1983	Furthermore, a stepwise increase of TSH levels was observed following 4 intermittent injections of TRH; however, plasma PRL rapidly reached peak levels in 30 min following the 1st injection of TRH and a further 3 injections did not raise the levels of PRL.	Thyrotropin	36-39	thyrotropin releasing hormone	Homo sapiens	99-102
6317784-6	1983	A possible role for calmodulin in the action of TSH on the thyroid was demonstrated by studying the effects of phenothiazines and the naphthalene sulphonamide, W7, a more specific calmodulin inhibitor, on TSH-stimulated cyclic AMP levels in cultured thyroid cells.	Thyrotropin	48-51	calmodulin 1	Homo sapiens	20-30
6317784-6	1983	A possible role for calmodulin in the action of TSH on the thyroid was demonstrated by studying the effects of phenothiazines and the naphthalene sulphonamide, W7, a more specific calmodulin inhibitor, on TSH-stimulated cyclic AMP levels in cultured thyroid cells.	Thyrotropin	48-51	calmodulin 1	Homo sapiens	180-190
6415151-3	1983	TSH response to TRH administered intravenously did not differ between old and young rats.	Thyrotropin	0-3	thyrotropin releasing hormone	Rattus norvegicus	16-19
6414745-14	1983	In Group II females, PRL responsiveness to metoclopramide was associated with TSH non-responsiveness.	Thyrotropin	78-81	prolactin	Homo sapiens	21-24
6415988-1	1983	Forty mg TRH/day given orally for 3 weeks to 8 patients with mild primary hypothyroidism decreased serum TSH from a mean of 4.0 ng/ml +/- 1.2 (SE) to 2.0 ng/ml +/- 0.4 (49%), and their mean incremental TSH response to iv TRH was equally reduced from 8.6 ng/ml +/- 2.5 to 4.0 ng/ml +/- 1.9 (46%).	Thyrotropin	105-108	thyrotropin releasing hormone	Homo sapiens	9-12
6415988-4	1983	The incremental TSH responses to iv TRH increased 2.3-fold in euthyroid subjects pre-treated with metoclopramide, while no change was observed in the TSH responsiveness in patients with primary hypothyroidism following metoclopramide pre-treatment.	Thyrotropin	16-19	thyrotropin releasing hormone	Homo sapiens	36-39
6415989-3	1983	The serum TSH levels in Neo-TRH rats were significantly lower than those in controls on days 4 (male group only), 10 and 21 (only 10 micrograms/kg group).	Thyrotropin	10-13	thyrotropin releasing hormone	Rattus norvegicus	28-31
6415989-6	1983	However, the response of serum TSH to exogenous TRH (10 micrograms/kg/ip) was blunted in Neo-TRH rats on days 10, 21 and 90.	Thyrotropin	31-34	thyrotropin releasing hormone	Rattus norvegicus	48-51
6415989-6	1983	However, the response of serum TSH to exogenous TRH (10 micrograms/kg/ip) was blunted in Neo-TRH rats on days 10, 21 and 90.	Thyrotropin	31-34	thyrotropin releasing hormone	Rattus norvegicus	93-96
6412238-6	1983	Treatment with a high dosage (2 micrograms) of TRH induced a sixfold rise in plasma TSH during both phases of gestation.	Thyrotropin	84-87	thyrotropin releasing hormone	Rattus norvegicus	47-50
6137925-6	1983	In the presence of TSH, the cGMP response to norepinephrine was not modified; however, the increase of cAMP levels was inhibited by norepinephrine at doses inactive on cAMP accumulation, but active on cGMP levels.	Thyrotropin	19-22	cathelicidin antimicrobial peptide	Homo sapiens	103-107
6413880-4	1983	Penfluridol reversibly abolished the stimulatory effect of thyrotropin-releasing hormone (TRH) on TSH release in perifused dispersed pituitary cells.	Thyrotropin	98-101	thyrotropin releasing hormone	Homo sapiens	59-88
6872946-2	1983	The opioid peptide beta-endorphin was found to increase TSH secretion in a dose-related manner from either dispersed pituitary cells or pituitary fragments.	Thyrotropin	56-59	proopiomelanocortin	Homo sapiens	19-33
6414828-5	1983	A delay in peak response of TSH to TRH stimulation (30" rather than 20") was noted in anorexia and malnourished patients.	Thyrotropin	28-31	thyrotropin releasing hormone	Homo sapiens	35-38
6872946-4	1983	In contrast, somatostatin (10(-9) M) significantly decreased beta-endorphin-stimulated TSH secretion.	Thyrotropin	87-90	proopiomelanocortin	Homo sapiens	61-75
6408115-2	1983	Short term fasting caused a 29% decrement in the maximum serum TSH increment and a 32% decrement in the integrated TSH response to TRH (P less than 0.01).	Thyrotropin	115-118	thyrotropin releasing hormone	Homo sapiens	131-134
6224835-2	1983	A significant positive correlation between TSH response to TRH and urinary MHPG was found in the men, though not in the women.	Thyrotropin	43-46	thyrotropin releasing hormone	Homo sapiens	59-62
6224835-3	1983	These findings suggest that at least for depressed men, central norepinephrine deficiency may be the neurobiological substrate of blunted TSH responses to TRH.	Thyrotropin	138-141	thyrotropin releasing hormone	Homo sapiens	155-158
6417218-6	1983	The administration of a second pulse of TRH led to a further increment of TSH secretion in the patients.	Thyrotropin	74-77	thyrotropin releasing hormone	Homo sapiens	40-43
6410033-10	1983	Complete suppression of TRH-induced TSH release did not occur until a daily dose of 300 micrograms triiodothyronine was administered.	Thyrotropin	36-39	thyrotropin releasing hormone	Homo sapiens	24-27
6408930-4	1983	In cells from euthyroid animals, TRH induced TSH secretion only in the eutopic cells but induced PRL secretion in both eutopic and heterotopic cells.	Thyrotropin	45-48	thyrotropin releasing hormone	Rattus norvegicus	33-36
6408930-5	1983	Hypothyroidism increased TRH-induced TSH secretion and content in the cell lysate in both eutopic and heterotopic cells but increased TRH-induced PRL secretion only in the eutopic cells.	Thyrotropin	37-40	thyrotropin releasing hormone	Rattus norvegicus	25-28
6411392-10	1983	Mild thyroid hypofunction is common after mantle irradiation for Hodgkin"s disease and raised serum thyroglobulin levels are a sensitive indicator of TSH stimulation of the damaged thyroid gland.	Thyrotropin	150-153	thyroglobulin	Homo sapiens	100-113
6194648-1	1983	Serum alpha-fetoprotein (AFP) was analysed at 10-30 days of age in infants with positive TSH screening tests for congenital hypothyroidism.	Thyrotropin	89-92	alpha fetoprotein	Homo sapiens	6-23
6860668-3	1983	TSH-dependent increases in labeling of histones H1 and H3, and of the high mobility group protein HMG 14, were observed at 2 h; however, there were no apparent changes in TSH-dependent labeling between 2 and 5 h, in nuclease-sensitive or in bulk chromatin.	Thyrotropin	0-3	high mobility group nucleosome binding domain 1	Homo sapiens	98-104
6411454-5	1983	Finally, BW48-80 promoted an elevation of TSH serum concentration in T4-primed thyroidectomized rats.	Thyrotropin	42-45	Body weight QTL 48	Rattus norvegicus	9-13
6862166-9	1983	Since PRL is without effects on thyroid hormone clearance patterns or deiodination rate, we conclude that PRL prevents TSH-induced increases in serum T4 in this species by directly affecting thyroid function.	Thyrotropin	119-122	prolactin	Fundulus heteroclitus	106-109
6407480-0	1983	Neurotensin regulation of TSH secretion in the rat.	Thyrotropin	26-29	neurotensin	Rattus norvegicus	0-11
6407480-3	1983	In addition neurotensin has a direct inhibitory effect on TRH-stimulated TSH release from anterior pituitary in vitro.	Thyrotropin	73-76	neurotensin	Rattus norvegicus	12-23
6407480-4	1983	These observations suggest a physiological role for neurotensin in the control of TSH secretion in the rat.	Thyrotropin	82-85	neurotensin	Rattus norvegicus	52-63
6601001-6	1983	EGF added at the same concentrations that stimulated incorporation of [3H]thymidine was found to reduce iodide metabolism of the follicles within 30 min of addition; both TSH-stimulated efflux and organification of [125I]iodide were suppressed by the addition of EGF.	Thyrotropin	171-174	epidermal growth factor	Homo sapiens	0-3
6601001-6	1983	EGF added at the same concentrations that stimulated incorporation of [3H]thymidine was found to reduce iodide metabolism of the follicles within 30 min of addition; both TSH-stimulated efflux and organification of [125I]iodide were suppressed by the addition of EGF.	Thyrotropin	171-174	epidermal growth factor	Homo sapiens	263-266
6407102-6	1983	In euthyroid TRH-TSH-unresponsive patients under T4 (simple goiter, differentiated thyroid carcinoma) thyrotropic function may not be completely suppressed.	Thyrotropin	17-20	thyrotropin releasing hormone	Homo sapiens	13-16
6306431-13	1983	The same dose of TSH produced only a 3-fold induction of ODC in rats hypophysectomized 2 weeks previously.	Thyrotropin	17-20	ornithine decarboxylase 1	Rattus norvegicus	57-60
6306431-15	1983	Thyroids from rats chronically stimulated for 14 days showed an increase in ornithine decarboxylase following TSH administration similar to that of control rats.	Thyrotropin	110-113	ornithine decarboxylase 1	Rattus norvegicus	76-99
6407102-7	1983	In euthyroid TRH-TSH-unresponsive patients with an autonomously functioning adenoma, additional exogenous suppression should be evaluated for protection of paranodular tissue before ablative radioiodine is given.	Thyrotropin	17-20	thyrotropin releasing hormone	Homo sapiens	13-16
6842121-1	1983	Neurotensin is a hypothalamic peptide which inhibits secretion of TSH in the rat in vivo.	Thyrotropin	66-69	neurotensin	Rattus norvegicus	0-11
6416819-0	1983	The suppression of TSH in the presence of the normal PRL responses to TRH out of 26 patients with primary hyperparathyroidism.	Thyrotropin	19-22	prolactin	Homo sapiens	53-56
6304605-3	1983	In order to study the role of thyroid releasing hormone (TRH) in the control of thyroid stimulating hormone (TSH) secretion during the neonatal period, we measured the binding of [3H]-TRH to pituitary homogenate of rats at various stages of development.	Thyrotropin	80-107	thyrotropin releasing hormone	Rattus norvegicus	57-60
6304605-3	1983	In order to study the role of thyroid releasing hormone (TRH) in the control of thyroid stimulating hormone (TSH) secretion during the neonatal period, we measured the binding of [3H]-TRH to pituitary homogenate of rats at various stages of development.	Thyrotropin	109-112	thyrotropin releasing hormone	Rattus norvegicus	57-60
6304605-3	1983	In order to study the role of thyroid releasing hormone (TRH) in the control of thyroid stimulating hormone (TSH) secretion during the neonatal period, we measured the binding of [3H]-TRH to pituitary homogenate of rats at various stages of development.	Thyrotropin	109-112	thyrotropin releasing hormone	Rattus norvegicus	184-187
6304605-8	1983	These studies thus indicate that TRH binding sites are present during the neonatal period in the rat and suggest that TRH may be an important modulator of TSH secretion during this period in the rat and that these effects are mediated by postreceptor mechanisms.	Thyrotropin	155-158	thyrotropin releasing hormone	Rattus norvegicus	33-36
6304605-8	1983	These studies thus indicate that TRH binding sites are present during the neonatal period in the rat and suggest that TRH may be an important modulator of TSH secretion during this period in the rat and that these effects are mediated by postreceptor mechanisms.	Thyrotropin	155-158	thyrotropin releasing hormone	Rattus norvegicus	118-121
6401762-1	1983	To determine the impact of induced hypo- and hypercalcemia on TRH (400 micrograms)-stimulated TSH and PRL release, healthy subjects (n = 11) were infused with 5% glucose in water (n = 11), disodium EDTA (n = 11), or calcium gluconate (n = 7).	Thyrotropin	94-97	thyrotropin releasing hormone	Homo sapiens	62-65
6862357-0	1983	Effect of hypophysectomy and administration of TSH on the activity of monoamine oxidase in the thyroid gland of rats.	Thyrotropin	47-50	monoamine oxidase A	Rattus norvegicus	70-87
6862357-1	1983	The thyroid monoamine oxidase (MAO) activity was measured in rats after hypophysectomy and TSH treatment to find out whether the thyroid MAO activity can be modified with TSH.	Thyrotropin	91-94	monoamine oxidase A	Rattus norvegicus	12-29
6862357-1	1983	The thyroid monoamine oxidase (MAO) activity was measured in rats after hypophysectomy and TSH treatment to find out whether the thyroid MAO activity can be modified with TSH.	Thyrotropin	91-94	monoamine oxidase A	Rattus norvegicus	31-34
6862357-1	1983	The thyroid monoamine oxidase (MAO) activity was measured in rats after hypophysectomy and TSH treatment to find out whether the thyroid MAO activity can be modified with TSH.	Thyrotropin	171-174	monoamine oxidase A	Rattus norvegicus	137-140
6862357-3	1983	The administration of TSH (2.5 U kg-1 daily for 5 days) to hypophysectomized rats increased MAO activity and fully compensated the absence of the pituitary.	Thyrotropin	22-25	monoamine oxidase A	Rattus norvegicus	92-95
6844904-9	1983	TG is TSH-dependent and increases after withdrawal of T3 replacement therapy.	Thyrotropin	6-9	thyroglobulin	Homo sapiens	0-2
6132345-6	1983	The inclusion of somatostatin-14 (3 X 10(-9) M) in the perfusate inhibited TRH-stimulated TSH release.	Thyrotropin	90-93	thyrotropin releasing hormone	Rattus norvegicus	75-78
6404226-3	1983	Among children known to be hypothyroid 93% had abnormal TRH stimulation tests, but 35% of those children who were clinically euthyroid and who had normal serum thyroxin levels also had abnormal TSH responses to TRH.	Thyrotropin	194-197	thyrotropin releasing hormone	Homo sapiens	211-214
6406112-8	1983	A delayed (hypothalamic) serum TSH response to TRH (60 greater than 20-min level) developed at 6 months.	Thyrotropin	31-34	thyrotropin releasing hormone	Homo sapiens	47-50
6403887-0	1983	Factors involved in the attenuation of the TSH response to a second injection of TRH in the rat.	Thyrotropin	43-46	thyrotropin releasing hormone	Rattus norvegicus	81-84
6146290-8	1983	In conclusion, the inhibiting effect of exogenous Somatostatin is evident whenever TSH levels are high for pathological conditions or for drug stimulation.	Thyrotropin	83-86	somatostatin	Homo sapiens	50-62
6847868-4	1983	On the other hand, a positive correlation was found between serum TSH and Tg levels (rs = 0.455; r = 0.421; P less than 0.01).	Thyrotropin	66-69	thyroglobulin	Homo sapiens	74-76
6297216-6	1983	The results suggest that this serum contained an anti-TSH receptor auto-antibody directed towards a different determinant on the TSH receptor than the TSH binding site.	Thyrotropin	54-57	thyroid stimulating hormone receptor	Homo sapiens	129-141
6847868-7	1983	Also, a direct correlation was noted between serum TSH and Tg levels.	Thyrotropin	51-54	thyroglobulin	Homo sapiens	59-61
6817414-5	1982	All groups, including the group without measurable TSH response (1 mE/1) showed an increase in peripheral thyroid hormone concentration after TRH.	Thyrotropin	51-54	thyrotropin releasing hormone	Homo sapiens	142-145
6298681-2	1983	3/6 patients receiving only cytotoxic drugs developed a marked suppression of the TSH response to TRH and 1 of these patients showed an impairment of the adrenal function under chemotherapy.	Thyrotropin	82-85	thyrotropin releasing hormone	Homo sapiens	98-101
6412314-0	1983	The TSH-response to TRH: A possible predictor of outcome to antidepressant and neuroleptic treatment.	Thyrotropin	4-7	thyrotropin releasing hormone	Homo sapiens	20-23
6412314-4	1983	The change of TSH-response to TRH during treatment, i.e. the treatment associated normalization of a former blunted TSH-response, can tentatively be regarded as a predictor of outcome for depressive and paranoid-hallucinatory patients to their respective drug treatments.	Thyrotropin	14-17	thyrotropin releasing hormone	Homo sapiens	30-33
6412314-4	1983	The change of TSH-response to TRH during treatment, i.e. the treatment associated normalization of a former blunted TSH-response, can tentatively be regarded as a predictor of outcome for depressive and paranoid-hallucinatory patients to their respective drug treatments.	Thyrotropin	116-119	thyrotropin releasing hormone	Homo sapiens	30-33
6128803-5	1982	In this subject SS-28 was found to be approximately 16 times more potent than SS-14 in the inhibition of TSH release.	Thyrotropin	105-108	somatostatin	Homo sapiens	16-21
6128803-5	1982	In this subject SS-28 was found to be approximately 16 times more potent than SS-14 in the inhibition of TSH release.	Thyrotropin	105-108	somatostatin	Homo sapiens	78-83
6818803-6	1982	In all 4 cases serum TSH sharply increased after TRH administration.	Thyrotropin	21-24	thyrotropin releasing hormone	Homo sapiens	49-52
6819904-0	1982	Effects of oral and intravenous TRH and metoclopramide on PRL and TSH secretion in women.	Thyrotropin	66-69	thyrotropin releasing hormone	Homo sapiens	32-35
6819904-13	1982	These results demonstrate that dopaminergic and TRH-mediated mechanisms are related in the control of PRL and TSH secretions, perhaps directly or through thyroid hormones.	Thyrotropin	110-113	thyrotropin releasing hormone	Homo sapiens	48-51
6222895-7	1982	The plasma TSH response to TRH was decreased, but not significantly.	Thyrotropin	11-14	thyrotropin releasing hormone	Rattus norvegicus	27-30
7140639-3	1982	At 10(-5) M, the two agents used for cholecystography (ipodate and iopanoic acid) inhibited the TSH-stimulated secretion of T3 [ipodate, 69 +/- 8% of control (P less than 0.05); mean +/- SE; n =4] and rT2 [iopanoic acid 59 +/- 9% (P less than 0.01); iopanoic acid, 61 +/- 9% (P less than 0.05)], whereas T4 secretion was not significantly altered.	Thyrotropin	96-99	brachyury 2	Rattus norvegicus	201-204
6818805-0	1982	Lack of influence of the antidopaminergic drug domperidone on basal and TRH-stimulated TSH-serum levels after oral administration.	Thyrotropin	87-90	thyrotropin releasing hormone	Homo sapiens	72-75
6818805-1	1982	Since antidopaminergic drugs are known to elevate basal and TRH-stimulated TSH-serum levels and since this effect was also shown after iv administration of the novel dopamine antagonistic agent domperidone, it was investigated, whether this antiemetic drug could interfere after oral intake with the evaluation of thyroid function.	Thyrotropin	75-78	thyrotropin releasing hormone	Homo sapiens	60-63
6131817-8	1982	PRL and TSH secretion is more dependent on the presence of extracellular Ca2+ than the release of GH.	Thyrotropin	8-11	carbonic anhydrase 2	Rattus norvegicus	73-76
7143091-6	1982	These data indicate that the duration and the severity of hypothyroidism are important factors in the rise of serum Mb, and that the normalization of serum Mb is faster than that of serum TSH and requires less L-T4 than that needed for normal TSH secretion.	Thyrotropin	243-246	myoglobin	Homo sapiens	156-158
6127595-8	1982	The presence of 10(-4)m cycloheximide in NaCl(+) medium enhanced the c-AMP response to physiological concentrations of TSH.	Thyrotropin	119-122	cathelicidin antimicrobial peptide	Homo sapiens	69-74
6816488-20	1982	TSH responses following TRH stimulation were significantly less in the MD patients (323 +/- 141 v. 529 +/- 240%; P less than 0.0025).	Thyrotropin	0-3	thyrotropin releasing hormone	Homo sapiens	24-27
6816488-29	1982	It is concluded that in MD: 1 palpable thyroid gland abnormalities occur with increased frequency, 15% (three/twenty) in the present study and 20% (twenty/102 case reports) from a review of the literature; 2 TSH responses to TRH are significantly reduced; 3 circulating thyroid hormone levels are usually normal.	Thyrotropin	208-211	thyrotropin releasing hormone	Homo sapiens	225-228
6814369-7	1982	There was good overall correlation of peak prolactin with peak, TSH concentrations.	Thyrotropin	64-67	prolactin	Homo sapiens	43-52
6819131-4	1982	Response of TSH secretion to iv TRH was found to be either normal, lowered or absent.	Thyrotropin	12-15	thyrotropin releasing hormone	Homo sapiens	32-35
6812433-7	1982	We conclude that TRH displaced Ca2+ from an energy-dependent, membrane-bound pool(s) within TtT cells and that this may be one mechanism by which the concentration of intracellular free Ca2+ is raised so that is couples stimulation by TRH to TSH secretion.	Thyrotropin	242-245	thyrotropin releasing hormone	Mus musculus	17-20
6812433-7	1982	We conclude that TRH displaced Ca2+ from an energy-dependent, membrane-bound pool(s) within TtT cells and that this may be one mechanism by which the concentration of intracellular free Ca2+ is raised so that is couples stimulation by TRH to TSH secretion.	Thyrotropin	242-245	thyrotropin releasing hormone	Mus musculus	235-238
6819131-6	1982	Although decreased thyroxine levels may be due to increased thyroid hormone degradation it appears that associated impaired TSH responsiveness to TRH may result from illness-related inhibition of pituitary TSH release.	Thyrotropin	124-127	thyrotropin releasing hormone	Homo sapiens	146-149
6806525-3	1982	However, after prolonged oral stimulation with 40 mg TRH, after 120-180 min TSH was normal (greater than 2.7 microU/ml) in 15 and subnormal (less than 2.7 microU/ml) in two patients.	Thyrotropin	76-79	thyrotropin releasing hormone	Homo sapiens	53-56
6804214-7	1982	On the other hand, TRH induced the release of TSH and PRL from the first day of life and no sex difference was observed.	Thyrotropin	46-49	thyrotropin releasing hormone	Rattus norvegicus	19-22
6801992-0	1982	Evidence that TRH stimulates secretion of TSH by two calcium-mediated mechanisms.	Thyrotropin	42-45	thyrotropin releasing hormone	Mus musculus	14-17
6804446-2	1982	The TSH response to TRH infusion curves for unipolar and bipolar depressives were significantly different.	Thyrotropin	4-7	thyrotropin releasing hormone	Homo sapiens	20-23
6804753-4	1982	Following intravenous injection of TRH, basal TSH levels of 2.7 and 2.8 microunits/ml increased to peak values of 17 and 21 microunits/ml at 30 min in the daughter and mother, respectively.	Thyrotropin	46-49	thyrotropin releasing hormone	Homo sapiens	35-38
6804753-5	1982	Administration of exogenous T3 followed by sequential testing with boluses of TRH revealed retention of TSH responsiveness in both daughter and mother during pretreatment with dosage regimens of T3 below 125 micrograms daily.	Thyrotropin	104-107	thyrotropin releasing hormone	Homo sapiens	78-81
6804753-6	1982	Maintenance of TSH responsiveness to TRH in the presence of elevated levels of serum free T4 and serum T3 indicates relative pituitary insensitivity to thyroid hormone which could be overridden by increasing the circulating levels of serum T3 three to fivefold over the already elevated basal levels.	Thyrotropin	15-18	thyrotropin releasing hormone	Homo sapiens	37-40
6460611-0	1982	TSH stimulates 32P-labeling of thyroid nuclear HMG 14, a protein associated with actively transcribed chromatin.	Thyrotropin	0-3	high mobility group nucleosome binding domain 1	Homo sapiens	47-53
6460611-3	1982	We found that TSH enhanced the labeling of the high mobility group protein HMG 14, a protein that is preferentially associated with actively transcribed chromatin.	Thyrotropin	14-17	high mobility group nucleosome binding domain 1	Homo sapiens	75-81
6460611-4	1982	This observation suggests that changes in HMG 14 phosphorylation may be involved in mediating TSH-induced effects on the structure and function of active chromatin.	Thyrotropin	94-97	high mobility group nucleosome binding domain 1	Homo sapiens	42-48
6801992-2	1982	We demonstrate that TRH action in TtT cells does not require extracellular Ca2+ but that Ca2+ influx induced by TRH can augment TSH secretion.	Thyrotropin	128-131	thyrotropin releasing hormone	Mus musculus	20-23
6801992-2	1982	We demonstrate that TRH action in TtT cells does not require extracellular Ca2+ but that Ca2+ influx induced by TRH can augment TSH secretion.	Thyrotropin	128-131	thyrotropin releasing hormone	Mus musculus	112-115
6801992-5	1982	In contrast to the effect of 50 mM K+, which also causes Ca2+ influx, TRH caused 45Ca2+ efflux and TSH release from TtT cells even when the concentration of Ca2+ in the medium was lowered below 100 micro M. TRH stimulated TSH release during perifusion in medium in which the free Ca2+ concentration was lowered to approximately 0.02 micro M, and reintroduction of Ca2+ into the medium simultaneously with TRH markedly increased TSH release.	Thyrotropin	99-102	thyrotropin releasing hormone	Mus musculus	70-73
6801992-5	1982	In contrast to the effect of 50 mM K+, which also causes Ca2+ influx, TRH caused 45Ca2+ efflux and TSH release from TtT cells even when the concentration of Ca2+ in the medium was lowered below 100 micro M. TRH stimulated TSH release during perifusion in medium in which the free Ca2+ concentration was lowered to approximately 0.02 micro M, and reintroduction of Ca2+ into the medium simultaneously with TRH markedly increased TSH release.	Thyrotropin	222-225	thyrotropin releasing hormone	Mus musculus	70-73
6801992-5	1982	In contrast to the effect of 50 mM K+, which also causes Ca2+ influx, TRH caused 45Ca2+ efflux and TSH release from TtT cells even when the concentration of Ca2+ in the medium was lowered below 100 micro M. TRH stimulated TSH release during perifusion in medium in which the free Ca2+ concentration was lowered to approximately 0.02 micro M, and reintroduction of Ca2+ into the medium simultaneously with TRH markedly increased TSH release.	Thyrotropin	222-225	thyrotropin releasing hormone	Mus musculus	70-73
6801992-6	1982	We suggest that TRH may affect Ca2+ metabolism in TtT cells by both extracellular Ca2+-independent and -dependent mechanisms and that this dual mechanism of action serves to augment further TSH secretion induced by TRH.	Thyrotropin	190-193	thyrotropin releasing hormone	Mus musculus	16-19
6801992-6	1982	We suggest that TRH may affect Ca2+ metabolism in TtT cells by both extracellular Ca2+-independent and -dependent mechanisms and that this dual mechanism of action serves to augment further TSH secretion induced by TRH.	Thyrotropin	190-193	thyrotropin releasing hormone	Mus musculus	215-218
6119059-5	1982	Mean serum GGT levels were decreased in patients with hypothyroidism and correlated well with serum TSH levels.	Thyrotropin	100-103	gamma-glutamyltransferase 2, pseudogene	Homo sapiens	11-14
6820240-7	1982	When hemipituitaries of ovariectomized rats were incubated in vitro, neurotensin elevated prolactin and TSH release into the medium.	Thyrotropin	104-107	neurotensin	Rattus norvegicus	69-80
6896174-5	1982	As could be predicted by its trophic action, TSH stimulated the generation of NADPH by glucose 6-phosphate dehydrogenase.	Thyrotropin	45-48	glucose-6-phosphate dehydrogenase	Homo sapiens	87-120
6126274-2	1982	At day 1, control cells cultured without TSH formed flat, cylinder-like aggregates in which APN was mainly located on the lateral surface.	Thyrotropin	41-44	alanyl aminopeptidase, membrane	Homo sapiens	92-95
6758014-3	1982	Serum GH concentration increased after GnRH in both normal and depressed men; serum TSH increased after GnRH in both normal women and bipolar women, but not in unipolar depressed women.	Thyrotropin	84-87	gonadotropin releasing hormone 1	Homo sapiens	104-108
6808537-0	1982	Delayed TSH release in anorexia nervosa following injection of thyrotropin-releasing hormone (TRH).	Thyrotropin	8-11	thyrotropin releasing hormone	Homo sapiens	63-92
6808537-0	1982	Delayed TSH release in anorexia nervosa following injection of thyrotropin-releasing hormone (TRH).	Thyrotropin	8-11	thyrotropin releasing hormone	Homo sapiens	94-97
6758014-4	1982	Further studies comparing GnRH to saline infusion will be necessary to determine if the GH and TSH responses seen in this study are due to GnRH or result from the stress of the experimental procedures.	Thyrotropin	95-98	gonadotropin releasing hormone 1	Homo sapiens	26-30
6808537-3	1982	The TSH secretory response to TRH was delayed and prolonged during the initial study but showed a normal overall quantitative response, except for two patients who showed no TSH rise.	Thyrotropin	4-7	thyrotropin releasing hormone	Homo sapiens	30-33
6758014-4	1982	Further studies comparing GnRH to saline infusion will be necessary to determine if the GH and TSH responses seen in this study are due to GnRH or result from the stress of the experimental procedures.	Thyrotropin	95-98	gonadotropin releasing hormone 1	Homo sapiens	139-143
6793616-2	1981	Initial serum concentrations of T4, T3, and TSH were 22.1 micrograms/dl, 334 ng/dl, and 7.6 microunits/ml, respectively; infusion of synthetic TRH increased the serum TSH to 47.4 microunits/ml, an exaggerated response.	Thyrotropin	44-47	thyrotropin releasing hormone	Homo sapiens	143-146
6817360-5	1982	On the other hand, a.m. and p.m. basal and TRH-stimulated TSH responses were virtually identical.	Thyrotropin	58-61	thyrotropin releasing hormone	Homo sapiens	43-46
6802152-0	1981	[Behavior of triiodothyronine, tetraiodothyronine and thyrotropin during the TRH test].	Thyrotropin	54-65	thyrotropin releasing hormone	Homo sapiens	77-80
6795032-5	1981	mPO lesions anterior to the PVN induced a transient elevation of plasma TSH and GH only in hypothyroid rats.	Thyrotropin	72-75	myeloperoxidase	Mus musculus	0-3
7327291-2	1981	Both exogenous and endogenous TSH promptly stimulated the activity of thyroid ornithine decarboxylase (ODC) and S-adenosyl-L-methionine decarboxylase.	Thyrotropin	30-33	ornithine decarboxylase 1	Homo sapiens	78-101
7327291-2	1981	Both exogenous and endogenous TSH promptly stimulated the activity of thyroid ornithine decarboxylase (ODC) and S-adenosyl-L-methionine decarboxylase.	Thyrotropin	30-33	ornithine decarboxylase 1	Homo sapiens	103-106
6272954-2	1981	Membrane 123I-insulin binding was inhibited by unlabelled insulin, at a lower degree by proinsulin, not at all by TSH and GH.	Thyrotropin	114-117	insulin	Bos taurus	14-21
6795101-5	1981	Combined administration of prolactin and TSH to hypophysectomized animals showed that prolactin is capable of partially inhibiting the TSH-induced increase.	Thyrotropin	41-44	prolactin	Rattus norvegicus	86-95
6793616-2	1981	Initial serum concentrations of T4, T3, and TSH were 22.1 micrograms/dl, 334 ng/dl, and 7.6 microunits/ml, respectively; infusion of synthetic TRH increased the serum TSH to 47.4 microunits/ml, an exaggerated response.	Thyrotropin	167-170	thyrotropin releasing hormone	Homo sapiens	143-146
6793616-4	1981	Four times the calculated replacement dose of T3 (40 micrograms/day) was required to normalize the serum T4 and the serum TSH response to TRH.	Thyrotropin	122-125	thyrotropin releasing hormone	Homo sapiens	138-141
6793616-5	1981	After administration of 80 micrograms/day T3, the serum TSH response to TRH was virtually abolished, but no clinical signs of thyroid hormone excess were observed.	Thyrotropin	56-59	thyrotropin releasing hormone	Homo sapiens	72-75
6792914-5	1981	Two patients who had previously undergone subtotal thyroidectomy had elevated baseline serum TSH levels and exaggerated TSH responses to the administration of TRH suggesting subclinical hypothyroidism despite elevated total and free thyroid hormone levels.	Thyrotropin	120-123	thyrotropin releasing hormone	Homo sapiens	159-162
6798539-6	1981	Administration of TRH resulted in a clear increase in both TSH and T4 levels in all infants.	Thyrotropin	59-62	thyrotropin releasing hormone	Homo sapiens	18-21
6792914-7	1981	In addition, the absence of hypothyroidism and normal responsiveness of serum TSH to TRH and L-triiodothyronine administration in untreated family members suggest that the thyroid has compensated for the hormone resistance by increased secretory activity under the control of pituitary TSH secretion.	Thyrotropin	78-81	thyrotropin releasing hormone	Homo sapiens	85-88
6803047-5	1981	the TRH test revealed normal but delayed response of TSH.	Thyrotropin	53-56	thyrotropin releasing hormone	Homo sapiens	4-7
6114108-4	1981	Tg (3 X 10(-8) M) caused a significant reduction in the TSH- and TSI-stimulated adenylate cyclase activities, but did not influence stimulation with NaF (8 mM).	Thyrotropin	56-59	thyroglobulin	Homo sapiens	0-2
6114108-6	1981	Thus, Tg is an efficient inhibitor of basal and TSH- or TSI- stimulated adenylate cyclase activities, and might be involved in a short loop counterregulation of thyroid adenylate cyclase sensitivity in vivo.	Thyrotropin	48-51	thyroglobulin	Homo sapiens	6-8
7215306-2	1981	Treated under the same conditions [3 h at 37 C; enzyme to hCG ratio, 0.04 (wt/wt)], partially and highly purified hCG preparations display an increase of about 300% in thyroid AC-stimulating activity, while TSH displays a 30% decrease.	Thyrotropin	207-210	chorionic gonadotropin subunit beta 5	Homo sapiens	114-117
6785072-3	1981	TRH, high K+, and Ba2+ resulted in a 2-fold or greater stimulation of TSH release.	Thyrotropin	70-73	thyrotropin releasing hormone	Rattus norvegicus	0-3
6785072-6	1981	Perifusion with 3.5 x 10(-5) M cycloheximide or 10(-6) M actinomycin D 1 h before and during T3 administration led to greater TSH release with TRH than in the presence of T3 alone.	Thyrotropin	126-129	thyrotropin releasing hormone	Rattus norvegicus	143-146
6784424-6	1981	The peak TSH response to TRH was 18.4 +/- 7.4 muU/ml in testicular failure and significantly greater than in the young controls, where it was 11.5 +/- 5.0 muU/ml.	Thyrotropin	9-12	thyrotropin releasing hormone	Homo sapiens	25-28
6787920-0	1981	Blunted TSH response to TRH in patients with central nervous system disease.	Thyrotropin	8-11	thyrotropin releasing hormone	Homo sapiens	24-27
7211104-2	1981	The maximal increment of plasma TSH to TRH was 3.8 +/- 2.2 vs 8.7 +/- 2.9 muU/ml (patients with Cushing"s disease vs controls; mean +/- SD; P less than 0.001).	Thyrotropin	32-35	thyrotropin releasing hormone	Homo sapiens	39-42
6273137-5	1981	There was a definite inverse correlation between ;the logarithm for urinary 17-OHCS excretion and the peak TSH response to TRH.	Thyrotropin	107-110	thyrotropin releasing hormone	Homo sapiens	123-126
6781874-2	1981	Subcutaneous administration of 1 ng/g BW TRH caused a greater rise in plasma TSH in the hypothyroid pups than in their mothers.	Thyrotropin	77-80	thyrotropin releasing hormone	Rattus norvegicus	41-44
6782115-7	1981	The significance of these findings is discussed in relation to the milk let-down reflex and the relationship of TSH to PRL.	Thyrotropin	112-115	prolactin	Homo sapiens	119-122
6455462-6	1981	In the bipolar group, the premenopausal depressive patients had a significantly lower TSH response to TRH than premenopausal controls.	Thyrotropin	86-89	thyrotropin releasing hormone	Homo sapiens	102-105
7212062-17	1981	It was concluded that 1) the plasma T4 exerts a negative feedback on basal TSH secretion in addition to that due to plasma T3 and 2) small amounts of T4 replacement enhance the TSH response to exogenous TRH in short-term hypothyroid rats.	Thyrotropin	75-78	thyrotropin releasing hormone	Rattus norvegicus	203-206
7212062-17	1981	It was concluded that 1) the plasma T4 exerts a negative feedback on basal TSH secretion in addition to that due to plasma T3 and 2) small amounts of T4 replacement enhance the TSH response to exogenous TRH in short-term hypothyroid rats.	Thyrotropin	177-180	thyrotropin releasing hormone	Rattus norvegicus	203-206
6787114-1	1981	Previous studies have demonstrated immunocytochemical staining for beta chains of thyroid stimulating hormone (TSH-beta) in rough endoplasmic reticulum of pituitary cells hypertrophied after thyroidectomy ("thyroidectomy cells") (Moriarty CG(1976): J Histochem Cytochem (24:846; Moriarty GC, Tobin RB (1976): J Histochem Cytochem 24:1140).	Thyrotropin	82-109	thyroid stimulating hormone subunit beta	Rattus norvegicus	111-119
7227969-1	1981	Daunomycin (DM), a potent chemotherapeutic agent, was linked to bovine thyrotropin (TSH) directly (TSH-DM) and indirectly (TSH-alpha-lactalbumin-DM) by covalent cross-linking methods.	Thyrotropin	84-87	glycoprotein hormones, alpha polypeptide	Bos taurus	123-132
6787114-6	1981	In this study, the radioimmunoassay showed that TSH content rose dramatically in the hypothyroid animals treated with PTU for 77 days and thyroxine for 2 days before death (from 8.5--64.1 mU/mg wet wt); however, the rise in TRH content was minimal (5.8--9.8 pg/mg wet wt).	Thyrotropin	48-51	thyrotropin releasing hormone	Rattus norvegicus	224-227
6893991-3	1981	The CEA levels were inversely correlated with the serum T4 concentrations (P less than 0.001) and were positively correlated with the serum TSH concentrations (P less than 0.001), but not with the titers of serum antithyroid antibodies or the size of goiter in autoimmune thyroid disease.	Thyrotropin	140-143	CEA cell adhesion molecule 3	Homo sapiens	4-7
6455047-8	1981	Therefore, 1) decreased TSH release in TX rats treated with T3 was induced by the block of TRH release from the AHN and ME as compared with the TX group, and 2) elevated serum TSH levels in 4 degrees C cold stress might be induced by the release of TRH from the PMD and PV.	Thyrotropin	24-27	thyrotropin releasing hormone	Rattus norvegicus	91-94
6455047-8	1981	Therefore, 1) decreased TSH release in TX rats treated with T3 was induced by the block of TRH release from the AHN and ME as compared with the TX group, and 2) elevated serum TSH levels in 4 degrees C cold stress might be induced by the release of TRH from the PMD and PV.	Thyrotropin	176-179	thyrotropin releasing hormone	Rattus norvegicus	249-252
6790201-8	1981	The presence of an exaggerated TSH response to DA antagonism in a euthyroid, radiologically normal (plain skull X-ray), hyperprolactinaemic patient is compatible with the presence of an autonomously-functioning, PRL secreting, pituitary microadenoma and the TSH changes seen in these patients after DA antagonist administration can be readily detected by sensitive TSH radioimmunoassay.	Thyrotropin	31-34	prolactin	Homo sapiens	212-215
6781851-5	1981	Correspondingly, TRH-stimulated TSH secretion was definitely lower on the day of treatment.	Thyrotropin	32-35	thyrotropin releasing hormone	Homo sapiens	17-20
6114918-5	1981	T3 (2.0 microgram/dl) inhibits TRH-induced TSH secretion by superfused pituitary fragments, but not by dispersed cells.	Thyrotropin	43-46	thyrotropin releasing hormone	Homo sapiens	31-34
6782838-2	1981	The basal as well as the TRH-stimulated increase in serum PRL was significantly elevated in the cirrhotic males, while the increase in serum TSH was unchanged, compared with hypertensive and normal men.	Thyrotropin	141-144	thyrotropin releasing hormone	Homo sapiens	25-28
6791450-2	1981	In all patients (age 15-91 years) maximal TSH-levels 180 min after 40 mg TRH are significantly (p less than 0.01) higher than maximal TSH-levels 30 min after 100 micrograms TRH.	Thyrotropin	42-45	thyrotropin releasing hormone	Homo sapiens	73-76
6791450-11	1981	40 mg TRH orally does not show any false positive findings, because TSH-stimulation is longer and more intensive.	Thyrotropin	68-71	thyrotropin releasing hormone	Homo sapiens	6-9
6787109-2	1981	After a significant rise the serum T4 concentration for 5 days in euthyroid and for 11 days in hypothyroid patients an inhibition of basal and of TRH stimulated TSH release was observed.	Thyrotropin	161-164	thyrotropin releasing hormone	Homo sapiens	146-149
6780312-4	1981	The administration of synthetic TRH during the neonatal period induced a significant increase of serum TSH in the newborn; however, TSH release by the pituitary gland increased progressively from days 3-10.	Thyrotropin	103-106	thyrotropin releasing hormone	Rattus norvegicus	32-35
6780312-4	1981	The administration of synthetic TRH during the neonatal period induced a significant increase of serum TSH in the newborn; however, TSH release by the pituitary gland increased progressively from days 3-10.	Thyrotropin	132-135	thyrotropin releasing hormone	Rattus norvegicus	32-35
6780312-7	1981	It is concluded that neonatal pituitary-thyroid function in the rat is not physiologically dependent upon TRH secretion, although synthetic TRH is able to stimulate the secretion of TSH at birth.	Thyrotropin	182-185	thyrotropin releasing hormone	Rattus norvegicus	140-143
6452643-0	1981	Lithium influence of TSH response of TRH in depressed patients.	Thyrotropin	21-24	thyrotropin releasing hormone	Homo sapiens	37-40
6782601-2	1981	The plasma TSH responses to TRH were not different between the two groups before lithium treatment.	Thyrotropin	11-14	thyrotropin releasing hormone	Homo sapiens	28-31
6780753-0	1981	TSH response to TRH in euthyroid, hypercholesterolemic patients treated with graded doses of dextrothyroxine.	Thyrotropin	0-3	thyrotropin releasing hormone	Homo sapiens	16-19
6782601-3	1981	Lithium administration did not alter non-stimulated secretion of TSH in any groups, but resulted in exaggerated responses of plasma TSH to TRH in both groups.	Thyrotropin	132-135	thyrotropin releasing hormone	Homo sapiens	139-142
7236239-4	1980	This iodination was linear for 6h with no apparent Km for iodide of 1.5 muM, was stimulated by thyrotropin or N6O2"-dibutyryladenosine 3":5"-cyclic monophosphate, yielded mostly iodinated thyroglobulin and was efficient for tetraiodothyronine synthesis.	Thyrotropin	95-106	latexin	Homo sapiens	72-75
6185989-2	1981	After 4 days of culture and 1-hr labelling with 35S Met, Tgb specific radioactivity was 10 times higher in TSH-treated cells than in control cells.	Thyrotropin	107-110	thyroglobulin	Homo sapiens	57-60
6185989-6	1981	ii) The relative amount of Tgb mRNA in the cytoplasm of TSH-treated cells was 3 times higher than in the control cells.	Thyrotropin	56-59	thyroglobulin	Homo sapiens	27-30
6185989-7	1981	This correlates with the fact that Tgb biosynthesis relative to total protein synthesis increased similarly, indicating that TSH controls relative Tgb biosynthesis by specifically regulating cytoplasmic Tgb mRNA content.	Thyrotropin	125-128	thyroglobulin	Homo sapiens	35-38
6185989-7	1981	This correlates with the fact that Tgb biosynthesis relative to total protein synthesis increased similarly, indicating that TSH controls relative Tgb biosynthesis by specifically regulating cytoplasmic Tgb mRNA content.	Thyrotropin	125-128	thyroglobulin	Homo sapiens	147-150
6185989-7	1981	This correlates with the fact that Tgb biosynthesis relative to total protein synthesis increased similarly, indicating that TSH controls relative Tgb biosynthesis by specifically regulating cytoplasmic Tgb mRNA content.	Thyrotropin	125-128	thyroglobulin	Homo sapiens	147-150
6775240-8	1980	It is known that TRH not only stimulates TSH secretion but will stimulate prolactin secretion as well.	Thyrotropin	41-44	thyrotropin releasing hormone	Rattus norvegicus	17-20
6159206-3	1980	TSH, dibutyryl cAMP, prostaglandin E1 (PGE1), and cholera toxin all stimulated dog thyroid ODC activity.	Thyrotropin	0-3	ornithine decarboxylase 1	Canis lupus familiaris	91-94
6165573-6	1980	The immunostained TSH, LH and FSH cells are different from the beta(R) corticotrophs, because anti-ACTH serum never reacts to the TSH, LH and FSH cells in the two adjacent sections.	Thyrotropin	18-21	proopiomelanocortin	Homo sapiens	99-103
6156819-3	1980	Dibutyryl cAMP, methylisobutylxanthine, and cholera toxin caused an increase in TSH release which was additive to that of TRH.	Thyrotropin	80-83	thyrotropin releasing hormone	Mus musculus	122-125
6156819-4	1980	TRH stimulated TSH release in a dose-dependent fashion; half-maximal stimulation occurred at approximately 0.6 nM but had no effect on total intracellular cAMP levels measured in the presence or absence of methylisobutylxanthine.	Thyrotropin	15-18	thyrotropin releasing hormone	Mus musculus	0-3
7430900-5	1980	Thyrotrophin (TSH) increased the rate of thyroglobulin hydrolysis and hormone release from both pools by up to four to six times the basal rate, the effect being maximal 2 h after administration of TSH and lasting for 6-8 h. The rate of thyroglobulin hydrolysis after TSH was similar in both pools but the rate of release of labelled iodothyronines was significantly higher from from the old pool.	Thyrotropin	14-17	thyroglobulin	Mus musculus	41-54
7430900-5	1980	Thyrotrophin (TSH) increased the rate of thyroglobulin hydrolysis and hormone release from both pools by up to four to six times the basal rate, the effect being maximal 2 h after administration of TSH and lasting for 6-8 h. The rate of thyroglobulin hydrolysis after TSH was similar in both pools but the rate of release of labelled iodothyronines was significantly higher from from the old pool.	Thyrotropin	14-17	thyroglobulin	Mus musculus	237-250
7372784-4	1980	The prevalence of a raised TSH concentration in late-onset insulin-dependent diabetics was no greater in patients requiring insulin within 3 months of diagnosis of diabetes than in those exhibiting secondary sulfonylurea failure, who required insulin more than 3 months after diagnosis.	Thyrotropin	27-30	insulin	Homo sapiens	59-66
6777284-4	1980	Basal and TRH-stimulated TSH release was markedly greater in the rats radiothyroidectomized within 12 h of birth than for the other 3 groups, probably reflecting greater thyroid damage at a critical time in development.	Thyrotropin	25-28	thyrotropin releasing hormone	Rattus norvegicus	10-13
7372784-4	1980	The prevalence of a raised TSH concentration in late-onset insulin-dependent diabetics was no greater in patients requiring insulin within 3 months of diagnosis of diabetes than in those exhibiting secondary sulfonylurea failure, who required insulin more than 3 months after diagnosis.	Thyrotropin	27-30	insulin	Homo sapiens	124-131
6775189-8	1980	TRH induced TSH release (indicating the activity of the regulatory system) is unchanged from 2/12 to 14 years.	Thyrotropin	12-15	thyrotropin releasing hormone	Homo sapiens	0-3
6773712-5	1980	However, a slight negative correlation between the dose of prednisolone administered and TSh responsiveness to TRH as well as serum triiodothyronine was established (P &lt; 0.05).	Thyrotropin	89-92	thyrotropin releasing hormone	Homo sapiens	111-114
6770566-3	1980	TSH response to synthetic thyrotrophin-releasing hormone (TRH) (200 microgram iv) was carried out in two cases and thyroid hormone response to bovine TSH (5 IU iv) was evaluated in 3 cases.	Thyrotropin	0-3	thyrotropin releasing hormone	Bos taurus	26-56
6770280-3	1980	Basal and TRH-stimulated thyroid-stimulating hormone (TSH) levels were higher in the hypothyroids, and the developmental patterns of basal TSH secretion and TSH reserve were parallel in the two groups, with maximal TSH secretion occurring at 30 days.	Thyrotropin	54-57	thyrotropin releasing hormone	Rattus norvegicus	10-13
6770566-3	1980	TSH response to synthetic thyrotrophin-releasing hormone (TRH) (200 microgram iv) was carried out in two cases and thyroid hormone response to bovine TSH (5 IU iv) was evaluated in 3 cases.	Thyrotropin	0-3	thyrotropin releasing hormone	Bos taurus	58-61
6770567-5	1980	Oral TRH entirely blocked the TSH response and significantly (P less than 0.01) blunted the Prl response to iv TRH stimulation.	Thyrotropin	30-33	thyrotropin releasing hormone	Homo sapiens	5-8
6992487-5	1980	The effect of TRH on TSH biosynthesis is presented as a biological application of this procedure.	Thyrotropin	21-24	thyrotropin releasing hormone	Rattus norvegicus	14-17
6769064-5	1980	In addition, TRH (0.1--10 mg/kg IP) or beta-Ala TRH treatment (1.0--10 mg/kg IP) for 9 days significantly reduced serum TSH levels in rats.	Thyrotropin	120-123	thyrotropin releasing hormone	Rattus norvegicus	13-16
6769064-5	1980	In addition, TRH (0.1--10 mg/kg IP) or beta-Ala TRH treatment (1.0--10 mg/kg IP) for 9 days significantly reduced serum TSH levels in rats.	Thyrotropin	120-123	thyrotropin releasing hormone	Rattus norvegicus	48-51
6784435-2	1980	In euthyroidism, TRH induced TSH response ranged from 2.5 microU to 45 microU TSH, measured three hours after oral administration.	Thyrotropin	29-32	thyrotropin releasing hormone	Homo sapiens	17-20
6892672-4	1980	Among patients who had positive responses of TSH to TRH, approximately 10 patients every 6 months were asked to stop thionamide therapy and were followed up for at least 1 year after discontinuation of drugs.	Thyrotropin	45-48	thyrotropin releasing hormone	Homo sapiens	52-55
6249567-6	1980	LH, FSH, ACTH, prolactin and insulin competed with TSH for the binding sites only in relatively very high concentrations.	Thyrotropin	51-54	proopiomelanocortin	Homo sapiens	9-13
6249567-6	1980	LH, FSH, ACTH, prolactin and insulin competed with TSH for the binding sites only in relatively very high concentrations.	Thyrotropin	51-54	insulin	Homo sapiens	29-36
6799705-0	1980	The effect of TRH and its analogues, (Pro-NH-NH2)3TRH and (2-Picolyl)1-TRH on TSH level in rat serum.	Thyrotropin	78-81	thyrotropin releasing hormone	Homo sapiens	14-17
6251967-3	1980	It is therefore suggested that cAMP may be a mediator of the proliferogenic effect of TSH on the thyroid in vivo.	Thyrotropin	86-89	cathelicidin antimicrobial peptide	Rattus norvegicus	31-35
6774943-0	1980	Prolactin, thyrotrophin interaction in the regulation of glucose-6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase activities in rat mammary glands.	Thyrotropin	11-23	glucose-6-phosphate dehydrogenase	Rattus norvegicus	57-90
6774943-1	1980	The roles of prolactin and thyrotrophin (TSH) in the regulation of glucose-6-phosphate dehydrogenase (G6PDH) and 6-phosphogluconate dehydrogenase (6PGDH) activities in rat mammary glands were investigated by the administration of thyroid hormone-releasing hormone (TRH), bromocriptine, prolactin, TSH and triiodo-1-thyronine (T(3)).	Thyrotropin	41-44	glucose-6-phosphate dehydrogenase	Rattus norvegicus	67-100
6774943-1	1980	The roles of prolactin and thyrotrophin (TSH) in the regulation of glucose-6-phosphate dehydrogenase (G6PDH) and 6-phosphogluconate dehydrogenase (6PGDH) activities in rat mammary glands were investigated by the administration of thyroid hormone-releasing hormone (TRH), bromocriptine, prolactin, TSH and triiodo-1-thyronine (T(3)).	Thyrotropin	41-44	glucose-6-phosphate dehydrogenase	Rattus norvegicus	102-107
6774943-1	1980	The roles of prolactin and thyrotrophin (TSH) in the regulation of glucose-6-phosphate dehydrogenase (G6PDH) and 6-phosphogluconate dehydrogenase (6PGDH) activities in rat mammary glands were investigated by the administration of thyroid hormone-releasing hormone (TRH), bromocriptine, prolactin, TSH and triiodo-1-thyronine (T(3)).	Thyrotropin	41-44	thyrotropin releasing hormone	Rattus norvegicus	230-263
6774943-1	1980	The roles of prolactin and thyrotrophin (TSH) in the regulation of glucose-6-phosphate dehydrogenase (G6PDH) and 6-phosphogluconate dehydrogenase (6PGDH) activities in rat mammary glands were investigated by the administration of thyroid hormone-releasing hormone (TRH), bromocriptine, prolactin, TSH and triiodo-1-thyronine (T(3)).	Thyrotropin	41-44	thyrotropin releasing hormone	Rattus norvegicus	265-268
6774943-1	1980	The roles of prolactin and thyrotrophin (TSH) in the regulation of glucose-6-phosphate dehydrogenase (G6PDH) and 6-phosphogluconate dehydrogenase (6PGDH) activities in rat mammary glands were investigated by the administration of thyroid hormone-releasing hormone (TRH), bromocriptine, prolactin, TSH and triiodo-1-thyronine (T(3)).	Thyrotropin	41-44	prolactin	Rattus norvegicus	286-295
6774943-8	1980	Combined administration of prolactin and TSH showed that prolactin is capable of partially inhibiting the TSH-induced increases.	Thyrotropin	41-44	prolactin	Rattus norvegicus	57-66
7392641-0	1980	Effect of TSH stimulation on serum thyroglobulin in metastatic thyroid cancer.	Thyrotropin	10-13	thyroglobulin	Homo sapiens	35-48
6766202-0	1980	Nature of suppressed TSH secretion during undernutrition: effect of fasting and refeeding on TSH responses to prolonged TRH infusions.	Thyrotropin	93-96	thyrotropin releasing hormone	Homo sapiens	120-123
6766202-1	1980	TSH responses to 4-hr continuous TRH infusions of approximately 0.8 microgram/min were assessed during feeding (1500 Kcal), fasting, and refeeding (1500 Kcal) intervals in 9 euthyroid obese subjects.	Thyrotropin	0-3	thyrotropin releasing hormone	Homo sapiens	33-36
119318-2	1979	Oral TRH (40 mg) exerts a marked and protracted stimulatory effect on TSH release.	Thyrotropin	70-73	thyrotropin releasing hormone	Homo sapiens	5-8
120164-5	1979	These findings suggest that TRH stimulates the thyrotroph and accelerates synchronously the secretion as well as the synthesis of TSH.	Thyrotropin	130-133	thyrotropin releasing hormone	Rattus norvegicus	28-31
517049-5	1979	In 11 subjects given iopanoic acid, the response to TSH to TRH (500 micrograms, iv) was increased but the T3 response was unchanged.	Thyrotropin	52-55	thyrotropin releasing hormone	Bos taurus	59-62
119318-3	1979	The potency of oral TRH in stimulating TSH and T3 was evaluated in 26 euthyroid patients with absent or impaired TSH response in the i.v.	Thyrotropin	39-42	thyrotropin releasing hormone	Homo sapiens	20-23
119318-22	1979	TRH, a marked increase in T3 could be demonstrated (0.5 +/- 0.1 ng/ml and 0.6 +/- 0.1 ng/ml in "non-responders" and "low-responders" respectively, p less than 0.01); thus, oral administration allows simultaneous stimulation of TSH and triiodothyronine.	Thyrotropin	227-230	thyrotropin releasing hormone	Homo sapiens	0-3
91625-11	1979	One of these subjects had had a clearly elevated serum TSH concentration in 1972, and the remaining two had exhibited the highest responses of serum TSH (36, 26 muU/ml) to thyrotropin-releasing hormone among 10 patients tested in 1972.	Thyrotropin	149-152	thyrotropin releasing hormone	Homo sapiens	172-201
230279-7	1979	The specificity for prolactin was shown in the mammary gland and corpus luteum by the failure of ovine FSH, LH, GH and TSH to displace 125I-labelled ovine prolactin, whereas it was displaced readily by both ovine and bovine prolactin.	Thyrotropin	119-122	prolactin	Bos taurus	20-29
120979-5	1979	From these results two important conclusions can be drawn: 1. the T3 and T4 levels interact with PRL secretion concomitantly with TSH only when they undergo a huge deviation from the normal range; 2. the goitrogenic action of PRL that has been reported in experimental animals cannot be excluded in man.	Thyrotropin	130-133	prolactin	Homo sapiens	97-100
120979-5	1979	From these results two important conclusions can be drawn: 1. the T3 and T4 levels interact with PRL secretion concomitantly with TSH only when they undergo a huge deviation from the normal range; 2. the goitrogenic action of PRL that has been reported in experimental animals cannot be excluded in man.	Thyrotropin	130-133	prolactin	Homo sapiens	226-229
115728-6	1979	Plasma levels of TRH increased in two phases, and increments of plasma TSH were dose dependable to the dosage of TRH.	Thyrotropin	71-74	thyrotropin releasing hormone	Homo sapiens	17-20
115728-6	1979	Plasma levels of TRH increased in two phases, and increments of plasma TSH were dose dependable to the dosage of TRH.	Thyrotropin	71-74	thyrotropin releasing hormone	Homo sapiens	113-116
230279-7	1979	The specificity for prolactin was shown in the mammary gland and corpus luteum by the failure of ovine FSH, LH, GH and TSH to displace 125I-labelled ovine prolactin, whereas it was displaced readily by both ovine and bovine prolactin.	Thyrotropin	119-122	prolactin	Bos taurus	155-164
230279-7	1979	The specificity for prolactin was shown in the mammary gland and corpus luteum by the failure of ovine FSH, LH, GH and TSH to displace 125I-labelled ovine prolactin, whereas it was displaced readily by both ovine and bovine prolactin.	Thyrotropin	119-122	prolactin	Bos taurus	155-164
115671-1	1979	We have studied the effect of two inhibitors of prostaglandin synthesis on the basal and TRH-stimulated plasma TSH levels in the rat.	Thyrotropin	111-114	thyrotropin releasing hormone	Rattus norvegicus	89-92
115671-9	1979	The increased sensitivity of plasma TSH response to exogenous TRH in the indomethacin group is presumably due to higher pituitary TSH content than in the controls.	Thyrotropin	36-39	thyrotropin releasing hormone	Rattus norvegicus	62-65
455255-4	1979	The development of a hypermetabolic syndrome in patients with choriocarcinoma may be due to secondary thyrotoxicosis from either the TSH-like activity of hCG or from the concomitant production of molar thyrotropin by the tumor.	Thyrotropin	133-136	hypertrichosis 2 (generalised, congenital)	Homo sapiens	154-157
474748-3	1979	The increment in serum TSH after injection of thyrotropin-releasing hormone (TRH) was not significantly different at any of the ages studied, but the old animals had significantly lower increments in serum T4 and T3 after subcutaneous administration of bovine TSH.	Thyrotropin	23-26	thyrotropin releasing hormone	Bos taurus	46-75
482130-4	1979	Conversely, TSH maintained the initial Tgb mRNA level in cells cultured in its presence, and TSH concentrations 50 micronU/ml or 5 mU/ml gave identical results.	Thyrotropin	12-15	thyroglobulin	Homo sapiens	39-42
112792-7	1979	Increased serum TSH is found in hepatic cirrhois and is often accompanied by an abnormal TSH response to thyrotropin-releasing hormone (TRH) suggesting, in addition, disordered hypothalamic-pituitary control of thyroid function in these patients.	Thyrotropin	16-19	thyrotropin releasing hormone	Homo sapiens	105-134
446418-5	1979	However, CCh pretreatment reduced and atropine pretreatment enhanced the TSH-induced BRI increase in such animals.	Thyrotropin	73-76	integral membrane protein 2B	Mus musculus	85-88
111447-0	1979	Enhanced TSH stimulating effect of TRH by sulpiride in man.	Thyrotropin	9-12	thyrotropin releasing hormone	Homo sapiens	35-38
496532-1	1979	Hypothyroidism secondary to isolated thyrotropin (TSH) deficiency was confirmed by low TSH levels during TRF test.	Thyrotropin	50-53	telomeric repeat binding factor 1	Homo sapiens	105-108
429524-9	1979	We propose that hCG, as a weak thyroid stimulator, causes a modest rise in free thyroid hormone levels early in pregnancy which in turn causes a modest reduction in pituitary TSH secretion.	Thyrotropin	175-178	hypertrichosis 2 (generalised, congenital)	Homo sapiens	16-19
108290-2	1979	TRH-antiserum (TRH-AS) raised in rabbits and administered daily to low iodine-propylthiouracil (LID-PTU)-fed pregnant rats from days 12 to 19 of gestation markedly impaired the rise in serum TSH to LID-PTU when compared with normal rabbit serum-treated controls.	Thyrotropin	191-194	thyrotropin releasing hormone	Oryctolagus cuniculus	0-3
113139-5	1979	Serum TSH levels decreased modestly with the nadir at 4 h after T3 ingestion and then returned to basal levels at 24 h. Augmentation of TSH responses to TRH occurred simultaneously with decreases in serum cholesterol, as well as increases in the pituitary prolactin response to TRH, and increase in the GH and cortisol response to insulin induced hypoglycaemia where these responses could be studied.	Thyrotropin	6-9	thyrotropin releasing hormone	Homo sapiens	153-156
113139-5	1979	Serum TSH levels decreased modestly with the nadir at 4 h after T3 ingestion and then returned to basal levels at 24 h. Augmentation of TSH responses to TRH occurred simultaneously with decreases in serum cholesterol, as well as increases in the pituitary prolactin response to TRH, and increase in the GH and cortisol response to insulin induced hypoglycaemia where these responses could be studied.	Thyrotropin	136-139	thyrotropin releasing hormone	Homo sapiens	153-156
113139-5	1979	Serum TSH levels decreased modestly with the nadir at 4 h after T3 ingestion and then returned to basal levels at 24 h. Augmentation of TSH responses to TRH occurred simultaneously with decreases in serum cholesterol, as well as increases in the pituitary prolactin response to TRH, and increase in the GH and cortisol response to insulin induced hypoglycaemia where these responses could be studied.	Thyrotropin	136-139	thyrotropin releasing hormone	Homo sapiens	278-281
108290-2	1979	TRH-antiserum (TRH-AS) raised in rabbits and administered daily to low iodine-propylthiouracil (LID-PTU)-fed pregnant rats from days 12 to 19 of gestation markedly impaired the rise in serum TSH to LID-PTU when compared with normal rabbit serum-treated controls.	Thyrotropin	191-194	thyrotropin releasing hormone	Oryctolagus cuniculus	15-18
108290-5	1979	Similarly, acute TRH-AS administration to the pregnant rat fed LID-PTU markedly decreased the serum TSH concentration in the mother, but not in the fetus, 60 min after TRH-AS administration.	Thyrotropin	100-103	thyrotropin releasing hormone	Rattus norvegicus	17-20
108290-6	1979	Chronic TRH-AS administration to neonatal rats whose nursing mothers were fed LID-PTU was in-effective in decreasing the elevated serum TSH in the neonate through day 8 of life, whereas a slight but significant decrease in serum TSH was observed on day 10.	Thyrotropin	136-139	thyrotropin releasing hormone	Rattus norvegicus	8-11
108290-6	1979	Chronic TRH-AS administration to neonatal rats whose nursing mothers were fed LID-PTU was in-effective in decreasing the elevated serum TSH in the neonate through day 8 of life, whereas a slight but significant decrease in serum TSH was observed on day 10.	Thyrotropin	229-232	thyrotropin releasing hormone	Rattus norvegicus	8-11
107181-8	1979	3) Both placental extract and synthetic TRH stimulated TSH release from rat pituitaries in vitro.	Thyrotropin	55-58	thyrotropin releasing hormone	Rattus norvegicus	40-43
107304-3	1979	The mean (+/- SD) postdelivery TSH peak was lower in the RDS group (32.8 +/- 9.6 muU/ml) than in the control group (60.9 +/- 21.8 muU/ml; P less than 0.005).	Thyrotropin	31-34	peripherin 2	Homo sapiens	57-60
555678-0	1979	Monoamine oxidase and aspartate aminotransferase in cellular fractions of thyroid gland in rats after hypophysectomy and TSH stimulation.	Thyrotropin	121-124	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	22-48
555678-2	1979	MAO and aspartate aminotransferase activities in thyroid mitochondria were decreased after hypophysectomy and significantly increased after daily injection of TSH during five days to hypophysectomized rats.	Thyrotropin	159-162	monoamine oxidase A	Rattus norvegicus	0-3
555678-2	1979	MAO and aspartate aminotransferase activities in thyroid mitochondria were decreased after hypophysectomy and significantly increased after daily injection of TSH during five days to hypophysectomized rats.	Thyrotropin	159-162	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	8-34
555678-4	1979	IN CONCLUSION: it is evident that MAO and aspartate aminotransferase in thyroid mitochondria the enzymes which could be a source for hydrogen peroxide to catalyze thyroid hormone synthesis are under the regulatory influence of TSH.	Thyrotropin	227-230	monoamine oxidase A	Rattus norvegicus	34-37
555678-4	1979	IN CONCLUSION: it is evident that MAO and aspartate aminotransferase in thyroid mitochondria the enzymes which could be a source for hydrogen peroxide to catalyze thyroid hormone synthesis are under the regulatory influence of TSH.	Thyrotropin	227-230	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	42-68
113269-1	1979	Since there are some patient groups whos symptoms do not improve despite the fact that the use of the antidepressants will alleviate the symptoms to some extent, we have conducted a TRH test for depression and found that there are not a few cases who show a low TSH response.	Thyrotropin	262-265	thyrotropin releasing hormone	Homo sapiens	182-185
117392-6	1979	Serum TSH responded to TRH after the stress as well.	Thyrotropin	6-9	thyrotropin releasing hormone	Rattus norvegicus	23-26
106341-4	1979	TRH injection to protein-deficient dams caused a marked reduction in pituitary TSH concentration, suggesting that the elevated plasma TSH seen in uninjected dams might be due to decreased metabolic clearance rather than to hypersecretion by the pituitary.	Thyrotropin	79-82	thyrotropin releasing hormone	Rattus norvegicus	0-3
114467-5	1979	TSH secretion was markedly increased by 500 pg TRH, whether or not plasma preincubation was employed.	Thyrotropin	0-3	thyrotropin releasing hormone	Rattus norvegicus	47-50
109291-0	1978	Effect of active and passive immunization with TRH on plasma TSH response to propylthiouracil.	Thyrotropin	61-64	thyrotropin releasing hormone	Rattus norvegicus	47-50
109291-3	1978	Similarly, the increased plasma TSH level following PTU treatment was significantly suppressed after iv injection of antiserum to TRH.	Thyrotropin	32-35	thyrotropin releasing hormone	Rattus norvegicus	130-133
106341-4	1979	TRH injection to protein-deficient dams caused a marked reduction in pituitary TSH concentration, suggesting that the elevated plasma TSH seen in uninjected dams might be due to decreased metabolic clearance rather than to hypersecretion by the pituitary.	Thyrotropin	134-137	thyrotropin releasing hormone	Rattus norvegicus	0-3
107021-4	1978	When TSH was administered simultaneously with T4 to Hx rats, hypothalamic TRH content was restored to normal.	Thyrotropin	5-8	thyrotropin releasing hormone	Rattus norvegicus	74-77
45473-0	1978	Somatostatin inhibits thyroid hormone secretion induced by exogenous TSH in man.	Thyrotropin	69-72	somatostatin	Homo sapiens	0-12
45473-3	1978	This increase was significantly lower (p less than 0.02) when somatostatin was given as a bolus injection into a peripheral vein 5 min prior to the administration of TSH, and followed by a continuous infusion for 60 min.	Thyrotropin	166-169	somatostatin	Homo sapiens	62-74
102540-8	1978	There was a negative correlation between serum TSH and serum TRH, but no significant correlation was noticed between serum TSH and urinary TRH levels.	Thyrotropin	47-50	thyrotropin releasing hormone	Homo sapiens	61-64
358720-3	1978	Basal PRL and TRH stimulated PRL and TSH levels were slightly reduced without statistical significance (P greater than 0.05).	Thyrotropin	37-40	prolactin	Homo sapiens	6-9
216569-3	1978	Dibutyryl c-AMP causes rise in TSH content, with no indication of its secretion.	Thyrotropin	31-34	cathelicidin antimicrobial peptide	Rattus norvegicus	10-15
95626-8	1978	The LH molecule formed from the recombination of highly purified hCG alpha and ovine LH beta subunits exhibited TSA in the bioassay that was 25 times greater than that expected based on the immunoreactive TSH contamination.	Thyrotropin	205-208	chorionic gonadotropin subunit beta 5	Homo sapiens	65-68
95626-8	1978	The LH molecule formed from the recombination of highly purified hCG alpha and ovine LH beta subunits exhibited TSA in the bioassay that was 25 times greater than that expected based on the immunoreactive TSH contamination.	Thyrotropin	205-208	luteinizing hormone subunit beta	Homo sapiens	85-92
105350-3	1978	Twenty per cent of patients with atrial dysrhythmias and 10% of those in sinus rhythm had exaggerated TSH response to TRH.	Thyrotropin	102-105	thyrotropin releasing hormone	Homo sapiens	118-121
99158-1	1978	1 The TSH response to TRH is suppressed 24 h after the commencement of i.v.	Thyrotropin	6-9	thyrotropin releasing hormone	Homo sapiens	22-25
80734-2	1978	Serum TSH and triiodothyronine (T3) responses to cold exposure (4 +/- 1 C) were abolished by administration of anti-TRH serum.	Thyrotropin	6-9	thyrotropin releasing hormone	Rattus norvegicus	116-119
80734-4	1978	These observations provide evidence that TRH is involved in the mechanism of enhanced TSH secretion from the pituitary following thyroidectomy and cold exposure.	Thyrotropin	86-89	thyrotropin releasing hormone	Rattus norvegicus	41-44
98684-2	1978	Five days starvation resulted in a significant decrease in serum TSH and a slightly enhanced serum TSH response to exogenous TRH, suggesting that the pituitary retains its sensitivity to TRH.	Thyrotropin	99-102	thyrotropin releasing hormone	Rattus norvegicus	125-128
122410-4	1978	When retested 3 months later, at which time the serum T4 was 5.5 micrograms/dl, the patient was somewhat less hypothyroid and there was an exaggerated TSH response to exogenous TRH, indicating recovery of pituitary TSH reserve.	Thyrotropin	151-154	thyrotropin releasing hormone	Homo sapiens	177-180
122410-6	1978	Repeat studies performed 7 months later indicated some improvements in this indirect assessment of endogenous TRH reserve capacity but a continued exaggerated TSH response to exogenous TRH administration.	Thyrotropin	159-162	thyrotropin releasing hormone	Homo sapiens	185-188
100262-1	1978	A 53-year-old woman with an early form of de Quervain"s disease involving both thyroid lobes was found to have her thyroid uptake of iodine suppressed, although the serum thyroid hormone concentrations were normal while the administration of TRH resulted in significant increase in the serum TSH concentrations.	Thyrotropin	292-295	thyrotropin releasing hormone	Homo sapiens	242-245
213036-0	1978	Effect of thyroid hormone, actinomycin D, cycloheximide and puromycin on TRH-induced secretion of TSH, as studied by pituitary concentration of cyclic AMP and intrathyroidal colloid droplet formation.	Thyrotropin	98-101	thyrotropin releasing hormone	Homo sapiens	73-76
98247-3	1978	The patients with barbiturate coma presented normal basal TSH and PRL, elevated basal GH and normal PRL but blunted TSH responses to TRH; their GH concentrations varied widely without consistent relation to TRH administration.	Thyrotropin	116-119	thyrotropin releasing hormone	Homo sapiens	133-136
217636-1	1978	Previously, we have shown that preparations of hCG bind to bovine thyroid membranes, as judged from their ability both to inhibit the binding of 125I-labeled bovine TSH (bTSH) and to activate adenylate cyclase (Amir, S.M., H. Uchimura, and S.H.	Thyrotropin	165-168	hypertrichosis 2 (generalised, congenital)	Homo sapiens	47-50
217640-5	1978	Testicular and thyroid TSH-binding sites also appeared to demonstrate a similar degree of cross-reactivity with a crude preparation of hCG.	Thyrotropin	23-26	hypertrichosis 2 (generalised, congenital)	Homo sapiens	135-138
217640-7	1978	Furthermore, the ability of hCG to inhibit the binding of TSH to thyroid membranes provides a possible mechanism for the known thyroid-stimulating properties of hCG.	Thyrotropin	58-61	hypertrichosis 2 (generalised, congenital)	Homo sapiens	28-31
217640-7	1978	Furthermore, the ability of hCG to inhibit the binding of TSH to thyroid membranes provides a possible mechanism for the known thyroid-stimulating properties of hCG.	Thyrotropin	58-61	hypertrichosis 2 (generalised, congenital)	Homo sapiens	161-164
99299-13	1978	The above morphological results are contradictory a plausible view that TRH acts only upon the thyrotrophs to release TSH.	Thyrotropin	118-121	thyrotropin releasing hormone	Rattus norvegicus	72-75
213036-2	1978	Small dose of TRH apparently augmented TSH secretion as evidenced by a marked increase of intrathyroidal colloid droplet, but failed to elevate the pituitary concentration of cyclic AMP.	Thyrotropin	39-42	thyrotropin releasing hormone	Homo sapiens	14-17
213036-3	1978	Triiodothyronine (T3) and thyroxine (T4) blocked an increase of TSH secretion produced by TRH, but they elevated pituitary concentration of cyclic AMP in vivo and in vitro.	Thyrotropin	64-67	thyrotropin releasing hormone	Homo sapiens	90-93
418309-2	1978	Mean (+/- SE) peak TSH responses to TRH were 168 +/- 64 microU/ml during 3,3"T2 administration and 168 +/- 65 muU/ml during 3,3"T2 administration.	Thyrotropin	19-22	thyrotropin releasing hormone	Rattus norvegicus	36-39
96241-4	1978	In five premature infants, injection of TRH elicited a TSH increment of 29.4 +/- 20.7 microunits/ml at 30 minutes.	Thyrotropin	55-58	thyrotropin releasing hormone	Homo sapiens	40-43
418309-5	1978	for 5 days had a mean TSH response to TRH stimulation of 0.051 +/- 0.003 mU/ml, whereas rats to whom saline or 3,3"T2 (50 microgram b.i.d.)	Thyrotropin	22-25	thyrotropin releasing hormone	Rattus norvegicus	38-41
418309-6	1978	had been given for the same time interval had mean TRH-induced TSH responses of 1.127 +/- 0.179 mU/ml and 1.324 +/- 0.286 mU/ml, respectively.	Thyrotropin	63-66	thyrotropin releasing hormone	Rattus norvegicus	51-54
668626-11	1978	Analyses of serum TSH, T4, T3 and of thyroidal iodine revealed that TSH-induced thyroid ODC activity was suppressed by increased circulating thyroid hormones and/or intrathyroidal iodine.	Thyrotropin	18-21	ornithine decarboxylase 1	Rattus norvegicus	88-91
25551-3	1978	NaF, at 1 and 5 mM, progressively increased this parameter while norepinephrine caused a similar effect at 10(-3) but not at 10(-6) M. Phentolamine (1 mM) blocked the stimulatory action of TSH; propranolol and atropine did not.	Thyrotropin	189-192	C-X-C motif chemokine ligand 8	Homo sapiens	0-3
114568-0	1978	The effect of TRH on the release of TSH, PRL and GH in man under basal conditions and following methysergide.	Thyrotropin	36-39	thyrotropin releasing hormone	Homo sapiens	14-17
114568-1	1978	Pretreatment with methysergide, a blocker of serotoninergic receptors, significantly reduced the TSH response to TRH in six male volunteers.	Thyrotropin	97-100	thyrotropin releasing hormone	Homo sapiens	113-116
225342-1	1978	The effect of thyroglobulin (TG) on binding of TSH to thyroid plasma membranes was studied in vitro.	Thyrotropin	47-50	thyroglobulin	Homo sapiens	14-27
225342-1	1978	The effect of thyroglobulin (TG) on binding of TSH to thyroid plasma membranes was studied in vitro.	Thyrotropin	47-50	thyroglobulin	Homo sapiens	29-31
225342-5	1978	Incubation of TG with TSH did not show an interaction, as assessed by sucrose gradient centrifugation.	Thyrotropin	22-25	thyroglobulin	Homo sapiens	14-16
225342-8	1978	In the presence of very high concentrations of TSH, TG binding was increased.	Thyrotropin	47-50	thyroglobulin	Homo sapiens	52-54
418584-2	1978	The effect of thyrotropin releasing hormone (TRH) on the secretion of HPRL and thyroid stimulating hormone (TSH) in late pregnancy was examined with special emphasis on the amount and time sequence of secretion of both hormones.	Thyrotropin	79-106	thyrotropin releasing hormone	Homo sapiens	14-43
415831-5	1978	Normal TSH response to TRH was restored by partial thyroidectomy and in some cases by propyl thiouracil administration.	Thyrotropin	7-10	thyrotropin releasing hormone	Homo sapiens	23-26
413840-9	1978	These studies demonstrate that TRH is required for TSH secretion in the normal, cold-exposed and proestrus rat and contributes, at least in part, to TSH secretion in the hypothyroid rat, but is not required for Prl secretion in these states.	Thyrotropin	51-54	thyrotropin releasing hormone	Rattus norvegicus	31-34
108288-0	1978	Blunting of TSH response after repeated oral administration of TRH in normal and hypothyroid subjects.	Thyrotropin	12-15	thyrotropin releasing hormone	Homo sapiens	63-66
413840-9	1978	These studies demonstrate that TRH is required for TSH secretion in the normal, cold-exposed and proestrus rat and contributes, at least in part, to TSH secretion in the hypothyroid rat, but is not required for Prl secretion in these states.	Thyrotropin	149-152	thyrotropin releasing hormone	Rattus norvegicus	31-34
99077-0	1978	[TSH-response to TRH in active coeliac disease in infants (author"s transl)].	Thyrotropin	1-4	thyrotropin releasing hormone	Homo sapiens	17-20
631380-15	1978	After a transient fluctuation caused by the operation, the serum Tg level in the patient increased progressively during 39 days after surgery with a concomitant increase in serum TSH; the levels at the 3rd, 6th and 9th day after surgery were 5,825 ng/ml, 7,910 ng/ml and 11,190 ng/ml, respectively.	Thyrotropin	179-182	thyroglobulin	Homo sapiens	65-67
631380-17	1978	Bovine TSH was administered to this patient at the 114th day, so as to study the effect of exogeneous TSH on serum Tg.	Thyrotropin	102-105	thyroglobulin	Homo sapiens	115-117
631380-21	1978	Despite complete removal of the thyroid gland, the increase in serum Tg after thyroidal stimulation with endogenous and exogenous TSH was observed in the patient.	Thyrotropin	130-133	thyroglobulin	Homo sapiens	69-71
631380-23	1978	These results indicate that the elevated serum Tg was released from metastatic tissue by TSH.	Thyrotropin	89-92	thyroglobulin	Homo sapiens	47-49
99077-1	1978	In 11 infants of 3-19 months of age with active gluten-induced enteropathy, an exaggerated and sustained response of plasma TSH to TRH was observed as compared to controls.	Thyrotropin	124-127	thyrotropin releasing hormone	Homo sapiens	131-134
201719-1	1977	Thyroid-stimulating antibodies (TSAb) were found to inhibit the binding of labelled thyrotrophin (TSH) to thyroid membranes in a dose-dependent manner and this effect was localized in the Fab part of the TSAb molecule.	Thyrotropin	84-96	FA complementation group B	Homo sapiens	188-191
413302-0	1978	Extrathyroidal effects of propylthiouracil and carbimazole on serum T4, T3, reverse T3 and TRH-induced TSH-release in man.	Thyrotropin	103-106	thyrotropin releasing hormone	Homo sapiens	91-94
415173-5	1978	After oral stimulation with 40 mg of TRH, TSH rises to a slightly higher maximum of 13.2 muU/ml after 3 h. The T3 increase from 1.5 to 2.19 ng/ml is significant and considerably higher than after intravenous stimulation.	Thyrotropin	42-45	thyrotropin releasing hormone	Homo sapiens	37-40
98724-3	1978	Plasma TSH concentration increased significantly (p less than 0.05) in response to TRH infusion (0.77 microgram/min) in both experiments, but plasma TSH levels plateaued and then declined in both cases despite continued TRH infusion and irrespective of the presence or absence of a thyroid gland.	Thyrotropin	7-10	thyrotropin releasing hormone	Bos taurus	83-86
414907-5	1977	In thyroidectomized rats the hypothalamic TRH levels were slightly reduced in spite of the marked increase of plasma TSH levels and decrease of pituitary TSH levels.	Thyrotropin	117-120	thyrotropin releasing hormone	Rattus norvegicus	42-45
201719-1	1977	Thyroid-stimulating antibodies (TSAb) were found to inhibit the binding of labelled thyrotrophin (TSH) to thyroid membranes in a dose-dependent manner and this effect was localized in the Fab part of the TSAb molecule.	Thyrotropin	98-101	FA complementation group B	Homo sapiens	188-191
198194-0	1977	In vitro stimulation of thyroid ornithine decarboxylase activity and polyamines by thyrotropin.	Thyrotropin	83-94	ornithine decarboxylase 1	Rattus norvegicus	32-55
411802-6	1977	Thyrotropin-releasing hormone (TRH) administration resulted in a marked increase in serum TSH concentrations.	Thyrotropin	90-93	thyrotropin releasing hormone	Homo sapiens	0-29
199013-0	1977	Inhibition by somatostatin of mouse thyroid activity following stimulation by thyrotrophin, isoprenaline and dibutyryl cyclic-AMP.	Thyrotropin	78-90	somatostatin	Mus musculus	14-26
198194-2	1977	The elevation in ODC activity was related to the concentration of TSH in the incubation medium with peak activity at a concentration of 25mU/ml.	Thyrotropin	66-69	ornithine decarboxylase 1	Rattus norvegicus	17-20
198194-5	1977	The increase in ODC activity with TSH and MIX was prevented by incubation with actinomycin D (10 microgram/ml) or puromycin (0.2 mM).	Thyrotropin	34-37	ornithine decarboxylase 1	Rattus norvegicus	16-19
198194-7	1977	The increase in tissue putrescine preceded a rise in [3H]uridine incorporation into acid-soluble material that occurred at 7 h. The results suggest that stimulation of thyroid ODC activity by TSH is mediated by a cyclic AMP; the data further are consistent with a role for polyamines in the control of RNA synthesis in the thyroid.	Thyrotropin	192-195	ornithine decarboxylase 1	Rattus norvegicus	176-179
410310-1	1977	Daily administration of estradiol benzoate (10 microgram/100 g body wt) to intact male rats led to a twofold increase of the plasma TSH (thyroid-stimulating hormone) response to thyrotropin-releasing hormone (TRH) after 4 and 7 days of treatment whereas the basal plasma TSH level was not affected.	Thyrotropin	132-135	thyrotropin releasing hormone	Rattus norvegicus	178-207
409301-4	1977	In the unipolar group, the TSH response showed a significant negative correlation with the serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA) in the CSF.	Thyrotropin	27-30	colony stimulating factor 2	Homo sapiens	155-158
410310-1	1977	Daily administration of estradiol benzoate (10 microgram/100 g body wt) to intact male rats led to a twofold increase of the plasma TSH (thyroid-stimulating hormone) response to thyrotropin-releasing hormone (TRH) after 4 and 7 days of treatment whereas the basal plasma TSH level was not affected.	Thyrotropin	132-135	thyrotropin releasing hormone	Rattus norvegicus	209-212
414194-0	1977	Plasma TSH and PRL response to synthetic TRH during the menstrual cycle.	Thyrotropin	7-10	thyrotropin releasing hormone	Homo sapiens	41-44
407241-0	1977	Heterogeneity of prolactin and TSH response to TRH in hypotonadotropic hypogonadism.	Thyrotropin	31-34	thyrotropin releasing hormone	Homo sapiens	47-50
72658-5	1977	Serum TSH concentrations in TBG deficiency were all in the normal range (1.0-4.2 muU/ml) and the maximum TSH increments following TRH 500 microgram iv were 8.9 +/- 2.0 muU/ml and of no significant difference from the normal control (10.2 +/- 4.5 muU/ml).	Thyrotropin	105-108	thyrotropin releasing hormone	Homo sapiens	130-133
407241-4	1977	TRH-induced TSH secretion, on the other hand, was attenuated in two out of 8 untreated and in two of 8 treated patients with hypogonadotropic hypogonadism.	Thyrotropin	12-15	thyrotropin releasing hormone	Homo sapiens	0-3
117732-1	1977	After a review concerning the present knowledge on the hypothalamic peptide releasing hormones, the response of TSH to intravenous administration of TRH in man (Thyreotrophin Releasing Hormone Stimulation Test) is discussed, with regard to clinical endocrinology.	Thyrotropin	112-115	thyrotropin releasing hormone	Homo sapiens	149-152
192538-4	1977	Contrary to findings with LHRH and LH, repeated injections of a small dose  (10 ng) of TRH in the afternoon of proestrus abolished PRL and TSH responses to subsequent injection of the neurohormone.	Thyrotropin	139-142	thyrotropin releasing hormone	Rattus norvegicus	87-90
406275-4	1977	In contrast, FA-Ca produced a significant reduction on the high basal serum TSH level in patients with primary hypothyroidism.	Thyrotropin	76-79	FA complementation group A	Homo sapiens	13-18
406275-6	1977	As in the case of L-Dopa, the effect of FA-Ca on serum TSH is most clearly demonstrated in patients with primary hypothyroidism.	Thyrotropin	55-58	FA complementation group A	Homo sapiens	40-45
405834-6	1977	There was an increase in the serum level of (TSH) from 3.4 +/- 0.3 (SEM) to 4.3 +/- 0.5 (SEM) ng/ml (P less than 0.05), and a decrease in the serum level of total T4 from 19.4 +/- 1.1 (SEM) to 5.8 +/- 0.8 (SEM) microng/100 ml in 13 patients from the first examination until the last time they were examined before restored TRH response.	Thyrotropin	45-48	thyrotropin releasing hormone	Homo sapiens	323-326
405834-8	1977	In 6 TRH non-responsive patients with Graves" disease, serum TSH levels were suppressed from 2.5 +/- 1.2 (SEM) ng/ml before the administration of a single dose of 3 mg T4 orally, to 0.9 +/- 0.2 (SEM) ng/ml, 7 days after the T4 administration.	Thyrotropin	61-64	thyrotropin releasing hormone	Homo sapiens	5-8
577079-0	1977	A re-assessment of the effect of thyrotrophin (TSH) on the tibial plate bioassay for growth hormone (GH).	Thyrotropin	47-50	gonadotropin releasing hormone receptor	Rattus norvegicus	85-99
577079-1	1977	The claim has been made that thyrotrophin (TSH) can augment the action of growth hormone (GH) to stimulate growth of the epiphysial cartilage plate of the hypophysectomized rat"s tibia.	Thyrotropin	29-41	gonadotropin releasing hormone receptor	Rattus norvegicus	74-88
577079-1	1977	The claim has been made that thyrotrophin (TSH) can augment the action of growth hormone (GH) to stimulate growth of the epiphysial cartilage plate of the hypophysectomized rat"s tibia.	Thyrotropin	29-41	gonadotropin releasing hormone receptor	Rattus norvegicus	90-92
577079-1	1977	The claim has been made that thyrotrophin (TSH) can augment the action of growth hormone (GH) to stimulate growth of the epiphysial cartilage plate of the hypophysectomized rat"s tibia.	Thyrotropin	43-46	gonadotropin releasing hormone receptor	Rattus norvegicus	74-88
577079-1	1977	The claim has been made that thyrotrophin (TSH) can augment the action of growth hormone (GH) to stimulate growth of the epiphysial cartilage plate of the hypophysectomized rat"s tibia.	Thyrotropin	43-46	gonadotropin releasing hormone receptor	Rattus norvegicus	90-92
577079-5	1977	Fractional aliquots of pituitary extracts from thyroidectomized rats were administered concomitantly with graded doses of exogenous GH to hypophysectomized rats to determine the point at which TSH in the extracts was sufficiently able to stimulate significant tibial plate growth when compared to recipients given GH alone.	Thyrotropin	193-196	gonadotropin releasing hormone receptor	Rattus norvegicus	132-134
577079-6	1977	Purified GH and TSH were also administered in various doses to hypophysectomized recipients in a further attempt to delineate the dose range at which TSH augments the action of GH to promote significant chondrogenesis of the epiphysial plate.	Thyrotropin	150-153	gonadotropin releasing hormone receptor	Rattus norvegicus	177-179
577079-8	1977	As little as 40 mU TSH augmented the growth effect of 400 microng GH on the cartilage plate, demonstrating that smaller quantities of TSH could potentiate larger quantities of GH.	Thyrotropin	19-22	gonadotropin releasing hormone receptor	Rattus norvegicus	66-68
577079-8	1977	As little as 40 mU TSH augmented the growth effect of 400 microng GH on the cartilage plate, demonstrating that smaller quantities of TSH could potentiate larger quantities of GH.	Thyrotropin	134-137	gonadotropin releasing hormone receptor	Rattus norvegicus	66-68
406108-0	1977	Decreased serum thyroid hormone levels and increased TSH response to TRH in infants with coeliac disease.	Thyrotropin	53-56	thyrotropin releasing hormone	Homo sapiens	69-72
577079-8	1977	As little as 40 mU TSH augmented the growth effect of 400 microng GH on the cartilage plate, demonstrating that smaller quantities of TSH could potentiate larger quantities of GH.	Thyrotropin	134-137	gonadotropin releasing hormone receptor	Rattus norvegicus	176-178
577079-10	1977	Fractions of glands greater than this may contain sufficient amounts of TSH to augment the appreciable quantities of GH already present.	Thyrotropin	72-75	gonadotropin releasing hormone receptor	Rattus norvegicus	117-119
404309-4	1977	Using the frequent sampling technique (samples every 20 min) in two normal volunteers and one untreated patient who was TRH-responsive, we first confirmed the observation that TSH secretion occurred episodically throughout the 24-h period.	Thyrotropin	176-179	thyrotropin releasing hormone	Homo sapiens	120-123
404309-8	1977	TRH tests were carried out only when random TSH concentrations were less than 0.6 micronU/ml.	Thyrotropin	44-47	thyrotropin releasing hormone	Homo sapiens	0-3
404309-9	1977	Seven of the twenty-six patients (27%) including two with thyroid cancer were TRH-responsive indicating a potential for TSH secretion.	Thyrotropin	120-123	thyrotropin releasing hormone	Homo sapiens	78-81
68540-0	1977	Effect of insulin-induced hypoglycemia on the level of serum TSH, total T4, free T4 and T3.	Thyrotropin	61-64	insulin	Homo sapiens	10-17
189996-8	1977	The increased TSH receptor occupancy which resulted from the increased association constant of the TSH-thyroid membrane interaction corresponded with a decrease in TSH-stimulated cyclic AMP formation.	Thyrotropin	99-102	thyroid stimulating hormone receptor	Homo sapiens	14-26
402379-1	1977	The effect of graded increments of chronically administered oral T4 or T3 on the TSH response to TRH was studied in normal young adult men.	Thyrotropin	81-84	thyrotropin releasing hormone	Homo sapiens	97-100
402383-5	1977	intervals, and the TSH response to exogenous thyrotropin-releasing hormone (TRH) was tested sequentially at each dose of L-T4 until a normal or slightly suppressed TSH response was obtained The L-T4 dosage which was associated with normal TSH responsiveness to TRH (the adequate L-T4 dose) was high in infancy (10 mug/kg/day), decreasing with age to a level of 3-4 mug/kg/day in pubertal children (correlation coefficient r=-0.820, P less than 0.01).	Thyrotropin	19-22	thyrotropin releasing hormone	Homo sapiens	76-79
402379-3	1977	Each thyroid hormone caused a dose-related decrease in the TSH response to TRH; thus the TSH response could be used as a bioassay for the biologic activity of the thyroid hormones in man.	Thyrotropin	59-62	thyrotropin releasing hormone	Homo sapiens	75-78
402379-3	1977	Each thyroid hormone caused a dose-related decrease in the TSH response to TRH; thus the TSH response could be used as a bioassay for the biologic activity of the thyroid hormones in man.	Thyrotropin	89-92	thyrotropin releasing hormone	Homo sapiens	75-78
63545-0	1977	Serum thyroid hormone and TSH concentrations in newborn infants with congenital absence of thyroxine-binding globulin.	Thyrotropin	26-29	serpin family A member 7	Homo sapiens	91-117
188629-12	1977	On the basis of these results, it is assumed that the central noradrenergic system has a stimulatory effect on the release of TRH from the hypothalamus, reflected in our experiments by the changes of serum TSH levels.	Thyrotropin	206-209	thyrotropin releasing hormone	Rattus norvegicus	126-129
576414-9	1977	The presence of normal free thyroid hormone concentrations in patients with impaired or absent TSH responses to TRH is interesting and challenges the concept that free thyroid hormones are the major controlling factors in the feedback control of TSH.	Thyrotropin	95-98	thyrotropin releasing hormone	Homo sapiens	112-115
576414-9	1977	The presence of normal free thyroid hormone concentrations in patients with impaired or absent TSH responses to TRH is interesting and challenges the concept that free thyroid hormones are the major controlling factors in the feedback control of TSH.	Thyrotropin	246-249	thyrotropin releasing hormone	Homo sapiens	112-115
12985-0	1977	Comparison of adiphenine and TRH effects on TSH release by rat pituitary in vitro.	Thyrotropin	44-47	thyrotropin releasing hormone	Rattus norvegicus	29-32
12985-2	1977	The comparative study showed that adiphenine and TRH were able to increase TSH release in a dose-dependent manner, had similar time courses of action for equipotent stimulating concentrations and produced similar aspects of stimulated TSH cells.	Thyrotropin	75-78	thyrotropin releasing hormone	Rattus norvegicus	49-52
402794-6	1977	The dose of TRH used caused a significant increase in the plasma level of TSH which indicated a normal pituitary responsiveness to TRH.	Thyrotropin	74-77	thyrotropin releasing hormone	Homo sapiens	12-15
416857-3	1977	Results indicate that TRH administered to lactating rats induces release of TSH from the pituitary of suckling pups.	Thyrotropin	76-79	thyrotropin releasing hormone	Rattus norvegicus	22-25
401484-16	1977	Thus, GH, but also possibly other substance(s) secreted by GH3 tumors in vivo a) suppress the production of tumor and pituitary PRL; b) suppress the release of TSH, causing mild hypothyroidism; c) inhibit the PRL and TSH responses to TRH; and d) decrease the production of PRL in tissue culture.	Thyrotropin	160-163	gonadotropin releasing hormone receptor	Rattus norvegicus	6-8
401484-16	1977	Thus, GH, but also possibly other substance(s) secreted by GH3 tumors in vivo a) suppress the production of tumor and pituitary PRL; b) suppress the release of TSH, causing mild hypothyroidism; c) inhibit the PRL and TSH responses to TRH; and d) decrease the production of PRL in tissue culture.	Thyrotropin	217-220	gonadotropin releasing hormone receptor	Rattus norvegicus	6-8
204879-0	1977	The effect of psychotropic drugs on the TSH-response to thyroliberin (TRH).	Thyrotropin	40-43	thyrotropin releasing hormone	Homo sapiens	70-73
409654-1	1977	Nineteen out of 51 depressed patients showed abnormal TSH response to TRH in terms of exaggerated, diminished and delayed responses.	Thyrotropin	54-57	thyrotropin releasing hormone	Homo sapiens	70-73
827812-3	1976	Oral TRH produces much stronger and more prolonged TSH stimulation similar to that of a depot preparation.	Thyrotropin	51-54	thyrotropin releasing hormone	Homo sapiens	5-8
1022527-3	1976	The release of TSH was also decreased by 160 nM GIF, and paradoxically increased by 1.6 muM GIF.	Thyrotropin	15-18	cobalamin binding intrinsic factor	Rattus norvegicus	48-51
1022527-3	1976	The release of TSH was also decreased by 160 nM GIF, and paradoxically increased by 1.6 muM GIF.	Thyrotropin	15-18	cobalamin binding intrinsic factor	Rattus norvegicus	92-95
1022527-7	1976	These results indicate that GIF not only inhibits the release of GH and TSH, but also stimulates that of GH and TSH in this system, depending on its dose.	Thyrotropin	72-75	cobalamin binding intrinsic factor	Rattus norvegicus	28-31
1022527-7	1976	These results indicate that GIF not only inhibits the release of GH and TSH, but also stimulates that of GH and TSH in this system, depending on its dose.	Thyrotropin	112-115	cobalamin binding intrinsic factor	Rattus norvegicus	28-31
1022527-4	1976	Increasing the dose of GIF to 16 muM resulted in an abrupt rise in the release of both GH and TSH during the perfusion; then the level of GH decreased to the nadir level followed by an elevation above the base line, while that of TSH promptly fell back toward the base line.	Thyrotropin	94-97	cobalamin binding intrinsic factor	Rattus norvegicus	23-26
1022527-4	1976	Increasing the dose of GIF to 16 muM resulted in an abrupt rise in the release of both GH and TSH during the perfusion; then the level of GH decreased to the nadir level followed by an elevation above the base line, while that of TSH promptly fell back toward the base line.	Thyrotropin	230-233	cobalamin binding intrinsic factor	Rattus norvegicus	23-26
826546-6	1976	It is postulated that in this patient there exists a partial selective resistance of the thyrotrophs to T4 and that the paradoxical increase in serum TSH associated with thyroxine therapy results from T4 dependent increase in the synthesis and secretion of endogenous TRH.	Thyrotropin	150-153	thyrotropin releasing hormone	Homo sapiens	268-271
825076-5	1976	Depressed patients, as do schizophrenics and normal patients, show diminished TSH responses to repeated challenges with TRH.	Thyrotropin	78-81	thyrotropin releasing hormone	Homo sapiens	120-123
825527-5	1976	Administration of TRH iv to the maternal monkey caused a larger response in the fetal plasma TSH than in that of the mother and was followed by larger increments in plasma T4 and T3 concentrations in the fetuses than in the mothers.	Thyrotropin	93-96	thyrotropin releasing hormone	Macaca mulatta	18-21
825527-6	1976	The larger increments of plasma TSH and thyroid hormones in the fetus compared with the mother also occurred when TRH was given iv to the fetus.	Thyrotropin	32-35	thyrotropin releasing hormone	Macaca mulatta	114-117
825528-4	1976	The patient was restudied seven months later, after discontinuing thyroid hormone replacement therapy for two months, and on this occasion repeat TRH administration produced small increments in serum TSH.	Thyrotropin	200-203	thyrotropin releasing hormone	Homo sapiens	146-149
825528-5	1976	After administration of 125I and 131I-T4 to assess thyroid hormone secretion, TRH was infused continuously for 6 h. Small increases in serum TSH were again observed, along with significant increases in PG125I/PB131I and urinary 125I/131I, reflecting increased thyroidal iodine secretion, although serum T3 and T4 did not change.	Thyrotropin	141-144	thyrotropin releasing hormone	Homo sapiens	78-81
825528-6	1976	These studies indicate that: 1) isolated TSH deficiency need not be complete and may be associated with detectable levels of immunoassayable TSH; 2) the TSH released possesses in vivo biological activity; and 3) therapy with thyroid hormone may have facilitated TSH release.	Thyrotropin	41-44	threonine synthase like 2	Homo sapiens	141-147
821960-6	1976	Peak and net 2 h secretion responses of TSH to TRH exhibited a significant inverse correlation with the levels of serum thyroxine and serum triiodothyronine, but were unrelated to the degree of thyroid suppressibility.	Thyrotropin	40-43	thyrotropin releasing hormone	Homo sapiens	47-50
827396-4	1976	The plasma TSH and prolactin levels achieved after 20 mg TRF were considerably greater and were maintained longer than those after 0-5 mg TRF.	Thyrotropin	11-14	thyrotropin releasing hormone	Homo sapiens	57-60
181237-0	1976	Effect of pharmacological blockade of ACTH and TSH secretion on the acute stimulation of prolactin release by exposure to cold and ether stress.	Thyrotropin	47-50	prolactin	Rattus norvegicus	89-98
60346-5	1976	There was an exaggerated response of TSH to a peak value of 550 muU/ml after intravenous administration of 200 mug thyrotropin-releasing hormone (TRH).	Thyrotropin	37-40	thyrotropin releasing hormone	Homo sapiens	115-144
181934-0	1976	Augmented secretion of TSH in response to TRH after pre-treatment with dexamethasone for six days in rats.	Thyrotropin	23-26	thyrotropin releasing hormone	Rattus norvegicus	42-45
828576-5	1976	Serum TSH concentrations in TBG deficiency were all in the normal range (1.0-4.2 micronM/ml) and the maximum TSH increments following TRH 500 microng iv were 8.9 +/- 2.0 micronU/ml and of no significant difference from the normal control (10.2 +/- 4.5 micronU/ml).	Thyrotropin	109-112	thyrotropin releasing hormone	Homo sapiens	134-137
820705-4	1976	The free fraction of thyroid hormones remained constant during treatment but a significant decrease of TSH concentration (30%) was noted after TRH injection on Acetylsalicylic Acid treatment whereas no changes were noted for PRL.	Thyrotropin	103-106	thyrotropin releasing hormone	Homo sapiens	143-146
820705-5	1976	As noted in the animal, this study indicates that in the human, prostaglandins potentiate the effect of TRH on TSH liberation by the pituitary where it has no effect on PRL.	Thyrotropin	111-114	thyrotropin releasing hormone	Homo sapiens	104-107
985824-5	1976	The administration of TRH (200 mug iv) led only to small increments of TSH and PRL levels.	Thyrotropin	71-74	thyrotropin releasing hormone	Homo sapiens	22-25
181577-5	1976	Serum T4 levels in mice injected, for instance, with 8MeS-cAMP (30 mg/kg) rose from 4.85 +/- 0.25 to 6.32 +/- 0.41 mug/100 ml in 1 h, the net increase in T4 being comparable to that produced by TSH (1 mU/mouse) under identical experimental conditions.	Thyrotropin	194-197	inversion, Chr X, Harwell 1	Mus musculus	126-132
821840-0	1976	Effect of iodine upon the TRH induced release of TSH in euthyroid, hypothyroid and hyperthyroid individuals.	Thyrotropin	49-52	thyrotropin releasing hormone	Homo sapiens	26-29
821840-3	1976	Administration of iodide (25 mg daily for two weeks) increased in healthy subjects the basal concentrations of TSH and the release of TSH in response to TRH (p less than 0.05-0.01).	Thyrotropin	134-137	thyrotropin releasing hormone	Homo sapiens	153-156
821840-6	1976	Two out of four hypothyroid patients also showed an increased response of TSH to TRH.	Thyrotropin	74-77	thyrotropin releasing hormone	Homo sapiens	81-84
183393-8	1976	TRH-test with radioimmunological determination of TSH.	Thyrotropin	50-53	thyrotropin releasing hormone	Homo sapiens	0-3
818859-4	1976	In untreated acromegaly with euthyroidism the response of serum TSH to TRH was significantly less than in normal controls, the increment being 7.1 mU/1 vs. 12.5 mU/1.	Thyrotropin	64-67	thyrotropin releasing hormone	Homo sapiens	71-74
818859-13	1976	In one of the hyperthyroid patients the basal TSH level was 6.5 and 8.9 mU/1 on two occasions in the thyrotoxic phase, showing a small response to TRH.	Thyrotropin	46-49	thyrotropin releasing hormone	Homo sapiens	147-150
819250-6	1976	In males, thyrotropin-releasing hormone (TRH) induced a significant elevation in serum TSH at all ages tested, but was less effective in increasing serum TSH on day 25 than on days 15 or 40 or in 3-4-month-old rats.	Thyrotropin	87-90	thyrotropin releasing hormone	Rattus norvegicus	10-39
819250-6	1976	In males, thyrotropin-releasing hormone (TRH) induced a significant elevation in serum TSH at all ages tested, but was less effective in increasing serum TSH on day 25 than on days 15 or 40 or in 3-4-month-old rats.	Thyrotropin	87-90	thyrotropin releasing hormone	Rattus norvegicus	41-44
819251-2	1976	In euthyroid control rats, intravenous injection of TRH (200 ng/100 g BW) resulted in a significant increase in both plasma GH and TSH.	Thyrotropin	131-134	thyrotropin releasing hormone	Rattus norvegicus	52-55
818102-0	1976	The TSH response to thyrotropin-releasing hormone (TRH) in young adult men: intra-individual variation and relation to basal serum TSH and thyroid hormones.	Thyrotropin	4-7	thyrotropin releasing hormone	Homo sapiens	20-49
819251-5	1976	These results suggest that altered thyroid status influences GH release as well as TSH secretion induced by TRH in rats.	Thyrotropin	83-86	thyrotropin releasing hormone	Rattus norvegicus	108-111
818102-0	1976	The TSH response to thyrotropin-releasing hormone (TRH) in young adult men: intra-individual variation and relation to basal serum TSH and thyroid hormones.	Thyrotropin	4-7	thyrotropin releasing hormone	Homo sapiens	51-54
818103-0	1976	TSH levels and TSH response to TRH as a guide to the replacement treatment of patients with thyroid carcinoma.	Thyrotropin	15-18	thyrotropin releasing hormone	Homo sapiens	31-34
819252-4	1976	PRL release was greater in response to a maximally effective dose of pSME than the release elicited by a maximal dose of TRH, and pSME administered together with a greater than mazimally effective dose of TRH caused additional PRL but not TSH secretion.	Thyrotropin	239-242	thyrotropin releasing hormone	Rattus norvegicus	205-208
818104-3	1976	In women 6 to 12 weeks pregnant, doses of 25 mug, 100 mug, or 500 mug TRH elicted similar increments to serum TSH.	Thyrotropin	110-113	thyrotropin releasing hormone	Homo sapiens	70-73
818104-4	1976	Women 16 to 20 weeks pregnant had a slightly higher baseline TSH and a greater TSH response to TRH than the 6-12 week pregnant group.	Thyrotropin	79-82	thyrotropin releasing hormone	Homo sapiens	95-98
819252-10	1976	TSH-releasing activity  eluted from the charcoal with methanol was considerably greater than that expected on the basis of the recovery of [3H]TRH, suggesting the presence in the crude extract of a TSH-release inhibitor or of a TSH-releasing factor other than TRH.	Thyrotropin	0-3	thyrotropin releasing hormone	Rattus norvegicus	228-248
819252-10	1976	TSH-releasing activity  eluted from the charcoal with methanol was considerably greater than that expected on the basis of the recovery of [3H]TRH, suggesting the presence in the crude extract of a TSH-release inhibitor or of a TSH-releasing factor other than TRH.	Thyrotropin	0-3	thyrotropin releasing hormone	Rattus norvegicus	260-263
819248-1	1976	Passive immunization of rats with an antiserum to synthetic somatostatin caused a 250% elevation of basal serum TSH levels and a nearly 200% increase in TSH-response to TRH.	Thyrotropin	153-156	thyrotropin releasing hormone	Rattus norvegicus	169-172
816723-3	1976	The TRH-induced TSH release was delayed in all patients in spite of a normalization of the circulating levels of thyroid hormones.	Thyrotropin	16-19	thyrotropin releasing hormone	Homo sapiens	4-7
813994-3	1976	The concentration of TRH giving half-maximal stimulation (ED50) of TSH release is only slightly increased from 1 to 3 x 10(-9) M in the presence of 10(-8) M somatostatin.	Thyrotropin	67-70	somatostatin	Rattus norvegicus	157-169
175094-9	1976	In mice on a low-iodine diet (LID) but not in animals on a regular diet (RD) NaI pretreatment also blunted TSH-induced thyroidal ODC activation and 131I release.	Thyrotropin	107-110	ornithine decarboxylase, structural 1	Mus musculus	129-132
175094-11	1976	Prior administration of exogenous TSH blunted the activation of thyroid ODC and thyroid hormone release induced by subsequent TSH administration in rat and mouse.	Thyrotropin	34-37	ornithine decarboxylase 1	Rattus norvegicus	72-75
175094-11	1976	Prior administration of exogenous TSH blunted the activation of thyroid ODC and thyroid hormone release induced by subsequent TSH administration in rat and mouse.	Thyrotropin	126-129	ornithine decarboxylase 1	Rattus norvegicus	72-75
174897-7	1976	The cells released significant amounts of PRL, TSH, and to a lesser extent, LH, in response to 1-5 X 10-3M N6,O2"-dibutyryl cyclic AMP, accompanied by remarkable elevation in total content (cells + medium) of PRL and TSH but not of LH.	Thyrotropin	217-220	prolactin	Rattus norvegicus	42-45
816176-1	1976	Selective defect of TSH release on TRF loading in a young woman with a history of severe depressive illness cured with thryoid hormone replacement therapy.	Thyrotropin	20-23	telomeric repeat binding factor 1	Homo sapiens	35-38
816807-9	1976	The primary hypothyroid patients required approximately 150 mug/m2/day of L-T4 for suppression of TSH response to TRH.	Thyrotropin	98-101	thyrotropin releasing hormone	Homo sapiens	114-117
946604-1	1976	UNLABELLED: We have studied the characteristics of the stimulation of adenyl cyclase (AC) activity in human thyroid plasma membranes by thyroid-stimulating hormone (TSH) and by immunoglobulin G (IgG) from the sera of patients with Graves" disease.	Thyrotropin	136-163	adenylate cyclase 1	Homo sapiens	70-84
946604-1	1976	UNLABELLED: We have studied the characteristics of the stimulation of adenyl cyclase (AC) activity in human thyroid plasma membranes by thyroid-stimulating hormone (TSH) and by immunoglobulin G (IgG) from the sera of patients with Graves" disease.	Thyrotropin	136-163	adenylate cyclase 1	Homo sapiens	86-88
946604-1	1976	UNLABELLED: We have studied the characteristics of the stimulation of adenyl cyclase (AC) activity in human thyroid plasma membranes by thyroid-stimulating hormone (TSH) and by immunoglobulin G (IgG) from the sera of patients with Graves" disease.	Thyrotropin	165-168	adenylate cyclase 1	Homo sapiens	70-84
946604-1	1976	UNLABELLED: We have studied the characteristics of the stimulation of adenyl cyclase (AC) activity in human thyroid plasma membranes by thyroid-stimulating hormone (TSH) and by immunoglobulin G (IgG) from the sera of patients with Graves" disease.	Thyrotropin	165-168	adenylate cyclase 1	Homo sapiens	86-88
946604-11	1976	However, an inhibitor of HTACS was detected in 2 of 4 IgGs; one of these two IgGs also inhibited AC stimulation by TSH.	Thyrotropin	115-118	adenylate cyclase 1	Homo sapiens	27-29
174885-5	1976	Thyrotropin releasing hormone (TRH) increased the release into the media and the production of TSH in a dose dependent manner.	Thyrotropin	95-98	thyrotropin releasing hormone	Mus musculus	0-29
174885-5	1976	Thyrotropin releasing hormone (TRH) increased the release into the media and the production of TSH in a dose dependent manner.	Thyrotropin	95-98	thyrotropin releasing hormone	Mus musculus	31-34
174885-7	1976	Thyroid hormones and somatostatin inhibited both basal and TRH induced effects on both TSH release and production.	Thyrotropin	87-90	thyrotropin releasing hormone	Mus musculus	59-62
174885-8	1976	TSH release as induced by TRH was calcium dependent.	Thyrotropin	0-3	thyrotropin releasing hormone	Mus musculus	26-29
811690-14	1975	If TRH secretion is responsible for cold-induced increases in plasma TSH concentrations, the increase in TRH secretion is of insufficient magnitude to alter periperal plasma TRH concentrations.	Thyrotropin	69-72	thyrotropin releasing hormone	Rattus norvegicus	3-6
822858-4	1976	Two of five patients who received TRH showed a grossly subnormal TSH response.	Thyrotropin	65-68	thyrotropin releasing hormone	Homo sapiens	34-37
1206095-0	1975	The effect of somatostatin on TSH levels in patients with primary hypothyroidism.	Thyrotropin	30-33	somatostatin	Homo sapiens	14-26
816092-11	1975	The Wolff-Chaikoff effect, which is induced by the administration of excess iodide, appears to be the cause of the observed increase in TSH secretion upon TRH administration in iodide-treated subjects.	Thyrotropin	136-139	thyrotropin releasing hormone	Homo sapiens	155-158
810342-3	1975	TRH administration via both routes resulted in substantial release of TSH.	Thyrotropin	70-73	thyrotropin releasing hormone	Rattus norvegicus	0-3
1812-6	1975	The role of lipid mobility in modulating hormone-receptor interaction is discussed with reference to the binding of thyroid stimulating hormone.	Thyrotropin	116-143	nuclear receptor subfamily 4 group A member 1	Homo sapiens	41-57
171142-2	1975	Hypophysectomized rats treated with 1 U TSH showed a 5-fold increase in thyroid ODC activity.	Thyrotropin	40-43	ornithine decarboxylase 1	Rattus norvegicus	80-83
171142-8	1975	Stimulation of ODC activity was 90% inhibited by the intraperitoneal administration of actinomycin D (80 mug/100 g body wt) or cycloheximide (400 mug/100 g body wt) given simultaneously with TSH.	Thyrotropin	191-194	ornithine decarboxylase 1	Rattus norvegicus	15-18
810342-4	1975	Following intraventricular injection of TRH, there was a delay in reached maximal TSH concentration when compared with the faster elevation and faster decline in TSH concentrations which followed intravenous injection of the same dose of TRH.	Thyrotropin	82-85	thyrotropin releasing hormone	Rattus norvegicus	40-43
810342-10	1975	The data support the view that TRH is able to cross the medium eminence from CSF into hypophysial portal blood and that it is capable of stimulating the pituitary gland to release TSH.	Thyrotropin	180-183	thyrotropin releasing hormone	Rattus norvegicus	31-34
809459-2	1975	TRH (200 mug/m2 administered intravenously) led to an exaggerated TSH response.	Thyrotropin	66-69	thyrotropin releasing hormone	Homo sapiens	0-3
1183410-6	1975	These results suggest that most, if not all of the thyrotropin-releasing factor (TRF) necessary for normal TSH secretion in resting conditions or during the hypothyroid state, is produced and released in the median eminence-arcuate nucleus area, the adequate activity of which, in turn, depends on intact connections with the anterior hypothalamus.	Thyrotropin	107-110	thyrotropin releasing hormone	Rattus norvegicus	51-79
1183410-6	1975	These results suggest that most, if not all of the thyrotropin-releasing factor (TRF) necessary for normal TSH secretion in resting conditions or during the hypothyroid state, is produced and released in the median eminence-arcuate nucleus area, the adequate activity of which, in turn, depends on intact connections with the anterior hypothalamus.	Thyrotropin	107-110	thyrotropin releasing hormone	Rattus norvegicus	81-84
809253-4	1975	As in CEEG findings, TSH plasma levels also indicate that oral TRH is indeed an active compound.	Thyrotropin	21-24	thyrotropin releasing hormone	Homo sapiens	63-66
1159077-6	1975	After T3, the TRH-stimulated TSH response was decreased but was still inappropriate for the elevated serum T3 levels.	Thyrotropin	29-32	thyrotropin releasing hormone	Homo sapiens	14-17
1243821-6	1975	2 of these subjects had hyperthyroid values of free and total T3 in serum and responded to TRH with an exaggerate TSH increment.	Thyrotropin	114-117	thyrotropin releasing hormone	Homo sapiens	91-94
1159077-9	1975	This patient represents a new syndrome of TSH-induced hyperthyroidism, differing from previous reports in the absence of an obvious pituitary tumor and in the responsiveness of the TSH to TRH stimulation and thyroid hormone suppression.	Thyrotropin	42-45	thyrotropin releasing hormone	Homo sapiens	188-191
1159077-9	1975	This patient represents a new syndrome of TSH-induced hyperthyroidism, differing from previous reports in the absence of an obvious pituitary tumor and in the responsiveness of the TSH to TRH stimulation and thyroid hormone suppression.	Thyrotropin	181-184	thyrotropin releasing hormone	Homo sapiens	188-191
165059-7	1975	Little TSH effect was noted before 3 h. Maximal ODC activity occurred between 4 and 5 h. The TSH stimulation of ODC could be inhibited by pretreatment with actinomycin D or cycloheximide, suggesting that the increase in ODC activity requires new RNA and protein synthesis.	Thyrotropin	93-96	ornithine decarboxylase 1	Rattus norvegicus	112-115
808615-3	1975	The TRH analog was 1.5 times more effective than TRH itself in releasing TSH in vivo from the anterior pituitary of mice.	Thyrotropin	73-76	thyrotropin releasing hormone	Mus musculus	4-7
808615-3	1975	The TRH analog was 1.5 times more effective than TRH itself in releasing TSH in vivo from the anterior pituitary of mice.	Thyrotropin	73-76	thyrotropin releasing hormone	Mus musculus	49-52
819255-1	1975	In order to evaluate the clinical usefulness of the TRH stimulation test in predicting premyxedematous state in chronic thyroiditis, serum TSH response to the i. v. injection of TRH was determined in 58 patients with chronic thyroiditis proven by needle or open biopsy.	Thyrotropin	139-142	thyrotropin releasing hormone	Homo sapiens	178-181
819255-6	1975	Responses of serum TSH to TRH was exaggerated in 67.1% of all patients; 80.0% in diffuse type and 47.4% in focal type.	Thyrotropin	19-22	thyrotropin releasing hormone	Homo sapiens	26-29
165059-3	1975	We studied the effects of TSH on rat thyroid ornithine decarboxylase (ODC) activity.	Thyrotropin	26-29	ornithine decarboxylase 1	Rattus norvegicus	45-68
165059-8	1975	Although pretreatment with agents that alter microtubule structure (e.g., colchicine and vinblastine) prevent stimulation of ODC activity by TSH, additional data suggest, but do not confirm, that hrmone secretion and ODC activation may be dissociable.	Thyrotropin	141-144	ornithine decarboxylase 1	Rattus norvegicus	125-128
165059-3	1975	We studied the effects of TSH on rat thyroid ornithine decarboxylase (ODC) activity.	Thyrotropin	26-29	ornithine decarboxylase 1	Rattus norvegicus	70-73
165059-6	1975	Thyroid ODC activity was also stimulated in a dose-related manner by administration of exogenous TSH.	Thyrotropin	97-100	ornithine decarboxylase 1	Rattus norvegicus	8-11
165059-12	1975	However, pre-treatment of rats with inhibitors of prostaglandin synthesis prevented the activation of thyroidal ODC BY TSH.	Thyrotropin	119-122	ornithine decarboxylase 1	Rattus norvegicus	112-115
165059-7	1975	Little TSH effect was noted before 3 h. Maximal ODC activity occurred between 4 and 5 h. The TSH stimulation of ODC could be inhibited by pretreatment with actinomycin D or cycloheximide, suggesting that the increase in ODC activity requires new RNA and protein synthesis.	Thyrotropin	7-10	ornithine decarboxylase 1	Rattus norvegicus	112-115
165059-7	1975	Little TSH effect was noted before 3 h. Maximal ODC activity occurred between 4 and 5 h. The TSH stimulation of ODC could be inhibited by pretreatment with actinomycin D or cycloheximide, suggesting that the increase in ODC activity requires new RNA and protein synthesis.	Thyrotropin	7-10	ornithine decarboxylase 1	Rattus norvegicus	112-115
165068-2	1975	Dexamethasone given 3 h before experiemtns significantly depressed both TRH- and cold-induced TSH responses at all dose levels.	Thyrotropin	94-97	thyrotropin releasing hormone	Rattus norvegicus	72-75
165059-7	1975	Little TSH effect was noted before 3 h. Maximal ODC activity occurred between 4 and 5 h. The TSH stimulation of ODC could be inhibited by pretreatment with actinomycin D or cycloheximide, suggesting that the increase in ODC activity requires new RNA and protein synthesis.	Thyrotropin	93-96	ornithine decarboxylase 1	Rattus norvegicus	48-51
165059-7	1975	Little TSH effect was noted before 3 h. Maximal ODC activity occurred between 4 and 5 h. The TSH stimulation of ODC could be inhibited by pretreatment with actinomycin D or cycloheximide, suggesting that the increase in ODC activity requires new RNA and protein synthesis.	Thyrotropin	93-96	ornithine decarboxylase 1	Rattus norvegicus	112-115
165069-10	1975	Addition of trypsin to the 3 h incubation abolished the subsequent increase in cAMP in TSH-Initial, while addition of TSH antiserum appreciably reduced this increase.	Thyrotropin	87-90	cathelicidin-7	Bos taurus	79-83
167373-5	1975	Inhibition curves and tests of cross reactivity with LH, FSH, TSH, and GH showed that binding of PRL to its receptors in the kidneys and adrenals was specific.	Thyrotropin	62-65	prolactin	Rattus norvegicus	97-100
809259-0	1975	Lack of TRH-induced TSH secretion in a patient with Klinefelter"s syndrome: a case report.	Thyrotropin	20-23	thyrotropin releasing hormone	Homo sapiens	8-11
804399-4	1975	Pretreatment with either T3 (50 mug/100 g body wt ip) significantly suppressed both plasma GH and TSH responses to TRH.	Thyrotropin	98-101	thyrotropin releasing hormone	Rattus norvegicus	115-118
808434-12	1975	Eight patients who suffered from collagen diseases (SLE:6, RA:1, PSS:1) without any evidence of thyroid disease also exhibited exaggerated TSH responses to TRH.	Thyrotropin	139-142	corneodesmosin	Homo sapiens	65-70
50954-2	1975	TRH tests were performed by measuring serum TSH levels before and 15, 30, 45, 60, 90 and 120 minutes after intravenous injection of 500 mug of synthetic TRH.	Thyrotropin	44-47	thyrotropin releasing hormone	Homo sapiens	0-3
808433-11	1975	There was a positive correlation between the maximum increase in serum PRL concentration above the base line (...PRL) and the increment in serum TSH (...TSH) after TRH administration in these subjects.	Thyrotropin	145-148	prolactin	Homo sapiens	71-74
808433-11	1975	There was a positive correlation between the maximum increase in serum PRL concentration above the base line (...PRL) and the increment in serum TSH (...TSH) after TRH administration in these subjects.	Thyrotropin	145-148	prolactin	Homo sapiens	113-116
808433-11	1975	There was a positive correlation between the maximum increase in serum PRL concentration above the base line (...PRL) and the increment in serum TSH (...TSH) after TRH administration in these subjects.	Thyrotropin	145-148	thyrotropin releasing hormone	Homo sapiens	164-167
808433-11	1975	There was a positive correlation between the maximum increase in serum PRL concentration above the base line (...PRL) and the increment in serum TSH (...TSH) after TRH administration in these subjects.	Thyrotropin	153-156	prolactin	Homo sapiens	71-74
808433-11	1975	There was a positive correlation between the maximum increase in serum PRL concentration above the base line (...PRL) and the increment in serum TSH (...TSH) after TRH administration in these subjects.	Thyrotropin	153-156	prolactin	Homo sapiens	113-116
808433-11	1975	There was a positive correlation between the maximum increase in serum PRL concentration above the base line (...PRL) and the increment in serum TSH (...TSH) after TRH administration in these subjects.	Thyrotropin	153-156	thyrotropin releasing hormone	Homo sapiens	164-167
805680-3	1975	Before treatment the TSH responses to TRH were absent in all patients.	Thyrotropin	21-24	thyrotropin releasing hormone	Homo sapiens	38-41
803974-3	1975	In contrast, TSH responses to TRH were significantly greater at the end of the iodide treatment period.	Thyrotropin	13-16	thyrotropin releasing hormone	Homo sapiens	30-33
803974-5	1975	Post-TRH mean peak serum TSH concentrations were 14.2 muU/ml before and 27.4 muU/ml after iodide (P smaller than 0.01).	Thyrotropin	25-28	thyrotropin releasing hormone	Homo sapiens	5-8
803976-6	1975	Plasma TSH responses to TRH were significantly blunted in patients with depression (P smaller than 0.05).	Thyrotropin	7-10	thyrotropin releasing hormone	Homo sapiens	24-27
803977-2	1975	The TSH, basally and in response to TRH, was significantly lower after the 36-h fast compared to that after 12 h. The mechanism for this effect is not clear, but may be related to the altered hormonal or fuel status associated with prolonged fasting.	Thyrotropin	4-7	thyrotropin releasing hormone	Homo sapiens	36-39
810186-9	1975	In all comparisons the males had higher serum TSH concentrations than females and usually had a greater response to TRH stimulation.	Thyrotropin	46-49	thyrotropin releasing hormone	Rattus norvegicus	116-119
805160-9	1975	Expressed as percent of base-line TSH concentration, TSH rose from 140 plus or minus 52 to 280 plus or minus 44% (control vs. PTU) at 15 min, 265 plus or minus 72 to 367 plus or minus 63% at 30 min, 223 plus or minus 54 to 313 plus or minus 54% at 45 min, 187 plus or minus 45 to 287 plus or minus 51% at 60 min, and 145 plus or minus 22 to 210 plus or minus 28% at 120 min after TRH.	Thyrotropin	53-56	thyrotropin releasing hormone	Homo sapiens	380-383
809721-8	1975	In PTU (propylthiouracil)-treated rats ingesting approximately the same amount of TRH, a plasma TSH increase failed to occur.	Thyrotropin	96-99	thyrotropin releasing hormone	Rattus norvegicus	82-85
809721-1	1975	Intravenous injection of the synthetic tripeptide (PyroGlu-His-Pro-NH2:TRH) effected the prompt release of TSH and prolactin (PRL) from the pituitary of the goitrous rat.	Thyrotropin	107-110	thyrotropin releasing hormone	Rattus norvegicus	71-74
809721-9	1975	The oral ingestion of TRH for 22-27 days by goitrous, TSH-rebounded rats resulted in a significant dimunution in the circulating levels of TSH and PRL, and in ultrastructural manifestations suggestive of impaired release by the adenohypophysis.	Thyrotropin	54-57	thyrotropin releasing hormone	Rattus norvegicus	22-25
809721-2	1975	Plasma TSH and PRL levels increased 2-3-fold within 1 min after the injection of 0.4 and 2 mug TRH.	Thyrotropin	7-10	thyrotropin releasing hormone	Rattus norvegicus	95-98
809721-7	1975	Ingestion of large amounts of TRH (1,700 mug daily for 8 and 14 days) by the euthyroid rat resulted in a 2-3-fold elevation of the plasma TSH level.	Thyrotropin	138-141	thyrotropin releasing hormone	Rattus norvegicus	30-33
809721-9	1975	The oral ingestion of TRH for 22-27 days by goitrous, TSH-rebounded rats resulted in a significant dimunution in the circulating levels of TSH and PRL, and in ultrastructural manifestations suggestive of impaired release by the adenohypophysis.	Thyrotropin	54-57	prolactin	Rattus norvegicus	147-150
809721-9	1975	The oral ingestion of TRH for 22-27 days by goitrous, TSH-rebounded rats resulted in a significant dimunution in the circulating levels of TSH and PRL, and in ultrastructural manifestations suggestive of impaired release by the adenohypophysis.	Thyrotropin	139-142	thyrotropin releasing hormone	Rattus norvegicus	22-25
809721-10	1975	It is concluded that the acute administration of TRH causes the rapid release of TSH and PRL from the pituitary of the chronically hypothyroid rat.	Thyrotropin	81-84	thyrotropin releasing hormone	Rattus norvegicus	49-52
124879-6	1975	It was concluded that higher amounts of Triton soluble thyroglobulin occurring during the postnatal period in rats reflects the availability of more substrate, i.e. thyroglobulin for pinocytosis and partially depends upon the TSH level.	Thyrotropin	226-229	thyroglobulin	Rattus norvegicus	55-68
4217275-0	1974	Effect of somatostatin (growth hormone inhibiting factor: GIF) on TRH-induced TSH release in rats.	Thyrotropin	78-81	somatostatin	Rattus norvegicus	10-22
1129272-8	1975	No difference was observed between 21 and 30-day old rats with respect to 131I excretory patterns,except for decreased urinary output in the TSH-E-2 groups; this decrease, however, appeared to be partially attributable to an increased thyroidal uptake of iodine in these animals.	Thyrotropin	141-144	dihydrolipoamide S-succinyltransferase	Rattus norvegicus	145-148
4448162-0	1974	Stimulation of pituitary glucose-6-phosphate dehydrogenase activity in the rat associated with increased TSH secretion.	Thyrotropin	105-108	glucose-6-phosphate dehydrogenase	Rattus norvegicus	25-58
4368648-0	1974	Effects of hypophysectomy and TSH replacement on the ultrastructural localization of thyroperoxidase.	Thyrotropin	30-33	thyroid peroxidase	Homo sapiens	85-100
4408388-0	1974	Thyroglobulin in serum after TSH stimulation in hyperthyroidism.	Thyrotropin	29-32	thyroglobulin	Homo sapiens	0-13
4214837-2	1974	Basal serum T4, T3, and TSH concentrations and the serum T4 and TSH responses to 400 mug TRH i.v.	Thyrotropin	64-67	thyrotropin releasing hormone	Homo sapiens	89-92
4428982-0	1974	Reduction of insulin response to hyperglycaemia in normal dogs after thyroid-stimulating hormone (TSH) therapy.	Thyrotropin	69-96	insulin	Canis lupus familiaris	13-20
4476658-0	1974	[Proceedings: Pituitary G-6-PDH activity in the accelerated period of TSH secretion].	Thyrotropin	70-73	hexose-6-phosphate dehydrogenase/glucose 1-dehydrogenase	Homo sapiens	24-31
4476662-0	1974	[Proceedings: Effect of a dopamine-beta-hydroxylase inhibitor (fusaric acid) on thyroid hormones and TSH].	Thyrotropin	101-104	dopamine beta-hydroxylase	Homo sapiens	26-51
4428982-0	1974	Reduction of insulin response to hyperglycaemia in normal dogs after thyroid-stimulating hormone (TSH) therapy.	Thyrotropin	98-101	insulin	Canis lupus familiaris	13-20
4199417-11	1973	In two patients with presumed TRH deficiency, the TSH responses were blunted by repetitive TRH doses but only when the serum T(3) and T(4) levels increased to within the normal ranges.	Thyrotropin	50-53	thyrotropin releasing hormone	Homo sapiens	30-33
4798487-0	1973	[Determination of the blood TSH level with the Radioimmunoassay Kit and its clinical application].	Thyrotropin	28-31	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	64-67
4203293-0	1973	Serum TSH responses to intravenously and orally administered TRH in man after thyroidectomy for carcinoma of the thyroid.	Thyrotropin	6-9	thyrotropin releasing hormone	Homo sapiens	61-64
4199417-6	1973	These data suggest that TRH-induced TSH release is extremely sensitive to inhibition by small elevations, not above the normal ranges, of serum T(3) and T(4) of endogenous origin.	Thyrotropin	36-39	thyrotropin releasing hormone	Homo sapiens	24-27
4198107-3	1973	Serum TSH concentrations increased after TRH administration in all subjects.	Thyrotropin	6-9	thyrotropin releasing hormone	Homo sapiens	41-44
4203687-0	1973	Stimulation of TSH release and glucose oxidation in pituitaries from thyroidectomized rats by thyrotropin releasing factor (TRF).	Thyrotropin	15-18	thyrotropin releasing hormone	Rattus norvegicus	94-122
4203687-0	1973	Stimulation of TSH release and glucose oxidation in pituitaries from thyroidectomized rats by thyrotropin releasing factor (TRF).	Thyrotropin	15-18	thyrotropin releasing hormone	Rattus norvegicus	124-127
4197189-0	1973	Release of thyroid stimulating hormone from chick anterior pituitary glands by thyrotropin releasing hormone (TRH).	Thyrotropin	11-38	thyrotropin releasing hormone	Gallus gallus	79-108
4197189-0	1973	Release of thyroid stimulating hormone from chick anterior pituitary glands by thyrotropin releasing hormone (TRH).	Thyrotropin	11-38	thyrotropin releasing hormone	Gallus gallus	110-113
4349546-0	1973	Control by TSH of a phospholipase A 2  activity, a limiting factor in the biosynthesis of prostaglandins in the thyroid.	Thyrotropin	11-14	phospholipase A2 group IB	Homo sapiens	20-37
4198866-0	1973	Influence of dexamethasone on TRF induced TSH release in rats.	Thyrotropin	42-45	interleukin 5	Rattus norvegicus	30-33
4632689-5	1973	Thyrotropin-releasing hormone (TRH), 200 mug i.v., caused a brisk rise in TSH to 28 muU per ml, with T(4) rising to 28 mug per 100 ml, free T(4) to 5.6, and T(3) to 730 ng per 100 ml, thus indicating that the pituitary-thyroid system was intact and that the patient"s TSH was biologically active.	Thyrotropin	74-77	thyrotropin releasing hormone	Homo sapiens	0-29
4632689-5	1973	Thyrotropin-releasing hormone (TRH), 200 mug i.v., caused a brisk rise in TSH to 28 muU per ml, with T(4) rising to 28 mug per 100 ml, free T(4) to 5.6, and T(3) to 730 ng per 100 ml, thus indicating that the pituitary-thyroid system was intact and that the patient"s TSH was biologically active.	Thyrotropin	74-77	thyrotropin releasing hormone	Homo sapiens	31-34
4336437-0	1972	Adenyl-cyclase in a transplantable thyroid tumor: loss of ability to respond to TSH.	Thyrotropin	80-83	adenylate cyclase 1	Homo sapiens	0-14
4631660-0	1972	Triiodothyronine and thyrotropin-releasing hormone interaction on TSH release in man.	Thyrotropin	66-69	thyrotropin releasing hormone	Homo sapiens	21-50
4621744-0	1972	[Stimulation of TSH secfetion by TRF load in hypothalamic and pituitary diseases].	Thyrotropin	16-19	telomeric repeat binding factor 1	Homo sapiens	33-36
4999143-0	1971	Release of TSH by TRF infused directly into a pituitary stalk portal vessel.	Thyrotropin	11-14	telomeric repeat binding factor 1	Homo sapiens	18-21
4330007-5	1971	In four of eight children in group III who responded to TRF, the TSH response was delayed and the initial rise in plasma TSH was not detectable until 10-60 min.	Thyrotropin	65-68	thyrotropin releasing hormone	Homo sapiens	56-59
4330007-5	1971	In four of eight children in group III who responded to TRF, the TSH response was delayed and the initial rise in plasma TSH was not detectable until 10-60 min.	Thyrotropin	121-124	thyrotropin releasing hormone	Homo sapiens	56-59
4989616-10	1970	This suggested that fetal TSH secretion was responsive to FT4 levels from very early in gestation, possibly as early as 11 wk.Thyroxine-binding globulin (TBG) was detected in a fetus of 78 days gestation (1.4 mug/100 ml).	Thyrotropin	26-29	serpin family A member 7	Homo sapiens	154-157
4102606-1	1971	Synthetic thyrotrophin-releasing hormone (TRH) given intravenously in doses of 50 mug or more causes a significant rise in serum thyroid-stimulating hormone (TSH) levels but has no effect on serum growth hormone, plasma luteinizing hormone, or plasma 11-hydroxycorticosteroids under carefully controlled basal conditions.The peak TSH response to intravenous TRH occurs at 20 minutes.	Thyrotropin	129-156	thyrotropin releasing hormone	Homo sapiens	42-45
4102606-1	1971	Synthetic thyrotrophin-releasing hormone (TRH) given intravenously in doses of 50 mug or more causes a significant rise in serum thyroid-stimulating hormone (TSH) levels but has no effect on serum growth hormone, plasma luteinizing hormone, or plasma 11-hydroxycorticosteroids under carefully controlled basal conditions.The peak TSH response to intravenous TRH occurs at 20 minutes.	Thyrotropin	158-161	thyrotropin releasing hormone	Homo sapiens	42-45
4102606-6	1971	follows that of TSH, a consistent response being observed at 40-mg doses of TRH orally.	Thyrotropin	16-19	thyrotropin releasing hormone	Homo sapiens	76-79
13819726-0	1960	Thyrotrophin as an aid in radioiodine treatment.	Thyrotropin	0-12	activation induced cytidine deaminase	Homo sapiens	19-22
4984011-0	1970	Release of TSH by oral administration of synthetic peptide derivatives with TRF activity.	Thyrotropin	11-14	telomeric repeat binding factor 1	Homo sapiens	76-79
5692033-0	1968	The effect of TSH on the acid phosphatase and thyroglobulin hydrolyzing activities in the guinea pig thyroid.	Thyrotropin	14-17	thyroglobulin	Cavia porcellus	46-59
6028912-0	1967	Competition between thyroxine and TRF at the pituitary level in the release of TSH.	Thyrotropin	79-82	telomeric repeat binding factor 1	Homo sapiens	34-37
14452808-0	1962	Studies on the metabolism of adipose tissue; the stimulation of oxygen consumption by TSH preparations in relation to growth hormone and other pituitary fractions.	Thyrotropin	86-89	growth hormone 1	Homo sapiens	118-132
13248429-0	1955	The nuclear volume and the uptake of P32 in the thyroid gland after stimulation with thyrotrophin.	Thyrotropin	85-97	inhibitor of growth family member 2	Homo sapiens	37-40
13104062-0	1953	Relationship between the uptake of P32, the histological changes and the change in thyroid weight after thyrotrophin treatment.	Thyrotropin	104-116	inhibitor of growth family member 2	Homo sapiens	35-38
34047515-2	2021	The aim of the research is to analyze the correlation between serum IL-1alpha concentration, its gene rs1800587 (C/T) genotype carrier and thyroid-stimulating hormone (TSH), thyroid hormones (triiodothyronine (T3) and tetraiodothyronine (T4)), and evaluate the prognostic significance of their combinations in women with tube-peritoneal infertility under the IVF program.	Thyrotropin	168-171	interleukin 1 alpha	Homo sapiens	68-77
33862186-0	2021	TSH attenuates fatty acid oxidation in hepatocytes by reducing the mitochondrial distribution of miR-449a/449b-5p/5194.	Thyrotropin	0-3	microRNA 449a	Homo sapiens	97-118
33862186-3	2021	Here, we found that TSH significantly reduced the distribution of some miRNAs in mitochondria of hepatocytes, especially miR-449a, miR-449b-5p, and miR-5194.	Thyrotropin	20-23	microRNA 449a	Homo sapiens	121-129
33862186-3	2021	Here, we found that TSH significantly reduced the distribution of some miRNAs in mitochondria of hepatocytes, especially miR-449a, miR-449b-5p, and miR-5194.	Thyrotropin	20-23	microRNA 449b	Homo sapiens	131-139
33862186-3	2021	Here, we found that TSH significantly reduced the distribution of some miRNAs in mitochondria of hepatocytes, especially miR-449a, miR-449b-5p, and miR-5194.	Thyrotropin	20-23	microRNA 5194	Homo sapiens	148-156
33683214-10	2021	Cortisol, CRP and IL-6 levels were higher in patients with low TSH and FT3 levels.	Thyrotropin	63-66	interleukin 6	Homo sapiens	18-22
33581413-11	2021	In girls, lower AChE activity was associated with higher fT4 levels (beta=0.05 ng/dL [0.01, 0.10]) and lower TSH concentrations (beta = -0.51 muIU/ml, [-1.00, -0.023]).	Thyrotropin	109-112	acetylcholinesterase (Cartwright blood group)	Homo sapiens	16-20
2853681-4	1988	TSH secretion by control glands was nondetectable, but glands exposed to TRH increased their secretion of TSH in a dose-dependent manner.	Thyrotropin	106-109	thyrotropin releasing hormone	Homo sapiens	73-76
33935526-8	2021	Multiple regression analyses revealed that age, TG, waist circumference (WC), and body mass index were independent predictors for abnormal TSH serum levels.	Thyrotropin	139-142	renin binding protein	Homo sapiens	43-46
33935526-12	2021	Further multiple regression analysis revealed that age, TG, WC and heart rate were independent predictors of blood TSH.	Thyrotropin	115-118	renin binding protein	Homo sapiens	51-54
33935973-7	2021	Conclusions: Our report expands the phenotypic spectrum of patients with GLIS3 mutations and adds important information on the clinical course, highlighting the possible beneficial effects of pancreatic enzyme and antioxidative vitamin substitutions on characteristic NDH syndrome manifestations such as TSH resistance and cholestasis.	Thyrotropin	304-307	GLIS family zinc finger 3	Homo sapiens	73-78
33935973-7	2021	Conclusions: Our report expands the phenotypic spectrum of patients with GLIS3 mutations and adds important information on the clinical course, highlighting the possible beneficial effects of pancreatic enzyme and antioxidative vitamin substitutions on characteristic NDH syndrome manifestations such as TSH resistance and cholestasis.	Thyrotropin	304-307	GLIS family zinc finger 3	Homo sapiens	268-271
33851697-0	2021	TSH activates macrophage inflammation by G13 and G15-dependent pathways.	Thyrotropin	0-3	G protein subunit alpha 13	Homo sapiens	41-44
33851697-0	2021	TSH activates macrophage inflammation by G13 and G15-dependent pathways.	Thyrotropin	0-3	RNA binding motif protein 5	Homo sapiens	49-52
33851697-1	2021	Thyroid-stimulating hormone (TSH) treatment activates IkappaB/NFkappaB (p65) and ERK, P38 in macrophages, but how these pathways are activated, and how they contribute to the pro-inflammatory effect of TSH on macrophages remain unknown.	Thyrotropin	29-32	nuclear factor kappa B subunit 1	Homo sapiens	62-70
33851697-1	2021	Thyroid-stimulating hormone (TSH) treatment activates IkappaB/NFkappaB (p65) and ERK, P38 in macrophages, but how these pathways are activated, and how they contribute to the pro-inflammatory effect of TSH on macrophages remain unknown.	Thyrotropin	29-32	RELA proto-oncogene, NF-kB subunit	Homo sapiens	72-75
33851697-1	2021	Thyroid-stimulating hormone (TSH) treatment activates IkappaB/NFkappaB (p65) and ERK, P38 in macrophages, but how these pathways are activated, and how they contribute to the pro-inflammatory effect of TSH on macrophages remain unknown.	Thyrotropin	29-32	mitogen-activated protein kinase 1	Homo sapiens	81-84
33851697-1	2021	Thyroid-stimulating hormone (TSH) treatment activates IkappaB/NFkappaB (p65) and ERK, P38 in macrophages, but how these pathways are activated, and how they contribute to the pro-inflammatory effect of TSH on macrophages remain unknown.	Thyrotropin	29-32	mitogen-activated protein kinase 14	Homo sapiens	86-89
33851697-6	2021	While TSH-induced IkappaB phosphorylation was not inhibited by Gs inhibitor NF449, Gi inhibitor pertussis toxin, Gq or G11 siRNA, it was blocked by phospholipase C inhibitor U73122 or G15 siRNA interference.	Thyrotropin	6-9	RNA binding motif protein 5	Homo sapiens	184-187
33851697-7	2021	TSH-induced ERK and P38 phosphorylation was blocked by G13 but not G12 siRNA interference.	Thyrotropin	0-3	mitogen-activated protein kinase 1	Homo sapiens	12-15
33851697-7	2021	TSH-induced ERK and P38 phosphorylation was blocked by G13 but not G12 siRNA interference.	Thyrotropin	0-3	mitogen-activated protein kinase 14	Homo sapiens	20-23
33851697-7	2021	TSH-induced ERK and P38 phosphorylation was blocked by G13 but not G12 siRNA interference.	Thyrotropin	0-3	G protein subunit alpha 13	Homo sapiens	55-58
33851697-8	2021	Interfering either G13 or G15 was able to block the pro-inflammatory effect of TSH on macrophages.	Thyrotropin	79-82	G protein subunit alpha 13	Homo sapiens	19-22
33851697-8	2021	Interfering either G13 or G15 was able to block the pro-inflammatory effect of TSH on macrophages.	Thyrotropin	79-82	RNA binding motif protein 5	Homo sapiens	26-29
33851697-9	2021	The present study demonstrate that TSH activates macrophage inflammation by G13/ERK-P38/Rho GTPases and G15/PLC/PKCs/IkappaB pathways.	Thyrotropin	35-38	G protein subunit alpha 13	Homo sapiens	76-79
33851697-9	2021	The present study demonstrate that TSH activates macrophage inflammation by G13/ERK-P38/Rho GTPases and G15/PLC/PKCs/IkappaB pathways.	Thyrotropin	35-38	RNA binding motif protein 5	Homo sapiens	104-107
33828532-5	2021	New findings will be discussed demonstrating the direct process through which the immune system-derived thyroid stimulating hormone (TSH) controls thyroid hormone synthesis and bone metamorphosis, particularly in the context of a novel splice variant of TSHbeta made by peripheral blood leukocytes (PBL).	Thyrotropin	104-131	glycoprotein hormones, alpha polypeptide	Homo sapiens	254-261
33828532-5	2021	New findings will be discussed demonstrating the direct process through which the immune system-derived thyroid stimulating hormone (TSH) controls thyroid hormone synthesis and bone metamorphosis, particularly in the context of a novel splice variant of TSHbeta made by peripheral blood leukocytes (PBL).	Thyrotropin	133-136	glycoprotein hormones, alpha polypeptide	Homo sapiens	254-261
33828533-13	2021	In GH and TSH staining, many GH-positive and TSH-positive cells were observed.	Thyrotropin	10-13	growth hormone 1	Homo sapiens	29-31
33828533-13	2021	In GH and TSH staining, many GH-positive and TSH-positive cells were observed.	Thyrotropin	45-48	growth hormone 1	Homo sapiens	3-5
33743173-8	2021	TSH production was measured by RIA after time-dependent stimulation with TRH.	Thyrotropin	0-3	thyrotropin releasing hormone	Rattus norvegicus	73-76
33726721-7	2021	TSH at concentrations of 10 mU/mL and 100 mU/mL significantly increased the mRNA levels of ALP, COI1 and Runx2 compared with those of the control (P < 0.05, P < 0.01).	Thyrotropin	0-3	PDZ and LIM domain 3	Rattus norvegicus	91-94
33726721-7	2021	TSH at concentrations of 10 mU/mL and 100 mU/mL significantly increased the mRNA levels of ALP, COI1 and Runx2 compared with those of the control (P < 0.05, P < 0.01).	Thyrotropin	0-3	RUNX family transcription factor 2	Rattus norvegicus	105-110
33726721-8	2021	Bone morphogenetic protein (BMP)2 activity was enhanced with both increased TSH concentration and increased time.	Thyrotropin	76-79	bone morphogenetic protein 2	Rattus norvegicus	28-33
33743173-14	2021	CONCLUSION: Our data indicate that the expression of Ca2+/CaMK in rat anterior pituitary are correlated to the role of CREB in the genetic regulation of TSH, and that TRH stimulation activates CaMKIV, which in turn phosphorylates CREB.	Thyrotropin	153-156	cAMP responsive element binding protein 1	Rattus norvegicus	119-123
33743173-14	2021	CONCLUSION: Our data indicate that the expression of Ca2+/CaMK in rat anterior pituitary are correlated to the role of CREB in the genetic regulation of TSH, and that TRH stimulation activates CaMKIV, which in turn phosphorylates CREB.	Thyrotropin	153-156	thyrotropin releasing hormone	Rattus norvegicus	167-170
33660355-9	2022	co-administration of Apelin with T4 may offer valuable therapeutic benefits, specifically lowering blood plasma TSH, and lipid disorder and atherosclerosis biomarkers, in PTU-induced hypothyroid rats.	Thyrotropin	112-115	apelin	Rattus norvegicus	21-27
33677813-11	2021	Furthermore, lncRNA NEAT1 was upregulated upon TSH treatment and could function as a ceRNA and bind to miR-126, thus, modulating its expression level and vascular function.	Thyrotropin	47-50	nuclear paraspeckle assembly transcript 1 (non-protein coding)	Mus musculus	20-25
33677813-11	2021	Furthermore, lncRNA NEAT1 was upregulated upon TSH treatment and could function as a ceRNA and bind to miR-126, thus, modulating its expression level and vascular function.	Thyrotropin	47-50	microRNA 126a	Mus musculus	103-110
33718264-10	2021	Fasting serum insulin, Homeostatic Model Assessment for Insulin Resistance, and hemoglobin A1 were elevated in the Abnormal Group (P<0.05), showing the presence of insulin resistance in individuals with abnormal higher serum TSH levels.	Thyrotropin	225-228	insulin	Homo sapiens	164-171
33669123-0	2021	Central TSH Dysregulation in a Patient with Familial Non-Autoimmune Autosomal Dominant Hyperthyroidism Due to a Novel Thyroid-Stimulating Hormone Receptor Disease-Causing Variant.	Thyrotropin	8-11	thyroid stimulating hormone receptor	Homo sapiens	118-154
33583874-8	2021	TSH, forskolin and dbcAMP also induced strong localization of Slc26a7 to the cell membrane according to immunofluorescence staining and confocal laser scanning microscopy.	Thyrotropin	0-3	solute carrier family 26 member 7	Rattus norvegicus	62-69
33583874-9	2021	Together, these results suggest that TSH suppresses the expression level of Slc26a7 but induces its accumulation at the cell membrane, where it functions as an iodine transporter.	Thyrotropin	37-40	solute carrier family 26 member 7	Rattus norvegicus	76-83
32935630-3	2021	Here, we sought to elucidate the mechanisms that regulate NF-kappaB signaling activation in response to TSH stimulation.	Thyrotropin	104-107	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	58-67
33578589-7	2021	The increased PRL may be a putative mechanism that underlies the onset in female patients with a moderate inverse relationship between TSH and PRL.	Thyrotropin	135-138	prolactin	Homo sapiens	14-17
33578589-7	2021	The increased PRL may be a putative mechanism that underlies the onset in female patients with a moderate inverse relationship between TSH and PRL.	Thyrotropin	135-138	prolactin	Homo sapiens	143-146
33613448-10	2020	Conclusion: A maternal TSH concentration of 2.5-4.0 mIU/L was associated with a lower risk of LBW when combined with TPO Ab-, whereas subjects with a TSH concentration of >4.0 mIU/L had an increased risk of LBW.	Thyrotropin	23-26	thyroid peroxidase	Homo sapiens	117-120
32949324-9	2021	The standardized incidence ratios for stroke were significantly higher in the ACTH + TSH and NFPA groups, which also had higher risks of CVD-related mortality, relative to the PRL and GH groups.	Thyrotropin	85-88	proopiomelanocortin	Homo sapiens	78-82
32935630-9	2021	Moreover, TSH stimulation phosphorylated the kinase TAK-1, and its knock-down abolished TSH-induced NF-kappaB transcriptional activity.	Thyrotropin	10-13	mitogen-activated protein kinase kinase kinase 7	Mus musculus	52-57
32935630-9	2021	Moreover, TSH stimulation phosphorylated the kinase TAK-1, and its knock-down abolished TSH-induced NF-kappaB transcriptional activity.	Thyrotropin	10-13	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	100-109
32935630-9	2021	Moreover, TSH stimulation phosphorylated the kinase TAK-1, and its knock-down abolished TSH-induced NF-kappaB transcriptional activity.	Thyrotropin	88-91	mitogen-activated protein kinase kinase kinase 7	Mus musculus	52-57
32935630-9	2021	Moreover, TSH stimulation phosphorylated the kinase TAK-1, and its knock-down abolished TSH-induced NF-kappaB transcriptional activity.	Thyrotropin	88-91	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	100-109
32935630-12	2021	Evaluation of the role played by NF-kappaB in thyroid physiology demonstrated that the canonical NF-kappaB inhibitor BAY11-7082 reduced TSH-induced expression of thyroid differentiation markers.	Thyrotropin	136-139	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	33-42
32935630-12	2021	Evaluation of the role played by NF-kappaB in thyroid physiology demonstrated that the canonical NF-kappaB inhibitor BAY11-7082 reduced TSH-induced expression of thyroid differentiation markers.	Thyrotropin	136-139	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	97-106
32935630-13	2021	Of note, the involvement of NF-kappaB signaling in thyroid physiology was confirmed by assessing the TSH-induced gene expression in primary cultures of NEMO-deficient mice thyrocytes.	Thyrotropin	101-104	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	28-37
32935630-13	2021	Of note, the involvement of NF-kappaB signaling in thyroid physiology was confirmed by assessing the TSH-induced gene expression in primary cultures of NEMO-deficient mice thyrocytes.	Thyrotropin	101-104	inhibitor of kappaB kinase gamma	Mus musculus	152-156
32935630-14	2021	Moreover, chromatin immunoprecipitation and the knock-down experiments revealed that p65 is a nuclear effector of TSH actions, inducing the transcripcional expression of thyroid differentiation markers.	Thyrotropin	114-117	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	85-88
32935630-15	2021	CONCLUSIONS: Taken together, our results point to NF-kappaB being a pivotal mediator in the TSH-induced thyroid follicular cell differentiation, a relevant finding with potential physiological and pathophysiological implications.	Thyrotropin	92-95	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	50-59
33505608-1	2020	The purpose of the present study is to examine the diagnostic and predictive accuracy of the thyroglobulin (Tg) to thyroid stimulating hormone (TSH) and TSH/Tg ratios in normothyroid patients with differentiated thyroid cancer (DTC).	Thyrotropin	144-147	thyroglobulin	Homo sapiens	93-106
33959275-5	2021	Roxadustat has structural similarity with T3 and is a selective activating ligand for thyroid hormone receptor-beta possibly suppressing TSH release.	Thyrotropin	137-140	thyroid hormone receptor beta	Homo sapiens	86-115
33432478-12	2021	Serum TSH had significant positive correlation (r = 0.391, P < 0.01) with 24-h proteinuria and negative correlation with serum albumin (r =  - 0.303, P < 0.01) in nephrosis.	Thyrotropin	6-9	albumin	Homo sapiens	127-134
32689903-10	2021	Keap1<sup>KD</sup> mice also showed decreased T4 levels in early adult life that were eventually well-compensated over time by increased TSH levels.	Thyrotropin	137-140	kelch-like ECH-associated protein 1	Mus musculus	0-5
33035188-12	2020	TRH stimulation test before GH therapy could identify such patients and provoke careful follow-up evaluation of serum FT4 and TSH concentrations.	Thyrotropin	126-129	thyrotropin releasing hormone	Homo sapiens	0-3
33752829-4	2021	Tanycytes, specialized glial cells lining the third ventricle (3V), are responsible for this TH output through the opposite, PT-TSH-driven, seasonal control of deiodinases 2/3 (Dio 2/3).	Thyrotropin	128-131	iodothyronine deiodinase 2	Homo sapiens	160-175
33752829-4	2021	Tanycytes, specialized glial cells lining the third ventricle (3V), are responsible for this TH output through the opposite, PT-TSH-driven, seasonal control of deiodinases 2/3 (Dio 2/3).	Thyrotropin	128-131	iodothyronine deiodinase 2	Homo sapiens	177-184
32950025-3	2020	TSLP production from human adipocytes is stimulated by thyroid-stimulating hormone (TSH).	Thyrotropin	55-82	thymic stromal lymphopoietin	Homo sapiens	0-4
32950025-3	2020	TSLP production from human adipocytes is stimulated by thyroid-stimulating hormone (TSH).	Thyrotropin	84-87	thymic stromal lymphopoietin	Homo sapiens	0-4
32950025-4	2020	This study aimed to identify TSH-dependent signaling routes that regulate TSLP, to determine if TSLP production is stimulated by other cytokines (IL-1beta and TNF-alpha), and to examine if TSLP production depends on the adipose depot.	Thyrotropin	29-32	thymic stromal lymphopoietin	Homo sapiens	74-78
32950025-8	2020	TSH-stimulated TSLP secretion from subcutaneous adipocytes was enhanced by IBMX (raises cAMP levels) and was blocked by UO126 (inhibitor of MEK1/2-ERK1/2).	Thyrotropin	0-3	thymic stromal lymphopoietin	Homo sapiens	15-19
32950025-8	2020	TSH-stimulated TSLP secretion from subcutaneous adipocytes was enhanced by IBMX (raises cAMP levels) and was blocked by UO126 (inhibitor of MEK1/2-ERK1/2).	Thyrotropin	0-3	mitogen-activated protein kinase kinase 1	Homo sapiens	140-146
32950025-8	2020	TSH-stimulated TSLP secretion from subcutaneous adipocytes was enhanced by IBMX (raises cAMP levels) and was blocked by UO126 (inhibitor of MEK1/2-ERK1/2).	Thyrotropin	0-3	mitogen-activated protein kinase 3	Homo sapiens	147-153
32941925-3	2020	Herein we show that NKX2-1, FOXE1 and PAX8 are required for TSH-induced upregulation of the mRNA levels of TG, TPO, DIO2, NIS, and TSHR whereas HHEX has little effect on the levels of these thyroid-specific gene mRNAs.	Thyrotropin	60-63	NK2 homeobox 1	Homo sapiens	20-26
32941925-3	2020	Herein we show that NKX2-1, FOXE1 and PAX8 are required for TSH-induced upregulation of the mRNA levels of TG, TPO, DIO2, NIS, and TSHR whereas HHEX has little effect on the levels of these thyroid-specific gene mRNAs.	Thyrotropin	60-63	forkhead box E1	Homo sapiens	28-33
32941925-3	2020	Herein we show that NKX2-1, FOXE1 and PAX8 are required for TSH-induced upregulation of the mRNA levels of TG, TPO, DIO2, NIS, and TSHR whereas HHEX has little effect on the levels of these thyroid-specific gene mRNAs.	Thyrotropin	60-63	paired box 8	Homo sapiens	38-42
32941925-3	2020	Herein we show that NKX2-1, FOXE1 and PAX8 are required for TSH-induced upregulation of the mRNA levels of TG, TPO, DIO2, NIS, and TSHR whereas HHEX has little effect on the levels of these thyroid-specific gene mRNAs.	Thyrotropin	60-63	thyroid peroxidase	Homo sapiens	111-114
32941925-3	2020	Herein we show that NKX2-1, FOXE1 and PAX8 are required for TSH-induced upregulation of the mRNA levels of TG, TPO, DIO2, NIS, and TSHR whereas HHEX has little effect on the levels of these thyroid-specific gene mRNAs.	Thyrotropin	60-63	iodothyronine deiodinase 2	Homo sapiens	116-120
32941925-3	2020	Herein we show that NKX2-1, FOXE1 and PAX8 are required for TSH-induced upregulation of the mRNA levels of TG, TPO, DIO2, NIS, and TSHR whereas HHEX has little effect on the levels of these thyroid-specific gene mRNAs.	Thyrotropin	60-63	thyroid stimulating hormone receptor	Homo sapiens	131-135
32941925-3	2020	Herein we show that NKX2-1, FOXE1 and PAX8 are required for TSH-induced upregulation of the mRNA levels of TG, TPO, DIO2, NIS, and TSHR whereas HHEX has little effect on the levels of these thyroid-specific gene mRNAs.	Thyrotropin	60-63	hematopoietically expressed homeobox	Homo sapiens	144-148
32941925-5	2020	In contrast to the IUDRC of thyroid-specific genes, TSH effects on the levels of the mRNAs for NKX2-1, FOXE1 and PAX8 exhibit monophasic decreases at high doses of TSH whereas TSH regulation of HHEX mRNA levels exhibits an IUDRC that overlaps the IUDRC of thyroid-specific genes.	Thyrotropin	52-55	NK2 homeobox 1	Homo sapiens	95-101
32941925-5	2020	In contrast to the IUDRC of thyroid-specific genes, TSH effects on the levels of the mRNAs for NKX2-1, FOXE1 and PAX8 exhibit monophasic decreases at high doses of TSH whereas TSH regulation of HHEX mRNA levels exhibits an IUDRC that overlaps the IUDRC of thyroid-specific genes.	Thyrotropin	52-55	forkhead box E1	Homo sapiens	103-108
32941925-5	2020	In contrast to the IUDRC of thyroid-specific genes, TSH effects on the levels of the mRNAs for NKX2-1, FOXE1 and PAX8 exhibit monophasic decreases at high doses of TSH whereas TSH regulation of HHEX mRNA levels exhibits an IUDRC that overlaps the IUDRC of thyroid-specific genes.	Thyrotropin	52-55	paired box 8	Homo sapiens	113-117
32941925-5	2020	In contrast to the IUDRC of thyroid-specific genes, TSH effects on the levels of the mRNAs for NKX2-1, FOXE1 and PAX8 exhibit monophasic decreases at high doses of TSH whereas TSH regulation of HHEX mRNA levels exhibits an IUDRC that overlaps the IUDRC of thyroid-specific genes.	Thyrotropin	52-55	hematopoietically expressed homeobox	Homo sapiens	194-198
32941925-5	2020	In contrast to the IUDRC of thyroid-specific genes, TSH effects on the levels of the mRNAs for NKX2-1, FOXE1 and PAX8 exhibit monophasic decreases at high doses of TSH whereas TSH regulation of HHEX mRNA levels exhibits an IUDRC that overlaps the IUDRC of thyroid-specific genes.	Thyrotropin	164-167	NK2 homeobox 1	Homo sapiens	95-101
32941925-5	2020	In contrast to the IUDRC of thyroid-specific genes, TSH effects on the levels of the mRNAs for NKX2-1, FOXE1 and PAX8 exhibit monophasic decreases at high doses of TSH whereas TSH regulation of HHEX mRNA levels exhibits an IUDRC that overlaps the IUDRC of thyroid-specific genes.	Thyrotropin	164-167	forkhead box E1	Homo sapiens	103-108
32941925-5	2020	In contrast to the IUDRC of thyroid-specific genes, TSH effects on the levels of the mRNAs for NKX2-1, FOXE1 and PAX8 exhibit monophasic decreases at high doses of TSH whereas TSH regulation of HHEX mRNA levels exhibits an IUDRC that overlaps the IUDRC of thyroid-specific genes.	Thyrotropin	164-167	paired box 8	Homo sapiens	113-117
32941925-5	2020	In contrast to the IUDRC of thyroid-specific genes, TSH effects on the levels of the mRNAs for NKX2-1, FOXE1 and PAX8 exhibit monophasic decreases at high doses of TSH whereas TSH regulation of HHEX mRNA levels exhibits an IUDRC that overlaps the IUDRC of thyroid-specific genes.	Thyrotropin	164-167	hematopoietically expressed homeobox	Homo sapiens	194-198
32496604-11	2020	CONCLUSIONS: The delayed decrease in the TSH concentration after the peak for the TRH tests and decreased levels of rT3 suggest that the main etiology for THOP is suppression at the level of the hypothalamus, but not inactivation of peripheral thyroid hormone metabolism.	Thyrotropin	41-44	thyrotropin releasing hormone	Homo sapiens	82-85
32438896-8	2020	RESULTS: The cerebral Abeta burden in the high-normal TSH group was significantly higher than in the low-normal TSH group (1.53 +- 0.31 vs. 1.35 +- 0.22, p = 0.009).	Thyrotropin	54-57	amyloid beta precursor protein	Homo sapiens	22-27
32438896-8	2020	RESULTS: The cerebral Abeta burden in the high-normal TSH group was significantly higher than in the low-normal TSH group (1.53 +- 0.31 vs. 1.35 +- 0.22, p = 0.009).	Thyrotropin	112-115	amyloid beta precursor protein	Homo sapiens	22-27
32505587-8	2020	A thyrotropin-releasing hormone (TRH) stimulation test showed a normal TSH response to TRH stimulation.	Thyrotropin	71-74	thyrotropin releasing hormone	Homo sapiens	2-31
32581146-0	2020	Cognitive dysfunction associated with activation of the mTOR signaling pathway after TSH suppression therapy in rats.	Thyrotropin	85-88	mechanistic target of rapamycin kinase	Rattus norvegicus	56-60
32581146-10	2020	These results indicated that TSH suppression therapy after total thyroidectomy in rats could impair cognitive function, which might be related to the activation of the mTOR signaling pathway and the damage and necrosis of hippocampal neurons.	Thyrotropin	29-32	mechanistic target of rapamycin kinase	Rattus norvegicus	168-172
32505587-8	2020	A thyrotropin-releasing hormone (TRH) stimulation test showed a normal TSH response to TRH stimulation.	Thyrotropin	71-74	thyrotropin releasing hormone	Homo sapiens	33-36
32580148-8	2020	CONCLUSION: This evaluation shows that the Dutch stepwise T4-TSH-TBG NBS algorithm with a calculated T4/TBG ratio is of great value for the detection of both CH-T and CH-C in the Netherlands, at the cost of a lower PPV compared to TSH-based NBS strategies.	Thyrotropin	61-64	serpin family A member 7	Homo sapiens	65-68
32798586-4	2020	The results showed that BP1 and BP5 significantly increased serum T3/T4 ratio and TSH level, while BP10 reduced the level of T4 significantly without any apparent consequences on TSH and T3 levels.	Thyrotropin	82-85	Blood pressure QTL 1	Rattus norvegicus	24-27
32798586-4	2020	The results showed that BP1 and BP5 significantly increased serum T3/T4 ratio and TSH level, while BP10 reduced the level of T4 significantly without any apparent consequences on TSH and T3 levels.	Thyrotropin	82-85	Blood pressure QTL 5	Rattus norvegicus	32-35
33101075-4	2020	Compared to controls, schizoaffective and bipolar patients showed (1) lower DeltaDeltaTSH values (i.e., difference between 11 PM and 8 AM TRH-TSH responses), (2) lower APO-induced PRL suppression, (3) lower CLO-induced GH stimulation, and (4) higher post-dexamethasone cortisol values.	Thyrotropin	86-89	thyrotropin releasing hormone	Homo sapiens	138-141
32580148-8	2020	CONCLUSION: This evaluation shows that the Dutch stepwise T4-TSH-TBG NBS algorithm with a calculated T4/TBG ratio is of great value for the detection of both CH-T and CH-C in the Netherlands, at the cost of a lower PPV compared to TSH-based NBS strategies.	Thyrotropin	61-64	serpin family A member 7	Homo sapiens	104-107
32188309-11	2020	These results indicate that TPO-antibody positivity could be the most important factor of pregnancy outcomes independent of the TSH levels or adequacy of levothyroxine therapy.	Thyrotropin	128-131	thyroid peroxidase	Homo sapiens	28-31
32420901-2	2020	TSH is the major endogenous ligand of the TSH receptor (TSHR) and its role is dependent on signal transduction of TSHR.	Thyrotropin	0-3	thyroid stimulating hormone receptor	Mus musculus	42-54
32867237-0	2020	Strong Positive Correlation between TSH and Ghrelin in Euthyroid Non-Growth Hormone-Deficient Children with Short Stature.	Thyrotropin	36-39	ghrelin and obestatin prepropeptide	Rattus norvegicus	44-51
32760346-9	2020	Following terminal differentiation with TSH, there was enhanced thyroid follicle formation, high expression of the thyroid specific genes-TG, TPO, TSHR and NIS, and secretion of thyroid hormone (T4) in vitro.	Thyrotropin	40-43	thyroid peroxidase	Homo sapiens	142-145
32760346-9	2020	Following terminal differentiation with TSH, there was enhanced thyroid follicle formation, high expression of the thyroid specific genes-TG, TPO, TSHR and NIS, and secretion of thyroid hormone (T4) in vitro.	Thyrotropin	40-43	thyroid stimulating hormone receptor	Homo sapiens	147-151
32760346-9	2020	Following terminal differentiation with TSH, there was enhanced thyroid follicle formation, high expression of the thyroid specific genes-TG, TPO, TSHR and NIS, and secretion of thyroid hormone (T4) in vitro.	Thyrotropin	40-43	solute carrier family 5 member 5	Homo sapiens	156-159
32867237-7	2020	A higher ghrelin but lower nocturnal GH and lower IGF-I were observed in children with higher normal TSH concentration than those in children with lower normal TSH.	Thyrotropin	101-104	ghrelin and obestatin prepropeptide	Rattus norvegicus	9-16
32867237-7	2020	A higher ghrelin but lower nocturnal GH and lower IGF-I were observed in children with higher normal TSH concentration than those in children with lower normal TSH.	Thyrotropin	101-104	insulin like growth factor 1	Homo sapiens	50-55
32867237-7	2020	A higher ghrelin but lower nocturnal GH and lower IGF-I were observed in children with higher normal TSH concentration than those in children with lower normal TSH.	Thyrotropin	160-163	ghrelin and obestatin prepropeptide	Rattus norvegicus	9-16
32420901-2	2020	TSH is the major endogenous ligand of the TSH receptor (TSHR) and its role is dependent on signal transduction of TSHR.	Thyrotropin	0-3	thyroid stimulating hormone receptor	Mus musculus	56-60
32420901-2	2020	TSH is the major endogenous ligand of the TSH receptor (TSHR) and its role is dependent on signal transduction of TSHR.	Thyrotropin	0-3	thyroid stimulating hormone receptor	Mus musculus	114-118
32243904-11	2020	Furthermore, ubiquitous ectopic expression of tsh/tio induces developmental retardation and eventually larval lethality.	Thyrotropin	46-49	tiptop	Drosophila melanogaster	50-53
32676053-10	2020	This unexpected inhibitory property of MSq1 could be blocked in the presence of a PKC inhibitor resulting in derepressing TSH induced protein kinase A (PKA) signals and resulting in the induction of proliferation.	Thyrotropin	122-125	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	134-150
32676053-10	2020	This unexpected inhibitory property of MSq1 could be blocked in the presence of a PKC inhibitor resulting in derepressing TSH induced protein kinase A (PKA) signals and resulting in the induction of proliferation.	Thyrotropin	122-125	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	152-155
32243904-12	2020	These data reveal evolutionarily conserved functions of tsh/tio in controlling adult appendage patterning, as well as the novel function of regulating larval pigmentation in B. mori, providing novel insights into how tsh/tio regulates insect growth and development.	Thyrotropin	56-59	tiptop	Drosophila melanogaster	47-50
32243904-12	2020	These data reveal evolutionarily conserved functions of tsh/tio in controlling adult appendage patterning, as well as the novel function of regulating larval pigmentation in B. mori, providing novel insights into how tsh/tio regulates insect growth and development.	Thyrotropin	217-220	tiptop	Drosophila melanogaster	23-26
32243904-12	2020	These data reveal evolutionarily conserved functions of tsh/tio in controlling adult appendage patterning, as well as the novel function of regulating larval pigmentation in B. mori, providing novel insights into how tsh/tio regulates insect growth and development.	Thyrotropin	217-220	tiptop	Drosophila melanogaster	47-50
32313526-6	2020	The serum TSH level was associated with caveolin-1 expression in thyroid epithelial cells.	Thyrotropin	10-13	caveolin 1	Homo sapiens	40-50
32671315-5	2020	In contrast, TSH increased both LC3 puncta and p62 levels, but at the same time stabilized p62 protein by inhibiting p62 degradation, indicating TSH induction of autophagy.	Thyrotropin	13-16	KH RNA binding domain containing, signal transduction associated 1	Rattus norvegicus	47-50
32671315-5	2020	In contrast, TSH increased both LC3 puncta and p62 levels, but at the same time stabilized p62 protein by inhibiting p62 degradation, indicating TSH induction of autophagy.	Thyrotropin	13-16	KH RNA binding domain containing, signal transduction associated 1	Rattus norvegicus	91-94
32671315-5	2020	In contrast, TSH increased both LC3 puncta and p62 levels, but at the same time stabilized p62 protein by inhibiting p62 degradation, indicating TSH induction of autophagy.	Thyrotropin	13-16	KH RNA binding domain containing, signal transduction associated 1	Rattus norvegicus	91-94
32671315-5	2020	In contrast, TSH increased both LC3 puncta and p62 levels, but at the same time stabilized p62 protein by inhibiting p62 degradation, indicating TSH induction of autophagy.	Thyrotropin	145-148	KH RNA binding domain containing, signal transduction associated 1	Rattus norvegicus	91-94
32671315-5	2020	In contrast, TSH increased both LC3 puncta and p62 levels, but at the same time stabilized p62 protein by inhibiting p62 degradation, indicating TSH induction of autophagy.	Thyrotropin	145-148	KH RNA binding domain containing, signal transduction associated 1	Rattus norvegicus	91-94
32671315-9	2020	We therefore conclude that TSH positively regulates autophagic activity through the cAMP-PKA-cAMP response element binding protein/ERK and PKC signaling pathways, whereas thyroid hormones inhibit its activity in thyrocytes.	Thyrotropin	27-30	mitogen-activated protein kinase 1	Mus musculus	131-134
32581401-9	2020	Patients with metastatic RAI accumulation showed a significantly higher frequency of pathological N1 (pN1) and serum thyroglobulin (Tg) > 1.5 ng/ml under TSH stimulation (p = 0.035 and p = 0.031, respectively).	Thyrotropin	154-157	thyroglobulin	Homo sapiens	117-130
32454820-12	2020	The main effect analysis showed an independent main effect of either LDL-C (p = 0.041) or TSH (p=0.022) on gp91phox without interaction (p=0.299).	Thyrotropin	90-93	cytochrome b-245 beta chain	Homo sapiens	107-115
32454820-14	2020	And LDL-C and TSH were both independent predictors of gp91phox.	Thyrotropin	14-17	cytochrome b-245 beta chain	Homo sapiens	54-62
32303903-3	2020	This review summarises clinical aspects of constitutive TSH receptor activation by naturally occurring somatic or germline TSHR mutations resulting in TSH-independent thyroid function and cell proliferation.	Thyrotropin	56-59	thyroid stimulating hormone receptor	Homo sapiens	123-127
32088313-4	2020	The enzyme activity of the mutations in TPO was investigated in vitro, and patients with less than 15% residual enzyme activity showed severe CH, such as markedly increased thyroid-stimulating hormone (TSH) at diagnosis (>100 muIU/mL) and pronounced goiter, and required a higher dose of L-thyroxine to maintain the euthyroid.	Thyrotropin	173-200	thyroid peroxidase	Homo sapiens	40-43
32243397-1	2020	Although serum thyroglobulin (Tg) is a reliable differentiated thyroid carcinoma (DTC) prognostic marker, its cutoff values can be affected by TSH stimulation status.	Thyrotropin	143-146	thyroglobulin	Homo sapiens	15-28
32088313-4	2020	The enzyme activity of the mutations in TPO was investigated in vitro, and patients with less than 15% residual enzyme activity showed severe CH, such as markedly increased thyroid-stimulating hormone (TSH) at diagnosis (>100 muIU/mL) and pronounced goiter, and required a higher dose of L-thyroxine to maintain the euthyroid.	Thyrotropin	202-205	thyroid peroxidase	Homo sapiens	40-43
32164046-11	2020	A positive correlation was observed between TSH level and insulin level, HOMA-IR, and TG level.	Thyrotropin	44-47	insulin	Homo sapiens	58-65
32086386-6	2020	In this study we report that thyrotropin (TSH) and the pathogenic, GD-specific monoclonal autoantibody, M22, robustly induce IL-23 in human fibrocytes; however, IL-12 expression is essentially undetectable in these cells under basal conditions or following TSH-stimulation.	Thyrotropin	42-45	interleukin 23 subunit alpha	Homo sapiens	125-130
32114434-7	2020	We suggest that the sex difference in TSH secretion kinetics is driven not only at the level of paraventricular nucleus TRH neurons, but also by differences in post-secretory catabolism of TRH, with enhancement of TRH-degrading activity more sustained in male than female animals.	Thyrotropin	38-41	thyrotropin releasing hormone	Rattus norvegicus	120-123
32114434-7	2020	We suggest that the sex difference in TSH secretion kinetics is driven not only at the level of paraventricular nucleus TRH neurons, but also by differences in post-secretory catabolism of TRH, with enhancement of TRH-degrading activity more sustained in male than female animals.	Thyrotropin	38-41	thyrotropin releasing hormone	Rattus norvegicus	189-192
32114434-7	2020	We suggest that the sex difference in TSH secretion kinetics is driven not only at the level of paraventricular nucleus TRH neurons, but also by differences in post-secretory catabolism of TRH, with enhancement of TRH-degrading activity more sustained in male than female animals.	Thyrotropin	38-41	thyrotropin releasing hormone	Rattus norvegicus	189-192
32049985-11	2020	Additionally, TNF-alpha and PMA were shown to have a negative impact on TSH-induced iodide uptake, consistent with the observed transcriptional downregulation of NIS.	Thyrotropin	72-75	tumor necrosis factor	Homo sapiens	14-23
32049985-11	2020	Additionally, TNF-alpha and PMA were shown to have a negative impact on TSH-induced iodide uptake, consistent with the observed transcriptional downregulation of NIS.	Thyrotropin	72-75	solute carrier family 5 member 5	Homo sapiens	162-165
32049985-8	2020	We confirmed that TNF-alpha leads to downregulation of TSH-induced NIS expression in non-neoplastic thyroid follicular cell-derived models.	Thyrotropin	55-58	tumor necrosis factor	Homo sapiens	18-27
31861014-0	2019	Can the basal serum thyroglobulin level be used to predict the recombinant human TSH-stimulated thyroglobulin level in differentiated patients with thyroid cancer?	Thyrotropin	81-84	thyroglobulin	Homo sapiens	20-33
32049985-8	2020	We confirmed that TNF-alpha leads to downregulation of TSH-induced NIS expression in non-neoplastic thyroid follicular cell-derived models.	Thyrotropin	55-58	solute carrier family 5 member 5	Homo sapiens	67-70
31504637-13	2019	Assessing relationships between serum PRL levels and TRH-stimulated TSH levels would contribute to predict the etiologies of congenital i-TSHD.	Thyrotropin	68-71	prolactin	Homo sapiens	38-41
31940421-0	2020	Liganded T3 receptor beta2 inhibits the positive feedback autoregulation of the gene for GATA2, a transcription factor critical for thyrotropin production.	Thyrotropin	132-143	hemoglobin, beta adult minor chain	Mus musculus	21-26
31940421-0	2020	Liganded T3 receptor beta2 inhibits the positive feedback autoregulation of the gene for GATA2, a transcription factor critical for thyrotropin production.	Thyrotropin	132-143	GATA binding protein 2	Mus musculus	89-94
33132244-9	2020	In mouse thyroid follicular epithelial cells co-cultured with CD4+PD-1+ and CD8+PD-1+ T lymphocytes, the cell viability, TH and TRAb levels and inflammatory cytokines level were the highest, while the TSH level and apoptosis were the lowest.	Thyrotropin	201-204	CD4 antigen	Mus musculus	62-65
31704717-5	2020	A high TSH dose (100 mU/ml) caused a 33% decrease in cell-surface TSHR.	Thyrotropin	7-10	thyroid stimulating hormone receptor	Homo sapiens	66-70
31704717-9	2020	These data show that biphasic regulation of cAMP production is mediated by Gs and Gi/Go at low and high TSH doses, respectively, which may represent a mechanism to prevent overstimulation in TSHR-expressing cells.	Thyrotropin	104-107	thyroid stimulating hormone receptor	Homo sapiens	191-195
31934554-1	2019	Background: Resistance to thyroid hormone beta (RTHbeta) is characterized by elevated thyroid hormone and unsuppressed thyroid-stimulating hormone (TSH), caused by thyroid hormone receptor beta gene (THRB) defects.	Thyrotropin	148-151	thyroid hormone receptor beta	Homo sapiens	200-204
31861014-0	2019	Can the basal serum thyroglobulin level be used to predict the recombinant human TSH-stimulated thyroglobulin level in differentiated patients with thyroid cancer?	Thyrotropin	81-84	thyroglobulin	Homo sapiens	96-109
31441387-8	2019	A compensatory increase of thyroid stimulating hormone subunit beta expression in the pituitary and increased serum TSH concentrations, but reduced expression of thyroid differentiation markers were found in old mice.	Thyrotropin	116-119	thyroid stimulating hormone, beta subunit	Mus musculus	27-67
31345521-2	2019	Gestational thyrotoxicosis is due to homology of the structure of TSH and HCG, which weakly stimulates the TSH receptor.	Thyrotropin	66-69	thyroid stimulating hormone receptor	Homo sapiens	107-119
31276853-15	2019	SSTR2 and SSTR3 are highly expressed in TSH-secreting pituitary adenomas.	Thyrotropin	40-43	somatostatin receptor 3	Homo sapiens	10-15
31178506-4	2019	A correlation has been reported between elevated VEGF and TSH levels in patients with hypothyroidism.	Thyrotropin	58-61	vascular endothelial growth factor A	Homo sapiens	49-53
31703413-1	2019	1) Background: Central congenital hypothyroidism (CCH) is a rare endocrine disorder that can be caused by mutations in the beta-subunit of thyrotropin (TSHB).	Thyrotropin	139-150	thyroid stimulating hormone subunit beta	Homo sapiens	152-156
31606200-0	2019	TSH inhibits eNOS expression in HMEC-1 cells through the TSHR/PI3K/AKT signaling pathway.	Thyrotropin	0-3	nitric oxide synthase 3	Homo sapiens	13-17
31606200-0	2019	TSH inhibits eNOS expression in HMEC-1 cells through the TSHR/PI3K/AKT signaling pathway.	Thyrotropin	0-3	thyroid stimulating hormone receptor	Homo sapiens	57-61
31606200-0	2019	TSH inhibits eNOS expression in HMEC-1 cells through the TSHR/PI3K/AKT signaling pathway.	Thyrotropin	0-3	AKT serine/threonine kinase 1	Homo sapiens	67-70
31606200-7	2019	Mechanism studies demonstrated that TSH promoted AKT phosphorylation (P<0.05), and that LY294002 inhibited the reduction of eNOS expression by TSH.	Thyrotropin	36-39	AKT serine/threonine kinase 1	Homo sapiens	49-52
31606200-7	2019	Mechanism studies demonstrated that TSH promoted AKT phosphorylation (P<0.05), and that LY294002 inhibited the reduction of eNOS expression by TSH.	Thyrotropin	143-146	nitric oxide synthase 3	Homo sapiens	124-128
31606200-8	2019	Moreover, TSH activated the AKT signaling pathway through binding to TSHR on HMEC-1 cells.	Thyrotropin	10-13	AKT serine/threonine kinase 1	Homo sapiens	28-31
31606200-8	2019	Moreover, TSH activated the AKT signaling pathway through binding to TSHR on HMEC-1 cells.	Thyrotropin	10-13	thyroid stimulating hormone receptor	Homo sapiens	69-73
30843173-6	2019	We also found a genome-wide significant association for variant rs13037502 upstream of the PTPN1 gene and TSH plasma levels (P = 1.67 x 10-8).	Thyrotropin	106-109	protein tyrosine phosphatase non-receptor type 1	Homo sapiens	91-96
31399504-1	2019	The large TSH-bound ectodomain of the thyrotropin receptor (TSHR) activates the transmembrane domain (TMD) indirectly via an internal agonist (IA).	Thyrotropin	10-13	thyroid stimulating hormone receptor	Homo sapiens	38-58
31399504-1	2019	The large TSH-bound ectodomain of the thyrotropin receptor (TSHR) activates the transmembrane domain (TMD) indirectly via an internal agonist (IA).	Thyrotropin	10-13	thyroid stimulating hormone receptor	Homo sapiens	60-64
31399504-7	2019	At this new allosteric interaction site, NAM S37a blocks both TSH- and PAM-induced activation of the TSHR.	Thyrotropin	62-65	thyroid stimulating hormone receptor	Homo sapiens	101-105
31276853-15	2019	SSTR2 and SSTR3 are highly expressed in TSH-secreting pituitary adenomas.	Thyrotropin	40-43	somatostatin receptor 2	Homo sapiens	0-5
31136983-2	2019	Here, we tested the effect of mir-22 in TSH induced proliferation and lipid metabolism of thyroid cells.	Thyrotropin	40-43	microRNA 22	Homo sapiens	30-36
30725214-15	2019	Further changes in absolute levels of serum TSH in subclinical hypothyroidism may result in reduced CAVI improvement by acute aerobic exercise.	Thyrotropin	44-47	carbonic anhydrase 6	Homo sapiens	100-104
29792121-8	2019	Patients with the CYP3A5 rs776746 GG-genotype had a significantly longer time-to-TSH-increase at day 1 compared to GA-patients: 11 vs. 5 cycles (p = 0.0071).	Thyrotropin	81-84	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	18-24
29792121-9	2019	Significant associations were also found between PDGFRA rs35597368 and rs1800812 and time-to-TSH-increase at day 28.	Thyrotropin	93-96	platelet derived growth factor receptor alpha	Homo sapiens	49-55
31136983-4	2019	Overexpression of miR-22-3p significantly inhibited TSH- induced expression of lipid metabolic marker genes and increased the expression of lipid catabolism markers and IL6R and led to accumulation of intracellular lipid.	Thyrotropin	52-55	microRNA 223	Homo sapiens	18-27
31136983-4	2019	Overexpression of miR-22-3p significantly inhibited TSH- induced expression of lipid metabolic marker genes and increased the expression of lipid catabolism markers and IL6R and led to accumulation of intracellular lipid.	Thyrotropin	52-55	interleukin 6 receptor	Homo sapiens	169-173
31136983-6	2019	In conclusion, miR-22 regulates TSH-induced thyroid cell proliferation and lipid metabolism disorder by impacting IL6R.	Thyrotropin	32-35	microRNA 22	Homo sapiens	15-21
31136983-6	2019	In conclusion, miR-22 regulates TSH-induced thyroid cell proliferation and lipid metabolism disorder by impacting IL6R.	Thyrotropin	32-35	interleukin 6 receptor	Homo sapiens	114-118
30597745-0	2019	Dipeptidyl peptidase-4 inhibitors attenuate thyroid-stimulating hormone concentrations.	Thyrotropin	44-71	dipeptidyl peptidase 4	Homo sapiens	0-22
25905272-1	2000	This is postulated to be secondary to human chorionic gonadotropin (hCG) stimulation of the thyroid due to the structural homology between the TSH and hCG molecules and their receptors.	Thyrotropin	143-146	hypertrichosis 2 (generalised, congenital)	Homo sapiens	68-71
30940720-4	2019	These results were also observed in myeloid-specific Tshr-deficient ApoE -/- mice, which indicated macrophages to be a critical target of the proinflammatory and atherogenic effects of TSH.	Thyrotropin	185-188	thyroid stimulating hormone receptor	Mus musculus	53-57
30940720-4	2019	These results were also observed in myeloid-specific Tshr-deficient ApoE -/- mice, which indicated macrophages to be a critical target of the proinflammatory and atherogenic effects of TSH.	Thyrotropin	185-188	apolipoprotein E	Mus musculus	68-72
30940720-5	2019	In vitro experiments further revealed that TSH activated MAPKs (ERK1/2, p38alpha, and JNK) and IkappaB/p65 pathways in macrophages and increased inflammatory cytokine production and their recruitment of monocytes.	Thyrotropin	43-46	mitogen-activated protein kinase 3	Mus musculus	64-70
30940720-5	2019	In vitro experiments further revealed that TSH activated MAPKs (ERK1/2, p38alpha, and JNK) and IkappaB/p65 pathways in macrophages and increased inflammatory cytokine production and their recruitment of monocytes.	Thyrotropin	43-46	mitogen-activated protein kinase 14	Mus musculus	72-80
30940720-5	2019	In vitro experiments further revealed that TSH activated MAPKs (ERK1/2, p38alpha, and JNK) and IkappaB/p65 pathways in macrophages and increased inflammatory cytokine production and their recruitment of monocytes.	Thyrotropin	43-46	mitogen-activated protein kinase 8	Mus musculus	86-89
30940720-5	2019	In vitro experiments further revealed that TSH activated MAPKs (ERK1/2, p38alpha, and JNK) and IkappaB/p65 pathways in macrophages and increased inflammatory cytokine production and their recruitment of monocytes.	Thyrotropin	43-46	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	103-106
30944161-4	2019	Unexpectedly, in transgenic mice, injecting TSHR A-subunit-ITE nanoparticles (not ITE-nanoparticles or buffer) accelerated and enhanced the development of pathogenic TSHR Abs measured by inhibition of TSH binding to the TSHR.	Thyrotropin	44-47	thyroid stimulating hormone receptor	Mus musculus	166-170
30944161-4	2019	Unexpectedly, in transgenic mice, injecting TSHR A-subunit-ITE nanoparticles (not ITE-nanoparticles or buffer) accelerated and enhanced the development of pathogenic TSHR Abs measured by inhibition of TSH binding to the TSHR.	Thyrotropin	44-47	thyroid stimulating hormone receptor	Mus musculus	166-170
30652527-9	2019	It was found that both CRE-binding protein and CRE modulator were necessary for the TSH-mediated induction of Foxe1 expression via the cAMP/PKA signaling pathway.	Thyrotropin	84-87	cAMP responsive element modulator	Rattus norvegicus	47-60
30652527-9	2019	It was found that both CRE-binding protein and CRE modulator were necessary for the TSH-mediated induction of Foxe1 expression via the cAMP/PKA signaling pathway.	Thyrotropin	84-87	forkhead box E1	Rattus norvegicus	110-115
25905272-3	2000	A negative correlation was later demonstrated between hCG and TSH in women undergoing elective abortion.	Thyrotropin	62-65	hypertrichosis 2 (generalised, congenital)	Homo sapiens	54-57
30390035-11	2019	This study shows that GATA3 immunoreactivity is characteristic of pituitary gonadotroph and TSH-producing tumors.	Thyrotropin	92-95	trans-acting T-cell-specific transcription factor GATA-3	Meleagris gallopavo	22-27
31024459-8	2019	TSH level is positively associated with TG, apoB, free T, FAI, and negatively associated with apoA (all p &lt; 0.05).	Thyrotropin	0-3	apolipoprotein B	Homo sapiens	44-48
30566234-11	2019	TSH levels correlate with TgAb levels in male NOD.H2h4 mice, suggesting a possible role for TSH in TgAb development.	Thyrotropin	0-3	atrophin 1	Homo sapiens	46-49
30566234-11	2019	TSH levels correlate with TgAb levels in male NOD.H2h4 mice, suggesting a possible role for TSH in TgAb development.	Thyrotropin	92-95	atrophin 1	Homo sapiens	46-49
30888403-3	2019	The frequency of IL-10 producing Bregs and the expression of IL-10 in response to thyroid-stimulating hormone (TSH) stimulation were measured by flow cytometry.	Thyrotropin	111-114	interleukin 10	Homo sapiens	61-66
31002090-6	2019	Thyroid hormone and TSH responses to TRH administration were not different between horses with PPID and normal horses.	Thyrotropin	20-23	thyrotropin releasing hormone	Equus caballus	37-40
30888403-3	2019	The frequency of IL-10 producing Bregs and the expression of IL-10 in response to thyroid-stimulating hormone (TSH) stimulation were measured by flow cytometry.	Thyrotropin	82-109	interleukin 10	Homo sapiens	61-66
31086841-8	2019	Results: Group A patients with Anti TPO antibody positivity had more elevated TSH levels (p&lt;0.0001), proteinuria (p=0.0011) and serum creatinine (p=0.0137) as compared to group B patients.	Thyrotropin	78-81	thyroid peroxidase	Homo sapiens	36-39
30895267-8	2019	Thyroid peroxidase antibodies have also impaired outcomes in some studies whereas others have shown an effect only in combination with high normal TSH levels.	Thyrotropin	147-150	thyroid peroxidase	Homo sapiens	0-18
30881348-8	2019	Moreover, TSH-induced goiter and BRAF T1799A -induced PTC animal models also showed FAM83F activation.	Thyrotropin	10-13	family with sequence similarity 83 member F	Homo sapiens	84-90
30882687-9	2019	At baseline, the serum levels of IGF-1 in the HY and EU patients were positively associated with fT4 (beta = 29.02, P = .002) and negatively associated with TSH (beta = -31.46, P = .042) and logTSH (beta = -29.04, P = .007).	Thyrotropin	157-160	insulin like growth factor 1	Homo sapiens	33-38
31043143-6	2019	Immunization of mice with TSH led to the generation of 7G11E3, an anti-beta-TSH IgG1-secreting hybridoma.	Thyrotropin	26-29	LOC105243590	Mus musculus	80-84
30616679-3	2019	The subtype 1B, classically associated with resistance to PTH and TSH, derives from the epigenetic dysregulation of the GNAS locus.	Thyrotropin	66-69	GNAS complex locus	Homo sapiens	120-124
30314969-7	2019	TSH significantly upregulated VEGF-A and CXCL8 expressions in BHP10-3SCp cells via AKT and ERK signaling, resulting in higher concentrations of VEGF-A and CXCL8 in conditioned medium of TSH-treated BHP10-3SCp cells (TSH-CM) compared with controls.	Thyrotropin	0-3	vascular endothelial growth factor A	Homo sapiens	30-36
30314969-7	2019	TSH significantly upregulated VEGF-A and CXCL8 expressions in BHP10-3SCp cells via AKT and ERK signaling, resulting in higher concentrations of VEGF-A and CXCL8 in conditioned medium of TSH-treated BHP10-3SCp cells (TSH-CM) compared with controls.	Thyrotropin	0-3	C-X-C motif chemokine ligand 8	Homo sapiens	41-46
30314969-7	2019	TSH significantly upregulated VEGF-A and CXCL8 expressions in BHP10-3SCp cells via AKT and ERK signaling, resulting in higher concentrations of VEGF-A and CXCL8 in conditioned medium of TSH-treated BHP10-3SCp cells (TSH-CM) compared with controls.	Thyrotropin	0-3	AKT serine/threonine kinase 1	Homo sapiens	83-86
30314969-7	2019	TSH significantly upregulated VEGF-A and CXCL8 expressions in BHP10-3SCp cells via AKT and ERK signaling, resulting in higher concentrations of VEGF-A and CXCL8 in conditioned medium of TSH-treated BHP10-3SCp cells (TSH-CM) compared with controls.	Thyrotropin	0-3	mitogen-activated protein kinase 1	Homo sapiens	91-94
30314969-7	2019	TSH significantly upregulated VEGF-A and CXCL8 expressions in BHP10-3SCp cells via AKT and ERK signaling, resulting in higher concentrations of VEGF-A and CXCL8 in conditioned medium of TSH-treated BHP10-3SCp cells (TSH-CM) compared with controls.	Thyrotropin	0-3	vascular endothelial growth factor A	Homo sapiens	144-150
30314969-7	2019	TSH significantly upregulated VEGF-A and CXCL8 expressions in BHP10-3SCp cells via AKT and ERK signaling, resulting in higher concentrations of VEGF-A and CXCL8 in conditioned medium of TSH-treated BHP10-3SCp cells (TSH-CM) compared with controls.	Thyrotropin	0-3	C-X-C motif chemokine ligand 8	Homo sapiens	155-160
30314969-7	2019	TSH significantly upregulated VEGF-A and CXCL8 expressions in BHP10-3SCp cells via AKT and ERK signaling, resulting in higher concentrations of VEGF-A and CXCL8 in conditioned medium of TSH-treated BHP10-3SCp cells (TSH-CM) compared with controls.	Thyrotropin	186-189	vascular endothelial growth factor A	Homo sapiens	30-36
30314969-7	2019	TSH significantly upregulated VEGF-A and CXCL8 expressions in BHP10-3SCp cells via AKT and ERK signaling, resulting in higher concentrations of VEGF-A and CXCL8 in conditioned medium of TSH-treated BHP10-3SCp cells (TSH-CM) compared with controls.	Thyrotropin	186-189	C-X-C motif chemokine ligand 8	Homo sapiens	41-46
30314969-7	2019	TSH significantly upregulated VEGF-A and CXCL8 expressions in BHP10-3SCp cells via AKT and ERK signaling, resulting in higher concentrations of VEGF-A and CXCL8 in conditioned medium of TSH-treated BHP10-3SCp cells (TSH-CM) compared with controls.	Thyrotropin	186-189	vascular endothelial growth factor A	Homo sapiens	144-150
30314969-7	2019	TSH significantly upregulated VEGF-A and CXCL8 expressions in BHP10-3SCp cells via AKT and ERK signaling, resulting in higher concentrations of VEGF-A and CXCL8 in conditioned medium of TSH-treated BHP10-3SCp cells (TSH-CM) compared with controls.	Thyrotropin	186-189	C-X-C motif chemokine ligand 8	Homo sapiens	155-160
30314969-8	2019	TSH-CM treatment enhanced tube formation potentials of endothelial cells, and blocking VEGF and/or CXCL8 reduced them.	Thyrotropin	0-3	vascular endothelial growth factor A	Homo sapiens	87-91
30314969-8	2019	TSH-CM treatment enhanced tube formation potentials of endothelial cells, and blocking VEGF and/or CXCL8 reduced them.	Thyrotropin	0-3	C-X-C motif chemokine ligand 8	Homo sapiens	99-104
30314969-9	2019	Blocking VEGF and/or CXCL8 also reduced TSH-dependent tumor growth with reduced tumor vasculature in vivo.	Thyrotropin	40-43	vascular endothelial growth factor A	Homo sapiens	9-13
30314969-9	2019	Blocking VEGF and/or CXCL8 also reduced TSH-dependent tumor growth with reduced tumor vasculature in vivo.	Thyrotropin	40-43	C-X-C motif chemokine ligand 8	Homo sapiens	21-26
25905212-2	2000	Contrary to previous RIAs, ultrasensitive TSH assays allow a clear distinction between patients with suppressed and those with non-suppressed circulating TSH concentrations, i.e. between patients with primary hyperthyroidism (Graves" disease or toxic nodular goiter) and those with central hyperthyroidism (TSH-oma or pituitary resistance to thyroid hormone action, PRTH).	Thyrotropin	42-45	thyroid hormone receptor beta	Homo sapiens	366-370
31530982-9	2019	ALT and AST activity were negatively related to baseline TSH levels.	Thyrotropin	57-60	solute carrier family 17 member 5	Homo sapiens	8-11
30641718-8	2019	There were significant and positive correlations between serum TSH levels and lipid parameters except HDL-C. PCSK9 had a significant and negative correlation with FT4.	Thyrotropin	63-66	proprotein convertase subtilisin/kexin type 9	Homo sapiens	109-114
29985205-7	2019	Meta-analysis also showed that the beta-coefficients of SBP and DBP associated with per 1 mIU/l increase in TSH level were 0.78 (95% CI 0.37-1.18, P &lt; 0.001) and 0.45 (95% CI 0.15-0.76, P = 0.004), respectively.	Thyrotropin	108-111	selenium binding protein 1	Homo sapiens	56-59
30607152-9	2018	Besides, the results of this study revealed that TSH treatment down-regulates TNF-alpha and IL-6.	Thyrotropin	49-52	tumor necrosis factor	Homo sapiens	78-87
30068892-8	2018	Serum TSH within new reference range had a linear correlation with SBP, TC and LDL-C in subjects aged &lt;60 years.	Thyrotropin	6-9	selenium binding protein 1	Homo sapiens	67-70
30911516-14	2019	Hypothyroidism was a common endocrinal abnormality and prolactin was inversely correlated to TSH levels in PCOS patients.	Thyrotropin	93-96	prolactin	Homo sapiens	55-64
30593422-5	2019	Second, thyrotropin-releasing hormone (TRH), which is stimulated by suckling in the puerperal period, induces the secretion of not only TSH and thus indirectly THs, but also prolactin (PRL), which can accelerate the development of breast cancer.	Thyrotropin	136-139	thyrotropin releasing hormone	Homo sapiens	8-37
31079115-14	2019	CONCLUSION: Decreased or normalized TSH levels after weight loss induced by RYGB might be mediated by the decline in leptin.	Thyrotropin	36-39	leptin	Homo sapiens	117-123
30513109-7	2018	Plasma ET-1 levels positively correlated with free T3 and T4 levels, and negatively with TSH levels.	Thyrotropin	89-92	endothelin 1	Homo sapiens	7-11
30607152-9	2018	Besides, the results of this study revealed that TSH treatment down-regulates TNF-alpha and IL-6.	Thyrotropin	49-52	interleukin 6	Homo sapiens	92-96
30607152-10	2018	Evaluating the gene and protein expression data revealed the upregulation of ICAM-1, E-selectin, and VEGF in TSH treated cases in different periods of exposure.	Thyrotropin	109-112	intercellular adhesion molecule 1	Homo sapiens	77-83
30607152-10	2018	Evaluating the gene and protein expression data revealed the upregulation of ICAM-1, E-selectin, and VEGF in TSH treated cases in different periods of exposure.	Thyrotropin	109-112	selectin E	Homo sapiens	85-95
30607152-10	2018	Evaluating the gene and protein expression data revealed the upregulation of ICAM-1, E-selectin, and VEGF in TSH treated cases in different periods of exposure.	Thyrotropin	109-112	vascular endothelial growth factor A	Homo sapiens	101-105
29910160-0	2018	Influence of thyroid peroxidase antibodies on TSH levels of pregnant women and maternal-fetal complications.	Thyrotropin	46-49	thyroid peroxidase	Homo sapiens	13-31
29973439-8	2018	In 4 patients (80%), a poor response of serum TSH levels was observed in the TRH test.	Thyrotropin	46-49	thyrotropin releasing hormone	Homo sapiens	77-80
30588957-10	2018	A higher TSH level was associated with hypertension, lower albumin level, fewer dialysis hours, and increased resistance to erythropoietin.	Thyrotropin	9-12	erythropoietin	Homo sapiens	124-138
29910160-3	2018	The objectives of this study were to analyze if a relationship exists between TSH and TPO levels during pregnancy and the potential effects on gestational and perinatal complications, and to assess whether detectable, but not positive, TPO levels have an impact on development of gestational SCH.	Thyrotropin	78-81	thyroid peroxidase	Homo sapiens	86-89
29910160-9	2018	Of the 1,670 pregnant women screened (84.34%), 142 (8.50%) had positive TPO antibodies and their presence was associated to diagnosis of SCH (P&lt;0.01) and to significantly higher mean TSH levels (3.51mU/L vs. 2.46mU/L, P=0.03).	Thyrotropin	186-189	thyroid peroxidase	Homo sapiens	72-75
29910160-12	2018	CONCLUSION: Presence of positive TPO antibodies is associated to higher TSH levels and higher risk of gestational SCH, but does not increase the rate of maternal-fetal complications.	Thyrotropin	72-75	thyroid peroxidase	Homo sapiens	33-36
31168186-4	2018	Thyroglobulin can be measured during thyroid hormone therapy or after thyroid-stimulating hormone (TSH) stimulation, through thyroid hormone withdrawal or the use of human recombinant TSH.	Thyrotropin	70-97	thyroglobulin	Homo sapiens	0-13
30267533-6	2018	RESULTS Serum prolactin concentrations were significantly higher in elderly people ($65 vs. &gt;65) and in men (70.65+-58.02 vs. 150.82+-114.05 mIU/L), as well as in patients with lower renal function (156.70+-127.23 vs. 72.53+-37.25 mIU/L, the bottom vs. top quartile of creatinine clearance), higher serum homocysteine and TSH concentrations, and in those who used NSAID and statins.	Thyrotropin	325-328	prolactin	Homo sapiens	14-23
30293294-6	2018	(3) High serum TSH level proportion was significantly higher in Uygur ethnic group, early pregnancy, thyroid peroxidase antibody positive and anti-thyroglobulin antibody positive group when compared with Han, late pregnancy, thyroid peroxidase antibody negative and anti-thyroglobulin antibody negative groups (all P&lt;0.05) .	Thyrotropin	15-18	thyroid peroxidase	Homo sapiens	101-119
30293294-6	2018	(3) High serum TSH level proportion was significantly higher in Uygur ethnic group, early pregnancy, thyroid peroxidase antibody positive and anti-thyroglobulin antibody positive group when compared with Han, late pregnancy, thyroid peroxidase antibody negative and anti-thyroglobulin antibody negative groups (all P&lt;0.05) .	Thyrotropin	15-18	thyroid peroxidase	Homo sapiens	225-243
31168186-4	2018	Thyroglobulin can be measured during thyroid hormone therapy or after thyroid-stimulating hormone (TSH) stimulation, through thyroid hormone withdrawal or the use of human recombinant TSH.	Thyrotropin	99-102	thyroglobulin	Homo sapiens	0-13
31168186-4	2018	Thyroglobulin can be measured during thyroid hormone therapy or after thyroid-stimulating hormone (TSH) stimulation, through thyroid hormone withdrawal or the use of human recombinant TSH.	Thyrotropin	184-187	thyroglobulin	Homo sapiens	0-13
29882482-3	2018	Thyroid growth is driven by the TSH/cAMP/PKA signaling pathway, and it has previously been shown that activation of PKA through genetic ablation of the regulatory subunit Prkar1a (Prkar1a KO) is sufficient to cause follicular thyroid cancer in mouse models.	Thyrotropin	32-35	protein kinase, cAMP dependent regulatory, type I, alpha	Mus musculus	180-187
29925743-10	2018	TSH ratio showed more than 1.0 in all patients with depression and CYP3A4 inducer users.	Thyrotropin	0-3	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	67-73
29991084-11	2018	Thyroid autoantibodies are not likely to influence ovarian reserve in euthyroid women whose TSH levels fall within the normal range although elevated TSH levels may be involved in the decline of serum AMH levels.	Thyrotropin	150-153	anti-Mullerian hormone	Homo sapiens	201-204
30118516-10	2018	In the subgroup analysis by risk group, TSH-stimulated serum Tg only predicted RAI-avid mLN in the low-risk group (cut-off = 1.0; HR: 5.3; p = 0.03).	Thyrotropin	40-43	thyroglobulin	Homo sapiens	61-63
30118516-10	2018	In the subgroup analysis by risk group, TSH-stimulated serum Tg only predicted RAI-avid mLN in the low-risk group (cut-off = 1.0; HR: 5.3; p = 0.03).	Thyrotropin	40-43	myoregulin	Mus musculus	88-91
30118516-11	2018	CONCLUSION: The incidence of RAI-avid mLN on postablation SPECT/CT was relatively high in both low- and intermediate-risk patients with PTC, and high preablation TSH-stimulated serum Tg level was a predictor of metastasis, especially in the low-risk group.	Thyrotropin	162-165	myoregulin	Mus musculus	38-41
30118516-11	2018	CONCLUSION: The incidence of RAI-avid mLN on postablation SPECT/CT was relatively high in both low- and intermediate-risk patients with PTC, and high preablation TSH-stimulated serum Tg level was a predictor of metastasis, especially in the low-risk group.	Thyrotropin	162-165	thyroglobulin	Homo sapiens	183-185
30118516-12	2018	A selective treatment approach should be considered in patients with high preablation TSH-stimulated serum Tg level.	Thyrotropin	86-89	thyroglobulin	Homo sapiens	107-109
30026730-6	2018	In cultured HUVECs, TSH can also up-regulate the expression of eNOS; however, it is accompanied by a reduced concentration of NO and increased level of superoxide anion, thereby indicating uncoupled eNOS.	Thyrotropin	20-23	nitric oxide synthase 3	Rattus norvegicus	63-67
30026730-6	2018	In cultured HUVECs, TSH can also up-regulate the expression of eNOS; however, it is accompanied by a reduced concentration of NO and increased level of superoxide anion, thereby indicating uncoupled eNOS.	Thyrotropin	20-23	nitric oxide synthase 3	Rattus norvegicus	199-203
30026730-7	2018	As eNOS is increased, we found that Akt in HUVECs were upregulated by TSH, as well as PGRN expression.	Thyrotropin	70-73	nitric oxide synthase 3	Rattus norvegicus	3-7
30026730-7	2018	As eNOS is increased, we found that Akt in HUVECs were upregulated by TSH, as well as PGRN expression.	Thyrotropin	70-73	AKT serine/threonine kinase 1	Rattus norvegicus	36-39
30026730-9	2018	In conclusion, SCH can induce vascular endothelial dysfunction in rats, and PGRN participated in the process of TSH-induced expression of Akt/eNOS in the endothelium.	Thyrotropin	112-115	granulin precursor	Rattus norvegicus	76-80
30026730-9	2018	In conclusion, SCH can induce vascular endothelial dysfunction in rats, and PGRN participated in the process of TSH-induced expression of Akt/eNOS in the endothelium.	Thyrotropin	112-115	AKT serine/threonine kinase 1	Rattus norvegicus	138-141
30026730-9	2018	In conclusion, SCH can induce vascular endothelial dysfunction in rats, and PGRN participated in the process of TSH-induced expression of Akt/eNOS in the endothelium.	Thyrotropin	112-115	nitric oxide synthase 3	Rattus norvegicus	142-146
29991084-10	2018	On the other hand, serum AMH levels negatively correlated with TSH levels in patients who were either positive for TPOAb or TgAb.	Thyrotropin	63-66	anti-Mullerian hormone	Homo sapiens	25-28
29290039-4	2018	Indeed, we demonstrate strong interaction between both the proteins which causes a suppressed activation of Gq/11 by TSH-stimulated TSHR.	Thyrotropin	117-120	thyroid stimulating hormone receptor	Homo sapiens	132-136
29671346-13	2018	Insulin resisance is associated with larger thyroid volume in patients with type 1 diabetes independently of sex, body mass index, TSH value and presence of autoimmune thyroid disease.	Thyrotropin	131-134	insulin	Homo sapiens	0-7
29353219-0	2018	Blocking mitochondrial cyclophilin D ameliorates TSH-impaired defensive barrier of artery.	Thyrotropin	49-52	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	23-36
29783652-14	2018	Arsenic was inversely related with TSH in premenopausal participants with ER- and PR- (beta = -0.305; beta = -0.304, respectively).	Thyrotropin	35-38	estrogen receptor 1	Homo sapiens	74-76
29783652-14	2018	Arsenic was inversely related with TSH in premenopausal participants with ER- and PR- (beta = -0.305; beta = -0.304, respectively).	Thyrotropin	35-38	progesterone receptor	Homo sapiens	82-84
29853881-4	2018	In our previous study, TSHR was identified in the liver; the major role of TSHR in cholesterol metabolism was illustrated, as TSH could regulate hepatic cholesterol metabolism via cAMP/PKA/CREB/HMGCR and SREBP2/HNF4alpha/CYP7A1 pathways.	Thyrotropin	23-26	cAMP responsive element binding protein 1	Mus musculus	189-193
29083246-0	2018	Reduced insulin sensitivity in differentiated thyroid cancer patients with suppressed TSH.	Thyrotropin	86-89	insulin	Homo sapiens	8-15
29353219-5	2018	We sought to investigate whether cyclophilin D (CypD), emerging as a crucial mediator in mitoOS, regulates effects of TSH on ECs.	Thyrotropin	118-121	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	33-46
29353219-5	2018	We sought to investigate whether cyclophilin D (CypD), emerging as a crucial mediator in mitoOS, regulates effects of TSH on ECs.	Thyrotropin	118-121	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	48-52
29353219-6	2018	METHODS AND RESULTS: SCH patients with TSH &gt; = 10mIU/L showed a positive correlation between serum TSH and endothelin-1 levels.	Thyrotropin	39-42	endothelin 1	Homo sapiens	110-122
29353219-8	2018	Supplemented with exogenous thyroxine to keep normal thyroid hormones, thyroid-specific TSH receptor (TSHR)-knockout mice with injection of exogenous TSH exhibited elevated serum TSH levels, significant endothelial oxidative injuries and disturbed endothelium-dependent vasodilation.	Thyrotropin	88-91	thyroid stimulating hormone receptor	Mus musculus	102-106
29353219-8	2018	Supplemented with exogenous thyroxine to keep normal thyroid hormones, thyroid-specific TSH receptor (TSHR)-knockout mice with injection of exogenous TSH exhibited elevated serum TSH levels, significant endothelial oxidative injuries and disturbed endothelium-dependent vasodilation.	Thyrotropin	102-105	thyroid stimulating hormone receptor	Mus musculus	88-100
29353219-11	2018	Genetic or pharmacological inhibition of CypD (the key regulator for mPTP opening) attenuated TSH-induced mitochondrial oxidative damages and further rescued endothelial functions.	Thyrotropin	94-97	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	41-45
29353219-12	2018	Finally, we confirmed that elevated TSH could activate CypD by enhancing CypD acetylation via inhibiting adenosine monophosphate-activated protein kinase/sirtuin-3 signaling pathway in ECs.	Thyrotropin	36-39	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	55-59
29353219-12	2018	Finally, we confirmed that elevated TSH could activate CypD by enhancing CypD acetylation via inhibiting adenosine monophosphate-activated protein kinase/sirtuin-3 signaling pathway in ECs.	Thyrotropin	36-39	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	73-77
29353219-13	2018	CONCLUSIONS: These findings reveal that elevated TSH triggers mitochondrial perturbations in ECs and provide insights that blocking mitochondrial CypD enhances the defensive ability of ECs under TSH exposure.	Thyrotropin	49-52	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	146-150
29321381-9	2018	According to our findings, rs225014 and rs225015 variants in DIO2, which catalyses the conversion of thyroxine (pro-hormone) to the active thyroid hormone, were associated with TSH levels.	Thyrotropin	177-180	iodothyronine deiodinase 2	Homo sapiens	61-65
29319368-6	2018	Increased EOMES RNA expression was associated with advancing age, lower thyroid volumes and higher peak adjusted TSH levels over the course of the disease.	Thyrotropin	113-116	eomesodermin	Homo sapiens	10-15
29488882-7	2018	PFAS concentrations [PFOA, PFOS, and perfluorononanoate (PFNA)] were inversely associated with TSH levels in TPOAb-positive women only.	Thyrotropin	95-98	phosphoribosylformylglycinamidine synthase	Homo sapiens	0-4
29594511-5	2018	In the assays studied here, poly(acrylic acid) (PAA) coated NaYF4:Yb3+,Er3+ type UCNPs were conjugated to two different antibodies against cardiac troponin I (cTnI) and thyroid stimulating hormone (TSH).	Thyrotropin	169-196	troponin I3, cardiac type	Homo sapiens	159-163
29594511-5	2018	In the assays studied here, poly(acrylic acid) (PAA) coated NaYF4:Yb3+,Er3+ type UCNPs were conjugated to two different antibodies against cardiac troponin I (cTnI) and thyroid stimulating hormone (TSH).	Thyrotropin	198-201	troponin I3, cardiac type	Homo sapiens	159-163
29074327-10	2018	These results suggest that CRHR2 expressed on thyrotropes is likely mediating CRH-induced TSH release in altricial avian species like it does in precocial species, and that the increased thyroid hormone levels towards fledging in altricial birds are the result of increased hypothalamic stimulation, in which the thyrotropic activity of CRH may initially play a role.	Thyrotropin	90-93	corticoliberin	Taeniopygia guttata	27-30
29074327-10	2018	These results suggest that CRHR2 expressed on thyrotropes is likely mediating CRH-induced TSH release in altricial avian species like it does in precocial species, and that the increased thyroid hormone levels towards fledging in altricial birds are the result of increased hypothalamic stimulation, in which the thyrotropic activity of CRH may initially play a role.	Thyrotropin	90-93	corticoliberin	Taeniopygia guttata	78-81
28846851-8	2018	These findings indicated that L-T4 increased BDNF and reelin protein expression by regulation of serum THs and TSH level in Abeta-induced AD rats.	Thyrotropin	111-114	reelin	Rattus norvegicus	54-60
28846851-8	2018	These findings indicated that L-T4 increased BDNF and reelin protein expression by regulation of serum THs and TSH level in Abeta-induced AD rats.	Thyrotropin	111-114	amyloid beta precursor protein	Rattus norvegicus	124-129
29074327-5	2018	In addition, isolated pituitary glands were stimulated with CRH to determine the effect on TSH release.	Thyrotropin	91-94	corticoliberin	Taeniopygia guttata	60-63
29074327-10	2018	These results suggest that CRHR2 expressed on thyrotropes is likely mediating CRH-induced TSH release in altricial avian species like it does in precocial species, and that the increased thyroid hormone levels towards fledging in altricial birds are the result of increased hypothalamic stimulation, in which the thyrotropic activity of CRH may initially play a role.	Thyrotropin	90-93	corticotropin-releasing factor receptor 2	Taeniopygia guttata	27-32
28923288-6	2018	Among women with a TSH1 between 2.5 and 4 mIU/L, the corresponding TSH in early pregnancy (TSH2) was &lt;2.5 mIU/L in 35 women (55%).	Thyrotropin	19-22	threonine synthase like 2	Homo sapiens	91-95
29396447-7	2018	Serum concentrations of several Penta-BDE congeners (BDE-28/33, 47, and 100) were positively associated with concentrations of TSH and free T3, while serum concentration of BDE-153 was negatively associated with total T3 concentrations.	Thyrotropin	127-130	homeobox D13	Homo sapiens	38-41
29054761-11	2018	Three miRNAs were associated with TSH levels in HT patients (miR-451, P=0.043; miR-375, P=0.043; miR-500a, P=0.043).	Thyrotropin	34-37	microRNA 451a	Homo sapiens	61-68
29054761-11	2018	Three miRNAs were associated with TSH levels in HT patients (miR-451, P=0.043; miR-375, P=0.043; miR-500a, P=0.043).	Thyrotropin	34-37	microRNA 375	Homo sapiens	79-86
29054761-11	2018	Three miRNAs were associated with TSH levels in HT patients (miR-451, P=0.043; miR-375, P=0.043; miR-500a, P=0.043).	Thyrotropin	34-37	microRNA 500a	Homo sapiens	97-105
29396447-7	2018	Serum concentrations of several Penta-BDE congeners (BDE-28/33, 47, and 100) were positively associated with concentrations of TSH and free T3, while serum concentration of BDE-153 was negatively associated with total T3 concentrations.	Thyrotropin	127-130	homeobox D13	Homo sapiens	53-56
29396447-7	2018	Serum concentrations of several Penta-BDE congeners (BDE-28/33, 47, and 100) were positively associated with concentrations of TSH and free T3, while serum concentration of BDE-153 was negatively associated with total T3 concentrations.	Thyrotropin	127-130	homeobox D13	Homo sapiens	53-56
29440225-9	2018	Based on Pearson correlation analysis, the levels of chemerin, TNF-alpha, ET-1, LDL-C, TC and triglyceride (TG) were positively correlated with TSH, but APN and NO levels were negatively correlated with TSH.	Thyrotropin	144-147	retinoic acid receptor responder 2	Rattus norvegicus	53-61
29440225-9	2018	Based on Pearson correlation analysis, the levels of chemerin, TNF-alpha, ET-1, LDL-C, TC and triglyceride (TG) were positively correlated with TSH, but APN and NO levels were negatively correlated with TSH.	Thyrotropin	144-147	tumor necrosis factor	Rattus norvegicus	63-72
29541701-4	2018	Patients with normal TSH concentrations were assessed for both clinical and biochemical hypothyroidism.We evaluated the effect of ACTH stimulation (performed on patients for assessment of adrenal function) on TSH concentration.	Thyrotropin	209-212	proopiomelanocortin	Homo sapiens	130-134
29386586-6	2018	Similarly, TSH stimulated GLUT2 promoter activity, while both a dominant-negative p38MAPK alpha isoform (p38MAPK alpha-DN) and the specific inhibitor for p38MAPK alpha abolished the stimulatory effect of TSH on GLUT2 promoter activity.	Thyrotropin	11-14	solute carrier family 2 member 2	Rattus norvegicus	26-31
29386586-6	2018	Similarly, TSH stimulated GLUT2 promoter activity, while both a dominant-negative p38MAPK alpha isoform (p38MAPK alpha-DN) and the specific inhibitor for p38MAPK alpha abolished the stimulatory effect of TSH on GLUT2 promoter activity.	Thyrotropin	11-14	solute carrier family 2 member 2	Rattus norvegicus	211-216
29363585-5	2018	We found that stimulating TSHR-Abs (S-TSHR-Abs) activated Galphas and, to a lesser extent, Galphaq but that C-TSHR-Abs failed to activate any of the G proteins normally activated in response to TSH.	Thyrotropin	26-29	thyroid stimulating hormone receptor	Homo sapiens	38-42
29363585-5	2018	We found that stimulating TSHR-Abs (S-TSHR-Abs) activated Galphas and, to a lesser extent, Galphaq but that C-TSHR-Abs failed to activate any of the G proteins normally activated in response to TSH.	Thyrotropin	26-29	thyroid stimulating hormone receptor	Homo sapiens	38-42
30083029-1	2018	Genetic defects of the TSH receptor (TSHR) signaling pathway cause a form of congenital hypothyroidism (CH) known as TSH resistance.	Thyrotropin	23-26	thyroid stimulating hormone receptor	Homo sapiens	37-41
29440950-9	2018	Also, we found a significant negative correlation between TNF-alpha and TSH levels (r=-0.366, p=0.015).	Thyrotropin	72-75	tumor necrosis factor	Homo sapiens	58-67
29357324-9	2018	Plasma TSH levels were positively correlated with miR-146a levels (r=0.321).	Thyrotropin	7-10	microRNA 146a	Homo sapiens	50-58
29357324-14	2018	Thus, miR-146a may have good predictive value for CHD among individuals with elevated TSH levels.	Thyrotropin	86-89	microRNA 146a	Homo sapiens	6-14
30083029-2	2018	Consistent with the physiological understanding that thyroidal iodine uptake is up-regulated by TSHR signaling, most patients with TSH resistance have low to normal thyroidal 123I uptake representing the classic TSH resistance.	Thyrotropin	131-134	thyroid stimulating hormone receptor	Homo sapiens	96-100
29171874-5	2018	RESULTS: In age- and sex-adjusted analysis, PON-1 activity (divided into tertiles) was positively related to TSH (beta = -0.045, P = .036) and inversely to free T4 (beta = -0.042, P = .050) but not to free T3 (beta = -0.027, P = .20).	Thyrotropin	109-112	paraoxonase 1	Homo sapiens	44-49
29468987-0	2018	Antithyroid Drugs Inactivate TSH Binding to the TSH Receptor by their Reducing Action.	Thyrotropin	29-32	thyroid stimulating hormone receptor	Homo sapiens	48-60
29468987-8	2018	CONCLUSION: ATDs inactivate the TSH-binding site of TSHR by reduction, although ATDs do not inactivate bTSH and TSAb activity.	Thyrotropin	32-35	thyroid stimulating hormone receptor	Homo sapiens	52-56
27921237-3	2017	The binding arrangements between the TSHR LRD and the thyroid-stimulating autoantibody M22 or TSH have become available from the crystal structure of the TSHR LRD-M22 complex and a comparative model of the TSHR LRD in complex with TSH, respectively.	Thyrotropin	37-40	thyroid stimulating hormone receptor	Homo sapiens	154-158
29246135-10	2017	MOK acupuncture significantly increased the level of TSH, and decreased the levels of T3 and T4 in hyperthyroidism rats.	Thyrotropin	53-56	MOK protein kinase	Rattus norvegicus	0-3
29093023-5	2017	Furthermore, CREB3L1 potentiated the TSH-induced increase in Golgi volume.	Thyrotropin	37-40	cAMP responsive element binding protein 3 like 1	Homo sapiens	13-20
29089368-1	2018	Recently, we showed that TSH-enhanced differentiation of a human preosteoblast-like cell model involved a beta-arrestin 1 (beta-Arr 1)-mediated pathway.	Thyrotropin	25-28	arrestin beta 1	Homo sapiens	106-121
29089368-1	2018	Recently, we showed that TSH-enhanced differentiation of a human preosteoblast-like cell model involved a beta-arrestin 1 (beta-Arr 1)-mediated pathway.	Thyrotropin	25-28	arrestin beta 1	Homo sapiens	123-133
29089368-5	2018	In DiscoverX1 cells, D3-betaArr stimulated beta-Arr 1 translocation with a 5.1-fold greater efficacy than TSH and therefore potentiated the effect of TSH in stimulating beta-Arr 1 translocation.	Thyrotropin	150-153	arrestin beta 1	Homo sapiens	169-179
29089368-7	2018	D3-betaArr alone had only a weak effect to upregulate these bone markers, but D3-betaArr potentiated TSH-induced upregulation of ALPL and OPN mRNA levels 1.6-fold and 5.5-fold, respectively, at the maximum dose of ligands.	Thyrotropin	101-104	alkaline phosphatase, biomineralization associated	Homo sapiens	129-133
29089368-7	2018	D3-betaArr alone had only a weak effect to upregulate these bone markers, but D3-betaArr potentiated TSH-induced upregulation of ALPL and OPN mRNA levels 1.6-fold and 5.5-fold, respectively, at the maximum dose of ligands.	Thyrotropin	101-104	secreted phosphoprotein 1	Homo sapiens	138-141
29089368-8	2018	Furthermore, the positive allosteric modulator effect of D3-betaArr resulted in an increase of TSH-induced secretion of OPN protein.	Thyrotropin	95-98	secreted phosphoprotein 1	Homo sapiens	120-123
29089368-10	2018	As D3-betaArr potentiates the effect of TSH to enhance differentiation of a human preosteoblast in an in vitro model, it will allow a novel experimental approach for probing the role of TSH-induced beta-Arr 1 signaling in osteoblast differentiation.	Thyrotropin	40-43	arrestin beta 1	Homo sapiens	198-208
29089368-10	2018	As D3-betaArr potentiates the effect of TSH to enhance differentiation of a human preosteoblast in an in vitro model, it will allow a novel experimental approach for probing the role of TSH-induced beta-Arr 1 signaling in osteoblast differentiation.	Thyrotropin	186-189	arrestin beta 1	Homo sapiens	198-208
29261514-0	2017	Association of prothrombotic adipokine (plasminogen activator inhibitor-1) with TSH in metabolic syndrome: a case control study.	Thyrotropin	80-83	serpin family E member 1	Homo sapiens	40-73
27921237-3	2017	The binding arrangements between the TSHR LRD and the thyroid-stimulating autoantibody M22 or TSH have become available from the crystal structure of the TSHR LRD-M22 complex and a comparative model of the TSHR LRD in complex with TSH, respectively.	Thyrotropin	37-40	thyroid stimulating hormone receptor	Homo sapiens	154-158
29131865-8	2017	Notably, higher thyroid stimulating hormone levels and lower parathyroid hormone levels were found in patients with rs2075912, rs2565200, and rs2742240 heterozygotes and rare homozygotes; similar results were observed between PTH levels and rs1800858.	Thyrotropin	16-43	parathyroid hormone	Homo sapiens	226-229
29083325-5	2017	The repression of cell proliferation of GLIS3-deficient thyroid follicular cells was due to the inhibition of TSH-mediated activation of the mTOR complex 1/ribosomal protein S6 (mTORC1/RPS6) pathway as well as the reduced expression of several cell division-related genes regulated directly by GLIS3.	Thyrotropin	110-113	CREB regulated transcription coactivator 1	Mus musculus	178-184
29083325-5	2017	The repression of cell proliferation of GLIS3-deficient thyroid follicular cells was due to the inhibition of TSH-mediated activation of the mTOR complex 1/ribosomal protein S6 (mTORC1/RPS6) pathway as well as the reduced expression of several cell division-related genes regulated directly by GLIS3.	Thyrotropin	110-113	ribosomal protein S6	Homo sapiens	185-189
29083325-5	2017	The repression of cell proliferation of GLIS3-deficient thyroid follicular cells was due to the inhibition of TSH-mediated activation of the mTOR complex 1/ribosomal protein S6 (mTORC1/RPS6) pathway as well as the reduced expression of several cell division-related genes regulated directly by GLIS3.	Thyrotropin	110-113	GLIS family zinc finger 3	Homo sapiens	40-45
29102040-3	2017	Multivariable logistic regression analyses were performed to assess the association between preconceptual TSH levels and anti-TPO antibodies.	Thyrotropin	106-109	thyroid peroxidase	Homo sapiens	126-129
28843902-7	2017	Moreover, in current SBDs (1) violent suicide attempters (n=15) showed lower FT4B levels, lower TSH-TRH responses (both at 0800h and 2300h), and lower DeltaDeltaTSH and DeltaDeltaPRL values than controls, while (2) non-violent suicide attempters (n=56) showed lower DeltaDeltaTSH values than controls and higher TSH-TRH responses (both at 0800h and 2300h) than violent suicide attempters.	Thyrotropin	96-99	SBDS ribosome maturation factor	Homo sapiens	21-25
28843902-7	2017	Moreover, in current SBDs (1) violent suicide attempters (n=15) showed lower FT4B levels, lower TSH-TRH responses (both at 0800h and 2300h), and lower DeltaDeltaTSH and DeltaDeltaPRL values than controls, while (2) non-violent suicide attempters (n=56) showed lower DeltaDeltaTSH values than controls and higher TSH-TRH responses (both at 0800h and 2300h) than violent suicide attempters.	Thyrotropin	161-164	SBDS ribosome maturation factor	Homo sapiens	21-25
28771744-5	2017	Snx5-/- thyrocytes exhibited a higher growth potential and higher sensitivity to thyroid-stimulating hormone (TSH).	Thyrotropin	110-113	sorting nexin 5	Mus musculus	0-4
28771744-8	2017	The increased TSH sensitivities in Snx5-/- thyrocytes were also confirmed by results showing that Snx5-/- mice steadily developed thyroid tumors with high metastatic potential under high TSH.	Thyrotropin	14-17	sorting nexin 5	Mus musculus	35-39
28771744-8	2017	The increased TSH sensitivities in Snx5-/- thyrocytes were also confirmed by results showing that Snx5-/- mice steadily developed thyroid tumors with high metastatic potential under high TSH.	Thyrotropin	14-17	sorting nexin 5	Mus musculus	98-102
28771744-8	2017	The increased TSH sensitivities in Snx5-/- thyrocytes were also confirmed by results showing that Snx5-/- mice steadily developed thyroid tumors with high metastatic potential under high TSH.	Thyrotropin	187-190	sorting nexin 5	Mus musculus	35-39
28771744-8	2017	The increased TSH sensitivities in Snx5-/- thyrocytes were also confirmed by results showing that Snx5-/- mice steadily developed thyroid tumors with high metastatic potential under high TSH.	Thyrotropin	187-190	sorting nexin 5	Mus musculus	98-102
28771744-10	2017	Our results suggest that thyrocytes require Snx5 to lessen tumorigenic signaling driven by TSH, which is a major risk factor for thyroid carcinoma.	Thyrotropin	91-94	sorting nexin 5	Mus musculus	44-48
28987238-0	2017	Thyroid stimulating hormone exhibits the impact on LDLR/LDL-c via up-regulating hepatic PCSK9 expression.	Thyrotropin	0-27	low density lipoprotein receptor	Homo sapiens	51-55
28987238-0	2017	Thyroid stimulating hormone exhibits the impact on LDLR/LDL-c via up-regulating hepatic PCSK9 expression.	Thyrotropin	0-27	component of oligomeric golgi complex 2	Homo sapiens	56-61
28987238-0	2017	Thyroid stimulating hormone exhibits the impact on LDLR/LDL-c via up-regulating hepatic PCSK9 expression.	Thyrotropin	0-27	proprotein convertase subtilisin/kexin type 9	Homo sapiens	88-93
28987238-5	2017	Then, an in vitro study was conducted to validate the effects of TSH on hepatic PCSK9 expression in HepG2 cells.	Thyrotropin	65-68	proprotein convertase subtilisin/kexin type 9	Homo sapiens	80-85
28987238-6	2017	RESULTS: Serum TSH concentrations positively correlated with LDL-c levels in euthyroid subjects.	Thyrotropin	15-18	component of oligomeric golgi complex 2	Homo sapiens	61-66
28987238-7	2017	Subclinical hypothyroidism patients with higher serum TSH levels showed significantly increased serum PCSK9 levels than the matched euthyroid participants (151.29 (89.51-293.03) vs. 84.70 (34.98-141.72) ng/ml, P&lt;0.001), along with increased LDL-c concentrations.	Thyrotropin	54-57	proprotein convertase subtilisin/kexin type 9	Homo sapiens	102-107
28987238-7	2017	Subclinical hypothyroidism patients with higher serum TSH levels showed significantly increased serum PCSK9 levels than the matched euthyroid participants (151.29 (89.51-293.03) vs. 84.70 (34.98-141.72) ng/ml, P&lt;0.001), along with increased LDL-c concentrations.	Thyrotropin	54-57	component of oligomeric golgi complex 2	Homo sapiens	244-249
28987238-8	2017	In HepG2 cells, LDLR expression on the plasma membrane was decreased, and PCSK9 mRNA and protein levels were synchronously upregulated after recombinant human TSH (rhTSH) treatment, while the effects could be blocked by TSH receptor blocking antibody K1-70.	Thyrotropin	159-162	proprotein convertase subtilisin/kexin type 9	Homo sapiens	74-79
28987238-11	2017	CONCLUSION: We conclude a regulating role of TSH on hepatic PCSK9 expression, which further contributing to a higher LDL-c level.	Thyrotropin	45-48	proprotein convertase subtilisin/kexin type 9	Homo sapiens	60-65
28987238-11	2017	CONCLUSION: We conclude a regulating role of TSH on hepatic PCSK9 expression, which further contributing to a higher LDL-c level.	Thyrotropin	45-48	component of oligomeric golgi complex 2	Homo sapiens	117-122
28931076-3	2017	The present study shows a ghrelin-induced decrease in the thyroid-stimulating hormone (TSH)-induced production of thyroglobulin and mRNA expression of thyroperoxidase in a primary culture of human thyroid cells obtained from paranodular tissue.	Thyrotropin	58-85	thyroid peroxidase	Homo sapiens	151-166
28895537-10	2017	Subjects with positive TPO antibodies had higher TSH levels (3.34muIU/L versus 2.14muIU/mL, P=.001; odds ratio=2.42).	Thyrotropin	49-52	thyroid peroxidase	Homo sapiens	23-26
28743746-5	2017	Conversely, de novo T3 that can be formed upon iodination of TG secreted from PCCL3 (rat thyrocyte) cells was augmented from cells previously exposed to increased TSH, a TSHR agonist, a cAMP analog, or a TSHR-stimulating antibody.	Thyrotropin	163-166	thyroid stimulating hormone receptor	Rattus norvegicus	170-174
28743746-5	2017	Conversely, de novo T3 that can be formed upon iodination of TG secreted from PCCL3 (rat thyrocyte) cells was augmented from cells previously exposed to increased TSH, a TSHR agonist, a cAMP analog, or a TSHR-stimulating antibody.	Thyrotropin	163-166	thyroid stimulating hormone receptor	Rattus norvegicus	204-208
28743746-6	2017	We present data suggesting that TSH-stimulated TG phosphorylation contributes to enhanced de novo T3 formation.	Thyrotropin	32-35	thyroglobulin	Homo sapiens	47-49
29057835-9	2017	We found a high release of hypothalamic TRH, which along with reduced MBH PPII activity, increased TSH levels in Zn-deficient pups independently of changes in TH concentration.	Thyrotropin	99-102	thyrotropin releasing hormone	Rattus norvegicus	40-43
28938449-7	2017	In support of a role for Gi/Go proteins in ERK1/2 phosphorylation, we found that knockdown of Gi(1-3) and Go in HEK-TSHRs inhibited ERK1/2 phosphorylation stimulated by TSH and TSH plus IGF-1.	Thyrotropin	116-119	mitogen-activated protein kinase 3	Homo sapiens	43-49
28938449-7	2017	In support of a role for Gi/Go proteins in ERK1/2 phosphorylation, we found that knockdown of Gi(1-3) and Go in HEK-TSHRs inhibited ERK1/2 phosphorylation stimulated by TSH and TSH plus IGF-1.	Thyrotropin	116-119	mitogen-activated protein kinase 3	Homo sapiens	132-138
28938449-7	2017	In support of a role for Gi/Go proteins in ERK1/2 phosphorylation, we found that knockdown of Gi(1-3) and Go in HEK-TSHRs inhibited ERK1/2 phosphorylation stimulated by TSH and TSH plus IGF-1.	Thyrotropin	116-119	insulin like growth factor 1	Homo sapiens	186-191
28382505-10	2017	CONCLUSIONS: SH2B3 gene has previously been associated with susceptibility to several autoimmune diseases, whereas PDE8B has been associated with TSH levels and suggested to modulate thyroid physiology that may influence the manifestation of thyroid disease.	Thyrotropin	146-149	phosphodiesterase 8B	Homo sapiens	115-120
28954485-6	2017	The anti-TPO and TSH serum levels correlated both in patients with high thyroid antibody titers, and in the anti-TPO negative groups.	Thyrotropin	17-20	thyroid peroxidase	Homo sapiens	113-116
28931076-3	2017	The present study shows a ghrelin-induced decrease in the thyroid-stimulating hormone (TSH)-induced production of thyroglobulin and mRNA expression of thyroperoxidase in a primary culture of human thyroid cells obtained from paranodular tissue.	Thyrotropin	87-90	thyroid peroxidase	Homo sapiens	151-166
28931076-4	2017	Accordingly, a trend was noted for an inhibition of TSH-stimulated expression of the sodium-iodine symporter and the TSH-receptor.	Thyrotropin	52-55	thyroid stimulating hormone receptor	Homo sapiens	117-129
28620714-3	2017	Successful ablation was defined as the absence of visible iodine-131 (I-131) accumulation in the thyroid bed after whole-body scans and thyroglobulin levels &lt;2 ng/ml in a TSH-stimulated state after ablation.	Thyrotropin	174-177	thyroglobulin	Homo sapiens	136-149
28586435-9	2017	Results: Adult humans and mice without RTH-beta, exposed to high maternal TH in utero, showed persistent central resistance to TH, as evidenced by reduced responses of serum TSH to TRH when treated with T3.	Thyrotropin	174-177	thyrotropin releasing hormone	Mus musculus	181-184
28874659-4	2017	Blocking receptor internalization, inhibiting PKA II/interfering with its Golgi/TGN localization, silencing retromer or disrupting Golgi/TGN organization all impair efficient TSH-dependent cAMP response element binding protein (CREB) phosphorylation.	Thyrotropin	175-178	cAMP responsive element binding protein 1	Homo sapiens	189-226
28874659-4	2017	Blocking receptor internalization, inhibiting PKA II/interfering with its Golgi/TGN localization, silencing retromer or disrupting Golgi/TGN organization all impair efficient TSH-dependent cAMP response element binding protein (CREB) phosphorylation.	Thyrotropin	175-178	cAMP responsive element binding protein 1	Homo sapiens	228-232
28576880-8	2017	Furthermore, a stronger expression of MCT8 was demonstrated in PCCL3 cells after TSH stimulation.	Thyrotropin	81-84	solute carrier family 16 member 2	Rattus norvegicus	38-42
28576880-11	2017	Consistent upregulation of MCT8 in GD is in line with increased TH release in hyperthyroidism, an assumption supported by our in vitro results showing TSH-dependent upregulation of MCT8.	Thyrotropin	151-154	solute carrier family 16 member 2	Rattus norvegicus	27-31
28576880-11	2017	Consistent upregulation of MCT8 in GD is in line with increased TH release in hyperthyroidism, an assumption supported by our in vitro results showing TSH-dependent upregulation of MCT8.	Thyrotropin	151-154	solute carrier family 16 member 2	Rattus norvegicus	181-185
28626114-7	2017	More interestingly, the expression of autophagic markers Beclin-1 and LC3II was reduced in TSH stimulated chondrocytes, accompanied by less autophagosomes and accumulated p62 protein, indicating an impaired autophagic flux.	Thyrotropin	91-94	nucleoporin 62	Mus musculus	171-174
28108058-9	2017	Multiple linear regression demonstrated that Co, I, and Li were directly related to circulating TSH levels, whereas V concentration was negatively interrelated.	Thyrotropin	96-99	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	45-50
28699428-6	2017	RESULTS: Approximately 74% of TST patients and 11% of No-TST patients had suppressed serum TSH levels (&lt;2 mIU/L).	Thyrotropin	91-94	thiosulfate sulfurtransferase	Homo sapiens	30-33
28699428-6	2017	RESULTS: Approximately 74% of TST patients and 11% of No-TST patients had suppressed serum TSH levels (&lt;2 mIU/L).	Thyrotropin	91-94	thiosulfate sulfurtransferase	Homo sapiens	57-60
28626114-7	2017	More interestingly, the expression of autophagic markers Beclin-1 and LC3II was reduced in TSH stimulated chondrocytes, accompanied by less autophagosomes and accumulated p62 protein, indicating an impaired autophagic flux.	Thyrotropin	91-94	beclin 1, autophagy related	Mus musculus	57-65
28291505-7	2017	CONCLUSION: The high prevalence of reversible hypothyroidism and the TSH-dependent elevation of the serum Tg levels was suggested in Japanese patients with advanced CKD.	Thyrotropin	69-72	thyroglobulin	Homo sapiens	106-108
28549315-12	2017	There was a positive association between the four quartiles of thyroid stimulating hormones and TC, TG, and APOB.	Thyrotropin	63-91	apolipoprotein B	Homo sapiens	108-112
28419241-11	2017	Conclusions: A unique missense TRHR defect identified in a consanguineous family is associated with central hypothyroidism in homozygotes and hyperthyrotropinemia in heterozygotes, suggesting compensatory elevation of TSH with reduced biopotency.	Thyrotropin	218-221	thyrotropin releasing hormone receptor	Homo sapiens	31-35
28635216-9	2017	It was also found that RET/PTC rearrangement was associated with an abnormal increase in TSH level of one month after surgery (P= 0.037).	Thyrotropin	89-92	ret proto-oncogene	Homo sapiens	23-26
28635216-9	2017	It was also found that RET/PTC rearrangement was associated with an abnormal increase in TSH level of one month after surgery (P= 0.037).	Thyrotropin	89-92	ret proto-oncogene	Homo sapiens	27-30
28379580-9	2017	Results: At baseline, serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triacylglycerol (TAG), and monocyte chemotactic protein 1 concentrations were significantly associated with serum TSH concentrations.	Thyrotropin	211-214	C-C motif chemokine ligand 2	Homo sapiens	124-154
28212844-0	2017	Thyroid stimulating hormone increases hepatic gluconeogenesis via CRTC2.	Thyrotropin	0-27	CREB regulated transcription coactivator 2	Mus musculus	66-71
28212844-6	2017	Thus, we explore whether CRTC2 is involved in the process of TSH-induced gluconeogenesis.	Thyrotropin	61-64	CREB regulated transcription coactivator 2	Mus musculus	25-30
28212844-8	2017	Furthermore, TSH stimulates CRTC2 dephosphorylation and upregulates p-CREB (Ser133) in HepG2 cells.	Thyrotropin	13-16	CREB regulated transcription coactivator 2	Homo sapiens	28-33
28212844-8	2017	Furthermore, TSH stimulates CRTC2 dephosphorylation and upregulates p-CREB (Ser133) in HepG2 cells.	Thyrotropin	13-16	cAMP responsive element binding protein 1	Homo sapiens	70-74
28212844-11	2017	This study demonstrates that TSH activates CRTC2 via the TSHR/cAMP/PKA pathway, leading to the formation of a CRTC2:CREB complex and increases hepatic gluconeogenesis.	Thyrotropin	29-32	CREB regulated transcription coactivator 2	Mus musculus	43-48
28212844-11	2017	This study demonstrates that TSH activates CRTC2 via the TSHR/cAMP/PKA pathway, leading to the formation of a CRTC2:CREB complex and increases hepatic gluconeogenesis.	Thyrotropin	29-32	thyroid stimulating hormone receptor	Mus musculus	57-61
28212844-11	2017	This study demonstrates that TSH activates CRTC2 via the TSHR/cAMP/PKA pathway, leading to the formation of a CRTC2:CREB complex and increases hepatic gluconeogenesis.	Thyrotropin	29-32	CREB regulated transcription coactivator 2	Mus musculus	110-115
28212844-11	2017	This study demonstrates that TSH activates CRTC2 via the TSHR/cAMP/PKA pathway, leading to the formation of a CRTC2:CREB complex and increases hepatic gluconeogenesis.	Thyrotropin	29-32	cAMP responsive element binding protein 1	Mus musculus	116-120
28588551-4	2017	Further treatment with thyroid-stimulating hormone (TSH) induced TFCs expressing various types of thyroid proteins including TSH receptor, sodium-iodide symporter, thyroglobulin, and thyroid peroxidase.	Thyrotropin	23-50	thyroid stimulating hormone receptor	Homo sapiens	125-137
28588551-4	2017	Further treatment with thyroid-stimulating hormone (TSH) induced TFCs expressing various types of thyroid proteins including TSH receptor, sodium-iodide symporter, thyroglobulin, and thyroid peroxidase.	Thyrotropin	23-50	thyroid peroxidase	Homo sapiens	139-201
28588551-4	2017	Further treatment with thyroid-stimulating hormone (TSH) induced TFCs expressing various types of thyroid proteins including TSH receptor, sodium-iodide symporter, thyroglobulin, and thyroid peroxidase.	Thyrotropin	52-55	thyroid stimulating hormone receptor	Homo sapiens	125-137
28588551-4	2017	Further treatment with thyroid-stimulating hormone (TSH) induced TFCs expressing various types of thyroid proteins including TSH receptor, sodium-iodide symporter, thyroglobulin, and thyroid peroxidase.	Thyrotropin	52-55	thyroid peroxidase	Homo sapiens	139-201
28303322-4	2017	We have developed a super-sensitive TSH immunoassay utilizing nanoparticle labels with a detection limit of 60 nU L-1 in preprocessed serum samples by reducing nonspecific binding.	Thyrotropin	36-39	immunoglobulin kappa variable 1-16	Homo sapiens	114-117
28300671-9	2017	The PRL level was increased only in the 1nM dose of CART, while the 10nM and 100nM CART doses markedly enhanced GH and TSH.	Thyrotropin	119-122	CART prepropeptide	Rattus norvegicus	83-87
28277129-8	2017	The multivariate regression analysis revealed that the daytime changes of prolactin level are proportional to TSH concentration and coexistence of PCOS as well as inversely relative to BMI.	Thyrotropin	110-113	prolactin	Homo sapiens	74-83
28178642-0	2017	P21-activated kinase 4 involves TSH induced papillary thyroid cancer cell proliferation.	Thyrotropin	32-35	p21 (RAC1) activated kinase 4	Homo sapiens	0-22
28178642-6	2017	Moreover, thyroid stimulating hormone-induced cellular proliferation in papillary thyroid cancer was found to be dependent on TSHR/cAMP/PKA/PAK4 signaling, with levels of phosphorylated PAK4 correlating positively with serum thyroid stimulating hormone and PKA Calpha levels in patients with papillary thyroid cancer.	Thyrotropin	10-37	thyroid stimulating hormone receptor	Homo sapiens	126-130
28178642-6	2017	Moreover, thyroid stimulating hormone-induced cellular proliferation in papillary thyroid cancer was found to be dependent on TSHR/cAMP/PKA/PAK4 signaling, with levels of phosphorylated PAK4 correlating positively with serum thyroid stimulating hormone and PKA Calpha levels in patients with papillary thyroid cancer.	Thyrotropin	10-37	p21 (RAC1) activated kinase 4	Homo sapiens	140-144
28178642-6	2017	Moreover, thyroid stimulating hormone-induced cellular proliferation in papillary thyroid cancer was found to be dependent on TSHR/cAMP/PKA/PAK4 signaling, with levels of phosphorylated PAK4 correlating positively with serum thyroid stimulating hormone and PKA Calpha levels in patients with papillary thyroid cancer.	Thyrotropin	10-37	p21 (RAC1) activated kinase 4	Homo sapiens	186-190
28178642-6	2017	Moreover, thyroid stimulating hormone-induced cellular proliferation in papillary thyroid cancer was found to be dependent on TSHR/cAMP/PKA/PAK4 signaling, with levels of phosphorylated PAK4 correlating positively with serum thyroid stimulating hormone and PKA Calpha levels in patients with papillary thyroid cancer.	Thyrotropin	225-252	thyroid stimulating hormone receptor	Homo sapiens	126-130
28178642-6	2017	Moreover, thyroid stimulating hormone-induced cellular proliferation in papillary thyroid cancer was found to be dependent on TSHR/cAMP/PKA/PAK4 signaling, with levels of phosphorylated PAK4 correlating positively with serum thyroid stimulating hormone and PKA Calpha levels in patients with papillary thyroid cancer.	Thyrotropin	225-252	p21 (RAC1) activated kinase 4	Homo sapiens	186-190
28262687-7	2017	Furthermore, IGSF1 stimulates transcription of the thyrotropin-releasing hormone receptor (TRHR) by negative modulation of the TGFbeta1-Smad signaling pathway, and enhances the synthesis and biopotency of TSH, the hormone secreted by thyrotropes.	Thyrotropin	205-208	immunoglobulin superfamily member 1	Homo sapiens	13-18
27848228-3	2017	This fact aroused our interest in whether the alteration of DNA polymerase beta activity depends on DNA polymerase beta (DNA poly beta) mRNA levels, which may be modulated by thyroid-stimulating hormone (TSH) or thyroid-stimulating substances, i.e. TSH receptor antibody (TRAb).	Thyrotropin	175-202	DNA polymerase beta	Homo sapiens	60-79
27848228-3	2017	This fact aroused our interest in whether the alteration of DNA polymerase beta activity depends on DNA polymerase beta (DNA poly beta) mRNA levels, which may be modulated by thyroid-stimulating hormone (TSH) or thyroid-stimulating substances, i.e. TSH receptor antibody (TRAb).	Thyrotropin	175-202	DNA polymerase beta	Homo sapiens	100-119
27848228-3	2017	This fact aroused our interest in whether the alteration of DNA polymerase beta activity depends on DNA polymerase beta (DNA poly beta) mRNA levels, which may be modulated by thyroid-stimulating hormone (TSH) or thyroid-stimulating substances, i.e. TSH receptor antibody (TRAb).	Thyrotropin	204-207	DNA polymerase beta	Homo sapiens	60-79
27848228-3	2017	This fact aroused our interest in whether the alteration of DNA polymerase beta activity depends on DNA polymerase beta (DNA poly beta) mRNA levels, which may be modulated by thyroid-stimulating hormone (TSH) or thyroid-stimulating substances, i.e. TSH receptor antibody (TRAb).	Thyrotropin	204-207	DNA polymerase beta	Homo sapiens	100-119
28376799-15	2017	4) BMP-4 levels were significantly higher in the obesity with slightly increased thyroid stimulating hormone(TSH) than the obesity without slightly increased TSH (902.08 +- 354.74 pg/ml vs. 720.24 +- 306.41 pg/ml, P &lt; 0.05).	Thyrotropin	81-108	bone morphogenetic protein 4	Homo sapiens	3-8
28376799-15	2017	4) BMP-4 levels were significantly higher in the obesity with slightly increased thyroid stimulating hormone(TSH) than the obesity without slightly increased TSH (902.08 +- 354.74 pg/ml vs. 720.24 +- 306.41 pg/ml, P &lt; 0.05).	Thyrotropin	109-112	bone morphogenetic protein 4	Homo sapiens	3-8
28376799-15	2017	4) BMP-4 levels were significantly higher in the obesity with slightly increased thyroid stimulating hormone(TSH) than the obesity without slightly increased TSH (902.08 +- 354.74 pg/ml vs. 720.24 +- 306.41 pg/ml, P &lt; 0.05).	Thyrotropin	158-161	bone morphogenetic protein 4	Homo sapiens	3-8
28324000-7	2017	Under standard laboratory conditions, Igsf1-deficient males exhibit normal serum TSH levels as well as normal numbers of TSH-expressing thyrotropes.	Thyrotropin	81-84	immunoglobulin superfamily, member 1	Mus musculus	38-43
28324000-9	2017	When challenged with exogenous TRH, Igsf1-deficient males release TSH, but to a significantly lesser extent than do their wild-type littermates.	Thyrotropin	66-69	thyrotropin releasing hormone	Mus musculus	31-34
28324000-9	2017	When challenged with exogenous TRH, Igsf1-deficient males release TSH, but to a significantly lesser extent than do their wild-type littermates.	Thyrotropin	66-69	immunoglobulin superfamily, member 1	Mus musculus	36-41
28868249-13	2017	TSH levels showed positive correlation with lean body mass (p=0.032), total cholesterol (p=0.046, insulin (p=0.048) and prolactin (p=0.047).	Thyrotropin	0-3	insulin	Homo sapiens	98-105
28868249-14	2017	Backward multiple regression model retained TC, insulin, and PRL as predictors of TSH levels (p=0.011).	Thyrotropin	82-85	insulin	Homo sapiens	48-55
28648506-7	2017	Thyroid findings in GLIS3 patients include thyroid aplasia, diminished colloid with interstitial fibrosis at post-mortem, and apparently normal gross thyroid anatomy on ultrasonography but with temporary TSH resistance on treatment.	Thyrotropin	204-207	GLIS family zinc finger 3	Homo sapiens	20-25
27627987-0	2017	Carriers of a VEGFA enhancer polymorphism selectively binding CHOP/DDIT3 are predisposed to increased circulating levels of thyroid-stimulating hormone.	Thyrotropin	124-151	vascular endothelial growth factor A	Homo sapiens	14-19
27627987-0	2017	Carriers of a VEGFA enhancer polymorphism selectively binding CHOP/DDIT3 are predisposed to increased circulating levels of thyroid-stimulating hormone.	Thyrotropin	124-151	DNA damage inducible transcript 3	Homo sapiens	67-72
27627987-0	2017	Carriers of a VEGFA enhancer polymorphism selectively binding CHOP/DDIT3 are predisposed to increased circulating levels of thyroid-stimulating hormone.	Thyrotropin	124-151	DNA damage inducible transcript 3	Homo sapiens	62-66
27627987-2	2017	Genetic variants in the vascular endothelial growth factor A (VEGFA) gene are associated with TSH levels.	Thyrotropin	94-97	vascular endothelial growth factor A	Homo sapiens	24-60
27627987-2	2017	Genetic variants in the vascular endothelial growth factor A (VEGFA) gene are associated with TSH levels.	Thyrotropin	94-97	vascular endothelial growth factor A	Homo sapiens	62-67
27627987-6	2017	RESULTS: Four SNPs in VEGFA were associated with circulating TSH (rs9472138, rs881858, rs943080 and rs4711751).	Thyrotropin	61-64	vascular endothelial growth factor A	Homo sapiens	22-27
27627987-12	2017	We show that VEGFA variation giving allele-specific response to transcription factors with overlapping binding sites associate closely with circulating TSH levels.	Thyrotropin	152-155	vascular endothelial growth factor A	Homo sapiens	13-18
31265665-0	2016	Erratum: Serum Spot 14 concentration is negatively associated with thyroid-stimulating hormone level: Erratum.	Thyrotropin	67-94	thyroid hormone responsive	Homo sapiens	15-22
27627987-13	2017	Because CHOP is induced by several types of intracellular stress, this indicates that cellular stress could be involved in the normal or pathophysiological response of the thyroid to TSH.	Thyrotropin	183-186	DNA damage inducible transcript 3	Homo sapiens	8-12
27832672-3	2017	Here we established relationships of plasma tumor necrosis factor-alpha (TNF-alpha) with thyroid stimulating hormone (TSH) and free thyroxine (free T4) in euthyroid subjects with and without Type 2 diabetes mellitus (T2DM).	Thyrotropin	89-116	tumor necrosis factor	Homo sapiens	44-71
27832672-3	2017	Here we established relationships of plasma tumor necrosis factor-alpha (TNF-alpha) with thyroid stimulating hormone (TSH) and free thyroxine (free T4) in euthyroid subjects with and without Type 2 diabetes mellitus (T2DM).	Thyrotropin	89-116	tumor necrosis factor	Homo sapiens	73-82
26337490-3	2017	The aim of this study was to follow-up P300 latencies and amplitudes in patients with subclinical hypothyroidism and to evaluate the influence of thyroxine treatment which led to the normalization of TSH level in serum.	Thyrotropin	200-203	E1A binding protein p300	Homo sapiens	39-43
27144920-1	2017	BACKGROUND: Stimulated thyroglobulin (STg) levels in patients with differentiated thyroid carcinomas (DTCs) after total thyroidectomy (TT) and before radioactive iodine (131I) ablation/therapy (RIT) are predictive of therapeutic success but can be influenced by the thyroid-stimulating hormone (TSH) level.	Thyrotropin	266-293	thyroglobulin	Homo sapiens	23-36
27144920-1	2017	BACKGROUND: Stimulated thyroglobulin (STg) levels in patients with differentiated thyroid carcinomas (DTCs) after total thyroidectomy (TT) and before radioactive iodine (131I) ablation/therapy (RIT) are predictive of therapeutic success but can be influenced by the thyroid-stimulating hormone (TSH) level.	Thyrotropin	295-298	thyroglobulin	Homo sapiens	23-36
27832672-3	2017	Here we established relationships of plasma tumor necrosis factor-alpha (TNF-alpha) with thyroid stimulating hormone (TSH) and free thyroxine (free T4) in euthyroid subjects with and without Type 2 diabetes mellitus (T2DM).	Thyrotropin	118-121	tumor necrosis factor	Homo sapiens	44-71
27832672-3	2017	Here we established relationships of plasma tumor necrosis factor-alpha (TNF-alpha) with thyroid stimulating hormone (TSH) and free thyroxine (free T4) in euthyroid subjects with and without Type 2 diabetes mellitus (T2DM).	Thyrotropin	118-121	tumor necrosis factor	Homo sapiens	73-82
27374871-7	2017	Higher baseline TSH associated with higher total cholesterol (beta = 0 056, SE = 0 026, P = 0 033), LDL cholesterol (beta = 0 057, SE = 0 023, P = 0 015) and apolipoprotein B (beta = 0 012, SE = 0 006, P = 0 028) at follow-up in women, but not with any lipid outcomes in men.	Thyrotropin	16-19	apolipoprotein B	Homo sapiens	158-174
28527577-3	2017	Patients with mutations in THRB, exhibiting resistance within the hypothalamic-pituitary-thyroid axis with elevated TH and nonsuppressed thyroid-stimulating hormone (TSH) levels, were first described decades ago.	Thyrotropin	137-164	thyroid hormone receptor beta	Homo sapiens	27-31
28527577-3	2017	Patients with mutations in THRB, exhibiting resistance within the hypothalamic-pituitary-thyroid axis with elevated TH and nonsuppressed thyroid-stimulating hormone (TSH) levels, were first described decades ago.	Thyrotropin	166-169	thyroid hormone receptor beta	Homo sapiens	27-31
27531173-10	2017	CONCLUSION: The lower expression of NIS in lactating breast may be due to the 173 AA deletion in the TSHR resulting the lower binding of TSH to the TSHR.	Thyrotropin	101-104	thyroid stimulating hormone receptor	Mus musculus	148-152
27864993-6	2017	We demonstrated that TSH protected thymocytes from apoptosis as evidenced by a significant decrease of Annexin V-positive thymocytes in SCH mice.	Thyrotropin	21-24	annexin A5	Mus musculus	103-112
27920545-9	2016	A significant positive correlation was found between TSH and antithyroid antibodies (anti-Tg, anti-TPO; P=0.002 and P=0.043, respectively) and between TSH and thyroid-gland volume (P=0.002) in diabetic patients.	Thyrotropin	53-56	thyroid peroxidase	Homo sapiens	99-102
27700539-10	2016	A serum TSH level below the mean in LT4-treated participants was associated with a higher serum free T4 but similar free and total T3; yet those with lower serum TSH levels exhibited higher serum high-density lipoprotein and lower serum low-density lipoprotein, triglycerides, and C-reactive protein.	Thyrotropin	8-11	C-reactive protein	Homo sapiens	281-299
27638195-6	2016	The IGF-1R tyrosine kinase inhibitor linsitinib inhibited TSH-stimulated upregulation of NIS but not TG, indicating that NIS regulation is in part IGF-1R dependent and occurs via receptor crosstalk.	Thyrotropin	58-61	insulin like growth factor 1 receptor	Homo sapiens	4-10
27638195-6	2016	The IGF-1R tyrosine kinase inhibitor linsitinib inhibited TSH-stimulated upregulation of NIS but not TG, indicating that NIS regulation is in part IGF-1R dependent and occurs via receptor crosstalk.	Thyrotropin	58-61	insulin like growth factor 1 receptor	Homo sapiens	147-153
27638195-9	2016	Pharmacological inhibition of ERK1/2 by the MEK1/2 inhibitor U0126 and of Akt by MK-2206 virtually abolished NIS stimulation by TSH and the synergistic effect of IGF-1.	Thyrotropin	128-131	mitogen-activated protein kinase 3	Homo sapiens	30-36
27638195-9	2016	Pharmacological inhibition of ERK1/2 by the MEK1/2 inhibitor U0126 and of Akt by MK-2206 virtually abolished NIS stimulation by TSH and the synergistic effect of IGF-1.	Thyrotropin	128-131	AKT serine/threonine kinase 1	Homo sapiens	74-77
27765629-5	2016	In situ hybridization and immunohistochemical analyses showed that both THY1 mRNA and protein were present in almost, if not all, thyroid-stimulating hormone (TSH)-immunopositive cells (thyrotropes) and that ITGB2 was co-expressed in these cells.	Thyrotropin	159-162	Thy-1 cell surface antigen	Rattus norvegicus	72-76
27511825-8	2016	When PCOS patients were classified on the basis of BMI, TSH levels significantly correlated with insulin secretion, insulin resistance, DHEAS and cortisol levels in obese PCOS women.	Thyrotropin	56-59	insulin	Homo sapiens	97-104
27765629-5	2016	In situ hybridization and immunohistochemical analyses showed that both THY1 mRNA and protein were present in almost, if not all, thyroid-stimulating hormone (TSH)-immunopositive cells (thyrotropes) and that ITGB2 was co-expressed in these cells.	Thyrotropin	130-157	Thy-1 cell surface antigen	Rattus norvegicus	72-76
26906498-8	2016	A correlation analysis demonstrated that endocan levels were positively correlated with body mass index (BMI), thyroid-stimulating hormone (TSH), anti-thyroid peroxidase, and anti-thyroglobulin and negatively correlated with free thyroid hormone 4 (FT4) and vitamin D levels.	Thyrotropin	111-138	endothelial cell specific molecule 1	Homo sapiens	41-48
26906498-8	2016	A correlation analysis demonstrated that endocan levels were positively correlated with body mass index (BMI), thyroid-stimulating hormone (TSH), anti-thyroid peroxidase, and anti-thyroglobulin and negatively correlated with free thyroid hormone 4 (FT4) and vitamin D levels.	Thyrotropin	140-143	endothelial cell specific molecule 1	Homo sapiens	41-48
27452800-0	2016	Thyroid-stimulating hormone improves insulin sensitivity in skeletal muscle cells via cAMP/PKA/CREB pathway-dependent upregulation of insulin receptor substrate-1 expression.	Thyrotropin	0-27	cAMP responsive element binding protein 1	Mus musculus	95-99
27452800-0	2016	Thyroid-stimulating hormone improves insulin sensitivity in skeletal muscle cells via cAMP/PKA/CREB pathway-dependent upregulation of insulin receptor substrate-1 expression.	Thyrotropin	0-27	insulin receptor substrate 1	Mus musculus	134-162
27511825-8	2016	When PCOS patients were classified on the basis of BMI, TSH levels significantly correlated with insulin secretion, insulin resistance, DHEAS and cortisol levels in obese PCOS women.	Thyrotropin	56-59	sulfotransferase family 2A member 1	Homo sapiens	136-141
27511825-9	2016	Inverse correlations were found between TSH and both oestradiol and SHBG in the same group.	Thyrotropin	40-43	sex hormone binding globulin	Homo sapiens	68-72
27060411-1	2016	Thyrotropin Releasing Hormone (TRH) is a tripeptide that induces the release of Thyroid Stimulating Hormone (TSH) in the blood.	Thyrotropin	80-107	thyrotropin releasing hormone	Mus musculus	0-29
27902589-6	2016	Stepwise linear regression analyses showed that TgAb, thyroid volume, goiter, gender, age, and TSH levels were correlated with Tg.In adults from regions with adequate and more than adequate iodine intake, we found that Tg may be a suitable marker of iodine status; gender-specific Tg RI was unnecessary; there was no difference between Tg RIs in regions with adequate and more than adequate iodine intake; and the TSH criterion for selecting the Tg reference population could follow the local TSH reference rather than 0.5 to 2.0 mIU/L.	Thyrotropin	95-98	thyroglobulin	Homo sapiens	127-129
27902589-6	2016	Stepwise linear regression analyses showed that TgAb, thyroid volume, goiter, gender, age, and TSH levels were correlated with Tg.In adults from regions with adequate and more than adequate iodine intake, we found that Tg may be a suitable marker of iodine status; gender-specific Tg RI was unnecessary; there was no difference between Tg RIs in regions with adequate and more than adequate iodine intake; and the TSH criterion for selecting the Tg reference population could follow the local TSH reference rather than 0.5 to 2.0 mIU/L.	Thyrotropin	95-98	thyroglobulin	Homo sapiens	127-129
27902589-6	2016	Stepwise linear regression analyses showed that TgAb, thyroid volume, goiter, gender, age, and TSH levels were correlated with Tg.In adults from regions with adequate and more than adequate iodine intake, we found that Tg may be a suitable marker of iodine status; gender-specific Tg RI was unnecessary; there was no difference between Tg RIs in regions with adequate and more than adequate iodine intake; and the TSH criterion for selecting the Tg reference population could follow the local TSH reference rather than 0.5 to 2.0 mIU/L.	Thyrotropin	95-98	thyroglobulin	Homo sapiens	127-129
27902589-6	2016	Stepwise linear regression analyses showed that TgAb, thyroid volume, goiter, gender, age, and TSH levels were correlated with Tg.In adults from regions with adequate and more than adequate iodine intake, we found that Tg may be a suitable marker of iodine status; gender-specific Tg RI was unnecessary; there was no difference between Tg RIs in regions with adequate and more than adequate iodine intake; and the TSH criterion for selecting the Tg reference population could follow the local TSH reference rather than 0.5 to 2.0 mIU/L.	Thyrotropin	95-98	thyroglobulin	Homo sapiens	127-129
27060411-1	2016	Thyrotropin Releasing Hormone (TRH) is a tripeptide that induces the release of Thyroid Stimulating Hormone (TSH) in the blood.	Thyrotropin	80-107	thyrotropin releasing hormone	Mus musculus	31-34
27060411-1	2016	Thyrotropin Releasing Hormone (TRH) is a tripeptide that induces the release of Thyroid Stimulating Hormone (TSH) in the blood.	Thyrotropin	109-112	thyrotropin releasing hormone	Mus musculus	0-29
27060411-1	2016	Thyrotropin Releasing Hormone (TRH) is a tripeptide that induces the release of Thyroid Stimulating Hormone (TSH) in the blood.	Thyrotropin	109-112	thyrotropin releasing hormone	Mus musculus	31-34
27471912-10	2016	Our results indicate that CXCL-12 enhances TSH actions in fibrocytes but inhibits them in GD-OF, a dichotomy imposed by factors emanating from CD34- OF.	Thyrotropin	43-46	C-X-C motif chemokine ligand 12	Homo sapiens	26-33
27802347-0	2016	RET/PTC Rearrangements Are Associated with Elevated Postoperative TSH Levels and Multifocal Lesions in Papillary Thyroid Cancer without Concomitant Thyroid Benign Disease.	Thyrotropin	66-69	ret proto-oncogene	Homo sapiens	0-3
27802347-0	2016	RET/PTC Rearrangements Are Associated with Elevated Postoperative TSH Levels and Multifocal Lesions in Papillary Thyroid Cancer without Concomitant Thyroid Benign Disease.	Thyrotropin	66-69	ret proto-oncogene	Homo sapiens	4-7
27802347-10	2016	RET/PTC rearrangement was also correlated with higher TSH levels at one month post-surgery (P = 0.037).	Thyrotropin	54-57	ret proto-oncogene	Homo sapiens	0-3
27802347-10	2016	RET/PTC rearrangement was also correlated with higher TSH levels at one month post-surgery (P = 0.037).	Thyrotropin	54-57	ret proto-oncogene	Homo sapiens	4-7
27418060-12	2016	A positive correlation was found between TSH and CSA (R=0.155, P=0.05) before treatment.	Thyrotropin	41-44	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	49-52
27734684-3	2016	The paper summarizes current knowledge related to the associations of lower free thyroxine (fT4) level and higher levels of both free triiodothyronine (fT3) and TSH with body adiposity, metabolic syndrome and insulin resistance in euthyroid subjects.	Thyrotropin	161-164	insulin	Homo sapiens	209-216
27198614-10	2016	Anti-C1q antibody levels increase during pregnancy in general and even more in the context of AITD, where they correlate with thyroid stimulating hormone levels.	Thyrotropin	126-153	complement C1q A chain	Homo sapiens	5-8
27775795-9	2016	CONCLUSIONS: The infection by H. pylori strains expressing CagA is associated with increased TPO Ab and TSH levels in LADA patients, suggesting a possible mechanism involved in thyroid autoimmunity and dysfunction of the gland.	Thyrotropin	104-107	S100 calcium binding protein A8	Homo sapiens	59-63
27198614-8	2016	Anti-C1q-positive pregnant women screened positive for AITD had higher thyroid-stimulating hormone (TSH) levels than anti-C1q-negative women (2 41 versus 1 94 mU/l, P = 0 01), and TSH correlated positively with anti-C1q (r = 0 226, P = 0 045) in the TPOAb-positive women.	Thyrotropin	71-98	complement C1q A chain	Homo sapiens	5-8
27198614-8	2016	Anti-C1q-positive pregnant women screened positive for AITD had higher thyroid-stimulating hormone (TSH) levels than anti-C1q-negative women (2 41 versus 1 94 mU/l, P = 0 01), and TSH correlated positively with anti-C1q (r = 0 226, P = 0 045) in the TPOAb-positive women.	Thyrotropin	100-103	complement C1q A chain	Homo sapiens	5-8
27198614-8	2016	Anti-C1q-positive pregnant women screened positive for AITD had higher thyroid-stimulating hormone (TSH) levels than anti-C1q-negative women (2 41 versus 1 94 mU/l, P = 0 01), and TSH correlated positively with anti-C1q (r = 0 226, P = 0 045) in the TPOAb-positive women.	Thyrotropin	180-183	complement C1q A chain	Homo sapiens	5-8
27749565-5	2016	In univariate linear regression, the log-transformed S14 level (logS14) was positively associated with fT4 but negatively associated with creatinine (Cre), total cholesterol (T-C), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and TSH.	Thyrotropin	249-252	thyroid hormone responsive	Homo sapiens	53-56
27657042-6	2016	In vitro, results showed that different concentration and time gradients of TSH stimulation could increase the expression of OPN, VCAM-1, and integrin alphavbeta3, and this was accompanied by extracellular signal regulated kinase 1/2 (Erk1/2) and Akt activation in human umbilical vein endothelial cells (HUVECs).	Thyrotropin	76-79	secreted phosphoprotein 1	Homo sapiens	125-128
27657042-6	2016	In vitro, results showed that different concentration and time gradients of TSH stimulation could increase the expression of OPN, VCAM-1, and integrin alphavbeta3, and this was accompanied by extracellular signal regulated kinase 1/2 (Erk1/2) and Akt activation in human umbilical vein endothelial cells (HUVECs).	Thyrotropin	76-79	vascular cell adhesion molecule 1	Homo sapiens	130-136
27657042-6	2016	In vitro, results showed that different concentration and time gradients of TSH stimulation could increase the expression of OPN, VCAM-1, and integrin alphavbeta3, and this was accompanied by extracellular signal regulated kinase 1/2 (Erk1/2) and Akt activation in human umbilical vein endothelial cells (HUVECs).	Thyrotropin	76-79	integrin subunit alpha V	Homo sapiens	142-162
27657042-6	2016	In vitro, results showed that different concentration and time gradients of TSH stimulation could increase the expression of OPN, VCAM-1, and integrin alphavbeta3, and this was accompanied by extracellular signal regulated kinase 1/2 (Erk1/2) and Akt activation in human umbilical vein endothelial cells (HUVECs).	Thyrotropin	76-79	mitogen-activated protein kinase 1	Homo sapiens	192-233
27657042-6	2016	In vitro, results showed that different concentration and time gradients of TSH stimulation could increase the expression of OPN, VCAM-1, and integrin alphavbeta3, and this was accompanied by extracellular signal regulated kinase 1/2 (Erk1/2) and Akt activation in human umbilical vein endothelial cells (HUVECs).	Thyrotropin	76-79	mitogen-activated protein kinase 3	Homo sapiens	235-241
27657042-6	2016	In vitro, results showed that different concentration and time gradients of TSH stimulation could increase the expression of OPN, VCAM-1, and integrin alphavbeta3, and this was accompanied by extracellular signal regulated kinase 1/2 (Erk1/2) and Akt activation in human umbilical vein endothelial cells (HUVECs).	Thyrotropin	76-79	AKT serine/threonine kinase 1	Homo sapiens	247-250
27657042-7	2016	TSH induced elevation of these proatherosclerotic factors was partially suppressed by a specific Akt inhibitor but not by a specific Erk inhibitor.	Thyrotropin	0-3	AKT serine/threonine kinase 1	Rattus norvegicus	97-100
27631497-0	2016	CD40 Expression in Fibrocytes Is Induced by TSH: Potential Synergistic Immune Activation.	Thyrotropin	44-47	CD40 molecule	Homo sapiens	0-4
27631497-6	2016	Production of IL-6 and TNF-alpha after costimulation with TSH and CD40L was greater than that after TSH or CD40L stimulation alone.	Thyrotropin	58-61	interleukin 6	Homo sapiens	14-18
27631497-6	2016	Production of IL-6 and TNF-alpha after costimulation with TSH and CD40L was greater than that after TSH or CD40L stimulation alone.	Thyrotropin	58-61	tumor necrosis factor	Homo sapiens	23-32
27631497-6	2016	Production of IL-6 and TNF-alpha after costimulation with TSH and CD40L was greater than that after TSH or CD40L stimulation alone.	Thyrotropin	100-103	interleukin 6	Homo sapiens	14-18
27631497-6	2016	Production of IL-6 and TNF-alpha after costimulation with TSH and CD40L was greater than that after TSH or CD40L stimulation alone.	Thyrotropin	100-103	CD40 ligand	Homo sapiens	66-71
27631497-8	2016	Akt and nuclear factor (NF)-kappaB inhibitors significantly reduced cytokine production after TSH and CD40L costimulation.	Thyrotropin	94-97	nuclear factor kappa B subunit 1	Homo sapiens	8-34
27094046-1	2016	OBJECTIVE: The low-density lipoprotein receptor associated protein (RAP) is expressed by thyroid epithelial cells (TEC) in a TSH-dependent manner.	Thyrotropin	125-128	low density lipoprotein receptor-related protein associated protein 1	Mus musculus	68-71
27607246-9	2016	Long term follow-up of AIT patients with high TPO-Abs level (&gt;500 IU/ml) showed an increase of TSH levels (mean: 0.5 mIU/l; range: 2.52+-2.73 to 3.02+-3.05 mIU/l; p=0.0420).	Thyrotropin	98-101	thyroid peroxidase	Homo sapiens	46-49
27607246-6	2016	Patients with TPO-Ab levels&gt;500 IU/ml showed a moderately increased risk of having elevated TSH levels [p=0.0023; relative risk (95% confidence interval): 1.343 (1.108-1.627)] compared to those below this threshold.	Thyrotropin	95-98	thyroid peroxidase	Homo sapiens	14-17
27539723-8	2016	Further analysis showed that hepatic endoplasmic reticulum stress (ER stress) was induced in the SCH mice or by the elevation of TSH in vitro, likely via the IRE1alpha/XBP-1 pathway.	Thyrotropin	129-132	endoplasmic reticulum (ER) to nucleus signalling 1	Mus musculus	158-167
27539723-8	2016	Further analysis showed that hepatic endoplasmic reticulum stress (ER stress) was induced in the SCH mice or by the elevation of TSH in vitro, likely via the IRE1alpha/XBP-1 pathway.	Thyrotropin	129-132	X-box binding protein 1	Mus musculus	168-173
26394780-11	2016	Conclusion The reduced VAT volume, leptin, and resistin levels in SH patients following treatment may support the idea that TSH affects adipose tissue functions.	Thyrotropin	124-127	leptin	Homo sapiens	35-41
27485208-2	2016	Prior studies aiming at unravelling the mechanisms underlying these high TSH concentrations mainly focused on factors promoting thyrotropin releasing hormone (TRH) production as a cause for high TSH concentrations.	Thyrotropin	73-76	thyrotropin releasing hormone	Homo sapiens	128-157
27485208-2	2016	Prior studies aiming at unravelling the mechanisms underlying these high TSH concentrations mainly focused on factors promoting thyrotropin releasing hormone (TRH) production as a cause for high TSH concentrations.	Thyrotropin	73-76	thyrotropin releasing hormone	Homo sapiens	159-162
27485208-6	2016	These results suggest that pituitary TSH release in response to TRH stimulation might be an important factor contributing to high normal serum TSH concentrations, which is a regular finding in children with overweight and obesity.	Thyrotropin	37-40	thyrotropin releasing hormone	Homo sapiens	64-67
27179782-7	2016	TSH upregulated hepatic ABCA1 to promote the efflux of intercellular cumulative cholesterol, resulting in increased plasma cholesterol.	Thyrotropin	0-3	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	24-29
27986127-9	2016	Myostatin levels were positively correlated with age, body mass index (BMI), FT4, HOMA-IR (p = 0.001, p = 0.04, p = 0.003, p = 0.03, respectively) and negatively correlated with TSH (p = 0.01).	Thyrotropin	178-181	myostatin	Homo sapiens	0-9
27986128-10	2016	In addition, serum TSH levels showed a correlation for waist circumference, weight, BMI, A1c, insulin, IL-6, leptin, ICAM-1 and E-selectin.	Thyrotropin	19-22	insulin	Homo sapiens	94-101
27986128-10	2016	In addition, serum TSH levels showed a correlation for waist circumference, weight, BMI, A1c, insulin, IL-6, leptin, ICAM-1 and E-selectin.	Thyrotropin	19-22	interleukin 6	Homo sapiens	103-107
27986128-10	2016	In addition, serum TSH levels showed a correlation for waist circumference, weight, BMI, A1c, insulin, IL-6, leptin, ICAM-1 and E-selectin.	Thyrotropin	19-22	intercellular adhesion molecule 1	Homo sapiens	117-123
27986128-10	2016	In addition, serum TSH levels showed a correlation for waist circumference, weight, BMI, A1c, insulin, IL-6, leptin, ICAM-1 and E-selectin.	Thyrotropin	19-22	selectin E	Homo sapiens	128-138
26394780-11	2016	Conclusion The reduced VAT volume, leptin, and resistin levels in SH patients following treatment may support the idea that TSH affects adipose tissue functions.	Thyrotropin	124-127	resistin	Homo sapiens	47-55
27108200-9	2016	The accumulation of defects in DUOX2 contribute to the more severe disease regarding thyroid stimulating hormone (TSH) levels, free thyroxine (FT4) levels and initial dose of l-thyroxine (L-T4).	Thyrotropin	85-112	dual oxidase 2	Homo sapiens	31-36
27108200-9	2016	The accumulation of defects in DUOX2 contribute to the more severe disease regarding thyroid stimulating hormone (TSH) levels, free thyroxine (FT4) levels and initial dose of l-thyroxine (L-T4).	Thyrotropin	114-117	dual oxidase 2	Homo sapiens	31-36
27165095-9	2016	CONCLUSIONS: Even after adjustment for thyroid autoimmunity and age, TSH &lt;3.0muIU/mL in euthyroid infertility patients is associated with significantly better FOR (higher AMH) than TSH &gt;=3.0muIU/mL.	Thyrotropin	69-72	anti-Mullerian hormone	Homo sapiens	174-177
26916531-13	2016	In conclusion, low-normal thyroid function, as indicated by higher TSH levels within the euthyroid range, may influence the metabolism of triglyceride-rich lipoproteins by affecting apoE regulation.	Thyrotropin	67-70	apolipoprotein E	Homo sapiens	182-186
27462589-12	2016	TBG excess should be considered as a potential differential diagnosis for hyperthyroxinemia and especially high T3 levels with normal TSH concentration.	Thyrotropin	134-137	serpin family A member 7	Homo sapiens	0-3
27035650-1	2016	Iodine deficiency (ID) induces TSH-independent microvascular activation in the thyroid via the reactive oxygen species/nitric oxide-hypoxia-inducible factor-1alpha/vascular endothelial growth factor (VEGF) pathway.	Thyrotropin	31-34	vascular endothelial growth factor A	Mus musculus	200-204
27035650-11	2016	AMPK negatively regulates this pathway, which may account for the transient nature of ID-induced TSH-independent vascular effects under benign conditions.	Thyrotropin	97-100	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	0-4
27275361-2	2016	The purpose of this study was to assess (1) the usefulness of (18)F-fluorodeoxyglucose (F-18 FDG) positron emission tomography (PET)/computed tomography (CT) for PTC patients with negative diagnostic radioiodine scan and elevated serum Tg level or positive anti-thyroglobulin antibody (TgAb), and (2) the effect of endogenous thyroid stimulating hormone (TSH) stimulation (ETS) on detecting recurrence in these circumstances.	Thyrotropin	326-353	mastermind like domain containing 1	Homo sapiens	88-92
27275361-2	2016	The purpose of this study was to assess (1) the usefulness of (18)F-fluorodeoxyglucose (F-18 FDG) positron emission tomography (PET)/computed tomography (CT) for PTC patients with negative diagnostic radioiodine scan and elevated serum Tg level or positive anti-thyroglobulin antibody (TgAb), and (2) the effect of endogenous thyroid stimulating hormone (TSH) stimulation (ETS) on detecting recurrence in these circumstances.	Thyrotropin	355-358	mastermind like domain containing 1	Homo sapiens	88-92
26997566-9	2016	The serum TSH levels were significantly correlated with the levels of cPLA2 (r=+0.65), 11-dehydroTXB2 (r=+0.32) and 11-dehydroTXB2/6-Keto-PGF1a (r=+0.37).	Thyrotropin	10-13	phospholipase A2 group IVA	Homo sapiens	70-75
27101096-8	2016	The fasting insulin (FINS) and C reactive protein (CRP) levels were significantly higher in obese patients complicated by mild increased TSH when compared to the obese patients with normal TSH (p&lt;0.01).	Thyrotropin	137-140	insulin	Homo sapiens	12-19
26950201-4	2016	We demonstrated that TSH-induced up-regulation of IL-11 is primarily mediated via the Gs pathway as IL-11 was up-regulated by forskolin (FSK), an adenylyl cyclase activator, and inhibited by protein kinase A inhibitor H-89 and by silencing of Galphas by small interfering RNA.	Thyrotropin	21-24	interleukin 11	Homo sapiens	50-55
26950201-4	2016	We demonstrated that TSH-induced up-regulation of IL-11 is primarily mediated via the Gs pathway as IL-11 was up-regulated by forskolin (FSK), an adenylyl cyclase activator, and inhibited by protein kinase A inhibitor H-89 and by silencing of Galphas by small interfering RNA.	Thyrotropin	21-24	interleukin 11	Homo sapiens	100-105
26950201-6	2016	Pertussis toxin decreased p38 MAPK kinase phosphorylation, and a p38 inhibitor and small interfering RNA knockdown of p38alpha inhibited OPN induction by TSH.	Thyrotropin	154-157	mitogen-activated protein kinase 1	Homo sapiens	65-68
26950201-6	2016	Pertussis toxin decreased p38 MAPK kinase phosphorylation, and a p38 inhibitor and small interfering RNA knockdown of p38alpha inhibited OPN induction by TSH.	Thyrotropin	154-157	mitogen-activated protein kinase 14	Homo sapiens	118-126
26950201-6	2016	Pertussis toxin decreased p38 MAPK kinase phosphorylation, and a p38 inhibitor and small interfering RNA knockdown of p38alpha inhibited OPN induction by TSH.	Thyrotropin	154-157	secreted phosphoprotein 1	Homo sapiens	137-140
26950201-9	2016	Knockdown of Galphaq/11 and a protein kinase C inhibitor decreased TSH-stimulated up-regulation of ALPL, whereas a protein kinase C activator increased ALPL levels.	Thyrotropin	67-70	alkaline phosphatase, biomineralization associated	Homo sapiens	99-103
26950201-10	2016	A MAPK inhibitor and silencing of ERK1/2 inhibited TSH-stimulated ALPL expression.	Thyrotropin	51-54	mitogen-activated protein kinase 3	Homo sapiens	34-40
26950201-10	2016	A MAPK inhibitor and silencing of ERK1/2 inhibited TSH-stimulated ALPL expression.	Thyrotropin	51-54	alkaline phosphatase, biomineralization associated	Homo sapiens	66-70
27101096-8	2016	The fasting insulin (FINS) and C reactive protein (CRP) levels were significantly higher in obese patients complicated by mild increased TSH when compared to the obese patients with normal TSH (p&lt;0.01).	Thyrotropin	137-140	C-reactive protein	Homo sapiens	31-49
27101096-8	2016	The fasting insulin (FINS) and C reactive protein (CRP) levels were significantly higher in obese patients complicated by mild increased TSH when compared to the obese patients with normal TSH (p&lt;0.01).	Thyrotropin	137-140	C-reactive protein	Homo sapiens	51-54
27101096-11	2016	2) In the obese patients complicated by mild increased TSH group, serum TSH was significantly positively correlated with ALT, AST and CP (p&lt;0.05).	Thyrotropin	72-75	solute carrier family 17 member 5	Homo sapiens	126-129
27376428-11	2016	However, a higher preoperative serum TSH:Tg ratio may hint at an increased risk for thyroid carcinoma.	Thyrotropin	37-40	thyroglobulin	Homo sapiens	41-43
26928603-6	2016	TSH was negatively and FT4 was positively correlated with IL-17 (p=0.016 for TSH and p=0.004 for FT4) and IL-23 (p&lt;0.001 for TSH and p=0.003 for FT4) levels.	Thyrotropin	0-3	interleukin 17A	Homo sapiens	58-63
26928603-6	2016	TSH was negatively and FT4 was positively correlated with IL-17 (p=0.016 for TSH and p=0.004 for FT4) and IL-23 (p&lt;0.001 for TSH and p=0.003 for FT4) levels.	Thyrotropin	0-3	interleukin 37	Homo sapiens	106-111
26928603-6	2016	TSH was negatively and FT4 was positively correlated with IL-17 (p=0.016 for TSH and p=0.004 for FT4) and IL-23 (p&lt;0.001 for TSH and p=0.003 for FT4) levels.	Thyrotropin	77-80	interleukin 17A	Homo sapiens	58-63
27186560-13	2016	Significantly greater reduction in TPO-Ab titers was observed in AITD with TSH &lt;= 10 mIU/L compared to TSH &gt; 10 mIU/L.	Thyrotropin	75-78	thyroid peroxidase	Homo sapiens	35-38
27186560-13	2016	Significantly greater reduction in TPO-Ab titers was observed in AITD with TSH &lt;= 10 mIU/L compared to TSH &gt; 10 mIU/L.	Thyrotropin	106-109	thyroid peroxidase	Homo sapiens	35-38
27376428-8	2016	TSH:Tg levels were found to be significantly higher in patients with malignant thyroid diseases (0.24+-1 vs. 0.87+-3.4, p=0.024).	Thyrotropin	0-3	thyroglobulin	Homo sapiens	4-6
27376428-9	2016	Although univariate analysis showed that the TSH:Tg ratio was a predictor for thyroid malignancy (OR 0.001; 95% CI, 0.01-0.125; p=0.007) in conjunction with FNAB, multivariate analysis failed to demonstrate any statistical significance for any factor except FNAB.	Thyrotropin	45-48	thyroglobulin	Homo sapiens	49-51
26587909-0	2015	S-Nitrosylation of NF-kappaB p65 Inhibits TSH-Induced Na(+)/I(-) Symporter Expression.	Thyrotropin	42-45	RELA proto-oncogene, NF-kB subunit	Homo sapiens	29-32
26751190-8	2016	This was dramatically enhanced further by TSH; triple combination of PLX4032, SAHA, and TSH showed the most robust effect on thyroid gene expression and RAI uptake in cells harboring BRAF V600E.	Thyrotropin	42-45	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	183-187
26751190-10	2016	CONCLUSIONS: Simultaneously suppressing BRAF V600E and HDAC, particularly when cotreated with TSH, induced a far more robust expression of thyroid genes and RAI uptake in thyroid cancer cells than suppressing BRAF V600E alone.	Thyrotropin	94-97	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	40-44
26751190-10	2016	CONCLUSIONS: Simultaneously suppressing BRAF V600E and HDAC, particularly when cotreated with TSH, induced a far more robust expression of thyroid genes and RAI uptake in thyroid cancer cells than suppressing BRAF V600E alone.	Thyrotropin	94-97	histone deacetylase 9	Homo sapiens	55-59
26244671-2	2016	We present here the case of an 11-year-old boy with type 1 autoimmune polyglandular syndrome (APS1) and TSHoma which was diagnosed by elevated thyroid - stimulating hormone and thyroid hormones levels without evident clinical signs of hyperthyroidism.	Thyrotropin	143-172	autoimmune regulator	Homo sapiens	94-98
26264603-8	2016	There were positive associations between TSH concentrations and P1NP, BAP, osteocalcin, and CTX (p &lt; 0.01) in women but not in men.	Thyrotropin	41-44	bone gamma-carboxyglutamate protein	Homo sapiens	75-86
26610751-0	2016	Nitric oxide-repressed Forkhead factor FoxE1 expression is involved in the inhibition of TSH-induced thyroid peroxidase levels.	Thyrotropin	89-92	forkhead box E1	Homo sapiens	39-44
26610751-0	2016	Nitric oxide-repressed Forkhead factor FoxE1 expression is involved in the inhibition of TSH-induced thyroid peroxidase levels.	Thyrotropin	89-92	thyroid peroxidase	Homo sapiens	101-119
26610751-6	2016	We demonstrated that NO donors inhibited TSH-stimulated TPO expression by inducing a cyclic guanosine monophosphate-dependent protein kinase-mediated transcriptional repression of the TPO gene.	Thyrotropin	41-44	thyroid peroxidase	Homo sapiens	56-59
26610751-6	2016	We demonstrated that NO donors inhibited TSH-stimulated TPO expression by inducing a cyclic guanosine monophosphate-dependent protein kinase-mediated transcriptional repression of the TPO gene.	Thyrotropin	41-44	thyroid peroxidase	Homo sapiens	184-187
26164179-1	2016	PURPOSE: We investigated the potential value of TSH-stimulated serum thyroglobulin (sTg) to characterize subcentimeter-sized, F-FDG avid cervical lymph nodes (LNs) on 18PET/CT and their responsiveness to 131I ablation therapy (IAT) in patients with papillary thyroid cancer.	Thyrotropin	48-51	thyroglobulin	Homo sapiens	69-82
27403655-11	2016	In most cases TSH is co-expressed with GH in patients with acromegaly and is not accompanied by hyperthyroidism.	Thyrotropin	14-17	growth hormone 1	Homo sapiens	39-41
27207603-8	2016	RESULTS: Direct sequencing of the PAX8 gene revealed a novel single nucleotide substitution (c.162 A&gt;T) in exon 2 that resulted in the substitution of the normal serine 54 with a cysteine (S54C), which segregated with elevated serum TSH levels.	Thyrotropin	236-239	paired box 8	Homo sapiens	34-38
26336917-10	2016	CONCLUSION: The altered TSH secretion pattern is consistent with the previously hypothesized defect in thyrotropin-releasing hormone signaling in IGSF1 deficiency.	Thyrotropin	24-27	thyrotropin releasing hormone	Homo sapiens	103-132
26754589-7	2016	CONCLUSION: We concluded that PTU, KClO4, or TSH relieved the mitochondrial oxidative stress induced by high concentrations of iodide in the thyroids of both MT-I/II KO and WT mice.	Thyrotropin	45-48	metallothionein 1	Mus musculus	158-168
26787873-3	2016	To reset the endogenous thyrotrophic feedback control, we designed a synthetic mammalian gene circuit that maintains thyroid hormone homeostasis by monitoring thyroid hormone levels and coordinating the expression of a thyroid-stimulating hormone receptor antagonist (TSHAntag), which competitively inhibits the binding of thyroid-stimulating hormone or the human autoantibody to TSHR.	Thyrotropin	219-246	thyroid stimulating hormone receptor	Homo sapiens	380-384
27349005-8	2016	After adjusting for gender, age, and smoking status, the TSH levels were found to be positively correlated with body mass index, waist circumference, diastolic blood pressure (DBP), and TG, TC, LDL-C, ApoB, Hcy, and hs-CRP levels (p &lt; 0.05 for all), but negatively correlated with the HDL-C levels (p &lt; 0.01).	Thyrotropin	57-60	apolipoprotein B	Homo sapiens	201-205
27649316-7	2016	The epsilon4 APOE polymorphism was associated with a higher concentration of thyroid-stimulating hormone and lower concentrations of free triiodothyronine and total triiodothyronine.	Thyrotropin	77-104	apolipoprotein E	Homo sapiens	13-17
27403655-6	2016	TSH-immunopositive adenomas are immunostained also to detect somatostatin receptor subtypes (SSTR 1-5).	Thyrotropin	0-3	somatostatin receptor 1	Homo sapiens	93-99
26587909-0	2015	S-Nitrosylation of NF-kappaB p65 Inhibits TSH-Induced Na(+)/I(-) Symporter Expression.	Thyrotropin	42-45	solute carrier family 5 member 5	Homo sapiens	54-74
26587909-7	2015	We observed that NO donors repress TSH-induced NIS gene expression by reducing the transcriptional activity of the nuclear factor-kappaB subunit p65.	Thyrotropin	35-38	RELA proto-oncogene, NF-kB subunit	Homo sapiens	145-148
26287404-0	2015	Pentraxin-3 Is a TSH-Inducible Protein in Human Fibrocytes and Orbital Fibroblasts.	Thyrotropin	17-20	pentraxin 3	Homo sapiens	0-11
26287404-5	2015	Here we sought to determine whether pentraxin-3 (PTX-3), an acute-phase protein involved in inflammation and autoimmunity, might be induced by TSH in fibrocytes and OFs.	Thyrotropin	143-146	pentraxin 3	Homo sapiens	36-47
26287404-5	2015	Here we sought to determine whether pentraxin-3 (PTX-3), an acute-phase protein involved in inflammation and autoimmunity, might be induced by TSH in fibrocytes and OFs.	Thyrotropin	143-146	pentraxin 3	Homo sapiens	49-54
26177236-11	2015	CONCLUSIONS: In this cross-sectional evaluation, high TSH quintiles were associated to insulin resistance/metabolic syndrome.	Thyrotropin	54-57	insulin	Homo sapiens	87-94
26342297-0	2015	Increase in thyroid stimulating hormone levels in patients with gout treated with inhibitors of xanthine oxidoreductase.	Thyrotropin	12-39	xanthine dehydrogenase	Homo sapiens	96-119
26146959-0	2015	KRAS(G12D)-mediated oncogenic transformation of thyroid follicular cells requires long-term TSH stimulation and is regulated by SPRY1.	Thyrotropin	92-95	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	0-4
26296153-6	2015	Thyrotrope-specific disruption of Isl1 with Tshb-cre is permissive for normal serum TSH, but T4 levels are decreased, suggesting decreased thyrotrope function.	Thyrotropin	84-87	ISL1 transcription factor, LIM/homeodomain	Mus musculus	34-38
26189599-9	2015	In summary, serum ANGPTL6 levels increased in patients with a hypothyroid status, and both TSH and free T4 levels are associated with ANGPLT6 levels, suggesting a possible association between thyroid function and ANGPTL6 levels.	Thyrotropin	91-94	angiopoietin like 6	Homo sapiens	213-220
26296153-6	2015	Thyrotrope-specific disruption of Isl1 with Tshb-cre is permissive for normal serum TSH, but T4 levels are decreased, suggesting decreased thyrotrope function.	Thyrotropin	84-87	thyroid stimulating hormone, beta subunit	Mus musculus	44-48
25655684-5	2015	TSH-induced downregulation of FASN was partially abolished by inhibition of PKA and ERK, but not JNK.	Thyrotropin	0-3	fatty acid synthase	Mus musculus	30-34
26486480-2	2015	Definition of this unit is laboratory: in presence of normal level of thyroxine (T4) TSH value is changed: in lower TSH level the subclinical hyperthyroidism (STx) in increase TSH levels subclinical hypothyroidism (SH) is present.	Thyrotropin	85-88	ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2	Homo sapiens	159-162
26486480-2	2015	Definition of this unit is laboratory: in presence of normal level of thyroxine (T4) TSH value is changed: in lower TSH level the subclinical hyperthyroidism (STx) in increase TSH levels subclinical hypothyroidism (SH) is present.	Thyrotropin	116-119	ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2	Homo sapiens	159-162
26121443-7	2015	RESULTS: Increasing serum TSH concentration was associated with a lower probability of having the receptor expression profile ER+ PR+ Her2/neu+ compared to patients with the ER+ PR+ Her2/neu- profile (odds ratio [OR] = 0.52, P = .0045).	Thyrotropin	26-29	erb-b2 receptor tyrosine kinase 2	Homo sapiens	134-138
26158397-4	2015	Guided by the hypothalamus-pituitary-thyroid axis as a fixed set-point regulator in thyroid hormone metabolism, we used a murine model and compared at key junctures the capacity of circulating thyroglobulin level (raised by thyroid-stimulating hormone or exogenous thyroglobulin administration) to strengthen self-tolerance and resist autoimmune thyroiditis.	Thyrotropin	224-251	thyroglobulin	Mus musculus	193-206
25655684-5	2015	TSH-induced downregulation of FASN was partially abolished by inhibition of PKA and ERK, but not JNK.	Thyrotropin	0-3	mitogen-activated protein kinase 1	Mus musculus	84-87
25502943-1	2015	Subclinical hypothyroidism, characterized by an isolated rise in TSH serum levels with normal thyroid function, is a pro-inflammatory state associated with insulin resistance.	Thyrotropin	65-68	insulin	Homo sapiens	156-163
26302721-7	2015	When HepG2 cells were treated with TSH, the phosphorylation of HNF-4alpha increased and its nuclear localization was interrupted.	Thyrotropin	35-38	hepatocyte nuclear factor 4 alpha	Homo sapiens	63-73
26302721-9	2015	When the cAMP/PKA pathway was inhibited by the PKA inhibitor H89 and the adenylate cyclase (AC) inhibitor SQ22536, the TSH-mediated phosphorylation of HNF-4alpha was disrupted.	Thyrotropin	119-122	hepatocyte nuclear factor 4 alpha	Homo sapiens	151-161
26018720-0	2015	Pituitary 18F-FDG Uptake Correlates With Serum TSH Levels in Subjects With Diffuse Thyroid 18F-FDG Uptake.	Thyrotropin	47-50	single-strand-selective monofunctional uracil-DNA glycosylase 1	Homo sapiens	14-17
26018720-0	2015	Pituitary 18F-FDG Uptake Correlates With Serum TSH Levels in Subjects With Diffuse Thyroid 18F-FDG Uptake.	Thyrotropin	47-50	single-strand-selective monofunctional uracil-DNA glycosylase 1	Homo sapiens	95-98
25502943-6	2015	TSH activated cPKC, and Go6976, a PKCalpha and -beta1 inhibitor, prevented the inhibitory effect of TSH on the insulin response.	Thyrotropin	0-3	insulin	Homo sapiens	111-118
25502943-7	2015	Insulin reduced the ability of TSH to activate cPKC and to stimulate lipolysis.Our data reveal novel interactions between TSH and insulin.	Thyrotropin	31-34	insulin	Homo sapiens	0-7
25502943-7	2015	Insulin reduced the ability of TSH to activate cPKC and to stimulate lipolysis.Our data reveal novel interactions between TSH and insulin.	Thyrotropin	31-34	insulin	Homo sapiens	130-137
25502943-7	2015	Insulin reduced the ability of TSH to activate cPKC and to stimulate lipolysis.Our data reveal novel interactions between TSH and insulin.	Thyrotropin	122-125	insulin	Homo sapiens	0-7
25502943-7	2015	Insulin reduced the ability of TSH to activate cPKC and to stimulate lipolysis.Our data reveal novel interactions between TSH and insulin.	Thyrotropin	122-125	insulin	Homo sapiens	130-137
25502943-8	2015	TSH inhibits insulin-stimulated Akt signaling in a cPKC-dependent fashion, whereas insulin blocks TSH-stimulated cPKC activity and lipolysis.	Thyrotropin	0-3	insulin	Homo sapiens	13-20
25502943-8	2015	TSH inhibits insulin-stimulated Akt signaling in a cPKC-dependent fashion, whereas insulin blocks TSH-stimulated cPKC activity and lipolysis.	Thyrotropin	0-3	AKT serine/threonine kinase 1	Homo sapiens	32-35
26087256-6	2015	AIM: To characterize the molecular mechanisms underlying TSH-induced TNFalpha production by FCs, and the role of IGF-1R blockade by TMB.	Thyrotropin	57-60	tumor necrosis factor	Homo sapiens	69-77
25895485-5	2015	Stimulation of Tg was achieved by thyroid hormone withdrawal to achieve serum thyroid stimulating hormone (TSH) &gt;=30 mU/L.	Thyrotropin	107-110	thyroglobulin	Homo sapiens	15-17
25976636-7	2015	The concentration of IL-6 was negatively correlated with TT3 and TSH concentrations and the TT3 concentration was negatively correlated with serum urea and creatinine concentrations.	Thyrotropin	65-68	interleukin 6	Canis lupus familiaris	21-25
25860033-7	2015	The TSHR-ECD-D1 in conditioned medium was folded correctly, as demonstrated by its ability to inhibit radiolabeled TSH binding to the TSH holoreceptor.	Thyrotropin	4-7	ecdysoneless cell cycle regulator	Homo sapiens	9-12
26087256-11	2015	TMB decreased TSH-induced TNFalpha protein production in circulating FCs from mean fluorescent index (MFI) value of 2.92 to 1.91, and mRNA expression in cultured FCs from 141- to 52-fold expression (p&lt;0.0001).	Thyrotropin	14-17	tumor necrosis factor	Homo sapiens	26-34
25878058-6	2015	Treatment of primary tanycyte/ependymal cultures with TSH (100  IU/l) increased cAMP as assessed by ELISA and induced a cAMP-independent increase in the phosphorylation of ERK1/2 as assessed by western blot analysis.	Thyrotropin	54-57	mitogen activated protein kinase 3	Rattus norvegicus	172-178
26137119-7	2015	Patients harboring the BRAF V600E mutation had higher thyroid stimulating hormone levels (2.453+-1.464 vs. 1.966+-1.296 mIU/l), a reduced occurrence of papillary thyroid microcarcinoma (55.0 vs. 88%), and a higher occurrence of lymph node metastasis (LNM; 42.5 vs. 16.0%) compared with those with wild-type BRAF (all P&lt;0.05).	Thyrotropin	54-81	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	23-27
25805895-9	2015	A significant correlation was also found between TSH levels and TAT volume (r=0.572; P&lt;0.001).	Thyrotropin	49-52	tyrosine aminotransferase	Homo sapiens	64-67
26149144-14	2015	Tg/ TSH,which means the ratio of sTg variation to TSH variation,may be a useful diagnostic marker for predicting distant metastases in DTC.	Thyrotropin	4-7	chromosome 6 open reading frame 15	Homo sapiens	33-36
25805895-11	2015	CONCLUSIONS: Our findings indicate that SH patients have significantly higher TAT values than controls and that increased TAT levels correlate with increased TSH levels.	Thyrotropin	158-161	tyrosine aminotransferase	Homo sapiens	122-125
25933205-1	2015	Our previous study found that thyroid-stimulating hormone promoted sterol regulatory element-binding protein-2 (SREBP-2) expression and suppressed AMP-activated protein kinase (AMPK) activity in the liver, but it was unclear whether there was a direct link between TSH, AMPK and SREBP-2.	Thyrotropin	30-57	sterol regulatory element binding transcription factor 2	Homo sapiens	67-110
25713102-4	2015	Our previous study found that thyroid-stimulating hormone (TSH) increased the hepatocytic HMGCR expression, but it was still unclear whether TSH affected hepatic HMGCR phosphorylation associated with AMPK.	Thyrotropin	59-62	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	90-95
25533663-10	2015	TSH administration led to a decrease in BA content and CYP7A1 activity in thyroidectomized rats supplemented with thyroxine.	Thyrotropin	0-3	cytochrome P450 family 7 subfamily A member 1	Rattus norvegicus	55-61
25933205-1	2015	Our previous study found that thyroid-stimulating hormone promoted sterol regulatory element-binding protein-2 (SREBP-2) expression and suppressed AMP-activated protein kinase (AMPK) activity in the liver, but it was unclear whether there was a direct link between TSH, AMPK and SREBP-2.	Thyrotropin	30-57	sterol regulatory element binding transcription factor 2	Homo sapiens	112-119
25933205-1	2015	Our previous study found that thyroid-stimulating hormone promoted sterol regulatory element-binding protein-2 (SREBP-2) expression and suppressed AMP-activated protein kinase (AMPK) activity in the liver, but it was unclear whether there was a direct link between TSH, AMPK and SREBP-2.	Thyrotropin	30-57	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	147-175
25933205-1	2015	Our previous study found that thyroid-stimulating hormone promoted sterol regulatory element-binding protein-2 (SREBP-2) expression and suppressed AMP-activated protein kinase (AMPK) activity in the liver, but it was unclear whether there was a direct link between TSH, AMPK and SREBP-2.	Thyrotropin	30-57	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	177-181
25933205-1	2015	Our previous study found that thyroid-stimulating hormone promoted sterol regulatory element-binding protein-2 (SREBP-2) expression and suppressed AMP-activated protein kinase (AMPK) activity in the liver, but it was unclear whether there was a direct link between TSH, AMPK and SREBP-2.	Thyrotropin	30-57	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	270-274
25933205-1	2015	Our previous study found that thyroid-stimulating hormone promoted sterol regulatory element-binding protein-2 (SREBP-2) expression and suppressed AMP-activated protein kinase (AMPK) activity in the liver, but it was unclear whether there was a direct link between TSH, AMPK and SREBP-2.	Thyrotropin	30-57	sterol regulatory element binding transcription factor 2	Homo sapiens	279-286
25933205-4	2015	These findings may represent a molecular mechanism by which AMPK ameliorates the hepatic steatosis and hypercholesterolemia associated with high TSH levels in patients with subclinical hypothyroidism (SCH).	Thyrotropin	145-148	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	60-64
25777801-3	2015	The objective of this study was to determine the relationship between TSH concentrations and insulin sensitivity, lipids, and adipokines in euthyroid, non-diabetic, obese adolescents.	Thyrotropin	70-73	insulin	Homo sapiens	93-100
25777801-14	2015	CONCLUSIONS: This study suggests a sex-specific association between TSH and insulin sensitivity in euthyroid, non-diabetic, obese adolescent males.	Thyrotropin	68-71	insulin	Homo sapiens	76-83
25802348-4	2015	Epigenetic changes in GNAS have also been reported in patients who display mild Albright"s hereditary osteodystrophy or mild thyroid-stimulating hormone (TSH) resistance without mutation of GNAS.	Thyrotropin	125-152	GNAS complex locus	Homo sapiens	22-26
24486115-8	2015	A higher TSH value in the newborn was related to an older age of the mother, higher levels of thyroid peroxidase (TPO) antibody during pregnancy and lower birth weight.	Thyrotropin	9-12	thyroid peroxidase	Homo sapiens	94-112
24486115-8	2015	A higher TSH value in the newborn was related to an older age of the mother, higher levels of thyroid peroxidase (TPO) antibody during pregnancy and lower birth weight.	Thyrotropin	9-12	thyroid peroxidase	Homo sapiens	114-117
25802348-4	2015	Epigenetic changes in GNAS have also been reported in patients who display mild Albright"s hereditary osteodystrophy or mild thyroid-stimulating hormone (TSH) resistance without mutation of GNAS.	Thyrotropin	154-157	GNAS complex locus	Homo sapiens	22-26
25372777-12	2015	EPAC1 expression and cellular response to EPAC activation in rat FRTL5 cells reflect cellular responses to cAMP and TSH stimulation in non-transformed thyroid cells.	Thyrotropin	116-119	Rap guanine nucleotide exchange factor 3	Rattus norvegicus	0-5
25887732-9	2015	In females, total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-c) level was significant lower in subjects with TSH &lt;2.5uIU/mL.	Thyrotropin	128-131	component of oligomeric golgi complex 2	Homo sapiens	39-74
25887732-9	2015	In females, total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-c) level was significant lower in subjects with TSH &lt;2.5uIU/mL.	Thyrotropin	128-131	component of oligomeric golgi complex 2	Homo sapiens	76-81
25887732-10	2015	TSH was significantly associated with TC and LDL-c, even in a partial correlation analysis (P = 0.006 and 0.011, respectively).	Thyrotropin	0-3	component of oligomeric golgi complex 2	Homo sapiens	45-50
25887732-11	2015	In a multiple linear regression analysis (stepwise), TSH was positive associated with TC (beta = 0.202, P = 0.005) and LDL-c (beta = 0.144, P = 0.010).	Thyrotropin	53-56	component of oligomeric golgi complex 2	Homo sapiens	119-124
25887732-14	2015	CONCLUSIONS: In conclusion, we identified TSH was positively associated with serum TC and LDL-c in euthyroid diabetic women.	Thyrotropin	42-45	component of oligomeric golgi complex 2	Homo sapiens	90-95
25662278-4	2015	Tshr increased during brown adipocyte differentiation, was up-regulated by insulin and low TSH concentrations and down-regulated by high TSH concentrations, T3 and/or NE.	Thyrotropin	91-94	thyroid stimulating hormone receptor	Rattus norvegicus	0-4
25662278-4	2015	Tshr increased during brown adipocyte differentiation, was up-regulated by insulin and low TSH concentrations and down-regulated by high TSH concentrations, T3 and/or NE.	Thyrotropin	137-140	thyroid stimulating hormone receptor	Rattus norvegicus	0-4
25662278-6	2015	High TSH concentrations increased basal Dio2 mRNA (12-fold) and were synergistic with T3 (100-fold), but decreased Dio2 mRNA in T3+NE-treated cells.	Thyrotropin	5-8	iodothyronine deiodinase 2	Rattus norvegicus	40-44
25662278-6	2015	High TSH concentrations increased basal Dio2 mRNA (12-fold) and were synergistic with T3 (100-fold), but decreased Dio2 mRNA in T3+NE-treated cells.	Thyrotropin	5-8	iodothyronine deiodinase 2	Rattus norvegicus	115-119
25372777-12	2015	EPAC1 expression and cellular response to EPAC activation in rat FRTL5 cells reflect cellular responses to cAMP and TSH stimulation in non-transformed thyroid cells.	Thyrotropin	116-119	Rap guanine nucleotide exchange factor 3	Rattus norvegicus	0-4
25210750-9	2015	Presence of anti-TPO antibodies was associated with higher TSH levels (odds ratio 2.34, 95% CI 1.36-4.04; p=0.007).	Thyrotropin	59-62	thyroid peroxidase	Homo sapiens	17-20
25729691-14	2015	There is a highly significant correlation (P = 0.01) between TSH and CD4 count.	Thyrotropin	61-64	CD4 molecule	Homo sapiens	69-72
25490145-9	2015	Dyrk1A(+/++) young adult mice have significantly lower plasma T4 (2.4 ng/mL versus WT, 3.7 ng/mL; P = 0.019) and nonsignificantly higher plasma TSH (114 mUI/L versus WT, 73mUI/L; P = .09).	Thyrotropin	144-147	dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1a	Mus musculus	0-6
25663898-1	2015	The analysis of serum thyroglobulin (Tg) following thyroid-stimulating hormone (TSH) stimulation (sTg) has been recommended in the follow-up of differentiated thyroid carcinoma (DTC) patients, however, its routine use remains controversial.	Thyrotropin	51-78	thyroglobulin	Homo sapiens	22-35
25954648-11	2015	It was only in the control group that prolactin correlated positively and significantly with TSH.	Thyrotropin	93-96	prolactin	Homo sapiens	38-47
25663898-1	2015	The analysis of serum thyroglobulin (Tg) following thyroid-stimulating hormone (TSH) stimulation (sTg) has been recommended in the follow-up of differentiated thyroid carcinoma (DTC) patients, however, its routine use remains controversial.	Thyrotropin	51-78	thyroglobulin	Homo sapiens	37-39
25663898-1	2015	The analysis of serum thyroglobulin (Tg) following thyroid-stimulating hormone (TSH) stimulation (sTg) has been recommended in the follow-up of differentiated thyroid carcinoma (DTC) patients, however, its routine use remains controversial.	Thyrotropin	51-78	chromosome 6 open reading frame 15	Homo sapiens	98-101
25663898-1	2015	The analysis of serum thyroglobulin (Tg) following thyroid-stimulating hormone (TSH) stimulation (sTg) has been recommended in the follow-up of differentiated thyroid carcinoma (DTC) patients, however, its routine use remains controversial.	Thyrotropin	80-83	thyroglobulin	Homo sapiens	22-35
25663898-1	2015	The analysis of serum thyroglobulin (Tg) following thyroid-stimulating hormone (TSH) stimulation (sTg) has been recommended in the follow-up of differentiated thyroid carcinoma (DTC) patients, however, its routine use remains controversial.	Thyrotropin	80-83	thyroglobulin	Homo sapiens	37-39
25663898-1	2015	The analysis of serum thyroglobulin (Tg) following thyroid-stimulating hormone (TSH) stimulation (sTg) has been recommended in the follow-up of differentiated thyroid carcinoma (DTC) patients, however, its routine use remains controversial.	Thyrotropin	80-83	chromosome 6 open reading frame 15	Homo sapiens	98-101
25557138-1	2015	BACKGROUND: Loss-of-function mutations in the thyrotropin receptor (TSHR) gene lead to resistance to TSH (RTSH) presenting with either congenital hypothyroidism (CH) or subclinical hypothyroidism (SCH).	Thyrotropin	68-71	thyroid stimulating hormone receptor	Homo sapiens	46-66
25590597-3	2015	Thus far, it is unclear whether TSH has a direct effect on the expression of ATGL.	Thyrotropin	32-35	patatin-like phospholipase domain containing 2	Mus musculus	77-81
25404419-3	2015	Levels of TSH-stimulated Tg prior to ablation (stimTg) and serum Tg sampled immediately after RAI therapy (Day 3) were measured (immTg).	Thyrotropin	10-13	thyroglobulin	Homo sapiens	25-27
25495063-6	2015	Our experience suggests that patients" carrier of a mutation of FSHr gene are at risk of ovarian pathologies also when non-pregnant and in the presence of low TSH levels.	Thyrotropin	159-162	follicle stimulating hormone receptor	Homo sapiens	64-68
25488203-8	2015	CONCLUSIONS: AMH levels were inversely correlated with TSH levels in infertile women of reproductive age.	Thyrotropin	55-58	anti-Mullerian hormone	Homo sapiens	13-16
25785116-1	2015	BACKGROUND: A study had reported that a low TSH level is associated with elevated plasma fibrinogen (FIB) levels.	Thyrotropin	44-47	fibrinogen beta chain	Homo sapiens	89-99
25785116-1	2015	BACKGROUND: A study had reported that a low TSH level is associated with elevated plasma fibrinogen (FIB) levels.	Thyrotropin	44-47	fibrinogen beta chain	Homo sapiens	101-104
29204374-9	2015	Serum TSH levels were significantly and positively associated with BMI, systolic and diastolic BP, serum triglyceride and HbA1c levels, whereas negatively with eGFR.	Thyrotropin	6-9	epidermal growth factor receptor	Homo sapiens	160-164
25246335-9	2015	In secondary analyses, we observed that a 10 mL/min/1.73 m(2) lower eGFR was associated with a 0.11 mIU/L higher serum TSH (95% CI 0.10-0.11 mIU/L higher serum TSH, P &lt; 0.001).	Thyrotropin	119-122	CD59 molecule (CD59 blood group)	Homo sapiens	48-53
25246335-9	2015	In secondary analyses, we observed that a 10 mL/min/1.73 m(2) lower eGFR was associated with a 0.11 mIU/L higher serum TSH (95% CI 0.10-0.11 mIU/L higher serum TSH, P &lt; 0.001).	Thyrotropin	160-163	CD59 molecule (CD59 blood group)	Homo sapiens	48-53
25590597-10	2015	The inhibitory effects of TSH on ATGL expression were abolished by H89, which is a protein kinase A (PKA) inhibitor.	Thyrotropin	26-29	patatin-like phospholipase domain containing 2	Mus musculus	33-37
25559747-6	2015	TSH could directly induce the activity of glycerol-3-phosphate-acyltransferase 3 (GPAT3), the rate-limiting enzyme in TG synthesis, in differentiated 3T3-L1 adipocytes.	Thyrotropin	0-3	glycerol-3-phosphate acyltransferase 3	Mus musculus	42-80
25923090-13	2015	After excluding patients with a thyroid dysfunction, a significant difference in TSH levels between anti-TPO positive and negative group was found [median (IQR): 2.11 microIU/mL (1.29-3.31) vs 1.66 microIU/mL (1.29-3.31); p = 0.04].	Thyrotropin	81-84	thyroid peroxidase	Homo sapiens	105-108
25559747-6	2015	TSH could directly induce the activity of glycerol-3-phosphate-acyltransferase 3 (GPAT3), the rate-limiting enzyme in TG synthesis, in differentiated 3T3-L1 adipocytes.	Thyrotropin	0-3	glycerol-3-phosphate acyltransferase 3	Mus musculus	82-87
25559747-8	2015	The over-expression of PPARgamma or the expression of an AMPK dominant negative mutant reversed the TSH-induced changes.	Thyrotropin	100-103	peroxisome proliferator activated receptor gamma	Mus musculus	23-32
26613079-16	2015	Moreover, TPO-Ab positive patients were older and had significantly higher serum TSH as compared to TPO-Ab negative HCV patients.	Thyrotropin	81-84	thyroid peroxidase	Homo sapiens	10-13
25835179-6	2015	Significant association was found between variant genotype of codon 72 of TP53 gene and young age group, female gender, urban dwellers, non-smokers and patients with elevated TSH levels (P &lt; 0.05).	Thyrotropin	175-178	tumor protein p53	Homo sapiens	74-78
25835179-7	2015	CONCLUSION: It is evident from our study that Arg72Pro SNP of TP53 gene is connected with higher susceptibility to thyroid cancer especially in young age group, female gender, non-smokers and patients with elevated TSH levels, hence, implicated in thyroid carcinogenesis.	Thyrotropin	215-218	tumor protein p53	Homo sapiens	62-66
25822940-10	2015	Anti-TPO was correlated positively with estradiol, estradiol/progesterone ratio, and TSH.	Thyrotropin	85-88	thyroid peroxidase	Homo sapiens	5-8
25756047-6	2015	Furthermore, VEGF value in CSU/Hashimoto patients during the remission was similar to that of the active period and significantly higher than the healthy subjects; VEGF concentration was significantly correlated with TSH.	Thyrotropin	217-220	vascular endothelial growth factor A	Homo sapiens	164-168
24679183-6	2015	TSH was positively correlated with TC, LDL-c and oxLDL in all of the study subjects after adjusting for age and BMI.	Thyrotropin	0-3	component of oligomeric golgi complex 2	Homo sapiens	39-44
24679183-8	2015	When further stratified by TSH levels, both the subgroup of mildly elevated TSH (4.78-9.99 mU/L) and overtly elevated TSH (&gt;10.00 mU/L) exhibited significantly higher serum levels of TC, TG, LDL-c and oxLDL compared to the normal TSH subgroup.	Thyrotropin	76-79	component of oligomeric golgi complex 2	Homo sapiens	194-199
26194271-1	2015	Human chorionic gonadotropin (hCG) has weak thyroid-stimulating activity because of its homology with thyroid stimulating hormone (TSH).	Thyrotropin	102-129	chorionic gonadotropin subunit beta 5	Homo sapiens	6-34
26194271-1	2015	Human chorionic gonadotropin (hCG) has weak thyroid-stimulating activity because of its homology with thyroid stimulating hormone (TSH).	Thyrotropin	131-134	chorionic gonadotropin subunit beta 5	Homo sapiens	6-34
26273293-0	2015	Association between rs12045440 Polymorphism in the CAPZB Intron and Serum TSH Concentrations in Chinese Thyroid Tumor Patients.	Thyrotropin	74-77	capping actin protein of muscle Z-line subunit beta	Homo sapiens	51-56
26457493-23	2015	Among all of the women, serum TSH concentration was significantly correlated with BMI, waist circumference, WHR, systolic blood pressure, cholesterol, triglycerides, and TPO-Abs.	Thyrotropin	30-33	thyroid peroxidase	Homo sapiens	170-173
26457493-24	2015	When the variables of subjects with upper quartile of TSH were compared with lower quartile of TSH, we found significantly higher BMI, waist circumference, WHR, increased concentration of IL-6, cholesterol, triglycerides, and T-Abs, and concentrations of cHDL and fT4 were lower.	Thyrotropin	54-57	interleukin 6	Homo sapiens	188-192
26457493-24	2015	When the variables of subjects with upper quartile of TSH were compared with lower quartile of TSH, we found significantly higher BMI, waist circumference, WHR, increased concentration of IL-6, cholesterol, triglycerides, and T-Abs, and concentrations of cHDL and fT4 were lower.	Thyrotropin	54-57	chromodomain helicase DNA binding protein 1 like	Homo sapiens	255-259
26370556-2	2015	Tg significantly suppressed the expression of genes necessary for iodide transport and TH synthesis by counteracting stimulation by TSH.	Thyrotropin	132-135	thyroglobulin	Rattus norvegicus	0-2
26370556-6	2015	Although both the sodium/iodide symporter (NIS), an essential transporter of iodide from blood into the thyroid, and MCT8, a transporter of synthesized TH from the gland, were co-localized on the basolateral membrane of rat thyrocytes in vivo, Tg decreased NIS expression and increased the expression of MCT8 by counteracting TSH action.	Thyrotropin	326-329	solute carrier family 16 member 2	Rattus norvegicus	117-121
26065245-2	2015	Findings are that workers with long length of service, having no health disorders, increased CNTF level is associated with high TSH, increased IgG level is connected with ACTH growth.	Thyrotropin	128-131	ciliary neurotrophic factor	Homo sapiens	93-97
25189990-7	2014	RESULTS: Linear mixed model effect analyses revealed that baseline TSH level was negatively associated with changes of serum BDNF from baseline to 3 months (F=7.58, p=0.007) after adjusting for age, sex, and body mass index, but was not associated with plasma and platelet BDNF.	Thyrotropin	67-70	brain derived neurotrophic factor	Homo sapiens	125-129
26028188-9	2015	CONCLUSION: Less than four months after 131I ablation is too early to perform radioiodine diagnostic whole body scintigraphy with concurrent TSH stimulated Tg measurement.	Thyrotropin	141-144	thyroglobulin	Homo sapiens	156-158
24961827-10	2014	The frequencies of retinopathy and GFR &lt; 60 mL/min/1.73 m(2) were higher not only in patients with TSH &gt;= 4.5 mU/l (odds ratio 1.878 and 2.271, respectively) but also in those with TSH levels of 2.5-4.4 mU/l (odds ratio 1.493 and 2.286, respectively), when compared with patients with TSH levels of 0.4-2.5 mU/l.	Thyrotropin	102-105	CD59 molecule (CD59 blood group)	Homo sapiens	50-55
24819468-5	2014	CREB phosphorylation was stimulated by TSH and forskolin in TAD-2 cells.	Thyrotropin	39-42	cAMP responsive element binding protein 1	Homo sapiens	0-4
24819468-6	2014	Ras(V12) expression negatively regulated the TSH-stimulated CREB phosphorylation but was ineffective on forskolin-stimulated CREB phosphorylation.	Thyrotropin	45-48	immunoglobulin lambda variable 2-8	Homo sapiens	0-7
24819468-6	2014	Ras(V12) expression negatively regulated the TSH-stimulated CREB phosphorylation but was ineffective on forskolin-stimulated CREB phosphorylation.	Thyrotropin	45-48	cAMP responsive element binding protein 1	Homo sapiens	60-64
24819468-7	2014	Phosphodiesterase inhibition by IBMX enhanced TSH-stimulated CREB phosphorylation, but did not restore TSH-stimulated CREB phosphorylation inhibited by Ras oncoprotein.	Thyrotropin	46-49	cAMP responsive element binding protein 1	Homo sapiens	61-65
25016220-14	2014	The mechanism, underlying TSH-induced liver triglyceride accumulation, involved that TSH, through its receptor TSHR, triggered hepatic SREBP-1c activity via the cAMP/PKA/PPARalpha pathway associated with decreased AMPK, which further increased the expression of genes associated with lipogenesis.	Thyrotropin	26-29	thyroid stimulating hormone receptor	Mus musculus	111-115
25016220-14	2014	The mechanism, underlying TSH-induced liver triglyceride accumulation, involved that TSH, through its receptor TSHR, triggered hepatic SREBP-1c activity via the cAMP/PKA/PPARalpha pathway associated with decreased AMPK, which further increased the expression of genes associated with lipogenesis.	Thyrotropin	26-29	sterol regulatory element binding transcription factor 1	Mus musculus	135-143
25016220-14	2014	The mechanism, underlying TSH-induced liver triglyceride accumulation, involved that TSH, through its receptor TSHR, triggered hepatic SREBP-1c activity via the cAMP/PKA/PPARalpha pathway associated with decreased AMPK, which further increased the expression of genes associated with lipogenesis.	Thyrotropin	26-29	peroxisome proliferator activated receptor alpha	Mus musculus	170-179
25189990-7	2014	RESULTS: Linear mixed model effect analyses revealed that baseline TSH level was negatively associated with changes of serum BDNF from baseline to 3 months (F=7.58, p=0.007) after adjusting for age, sex, and body mass index, but was not associated with plasma and platelet BDNF.	Thyrotropin	67-70	brain derived neurotrophic factor	Homo sapiens	273-277
25189990-9	2014	Patients in the highest quartile of TSH showed significantly lower serum BDNF than in the other quartiles (F=4.54, p=0.038), but no significant differences were found based on T3 and T4 levels.	Thyrotropin	36-39	brain derived neurotrophic factor	Homo sapiens	73-77
25537909-7	2014	Serum VEGF-D level was higher in PTC patients with lymph node metastasis (P&lt;0.05) and elevated TSH level (P&lt;0.01) without association with the clinical stage, tumor diameter, age, or gender.	Thyrotropin	98-101	vascular endothelial growth factor D	Homo sapiens	6-12
25436638-2	2014	Genome-wide association studies (GWAS) have identified variants in PDE8B and FOXE1 that are associated with TSH levels.	Thyrotropin	108-111	phosphodiesterase 8B	Homo sapiens	67-72
25436638-2	2014	Genome-wide association studies (GWAS) have identified variants in PDE8B and FOXE1 that are associated with TSH levels.	Thyrotropin	108-111	forkhead box E1	Homo sapiens	77-82
25436638-8	2014	Our results replicate the known association of PDE8B with serum TSH levels in European Americans (rs2046045 p = 1.85x10-17, beta = 0.09).	Thyrotropin	64-67	phosphodiesterase 8B	Homo sapiens	47-52
25436638-11	2014	However, multiple known associations with TSH levels in European ancestry were nominally significant in African Americans, including PDE8B (rs2046045 p = 0.03, beta = -0.09), VEGFA (rs11755845 p = 0.01, beta = -0.13), and NFIA (rs334699 p = 1.50x10-3, beta = -0.17).	Thyrotropin	42-45	phosphodiesterase 8B	Homo sapiens	133-138
25436638-11	2014	However, multiple known associations with TSH levels in European ancestry were nominally significant in African Americans, including PDE8B (rs2046045 p = 0.03, beta = -0.09), VEGFA (rs11755845 p = 0.01, beta = -0.13), and NFIA (rs334699 p = 1.50x10-3, beta = -0.17).	Thyrotropin	42-45	vascular endothelial growth factor A	Homo sapiens	175-180
25436638-11	2014	However, multiple known associations with TSH levels in European ancestry were nominally significant in African Americans, including PDE8B (rs2046045 p = 0.03, beta = -0.09), VEGFA (rs11755845 p = 0.01, beta = -0.13), and NFIA (rs334699 p = 1.50x10-3, beta = -0.17).	Thyrotropin	42-45	nuclear factor I A	Homo sapiens	222-226
25185682-5	2014	RESULTS: In bivariate association analyses, TSH level was significantly associated with body mass index (BMI), smoking, diastolic blood pressure, triglyceride and insulin levels (p &lt; 0.001).	Thyrotropin	44-47	insulin	Homo sapiens	163-170
25455223-3	2014	The proposed MOA consists of an initial effect on the liver by activating the constitutive androstane (Car) and pregnane X (Pxr) nuclear receptors causing increased elimination of thyroid hormones followed by an increased secretion of thyroid stimulating hormone (TSH).	Thyrotropin	264-267	nuclear receptor subfamily 1, group I, member 3	Mus musculus	103-106
24910925-1	2014	AIM: To evaluate the impact of genetic polymorphisms in uridine 5"-glucuronosylytansferases UGT1A1 and UGT1A3 and iodothyronine-deiodinases types 1 and 2 on levothyroxine (T4 ; 3,5,3",5"-triiodo-L-thyronine) dose requirement for suppression of thyrotropin (TSH) secretion in patients with differentiated thyroid cancer (DTC).	Thyrotropin	257-260	UDP glucuronosyltransferase family 1 member A3	Homo sapiens	103-109
25469340-0	2014	Subclinical hypothyroidism diagnosed by thyrotropin-releasing hormone stimulation test in infertile women with basal thyroid-stimulating hormone levels of 2.5 to 5.0 mIU/L.	Thyrotropin	117-144	thyrotropin releasing hormone	Homo sapiens	40-69
25454367-6	2014	NBR-KO mice exhibited a 56% higher increase in serum TSH in response to an acute single intraperitoneal injection of TRH concomitant with a non-significant increase in pituitary TRH receptor (Trhr) mRNA at basal state.	Thyrotropin	53-56	thyrotropin releasing hormone	Mus musculus	117-120
25454367-7	2014	The phenotype of female NBR-KO mice at the hypothalamus-pituitary axis revealed alterations in pituitary and hypothalamic gene expression, associated with reduced serum T3, and higher TSH response to TRH, with apparently normal thyroid morphology and hormonal production.	Thyrotropin	184-187	thyrotropin releasing hormone	Mus musculus	200-203
24845024-8	2014	In that prolonged phase of illness, hypothalamic thyrotropin releasing hormone (TRH) expression is suppressed and explains reduced TSH secretion and whereby reduced thyroidal hormone release.	Thyrotropin	131-134	thyrotropin releasing hormone	Homo sapiens	49-78
25234940-11	2014	H-FABP was significantly and positively correlated with age, systolic blood pressure, thyroid stimulating hormone (TSH) levels, and CIMT, and negatively correlated with fT4 levels.	Thyrotropin	86-113	fatty acid binding protein 3	Homo sapiens	0-6
25234940-11	2014	H-FABP was significantly and positively correlated with age, systolic blood pressure, thyroid stimulating hormone (TSH) levels, and CIMT, and negatively correlated with fT4 levels.	Thyrotropin	115-118	fatty acid binding protein 3	Homo sapiens	0-6
24852370-10	2014	Our findings suggest that the SNPs in XKR4 and near FOXE1 are involved in the regulation of TSH levels.	Thyrotropin	92-95	XK related 4	Homo sapiens	38-42
24852370-10	2014	Our findings suggest that the SNPs in XKR4 and near FOXE1 are involved in the regulation of TSH levels.	Thyrotropin	92-95	forkhead box E1	Homo sapiens	52-57
25135573-2	2014	Patients with mutations in THRB present with resistance to thyroid hormone beta (RTHbeta), which is a disorder characterized by elevated levels of thyroid hormone, normal or elevated levels of TSH and goitre.	Thyrotropin	193-196	thyroid hormone receptor beta	Homo sapiens	27-31
25029414-5	2014	RESULTS: TSH/cAMP-induced growth of PCCL3 cells requires mTOR, which is stimulated via protein kinase A in a MAPK kinase (MEK)- and AKT-independent manner.	Thyrotropin	9-12	mechanistic target of rapamycin kinase	Rattus norvegicus	57-61
25029414-5	2014	RESULTS: TSH/cAMP-induced growth of PCCL3 cells requires mTOR, which is stimulated via protein kinase A in a MAPK kinase (MEK)- and AKT-independent manner.	Thyrotropin	9-12	mitogen-activated protein kinase kinase 7	Homo sapiens	122-125
25029414-5	2014	RESULTS: TSH/cAMP-induced growth of PCCL3 cells requires mTOR, which is stimulated via protein kinase A in a MAPK kinase (MEK)- and AKT-independent manner.	Thyrotropin	9-12	AKT serine/threonine kinase 1	Rattus norvegicus	132-135
25029414-12	2014	CONCLUSION: Thyroid cancer cells lose TSH/cAMP dependency of mTOR signaling and cell growth.	Thyrotropin	38-41	mechanistic target of rapamycin kinase	Homo sapiens	61-65
25102448-9	2014	The negative correlation between irisin and TSH levels was demonstrated (r=-0.4924, p=0.0230), as well as the positive correlation between irisin and FT4 levels (r=0.4833, p=0.0360).	Thyrotropin	44-47	fibronectin type III domain containing 5	Homo sapiens	33-39
25988151-10	2014	The young age of the patient, the rarity of BRAF mutations in childhood and the high dissemination of the malignancy, lead us to the speculation that increased TSH stimulation in a RTH background and oncogenic activation of BRAF could have served as (co) drivers and might have triggered an advanced stage of the neoplastic disease.	Thyrotropin	160-163	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	44-48
25251414-8	2014	P300 latency and amplitude correlated with a number of hormones: follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol, estrone, estriol, DHEA, pregnenolone, progesterone, free and total testosterone, thyroid stimulating hormone (TSH), Vitamins D 1.25 and D 25OH, leptin, and insulin-like growth factor-binding protein 3 (IGF-BP3).	Thyrotropin	219-246	E1A binding protein p300	Homo sapiens	0-4
25251414-8	2014	P300 latency and amplitude correlated with a number of hormones: follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol, estrone, estriol, DHEA, pregnenolone, progesterone, free and total testosterone, thyroid stimulating hormone (TSH), Vitamins D 1.25 and D 25OH, leptin, and insulin-like growth factor-binding protein 3 (IGF-BP3).	Thyrotropin	248-251	E1A binding protein p300	Homo sapiens	0-4
25580384-11	2014	TSH levels positively and moderately correlated with insulin (r= 0.43 P=0.03) and HOMA IR (r =0.48; P= 0.01).	Thyrotropin	0-3	insulin	Homo sapiens	53-60
25102228-0	2014	Induction of adrenomedullin 2/intermedin expression by thyroid stimulating hormone in thyroid.	Thyrotropin	55-82	adrenomedullin 2	Rattus norvegicus	13-29
25102228-0	2014	Induction of adrenomedullin 2/intermedin expression by thyroid stimulating hormone in thyroid.	Thyrotropin	55-82	adrenomedullin 2	Rattus norvegicus	30-40
24721478-5	2014	Native hCG is weakly thyrotropic but is produced in prodigious quantities and suppresses the production of thyroid stimulating hormone (TSH) but not curiously when TSH levels are in the higher deciles.	Thyrotropin	107-134	hypertrichosis 2 (generalised, congenital)	Homo sapiens	7-10
24721478-5	2014	Native hCG is weakly thyrotropic but is produced in prodigious quantities and suppresses the production of thyroid stimulating hormone (TSH) but not curiously when TSH levels are in the higher deciles.	Thyrotropin	136-139	hypertrichosis 2 (generalised, congenital)	Homo sapiens	7-10
24721478-5	2014	Native hCG is weakly thyrotropic but is produced in prodigious quantities and suppresses the production of thyroid stimulating hormone (TSH) but not curiously when TSH levels are in the higher deciles.	Thyrotropin	164-167	hypertrichosis 2 (generalised, congenital)	Homo sapiens	7-10
24836306-5	2014	The results indicate that the intracellular uptake of TSH-nanoliposomes is increased in cells expressing the TSHr.	Thyrotropin	54-57	thyroid stimulating hormone receptor	Homo sapiens	109-113
24722205-6	2014	An intronic variant in VAV3, rs12126655, which has been reported in Europeans, was significantly associated with plasma TSH concentration in the joint Stages 1 and 2 analyses (P = 2.2 x 10(-8)).	Thyrotropin	120-123	vav guanine nucleotide exchange factor 3	Homo sapiens	23-27
24723693-3	2014	We found TSH-induced phosphorylation of these kinases in 2 cell lines engineered to express TSHRs, human embryonic kidney HEK-TSHR cells and human osteoblastic U2OS-TSHR cells.	Thyrotropin	9-12	thyroid stimulating hormone receptor	Homo sapiens	92-96
24939214-17	2014	Serial monitoring of serum TSH may help define VEGFR-2-dependent or VEGFR-2-independent drug resistance.	Thyrotropin	27-30	kinase insert domain receptor	Homo sapiens	47-54
24939214-17	2014	Serial monitoring of serum TSH may help define VEGFR-2-dependent or VEGFR-2-independent drug resistance.	Thyrotropin	27-30	kinase insert domain receptor	Homo sapiens	68-75
24723693-3	2014	We found TSH-induced phosphorylation of these kinases in 2 cell lines engineered to express TSHRs, human embryonic kidney HEK-TSHR cells and human osteoblastic U2OS-TSHR cells.	Thyrotropin	9-12	thyroid stimulating hormone receptor	Homo sapiens	126-130
24723693-8	2014	Down-regulation of beta-arrestin-1 by siRNA inhibited TSH-stimulated phosphorylation of ERK1/2, p38alpha, and AKT1, whereas down-regulation of beta-arrestin-2 increased phosphorylation of AKT1 in both cell types and of ERK1/2 in HEK-TSHR cells.	Thyrotropin	54-57	arrestin beta 1	Homo sapiens	19-34
24723693-8	2014	Down-regulation of beta-arrestin-1 by siRNA inhibited TSH-stimulated phosphorylation of ERK1/2, p38alpha, and AKT1, whereas down-regulation of beta-arrestin-2 increased phosphorylation of AKT1 in both cell types and of ERK1/2 in HEK-TSHR cells.	Thyrotropin	54-57	mitogen-activated protein kinase 3	Homo sapiens	88-94
24723693-8	2014	Down-regulation of beta-arrestin-1 by siRNA inhibited TSH-stimulated phosphorylation of ERK1/2, p38alpha, and AKT1, whereas down-regulation of beta-arrestin-2 increased phosphorylation of AKT1 in both cell types and of ERK1/2 in HEK-TSHR cells.	Thyrotropin	54-57	mitogen-activated protein kinase 14	Homo sapiens	96-104
24723693-8	2014	Down-regulation of beta-arrestin-1 by siRNA inhibited TSH-stimulated phosphorylation of ERK1/2, p38alpha, and AKT1, whereas down-regulation of beta-arrestin-2 increased phosphorylation of AKT1 in both cell types and of ERK1/2 in HEK-TSHR cells.	Thyrotropin	54-57	AKT serine/threonine kinase 1	Homo sapiens	110-114
24723693-8	2014	Down-regulation of beta-arrestin-1 by siRNA inhibited TSH-stimulated phosphorylation of ERK1/2, p38alpha, and AKT1, whereas down-regulation of beta-arrestin-2 increased phosphorylation of AKT1 in both cell types and of ERK1/2 in HEK-TSHR cells.	Thyrotropin	54-57	AKT serine/threonine kinase 1	Homo sapiens	188-192
24723693-8	2014	Down-regulation of beta-arrestin-1 by siRNA inhibited TSH-stimulated phosphorylation of ERK1/2, p38alpha, and AKT1, whereas down-regulation of beta-arrestin-2 increased phosphorylation of AKT1 in both cell types and of ERK1/2 in HEK-TSHR cells.	Thyrotropin	54-57	mitogen-activated protein kinase 3	Homo sapiens	219-225
24723693-8	2014	Down-regulation of beta-arrestin-1 by siRNA inhibited TSH-stimulated phosphorylation of ERK1/2, p38alpha, and AKT1, whereas down-regulation of beta-arrestin-2 increased phosphorylation of AKT1 in both cell types and of ERK1/2 in HEK-TSHR cells.	Thyrotropin	54-57	thyroid stimulating hormone receptor	Homo sapiens	233-237
25002375-11	2014	When the TSH level was near the upper limit of the normal range (4.5-8.5 mIU/L), the TRH test result had a better correlation with hypothyroidism than the basal TSH level (p = 0.03).	Thyrotropin	9-12	thyrotropin releasing hormone	Homo sapiens	85-88
24962680-7	2014	The regression analysis adjusted for fibrinogen showed that in hyperthyroid patients, pre-treatment thyroid stimulating hormone (TSH) independently predicted Ks, while thrombin activatable fibrinolysis inhibitor (TAFI) antigen predicted CLT.	Thyrotropin	129-132	fibrinogen beta chain	Homo sapiens	37-47
25125991-3	2014	The aim of the current study was to investigate the influence of menopause and age on OPG and OC in women with different thyroid-stimulating hormone (TSH) levels.	Thyrotropin	121-148	TNF receptor superfamily member 11b	Homo sapiens	86-89
24065308-9	2014	The TSH-stimulated effects were suppressed by an adenylyl cyclase inhibitor, a protein kinase A (PKA) inhibitor and HMGCR inhibitors (all p &lt; 0.05).	Thyrotropin	4-7	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	79-95
24997767-9	2014	Preablative and postablative TSH-stimulated thyroglobulin (Tg) and antibodies against thyroglobulin (TgAbs) were measured in both groups, and comparison did not reveal differences.	Thyrotropin	29-32	thyroglobulin	Homo sapiens	44-57
24934827-12	2014	TSH response to TRH was significantly higher in premature foals compared to normal foals.	Thyrotropin	0-3	thyrotropin releasing hormone	Equus caballus	16-19
25775863-9	2014	In rats with prolonged mild DM1 after 150 and 210 days after the first treatment with STZ the levels of tT4, fT4 and tT3 were significantly reduced, but the concentration of TSH in rats with 210-day mild DM1 was increased by 119%.	Thyrotropin	174-177	immunoglobulin heavy diversity 1-7	Homo sapiens	28-31
25775863-9	2014	In rats with prolonged mild DM1 after 150 and 210 days after the first treatment with STZ the levels of tT4, fT4 and tT3 were significantly reduced, but the concentration of TSH in rats with 210-day mild DM1 was increased by 119%.	Thyrotropin	174-177	immunoglobulin heavy diversity 1-7	Homo sapiens	204-207
25775863-10	2014	The results obtained in the study of the thyroid status and TSH levels in rats with prolonged mild DM1 are in good agreement with the data obtained in the study of thyroid diseases in patients with DM1.	Thyrotropin	60-63	immunoglobulin heavy diversity 1-7	Homo sapiens	99-102
25775863-13	2014	The decrease of the AC effect of TSH varied among different groups of the diabetic animals: in the rats with acute DM1 this effect was reduced by 46% and in the rats with the 30- and 210-day mild DM1--by 18% and 34%.	Thyrotropin	33-36	immunoglobulin heavy diversity 1-7	Homo sapiens	115-118
25775863-13	2014	The decrease of the AC effect of TSH varied among different groups of the diabetic animals: in the rats with acute DM1 this effect was reduced by 46% and in the rats with the 30- and 210-day mild DM1--by 18% and 34%.	Thyrotropin	33-36	immunoglobulin heavy diversity 1-7	Homo sapiens	196-199
23718885-0	2014	Relationship between preoperative serum TSH levels and expression of VEGF in papillary thyroid carcinoma.	Thyrotropin	40-43	vascular endothelial growth factor A	Homo sapiens	69-73
23718885-3	2014	Thyroid stimulating hormone (TSH) is the major thyroid hormone, but its relationship with VEGF has seldom been studied.	Thyrotropin	0-27	vascular endothelial growth factor A	Homo sapiens	90-94
23718885-3	2014	Thyroid stimulating hormone (TSH) is the major thyroid hormone, but its relationship with VEGF has seldom been studied.	Thyrotropin	29-32	vascular endothelial growth factor A	Homo sapiens	90-94
23718885-4	2014	Therefore, we explored whether the immunohistochemical expression of VEGF was related to the serum TSH level.	Thyrotropin	99-102	vascular endothelial growth factor A	Homo sapiens	69-73
23718885-8	2014	The serum TSH levels revealed a positive correlation with VEGF expression, R = 0.592 (P &lt; 0.01).	Thyrotropin	10-13	vascular endothelial growth factor A	Homo sapiens	58-62
24065308-9	2014	The TSH-stimulated effects were suppressed by an adenylyl cyclase inhibitor, a protein kinase A (PKA) inhibitor and HMGCR inhibitors (all p &lt; 0.05).	Thyrotropin	4-7	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	97-100
24065308-9	2014	The TSH-stimulated effects were suppressed by an adenylyl cyclase inhibitor, a protein kinase A (PKA) inhibitor and HMGCR inhibitors (all p &lt; 0.05).	Thyrotropin	4-7	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	116-121
24065308-10	2014	The data indicate functional TSHR is expressed in ventricular myocytes and mediates TSH-induced BNP secretion and HMGCR up-regulation through the cAMP/PKA/pCREB signaling pathway.	Thyrotropin	29-32	natriuretic peptide B	Rattus norvegicus	96-99
24065308-10	2014	The data indicate functional TSHR is expressed in ventricular myocytes and mediates TSH-induced BNP secretion and HMGCR up-regulation through the cAMP/PKA/pCREB signaling pathway.	Thyrotropin	29-32	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	114-119
25031888-14	2014	TPO-Ab titer was also a helpful prognostic factor for SHT in cases with mildly elevated TSH.	Thyrotropin	88-91	thyroid peroxidase	Homo sapiens	0-3
24065308-10	2014	The data indicate functional TSHR is expressed in ventricular myocytes and mediates TSH-induced BNP secretion and HMGCR up-regulation through the cAMP/PKA/pCREB signaling pathway.	Thyrotropin	29-32	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	151-154
24768234-7	2014	There was a significant positive correlation between TSH and low density lipoprotein cholesterol (LDLc) (P=0.001), even after adjustment for age, body mass index, waist to hip ratio, fasting plasma glucose, homeostatic model assessment-insulin resistance and free androgen index (P&lt;0.001).	Thyrotropin	53-56	component of oligomeric golgi complex 2	Homo sapiens	98-102
25114873-12	2014	CONCLUSIONS: We demonstrated an association between serum TSH levels and discrete alleles of the TRHR gene in totally thyroidectomized patients under LT4 therapy.	Thyrotropin	58-61	thyrotropin releasing hormone receptor	Homo sapiens	97-101
23832789-3	2014	This highly sensitive CL beta-gal assay was applied to an EIA for thyroid-stimulating hormone (TSH) using beta-gal as a label enzyme; 0.02-100.0 muU/mL TSH in human serum could be assayed directly and with high reproducibility.	Thyrotropin	95-98	citramalyl-CoA lyase	Homo sapiens	22-29
24661543-4	2014	Our second objective was to investigate whether TSH induces other cytokines besides IL-6.	Thyrotropin	48-51	interleukin 6	Homo sapiens	84-88
24661543-5	2014	METHODS: TSH stimulation of either CHO cells expressing human TSH receptor or human abdominal subcutaneous differentiated adipocytes.	Thyrotropin	9-12	thyroid stimulating hormone receptor	Homo sapiens	62-74
24661543-2	2014	Increases in lipolysis and in expression and release of interleukin-6 (IL-6) occur in TSH-stimulated adipocytes, and levels of circulating free fatty acids and IL-6 rise following TSH administration to patients with previous thyroidectomy and radioablation for thyroid cancer.	Thyrotropin	86-89	interleukin 6	Homo sapiens	56-69
24661543-2	2014	Increases in lipolysis and in expression and release of interleukin-6 (IL-6) occur in TSH-stimulated adipocytes, and levels of circulating free fatty acids and IL-6 rise following TSH administration to patients with previous thyroidectomy and radioablation for thyroid cancer.	Thyrotropin	86-89	interleukin 6	Homo sapiens	71-75
24661543-2	2014	Increases in lipolysis and in expression and release of interleukin-6 (IL-6) occur in TSH-stimulated adipocytes, and levels of circulating free fatty acids and IL-6 rise following TSH administration to patients with previous thyroidectomy and radioablation for thyroid cancer.	Thyrotropin	180-183	interleukin 6	Homo sapiens	160-164
24661543-3	2014	Our first objective was to compare how TSH stimulates protein kinase A (PKA) and inhibitor of kappaB (IkappaB) kinase (IKK)-beta.	Thyrotropin	39-42	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	91-128
24661543-7	2014	Phosphorylation of protein kinase C-delta, an upstream regulator of NADPH oxidase, was increased by TSH, and rottlerin (PKCdelta inhibitor) reduced TSH-stimulated IKKbeta phosphorylation.	Thyrotropin	100-103	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	163-170
24661543-7	2014	Phosphorylation of protein kinase C-delta, an upstream regulator of NADPH oxidase, was increased by TSH, and rottlerin (PKCdelta inhibitor) reduced TSH-stimulated IKKbeta phosphorylation.	Thyrotropin	148-151	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	163-170
24661543-9	2014	H89 (PKA inhibitor) and sc-514 (IKKbeta inhibitor) each blocked TSH-stimulated MCP-1 mRNA expression and protein release, suggesting PKA and IKKbeta participate in this pathway.	Thyrotropin	64-67	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	32-39
24661543-9	2014	H89 (PKA inhibitor) and sc-514 (IKKbeta inhibitor) each blocked TSH-stimulated MCP-1 mRNA expression and protein release, suggesting PKA and IKKbeta participate in this pathway.	Thyrotropin	64-67	C-C motif chemokine ligand 2	Homo sapiens	79-84
24661543-9	2014	H89 (PKA inhibitor) and sc-514 (IKKbeta inhibitor) each blocked TSH-stimulated MCP-1 mRNA expression and protein release, suggesting PKA and IKKbeta participate in this pathway.	Thyrotropin	64-67	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	141-148
24808925-2	2014	Elevated serum TSH levels in euthyroid subjects were recently reported to correlate with high values of serum proprotein convertase subtilisin/kexin type 9 (PCSK9).	Thyrotropin	15-18	proprotein convertase subtilisin/kexin type 9	Homo sapiens	110-155
24866829-11	2014	The possibility that lipid rafts are strongly perturbed by hypergravity-induced CHO depletion by influencing TSH-TSHR interaction was discussed.	Thyrotropin	109-112	thyroid stimulating hormone receptor	Mus musculus	113-117
24550004-6	2014	Remarkably, NCoR(DeltaID/DeltaID) Src-1(-/-) mice have normal TH and TSH levels and are triiodothryonine (T(3)) sensitive at the level of the pituitary.	Thyrotropin	69-72	nuclear receptor co-repressor 1	Mus musculus	12-16
24400871-6	2014	RESULTS: We previously reported that Akt inhibition increased radioiodine accumulation in thyroid cells under chronic TSH stimulation.	Thyrotropin	118-121	AKT serine/threonine kinase 1	Rattus norvegicus	37-40
24400871-7	2014	Here, we identified Apigenin, a plant-derived flavonoid, as a reagent to further enhance the iodide influx rate increased by Akt inhibition in thyroid cells under acute TSH stimulation.	Thyrotropin	169-172	AKT serine/threonine kinase 1	Rattus norvegicus	125-128
24808925-2	2014	Elevated serum TSH levels in euthyroid subjects were recently reported to correlate with high values of serum proprotein convertase subtilisin/kexin type 9 (PCSK9).	Thyrotropin	15-18	proprotein convertase subtilisin/kexin type 9	Homo sapiens	157-162
24808925-4	2014	We tested whether an acute increase of TSH levels following administration of TSH in vivo would raise PCSK9 levels in patients who had previously undergone total thyroidectomy and radioablation for thyroid cancer.	Thyrotropin	39-42	proprotein convertase subtilisin/kexin type 9	Homo sapiens	102-107
24808925-4	2014	We tested whether an acute increase of TSH levels following administration of TSH in vivo would raise PCSK9 levels in patients who had previously undergone total thyroidectomy and radioablation for thyroid cancer.	Thyrotropin	78-81	proprotein convertase subtilisin/kexin type 9	Homo sapiens	102-107
24808925-7	2014	CONCLUSIONS: Although a positive correlation between TSH and PCSK9 in euthyroid subjects has raised the possibility that TSH might act on the liver to raise PCSK9 values, our data show that PCSK9 levels are not affected by acute elevations of TSH levels.	Thyrotropin	53-56	proprotein convertase subtilisin/kexin type 9	Homo sapiens	61-66
24446657-5	2014	When activated by TSH, they produce IL-6, IL-8, and TNF-alpha.	Thyrotropin	18-21	C-X-C motif chemokine ligand 8	Homo sapiens	42-46
24446657-5	2014	When activated by TSH, they produce IL-6, IL-8, and TNF-alpha.	Thyrotropin	18-21	tumor necrosis factor	Homo sapiens	52-61
24446657-5	2014	When activated by TSH, they produce IL-6, IL-8, and TNF-alpha.	Thyrotropin	18-21	interleukin 6	Homo sapiens	36-40
24446657-11	2014	RESULTS: TSH induces the expression of IL-1RA in fibrocytes and GD-OFs.	Thyrotropin	9-12	interleukin 1 receptor antagonist	Homo sapiens	39-45
24444496-8	2014	We also provide evidence indicating that TSH treatment promotes tumor necrosis factor alpha-induced endothelial cells interactions by upregulating the expression of the adhesion molecules intercellular adhesion molecule-1.	Thyrotropin	41-44	tumor necrosis factor	Homo sapiens	64-91
24338236-5	2014	We analyzed serum TSH-stimulated thyroglobulin (Tg) and RAI uptake at the time of RAI remnant ablation to compare surgical completeness in the two groups.	Thyrotropin	18-21	thyroglobulin	Homo sapiens	33-46
24338236-8	2014	In subgroup analysis of the robotic group by the period in which operations took place, TSH-stimulated Tg was significantly higher than in the open group in the first (13.28 +- 11.91 ng/ml) and second (10.45 +- 9.30 ng/ml) periods, but there was no significant difference in the third period (6.00 +- 6.26 ng/ml, P = 0.141).	Thyrotropin	88-91	thyroglobulin	Homo sapiens	103-105
24338236-9	2014	The RAI uptake rate at the first RAI ablation did not differ between the two groups, and TSH-stimulated Tg after RAI ablation was similar.	Thyrotropin	89-92	thyroglobulin	Homo sapiens	104-106
24444496-8	2014	We also provide evidence indicating that TSH treatment promotes tumor necrosis factor alpha-induced endothelial cells interactions by upregulating the expression of the adhesion molecules intercellular adhesion molecule-1.	Thyrotropin	41-44	intercellular adhesion molecule 1	Homo sapiens	188-221
24444496-9	2014	Furthermore, the expression of endothelial nitric oxide synthase (eNOS) and prostacyclin (PGI2) was significantly attenuated following treatment with TSH in dose- and time-dependent manner.	Thyrotropin	150-153	nitric oxide synthase 3	Homo sapiens	31-64
24444496-10	2014	Conversely, the results indicated that TSH upregulated endothelin-1 (ET1) mRNA and protein expression in HUVECs, similar effects were observed for plasminogen activator inhibitor-1 (PAI1) after treatment with various concentrations of TSH.	Thyrotropin	39-42	endothelin 1	Homo sapiens	55-67
24444496-10	2014	Conversely, the results indicated that TSH upregulated endothelin-1 (ET1) mRNA and protein expression in HUVECs, similar effects were observed for plasminogen activator inhibitor-1 (PAI1) after treatment with various concentrations of TSH.	Thyrotropin	39-42	endothelin 1	Homo sapiens	69-72
24444496-10	2014	Conversely, the results indicated that TSH upregulated endothelin-1 (ET1) mRNA and protein expression in HUVECs, similar effects were observed for plasminogen activator inhibitor-1 (PAI1) after treatment with various concentrations of TSH.	Thyrotropin	235-238	endothelin 1	Homo sapiens	55-67
24444496-10	2014	Conversely, the results indicated that TSH upregulated endothelin-1 (ET1) mRNA and protein expression in HUVECs, similar effects were observed for plasminogen activator inhibitor-1 (PAI1) after treatment with various concentrations of TSH.	Thyrotropin	235-238	serpin family E member 1	Homo sapiens	147-180
24479877-1	2014	Thyroglobulin (Tg), stored in the follicular lumen, has also been shown recently to perform two unexpected roles: as an autocrine negative-feedback suppressor of thyroid function in the presence of TSH and as a potent inducer of thyroid cell growth in the absence of TSH.	Thyrotropin	198-201	thyroglobulin	Rattus norvegicus	0-13
24423294-5	2014	PATIENTS AND METHODS: We quantified GNAS methylation alterations by both PCR-pyrosequencing and methylation specific-multiplex ligation-dependent probe amplification assay in genomic DNA from 63 patients with PHP-I and correlated these findings with clinical parameters (age at diagnosis; calcium, phosphorus, PTH, TSH levels; presence or absence of each AHO sign).	Thyrotropin	315-318	GNAS complex locus	Homo sapiens	36-40
24423310-10	2014	Moreover, the present data suggested that, together with goiter and PIOD, the most significant features to select patients for the DUOX2 analysis are the low free T4 and the high TSH concentrations at the first postnatal serum sampling, despite borderline blood spot TSH.	Thyrotropin	179-182	dual oxidase 2	Homo sapiens	131-136
24479877-1	2014	Thyroglobulin (Tg), stored in the follicular lumen, has also been shown recently to perform two unexpected roles: as an autocrine negative-feedback suppressor of thyroid function in the presence of TSH and as a potent inducer of thyroid cell growth in the absence of TSH.	Thyrotropin	198-201	thyroglobulin	Rattus norvegicus	15-17
24479877-1	2014	Thyroglobulin (Tg), stored in the follicular lumen, has also been shown recently to perform two unexpected roles: as an autocrine negative-feedback suppressor of thyroid function in the presence of TSH and as a potent inducer of thyroid cell growth in the absence of TSH.	Thyrotropin	267-270	thyroglobulin	Rattus norvegicus	0-13
24479877-1	2014	Thyroglobulin (Tg), stored in the follicular lumen, has also been shown recently to perform two unexpected roles: as an autocrine negative-feedback suppressor of thyroid function in the presence of TSH and as a potent inducer of thyroid cell growth in the absence of TSH.	Thyrotropin	267-270	thyroglobulin	Rattus norvegicus	15-17
24479877-6	2014	The expression of miR-16 and miR-195 target genes, Mapk8, Ccne1, and Cdc6, which were previously shown to be essential for TSH-stimulated thyroid cell growth, were also induced by Tg.	Thyrotropin	123-126	microRNA 16	Rattus norvegicus	18-24
24479877-6	2014	The expression of miR-16 and miR-195 target genes, Mapk8, Ccne1, and Cdc6, which were previously shown to be essential for TSH-stimulated thyroid cell growth, were also induced by Tg.	Thyrotropin	123-126	microRNA 195	Rattus norvegicus	29-36
24479877-6	2014	The expression of miR-16 and miR-195 target genes, Mapk8, Ccne1, and Cdc6, which were previously shown to be essential for TSH-stimulated thyroid cell growth, were also induced by Tg.	Thyrotropin	123-126	mitogen-activated protein kinase 8	Rattus norvegicus	51-56
24479877-6	2014	The expression of miR-16 and miR-195 target genes, Mapk8, Ccne1, and Cdc6, which were previously shown to be essential for TSH-stimulated thyroid cell growth, were also induced by Tg.	Thyrotropin	123-126	cyclin E1	Rattus norvegicus	58-63
24479877-6	2014	The expression of miR-16 and miR-195 target genes, Mapk8, Ccne1, and Cdc6, which were previously shown to be essential for TSH-stimulated thyroid cell growth, were also induced by Tg.	Thyrotropin	123-126	cell division cycle 6	Rattus norvegicus	69-73
24479877-6	2014	The expression of miR-16 and miR-195 target genes, Mapk8, Ccne1, and Cdc6, which were previously shown to be essential for TSH-stimulated thyroid cell growth, were also induced by Tg.	Thyrotropin	123-126	thyroglobulin	Rattus norvegicus	180-182
24498374-6	2014	The activation of TRH hypophysiotropic neurons by the thermode cooling of POA was indirectly assessed, in conditions in which thermoregulation was either fully operant (wakefulness) or not operant (REMS), by a radioimmunoassay determination of plasmatic levels of TSH.	Thyrotropin	264-267	thyrotropin releasing hormone	Rattus norvegicus	18-21
24701476-10	2014	Correlation study revealed a significant positive correlation between Lp(a) and TSH levels in hypothyroid patients.	Thyrotropin	80-83	lipoprotein(a)	Homo sapiens	70-75
23677510-11	2014	The carriers of CYP4F2 A1347A genotype required higher daily warfarin doses during initiation of warfarin therapy after heart valve surgery than comparing to G/G and G/A carriers, but during the longer periods of warfarin use, the dosage of warfarin depended significantly on VKORC1 *3 allele (G3730A polymorphism) and on the thyroid stimulating hormone level in the blood plasma.	Thyrotropin	326-353	cytochrome P450 family 4 subfamily F member 2	Homo sapiens	16-22
24497218-3	2014	AIM: The aim of this study was to evaluate frequency and effects on serum TSH of PDE8B gene polymorphisms in patients with sporadic NSH and verify if differences in serum TSH levels are associated to these polymorphic variants.	Thyrotropin	74-77	phosphodiesterase 8B	Homo sapiens	81-86
24497218-8	2014	CONCLUSIONS: A prevalence of the minor allele of PDE8B gene polymorphism associated with elevated serum levels of TSH was demonstrated in patients affected by sporadic NSH; however, significant differences in circulating TSH in patients with minor or major alleles for each polymorphism were not identified demonstrating the lack of association between the polymorphisms and serum TSH levels in these patients.	Thyrotropin	114-117	phosphodiesterase 8B	Homo sapiens	49-54
24497218-8	2014	CONCLUSIONS: A prevalence of the minor allele of PDE8B gene polymorphism associated with elevated serum levels of TSH was demonstrated in patients affected by sporadic NSH; however, significant differences in circulating TSH in patients with minor or major alleles for each polymorphism were not identified demonstrating the lack of association between the polymorphisms and serum TSH levels in these patients.	Thyrotropin	221-224	phosphodiesterase 8B	Homo sapiens	49-54
24497218-8	2014	CONCLUSIONS: A prevalence of the minor allele of PDE8B gene polymorphism associated with elevated serum levels of TSH was demonstrated in patients affected by sporadic NSH; however, significant differences in circulating TSH in patients with minor or major alleles for each polymorphism were not identified demonstrating the lack of association between the polymorphisms and serum TSH levels in these patients.	Thyrotropin	221-224	phosphodiesterase 8B	Homo sapiens	49-54
25214835-6	2014	Serum TSH was significantly positively correlated with waist circumference (beta = 1.512, P = 0.019), TC (beta = 0.160, P = 0.003), LDL-C (beta = 0.032, P = 0.008), and TG (beta = 0.095, P = 0.001).	Thyrotropin	6-9	component of oligomeric golgi complex 2	Homo sapiens	132-137
25214835-8	2014	Serum TSH within the reference range was positively associated with TC (beta = 0.173, P = 0.013), LDL-C (beta = 0.031, P = 0.043), and TG (beta = 0.132, P = 0.021).	Thyrotropin	6-9	component of oligomeric golgi complex 2	Homo sapiens	98-103
24840811-12	2014	RESULTS: TSH induces IL-1RA in fibrocytes and GD-OFs by activating the PI3K/AKT pathway.	Thyrotropin	9-12	interleukin 1 receptor antagonist	Homo sapiens	21-27
24840811-12	2014	RESULTS: TSH induces IL-1RA in fibrocytes and GD-OFs by activating the PI3K/AKT pathway.	Thyrotropin	9-12	AKT serine/threonine kinase 1	Homo sapiens	76-79
23982142-0	2013	IGF-1 receptor deficiency in thyrocytes impairs thyroid hormone secretion and completely inhibits TSH-stimulated goiter.	Thyrotropin	98-101	insulin-like growth factor 1	Mus musculus	0-5
24724428-7	2014	Loss-of-function mutations in the TSHR gene occur as TSH resistance, which is found to have euthyroid hyperthyrotropinemia or hypothyroidism because of the reduced responsiveness of the receptor to TSH.	Thyrotropin	53-56	thyroid stimulating hormone receptor	Homo sapiens	34-38
23969277-4	2013	NIS mRNA levels remained repressed in TSH-stimulated primary thyroid cells co-treated with epidermal growth factor (EGF) and pan-MEK inhibitor U0126 in the presence of 5% fetal bovine serum or, independently of serum, in 3D cultured thyroid follicles.	Thyrotropin	38-41	mitogen-activated protein kinase kinase 7	Homo sapiens	129-132
23886630-9	2013	Overexpression of S100A4 led to a reduced activation of NFAT by TSH.	Thyrotropin	64-67	S100 calcium binding protein A4	Homo sapiens	18-24
23982142-7	2013	These data reveal an essential role for IGF-1 receptor signaling in the regulation of thyroid function and TSH-stimulated goitrogenesis.	Thyrotropin	107-110	insulin-like growth factor 1	Mus musculus	40-45
24037891-2	2013	OBJECTIVES: Our objectives were to determine whether stimulated Tg levels, measured at the time of remnant ablation performed under recombinant human TSH (rhTSH) stimulation, has value in predicting absence of detectable disease 1 year after radioiodine therapy and to compare the results obtained with this approach with a cohort of patients submitted to ablation after THW.	Thyrotropin	150-153	thyroglobulin	Homo sapiens	64-66
24404516-8	2013	TSH level was associated with total cholesterol (P=0.05), fasting insulin (P=0.01), HOMA-IR (P=0.01), and UACR (P=0.005).	Thyrotropin	0-3	insulin	Homo sapiens	66-73
23633638-0	2013	Retinol-binding protein 4 is elevated and is associated with free testosterone and TSH in postmenopausal women.	Thyrotropin	83-86	retinol binding protein 4	Homo sapiens	0-25
23957782-7	2013	Moreover, among IR PCOS patients, 6 months treatment with insulin sensitizers significantly reduces TSH levels.	Thyrotropin	100-103	insulin	Homo sapiens	58-65
23633638-4	2013	RBP4 levels were negatively associated with free testosterone and positively associated with thyroid stimulating hormone in postmenopausal women.	Thyrotropin	93-120	retinol binding protein 4	Homo sapiens	0-4
23563316-7	2013	RESULTS: Transfection with pSVL-TSHR vector induced basal cAMP and IP production in the absence of TSH stimulation, indicating a constitutive activity for the TSHR.	Thyrotropin	32-35	thyroid stimulating hormone receptor	Homo sapiens	159-163
24167152-4	2013	Compared with the control group, administration of PCB 95 induced a reduction (P&lt;0.01) in serum concentrations of thyroxine, triiodothyronine, and GH and an increase (P&lt;0.01) in the serum concentration of TSH at PNDs 17 and 18.	Thyrotropin	211-214	pyruvate carboxylase	Rattus norvegicus	51-54
23453962-5	2013	DAergic activity encoding the light information is transmitted to the pars tuberalis, where thyroid-stimulating hormone, beta (TSHbeta) cells reside, and induces the release of TSH.	Thyrotropin	127-130	LOW QUALITY PROTEIN: thyrotropin subunit beta	Meleagris gallopavo	92-125
24079074-4	2013	TRbeta gene mutations cause resistance to thyroid hormones (RTH), characterized by inappropriately high thyroid-stimulating hormone (TSH) levels due to lack of feedback inhibition of thyroid hormones on the hypothalamus and pituitary gland, and to reduced sensitivity of other TRbeta target tissues to thyroid hormones.	Thyrotropin	133-136	T cell receptor beta locus	Homo sapiens	0-6
24808970-13	2014	Increased anti-TPO with raised TSH without any lymphoid infiltrate was seen in 5 cases and 5 cases showed only raised TSH without raised anti-TPO and without any lymphoid infiltrate.	Thyrotropin	31-34	thyroid peroxidase	Homo sapiens	15-18
23864495-9	2013	RESULTS: TNF-alpha secretion from adipocytes peaked 4 h after TSH treatment.	Thyrotropin	62-65	tumor necrosis factor	Bos taurus	9-18
23864495-13	2013	Bovine TSH and forskolin, which increases intracellular cAMP, simultaneously stimulated TNF-alpha secretion.	Thyrotropin	7-10	tumor necrosis factor	Bos taurus	88-97
23864495-14	2013	The IkappaBalpha/PKAc complex could be detected in TSH-treated cells, but complex formation was inhibited by H89.	Thyrotropin	51-54	NFKB inhibitor alpha	Bos taurus	4-16
23528896-2	2013	THRB mutations cause a disorder with central (hypothalamic-pituitary) resistance to thyroid hormone action with markedly elevated thyroid hormone and normal TSH levels.	Thyrotropin	157-160	thyroid hormone receptor beta	Homo sapiens	0-4
23190420-8	2013	RESULTS: In the fully adjusted model, percent change in Tg was significantly increased among females, smokers and subjects of older age and Tg increased with decreasing urinary iodine concentration, increasing serum TSH and increasing thyroid volume (P-values for trend &lt;0 0001), and presence of thyroid nodules (P &lt; 0 05).	Thyrotropin	216-219	thyroglobulin	Homo sapiens	56-58
23190420-8	2013	RESULTS: In the fully adjusted model, percent change in Tg was significantly increased among females, smokers and subjects of older age and Tg increased with decreasing urinary iodine concentration, increasing serum TSH and increasing thyroid volume (P-values for trend &lt;0 0001), and presence of thyroid nodules (P &lt; 0 05).	Thyrotropin	216-219	thyroglobulin	Homo sapiens	140-142
23941020-2	2013	The syndrome has been previously reported in rare instances of increased production of human chorionic gonadotrophin (hCG) such as multiple pregnancies, hydatiforme mole, polycystic ovary disease and elevated concentrations of thyroid-stimulating hormone (TSH) in hypothyreoidism.	Thyrotropin	256-259	hypertrichosis 2 (generalised, congenital)	Homo sapiens	118-121
23716650-0	2013	Genetic confirmation for a central role for TNFalpha in the direct action of thyroid stimulating hormone on the skeleton.	Thyrotropin	77-104	tumor necrosis factor	Mus musculus	44-52
23716650-4	2013	Studies using ex vivo bone marrow cell cultures showed that TSH inhibits and stimulates TNFalpha production from macrophages and osteoblasts, respectively.	Thyrotropin	60-63	tumor necrosis factor	Mus musculus	88-96
23833755-8	2013	RESULTS: TNM stages of PTCs correlated with higher preoperative TSH serum concentrations.	Thyrotropin	64-67	teneurin transmembrane protein 1	Homo sapiens	9-12
23833755-11	2013	CONCLUSION: In patients who have PTCs without clinical, immunological, or ultrasonographic evidence of thyroiditis, higher preoperative TSH serum concentrations within the normal range might suggest advanced TNM stages.	Thyrotropin	136-139	teneurin transmembrane protein 1	Homo sapiens	208-211
23672306-10	2013	In contrast, thyroid stimulating hormone, fT3 and fT4 levels (thyroid hormones) either trended towards a correlation, or were significantly correlated with serum hCG levels in the two groups.	Thyrotropin	13-40	hypertrichosis 2 (generalised, congenital)	Homo sapiens	162-165
23591524-3	2013	In this paper, we demonstrate that the stable expression of Smad4 C324Y mutation in FRTL-5 cells is responsible for TSH-independent growth ability.	Thyrotropin	116-119	SMAD family member 4	Rattus norvegicus	60-65
24396665-5	2013	However, treatment with TSH had little effect on the differentiation of muscle cells, although the expression of the muscle differention marker myogenin was significantly increased after TSH treatment.	Thyrotropin	187-190	myogenin	Mus musculus	144-152
22998776-0	2013	Thyroid stimulating hormone increases iodine uptake by thyroid cancer cells during BRAF silencing.	Thyrotropin	0-27	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	83-87
22998776-2	2013	We sought to evaluate the combined effect of BRAF inhibition and TSH supplementation on (131)I uptake of BRAF(V600E)-mutant human thyroid cancer cells.	Thyrotropin	65-68	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	105-110
23571008-13	2013	In addition, the reduced TSH concentrations in insulin-insensitive mares are consistent with our previous observation of elevated plasma triiodothyronine concentrations in hyperleptinemic horses (later shown to be insulin insensitive as well).	Thyrotropin	25-28	INS	Equus caballus	47-54
23511952-0	2013	Thyroid-specific inactivation of KIF3A alters the TSH signaling pathway and leads to hypothyroidism.	Thyrotropin	50-53	kinesin family member 3A	Mus musculus	33-38
23511952-3	2013	Our results indicate first that 3-week-old Pax8(Cre/)(+) mice used in these experiments present minor thyroid functional defects resulting in a slight increase in circulating bioactive TSH and intracellular cAMP levels, sufficient to maintain blood thyroxine levels in the normal range.	Thyrotropin	185-188	paired box 8	Mus musculus	43-47
23511952-5	2013	Finally, our results in mouse embryonic fibroblasts indicate that Kif3a inactivation in the absence of any Pax8 gene alteration leads to altered G protein-coupled receptor plasma membrane expression, as shown for the beta2 adrenergic receptor, and we suggest that a similar mechanism may explain the altered TSH signaling and mild hypothyroidism detected in Kif3a(Delta)(/flox) Pax8(Cre/)(+) mutant mice.	Thyrotropin	308-311	kinesin family member 3A	Mus musculus	66-71
23242661-7	2013	In addition, the decline of TSH levels was more prominent in ICAM1 469 E carrying subjects (KE + EE) in comparison with wild homozygotes (p &lt; 0.05).	Thyrotropin	28-31	intercellular adhesion molecule 1	Homo sapiens	61-66
23143351-5	2013	The GUCHD patients with serum TSH exceeding 5.6 mIU/L had a significantly higher level of serum NT-pro-BNP (195.1 [0.28; 5,280.3] vs 57.6 [0.00; 929.8]; p = 0.001) and CRP (0.30 [0.06; 1.87] vs 0.16 [0.00; 1.40]; p = 0.011] than those with a TSH level of 5.6 mIU/L or lower.	Thyrotropin	30-33	C-reactive protein	Homo sapiens	168-171
23255496-5	2013	In contrast to the in vitro data, fasted PPARalpha knockout mice revealed lower mRNA concentrations of pituitary TSHbeta (-64%) and TSH-regulated thyroid genes, and lower plasma concentrations of thyroxine (T4, -25%), triiodothyronine (T3, -25%), free T4 (-60%), and free T3 (-35%) than fasted WT mice (p &lt; 0.05).	Thyrotropin	113-116	peroxisome proliferator activated receptor alpha	Mus musculus	41-50
23325787-8	2013	Moreover, our results reveal that, in a secretory thyroid cell line (FRTL5), Rab1b expression increases in response to thyroid-stimulating hormone (TSH).	Thyrotropin	119-146	RAB1B, member RAS oncogene family	Homo sapiens	77-82
23616929-6	2013	In order to determine the relationship of low IGF-1 with that of LH, FSH, and TSH levels in subjects with CMD, we evaluated these levels (+- SD) in 944 patients.	Thyrotropin	78-81	insulin like growth factor 1	Homo sapiens	46-51
23325787-8	2013	Moreover, our results reveal that, in a secretory thyroid cell line (FRTL5), Rab1b expression increases in response to thyroid-stimulating hormone (TSH).	Thyrotropin	148-151	RAB1B, member RAS oncogene family	Homo sapiens	77-82
23456581-11	2013	The positivity in both anti-TPO and anti-Tg antibodies was correlated with abnormally high TSH concentrations after the age of 50 years, especially in female population.	Thyrotropin	91-94	thyroid peroxidase	Homo sapiens	28-31
23332130-6	2013	The second one had a neonatal persistent moderate TSH levels increase associated with a thyroid gland hypoplasia and was treated with L-T4 since the first months of life.These two cases support the recent association of TSH-R mutations inheritance as an autosomal dominant pattern with variable expressivity and suggest that the decision to start replacement therapy in patients with persistent SH due to TSH resistance should be individualized.	Thyrotropin	50-53	thyroid stimulating hormone receptor	Homo sapiens	220-225
22986485-8	2013	In all 36 patients, the reduction in the ApoB-48 levels correlated significantly with the reduction in TSH levels (r = 0.39, P&lt;0.05).	Thyrotropin	103-106	apolipoprotein B	Homo sapiens	41-48
24683474-12	2013	LEARNING POINTS: High TSH levels, as described in RTH syndrome, are known to be associated with an increased risk of developing thyroid nodules, with subsequent growth and malignancy.The exact role of TR beta mutants in thyroid carcinogenesis is still undefined.We report the first case of multiple Hurthle cell adenomas associated with RTH.	Thyrotropin	22-25	T cell receptor beta locus	Homo sapiens	201-208
23076042-5	2012	In both PHP 1a and PHP 1b, paternal imprinting of Galpha(s) leads to resistance to parathyroid hormone and TSH.	Thyrotropin	107-110	succinate-CoA ligase GDP/ADP-forming subunit alpha	Homo sapiens	50-56
23759753-11	2013	Multivariate analysis revealed a significant positive linear relationship between serum TSH concentrations and plasma FGF21 concentrations (beta = 0.192, p = 0.002) and a significant negative linear relationship between free T4 and plasma FGF21 concentrations (beta = -0.382, p = 0.037) after adjusting for gender, BMI and serum concentrations of triglycerides and glucose.	Thyrotropin	88-91	fibroblast growth factor 21	Homo sapiens	118-123
23922049-6	2013	RESULTS: Patients who recurred within ten years after remission exhibited significantly higher thyroid stimulating hormone (TSH) responses to TRH at the time of admission compared to those who did not recur.	Thyrotropin	95-122	thyrotropin releasing hormone	Homo sapiens	142-145
23922049-6	2013	RESULTS: Patients who recurred within ten years after remission exhibited significantly higher thyroid stimulating hormone (TSH) responses to TRH at the time of admission compared to those who did not recur.	Thyrotropin	124-127	thyrotropin releasing hormone	Homo sapiens	142-145
23437160-10	2013	Osteopontin is positively correlated with T3 and T4 (r = 0.62 and r = 0.75 respectively) while it is negatively correlated with thyroid stimulating hormone (r = -0.52) showing a significant correlation (p-value &lt;0.001).	Thyrotropin	128-155	secreted phosphoprotein 1	Homo sapiens	0-11
23237535-4	2012	Single nucleotide polymorphism (SNP) rs 4704397 in the PDE8B gene has been shown to be associated with variations in serum Thyroid Stimulating Hormone (TSH) and thyroxine (T4) levels.	Thyrotropin	123-150	phosphodiesterase 8B	Homo sapiens	55-60
23237535-4	2012	Single nucleotide polymorphism (SNP) rs 4704397 in the PDE8B gene has been shown to be associated with variations in serum Thyroid Stimulating Hormone (TSH) and thyroxine (T4) levels.	Thyrotropin	152-155	phosphodiesterase 8B	Homo sapiens	55-60
24575288-13	2013	Leptin level has more relationship with thyroxin than thyroid- stimulating hormone.	Thyrotropin	54-82	leptin	Homo sapiens	0-6
23024261-8	2012	Indeed, when challenged with TSH, the thyroids of MCH1R-KO mice secrete lower amounts of T(4).	Thyrotropin	29-32	melanin-concentrating hormone receptor 1	Mus musculus	50-55
23043630-5	2012	RESULTS: Treatment with CCl4 significantly (P&lt;0.01) reduced the levels of T3 and T4 and increased TSH levels.	Thyrotropin	101-104	C-C motif chemokine ligand 4	Rattus norvegicus	24-28
23469650-8	2012	All patients with abnormal TSH had significant higher levels of TG-Ab, TPO-Ab and TSI (in cases with hyperthyroidism only) than the patients with normal levels of TSH (p &lt; 0.001), the levels of TPO-Ab only of the most patients with abnormal TSH were above the normal reference range before the start of interferon therapy.	Thyrotropin	27-30	thyroid peroxidase	Homo sapiens	71-74
23469650-8	2012	All patients with abnormal TSH had significant higher levels of TG-Ab, TPO-Ab and TSI (in cases with hyperthyroidism only) than the patients with normal levels of TSH (p &lt; 0.001), the levels of TPO-Ab only of the most patients with abnormal TSH were above the normal reference range before the start of interferon therapy.	Thyrotropin	27-30	thyroid peroxidase	Homo sapiens	197-200
23008514-2	2012	In search for novel candidate genes implicated in thyroid function, we performed a gene expression analysis on thyroid cells revealing that TSH regulates the expression of several elements of the Notch pathway, including the ligand Jagged1.	Thyrotropin	140-143	jagged canonical Notch ligand 1a	Danio rerio	232-239
23064013-4	2012	We found a dose-dependent enhancement of TSH-induced TPO expression in response to LPS stimulation.	Thyrotropin	41-44	thyroid peroxidase	Homo sapiens	53-56
23786024-6	2012	The results of Alba application showed that in patients with thyroid pathology (diffuse nontoxic goiter, hyperthyroidism and chronic thyroiditis) it was possible to reduce the volume of thyroid, normalize its function, and decrease the level of AB-r TSH in diffuse toxic goiter.	Thyrotropin	250-253	afamin	Homo sapiens	15-19
23786024-6	2012	The results of Alba application showed that in patients with thyroid pathology (diffuse nontoxic goiter, hyperthyroidism and chronic thyroiditis) it was possible to reduce the volume of thyroid, normalize its function, and decrease the level of AB-r TSH in diffuse toxic goiter.	Thyrotropin	250-253	ABR activator of RhoGEF and GTPase	Homo sapiens	245-249
23002040-3	2012	Mutation to Ala of E409 at the junction with the transmembrane domain was the most potent in uncoupling TSH binding and signal transduction (~22-fold less sensitive than the wild-type TSHR) and was unique among the residues studied in reducing both the amplitude and the sensitivity of the ligand-induced signal.	Thyrotropin	104-107	thyroid stimulating hormone receptor	Homo sapiens	184-188
22878400-4	2012	It has been established to play a major role in the control of TSH secretion, because mice that express a mutant NCoR1 allele (NCoRDeltaID) that cannot interact with the TR have normal TSH levels despite low circulating TH levels.	Thyrotropin	63-66	nuclear receptor co-repressor 1	Mus musculus	113-118
22878400-11	2012	Furthermore, these studies suggest that endogenous NCoR1 levels in the pituitary could establish the set point of TSH secretion.	Thyrotropin	114-117	nuclear receptor co-repressor 1	Mus musculus	51-56
22780573-1	2012	BACKGROUND: Measurement of the serum thyroglobulin (Tg) level with TSH stimulation (sTg) is the cornerstone of monitoring for the recurrence or persistence of differentiated thyroid cancer (DTC) in patients who have undergone surgery and remnant ablation.	Thyrotropin	67-70	thyroglobulin	Homo sapiens	37-50
22730012-0	2012	PKC activation is required for TSH-mediated lipolysis via perilipin activation.	Thyrotropin	31-34	protein kinase C alpha	Homo sapiens	0-3
22730012-0	2012	PKC activation is required for TSH-mediated lipolysis via perilipin activation.	Thyrotropin	31-34	perilipin 1	Homo sapiens	58-67
22730012-2	2012	TSH activates PKC in thyrocytes.	Thyrotropin	0-3	protein kinase C alpha	Homo sapiens	14-17
22730012-9	2012	This cPKC stimulation in human adipocytes by TSH was reduced significantly by 40% or 48% in the presence of PKC inhibitor Go6983 or Go6976, respectively.	Thyrotropin	45-48	protein kinase C alpha	Homo sapiens	6-9
22730012-10	2012	Go6976 inhibited TSH-stimulated human adipocyte perilipin phosphorylation and NEFA release by 80% and 50%, respectively.	Thyrotropin	17-20	perilipin 1	Homo sapiens	48-57
22730012-12	2012	Based on the effects of cPKC inhibition, cPKC activation is required for TSH-stimulated perilipin phosphorylation and lipolysis in human differentiated adipocytes.	Thyrotropin	73-76	perilipin 1	Homo sapiens	88-97
22953992-7	2012	RESULTS: AMPK activation by AICAR induced a significant increase in glucose uptake by PCCL3 cells, an effect that was completely reversed by the AMPK inhibitor compound C. Also, the AICAR mediated increase in glucose uptake was detected either in the presence or absence of TSH.	Thyrotropin	274-277	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	9-13
22673962-7	2012	Though there were some inconsistencies in the regulation of stimulatory IGF binding protein-3 and -5 by TSH treatment, there was an overall increase at the mRNA abundance and protein levels.	Thyrotropin	104-107	insulin like growth factor binding protein 3	Homo sapiens	72-100
22673962-8	2012	Again, the inconsistency persisted at the regulation of the inhibitory IGFBPs 2, 4, and 6 especially at the level of mRNA expression due to TSH treatment, there is an overall decrease in the levels of IGFBP-2, 4, and 6 in the conditioned media (CM) of SaOS2 cell cultures.	Thyrotropin	140-143	insulin like growth factor binding protein 2	Homo sapiens	201-208
22673962-11	2012	TSH treatment significantly unregulated the expression of PAPP-A both at mRNA and protein levels.	Thyrotropin	0-3	pappalysin 1	Homo sapiens	58-64
22919057-3	2012	Similar to RTH patients with mutations of two alleles of the THRB gene, the Thrb(PV/PV) mouse exhibits elevated thyroid hormones accompanied by highly nonsuppressible TSH.	Thyrotropin	167-170	thyroid hormone receptor beta	Homo sapiens	76-80
22919057-11	2012	Therefore, mutation of a single allele of the Thrb gene is sufficient to drive the TSH-simulated hyperplastic thyroid follicular cells to undergo carcinogenesis.	Thyrotropin	83-86	thyroid hormone receptor beta	Mus musculus	46-50
22562051-12	2012	FT4 was positively associated with lactate dehydrogenase, r=0.45, p=0.020, and insulin was positively associated with thyroid-stimulating hormone with r=0.57, p=0.009.	Thyrotropin	118-145	insulin	Homo sapiens	79-86
22931295-4	2012	RESULTS: PCB exposure was positively associated with diabetes and age and inversely associated with thyroid stimulating hormone and triiodothyronine-uptake.	Thyrotropin	100-127	pyruvate carboxylase	Homo sapiens	9-12
22780573-1	2012	BACKGROUND: Measurement of the serum thyroglobulin (Tg) level with TSH stimulation (sTg) is the cornerstone of monitoring for the recurrence or persistence of differentiated thyroid cancer (DTC) in patients who have undergone surgery and remnant ablation.	Thyrotropin	67-70	chromosome 6 open reading frame 15	Homo sapiens	84-87
22496359-1	2012	We previously demonstrated that long-term pretreatment of rat FRTL-5 thyroid cells with TSH or cAMP-generating reagents potentiated IGF-I-dependent DNA synthesis.	Thyrotropin	88-91	insulin-like growth factor 1	Rattus norvegicus	132-137
22638834-10	2012	At 30 days-old, Lep offspring showed lower TSH ( - 48%), T3 ( - 20%), and mGPDm ( - 42%).	Thyrotropin	43-46	leptin	Rattus norvegicus	16-19
22307573-11	2012	CONCLUSIONS: The -258G/x DIO2 polymorphism variant is associated with a decreased rate of acute TSH-stimulated FT(4) secretion with a normal T(3) release from the thyroid gland consistent with a shift in the reaction equilibrium toward the product.	Thyrotropin	96-99	iodothyronine deiodinase 2	Homo sapiens	25-29
22387984-2	2012	Very little is known about TSH-TSH-R interactions in teleost fish.	Thyrotropin	27-30	thyroid stimulating hormone receptor	Homo sapiens	31-36
22285302-4	2012	Anti-thyroid peroxidase antibodies (TPO-Abs) were associated with the three SCL-90-R global indices Global Severity Index (GSI), Positive Symptom Distress Index (PSDI), and Positive Symptom Total (PST) as well as with somatization and obsessive-compulsive symptoms after adjustment for age, gender, and thyroid function as assessed by TSH levels (all p&lt;0.05).	Thyrotropin	335-338	thyroid peroxidase	Homo sapiens	5-23
22285302-4	2012	Anti-thyroid peroxidase antibodies (TPO-Abs) were associated with the three SCL-90-R global indices Global Severity Index (GSI), Positive Symptom Distress Index (PSDI), and Positive Symptom Total (PST) as well as with somatization and obsessive-compulsive symptoms after adjustment for age, gender, and thyroid function as assessed by TSH levels (all p&lt;0.05).	Thyrotropin	335-338	thyroid peroxidase	Homo sapiens	36-39
21909131-5	2012	Thrb(PV/PV) mice exhibit highly elevated serum thyroid-stimulating hormone levels and increased TH.	Thyrotropin	47-74	thyroid hormone receptor beta	Mus musculus	0-4
22399514-11	2012	These cells produce high levels of several cytokines and chemokines including IL-8, regulated upon activation, normal T cell expressed and secreted, and monocyte chemoattractant protein-1 when treated with TSH or M22.	Thyrotropin	206-209	C-X-C motif chemokine ligand 8	Homo sapiens	78-82
22399514-11	2012	These cells produce high levels of several cytokines and chemokines including IL-8, regulated upon activation, normal T cell expressed and secreted, and monocyte chemoattractant protein-1 when treated with TSH or M22.	Thyrotropin	206-209	C-C motif chemokine ligand 2	Homo sapiens	153-187
22399514-12	2012	TSH induces IL-8 production at the pretranslational level.	Thyrotropin	0-3	C-X-C motif chemokine ligand 8	Homo sapiens	12-16
22419707-9	2012	Increased intracellular cAMP concentrations after TSH treatment indicated the TSHR to be functional.	Thyrotropin	50-53	thyroid stimulating hormone receptor	Homo sapiens	78-82
22419707-12	2012	TSH induced phosphorylation of protein kinase S6K1, whereas TSHR blocking antibodies inhibited the phosphorylation of the protein kinase S6K1.	Thyrotropin	0-3	ribosomal protein S6 kinase B1	Homo sapiens	46-50
22419707-14	2012	CONCLUSION: Our findings provide strong evidence for a direct effect of TSH on angiogenesis through its receptor, via cAMP-mammalian target of rapamycin signaling and indicate that this effect is VEGF dependent.	Thyrotropin	72-75	vascular endothelial growth factor A	Homo sapiens	196-200
21848645-14	2012	Our study suggests that serum TSH levels affect LDL-C production or clearance rather than the LDL-C oxidation processes.	Thyrotropin	30-33	component of oligomeric golgi complex 2	Homo sapiens	48-53
22445893-0	2012	Thyroglobulin (Tg) activates MAPK pathway to induce thyroid cell growth in the absence of TSH, insulin and serum.	Thyrotropin	90-93	thyroglobulin	Homo sapiens	15-17
22445893-0	2012	Thyroglobulin (Tg) activates MAPK pathway to induce thyroid cell growth in the absence of TSH, insulin and serum.	Thyrotropin	90-93	mitogen-activated protein kinase 3	Homo sapiens	29-33
22445893-2	2012	However, we recently reported that thyroglobulin (Tg), a major product of the thyroid, also induces the growth of thyroid cells cultured in 0.2% serum in the absence of TSH and insulin.	Thyrotropin	169-172	thyroglobulin	Homo sapiens	35-48
22445893-2	2012	However, we recently reported that thyroglobulin (Tg), a major product of the thyroid, also induces the growth of thyroid cells cultured in 0.2% serum in the absence of TSH and insulin.	Thyrotropin	169-172	thyroglobulin	Homo sapiens	50-52
22445893-6	2012	The present results, together with the previous report, suggest that Tg utilizes multiple signaling cascades to induce thyroid cell growth independent of TSH/cAMP stimulation.	Thyrotropin	154-157	thyroglobulin	Homo sapiens	69-71
21950769-9	2012	The independent predictors of survival were younger age, surgical dissection of neck lymph nodes (LNs) and low TSH-stimulated Tg level (&lt;400 mug/l) at the discovery of metastasis.	Thyrotropin	111-114	thyroglobulin	Homo sapiens	126-128
25436706-1	2012	UNLABELLED: Abstract Background: Thyroid-stimulating hormone receptor (TSHR) is one of the members of glycoprotein hormone receptor family; activation of TSHR by thyroid-stimulating hormone (TSH) regulates thyroid function, proliferation, and differentiation.	Thyrotropin	162-189	thyroid stimulating hormone receptor	Homo sapiens	33-69
25436706-1	2012	UNLABELLED: Abstract Background: Thyroid-stimulating hormone receptor (TSHR) is one of the members of glycoprotein hormone receptor family; activation of TSHR by thyroid-stimulating hormone (TSH) regulates thyroid function, proliferation, and differentiation.	Thyrotropin	162-189	thyroid stimulating hormone receptor	Homo sapiens	71-75
25436706-1	2012	UNLABELLED: Abstract Background: Thyroid-stimulating hormone receptor (TSHR) is one of the members of glycoprotein hormone receptor family; activation of TSHR by thyroid-stimulating hormone (TSH) regulates thyroid function, proliferation, and differentiation.	Thyrotropin	162-189	nuclear receptor subfamily 4 group A member 1	Homo sapiens	53-69
25436706-1	2012	UNLABELLED: Abstract Background: Thyroid-stimulating hormone receptor (TSHR) is one of the members of glycoprotein hormone receptor family; activation of TSHR by thyroid-stimulating hormone (TSH) regulates thyroid function, proliferation, and differentiation.	Thyrotropin	162-189	thyroid stimulating hormone receptor	Homo sapiens	154-158
25436706-1	2012	UNLABELLED: Abstract Background: Thyroid-stimulating hormone receptor (TSHR) is one of the members of glycoprotein hormone receptor family; activation of TSHR by thyroid-stimulating hormone (TSH) regulates thyroid function, proliferation, and differentiation.	Thyrotropin	71-74	thyroid stimulating hormone receptor	Homo sapiens	33-69
25436706-1	2012	UNLABELLED: Abstract Background: Thyroid-stimulating hormone receptor (TSHR) is one of the members of glycoprotein hormone receptor family; activation of TSHR by thyroid-stimulating hormone (TSH) regulates thyroid function, proliferation, and differentiation.	Thyrotropin	71-74	nuclear receptor subfamily 4 group A member 1	Homo sapiens	53-69
25436706-1	2012	UNLABELLED: Abstract Background: Thyroid-stimulating hormone receptor (TSHR) is one of the members of glycoprotein hormone receptor family; activation of TSHR by thyroid-stimulating hormone (TSH) regulates thyroid function, proliferation, and differentiation.	Thyrotropin	71-74	thyroid stimulating hormone receptor	Homo sapiens	154-158
21986920-7	2012	Both SBP-Z and DBP-Z increased linearly with TSH concentration in boys after adjusting BMI (P &lt; 0.05); however, a similar linear trend was not observed in girls.	Thyrotropin	45-48	D-box binding PAR bZIP transcription factor	Homo sapiens	15-18
22127294-7	2012	Secretion of the active cathepsin C from FRTL-5 cells is stimulated by TSH, insulin, and/or somatostatin.	Thyrotropin	71-74	cathepsin C	Rattus norvegicus	24-35
21687973-4	2012	PACAP treatment increased ACTH, corticosterone, LH and FSH blood concentrations, while it decreased TSH levels.	Thyrotropin	100-103	adenylate cyclase activating polypeptide 1	Rattus norvegicus	0-5
22313426-0	2012	Consecutive mutational events in a TSHR allele of Arab families with resistance to thyroid stimulating hormone.	Thyrotropin	83-110	thyroid stimulating hormone receptor	Homo sapiens	35-39
21915816-2	2012	AIM: The aim of this study was to evaluate the association between smoking and serum TSH concentration and the presence of thyroperoxidase antibody (TPO Ab) in Tehranian adults.	Thyrotropin	85-88	thyroid peroxidase	Homo sapiens	123-138
22786447-7	2012	RESULTS: Serum apoB-48 level was correlated with TSH, total cholesterol (TC) and triglycerides (TG), but negatively with FT4 and FT3 level.	Thyrotropin	49-52	apolipoprotein B	Homo sapiens	15-22
22084153-2	2012	The polymorphism rs4704397 in the phosphodiesterase 8B (PDE8B) gene showed an association with TSH.	Thyrotropin	95-98	phosphodiesterase 8B	Homo sapiens	34-54
22084153-2	2012	The polymorphism rs4704397 in the phosphodiesterase 8B (PDE8B) gene showed an association with TSH.	Thyrotropin	95-98	phosphodiesterase 8B	Homo sapiens	56-61
22278068-9	2012	As human chorionic gonadotropin (hCG) has a thyroid stimulating hormone (TSH)-like effect, high hCG concentrations are associated with thyroid stimulation, both functionally (lower serum TSH concentrations) and anatomically (increased thyroid volume).	Thyrotropin	44-71	chorionic gonadotropin subunit beta 5	Homo sapiens	9-37
22278068-9	2012	As human chorionic gonadotropin (hCG) has a thyroid stimulating hormone (TSH)-like effect, high hCG concentrations are associated with thyroid stimulation, both functionally (lower serum TSH concentrations) and anatomically (increased thyroid volume).	Thyrotropin	44-71	chorionic gonadotropin subunit beta 5	Homo sapiens	33-36
22278068-9	2012	As human chorionic gonadotropin (hCG) has a thyroid stimulating hormone (TSH)-like effect, high hCG concentrations are associated with thyroid stimulation, both functionally (lower serum TSH concentrations) and anatomically (increased thyroid volume).	Thyrotropin	73-76	chorionic gonadotropin subunit beta 5	Homo sapiens	9-37
22278068-9	2012	As human chorionic gonadotropin (hCG) has a thyroid stimulating hormone (TSH)-like effect, high hCG concentrations are associated with thyroid stimulation, both functionally (lower serum TSH concentrations) and anatomically (increased thyroid volume).	Thyrotropin	73-76	chorionic gonadotropin subunit beta 5	Homo sapiens	33-36
22109890-6	2012	Results of immunoblot and immunofluorescence experiments reveal that TSH and forskolin rapidly increase pendrin abundance at the plasma membrane through the protein kinase A pathway in PCCL-3 rat thyroid cells.	Thyrotropin	69-72	solute carrier family 26 member 4	Rattus norvegicus	104-111
22109890-9	2012	These results demonstrate that pendrin translocates to the membrane in response to TSH and suggest that it may have a physiological role in apical iodide transport and thyroid hormone synthesis.	Thyrotropin	83-86	solute carrier family 26 member 4	Rattus norvegicus	31-38
21803077-8	2011	Lep group had hyperleptinemia (+19%), higher T4 (+20%) and T3 (+30%) with lower TSH (-55%), higher liver D1 (1.4 fold-increase), lower BAT D2 (-44%) and liver mGPD activities (-55%), higher adrenal catecholamines (+44%), lower hypothalamic OBR (-51%) and normal thyroid OBR.	Thyrotropin	80-83	leptin	Rattus norvegicus	0-3
23146791-6	2012	The body mass is positively correlated with serum leptin and elevated level of leptin is connected with an increase in TSH level.	Thyrotropin	119-122	leptin	Homo sapiens	79-85
22916127-7	2012	These results suggest that P556L TSHR has a dominant negative effect on TSHR(W) by impairing polymer to monomer dissociation, which decreases TSH responsiveness and induces hypothyroidism in C.RF-Tshr(hyt/wild) mice.	Thyrotropin	33-36	thyroid stimulating hormone receptor	Mus musculus	72-76
22916127-7	2012	These results suggest that P556L TSHR has a dominant negative effect on TSHR(W) by impairing polymer to monomer dissociation, which decreases TSH responsiveness and induces hypothyroidism in C.RF-Tshr(hyt/wild) mice.	Thyrotropin	33-36	thyroid stimulating hormone receptor	Mus musculus	196-200
22019301-6	2011	In a previous study we demonstrated that Tio can induce ectopic eye formation in a broader range of cell populations than Tsh and is also a more potent inducer of cell proliferation.	Thyrotropin	122-125	tiptop	Drosophila melanogaster	41-44
22152284-10	2011	A thyrotropin-releasing hormone provocation test showed a normal response of thyroid-stimulating hormone level and an over-response of prolactin at 30 minutes (142.7 ng/mL).	Thyrotropin	77-104	thyrotropin releasing hormone	Homo sapiens	2-31
21956421-11	2011	When treated with TSH, thyroid fibroblasts generate IL-6 and IL-8.	Thyrotropin	18-21	interleukin 6	Homo sapiens	52-56
21956421-11	2011	When treated with TSH, thyroid fibroblasts generate IL-6 and IL-8.	Thyrotropin	18-21	C-X-C motif chemokine ligand 8	Homo sapiens	61-65
21862125-6	2011	Acute central NPY but not HS014 administration significantly reduced plasma TSH concentrations within 30-60 min and plasma free T4 levels within 90-120 min.	Thyrotropin	76-79	neuropeptide Y	Rattus norvegicus	14-17
23285764-5	2012	Patients with and without HCTD showed the dependence of IgA levels on TSH concentration.	Thyrotropin	70-73	CD79a molecule	Homo sapiens	56-59
22773156-6	2012	The serum Tg level was measured under TSH stimulation prior to imaging.	Thyrotropin	38-41	thyroglobulin	Homo sapiens	10-12
22299049-2	2012	Since this modification is indispensable for the activation of TSH signaling, a non-functional TPST2 mutation (Tpst2(grt)) in DW/J-grt mice leads to congenital hypothyroidism (CH) characterized by severe thyroid hypoplasia and dwarfism related to TSH hyporesponsiveness.	Thyrotropin	63-66	protein-tyrosine sulfotransferase 2	Mus musculus	95-100
22299049-2	2012	Since this modification is indispensable for the activation of TSH signaling, a non-functional TPST2 mutation (Tpst2(grt)) in DW/J-grt mice leads to congenital hypothyroidism (CH) characterized by severe thyroid hypoplasia and dwarfism related to TSH hyporesponsiveness.	Thyrotropin	63-66	protein-tyrosine sulfotransferase 2	Mus musculus	111-116
21340678-7	2011	In all subjects, TPO-Ab levels were negatively correlated with FT4 (gamma = -0.17, p = 0.002) and positively with TSH (gamma = 0.13, p = 0.021).	Thyrotropin	114-117	thyroid peroxidase	Homo sapiens	17-20
22179183-8	2011	TSH also induced a greater reduction in thyroid follicle size in Apc                         (                            1638T/1638T                         ) mice than in Apc                         (+/+) mice.	Thyrotropin	0-3	APC, WNT signaling pathway regulator	Mus musculus	65-68
21945915-0	2011	Ghrelin potentiates TSH-induced expression of the thyroid tissue-specific genes thyroglobulin, thyroperoxidase and sodium-iodine symporter, in rat PC-Cl3 Cells.	Thyrotropin	20-23	ghrelin and obestatin prepropeptide	Rattus norvegicus	0-7
21980075-1	2011	Although TSH stimulates all aspects of thyroid physiology IGF-I signaling through a tyrosine kinase-containing transmembrane receptor exhibits a permissive impact on TSH action.	Thyrotropin	9-12	insulin-like growth factor 1	Mus musculus	58-63
21980075-4	2011	Targeted Igf1r inactivation did transiently reduce thyroid hormone levels and significantly increased TSH levels in both heterozygous and homozygous mice without affecting thyroid weight.	Thyrotropin	102-105	insulin-like growth factor I receptor	Mus musculus	9-14
21980075-9	2011	Our results suggest that the strong increase of TSH benefits papillary thyroid hyperplasia and completely compensates the loss of IGF-I receptor signaling at the level of thyroid hormones without significant increase in thyroid weight.	Thyrotropin	48-51	insulin-like growth factor I receptor	Mus musculus	130-144
21945915-0	2011	Ghrelin potentiates TSH-induced expression of the thyroid tissue-specific genes thyroglobulin, thyroperoxidase and sodium-iodine symporter, in rat PC-Cl3 Cells.	Thyrotropin	20-23	thyroglobulin	Rattus norvegicus	80-93
21945915-5	2011	Finally, we have determined the stimulatory effect of ghrelin on TSH-induced expression of the tissue-specific key genes involved in the synthesis of thyroid hormone: thyroglobulin, thyroperoxidase and sodium-iodine symporter.	Thyrotropin	65-68	ghrelin and obestatin prepropeptide	Rattus norvegicus	54-61
21945915-5	2011	Finally, we have determined the stimulatory effect of ghrelin on TSH-induced expression of the tissue-specific key genes involved in the synthesis of thyroid hormone: thyroglobulin, thyroperoxidase and sodium-iodine symporter.	Thyrotropin	65-68	thyroglobulin	Rattus norvegicus	167-180
21705666-6	2011	When L252P or C41S was expressed with TSHR, that is, when TSHR/L252P or TSHR/C41S heterodimers could only bind one TSH, TSH-stimulated IP1 production was decreased relative to cAMP production.	Thyrotropin	38-41	thyroid stimulating hormone receptor	Homo sapiens	58-62
22007937-11	2011	In patients with cytology suspicious for neoplasm (FN, HCN) malignancy risk was higher in those receiving thyroid hormone therapy than in nonthyroid hormone users (37.7% vs. 16.5%, p=0.0004; odds ratio: 3.1), although serum TSH values did not differ significantly between thyroid hormone users and nonusers.	Thyrotropin	224-227	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	55-58
21705666-6	2011	When L252P or C41S was expressed with TSHR, that is, when TSHR/L252P or TSHR/C41S heterodimers could only bind one TSH, TSH-stimulated IP1 production was decreased relative to cAMP production.	Thyrotropin	38-41	thyroid stimulating hormone receptor	Homo sapiens	58-62
21705666-6	2011	When L252P or C41S was expressed with TSHR, that is, when TSHR/L252P or TSHR/C41S heterodimers could only bind one TSH, TSH-stimulated IP1 production was decreased relative to cAMP production.	Thyrotropin	38-41	inhibitor of nuclear factor kappa B kinase regulatory subunit gamma	Homo sapiens	135-138
21705666-6	2011	When L252P or C41S was expressed with TSHR, that is, when TSHR/L252P or TSHR/C41S heterodimers could only bind one TSH, TSH-stimulated IP1 production was decreased relative to cAMP production.	Thyrotropin	58-61	thyroid stimulating hormone receptor	Homo sapiens	38-42
21705666-6	2011	When L252P or C41S was expressed with TSHR, that is, when TSHR/L252P or TSHR/C41S heterodimers could only bind one TSH, TSH-stimulated IP1 production was decreased relative to cAMP production.	Thyrotropin	58-61	inhibitor of nuclear factor kappa B kinase regulatory subunit gamma	Homo sapiens	135-138
23362728-5	2011	Ultra sensitive C reactive protein was significantly correlated with increased lipid risk factors of cardiovascular disease, thyroid stimulating hormone level and indices of oxidative stress in these patients.	Thyrotropin	125-152	C-reactive protein	Homo sapiens	16-34
21746794-1	2011	Mice bearing the genomic mutation Delta337T on the thyroid hormone receptor beta (TRbeta) gene present the classical signs of resistance to thyroid hormone (TH), with high serum TH and TSH.	Thyrotropin	185-188	thyroid hormone receptor beta	Mus musculus	51-80
21746794-1	2011	Mice bearing the genomic mutation Delta337T on the thyroid hormone receptor beta (TRbeta) gene present the classical signs of resistance to thyroid hormone (TH), with high serum TH and TSH.	Thyrotropin	185-188	thyroid hormone receptor beta	Mus musculus	82-88
21715540-3	2011	OBJECTIVE: Several polymorphisms have been described in D1 and D2 of which some are associated with serum TSH and iodothyronine levels.	Thyrotropin	106-109	leiomodin 1	Homo sapiens	56-65
22156674-3	2011	It is established that the high expression of VEGF is observed in thyroid tissue, which loses sensitivity to the thyroid stimulating hormone, and vice versa.	Thyrotropin	113-140	vascular endothelial growth factor A	Homo sapiens	46-50
21911383-0	2011	Thyroid-stimulating hormone induces a Wnt-dependent, feed-forward loop for osteoblastogenesis in embryonic stem cell cultures.	Thyrotropin	0-27	wingless-type MMTV integration site family, member 5A	Mus musculus	38-41
21911383-6	2011	We predict that a TSH-induced, fast-forward short loop in bone marrow permits Wnt5a production, which, in addition to enhancing osteoblast differentiation, also stimulates osteoprotegerin secretion to attenuate bone resorption by neighboring osteoclasts.	Thyrotropin	18-21	wingless-type MMTV integration site family, member 5A	Mus musculus	78-83
21911383-6	2011	We predict that a TSH-induced, fast-forward short loop in bone marrow permits Wnt5a production, which, in addition to enhancing osteoblast differentiation, also stimulates osteoprotegerin secretion to attenuate bone resorption by neighboring osteoclasts.	Thyrotropin	18-21	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	172-187
21835056-6	2011	Genetic disturbances of MCT8 in patients result in a biochemical constellation of high T3 levels in combination with low or normal TSH and thyroxine levels leading to a new syndrome of severe X-linked mental retardation.	Thyrotropin	131-134	solute carrier family 16 member 2	Homo sapiens	24-28
21317830-4	2011	These results are consistent with reduced T4 glucuronidation in patients with low-expression (TA)7 and (TA)8 alleles and provide the first evidence for association between UGT1A1-53(TA)n and T4-dose requirement for thyroid-stimulating hormone suppression in a natural clinical setting.	Thyrotropin	215-242	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	172-178
21525174-1	2011	The thyrotropin [thyroid-stimulating hormone (TSH)] receptor (TSHR) is known to acutely and persistently stimulate cAMP signaling and at higher TSH concentrations to acutely stimulate phosphoinositide signaling.	Thyrotropin	46-49	thyroid stimulating hormone receptor	Homo sapiens	62-66
21525174-2	2011	We measured persistent signaling by stimulating TSHR-expressing human embryonic kidney-EM293 cells with TSH and measuring cAMP or inositol monophosphate (IP1) production, a measure of phosphoinositide signaling, 60 min or longer after TSH removal.	Thyrotropin	104-107	thyroid stimulating hormone receptor	Homo sapiens	48-52
21745106-9	2011	Neutralizing antibody to OPG reversed the inhibitory effect of TSH on osteoclast differentiation evidencing that the TSH effect was at least in part mediated by increased OPG.	Thyrotropin	63-66	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	25-28
21745106-9	2011	Neutralizing antibody to OPG reversed the inhibitory effect of TSH on osteoclast differentiation evidencing that the TSH effect was at least in part mediated by increased OPG.	Thyrotropin	63-66	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	171-174
21745106-9	2011	Neutralizing antibody to OPG reversed the inhibitory effect of TSH on osteoclast differentiation evidencing that the TSH effect was at least in part mediated by increased OPG.	Thyrotropin	117-120	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	25-28
21745106-9	2011	Neutralizing antibody to OPG reversed the inhibitory effect of TSH on osteoclast differentiation evidencing that the TSH effect was at least in part mediated by increased OPG.	Thyrotropin	117-120	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	171-174
22049681-6	2011	Additionally, there exists another potential retrograde control pathway of seasonal breeding, which involves TSH-DIO2/DIO3 system.	Thyrotropin	109-112	iodothyronine deiodinase 2	Homo sapiens	113-117
22049681-6	2011	Additionally, there exists another potential retrograde control pathway of seasonal breeding, which involves TSH-DIO2/DIO3 system.	Thyrotropin	109-112	iodothyronine deiodinase 3	Homo sapiens	118-122
22049681-7	2011	TSH-DIO2/ DIO3 system affects synthesis and secretion of GnRH and is regulated by melatonin, as well as Kiss1/GPR54 system.	Thyrotropin	0-3	iodothyronine deiodinase 2	Homo sapiens	4-8
22049681-7	2011	TSH-DIO2/ DIO3 system affects synthesis and secretion of GnRH and is regulated by melatonin, as well as Kiss1/GPR54 system.	Thyrotropin	0-3	iodothyronine deiodinase 3	Homo sapiens	10-14
22049681-7	2011	TSH-DIO2/ DIO3 system affects synthesis and secretion of GnRH and is regulated by melatonin, as well as Kiss1/GPR54 system.	Thyrotropin	0-3	KiSS-1 metastasis suppressor	Homo sapiens	104-109
22049681-7	2011	TSH-DIO2/ DIO3 system affects synthesis and secretion of GnRH and is regulated by melatonin, as well as Kiss1/GPR54 system.	Thyrotropin	0-3	KISS1 receptor	Homo sapiens	110-115
22049681-8	2011	In this article, melatonin signal, especially the research advances of Kissl/GPR54 system and TSH-DIO2/DIO3 system were reviewed.	Thyrotropin	94-97	iodothyronine deiodinase 2	Homo sapiens	98-102
21389275-8	2011	Conversely, the adenylyl cyclase activator forskolin abolished the AMPK phosphorylation response induced by TSH withdrawal in PCCL3 cells.	Thyrotropin	108-111	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	67-71
21628383-0	2011	Identification of novel TSH interaction sites by systematic binding analysis of the TSHR hinge region.	Thyrotropin	24-27	thyroid stimulating hormone receptor	Homo sapiens	84-88
21389275-7	2011	The presence of TSH in the culture medium reduced AMPK phosphorylation in PCCL3 cells, while inhibition of protein kinase A (PKA) with H89 prevented this effect.	Thyrotropin	16-19	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	50-54
21751590-12	2011	On analysis of Pearson"s correlation coefficient CD4 count has strong inverse correlation with basal cortisol (r=-0.301, p&lt;0.0001), TSH (r=-0.257, p=0.002) and LH (r=-0.228, p=0.006), while there was a direct correlation with serum testosterone (r=0.175, p=0.037).	Thyrotropin	135-138	CD4 molecule	Homo sapiens	49-52
21466821-4	2011	Our results demonstrate that, in CHO-TSHr transfected cells, TSHr is activated in the presence of TSH, while it is inhibited following DDT exposure.	Thyrotropin	37-40	thyrotropin receptor	Cricetulus griseus	61-65
21086053-4	2011	We report the case of TSHoma in a 41-year-old man treated with octreotide LAR that caused a dramatic decrease of TSH and thyroid hormones and tumor shrinkage already after 3 months of pre-surgical therapy.	Thyrotropin	22-25	protein tyrosine phosphatase receptor type F	Homo sapiens	74-77
21207221-5	2011	Here, we measure IRAP activity fluorometrically using cystyl-beta-naphthylamide as the substrate, in the hypothalamus-pituitary-thyroid axis together with the circulating levels of OXT, and its relationship with circulating levels of TSH and free thyroxine (fT4), as markers of thyroid function in control rats and rats with breast cancer induced by NMU.	Thyrotropin	234-237	leucyl and cystinyl aminopeptidase	Rattus norvegicus	17-21
21207221-9	2011	Thus, high circulating levels of OXT decreased TSH release from the pituitary, and therefore, of thyroid hormones from the thyroid, supporting the association between breast cancer and thyroid function disruption.	Thyrotropin	47-50	oxytocin/neurophysin I prepropeptide	Rattus norvegicus	33-36
21292823-1	2011	Mice deficient in thyroid hormone receptor alpha (TRalpha) display hypersensitivity to thyroid hormone (TH), with normal serum TSH but diminished serum T(4).	Thyrotropin	127-130	thyroid hormone receptor alpha	Mus musculus	18-48
21367965-9	2011	Suggestive associations were detected for one FOXE1 (P=0.0028) and three THRB (P=0.0045) polymorphisms with TSH, and one SLC16A10 polymorphism (P=0.0110) with FT(4), but failed to reach the significant multiple-testing corrected P value (P&lt;0.0022 and P&lt;0.0033 respectively).	Thyrotropin	108-111	thyroid hormone receptor beta	Homo sapiens	73-77
21378092-4	2011	Thus, physiological concentrations of Tg significantly suppress thyroid-specific gene expression and antagonize the TSH-mediated stimulation that induces expression of thyroid-specific genes.	Thyrotropin	116-119	thyroglobulin	Homo sapiens	38-40
21378092-7	2011	These results indicate that Tg is an essential autocrine regulator of physiological thyroid follicular function that counteracts the effects of TSH.	Thyrotropin	144-147	thyroglobulin	Homo sapiens	28-30
21257724-7	2011	CONCLUSION: This prospective study shows that severe short-term hypothyroidism is associated with significantly lower levels of VWF:Ag, VWF:CBA, and FVIII:C. Administration of exogenous TSH has no effect on coagulation parameters.	Thyrotropin	186-189	von Willebrand factor	Homo sapiens	128-131
21257724-7	2011	CONCLUSION: This prospective study shows that severe short-term hypothyroidism is associated with significantly lower levels of VWF:Ag, VWF:CBA, and FVIII:C. Administration of exogenous TSH has no effect on coagulation parameters.	Thyrotropin	186-189	von Willebrand factor	Homo sapiens	136-139
21317282-1	2011	OBJECTIVE: Common variants in PDE8B are associated with TSH but apparently without any effect on thyroid hormone levels that is difficult to explain.	Thyrotropin	56-59	phosphodiesterase 8B	Homo sapiens	30-35
21360554-6	2011	Multivariate analysis revealed that PAPP-A and hCG were independently associated with HG after controlling for TSH, free T4, AST, and ALT.	Thyrotropin	111-114	pappalysin 1	Homo sapiens	36-42
21292823-1	2011	Mice deficient in thyroid hormone receptor alpha (TRalpha) display hypersensitivity to thyroid hormone (TH), with normal serum TSH but diminished serum T(4).	Thyrotropin	127-130	guanine nucleotide binding protein, alpha transducing 1	Mus musculus	50-57
21190937-6	2011	This phenomenon, suggesting a lower TSH affinity for the former, was surprising because both the TSHR ECD and TSH holoreceptor contain the entire TSH-binding site, and the TSH binding affinities for both receptor forms should, theoretically, be identical.	Thyrotropin	36-39	thyrotropin receptor	Cricetulus griseus	97-101
21258971-9	2011	Either presence of the histone deacetylase inhibitor trichostatin A or absence of thyroid-stimulating hormone induces NPM nuclear localization in non-tumorigenic thyroid cell lines.	Thyrotropin	82-109	nucleophosmin 1	Homo sapiens	118-121
21190937-7	2011	In ligand competition studies, we observed that the TSH binding affinity for the TSHR ECD-GPI was significantly lower than that for the TSH holoreceptor.	Thyrotropin	52-55	thyrotropin receptor	Cricetulus griseus	81-85
21401511-5	2011	These two dopaminergic pathways stimulate the secretion of pituitary hormones, which directly (GH) or indirectly (ACTH, TSH) activate hepatic nuclear/ cytosolic receptors controlling CYP genes.	Thyrotropin	120-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	183-186
21220306-9	2011	These data demonstrate the key role of TSH signaling in Braf-induced papillary thyroid cancer initiation and provide experimental support for recent observations in humans pointing to a strong association between TSH levels and thyroid cancer incidence.	Thyrotropin	39-42	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	56-60
21085047-5	2011	A Fisher rat thyroid cell line, FRTL5, which expresses rat sodium/iodide symporter when stimulated with thyroid-stimulating hormone, was used for comparison.	Thyrotropin	104-131	solute carrier family 5 member 5	Rattus norvegicus	59-82
20829366-7	2010	In multivariate regression analyses, adjusting for maternal and child characteristics, higher newborn TSH concentrations showed a decrease of 3.51 and 3.15 points on the MSCA general cognitive and executive function scores respectively and were associated with a higher risk of scoring below the 20th percentile (P20) on the quantitative score (odds ratio (OR)=2.64).	Thyrotropin	102-105	tubulin polymerization promoting protein family member 3	Homo sapiens	313-316
20826543-3	2011	Recent studies now indicate that immune system-derived TSH, in particular, a splice variant of TSHbeta that is preferentially made by cells of the immune system, is produced by a subset of hematopoietic cells that traffic to the thyroid.	Thyrotropin	55-58	thyroid stimulating hormone subunit beta	Homo sapiens	95-102
21913492-5	2011	Iodine oxidation is the initial step for thyroid hormone synthesis within thyroid, is mediated by thyroperoxidase enzyme (TPO), which itself is activated by TSH required for production of MIT and DIT.	Thyrotropin	157-160	thyroid peroxidase	Homo sapiens	98-120
21913492-5	2011	Iodine oxidation is the initial step for thyroid hormone synthesis within thyroid, is mediated by thyroperoxidase enzyme (TPO), which itself is activated by TSH required for production of MIT and DIT.	Thyrotropin	157-160	thyroid peroxidase	Homo sapiens	122-125
20886414-2	2011	In this study, we analyzed the in vivo effects of L-T4-mediated TSH suppression on elements of insulin/IGF-1-dependent growth-regulating pathways in tissues from patients with benign thyroid nodules.	Thyrotropin	64-67	insulin	Homo sapiens	95-102
20886414-2	2011	In this study, we analyzed the in vivo effects of L-T4-mediated TSH suppression on elements of insulin/IGF-1-dependent growth-regulating pathways in tissues from patients with benign thyroid nodules.	Thyrotropin	64-67	insulin like growth factor 1	Homo sapiens	103-108
21407156-10	2011	Peripheral CART administration caused a significant increase in PRL, GH and TSH levels in non-starved rats but no changes in investigated hormone levels were observed in starved animals when compared to saline injected controls.	Thyrotropin	76-79	CART prepropeptide	Rattus norvegicus	11-15
20619298-8	2010	Serum TSH concentrations negatively correlated with IGF-I, IGFBP-3 and IGF-I/IGFBP-3 ratios.	Thyrotropin	6-9	insulin like growth factor 1	Homo sapiens	52-57
20619298-8	2010	Serum TSH concentrations negatively correlated with IGF-I, IGFBP-3 and IGF-I/IGFBP-3 ratios.	Thyrotropin	6-9	insulin like growth factor binding protein 3	Homo sapiens	59-66
20619298-8	2010	Serum TSH concentrations negatively correlated with IGF-I, IGFBP-3 and IGF-I/IGFBP-3 ratios.	Thyrotropin	6-9	insulin like growth factor 1	Homo sapiens	71-76
20619298-8	2010	Serum TSH concentrations negatively correlated with IGF-I, IGFBP-3 and IGF-I/IGFBP-3 ratios.	Thyrotropin	6-9	insulin like growth factor binding protein 3	Homo sapiens	77-84
20843953-10	2010	These findings suggest interventions that target high TSH concentrations during weight loss in obese subjects may improve insulin sensitivity.	Thyrotropin	54-57	insulin	Homo sapiens	122-129
21179279-4	2010	The patients were classified according to surveillance DxWBS findings and TSH-stimulated Tg levels 6 to 12 months after the initial RAI.	Thyrotropin	74-77	thyroglobulin	Homo sapiens	89-91
21111944-1	2010	OBJECTIVE: Thyroid peroxidase antibodies (TPOAbs) have been found to be related to the levels of thyroid stimulating hormone (TSH) and to predict future development of thyroid failure in selected populations.	Thyrotropin	97-124	thyroid peroxidase	Homo sapiens	11-29
21111944-1	2010	OBJECTIVE: Thyroid peroxidase antibodies (TPOAbs) have been found to be related to the levels of thyroid stimulating hormone (TSH) and to predict future development of thyroid failure in selected populations.	Thyrotropin	126-129	thyroid peroxidase	Homo sapiens	11-29
20392823-0	2010	Acute exogenous TSH administration stimulates leptin secretion in vivo.	Thyrotropin	16-19	leptin	Homo sapiens	46-52
24899964-13	2010	The serum Tg level (TSH stimulated) was significantly different among groups A, B, and C (p = 0.0030).	Thyrotropin	20-23	thyroglobulin	Homo sapiens	10-12
26000111-3	2010	TMA and TPO were the most sensitive autoantibodies in subjects in both the bottom percentiles (19.8% and 18.5%, respectively) and the top percentiles (51.2% and 53.8%, respectively) of the TSH distribution.	Thyrotropin	189-192	thyroid peroxidase	Homo sapiens	8-11
20538910-3	2010	We measured persistent TSHR signaling as an accumulation of cAMP in HEK-EM293 cells permanently expressing human TSHRs incubated with isobutylmethylxanthine for 30 min after washing the cells to remove unbound TSH, and TSHR internalization by fluorescence microscopy using Alexa-tagged TSH and binding assays using (125)I-TSH.	Thyrotropin	23-26	thyroid stimulating hormone receptor	Homo sapiens	113-117
20561773-9	2010	In studies in which data were available for serum Tg levels during thyroid-stimulating hormone (TSH) suppression therapy or TSH withdrawal, 188 of 337 patients (56%) showed a decrease in serum Tg.	Thyrotropin	67-94	thyroglobulin	Homo sapiens	50-52
20561773-9	2010	In studies in which data were available for serum Tg levels during thyroid-stimulating hormone (TSH) suppression therapy or TSH withdrawal, 188 of 337 patients (56%) showed a decrease in serum Tg.	Thyrotropin	96-99	thyroglobulin	Homo sapiens	50-52
20561773-9	2010	In studies in which data were available for serum Tg levels during thyroid-stimulating hormone (TSH) suppression therapy or TSH withdrawal, 188 of 337 patients (56%) showed a decrease in serum Tg.	Thyrotropin	96-99	thyroglobulin	Homo sapiens	193-195
20561773-9	2010	In studies in which data were available for serum Tg levels during thyroid-stimulating hormone (TSH) suppression therapy or TSH withdrawal, 188 of 337 patients (56%) showed a decrease in serum Tg.	Thyrotropin	124-127	thyroglobulin	Homo sapiens	193-195
20668706-4	2010	Manipulation of SIRT1 level revealed that SIRT1 positively regulated the exocytosis of TSH-containing granules.	Thyrotropin	87-90	sirtuin 1	Mus musculus	16-21
20668706-4	2010	Manipulation of SIRT1 level revealed that SIRT1 positively regulated the exocytosis of TSH-containing granules.	Thyrotropin	87-90	sirtuin 1	Mus musculus	42-47
20668706-8	2010	SIRT1 knockdown decreased the levels of deacetylated PIP5Kgamma, PI(4,5)P(2), and reduced the secretion of TSH from pituitary cells.	Thyrotropin	107-110	sirtuin 1	Mus musculus	0-5
20668706-10	2010	CONCLUSIONS/SIGNIFICANCE: Our findings indicated that the control of TSH release by the SIRT1-PIP5Kgamma pathway is important for regulating the metabolism of the whole body.	Thyrotropin	69-72	sirtuin 1	Mus musculus	88-93
21114382-2	2010	Serum TSH has also been found to be positively associated with fasting and postload insulin concentrations and negatively associated with insulin sensitivity in euthyroid adults.	Thyrotropin	6-9	insulin	Homo sapiens	84-91
21114382-2	2010	Serum TSH has also been found to be positively associated with fasting and postload insulin concentrations and negatively associated with insulin sensitivity in euthyroid adults.	Thyrotropin	6-9	insulin	Homo sapiens	138-145
21114382-9	2010	TSH levels were also positively correlated with fasting insulin (r = 0.26, p = 0.002) and with HOMA (r = 0.27, p = 0.001).	Thyrotropin	0-3	insulin	Homo sapiens	56-63
21114382-12	2010	CONCLUSIONS: In euthyroid children without a history of hypo- or hyperthyroidism, increasing levels of TSH and decreasing levels of free T4 are associated with higher triglyceride levels and elevated markers of insulin resistance.	Thyrotropin	103-106	insulin	Homo sapiens	211-218
20691716-4	2010	This study evaluates the interaction between exposure to organophosphate compounds and PON1 enzyme activity on serum levels of TSH and thyroid hormones in a population of workers occupationally exposed to pesticides.	Thyrotropin	127-130	paraoxonase 1	Homo sapiens	87-91
20691716-10	2010	Thus, when PON1 activity was increased we observed a decrease in the percentage of variation of TSH level for each increment in one logarithmic unit of the SigmaDAP levels.	Thyrotropin	96-99	paraoxonase 1	Homo sapiens	11-15
20798227-11	2010	Moreover, IR and beta-cell function are inversely correlated with TSH, which may be explained by the decreasing insulin-antagonistic effects of thyroid hormones along with increasing TSH.	Thyrotropin	66-69	insulin	Homo sapiens	112-119
20929702-6	2010	Thyrotropin releasing hormone (TRH) stimulation test was performed in having elevated thyroid stimulating hormone (TSH) level.	Thyrotropin	86-113	thyrotropin releasing hormone	Homo sapiens	0-29
20929702-6	2010	Thyrotropin releasing hormone (TRH) stimulation test was performed in having elevated thyroid stimulating hormone (TSH) level.	Thyrotropin	115-118	thyrotropin releasing hormone	Homo sapiens	0-29
20648556-2	2010	Here, we demonstrated that in liver cells, TSH promoted the expression of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase (HMGCR), a rate-limiting enzyme in cholesterol synthesis, by acting on the TSH receptor in hepatocyte membranes and stimulating the cyclic adenosine monophosphate / protein kinase A / cyclic adenosine monophosphate-responsive element binding protein (cAMP/PKA/CREB) signaling system.	Thyrotropin	43-46	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	74-122
20648556-2	2010	Here, we demonstrated that in liver cells, TSH promoted the expression of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase (HMGCR), a rate-limiting enzyme in cholesterol synthesis, by acting on the TSH receptor in hepatocyte membranes and stimulating the cyclic adenosine monophosphate / protein kinase A / cyclic adenosine monophosphate-responsive element binding protein (cAMP/PKA/CREB) signaling system.	Thyrotropin	43-46	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	124-129
20648556-2	2010	Here, we demonstrated that in liver cells, TSH promoted the expression of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase (HMGCR), a rate-limiting enzyme in cholesterol synthesis, by acting on the TSH receptor in hepatocyte membranes and stimulating the cyclic adenosine monophosphate / protein kinase A / cyclic adenosine monophosphate-responsive element binding protein (cAMP/PKA/CREB) signaling system.	Thyrotropin	43-46	cathelicidin antimicrobial peptide	Rattus norvegicus	374-378
20648556-2	2010	Here, we demonstrated that in liver cells, TSH promoted the expression of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase (HMGCR), a rate-limiting enzyme in cholesterol synthesis, by acting on the TSH receptor in hepatocyte membranes and stimulating the cyclic adenosine monophosphate / protein kinase A / cyclic adenosine monophosphate-responsive element binding protein (cAMP/PKA/CREB) signaling system.	Thyrotropin	43-46	cAMP responsive element binding protein 1	Rattus norvegicus	383-387
20648556-3	2010	In thyroidectomized rats, the production of endogenous thyroid hormone was eliminated and endogenous TSH was suppressed through pituitary suppression with constant administration of exogenous thyroid hormone, and hepatic HMGCR expression was increased by administration of exogenous TSH.	Thyrotropin	283-286	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	221-226
20648556-4	2010	These results suggested that TSH could up-regulate hepatic HMGCR expression, which indicated a potential mechanism for hypercholesterolemia involving direct action of TSH on the liver.	Thyrotropin	29-32	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	59-64
20576801-4	2010	We showed TSH-stimulated expression of Sod3 via phospholipase C-Ca(2+) and cAMP-protein kinase A, a pathway that might be disrupted in thyroid cancer.	Thyrotropin	10-13	superoxide dismutase 3	Homo sapiens	39-43
20529371-2	2010	It is well known that NIS expression in thyroid is regulated by the thyroid statuses mainly through thyroid stimulating hormone (TSH).	Thyrotropin	100-127	solute carrier family 5 (sodium iodide symporter), member 5	Mus musculus	22-25
20484410-6	2010	However, like insulin, TSH/cAMP produced a stable increase in mTORC1 kinase activity that was associated with augmented 4E-BP1 binding to raptor.	Thyrotropin	23-26	CREB regulated transcription coactivator 1	Mus musculus	62-68
20484410-6	2010	However, like insulin, TSH/cAMP produced a stable increase in mTORC1 kinase activity that was associated with augmented 4E-BP1 binding to raptor.	Thyrotropin	23-26	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	120-126
20484410-3	2010	Here we show in PC Cl3 rat thyroid cells that TSH/cAMP, like insulin, activates the mammalian target of rapamycin (mTOR)-raptor complex (mTORC1) leading to phosphorylation of S6K1 and 4E-BP1.	Thyrotropin	46-49	insulin	Homo sapiens	61-68
20484410-3	2010	Here we show in PC Cl3 rat thyroid cells that TSH/cAMP, like insulin, activates the mammalian target of rapamycin (mTOR)-raptor complex (mTORC1) leading to phosphorylation of S6K1 and 4E-BP1.	Thyrotropin	46-49	mechanistic target of rapamycin kinase	Homo sapiens	84-113
20484410-3	2010	Here we show in PC Cl3 rat thyroid cells that TSH/cAMP, like insulin, activates the mammalian target of rapamycin (mTOR)-raptor complex (mTORC1) leading to phosphorylation of S6K1 and 4E-BP1.	Thyrotropin	46-49	mechanistic target of rapamycin kinase	Homo sapiens	115-119
20484410-3	2010	Here we show in PC Cl3 rat thyroid cells that TSH/cAMP, like insulin, activates the mammalian target of rapamycin (mTOR)-raptor complex (mTORC1) leading to phosphorylation of S6K1 and 4E-BP1.	Thyrotropin	46-49	CREB regulated transcription coactivator 1	Mus musculus	137-143
20484410-3	2010	Here we show in PC Cl3 rat thyroid cells that TSH/cAMP, like insulin, activates the mammalian target of rapamycin (mTOR)-raptor complex (mTORC1) leading to phosphorylation of S6K1 and 4E-BP1.	Thyrotropin	46-49	ribosomal protein S6 kinase B1	Homo sapiens	175-190
20529371-2	2010	It is well known that NIS expression in thyroid is regulated by the thyroid statuses mainly through thyroid stimulating hormone (TSH).	Thyrotropin	129-132	solute carrier family 5 (sodium iodide symporter), member 5	Mus musculus	22-25
19883729-6	2010	As such, the knowledge of BRAF mutation status can facilitate more accurate risk stratification and better decision making at various steps in the management of PTC, from preoperative planning of initial surgical scale to postoperative decisions about appropriate radioiodine treatment and thyroid-stimulating hormone suppression, and to selections of appropriate surveillance modalities for PTC recurrence.	Thyrotropin	290-317	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	26-30
20378412-4	2010	In most FSHR mutations, a hypersensitivity to human chorionic gonadotrophin (HCG) or thyroid-stimulating hormone (TSH) is described.	Thyrotropin	85-112	follicle stimulating hormone receptor	Homo sapiens	8-12
20378412-4	2010	In most FSHR mutations, a hypersensitivity to human chorionic gonadotrophin (HCG) or thyroid-stimulating hormone (TSH) is described.	Thyrotropin	114-117	follicle stimulating hormone receptor	Homo sapiens	8-12
20378412-10	2010	This report confirms for the first time the in-vitro findings in a single clinical case that TSH as well as HCG leads to spontaneous OHSS in patients with FSHR D567N mutation.	Thyrotropin	93-96	follicle stimulating hormone receptor	Homo sapiens	155-159
20447068-2	2010	In euthyroidism, the relationships between TSH and insulin resistance or the metabolic syndrome are less clear.	Thyrotropin	43-46	insulin	Homo sapiens	51-58
20447070-12	2010	CONCLUSIONS: This is the first study addressing the equivalency between L-T3 and L-T4 therapy measured by baseline and TRH-stimulated TSH.	Thyrotropin	134-137	thyrotropin releasing hormone	Homo sapiens	119-122
20181794-5	2010	A mouse TSHR cDNA generated by PCR was found to express a receptor with poor TSH-induced cAMP generation despite normal TSH binding.	Thyrotropin	77-80	thyroid stimulating hormone receptor	Mus musculus	8-12
20133453-3	2010	These mice, harboring a dominantly negative mutation (PV) of the thyroid hormone-beta receptor (TRbeta), exhibit increased serum thyroid hormone and elevated TSH.	Thyrotropin	158-161	apoptosis antagonizing transcription factor	Mus musculus	96-102
20181794-8	2010	To our knowledge, there are no previous examples of specific amino acid mutations in the TSHR LRD that dissociate TSH binding from TSHR signal transduction.	Thyrotropin	89-92	thyroid stimulating hormone receptor	Mus musculus	131-135
19846175-3	2010	Thyroid-stimulating hormone stimulated phosphorylation of perilipin and hormone-sensitive lipase (HSL).	Thyrotropin	0-27	perilipin 1	Homo sapiens	58-67
19846175-3	2010	Thyroid-stimulating hormone stimulated phosphorylation of perilipin and hormone-sensitive lipase (HSL).	Thyrotropin	0-27	lipase E, hormone sensitive type	Homo sapiens	72-96
19846175-3	2010	Thyroid-stimulating hormone stimulated phosphorylation of perilipin and hormone-sensitive lipase (HSL).	Thyrotropin	0-27	lipase E, hormone sensitive type	Homo sapiens	98-101
20373981-8	2010	CONCLUSIONS: The proposed mechanism by which PDE8B may influence TSH levels is through control of cAMP signaling.	Thyrotropin	65-68	phosphodiesterase 8B	Homo sapiens	45-50
20373981-9	2010	Our analysis revealed separate segregation of an inactivating PDE8B allele from the high-TSH-allele and showed low TSH levels in persons who carry an inactivating PDE8B allele.	Thyrotropin	115-118	phosphodiesterase 8B	Homo sapiens	163-168
20373981-10	2010	These data suggest that, indeed, PDE8B may be involved in regulation of TSH levels.	Thyrotropin	72-75	phosphodiesterase 8B	Homo sapiens	33-38
21341506-6	2010	Stimulation of the lipopolysaccharide-pretreated thyroid gland with thyroid-stimulating hormone increases resorbtion of thyroglobulin and thyroid hormone production.	Thyrotropin	68-95	thyroglobulin	Homo sapiens	120-133
20083144-3	2010	In a gene expression study in Fischer rat thyroid cells (FRTL-5) using cDNA microarrays we found a TSH-dependent regulation of several calcium binding proteins, S100A4, S100A6 and annexin A6.	Thyrotropin	99-102	S100 calcium-binding protein A4	Rattus norvegicus	161-167
20205098-4	2010	The aim of the study was to assess the usefulness of serum endostatin levels as a potential marker of metastases of well-differentiated thyroid cancer, and to estimate the effect of endogenous TSH stimulation on serum endostatin levels.	Thyrotropin	193-196	collagen type XVIII alpha 1 chain	Homo sapiens	218-228
20083144-3	2010	In a gene expression study in Fischer rat thyroid cells (FRTL-5) using cDNA microarrays we found a TSH-dependent regulation of several calcium binding proteins, S100A4, S100A6 and annexin A6.	Thyrotropin	99-102	S100 calcium binding protein A6	Rattus norvegicus	169-175
20083144-3	2010	In a gene expression study in Fischer rat thyroid cells (FRTL-5) using cDNA microarrays we found a TSH-dependent regulation of several calcium binding proteins, S100A4, S100A6 and annexin A6.	Thyrotropin	99-102	annexin A6	Rattus norvegicus	180-190
19437026-8	2010	If TSH level was deranged then free T4 and thyroperoxidase antibody level estimation were done.	Thyrotropin	3-6	thyroid peroxidase	Homo sapiens	36-58
20032565-3	2010	There were significant positive correlations between serum TSH levels and lipid parameters such as total cholesterol (TC), triglyceride (TG), HDL-cholesterol (HDL-C), LDL-cholesterol (LDL-C), non-HDL-C and LDL-C/HDL-C ratio (L/H).	Thyrotropin	59-62	component of oligomeric golgi complex 2	Homo sapiens	167-182
20032565-3	2010	There were significant positive correlations between serum TSH levels and lipid parameters such as total cholesterol (TC), triglyceride (TG), HDL-cholesterol (HDL-C), LDL-cholesterol (LDL-C), non-HDL-C and LDL-C/HDL-C ratio (L/H).	Thyrotropin	59-62	component of oligomeric golgi complex 2	Homo sapiens	184-189
20032565-3	2010	There were significant positive correlations between serum TSH levels and lipid parameters such as total cholesterol (TC), triglyceride (TG), HDL-cholesterol (HDL-C), LDL-cholesterol (LDL-C), non-HDL-C and LDL-C/HDL-C ratio (L/H).	Thyrotropin	59-62	component of oligomeric golgi complex 2	Homo sapiens	206-211
20938100-12	2010	In the hypothyroid patients (overt and subclinical) a positive correlation was found between TSH and PRL levels (r=0.208, p=0.003).	Thyrotropin	93-96	prolactin	Homo sapiens	101-104
20083144-12	2010	Taken together, the results suggest that S100A4 and other calcium binding proteins are part of a signaling network connecting TSH signaling to calcium-mediated events which play a role in thyroid physiology like H2O2 production or even thyroid cancer.	Thyrotropin	126-129	S100 calcium binding protein A4	Homo sapiens	41-47
19951699-3	2010	In conjunction with thyroid stimulating hormone (TSH) and iodide, Tg regulates thyroid follicle function, which is the minimal functional unit of the thyroid gland.	Thyrotropin	20-47	thyroglobulin	Rattus norvegicus	66-68
20351465-10	2010	Previous reports demonstrated that the thyroid stimulating activity of thyroid stimulating antibody (TSAb) was blocked by deglycosylated HCG (competitive antagonist of TSH binding to TSHR).	Thyrotropin	168-171	thyroid stimulating hormone receptor	Homo sapiens	183-187
19897675-9	2010	They express TSHR at high levels and TSH induces fibrocytes to produce IL-6 and TNF-alpha.	Thyrotropin	13-16	interleukin 6	Homo sapiens	71-75
19548061-6	2010	Serum parathyroid hormone (PTH) started to rise along with TSH, but a significant increase of PTH was only reached on Day 5 when the TSH concentration had fallen more than 80% of the peak value.	Thyrotropin	59-62	parathyroid hormone	Homo sapiens	6-25
19897675-9	2010	They express TSHR at high levels and TSH induces fibrocytes to produce IL-6 and TNF-alpha.	Thyrotropin	13-16	tumor necrosis factor	Homo sapiens	80-89
21050929-1	2010	Autoantibodies in autoimmune thyroid disease (AITD) bind to the TSH receptor (TSHR) and can act as either agonists, mimicking the biological activity of TSH, or as antagonists inhibiting the action of TSH.	Thyrotropin	64-67	thyroid stimulating hormone receptor	Homo sapiens	78-82
20608029-6	2010	The author showed direct correlations between the TSH level and proinflammatory cytokines--TNFalpha, IL-6, CRP and negative correlations between HOMA IR indexes and iodinuria.	Thyrotropin	50-53	tumor necrosis factor	Homo sapiens	91-99
20608029-6	2010	The author showed direct correlations between the TSH level and proinflammatory cytokines--TNFalpha, IL-6, CRP and negative correlations between HOMA IR indexes and iodinuria.	Thyrotropin	50-53	interleukin 6	Homo sapiens	101-105
19837722-8	2010	These data support the conclusion that the immunosuppressive mechanism by which MMI and C10 inhibit MHC gene expression mimics "normal" hormonal suppression by TSH/cAMP.	Thyrotropin	160-163	homeobox C10	Homo sapiens	88-91
20150864-3	2010	Neuropsychological test scores and TSH levels while hypothyroid were correlated with rCBF in hypothyroid-affected areas of the brain.	Thyrotropin	35-38	CCAAT/enhancer binding protein zeta	Rattus norvegicus	85-89
20150864-5	2010	CONCLUSIONS: Severity of psychomotor impairment and depression, and TSH level during hypothyroidism appeared to correlate with CBF to brain regions associated with motor activity, mood and vision, respectively; and previously shown to manifest significantly altered rCBF during hypothyroidism.	Thyrotropin	68-71	CCAAT/enhancer binding protein zeta	Rattus norvegicus	127-130
20150864-5	2010	CONCLUSIONS: Severity of psychomotor impairment and depression, and TSH level during hypothyroidism appeared to correlate with CBF to brain regions associated with motor activity, mood and vision, respectively; and previously shown to manifest significantly altered rCBF during hypothyroidism.	Thyrotropin	68-71	CCAAT/enhancer binding protein zeta	Rattus norvegicus	266-270
19850692-1	2009	CONTEXT: TSH receptor (TSHR) blocking antibodies (Abs) inhibit TSH-induced thyroid growth and function in some adults with chronic lymphocytic thyroiditis (CLT), but their role in the pediatric age range is unknown.	Thyrotropin	9-12	thyroid stimulating hormone receptor	Homo sapiens	23-27
20067380-6	2010	CONCLUSION: To our knowledge, this is the first case of a TSH/growth-hormone-secreting pituitary macroadenoma coexisting with PTC being successfully treated with octreotide and levothyroxine after thyroidectomy and recombinant human TSH-stimulated radioactive iodine remnant ablation.	Thyrotropin	58-61	growth hormone 1	Homo sapiens	62-76
19886789-3	2010	METHODS: E14 mouse ES cells were allowed to differentiate into embryoid bodies and then stimulated with thyroid-stimulating hormone, insulin, and potassium iodide.	Thyrotropin	104-131	skull morphology 21	Mus musculus	9-12
19505771-4	2009	If TSH can activate LH/CG-R, then, the TSH-R blocking autoantibodies could bind and block LH/CG-R in the corpus luteum through a similar cross-reactivity process.	Thyrotropin	3-6	luteinizing hormone/choriogonadotropin receptor	Homo sapiens	20-27
19505771-4	2009	If TSH can activate LH/CG-R, then, the TSH-R blocking autoantibodies could bind and block LH/CG-R in the corpus luteum through a similar cross-reactivity process.	Thyrotropin	3-6	thyroid stimulating hormone receptor	Homo sapiens	39-44
19505771-4	2009	If TSH can activate LH/CG-R, then, the TSH-R blocking autoantibodies could bind and block LH/CG-R in the corpus luteum through a similar cross-reactivity process.	Thyrotropin	3-6	luteinizing hormone/choriogonadotropin receptor	Homo sapiens	90-97
19820021-1	2009	CONTEXT: Mutations in TSH receptor (TSHR) are notoriously associated with congenital hypothyroidism as well as with non-autoimmune subclinical hypothyroidism, a mild form of TSH resistance that is not as well characterized by diagnostic procedures.	Thyrotropin	22-25	thyroid stimulating hormone receptor	Homo sapiens	36-40
19187127-9	2009	Given the pivotal role of the liver in body metabolism and many human diseases, our findings provide important implications for a potentially novel physiopathological role of TSH via acting on the TSHR in hepatocytes besides its classical role in regulating the thyroid function.	Thyrotropin	175-178	thyroid stimulating hormone receptor	Homo sapiens	197-201
27579061-0	2009	Effect of thyroid peroxidase antibodies on thyroid-stimulating hormone reference limits in a primarily Latina population.	Thyrotropin	43-70	thyroid peroxidase	Homo sapiens	10-28
19820008-3	2009	The single nucleotide polymorphism rs4704397 in the phosphodiesterase 8B (PDE8B) gene has been found to be associated with altered serum TSH concentrations in the general population.	Thyrotropin	137-140	phosphodiesterase 8B	Homo sapiens	52-72
19820008-3	2009	The single nucleotide polymorphism rs4704397 in the phosphodiesterase 8B (PDE8B) gene has been found to be associated with altered serum TSH concentrations in the general population.	Thyrotropin	137-140	phosphodiesterase 8B	Homo sapiens	74-79
19820008-11	2009	CONCLUSION: Genetic variation in TSH levels in pregnancy associated with the PDE8B rs4704397 genotype has implications for the number of women treated for subclinical hypothyroidism under current guidelines.	Thyrotropin	33-36	phosphodiesterase 8B	Homo sapiens	77-82
19720729-3	2009	We set out to determine whether PKA and/or Rap1 mediate extracellular signal-regulated kinase (ERK) activation by TSH.	Thyrotropin	114-117	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	32-35
19720729-3	2009	We set out to determine whether PKA and/or Rap1 mediate extracellular signal-regulated kinase (ERK) activation by TSH.	Thyrotropin	114-117	Eph receptor B1	Rattus norvegicus	56-93
19720729-8	2009	Silencing the expression of B-Raf also inhibited ERK activation by TSH, forskolin, and 6MB-cAMP, but not that stimulated by insulin or serum.	Thyrotropin	67-70	B-Raf proto-oncogene, serine/threonine kinase	Rattus norvegicus	28-33
19720729-8	2009	Silencing the expression of B-Raf also inhibited ERK activation by TSH, forskolin, and 6MB-cAMP, but not that stimulated by insulin or serum.	Thyrotropin	67-70	Eph receptor B1	Rattus norvegicus	49-52
19720729-3	2009	We set out to determine whether PKA and/or Rap1 mediate extracellular signal-regulated kinase (ERK) activation by TSH.	Thyrotropin	114-117	Eph receptor B1	Rattus norvegicus	95-98
19720729-7	2009	Expression of dominant-negative Ras inhibited ERK activation by TSH, forskolin, and N(6)-monobutyryl (6MB)-cAMP, a selective activator of PKA.	Thyrotropin	64-67	Eph receptor B1	Rattus norvegicus	46-49
20030174-5	2009	Serum apoB-48 concentration was measured by chemiluminescence enzyme immunoassay (CLEIA) and it correlated with thyroid stimulating hormone (TSH), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C) and triglycerides(TG), but negatively correlated with free thyroxine (FT4) and free triiodothyronine (FT3).	Thyrotropin	112-139	apolipoprotein B	Homo sapiens	6-13
20030174-5	2009	Serum apoB-48 concentration was measured by chemiluminescence enzyme immunoassay (CLEIA) and it correlated with thyroid stimulating hormone (TSH), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C) and triglycerides(TG), but negatively correlated with free thyroxine (FT4) and free triiodothyronine (FT3).	Thyrotropin	141-144	apolipoprotein B	Homo sapiens	6-13
19767733-2	2009	Here, we show that the potassium channel subunits KCNQ1 and KCNE2 form a thyroid-stimulating hormone-stimulated, constitutively active, thyrocyte K+ channel required for normal thyroid hormone biosynthesis.	Thyrotropin	73-100	potassium voltage-gated channel, subfamily Q, member 1	Mus musculus	50-55
19767733-2	2009	Here, we show that the potassium channel subunits KCNQ1 and KCNE2 form a thyroid-stimulating hormone-stimulated, constitutively active, thyrocyte K+ channel required for normal thyroid hormone biosynthesis.	Thyrotropin	73-100	potassium voltage-gated channel, Isk-related subfamily, gene 2	Mus musculus	60-65
19415532-3	2009	A deficiency in TBG is suspected when abnormally low serum total T4 and T3 are encountered in clinically euthyroid subjects in the presence of normal serum TSH.	Thyrotropin	156-159	serpin family A member 7	Homo sapiens	16-19
19477936-6	2009	Moreover, coexpression of TSH and Dio2 could also be demonstrated in the pituitary of wild-type mice, underlining the important role of this enzyme in the negative feedback regulation of TSH by thyroid hormone.	Thyrotropin	187-190	deiodinase, iodothyronine, type II	Mus musculus	34-38
19778476-6	2009	Women with thyroid-stimulating hormone &gt; or =2.5 mIU/l had a significantly higher body mass index (P = 0.003), higher fasting insulin concentrations (P = 0.02) and altered insulin resistance indices (P = 0.007), higher total testosterone (P = 0.009) and free androgen indices (P = 0.001) and decreased sex hormone-binding globulin concentrations (P = 0.01) in comparison with women with thyroid-stimulating hormone &lt;2.5 mIU/l.	Thyrotropin	11-38	insulin	Homo sapiens	129-136
19778476-6	2009	Women with thyroid-stimulating hormone &gt; or =2.5 mIU/l had a significantly higher body mass index (P = 0.003), higher fasting insulin concentrations (P = 0.02) and altered insulin resistance indices (P = 0.007), higher total testosterone (P = 0.009) and free androgen indices (P = 0.001) and decreased sex hormone-binding globulin concentrations (P = 0.01) in comparison with women with thyroid-stimulating hormone &lt;2.5 mIU/l.	Thyrotropin	11-38	insulin	Homo sapiens	175-182
19435853-8	2009	However, when TSH levels were increased through low-iodine chow and sodium perchlorate, the induced goiter was more prominent in caveolin-1 knockout mice.	Thyrotropin	14-17	caveolin 1, caveolae protein	Mus musculus	129-139
19652218-16	2009	CONCLUSION: (18)F-FDG uptake in the thyroid carcinoma cell line ML-1 is no longer regulated by TSH or cAMP or mediated by GLUT-1.	Thyrotropin	95-98	interleukin 17F	Homo sapiens	64-68
19454581-3	2009	An ultrashort negative feedback loop affecting TSH secretion by activating the pituitary TSH receptor with TSH receptor autoantibodies has been suggested as a possible mechanism of TSH suppression in these patients.	Thyrotropin	47-50	thyroid stimulating hormone receptor	Homo sapiens	89-101
19454581-3	2009	An ultrashort negative feedback loop affecting TSH secretion by activating the pituitary TSH receptor with TSH receptor autoantibodies has been suggested as a possible mechanism of TSH suppression in these patients.	Thyrotropin	47-50	thyroid stimulating hormone receptor	Homo sapiens	107-119
19466745-0	2009	TSH induces co-localization of TSH receptor and Na/K-ATPase in human erythrocytes.	Thyrotropin	0-3	thyroid stimulating hormone receptor	Homo sapiens	31-43
19466745-8	2009	We found that TSH receptor and Na/K-ATPase are localized on the membranes of both erythrocytes and erythrocyte ghosts; TSH receptor responds to TSH treatment by increasing intracellular cAMP levels from two to tenfold.	Thyrotropin	14-17	thyroid stimulating hormone receptor	Homo sapiens	119-131
19466745-9	2009	In ghost membranes TSH treatment enhances up to three fold co-localization of TSHR with Na/K-ATPase and co-immunoprecipitation confirms their direct physical interaction.	Thyrotropin	19-22	thyroid stimulating hormone receptor	Homo sapiens	78-82
19499413-3	2009	It may also depend on activating mutations of the FSH receptor (FSHR) gene that cause ovarian hyper-responsiveness to circulating FSH or even cross-responsiveness of FSHR to hormones having a structure similar to FSH, such as hCG or TSH.	Thyrotropin	233-236	follicle stimulating hormone receptor	Homo sapiens	50-62
19499413-3	2009	It may also depend on activating mutations of the FSH receptor (FSHR) gene that cause ovarian hyper-responsiveness to circulating FSH or even cross-responsiveness of FSHR to hormones having a structure similar to FSH, such as hCG or TSH.	Thyrotropin	233-236	follicle stimulating hormone receptor	Homo sapiens	64-68
19219417-1	2009	An excess of human chorionic gonadotropin (hCG) is a rare differential diagnosis of hyperthyroidism, due to the TSH-like effect of hCG.	Thyrotropin	112-115	hypertrichosis 2 (generalised, congenital)	Homo sapiens	43-46
19336661-6	2009	Signals involved in this regulation, such as VEGF-A, originate from thyrocytes as early TSH-independent responses to iodide scarcity.	Thyrotropin	88-91	vascular endothelial growth factor A	Homo sapiens	45-51
19649385-6	2009	Anti-TPO was positive in 25% and associated with higher TSH levels (p = 0.034) and older age (p = 0.009).	Thyrotropin	56-59	thyroid peroxidase	Homo sapiens	5-8
20329409-9	2009	There was an inverse correlation of CD4 counts with serum TSH levels (r = -0.470 with p &lt; 0.050).	Thyrotropin	58-61	CD4 molecule	Homo sapiens	36-39
19219417-1	2009	An excess of human chorionic gonadotropin (hCG) is a rare differential diagnosis of hyperthyroidism, due to the TSH-like effect of hCG.	Thyrotropin	112-115	hypertrichosis 2 (generalised, congenital)	Homo sapiens	131-134
19499990-4	2009	METHODS: The sensitivity to EGF stimulation was evaluated in follicular thyroid carcinoma WRO cells that retain some features of thyroid cell differentiation and in undifferentiated TSH-independent thyroid carcinoma FRO cells.	Thyrotropin	182-185	epidermal growth factor	Homo sapiens	28-31
19336512-2	2009	Previous studies report diminished serum TSH concentrations in patients with active acromegaly and decreased response to TRH.	Thyrotropin	41-44	thyrotropin releasing hormone	Homo sapiens	121-124
19336512-11	2009	Total TSH secretion correlated with TSH increase after TRH (R = 0.75; P = 0.0001), negatively with the log-transformed GH secretion rate (R = -0.52; P = 0.001), but not with adenoma size.	Thyrotropin	6-9	thyrotropin releasing hormone	Homo sapiens	55-58
19499990-7	2009	By contrast, the protracted stimulation of TSH-dependent WRO cells with EGF induced the loss of TSH dependency and the rearrangement of F-actin cytoskeleton.	Thyrotropin	43-46	epidermal growth factor	Homo sapiens	72-75
19499990-8	2009	CONCLUSIONS: These results suggest that the acquired sensitivity to EGF in these thyroid tumor cells may be responsible for the loss of differentiation in the transition toward a TSH-independent, invasive, and chemoresistant phenotype.	Thyrotropin	179-182	epidermal growth factor	Homo sapiens	68-71
19179432-10	2009	We propose that an increase in circulating thyroid hormone up-regulates PPII activity in tanycytes and enhances degradation of extracellular TRH in the median eminence through glial-axonal associations, contributing to the feedback regulation of thyroid hormone on anterior pituitary TSH secretion.	Thyrotropin	284-287	thyrotropin releasing hormone	Rattus norvegicus	141-144
19208852-9	2009	Although leptin restores the hypothalamus-pituitary axis during food restriction, it exerts a direct negative effect on the thyroid gland; thus normalization of serum thyroid hormones might depend on changes in deiodinase activities and the long-term thyroid stimulation by TSH to counterbalance the direct negative effects of leptin on the thyroid gland.	Thyrotropin	274-277	leptin	Rattus norvegicus	9-15
19498324-10	2009	There was a positive correlation between visfatin and TSH levels (r=0.701, p&lt;0.001).	Thyrotropin	54-57	nicotinamide phosphoribosyltransferase	Homo sapiens	41-49
19558833-10	2009	TSH may promote the development of thyroid carcinoma by TSH-Prx1-Trx1-HIF-1 signaling pathway.	Thyrotropin	0-3	peroxiredoxin 1	Homo sapiens	60-64
19221175-0	2009	Thyroid stimulating autoantibody M22 mimics TSH binding to the TSH receptor leucine rich domain: a comparative structural study of protein-protein interactions.	Thyrotropin	44-47	thyroid stimulating hormone receptor	Homo sapiens	63-75
19221175-1	2009	The TSH receptor (TSHR) ligands M22 (a thyroid stimulating human monoclonal antibody) and TSH, bind to the concave surface of the leucine rich repeats domain (LRD) of the TSHR and here, we show that M22 mimics closely the binding of TSH.	Thyrotropin	4-7	thyroid stimulating hormone receptor	Homo sapiens	18-22
19221175-1	2009	The TSH receptor (TSHR) ligands M22 (a thyroid stimulating human monoclonal antibody) and TSH, bind to the concave surface of the leucine rich repeats domain (LRD) of the TSHR and here, we show that M22 mimics closely the binding of TSH.	Thyrotropin	4-7	thyroid stimulating hormone receptor	Homo sapiens	171-175
19214582-3	2009	When transfected into HeLa cells and stimulated with TSH, the TSHr-FlAsH receptor exhibited a pronounced perinuclear labelling pattern, whereas labelling remained on the cell surface following pre-incubation with 1,1,1-trichloro-2,2-bis(p-chlorophenyl)ethane (DDT).	Thyrotropin	53-56	thyrotropin receptor	Cricetulus griseus	62-66
19214582-4	2009	Chinese hamster ovary (CHO)-TSHr cells probed with anti-TSHr antibodies were fluorescent mainly in the proximity of the plasma membrane, with fluorescence being primarily restricted to a juxta-nuclear position when exposed to 10 mU/ml TSH for 1 or 5 min.	Thyrotropin	28-31	thyrotropin receptor	Cricetulus griseus	56-60
19588843-10	2009	Residents in the Great Lakes area, USA, whose blood PCB levels are estimated to be higher than other places, have shown disorder of thyroid, T4, TSH levels, endometriosis, joint disorder, and low IQ score in children.	Thyrotropin	145-148	pyruvate carboxylase	Homo sapiens	52-55
18726107-1	2009	INTRODUCTION: The hormone human chorionic gonadotropin (hCG), secreted by molar tissue, is structurally similar to thyroid-stimulating hormone (TSH).	Thyrotropin	115-142	hypertrichosis 2 (generalised, congenital)	Homo sapiens	56-59
18726107-1	2009	INTRODUCTION: The hormone human chorionic gonadotropin (hCG), secreted by molar tissue, is structurally similar to thyroid-stimulating hormone (TSH).	Thyrotropin	144-147	hypertrichosis 2 (generalised, congenital)	Homo sapiens	56-59
19214582-2	2009	The observation that TSH administration caused the intracellular level of cAMP to increase in both TSHr-FlAsH-transfected cell types indicated that the FlAsH binding motif did not alter normal TSHr functioning.	Thyrotropin	21-24	thyrotropin receptor	Cricetulus griseus	99-103
18710470-2	2009	These mutational effects raise the question of whether polymorphic variation in SLC16A2 may also be associated with differences in serum levels of TH and/or TSH.	Thyrotropin	157-160	solute carrier family 16 member 2	Homo sapiens	80-87
19367049-6	2009	In addition, thyroid glands from PCB 153 groups had normal T(4) responses to exogenous TSH in vivo.	Thyrotropin	87-90	pyruvate carboxylase	Rattus norvegicus	33-36
19558833-10	2009	TSH may promote the development of thyroid carcinoma by TSH-Prx1-Trx1-HIF-1 signaling pathway.	Thyrotropin	0-3	thioredoxin	Homo sapiens	65-69
18996577-3	2009	Under control conditions the mean prolactin, TSH, and thyroxine concentrations were similar in intact and gonadectomised dogs, and administration of TRH provoked a significant (p&lt;0.01) increase in concentrations of the three hormones.	Thyrotropin	45-48	TRH	Canis lupus familiaris	149-152
18996577-6	2009	Corresponding TRH-stimulated TSH concentrations were not affected by cabergoline.	Thyrotropin	29-32	TRH	Canis lupus familiaris	14-17
19179434-3	2009	Hypothalamic TSH-releasing hormone (TRH) stimulates TSH secretion from the anterior pituitary.	Thyrotropin	13-16	thyrotropin releasing hormone	Homo sapiens	36-39
19196800-6	2009	TSH and iodide regulate iodide accumulation by modulating NIS activity via transcriptional and posttranscriptional mechanisms.	Thyrotropin	0-3	solute carrier family 5 member 5	Homo sapiens	58-61
19589104-5	2009	Six months after thyroid ablation (i.e., thyroidectomy plus radioiodine) serum Tg was measured during TSH-suppressive thyroxine (T4) treatment (onT4-Tg).	Thyrotropin	102-105	thyroglobulin	Homo sapiens	79-81
18927215-3	2009	Functional characterization of the Q489H-TSHR in transiently transfected HEK293 cells showed cell surface expression, normal TSH binding affinity, and its inability to generate intracellular cAMP in response to TSH stimulation.	Thyrotropin	125-128	thyroid stimulating hormone receptor	Homo sapiens	41-45
18927215-6	2009	This study shows that Q489H substitution impedes complete glycosylation of TSHR extracellular domain within the Golgi apparatus and that Q489H-TSHR expressed at the cell surface is unable to undergo intramolecular cleavage as well as to switch toward an active conformation under TSH stimulation.	Thyrotropin	75-78	thyroid stimulating hormone receptor	Homo sapiens	143-147
19186189-6	2009	We show here that ts1 infection in the small intestine is followed by loss of intestinal epithelial cell (IEC) thyroid-stimulating hormone (TSH) and cell cycling gradients (along the crypt-villus axes), accumulation of gPr80(env) in intestinal cells, apoptosis of developing T cells in the lamina propria (LP), and intestinal collapse by approximately 30 dpi.	Thyrotropin	111-138	Trichinella spiralis resistance 1	Mus musculus	18-21
18787023-8	2009	In females, a significant percentage of the cells expressing CRH-R1 also expressed transcript for prolactin (40%), LHbeta (10%), or TSH (3%), all novel sites of CRH-R1 expression.	Thyrotropin	132-135	corticotropin releasing hormone receptor 1	Mus musculus	61-67
18687776-2	2009	Here we found that sortilin is expressed in thyroid epithelial cells (thyrocytes) in a TSH-dependent manner, that the hormone precursor thyroglobulin (Tg) is a high-affinity sortilin ligand, and that binding to sortilin occurs after Tg endocytosis, resulting in Tg recycling.	Thyrotropin	87-90	sortilin 1	Rattus norvegicus	19-27
18687776-2	2009	Here we found that sortilin is expressed in thyroid epithelial cells (thyrocytes) in a TSH-dependent manner, that the hormone precursor thyroglobulin (Tg) is a high-affinity sortilin ligand, and that binding to sortilin occurs after Tg endocytosis, resulting in Tg recycling.	Thyrotropin	87-90	thyroglobulin	Rattus norvegicus	136-149
18687776-2	2009	Here we found that sortilin is expressed in thyroid epithelial cells (thyrocytes) in a TSH-dependent manner, that the hormone precursor thyroglobulin (Tg) is a high-affinity sortilin ligand, and that binding to sortilin occurs after Tg endocytosis, resulting in Tg recycling.	Thyrotropin	87-90	thyroglobulin	Rattus norvegicus	151-153
18687776-4	2009	Sortilin expression was demonstrated to be TSH dependent, both in FRTL-5 cells and in mice treated with methimazole and perchlorate.	Thyrotropin	43-46	sortilin 1	Rattus norvegicus	0-8
18787023-9	2009	Similarly in males, a percentage of CRH-R1-positive cells expressed prolactin (12%), LHbeta (13%), and TSH (5%).	Thyrotropin	103-106	corticotropin releasing hormone receptor 1	Mus musculus	36-42
19050673-10	2009	In the whole dataset, mean 24-h leptin levels were directly related to mean 24-h TSH levels after controlling for confounders this relationship was lost only after adjusting for fat mass.	Thyrotropin	81-84	leptin	Homo sapiens	32-38
18719020-2	2009	TSH is known to activate the thyroid epithelial cell via both Galphas-cAMP/protein kinase A/ERK and Galphaq-Akt/protein kinase C coupled signaling networks.	Thyrotropin	0-3	Eph receptor B1	Rattus norvegicus	92-95
18719020-2	2009	TSH is known to activate the thyroid epithelial cell via both Galphas-cAMP/protein kinase A/ERK and Galphaq-Akt/protein kinase C coupled signaling networks.	Thyrotropin	0-3	G protein subunit alpha q	Rattus norvegicus	100-107
18719020-2	2009	TSH is known to activate the thyroid epithelial cell via both Galphas-cAMP/protein kinase A/ERK and Galphaq-Akt/protein kinase C coupled signaling networks.	Thyrotropin	0-3	AKT serine/threonine kinase 1	Rattus norvegicus	108-111
19175736-12	2009	CONCLUSIONS AND CLINICAL IMPORTANCE: The biologic relevance of the altered TSH response to TRH in anhidrotic horses is uncertain, considering that TSH concentrations remained within previously reported normal ranges and thyroid hormone responses were not different between anhidrotic and control horses.	Thyrotropin	75-78	thyrotropin releasing hormone	Equus caballus	91-94
19092294-4	2008	OBJECTIVE: The aim of our study was to evaluate the acute effect of the recombinant human TSH (rhTSH)-induced TSH surge on serum leptin levels in thyroidectomized patients undergoing levothyroxine (L-T4) suppressive therapy for differentiated thyroid carcinoma (DTC).	Thyrotropin	90-93	leptin	Homo sapiens	129-135
18829452-9	2008	A triple NNN motif in mDia1 (amino acids 164-166), corresponding to the TSH motif in mDia2/3 (amino acids 183-185 and 190-192), and the epitope interacting with the Rho insert helix are essential for high affinity binding.	Thyrotropin	72-75	diaphanous related formin 1	Mus musculus	22-27
18829452-9	2008	A triple NNN motif in mDia1 (amino acids 164-166), corresponding to the TSH motif in mDia2/3 (amino acids 183-185 and 190-192), and the epitope interacting with the Rho insert helix are essential for high affinity binding.	Thyrotropin	72-75	diaphanous related formin 3	Mus musculus	85-92
18805917-8	2008	After the TRH test, TSH concentrations increased to 13.4-36.0 mU/l (normal range, 4.0-20.0 mU/l).	Thyrotropin	20-23	thyrotropin releasing hormone	Homo sapiens	10-13
18818971-9	2008	Some cell lines showed TSH-induced (e.g., 60% in XTC) or EGF-induced (e.g., 120% in TPC1) upregulation of endostatin secretion, while others did not, despite documented receptor expression.	Thyrotropin	23-26	collagen type XVIII alpha 1 chain	Homo sapiens	106-116
19337173-0	2008	Exaggerated TSH response to TRH ("sub-biochemical" hypothyroidism) in prepubertal and adolescent thalassaemic patients with iron overload: prevalence and 20-year natural history.	Thyrotropin	12-15	thyrotropin releasing hormone	Homo sapiens	28-31
19014658-11	2008	In DTC subjects, plasma fibrinogen concentrations correlated positively with insulin resistance, cholesterol and LDL-cholesterol, and negatively with TSH levels.	Thyrotropin	150-153	fibrinogen beta chain	Homo sapiens	24-34
18816177-3	2008	On evaluation, she had increased free thyroxine and TSH levels, normal serum glycoprotein alpha-subunit levels, and a significant TSH over-response to exogenous thyrotropin-releasing hormone stimulation.	Thyrotropin	130-133	thyrotropin releasing hormone	Homo sapiens	161-190
18844476-14	2008	Only THRB-in9-G/A was associated with higher serum TSH in a large population of Danish twins.	Thyrotropin	51-54	thyroid hormone receptor beta	Homo sapiens	5-9
18544616-7	2008	TSH concentrations at the 25th and fifth centiles become sharply lower at higher hCG levels, whereas 50th centile and above TSH concentrations are only slightly lower.	Thyrotropin	0-3	hypertrichosis 2 (generalised, congenital)	Homo sapiens	81-84
18768899-12	2008	Our findings suggest that IGF-1R might mediate some TSH-provoked signaling.	Thyrotropin	52-55	insulin like growth factor 1 receptor	Homo sapiens	26-32
18466214-9	2008	A total of 55.5% patients with positive anti-TPO antibodies had abnormal TSH levels.	Thyrotropin	73-76	thyroid peroxidase	Homo sapiens	45-48
18788923-5	2008	Before she was lost to followup the serum thyroglobulin (Tg) after recombinant TSH administration was 84 ng/ml (normal values &lt; 2 ng/ml) and there was no uptake on a radioiodine whole body scan.	Thyrotropin	79-82	thyroglobulin	Homo sapiens	42-55
18788923-5	2008	Before she was lost to followup the serum thyroglobulin (Tg) after recombinant TSH administration was 84 ng/ml (normal values &lt; 2 ng/ml) and there was no uptake on a radioiodine whole body scan.	Thyrotropin	79-82	thyroglobulin	Homo sapiens	57-59
18571155-5	2008	We show that zfh2 expression is delimited distally by Vg, Nub and Dpp signalling, and proximally by Tsh and Dpp.	Thyrotropin	100-103	Zn finger homeodomain 2	Drosophila melanogaster	13-17
18701481-3	2008	The expression of PPARdelta was induced coordinately with proliferation in primary human thyroid cells by the activation of serum, thyroid-stimulating hormone/cyclic AMP, or epidermal growth factor/mitogen-activated protein kinase mitogenic signaling pathways.	Thyrotropin	131-158	peroxisome proliferator activated receptor delta	Homo sapiens	18-27
18498765-4	2008	METHODS: We compared 6 different Tg immunometric assays in 53 treated DTC patients in whom serum Tg during TSH-suppression therapy was below an earlier established clinical decision limit of 3 pmol/l (2 ng/ml) by our routine Tg assay, which was one of these 6.	Thyrotropin	107-110	thyroglobulin	Homo sapiens	97-99
18498765-4	2008	METHODS: We compared 6 different Tg immunometric assays in 53 treated DTC patients in whom serum Tg during TSH-suppression therapy was below an earlier established clinical decision limit of 3 pmol/l (2 ng/ml) by our routine Tg assay, which was one of these 6.	Thyrotropin	107-110	thyroglobulin	Homo sapiens	97-99
18445595-3	2008	We evaluated TSH-elicited cellular responses in human follicular thyroid carcinoma cells stably expressing the TSHR and in primary, nonneoplastic human thyrocytes.	Thyrotropin	13-16	thyroid stimulating hormone receptor	Homo sapiens	111-115
18445595-4	2008	In these cellular models, stimulation with TSH caused activation of p44/42 MAPK and subsequent induction of c-Fos.	Thyrotropin	43-46	interferon induced protein 44	Homo sapiens	68-71
18445595-4	2008	In these cellular models, stimulation with TSH caused activation of p44/42 MAPK and subsequent induction of c-Fos.	Thyrotropin	43-46	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	108-113
18403485-2	2008	In previous studies we showed that pretreatment of rat FRTL-5 thyroid cells with TSH or other cAMP-generating agents markedly potentiated DNA synthesis induced by IGF-I.	Thyrotropin	81-84	insulin-like growth factor 1	Rattus norvegicus	163-168
18505435-9	2008	In contrast, in HT, anti-C1q correlated positively with TSH levels.	Thyrotropin	56-59	complement C1q A chain	Homo sapiens	20-28
18399766-6	2008	MAIN OUTCOME: TRH administration resulted in an increase of 4- to 14-fold rise in serum TSH (8.3 +/- 2.5-fold), and in a slight rise in serum PRL concentrations (3.8 +/- 1.5-fold).	Thyrotropin	88-91	thyrotropin releasing hormone	Homo sapiens	14-17
18636109-2	2008	Prop1 transgenic (Tg) mice have been shown to generate pituitary tumors that either produce TSH or are non-hormone producing.	Thyrotropin	92-95	paired like homeodomain factor 1	Mus musculus	0-5
18514160-0	2008	Phosphodiesterase 8B gene variants are associated with serum TSH levels and thyroid function.	Thyrotropin	61-64	phosphodiesterase 8B	Homo sapiens	0-20
18514160-6	2008	In addition to association of TSH levels with SNPs in PDE8B, our genome scan provided evidence for association with PDE10A and several biologically interesting candidates in a focused analysis of 24 genes.	Thyrotropin	30-33	phosphodiesterase 8B	Homo sapiens	54-59
18308843-0	2008	Thyroid-stimulating hormone induces interleukin-6 release from human adipocytes through activation of the nuclear factor-kappaB pathway.	Thyrotropin	0-27	interleukin 6	Homo sapiens	36-49
18308843-1	2008	Our objective was to identify the signaling pathway activated by TSH that induces IL-6 secretion from human abdominal sc differentiated adipocytes.	Thyrotropin	65-68	interleukin 6	Homo sapiens	82-86
18308843-3	2008	IL-6 release stimulated by TSH was inhibited by 35% (P &lt; 0.05) with SN50, an inhibitor of nuclear factor-kappaB (NF-kappaB) nuclear translocation, and 60% (P &lt; 0.01) with sc-514, an inhibitor of inhibitory-kappaB (IkappaB) kinase (IKK)-beta.	Thyrotropin	27-30	interleukin 6	Homo sapiens	0-4
18308843-3	2008	IL-6 release stimulated by TSH was inhibited by 35% (P &lt; 0.05) with SN50, an inhibitor of nuclear factor-kappaB (NF-kappaB) nuclear translocation, and 60% (P &lt; 0.01) with sc-514, an inhibitor of inhibitory-kappaB (IkappaB) kinase (IKK)-beta.	Thyrotropin	27-30	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	201-246
18308843-4	2008	Phosphorylation of IKKbeta increased upon TSH treatment (10.3-fold, P &lt; 0.01), and IkappaBalpha levels were reduced by 78% (P &lt; 0.01).	Thyrotropin	42-45	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	19-26
18308843-8	2008	Our data demonstrate that the IKKbeta/NF-kappaB pathway is a novel TSH target that is required for TSH-induced IL-6 release from human adipocytes.	Thyrotropin	67-70	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	30-37
18308843-8	2008	Our data demonstrate that the IKKbeta/NF-kappaB pathway is a novel TSH target that is required for TSH-induced IL-6 release from human adipocytes.	Thyrotropin	67-70	interleukin 6	Homo sapiens	111-115
18308843-8	2008	Our data demonstrate that the IKKbeta/NF-kappaB pathway is a novel TSH target that is required for TSH-induced IL-6 release from human adipocytes.	Thyrotropin	99-102	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	30-37
18308843-8	2008	Our data demonstrate that the IKKbeta/NF-kappaB pathway is a novel TSH target that is required for TSH-induced IL-6 release from human adipocytes.	Thyrotropin	99-102	interleukin 6	Homo sapiens	111-115
18243140-5	2008	Furthermore, in cultured lymphocytes we compared changes in Tg mRNA expression following stimulation with TSH.	Thyrotropin	106-109	thyroglobulin	Homo sapiens	60-62
18243140-10	2008	The levels of Tg mRNA in the TSH-stimulated lymphocytes were noticeably increased in subjects with thyroid disease.	Thyrotropin	29-32	thyroglobulin	Homo sapiens	14-16
18379900-7	2008	It is interesting to note that, in the pituitary adenoma, MSX1 was expressed in the nucleus of GH- and TSH-producing adenomas.	Thyrotropin	103-106	msh homeobox 1	Homo sapiens	58-62
18437010-4	2008	TSH rapidly increases the Id2 mRNA level in FRTL-5 thyroid cells but the Id2 protein showed biphasic regulatory patterns, being transiently reduced and subsequently induced by TSH treatment.	Thyrotropin	0-3	inhibitor of DNA binding 2	Rattus norvegicus	26-29
18437010-5	2008	Transient reduction of Id2 protein was noted within 2 hr of TSH treatment and was mediated by proteasomal degradation.	Thyrotropin	60-63	inhibitor of DNA binding 2	Rattus norvegicus	23-26
18437010-6	2008	Moreover, reduced Id2 expression correlated with the activity of the phosphatidylinositol 3 kinase pathway, which is activated by TSH.	Thyrotropin	130-133	inhibitor of DNA binding 2	Rattus norvegicus	18-21
18399765-14	2008	CONCLUSIONS: TSH suppression therapy with LT4 leading to subclinical hyperthyroidism may cause impaired endothelial function, increased oxidative stress, and decreased insulin sensitivity in euthyroid nodular goiter patients.	Thyrotropin	13-16	insulin	Homo sapiens	168-175
18313043-8	2008	A significant positive relationship was observed between serum TSH and different PCB congeners (PCB 138, PCB 180, non-coplanar congeners, mono-ortho coplanar congeners, dioxin-like PCBs), as well as SigmaPCB.	Thyrotropin	63-66	pyruvate carboxylase	Homo sapiens	81-84
18313043-8	2008	A significant positive relationship was observed between serum TSH and different PCB congeners (PCB 138, PCB 180, non-coplanar congeners, mono-ortho coplanar congeners, dioxin-like PCBs), as well as SigmaPCB.	Thyrotropin	63-66	pyruvate carboxylase	Homo sapiens	96-99
18313043-8	2008	A significant positive relationship was observed between serum TSH and different PCB congeners (PCB 138, PCB 180, non-coplanar congeners, mono-ortho coplanar congeners, dioxin-like PCBs), as well as SigmaPCB.	Thyrotropin	63-66	pyruvate carboxylase	Homo sapiens	96-99
18451066-8	2008	TSH and TSH in association with insulin or IGF-I stimulated GRK2 protein accumulation in normal human thyroid cells in primary culture.	Thyrotropin	0-3	insulin	Homo sapiens	32-39
18451066-8	2008	TSH and TSH in association with insulin or IGF-I stimulated GRK2 protein accumulation in normal human thyroid cells in primary culture.	Thyrotropin	0-3	insulin like growth factor 1	Homo sapiens	43-48
18451066-8	2008	TSH and TSH in association with insulin or IGF-I stimulated GRK2 protein accumulation in normal human thyroid cells in primary culture.	Thyrotropin	0-3	G protein-coupled receptor kinase 2	Homo sapiens	60-64
18451066-8	2008	TSH and TSH in association with insulin or IGF-I stimulated GRK2 protein accumulation in normal human thyroid cells in primary culture.	Thyrotropin	8-11	insulin	Homo sapiens	32-39
18451066-8	2008	TSH and TSH in association with insulin or IGF-I stimulated GRK2 protein accumulation in normal human thyroid cells in primary culture.	Thyrotropin	8-11	insulin like growth factor 1	Homo sapiens	43-48
18451066-8	2008	TSH and TSH in association with insulin or IGF-I stimulated GRK2 protein accumulation in normal human thyroid cells in primary culture.	Thyrotropin	8-11	G protein-coupled receptor kinase 2	Homo sapiens	60-64
18381580-10	2008	RBP4 level was positively correlated with TSH level (r = 0.241, P = 0.001) after adjustment for age, sex, and body mass index.	Thyrotropin	42-45	retinol binding protein 4	Homo sapiens	0-4
18689910-3	2008	Our hypothesis to explain this observation is that goserelin decreased serum thyroxine-binding-globulin (TBG), resulting in an increase in fT4 and thereby a decrease in serum TSH.	Thyrotropin	175-178	serpin family A member 7	Homo sapiens	77-103
18689910-3	2008	Our hypothesis to explain this observation is that goserelin decreased serum thyroxine-binding-globulin (TBG), resulting in an increase in fT4 and thereby a decrease in serum TSH.	Thyrotropin	175-178	serpin family A member 7	Homo sapiens	105-108
18399769-11	2008	The acute TSH administration results in an increase of PINP, an index of osteoblastic activity, associated with an increase of serum RANKL.	Thyrotropin	10-13	TNF superfamily member 11	Homo sapiens	133-138
18465687-10	2008	CONCLUSIONS: Early treatment results of well differentiated thyroid cancer depend on the clinical stage, and postoperative serum thyroglobulin level measured after endogenous TSH stimulation.	Thyrotropin	175-178	thyroglobulin	Homo sapiens	129-142
18313206-7	2008	Pretreatment with TSH potentiates the growth effects of ghrelin in thyroid cells, and p66Shc, a growth factor receptor adaptor protein, might mediate these synergistic effects.	Thyrotropin	18-21	ghrelin and obestatin prepropeptide	Rattus norvegicus	56-63
18313206-8	2008	Ghrelin phosphorylated TSH-induced p66Shc, which was inhibited by CPA.	Thyrotropin	23-26	ghrelin and obestatin prepropeptide	Rattus norvegicus	0-7
18313206-8	2008	Ghrelin phosphorylated TSH-induced p66Shc, which was inhibited by CPA.	Thyrotropin	23-26	SHC adaptor protein 1	Rattus norvegicus	35-41
18313206-10	2008	Thus, ghrelin-induced intracellular calcium signaling enhanced the TSH-induced proliferation of thyrocytes, possibly mediated by the p66Shc pathway.	Thyrotropin	67-70	ghrelin and obestatin prepropeptide	Rattus norvegicus	6-13
18313206-10	2008	Thus, ghrelin-induced intracellular calcium signaling enhanced the TSH-induced proliferation of thyrocytes, possibly mediated by the p66Shc pathway.	Thyrotropin	67-70	SHC adaptor protein 1	Rattus norvegicus	133-139
18280640-3	2008	In the latter cell type, secretion of IL-6 is stimulated notably by interleukin-1 (IL-1), thyroid-stimulating hormone (TSH) or forskolin (Fk), a cAMP elevating agent.	Thyrotropin	90-117	interleukin 6	Rattus norvegicus	38-42
18280640-3	2008	In the latter cell type, secretion of IL-6 is stimulated notably by interleukin-1 (IL-1), thyroid-stimulating hormone (TSH) or forskolin (Fk), a cAMP elevating agent.	Thyrotropin	119-122	interleukin 6	Rattus norvegicus	38-42
18398274-3	2008	We tested whether serum TSH concentrations were correlated with plasma total homocysteine concentration (tHcy), low-density lipoprotein cholesterol (LDL-C), very low-density lipoprotein cholesterol (VLDL-C), high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC) and triglycerides (TG).	Thyrotropin	24-27	component of oligomeric golgi complex 2	Homo sapiens	112-147
18398274-3	2008	We tested whether serum TSH concentrations were correlated with plasma total homocysteine concentration (tHcy), low-density lipoprotein cholesterol (LDL-C), very low-density lipoprotein cholesterol (VLDL-C), high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC) and triglycerides (TG).	Thyrotropin	24-27	component of oligomeric golgi complex 2	Homo sapiens	162-197
18398274-6	2008	Serum TSH was significantly correlated with plasma tHcy (r=0.55; P=.001), TC (r=0.52; P=.001), LDL-C (r=0.49; P=.001), TC/HDL-C (r=0.38; P=.002) and LDL-C/HDL-C (r=0.36; P=.004) across all participants.	Thyrotropin	6-9	component of oligomeric golgi complex 2	Homo sapiens	95-100
18398274-6	2008	Serum TSH was significantly correlated with plasma tHcy (r=0.55; P=.001), TC (r=0.52; P=.001), LDL-C (r=0.49; P=.001), TC/HDL-C (r=0.38; P=.002) and LDL-C/HDL-C (r=0.36; P=.004) across all participants.	Thyrotropin	6-9	component of oligomeric golgi complex 2	Homo sapiens	149-154
30764086-6	2008	Clinically, measurements of thyroid-stimulating hormone (TSH)-stimulated Tg after thyroid hormone withdrawal, or exogenous TSH administration in patients with undetectable serum Tg during thyroid hormone-suppression therapy, is recommended for revealing occult disease.	Thyrotropin	57-60	thyroglobulin	Homo sapiens	73-75
30764086-7	2008	Technically, the development of Tg assays with improved functional sensitivity enhances the value of Tg measurements, allowing us to measure Tg without any TSH stimulation during DTC with high negative predictive value.	Thyrotropin	156-159	thyroglobulin	Homo sapiens	32-34
18063584-6	2008	We have generated a new dominant negative Epac mutant that revealed that activation of Epac is required for thyroid-stimulating hormone or cAMP stimulation of DNA synthesis.	Thyrotropin	108-135	Rap guanine nucleotide exchange factor 3	Homo sapiens	42-46
17931717-2	2008	Previous study showed that mice with disruption of neuromedin B receptor (NBR-KO) have higher TSH release in response to thyrotropin-releasing hormone (TRH), although TSH seems to have decreased bioactivity.	Thyrotropin	94-97	neuromedin B receptor	Mus musculus	51-72
18063584-6	2008	We have generated a new dominant negative Epac mutant that revealed that activation of Epac is required for thyroid-stimulating hormone or cAMP stimulation of DNA synthesis.	Thyrotropin	108-135	Rap guanine nucleotide exchange factor 3	Homo sapiens	87-91
18042666-8	2008	All together, these data show that Cx32 acts as a downregulator of growth of thyroid gland; an excess of Cx32 limits growth of thyroid cells in the basal state, whereas a lack of Cx32 confers an additional growth potential to TSH-stimulated thyroid cells.	Thyrotropin	226-229	gap junction protein, beta 1	Mus musculus	35-39
17931717-2	2008	Previous study showed that mice with disruption of neuromedin B receptor (NBR-KO) have higher TSH release in response to thyrotropin-releasing hormone (TRH), although TSH seems to have decreased bioactivity.	Thyrotropin	94-97	thyrotropin releasing hormone	Mus musculus	121-150
17931717-9	2008	In conclusion, disruption of neuromedin B receptor did not interfere with the sensitivity of thyroid hormone-mediated suppression of TSH release, but impaired the ability of thyrotroph to increase serum TSH in hypothyroidism, which highlights the importance of NB in modulating the set point of the hypothalamus-pituitary-thyroid axis at hypothyroidism.	Thyrotropin	203-206	neuromedin B receptor	Mus musculus	29-50
18972269-13	2008	CONCLUSIONS: Anti-TPO was present in one-third of pregnant women with type 1 diabetes and associated with slightly higher TSH, but not poorer glycemic control or adverse birth outcome.	Thyrotropin	122-125	thyroid peroxidase	Homo sapiens	18-21
17363208-5	2008	TRH administration caused plasma TSH concentrations to rise significantly in the control dogs, but not in the hypothyroid dogs.	Thyrotropin	33-36	TRH	Canis lupus familiaris	0-3
18067893-5	2008	ERalpha-immunoreactive (ir) cells mainly corresponded to PRL-ir cells and, to a lesser extent, to TSH-, FSH- and GH-ir cells.	Thyrotropin	98-101	estrogen receptor 1	Rattus norvegicus	0-7
18216391-2	2008	TSH receptor (TSHR) is expressed mainly in thyroid follicular cells and is activated by TSH, which regulates the growth and function of thyroid follicular cells.	Thyrotropin	0-3	thyroid stimulating hormone receptor	Homo sapiens	14-18
18063289-24	2008	Pituitary response to TRH-mediated TSH release was not diminished after 8-daily oral doses of PFOS.	Thyrotropin	35-38	thyrotropin releasing hormone	Rattus norvegicus	22-25
18060877-3	2008	Iodinated Tg is stored in the lumen of the thyroid follicles and is released in response to specific hormonal stimulation by thyroid stimulating hormone (TSH).	Thyrotropin	125-152	thyroglobulin	Homo sapiens	10-12
18060877-3	2008	Iodinated Tg is stored in the lumen of the thyroid follicles and is released in response to specific hormonal stimulation by thyroid stimulating hormone (TSH).	Thyrotropin	154-157	thyroglobulin	Homo sapiens	10-12
17721928-8	2008	Contrary to the mutations described previously, the p.Ser128Tyr FSHR mutant displayed increase in affinity and sensitivity toward hCG and did not show any constitutive activity, nor promiscuous activation by TSH.	Thyrotropin	208-211	follicle stimulating hormone receptor	Homo sapiens	64-68
18085502-7	2008	Baseline characteristics associated with better improvement in the levels of TC and LDL-c were the presence of TPO-Ab, TSH levels &gt;8.0 microUI/ml, Body Mass Index &gt;or=25 kg/m2, and the presence of menopause.	Thyrotropin	119-122	component of oligomeric golgi complex 2	Homo sapiens	84-89
18296906-1	2008	Mice lacking the LDL receptor associated protein (RAP) have a severe defect of thyroglobulin secretion into the colloid, associated with moderately increased serum TSH levels and histological features of early goiter.	Thyrotropin	164-167	low density lipoprotein receptor-related protein associated protein 1	Mus musculus	50-53
18238739-7	2008	Among TPO-Ab-negative participants, TSH level was not associated with use of iodine-containing multivitamins, smoking, or race.	Thyrotropin	36-39	thyroid peroxidase	Homo sapiens	6-9
18238739-12	2008	CONCLUSION: TPO-Ab status of pregnant women should be considered when constructing trimester-specific reference ranges because elevated serum TPO-Ab levels are associated with higher TSH and lower T4 values.	Thyrotropin	183-186	thyroid peroxidase	Homo sapiens	142-145
17561976-1	2007	BACKGROUND: In recent years serum thyroglobulin (Tg) measurement during thyroxine (T4) treatment and/or after stimulation by endogenous TSH or recombinant human TSH (rhTSH) has eclipsed other diagnostic procedures in managing patients with differentiated thyroid cancer (DTC).	Thyrotropin	136-139	thyroglobulin	Homo sapiens	34-47
17938741-5	2007	OBJECTIVES: Our goals were to group PCB congeners based on their potential to induce microsomal enzymes in animals, and to examine the relationship between neonatal TSH levels and prenatal exposure to PCB congeners grouped according to their structure and potential mechanisms of action.	Thyrotropin	165-168	pyruvate carboxylase	Homo sapiens	201-204
18577349-1	2008	The authors present a 20-year follow-up of a typical case of hypopituitarism resulting from the Prop-1 gene mutation and diagnosed when the patient was 8 years of age based on growth deficit (-4 SD), delayed bone age (3.5 years), as well as proven deficit of GH and TSH, as well as LH and FSH detected in the peripubertal period.	Thyrotropin	266-269	PROP paired-like homeobox 1	Homo sapiens	96-102
19239789-11	2008	Children with positive a-TPO had higher TSH level (2.87+/-2.1 vs. 1.95+/-0.9) p&lt;0.01 and HbA1c level (8.32+/-1.64 vs. 7.59+/-1.67) p=0.03 than children without thyroid antibodies.	Thyrotropin	40-43	thyroid peroxidase	Homo sapiens	25-28
17690164-6	2007	The results of studies in newborns demonstrate that TRbeta(+/-) pups born to TRbeta(-/-) dams have persistent suppression of serum TSH without a peak.	Thyrotropin	131-134	apoptosis antagonizing transcription factor	Mus musculus	52-58
17690164-6	2007	The results of studies in newborns demonstrate that TRbeta(+/-) pups born to TRbeta(-/-) dams have persistent suppression of serum TSH without a peak.	Thyrotropin	131-134	apoptosis antagonizing transcription factor	Mus musculus	77-83
17690164-7	2007	On the other hand, TRbeta(-/-) pups born to TRbeta(+/-) dams have lower serum TSH at birth and a tendency to peak higher, compared with TRbeta(-/-) pups born to TRbeta(-/-) dams.	Thyrotropin	78-81	apoptosis antagonizing transcription factor	Mus musculus	19-25
17690164-7	2007	On the other hand, TRbeta(-/-) pups born to TRbeta(+/-) dams have lower serum TSH at birth and a tendency to peak higher, compared with TRbeta(-/-) pups born to TRbeta(-/-) dams.	Thyrotropin	78-81	apoptosis antagonizing transcription factor	Mus musculus	44-50
17690164-7	2007	On the other hand, TRbeta(-/-) pups born to TRbeta(+/-) dams have lower serum TSH at birth and a tendency to peak higher, compared with TRbeta(-/-) pups born to TRbeta(-/-) dams.	Thyrotropin	78-81	apoptosis antagonizing transcription factor	Mus musculus	44-50
17690164-7	2007	On the other hand, TRbeta(-/-) pups born to TRbeta(+/-) dams have lower serum TSH at birth and a tendency to peak higher, compared with TRbeta(-/-) pups born to TRbeta(-/-) dams.	Thyrotropin	78-81	apoptosis antagonizing transcription factor	Mus musculus	44-50
17561976-1	2007	BACKGROUND: In recent years serum thyroglobulin (Tg) measurement during thyroxine (T4) treatment and/or after stimulation by endogenous TSH or recombinant human TSH (rhTSH) has eclipsed other diagnostic procedures in managing patients with differentiated thyroid cancer (DTC).	Thyrotropin	161-164	thyroglobulin	Homo sapiens	34-47
17561976-1	2007	BACKGROUND: In recent years serum thyroglobulin (Tg) measurement during thyroxine (T4) treatment and/or after stimulation by endogenous TSH or recombinant human TSH (rhTSH) has eclipsed other diagnostic procedures in managing patients with differentiated thyroid cancer (DTC).	Thyrotropin	161-164	thyroglobulin	Homo sapiens	49-51
17804710-5	2007	We show that the in vivo proliferative response to chronic TSHR stimulation relies heavily on the activation of the mTOR/S6K1 axis, and that mTOR inhibition during goitrogenic stimulation abrogates the hyperplastic but not the hypertrophic thyrocyte responses to TSH, thus functionally uncoupling these two processes.	Thyrotropin	59-62	mechanistic target of rapamycin kinase	Homo sapiens	116-120
17893268-3	2007	We also hypothesized that endogenous TSH stimulation would affect serum VEGF level.	Thyrotropin	37-40	vascular endothelial growth factor A	Homo sapiens	72-76
17893268-13	2007	Endogenous TSH stimulation decreases VEGF levels in patients either with or without thyroid tissue, suggesting that its regulatory effects are through receptors located outside the thyrocytes.	Thyrotropin	11-14	vascular endothelial growth factor A	Homo sapiens	37-41
17666480-13	2007	Whereas high serum IGF-I levels are also related to thyroid nodules in men, they are related to decreased serum TSH levels in women.	Thyrotropin	112-115	insulin like growth factor 1	Homo sapiens	19-24
17535305-3	2007	Administration of the mAbs KSAb1 (IgG2b) or KSAb2 (IgG2a), which have similar stimulating properties but different TSH-binding blocking activity, resulted in significantly elevated serum thyroxine (T(4)) levels and thyroid hyperplasia.	Thyrotropin	115-118	immunoglobulin heavy variable V1-9	Mus musculus	51-56
17804710-5	2007	We show that the in vivo proliferative response to chronic TSHR stimulation relies heavily on the activation of the mTOR/S6K1 axis, and that mTOR inhibition during goitrogenic stimulation abrogates the hyperplastic but not the hypertrophic thyrocyte responses to TSH, thus functionally uncoupling these two processes.	Thyrotropin	59-62	ribosomal protein S6 kinase B1	Homo sapiens	121-125
17804710-6	2007	Strikingly, goitrogenesis was not associated with an increase in AKT phosphorylation levels, underlining the existence of an AKT-independent pathway leading to mTOR activation upon TSH stimulation.	Thyrotropin	181-184	AKT serine/threonine kinase 1	Homo sapiens	125-128
17804710-6	2007	Strikingly, goitrogenesis was not associated with an increase in AKT phosphorylation levels, underlining the existence of an AKT-independent pathway leading to mTOR activation upon TSH stimulation.	Thyrotropin	181-184	mechanistic target of rapamycin kinase	Homo sapiens	160-164
17426102-2	2007	AIM: The goal of the study is to compare the diagnostic values of seven methods for serum Tg measurement for detecting recurrent disease both during L-T4 treatment and after TSH stimulation.	Thyrotropin	174-177	thyroglobulin	Homo sapiens	90-92
17891252-0	2007	[Will the thyroglobulin assay with lower functional sensitivity whilst the patients are on L-T4 treatment replace the TSH-stimulated thyroglobulin assay in the follow-up of patients with differentiated thyroid cancer?].	Thyrotropin	118-121	thyroglobulin	Homo sapiens	133-146
17446190-1	2007	We previously reported that hormones important for the normal growth and function of FRTL-5 rat thyroid cells, TSH, or its cAMP signal plus insulin or IGF-I, could transcriptionally suppress constitutive and gamma-interferon (IFN)-increased synthesis of the 90K protein (also known as Mac-2BP).	Thyrotropin	111-114	galectin 3 binding protein	Rattus norvegicus	285-292
17446190-5	2007	Transfection with USF1 and USF2 cDNAs increases constitutive promoter activity, attenuates the ability of TSH/cAMP plus insulin/IGF-I to decrease constitutive or gamma-IFN-increased 90K gene expression but does not abrogate the ability of gamma-IFN itself to increase 90K gene expression.	Thyrotropin	106-109	upstream transcription factor 1	Rattus norvegicus	18-22
17446190-5	2007	Transfection with USF1 and USF2 cDNAs increases constitutive promoter activity, attenuates the ability of TSH/cAMP plus insulin/IGF-I to decrease constitutive or gamma-IFN-increased 90K gene expression but does not abrogate the ability of gamma-IFN itself to increase 90K gene expression.	Thyrotropin	106-109	upstream transcription factor 2, c-fos interacting	Rattus norvegicus	27-31
17456567-7	2007	In contrast, the efficacy of TSH for generating IP was more than 7-fold lower with the mutant compared with wild-type TSHR.	Thyrotropin	29-32	thyroid stimulating hormone receptor	Homo sapiens	118-122
17547687-1	2007	OBJECTIVE: To examine whether obesity, body fat distribution and insulin resistance have an independent effect on serum TSH and free thyroid hormones (FT3 and FT4) in a cohort of euthyroid women, represented by overweight and obese patients.	Thyrotropin	120-123	insulin	Homo sapiens	65-72
17937064-11	2007	CONCLUSIONS: The elevated TSH in these patients and prior demonstration of the in vitro ability of TSH to bind to the FSH receptor lead us to hypothesize that the gonadal stimulation in these patients is TSH-mediated.	Thyrotropin	99-102	follicle stimulating hormone receptor	Homo sapiens	118-130
17714035-0	2007	Nitric oxide/cGMP signaling inhibits TSH-stimulated iodide uptake and expression of thyroid peroxidase and thyroglobulin mRNA in FRTL-5 thyroid cells.	Thyrotropin	37-40	thyroglobulin	Rattus norvegicus	107-120
17440015-1	2007	OBJECTIVE: Therapy with the retinoid X receptor agonist bexarotene is associated with hypothyroidism caused by decreased pituitary TSH secretion.	Thyrotropin	131-134	retinoid X receptor alpha	Homo sapiens	28-47
17456567-6	2007	In transfected COS-7 cells, the mutant TSHR had normal surface expression, basal activity, and TSH-binding affinity, equally (2.2-fold) increased EC50 values for TSH-induced cAMP and IP accumulation, and normal maximum cAMP generation.	Thyrotropin	95-98	thyroid stimulating hormone receptor	Homo sapiens	39-43
17408420-1	2007	OBJECTIVES: The Asp727Glu polymorphism in the TSH receptor (TSHR) gene is associated with serum TSH levels.	Thyrotropin	46-49	thyroid stimulating hormone receptor	Homo sapiens	60-64
17408423-3	2007	This could be due to alterations in thyroid hormone activity, or to direct effects of TSH, as the TSH receptor (TSHR) is also expressed in adipose tissue.	Thyrotropin	86-89	thyroid stimulating hormone receptor	Homo sapiens	98-110
17352644-2	2007	TSH"s actions are mediated by its inhibitory effects on RANKL-induced osteoclast formation and bone resorption coupled with stimulatory effects on osteoblast differentiation and bone formation, suggesting TSH directly affects bone remodeling in vivo.	Thyrotropin	0-3	TNF superfamily member 11	Rattus norvegicus	56-61
17616857-3	2007	Exaggerated TSH response (&gt;30 mIU/l at 20, 40 or 60 min) following intravenous injection of 400 microg TRH was defined as SH.	Thyrotropin	12-15	thyrotropin releasing hormone	Homo sapiens	106-109
17356048-14	2007	CONCLUSIONS: Pediatric gonadal hyperstimulation associated with severe primary hypothyroidism is likely due to the actions of the elevated concentrations of TSH on the wild-type hFSHR, and this response is not dependent upon the hFSHR isoform.	Thyrotropin	157-160	follicle stimulating hormone receptor	Homo sapiens	178-183
17356048-14	2007	CONCLUSIONS: Pediatric gonadal hyperstimulation associated with severe primary hypothyroidism is likely due to the actions of the elevated concentrations of TSH on the wild-type hFSHR, and this response is not dependent upon the hFSHR isoform.	Thyrotropin	157-160	follicle stimulating hormone receptor	Homo sapiens	229-234
17352644-12	2007	In vitro studies suggest that TSH"s action is mediated by its inhibitory effects on RANKL-induced osteoclast formation, as shown in hematopoietic stem cells cultivated from TSH-treated OVX rats.	Thyrotropin	30-33	TNF superfamily member 11	Rattus norvegicus	84-89
17352644-13	2007	TSH also stimulates osteoblast differentiation, as shown by effects on alkaline phosphatase activity, osteocalcin expression, and mineralization rate.	Thyrotropin	0-3	bone gamma-carboxyglutamate protein	Rattus norvegicus	102-113
18214025-3	2007	Findings from Africa children indicate that VAD in severely-IDD-affected children increases TSH stimulation and thyroid size, and reduces risk for hypothyroidism.	Thyrotropin	92-95	potassium channel tetramerization domain containing 1	Rattus norvegicus	44-47
17140771-7	2007	In TPO-Ab positive offspring (n=11) a raised prevalence of 55% of thyroid failure (i.e. a raised serum TSH or l-thyroxine treatment) was evident.	Thyrotropin	103-106	thyroid peroxidase	Homo sapiens	3-6
17464430-3	2007	The aim of the present study was to determine whether thyroid IRS-1 content is modulated by TSH in vivo.	Thyrotropin	92-95	insulin receptor substrate 1	Rattus norvegicus	62-67
18214025-4	2007	In children with VAD, the higher TSH concentrations in the face of higher circulating total thyroxine suggest central resistance to normal TSH suppression by thyroid hormone.	Thyrotropin	33-36	potassium channel tetramerization domain containing 1	Rattus norvegicus	17-20
18214025-4	2007	In children with VAD, the higher TSH concentrations in the face of higher circulating total thyroxine suggest central resistance to normal TSH suppression by thyroid hormone.	Thyrotropin	139-142	potassium channel tetramerization domain containing 1	Rattus norvegicus	17-20
17430219-5	2007	TRalpha mediates tachycardia and much of the metabolic rate effect, while TRbeta mediates cholesterol and TSH lowering effects of thyroid hormones.	Thyrotropin	106-109	thyroid hormone receptor beta	Rattus norvegicus	74-80
17327419-5	2007	By contrast, adult TRbeta-/- mice with elevated TSH and thyroid hormone levels were osteoporotic with evidence of increased bone resorption, whereas juveniles had advanced ossification with increased bone mineral deposition.	Thyrotropin	48-51	apoptosis antagonizing transcription factor	Mus musculus	19-25
17349662-9	2007	The offspring of Lep mothers had at 180 days a higher T3 (p&lt;0.05) with normal thyroid (125)I uptake, T4 and TSH serum concentrations compared to the controls.	Thyrotropin	111-114	leptin	Rattus norvegicus	17-20
17379962-9	2007	Overexpression of USF-1 and USF-2 significantly suppressed TSH-stimulated [methyl-3H] thymidine uptake (p&lt;0.05), while it maintained TSH-stimulated cAMP production in FRTL-5 cells.	Thyrotropin	59-62	upstream transcription factor 1	Rattus norvegicus	18-23
17379962-9	2007	Overexpression of USF-1 and USF-2 significantly suppressed TSH-stimulated [methyl-3H] thymidine uptake (p&lt;0.05), while it maintained TSH-stimulated cAMP production in FRTL-5 cells.	Thyrotropin	59-62	upstream transcription factor 2, c-fos interacting	Rattus norvegicus	28-33
17043656-1	2007	Phosphatidylinositol 3-kinase (PI3K) is necessary for thyroid stimulating hormone (TSH)-induced cell cycle progression.	Thyrotropin	54-81	phosphoinositide-3-kinase regulatory subunit 1	Homo sapiens	0-29
17379962-9	2007	Overexpression of USF-1 and USF-2 significantly suppressed TSH-stimulated [methyl-3H] thymidine uptake (p&lt;0.05), while it maintained TSH-stimulated cAMP production in FRTL-5 cells.	Thyrotropin	136-139	upstream transcription factor 1	Rattus norvegicus	18-23
17379962-9	2007	Overexpression of USF-1 and USF-2 significantly suppressed TSH-stimulated [methyl-3H] thymidine uptake (p&lt;0.05), while it maintained TSH-stimulated cAMP production in FRTL-5 cells.	Thyrotropin	136-139	upstream transcription factor 2, c-fos interacting	Rattus norvegicus	28-33
17290351-2	2007	In this study, we evaluated the H-RAS mRNA and protein levels in human samples of nontoxic and toxic multinodular goiter samples, according to serum TSH levels.	Thyrotropin	149-152	HRas proto-oncogene, GTPase	Homo sapiens	32-37
17400807-10	2007	In addition, these final results suggest that TSH-induced increase in Wnt-1 levels in thyrocytes contributes to enhanced cellular growth via a PKC pathway that increases STAT3 serine phosphorylation and activation, whereas TSH-induced decrease in activation of beta-catenin simultaneously relieves transcriptional suppression of TPO.	Thyrotropin	46-49	Wnt family member 1	Rattus norvegicus	70-75
17400807-10	2007	In addition, these final results suggest that TSH-induced increase in Wnt-1 levels in thyrocytes contributes to enhanced cellular growth via a PKC pathway that increases STAT3 serine phosphorylation and activation, whereas TSH-induced decrease in activation of beta-catenin simultaneously relieves transcriptional suppression of TPO.	Thyrotropin	46-49	signal transducer and activator of transcription 3	Rattus norvegicus	170-175
17400807-10	2007	In addition, these final results suggest that TSH-induced increase in Wnt-1 levels in thyrocytes contributes to enhanced cellular growth via a PKC pathway that increases STAT3 serine phosphorylation and activation, whereas TSH-induced decrease in activation of beta-catenin simultaneously relieves transcriptional suppression of TPO.	Thyrotropin	46-49	catenin beta 1	Rattus norvegicus	261-273
17400807-10	2007	In addition, these final results suggest that TSH-induced increase in Wnt-1 levels in thyrocytes contributes to enhanced cellular growth via a PKC pathway that increases STAT3 serine phosphorylation and activation, whereas TSH-induced decrease in activation of beta-catenin simultaneously relieves transcriptional suppression of TPO.	Thyrotropin	46-49	thyroid peroxidase	Rattus norvegicus	329-332
17400807-10	2007	In addition, these final results suggest that TSH-induced increase in Wnt-1 levels in thyrocytes contributes to enhanced cellular growth via a PKC pathway that increases STAT3 serine phosphorylation and activation, whereas TSH-induced decrease in activation of beta-catenin simultaneously relieves transcriptional suppression of TPO.	Thyrotropin	223-226	Wnt family member 1	Rattus norvegicus	70-75
17400807-10	2007	In addition, these final results suggest that TSH-induced increase in Wnt-1 levels in thyrocytes contributes to enhanced cellular growth via a PKC pathway that increases STAT3 serine phosphorylation and activation, whereas TSH-induced decrease in activation of beta-catenin simultaneously relieves transcriptional suppression of TPO.	Thyrotropin	223-226	catenin beta 1	Rattus norvegicus	261-273
17400807-10	2007	In addition, these final results suggest that TSH-induced increase in Wnt-1 levels in thyrocytes contributes to enhanced cellular growth via a PKC pathway that increases STAT3 serine phosphorylation and activation, whereas TSH-induced decrease in activation of beta-catenin simultaneously relieves transcriptional suppression of TPO.	Thyrotropin	223-226	thyroid peroxidase	Rattus norvegicus	329-332
17479443-7	2007	Compared to insulin sensitive subjects, TSH levels were higher in insulin resistant subjects but it was not statistically significant.	Thyrotropin	40-43	insulin	Homo sapiens	66-73
17043656-5	2007	The p85alpha(PI3K) wild type not the p85A bound PKA regulatory subunit RIIbeta in cells stimulated with cAMP or TSH.	Thyrotropin	112-115	phosphoinositide-3-kinase regulatory subunit 1	Homo sapiens	4-12
17043656-10	2007	We suggest that (1) TSH-cAMP-induced PKA phosphorylates p85alpha(PI3K) at serine 83, (2) phosphorylated p85alpha(PI3K) binds RIIbeta-PKA and targets PKAII to the membrane, and (3) PI3K activity and p21Ras binding to PI3K increase and activate PI3K downstream targets.	Thyrotropin	20-23	phosphoinositide-3-kinase regulatory subunit 1	Homo sapiens	56-64
17043656-10	2007	We suggest that (1) TSH-cAMP-induced PKA phosphorylates p85alpha(PI3K) at serine 83, (2) phosphorylated p85alpha(PI3K) binds RIIbeta-PKA and targets PKAII to the membrane, and (3) PI3K activity and p21Ras binding to PI3K increase and activate PI3K downstream targets.	Thyrotropin	20-23	phosphoinositide-3-kinase regulatory subunit 1	Homo sapiens	104-112
17043656-10	2007	We suggest that (1) TSH-cAMP-induced PKA phosphorylates p85alpha(PI3K) at serine 83, (2) phosphorylated p85alpha(PI3K) binds RIIbeta-PKA and targets PKAII to the membrane, and (3) PI3K activity and p21Ras binding to PI3K increase and activate PI3K downstream targets.	Thyrotropin	20-23	HRas proto-oncogene, GTPase	Homo sapiens	198-204
17043656-1	2007	Phosphatidylinositol 3-kinase (PI3K) is necessary for thyroid stimulating hormone (TSH)-induced cell cycle progression.	Thyrotropin	83-86	phosphoinositide-3-kinase regulatory subunit 1	Homo sapiens	0-29
17043656-3	2007	Expression of an alanine mutant (p85A) abolished cyclic AMP/TSH-induced cell cycle progression and was lethal in thyroid cells (FRTL-5).	Thyrotropin	60-63	phosphoinositide-3-kinase regulatory subunit 1	Homo sapiens	33-37
17043656-4	2007	The aspartic version of the p85alpha(PI3K) (p85D) inhibited apoptosis following TSH withdrawal.	Thyrotropin	80-83	phosphoinositide-3-kinase regulatory subunit 1	Homo sapiens	28-36
17201802-10	2007	TSH-stimulated Tg levels before ablation and 6 months after initial therapy were independent prognostic indicators for death.	Thyrotropin	0-3	thyroglobulin	Homo sapiens	15-17
17174283-2	2007	As TRH co-localizes with cocaine- and amphetamine-regulated transcript (CART) in hypophysiotropic neurons of the PVN, and CART inhibits TRH-induced prolactin release but not TRH-induced TSH release in adenohypophyseal cell cultures, we raised the possibility that differential regulation of CART gene expression in the PVN may explain the differences in prolactin secretion following each of the two stimuli.	Thyrotropin	186-189	CART prepropeptide	Rattus norvegicus	122-126
17174283-2	2007	As TRH co-localizes with cocaine- and amphetamine-regulated transcript (CART) in hypophysiotropic neurons of the PVN, and CART inhibits TRH-induced prolactin release but not TRH-induced TSH release in adenohypophyseal cell cultures, we raised the possibility that differential regulation of CART gene expression in the PVN may explain the differences in prolactin secretion following each of the two stimuli.	Thyrotropin	186-189	CART prepropeptide	Rattus norvegicus	122-126
16914130-7	2007	On stepwise linear regression analysis in IUGR infants, insulin sensitivity was found to have a significant negative association with T(4) and significant positive association with TSH.	Thyrotropin	181-184	insulin	Homo sapiens	56-63
17208481-8	2007	Quantitative real time polymerase chain reaction analyses revealed a reduction in the steady-state levels of ING2 mRNA in the phallus/cliterophallus, lung, and liver by 48 h after TSH injection.	Thyrotropin	180-183	inhibitor of growth protein 2	Alligator mississippiensis	109-113
21851691-5	2007	Serum thyroid stimulating hormone (cTSH) concentration was within reference range.	Thyrotropin	6-33	cathepsin H	Canis lupus familiaris	35-39
17684393-6	2007	Indeed, thyroid function tests in patients with MCT8 mutations demonstrated marked elevations of serum T3 (in the thyrotoxic range), a significant decrease in serum T4 or fT4 and normal to elevated TSH levels.	Thyrotropin	198-201	solute carrier family 16 member 2	Homo sapiens	48-52
17380821-5	2006	Thyroid peroxidase antibody is estimated if the TSH level is high.	Thyrotropin	48-51	thyroid peroxidase	Homo sapiens	0-18
17161219-6	2007	Serum adiponectin had a positive correlation with serum thyroxine (r = .81, P &lt; .001) and triiodothyronine (r = 0.68, P = .03) and a negative correlation with serum thyroid-stimulating hormone (P = -.62, r = 0.015).	Thyrotropin	168-195	adiponectin, C1Q and collagen domain containing	Rattus norvegicus	6-17
17278718-2	2006	Thyrotropin-releasing hormone (TRH) is located in the hypothalamus and stimulates TSH, GH and PRL release from the pituitary gland.	Thyrotropin	82-85	thyrotropin releasing hormone	Gallus gallus	0-29
17278718-2	2006	Thyrotropin-releasing hormone (TRH) is located in the hypothalamus and stimulates TSH, GH and PRL release from the pituitary gland.	Thyrotropin	82-85	thyrotropin releasing hormone	Gallus gallus	31-34
17127619-6	2006	To determine the quaternary structure of Tsh in vitro, we purified Tshbeta from the outer membranes and showed that it is natively folded because it is heat modifiable and resistant to protease digestion.	Thyrotropin	41-44	thyroid stimulating hormone subunit beta	Homo sapiens	67-74
17198929-13	2007	In healthy volunteers T3 was related to tissue factor pathway inhibitor and platelet glycoprotein V was related to thyroid-stimulating hormone.	Thyrotropin	115-142	glycoprotein V platelet	Homo sapiens	76-99
17526952-1	2006	Loss-of-function mutations in the thyrotropin receptor (TSHR) gene were described as a syndrome characterized by thyroid hyposensivity to biologically active TSH, ranging from euthyroid to severe hypothyroidism.	Thyrotropin	56-59	thyroid stimulating hormone receptor	Homo sapiens	34-54
16887886-7	2006	Because PKA I stimulation could increase iodide uptake in FRTL5 cells without affecting gene transcription, PKA I may mediate TSH actions at posttranscriptional levels.	Thyrotropin	126-129	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	108-111
17199435-0	2006	Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves" patients.	Thyrotropin	31-34	thyroid stimulating hormone receptor	Homo sapiens	62-74
16884722-9	2006	TRbeta transcript levels were increased in the heart, lung, and gonad whereas estrogen receptor alpha transcript levels were elevated by TSH treatment only in the gonad.	Thyrotropin	137-140	estrogen receptor	Alligator mississippiensis	78-101
17123336-0	2006	TSH-Dependent expression of the LDL receptor-associated protein (RAP) in thyroid epithelial cells.	Thyrotropin	0-3	low density lipoprotein receptor-related protein associated protein 1	Mus musculus	65-68
17123336-7	2006	In hypothyroid mice with high serum TSH, RAP was markedly increased compared with euthyroid mice as observed by immunohistochemistry and Western blotting.	Thyrotropin	36-39	low density lipoprotein receptor-related protein associated protein 1	Mus musculus	41-44
17123336-8	2006	Based on these findings, we concluded that RAP is expressed by thyrocytes in a TSH-dependent manner, both in cultured thyroid cells and in vivo.	Thyrotropin	79-82	low density lipoprotein receptor-related protein associated protein 1	Mus musculus	43-46
16787990-9	2006	CONCLUSIONS: The Dutch incidence figures for CH belong to the highest worldwide, suggesting that the T(4)-TSH-TBG screening program is an efficient method to detect CH of variable etiology and severity.	Thyrotropin	106-109	serpin family A member 7	Homo sapiens	110-113
16950706-6	2006	In our patients, reduced (but within normal range) TSH level occurred in DM1 (median 0.97 mIU/l, IR 0.61-1.58 mIU/l versus median 1.66 mIU/l, IR 0.76-2.09 mIU/l; P &lt; 0.05).	Thyrotropin	51-54	immunoglobulin heavy diversity 1-7	Homo sapiens	73-76
16950706-7	2006	The presence of a negative linear correlation between thyroid volume and TSH concentration was noticed in patients with DM2 (RS = -0.38, P &lt; 0.01).	Thyrotropin	73-76	immunoglobulin heavy diversity 1-14 (non-functional)	Homo sapiens	120-123
16936513-8	2006	Compared with the controls (sudden unnatural deaths: Tg 23.3+/-27.6 ng/mL), the raised Tg values in the TBI cases were usually accompanied by a reduction in the intensity of immunohistochemical reactions relating to TSH and Tg.	Thyrotropin	216-219	thyroglobulin	Homo sapiens	87-89
16936513-8	2006	Compared with the controls (sudden unnatural deaths: Tg 23.3+/-27.6 ng/mL), the raised Tg values in the TBI cases were usually accompanied by a reduction in the intensity of immunohistochemical reactions relating to TSH and Tg.	Thyrotropin	216-219	thyroglobulin	Homo sapiens	87-89
16959467-2	2006	In the last American and European Consensus Conferences, a surveillance guideline has been extended to the use of thyrotropin (TSH)-stimulated Tg levels for thyroidectomized patients without clinical evidence of residual tumor with Tg below 1 microg/l during TSH suppression.	Thyrotropin	127-130	thyroglobulin	Homo sapiens	143-145
16959467-2	2006	In the last American and European Consensus Conferences, a surveillance guideline has been extended to the use of thyrotropin (TSH)-stimulated Tg levels for thyroidectomized patients without clinical evidence of residual tumor with Tg below 1 microg/l during TSH suppression.	Thyrotropin	127-130	thyroglobulin	Homo sapiens	232-234
16954431-4	2006	Elevated serum TSH, achieved by thyroid hormone withdrawal in athyreotic patients or after recombinant human thyrotropin administration, directly stimulates NIS gene expression and/or NIS trafficking to the plasma membrane, increasing radioiodide uptake.	Thyrotropin	15-18	solute carrier family 5 member 5	Homo sapiens	157-160
16954431-4	2006	Elevated serum TSH, achieved by thyroid hormone withdrawal in athyreotic patients or after recombinant human thyrotropin administration, directly stimulates NIS gene expression and/or NIS trafficking to the plasma membrane, increasing radioiodide uptake.	Thyrotropin	15-18	solute carrier family 5 member 5	Homo sapiens	184-187
16626768-7	2006	Treatment with Pyrethrins and NaPB increased hepatic microsomal thyroxine UDPglucuronosyltransferase activity and serum thyroid stimulating hormone levels (TSH), but reduced serum levels of either thyroxine (T4) and/or triiodothyronine (T3).	Thyrotropin	120-147	NSF attachment protein beta	Rattus norvegicus	30-34
16908863-5	2006	In parallel studies, we find that TSH directly inhibits TNFalpha production, reduces the number of TNFalpha-producing osteoclast precursors, and attenuates the induction of TNFalpha expression by IL-1, TNFalpha, and receptor activator of NF-kappaB ligand.	Thyrotropin	34-37	tumor necrosis factor	Mus musculus	56-64
16908863-5	2006	In parallel studies, we find that TSH directly inhibits TNFalpha production, reduces the number of TNFalpha-producing osteoclast precursors, and attenuates the induction of TNFalpha expression by IL-1, TNFalpha, and receptor activator of NF-kappaB ligand.	Thyrotropin	34-37	tumor necrosis factor	Mus musculus	99-107
16908863-5	2006	In parallel studies, we find that TSH directly inhibits TNFalpha production, reduces the number of TNFalpha-producing osteoclast precursors, and attenuates the induction of TNFalpha expression by IL-1, TNFalpha, and receptor activator of NF-kappaB ligand.	Thyrotropin	34-37	tumor necrosis factor	Mus musculus	99-107
16908863-5	2006	In parallel studies, we find that TSH directly inhibits TNFalpha production, reduces the number of TNFalpha-producing osteoclast precursors, and attenuates the induction of TNFalpha expression by IL-1, TNFalpha, and receptor activator of NF-kappaB ligand.	Thyrotropin	34-37	interleukin 1 complex	Mus musculus	196-254
16908863-10	2006	The results suggest that TNFalpha is the critical cytokine mediating the downstream antiresorptive effects of TSH on the skeleton.	Thyrotropin	110-113	tumor necrosis factor	Mus musculus	25-33
16601074-1	2006	Thyroid-specific enhancer-binding protein (T/ebp)/Nkx2.1-null mouse thyroids degenerate by embryonic day (E) 12-13 through apoptosis whereas T/ebp/Nkx2.1-heterogyzgous mice exhibit hypothyroidism with elevated TSH levels.	Thyrotropin	210-213	NK2 homeobox 1	Mus musculus	0-41
16601074-1	2006	Thyroid-specific enhancer-binding protein (T/ebp)/Nkx2.1-null mouse thyroids degenerate by embryonic day (E) 12-13 through apoptosis whereas T/ebp/Nkx2.1-heterogyzgous mice exhibit hypothyroidism with elevated TSH levels.	Thyrotropin	210-213	NK2 homeobox 1	Mus musculus	43-48
16910874-5	2006	Western blot analysis of the 2D gel images using a polyclonal antibody directed at phosphoserine/threonine sites showed that TSH induced the phosphorylation of hsp-90.	Thyrotropin	125-128	heat shock protein 90 alpha family class A member 1	Rattus norvegicus	160-166
16910874-6	2006	Western blotting of hsp-90 following stimulators of the signal transduction systems mediated by TSH indicated that TSH-mediated hsp-90 phosphorylation occurs through protein kinases A and C. CONCLUSION: In summary, we have demonstrated that TSH action stimulates the phosphorylation of hsp-90 in FRTL-5 thyroid cells.	Thyrotropin	96-99	heat shock protein 90 alpha family class A member 1	Rattus norvegicus	20-26
16910874-6	2006	Western blotting of hsp-90 following stimulators of the signal transduction systems mediated by TSH indicated that TSH-mediated hsp-90 phosphorylation occurs through protein kinases A and C. CONCLUSION: In summary, we have demonstrated that TSH action stimulates the phosphorylation of hsp-90 in FRTL-5 thyroid cells.	Thyrotropin	96-99	heat shock protein 90 alpha family class A member 1	Rattus norvegicus	128-134
16910874-6	2006	Western blotting of hsp-90 following stimulators of the signal transduction systems mediated by TSH indicated that TSH-mediated hsp-90 phosphorylation occurs through protein kinases A and C. CONCLUSION: In summary, we have demonstrated that TSH action stimulates the phosphorylation of hsp-90 in FRTL-5 thyroid cells.	Thyrotropin	96-99	heat shock protein 90 alpha family class A member 1	Rattus norvegicus	128-134
16910874-6	2006	Western blotting of hsp-90 following stimulators of the signal transduction systems mediated by TSH indicated that TSH-mediated hsp-90 phosphorylation occurs through protein kinases A and C. CONCLUSION: In summary, we have demonstrated that TSH action stimulates the phosphorylation of hsp-90 in FRTL-5 thyroid cells.	Thyrotropin	115-118	heat shock protein 90 alpha family class A member 1	Rattus norvegicus	20-26
16910874-6	2006	Western blotting of hsp-90 following stimulators of the signal transduction systems mediated by TSH indicated that TSH-mediated hsp-90 phosphorylation occurs through protein kinases A and C. CONCLUSION: In summary, we have demonstrated that TSH action stimulates the phosphorylation of hsp-90 in FRTL-5 thyroid cells.	Thyrotropin	115-118	heat shock protein 90 alpha family class A member 1	Rattus norvegicus	128-134
16910874-6	2006	Western blotting of hsp-90 following stimulators of the signal transduction systems mediated by TSH indicated that TSH-mediated hsp-90 phosphorylation occurs through protein kinases A and C. CONCLUSION: In summary, we have demonstrated that TSH action stimulates the phosphorylation of hsp-90 in FRTL-5 thyroid cells.	Thyrotropin	115-118	heat shock protein 90 alpha family class A member 1	Rattus norvegicus	128-134
16910874-6	2006	Western blotting of hsp-90 following stimulators of the signal transduction systems mediated by TSH indicated that TSH-mediated hsp-90 phosphorylation occurs through protein kinases A and C. CONCLUSION: In summary, we have demonstrated that TSH action stimulates the phosphorylation of hsp-90 in FRTL-5 thyroid cells.	Thyrotropin	115-118	heat shock protein 90 alpha family class A member 1	Rattus norvegicus	20-26
16910874-6	2006	Western blotting of hsp-90 following stimulators of the signal transduction systems mediated by TSH indicated that TSH-mediated hsp-90 phosphorylation occurs through protein kinases A and C. CONCLUSION: In summary, we have demonstrated that TSH action stimulates the phosphorylation of hsp-90 in FRTL-5 thyroid cells.	Thyrotropin	115-118	heat shock protein 90 alpha family class A member 1	Rattus norvegicus	128-134
16626768-7	2006	Treatment with Pyrethrins and NaPB increased hepatic microsomal thyroxine UDPglucuronosyltransferase activity and serum thyroid stimulating hormone levels (TSH), but reduced serum levels of either thyroxine (T4) and/or triiodothyronine (T3).	Thyrotropin	156-159	NSF attachment protein beta	Rattus norvegicus	30-34
16910874-6	2006	Western blotting of hsp-90 following stimulators of the signal transduction systems mediated by TSH indicated that TSH-mediated hsp-90 phosphorylation occurs through protein kinases A and C. CONCLUSION: In summary, we have demonstrated that TSH action stimulates the phosphorylation of hsp-90 in FRTL-5 thyroid cells.	Thyrotropin	115-118	heat shock protein 90 alpha family class A member 1	Rattus norvegicus	128-134
20355675-13	2006	Serum FT4, and TSH levels were found to be higher for infants at six weeks after birth, (FT4 =20.91 +/- 5.65 pmol/L) and median TSH = 2.28 mIU/ml (1.36, 0.86) mIU/rnl, compared to levels at 12 weeks postpartum: (FT4 = 17.53-*6.4 pmol/L) and median TSH = 2.02 mIU/ml, (0.84, 1.55) mIU/ml.	Thyrotropin	15-18	threonine synthase like 2	Homo sapiens	128-135
16888212-8	2006	Frog SS1 (homologous to mammalian somatostatin-14) and SS2 (homologous to mammalian cortistatin) did not affect the basal release of TSH but caused a concentration-dependent suppression of the PACAP-38-induced release of TSH.	Thyrotropin	221-224	somatostatin	Homo sapiens	5-8
16888212-8	2006	Frog SS1 (homologous to mammalian somatostatin-14) and SS2 (homologous to mammalian cortistatin) did not affect the basal release of TSH but caused a concentration-dependent suppression of the PACAP-38-induced release of TSH.	Thyrotropin	221-224	butyrophilin like 2	Homo sapiens	55-58
20355675-13	2006	Serum FT4, and TSH levels were found to be higher for infants at six weeks after birth, (FT4 =20.91 +/- 5.65 pmol/L) and median TSH = 2.28 mIU/ml (1.36, 0.86) mIU/rnl, compared to levels at 12 weeks postpartum: (FT4 = 17.53-*6.4 pmol/L) and median TSH = 2.02 mIU/ml, (0.84, 1.55) mIU/ml.	Thyrotropin	15-18	threonine synthase like 2	Homo sapiens	248-255
16943584-11	2006	In subjects with TSH levels higher than 5 microIU/mL, PPL risk was increased sevenfold.	Thyrotropin	17-20	periplakin	Homo sapiens	54-57
16682487-5	2006	IL-6 protein concentration in the medium was measured after TSH stimulation.	Thyrotropin	60-63	interleukin 6	Homo sapiens	0-4
16682487-8	2006	IL-6 responsiveness to TSH was observed upon differentiation, but only for subcutaneous adipocytes (1.9-fold over basal, P &lt; 0.001).	Thyrotropin	23-26	interleukin 6	Homo sapiens	0-4
16682487-9	2006	To determine if TSH could stimulate IL-6 release from extrathyroidal tissues in vivo, we measured serum IL-6 levels from five thyroidectomized patients who received recombinant human (rh) TSH and found that levels increased by threefold on days 3 and 4 (P &lt; 0.05) after its administration.	Thyrotropin	16-19	interleukin 6	Homo sapiens	36-40
16682487-10	2006	Our data demonstrate that stage of differentiation and fat depot origin affect basal and TSH-stimulated IL-6 release from adipose cells in culture.	Thyrotropin	89-92	interleukin 6	Homo sapiens	104-108
16682487-11	2006	Furthermore, rhTSH elevates serum IL-6 response in thyroidectomized patients, indicating an extrathyroidal site of TSH action.	Thyrotropin	15-18	interleukin 6	Homo sapiens	34-38
16707271-7	2006	Pregnancy is another condition in which serum TSH levels are altered (slightly lower); in this situation, it is the result of elevated human chorionic gonadotropin levels that cross-react with the TSH receptor.	Thyrotropin	46-49	thyroid stimulating hormone receptor	Homo sapiens	197-209
17100546-13	2006	When using Spearmans correlation coefficients, significant negative association appeared between PCB and TSH (p&lt;0.05), sum of organochlorines and TSH (p&lt;0.05) and ThV and TSH (p&lt;0.01).	Thyrotropin	105-108	pyruvate carboxylase	Homo sapiens	97-100
16805747-8	2006	Univariate analysis showed that both homocysteine and CRP levels significantly correlated with free T4 and TSH level (p &lt; 0.01 for both groups).	Thyrotropin	107-110	C-reactive protein	Homo sapiens	54-57
17100547-4	2006	The clinical sensitivity of Tg is greatest when endogenous TSH is elevated before radioiodine imaging.	Thyrotropin	59-62	thyroglobulin	Homo sapiens	28-30
16728541-8	2006	After exclusion of patients with subclinical hypothyroidism and/or TPO antibodies (n = 16), higher serum TSH significantly predicted response (response rate per tertile from low to high TSH: 36%, 42%, and 67%).	Thyrotropin	105-108	thyroid peroxidase	Homo sapiens	67-70
16756469-14	2006	To date, all of the patients with TSH resistance resulting from TSH receptor mutations identified in Japan possessed the R450H mutation at least in one allele.	Thyrotropin	34-37	thyroid stimulating hormone receptor	Homo sapiens	64-76
16839256-4	2006	MAIN OUTCOME: TSH stimulated the expression of thyroglobulin, peroxidase, sodium iodide symporter, vascular endothelial growth factor (VEGF)-A, VEGF-B, and placental growth factor (PGF) but decreased that of VEGF-C by half.	Thyrotropin	14-17	thyroglobulin	Homo sapiens	47-60
16839256-4	2006	MAIN OUTCOME: TSH stimulated the expression of thyroglobulin, peroxidase, sodium iodide symporter, vascular endothelial growth factor (VEGF)-A, VEGF-B, and placental growth factor (PGF) but decreased that of VEGF-C by half.	Thyrotropin	14-17	vascular endothelial growth factor A	Homo sapiens	99-133
16839256-4	2006	MAIN OUTCOME: TSH stimulated the expression of thyroglobulin, peroxidase, sodium iodide symporter, vascular endothelial growth factor (VEGF)-A, VEGF-B, and placental growth factor (PGF) but decreased that of VEGF-C by half.	Thyrotropin	14-17	vascular endothelial growth factor A	Homo sapiens	135-139
16839256-4	2006	MAIN OUTCOME: TSH stimulated the expression of thyroglobulin, peroxidase, sodium iodide symporter, vascular endothelial growth factor (VEGF)-A, VEGF-B, and placental growth factor (PGF) but decreased that of VEGF-C by half.	Thyrotropin	14-17	vascular endothelial growth factor B	Homo sapiens	144-150
16839256-4	2006	MAIN OUTCOME: TSH stimulated the expression of thyroglobulin, peroxidase, sodium iodide symporter, vascular endothelial growth factor (VEGF)-A, VEGF-B, and placental growth factor (PGF) but decreased that of VEGF-C by half.	Thyrotropin	14-17	placental growth factor	Homo sapiens	156-179
16839256-4	2006	MAIN OUTCOME: TSH stimulated the expression of thyroglobulin, peroxidase, sodium iodide symporter, vascular endothelial growth factor (VEGF)-A, VEGF-B, and placental growth factor (PGF) but decreased that of VEGF-C by half.	Thyrotropin	14-17	placental growth factor	Homo sapiens	181-184
16839256-4	2006	MAIN OUTCOME: TSH stimulated the expression of thyroglobulin, peroxidase, sodium iodide symporter, vascular endothelial growth factor (VEGF)-A, VEGF-B, and placental growth factor (PGF) but decreased that of VEGF-C by half.	Thyrotropin	14-17	vascular endothelial growth factor C	Homo sapiens	208-214
16839256-5	2006	When thyroid follicles were cultured in high-iodide (10(5) M) medium, TSH-induced expression of VEGF-A, VEGF-B, and PGF was decreased, accompanied by a reduction of VEGF-A release into the medium.	Thyrotropin	70-73	vascular endothelial growth factor A	Homo sapiens	96-102
16839256-5	2006	When thyroid follicles were cultured in high-iodide (10(5) M) medium, TSH-induced expression of VEGF-A, VEGF-B, and PGF was decreased, accompanied by a reduction of VEGF-A release into the medium.	Thyrotropin	70-73	vascular endothelial growth factor B	Homo sapiens	104-110
16839256-5	2006	When thyroid follicles were cultured in high-iodide (10(5) M) medium, TSH-induced expression of VEGF-A, VEGF-B, and PGF was decreased, accompanied by a reduction of VEGF-A release into the medium.	Thyrotropin	70-73	placental growth factor	Homo sapiens	116-119
16839256-5	2006	When thyroid follicles were cultured in high-iodide (10(5) M) medium, TSH-induced expression of VEGF-A, VEGF-B, and PGF was decreased, accompanied by a reduction of VEGF-A release into the medium.	Thyrotropin	70-73	vascular endothelial growth factor A	Homo sapiens	165-171
16804796-0	2006	Initially elevated TSH and congenital central hypothyroidism due to a homozygous mutation of the TSH beta subunit gene: case report and review of the literature.	Thyrotropin	19-22	thyroid stimulating hormone subunit beta	Homo sapiens	97-105
16648292-4	2006	In addition, we found that PDS gene was induced by TSH/cAMP and iodide in the presence of Tg.	Thyrotropin	51-54	solute carrier family 26 member 4	Homo sapiens	27-30
16242303-6	2006	TSAb activity was detected in most hyperthyroid mice, whereas virtually all immunized mice developed antibodies that inhibit [125I]TSH binding to the TSHR or recognize linear or conformational epitopes on the TSHR.	Thyrotropin	131-134	thyroid stimulating hormone receptor	Mus musculus	150-154
16487444-14	2006	In patients with SCHyper, serum TSH level was positively correlated with FX activity (r: 0.58, P &lt; 0.01) and inversely correlated with PAI-1 (r: -0.55.	Thyrotropin	32-35	serpin family E member 1	Homo sapiens	138-143
16339138-6	2006	TRbeta knock-out (KO) mice have significantly higher TH and TSH levels compared with wild-type mice, in contrast to double KO mice, which have reduced TH and TSH levels.	Thyrotropin	60-63	apoptosis antagonizing transcription factor	Mus musculus	0-6
16306084-9	2006	In vitro transfection and in vivo transgenic studies indicate that any RXR isotype can mediate TSH suppression by rexinoids, but the RXRgamma isotype is most efficient at mediating this response.	Thyrotropin	95-98	retinoid X receptor alpha	Homo sapiens	71-74
16571089-8	2006	CONCLUSION: PET/CT scans performed under TSH stimulation are an effective method of detecting of recurrence of PTC and direct surgical interventions, even in those with persistently elevated but relatively low Tg levels.	Thyrotropin	41-44	coiled-coil domain containing 6	Homo sapiens	111-114
16461928-2	2006	However, neuromedin B (NB), a bombesin-like peptide, highly concentrated in the pituitary, has been postulated to be a tonic inhibitor of TSH secretion.	Thyrotropin	138-141	neuromedin B	Mus musculus	9-21
16303831-6	2006	RESULTS: Elevated fibrinogen levels (&gt;3.25 g/liter) were observed in 14 subjects with increased serum TSH levels (32.6%), 973 euthyroid subjects (28.9%), 158 subjects with decreased serum TSH levels (40.7%), and six individuals with overt hyperthyroidism (54.4%).	Thyrotropin	105-108	fibrinogen beta chain	Homo sapiens	18-28
16303831-6	2006	RESULTS: Elevated fibrinogen levels (&gt;3.25 g/liter) were observed in 14 subjects with increased serum TSH levels (32.6%), 973 euthyroid subjects (28.9%), 158 subjects with decreased serum TSH levels (40.7%), and six individuals with overt hyperthyroidism (54.4%).	Thyrotropin	191-194	fibrinogen beta chain	Homo sapiens	18-28
16303831-7	2006	Logistic regression analysis revealed decreased serum TSH as an independent risk factor for elevated fibrinogen levels (odds ratio, 1.42; 95% confidence interval, 1.12-1.80).	Thyrotropin	54-57	fibrinogen beta chain	Homo sapiens	101-111
16303831-9	2006	Decreased serum TSH is an independent risk factor for elevated plasma fibrinogen levels as a possible explanation for the high cardiovascular mortality among affected subjects.	Thyrotropin	16-19	fibrinogen beta chain	Homo sapiens	70-80
16461928-10	2006	Therefore, the data suggest that NB receptor pathways are importantly involved in thyrotroph gene regulation and function, leading to a state where TSH release is facilitated especially in response to TRH, but probably with a less-bioactive TSH.	Thyrotropin	148-151	thyrotropin releasing hormone	Mus musculus	201-204
16095667-6	2006	The frequency of TSH level in the range of subclinical hypothyroidism (&gt; 4.0 mU/l) in pooled age groups from HNA was 13/324 (4.0%) and that of positive anti-TPO was 8/324 (2.5%), while no case of either increased TSH or positive anti-TPO was found in 109 children from LNA.	Thyrotropin	17-20	thyroid peroxidase	Homo sapiens	160-163
16095667-6	2006	The frequency of TSH level in the range of subclinical hypothyroidism (&gt; 4.0 mU/l) in pooled age groups from HNA was 13/324 (4.0%) and that of positive anti-TPO was 8/324 (2.5%), while no case of either increased TSH or positive anti-TPO was found in 109 children from LNA.	Thyrotropin	17-20	thyroid peroxidase	Homo sapiens	237-240
16357488-2	2006	To test the hypothesis that prolactin suppresses GnRH and TSH secretion in women, as preliminary evidence that a short-feedback dopamine loop also operates in the human, the effect of hyperprolactinemia on GnRH and TSH secretion was examined.	Thyrotropin	58-61	prolactin	Homo sapiens	28-37
16330391-6	2005	Apart from a slight correlation with age, Lp(a) exhibited significant positive correlations with apolipoproteins A-I and B, low density lipoprotein-cholesterol (LDL-C) (r =0.15), total cholesterol, high density lipoprotein-cholesterol (HDL-C), systolic blood pressure and log C-reactive protein, and inverse ones with thyroid stimulating hormone (r =-0.25) in men, and log gamma glutamyltransferase in women.	Thyrotropin	318-345	lipoprotein(a)	Homo sapiens	42-47
16294008-2	2006	The differentiation-associated mitogenic stimulation by TSH and cAMP specifically requires the assembly and activation of cyclin D3-cyclin-dependent kinase (CDK)4 associated to p27(kip1), while the dedifferentiating proliferation induced by growth factors is associated with induction of cyclin D1.	Thyrotropin	56-59	cyclin D3	Canis lupus familiaris	122-131
16294008-2	2006	The differentiation-associated mitogenic stimulation by TSH and cAMP specifically requires the assembly and activation of cyclin D3-cyclin-dependent kinase (CDK)4 associated to p27(kip1), while the dedifferentiating proliferation induced by growth factors is associated with induction of cyclin D1.	Thyrotropin	56-59	cyclin dependent kinase 4	Canis lupus familiaris	157-162
16294008-2	2006	The differentiation-associated mitogenic stimulation by TSH and cAMP specifically requires the assembly and activation of cyclin D3-cyclin-dependent kinase (CDK)4 associated to p27(kip1), while the dedifferentiating proliferation induced by growth factors is associated with induction of cyclin D1.	Thyrotropin	56-59	cyclin dependent kinase inhibitor 1B	Canis lupus familiaris	177-180
16294008-2	2006	The differentiation-associated mitogenic stimulation by TSH and cAMP specifically requires the assembly and activation of cyclin D3-cyclin-dependent kinase (CDK)4 associated to p27(kip1), while the dedifferentiating proliferation induced by growth factors is associated with induction of cyclin D1.	Thyrotropin	56-59	cyclin dependent kinase inhibitor 1B	Canis lupus familiaris	181-185
16294008-2	2006	The differentiation-associated mitogenic stimulation by TSH and cAMP specifically requires the assembly and activation of cyclin D3-cyclin-dependent kinase (CDK)4 associated to p27(kip1), while the dedifferentiating proliferation induced by growth factors is associated with induction of cyclin D1.	Thyrotropin	56-59	cyclin D1	Canis lupus familiaris	288-297
16294008-4	2006	p21 was induced by EGF + serum, but repressed by TSH, which, as previously shown, upregulates p27.	Thyrotropin	49-52	cyclin dependent kinase inhibitor 1B	Canis lupus familiaris	94-97
16294008-6	2006	Unexpectedly, partly different site-specificities of pRb-kinase activity, leading to similar differences in the phosphorylation pattern of pRb in intact cells, were associated with cyclin D3-CDK4 bound to p27 in TSH-stimulated cells, or with CDK4 bound to p21 in growth factor-stimulated cells.	Thyrotropin	212-215	cyclin D3	Canis lupus familiaris	181-190
16294008-6	2006	Unexpectedly, partly different site-specificities of pRb-kinase activity, leading to similar differences in the phosphorylation pattern of pRb in intact cells, were associated with cyclin D3-CDK4 bound to p27 in TSH-stimulated cells, or with CDK4 bound to p21 in growth factor-stimulated cells.	Thyrotropin	212-215	cyclin dependent kinase 4	Canis lupus familiaris	191-195
16294008-6	2006	Unexpectedly, partly different site-specificities of pRb-kinase activity, leading to similar differences in the phosphorylation pattern of pRb in intact cells, were associated with cyclin D3-CDK4 bound to p27 in TSH-stimulated cells, or with CDK4 bound to p21 in growth factor-stimulated cells.	Thyrotropin	212-215	cyclin dependent kinase inhibitor 1B	Canis lupus familiaris	205-208
16487017-6	2006	Serum TSH concentration was associated with fasting serum insulin levels and insulin resistance but not with serum leptin levels, body mass index (BMI), fat mass, and lean body mass.	Thyrotropin	6-9	insulin	Homo sapiens	58-65
16487017-6	2006	Serum TSH concentration was associated with fasting serum insulin levels and insulin resistance but not with serum leptin levels, body mass index (BMI), fat mass, and lean body mass.	Thyrotropin	6-9	insulin	Homo sapiens	77-84
16569353-7	2006	Both resting (Ca++)i levels and fMLP-induced (Ca++)i rise increased in the presence either of low-concentration TSH or of T4, but effects of TSH and T4 were not additive.	Thyrotropin	112-115	carbonic anhydrase 1	Homo sapiens	14-20
16569353-7	2006	Both resting (Ca++)i levels and fMLP-induced (Ca++)i rise increased in the presence either of low-concentration TSH or of T4, but effects of TSH and T4 were not additive.	Thyrotropin	112-115	formyl peptide receptor 1	Homo sapiens	32-36
16569353-7	2006	Both resting (Ca++)i levels and fMLP-induced (Ca++)i rise increased in the presence either of low-concentration TSH or of T4, but effects of TSH and T4 were not additive.	Thyrotropin	112-115	carbonic anhydrase 1	Homo sapiens	46-52
16246899-12	2005	SP22 may help regulate AP function and be particularly important for the control of GH and TSH secretion.	Thyrotropin	91-94	Parkinsonism associated deglycase	Rattus norvegicus	0-4
16225984-5	2005	These regulations provide molecular counterparts of in vivo physiological effects of TSH: angiogenesis (decreased thrombospondin 1), decreased apoptosis (decreased TNFR1) and actin filament disruption, macropinocytosis and thyroid hormone secretion (decreased RhoE).	Thyrotropin	85-88	thrombospondin 1	Canis lupus familiaris	114-130
15953673-4	2005	Moreover, IL-1beta and ceramides are demonstrated to inhibit the TSH-induced cAMP production via the implication of alphaGi subunit of the adenylyl cyclase system.	Thyrotropin	65-68	interleukin 1 beta	Homo sapiens	10-18
16123170-3	2005	TSH and forskolin, but not growth factors, rapidly inactivated RhoA, Rac1, and Cdc42, as assayed by detection of GTP-bound forms.	Thyrotropin	0-3	ras homolog family member A	Canis lupus familiaris	63-67
16123170-3	2005	TSH and forskolin, but not growth factors, rapidly inactivated RhoA, Rac1, and Cdc42, as assayed by detection of GTP-bound forms.	Thyrotropin	0-3	Rac family small GTPase 1	Canis lupus familiaris	69-73
16123170-3	2005	TSH and forskolin, but not growth factors, rapidly inactivated RhoA, Rac1, and Cdc42, as assayed by detection of GTP-bound forms.	Thyrotropin	0-3	cell division control protein 42 homolog	Canis lupus familiaris	79-84
16408618-11	2005	Increased thyroxine clearance contributes to the effects of nelfinavir on thyroid gland function and is probably a result of UDPGT induction that leads to elevated TSH levels in the rat and eventual thyroid neoplasia.	Thyrotropin	164-167	UDP glucuronosyltransferase family 2 member B15	Rattus norvegicus	125-130
16421339-4	2005	The effect of 0 to 1 microM TSH on IL-6 protein release into the medium over 0 to 24 hours was assessed.	Thyrotropin	28-31	interleukin 6	Mus musculus	35-39
15961562-3	2005	It is also expressed in the adult thyroid gland, in which it mediates TSH-induced modulation of the expression of important genes, such as those encoding thyroglobulin, thyroperoxidase, and the sodium/iodide symporter (NIS).	Thyrotropin	70-73	thyroid peroxidase	Homo sapiens	169-184
16498807-9	2005	In ChH patients a positive correlation was observed between serum TSH and anty-TPO (R=0.47, p&lt;0.01).	Thyrotropin	66-69	thyroid peroxidase	Homo sapiens	79-82
16091498-10	2005	TSH secretion was positively related to 24-h leptin concentrations (r2= 0.31; P = 0.007).	Thyrotropin	0-3	leptin	Homo sapiens	45-51
15928241-10	2005	CONCLUSIONS: Our data suggest that the phenotype associated with POU1F1 mutations may be more variable, with the occasional preservation of TSH secretion.	Thyrotropin	140-143	POU class 1 homeobox 1	Homo sapiens	65-71
15985488-9	2005	In three-dimensional graphs, there were strong positive associations between TSH and lipid parameters with adverse cardiac risks at low insulin sensitivity that were absent at higher insulin sensitivity.	Thyrotropin	77-80	insulin	Homo sapiens	136-143
15972576-8	2005	TSH-stimulated Tg fell spontaneously to less than 0.5 ng/ml in 50% of group 2 and 5% of group 3 over 1.7-5.0 yr.	Thyrotropin	0-3	thyroglobulin	Homo sapiens	15-17
15972576-12	2005	2) Repeated TSH-stimulated studies are appropriate for patients at risk of recurrence, especially those with an rhTSH-Tg greater than 1 ng/ml.	Thyrotropin	12-15	thyroglobulin	Homo sapiens	118-120
15972576-13	2005	3) A single rhTSH-Tg less than 0.5 ng/ml without Tg antibody has an approximately 98% likelihood of identifying patients completely free of tumor, a large group in which TSH suppression to less than 0.1 mIU/liter and frequent imaging and TSH-stimulated Tg testing are unnecessary.	Thyrotropin	14-17	thyroglobulin	Homo sapiens	18-20
15972576-13	2005	3) A single rhTSH-Tg less than 0.5 ng/ml without Tg antibody has an approximately 98% likelihood of identifying patients completely free of tumor, a large group in which TSH suppression to less than 0.1 mIU/liter and frequent imaging and TSH-stimulated Tg testing are unnecessary.	Thyrotropin	170-173	thyroglobulin	Homo sapiens	18-20
15790728-8	2005	Finally, TSH reduced both the intracellular Ca(2+) ([Ca(2+)](i)) rise and IL-6 release triggered by P2Rs stimulation.	Thyrotropin	9-12	interleukin 6	Homo sapiens	74-78
16088319-2	2005	The 3C3 mAb we produced was found to inhibit binding of TSH to human (h)TSHR but not to porcine (p)TSHR.	Thyrotropin	56-59	thyroid stimulating hormone receptor	Homo sapiens	72-76
16088319-3	2005	MATERIAL/METHODS: Purified 3C3 immunoglobulin G (IgG) and its antibody-binding fragment were prepared using standard methods and their ability to inhibit TSH binding to hTSHR or pTSHR was analyzed using a coated tube assay.	Thyrotropin	154-157	thyroid stimulating hormone receptor	Homo sapiens	169-174
15944919-1	2005	Thyrotropin-releasing hormone (TRH) synthesized in the hypothalamus has the capability of inducing the release of thyroid-stimulating hormone (TSH) from the anterior pituitary, which in turn stimulates the production of thyroid hormones in the thyroid gland.	Thyrotropin	114-141	thyrotropin releasing hormone	Rattus norvegicus	0-29
15944919-1	2005	Thyrotropin-releasing hormone (TRH) synthesized in the hypothalamus has the capability of inducing the release of thyroid-stimulating hormone (TSH) from the anterior pituitary, which in turn stimulates the production of thyroid hormones in the thyroid gland.	Thyrotropin	114-141	thyrotropin releasing hormone	Rattus norvegicus	31-34
15944919-1	2005	Thyrotropin-releasing hormone (TRH) synthesized in the hypothalamus has the capability of inducing the release of thyroid-stimulating hormone (TSH) from the anterior pituitary, which in turn stimulates the production of thyroid hormones in the thyroid gland.	Thyrotropin	143-146	thyrotropin releasing hormone	Rattus norvegicus	0-29
15944919-1	2005	Thyrotropin-releasing hormone (TRH) synthesized in the hypothalamus has the capability of inducing the release of thyroid-stimulating hormone (TSH) from the anterior pituitary, which in turn stimulates the production of thyroid hormones in the thyroid gland.	Thyrotropin	143-146	thyrotropin releasing hormone	Rattus norvegicus	31-34
15911145-6	2005	The thyroid-stimulating hormone (TSH, or thyrotropin) receptor (TSHR) is located on the surface of thyroid cells and binds TSH.	Thyrotropin	33-36	thyroid stimulating hormone receptor	Homo sapiens	64-68
15878230-4	2005	As expected from the knowledge that megalin mediates Tg transcytosis, serum Tg levels were significantly reduced in homozygous (megalin-/-) mice, which, more importantly, were found to be hypothyroid, as demonstrated by significantly reduced serum free thyroxine and significantly increased serum thyroid stimulating hormone (TSH) levels.	Thyrotropin	326-329	low density lipoprotein receptor-related protein 2	Mus musculus	36-43
15995048-10	2005	The introduction of the T(4)/TBG ratio into a program using a primary T(4) with supplemental TSH approach generates an extra cost of 11206 dollars per additional case detected.	Thyrotropin	93-96	serpin family A member 7	Homo sapiens	29-32
16050145-1	2005	The thyrotropin receptor (TSHR) is a seven transmembrane G-protein linked glycoprotein expressed on the thyroid cell surface and which, under the regulation of TSH, controls the production and secretion of thyroid hormone from the thyroid gland.	Thyrotropin	26-29	thyroid stimulating hormone receptor	Homo sapiens	4-24
16053383-1	2005	Analysis of nine mouse monoclonal antibodies (mAbs) to the thyrotropin receptor (TSHR) with TSH antagonist activity showed that only one of the mAbs (RSR B2) was an effective antagonist of the human thyroid stimulating autoantibody M22.	Thyrotropin	81-84	thyroid stimulating hormone receptor	Homo sapiens	59-79
15894109-0	2005	Intestinal TSH production is localized in crypt enterocytes and in villus "hotblocks" and is coupled to IL-7 production: evidence for involvement of TSH during acute enteric virus infection.	Thyrotropin	11-14	interleukin 7	Mus musculus	104-108
15894109-4	2005	Here, we demonstrate that TSH in the small intestine is specifically localized to regions below villus crypts as seen by immunocytochemical staining, which revealed high-level TSH staining in lower crypts in the absence of IL-7 staining, and TSH and IL-7 co-staining in upper crypt regions.	Thyrotropin	26-29	interleukin 7	Mus musculus	250-254
16008227-11	2005	Serum tT3, tT4, fT3, and TSH concentrations in response to TRH injections differed significantly between treated and untreated horses.	Thyrotropin	25-28	thyrotropin releasing hormone	Equus caballus	59-62
15878230-4	2005	As expected from the knowledge that megalin mediates Tg transcytosis, serum Tg levels were significantly reduced in homozygous (megalin-/-) mice, which, more importantly, were found to be hypothyroid, as demonstrated by significantly reduced serum free thyroxine and significantly increased serum thyroid stimulating hormone (TSH) levels.	Thyrotropin	326-329	thyroglobulin	Mus musculus	76-78
15878230-4	2005	As expected from the knowledge that megalin mediates Tg transcytosis, serum Tg levels were significantly reduced in homozygous (megalin-/-) mice, which, more importantly, were found to be hypothyroid, as demonstrated by significantly reduced serum free thyroxine and significantly increased serum thyroid stimulating hormone (TSH) levels.	Thyrotropin	326-329	low density lipoprotein receptor-related protein 2	Mus musculus	128-135
15863950-11	2005	Serum leptin levels are affected in thyroid disorders and the correlation of leptin with TSH is independent of thyroid hormones.	Thyrotropin	89-92	leptin	Homo sapiens	77-83
15899815-7	2005	Tg-BRAF2 and Tg-BRAF3 mice had increased thyroid-stimulating hormone levels (&gt;7- and approximately 2-fold, respectively).	Thyrotropin	41-68	Braf transforming gene	Mus musculus	3-8
15705774-7	2005	However, interestingly, IGF-I or epidermal growth factor increased the tyrosine phosphorylations of p66Shc, and this was enhanced by TSH pretreatment.	Thyrotropin	133-136	insulin like growth factor 1	Homo sapiens	24-29
15705774-11	2005	Moreover, we suggest that TSH potentiates the regulatory effect of IGF-I on thyrocyte growth, at least in part, by increasing the expression of p66Shc.	Thyrotropin	26-29	insulin like growth factor 1	Homo sapiens	67-72
15637292-1	2005	We previously demonstrated that TNF-alpha-dependent activation of p65 nuclear factor kappaB in rat thyroid FRTL-5 cells requires TSH.	Thyrotropin	129-132	tumor necrosis factor	Rattus norvegicus	32-41
15637292-1	2005	We previously demonstrated that TNF-alpha-dependent activation of p65 nuclear factor kappaB in rat thyroid FRTL-5 cells requires TSH.	Thyrotropin	129-132	synaptotagmin 1	Rattus norvegicus	66-69
15637292-4	2005	However, no DNA binding of p65 was detected in the absence of TSH, suggesting that posttranslational modification of p65 by TSH is required for its binding.	Thyrotropin	124-127	synaptotagmin 1	Rattus norvegicus	117-120
15637292-6	2005	However, transient block of TSH/cAMP-dependent activation of PKA catalytic subunit (PKAc) by adenylate cyclase inhibitor, SQ22536, had no effects on the p65 activation.	Thyrotropin	28-31	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	61-64
15637292-7	2005	Interestingly, it was found that PKAc formed a complex with IkappaBalpha and beta only in the presence of TSH, and this PKAc could be activated by TNF-alpha.	Thyrotropin	106-109	NFKB inhibitor alpha	Rattus norvegicus	60-72
15637292-7	2005	Interestingly, it was found that PKAc formed a complex with IkappaBalpha and beta only in the presence of TSH, and this PKAc could be activated by TNF-alpha.	Thyrotropin	106-109	tumor necrosis factor	Rattus norvegicus	147-156
15637292-9	2005	More than 3 h exposure of TSH was required for the complex formation and p65 activation.	Thyrotropin	26-29	synaptotagmin 1	Rattus norvegicus	73-76
15637292-10	2005	These results demonstrate that TSH induces the formation of PKAc/IkappaB complex in FRTL-5 cells and that this PKAc bound with IkappaB plays a critical role in TNF-alpha-dependent activation of p65.	Thyrotropin	31-34	tumor necrosis factor	Rattus norvegicus	160-169
15637292-10	2005	These results demonstrate that TSH induces the formation of PKAc/IkappaB complex in FRTL-5 cells and that this PKAc bound with IkappaB plays a critical role in TNF-alpha-dependent activation of p65.	Thyrotropin	31-34	synaptotagmin 1	Rattus norvegicus	194-197
15767687-4	2005	These results led us to suggest that rhophilin 2 could play an important role downstream of RhoB in the control of endocytosis during the thyroid secretory process which follows stimulation of the TSH/cAMP pathway.	Thyrotropin	197-200	rhophilin, Rho GTPase binding protein 2	Mus musculus	37-48
15748721-9	2005	By contrast, when comparing the FSHbeta with the beta-subunits of the Chinese soft-shell turtle luteinizing hormone and thyroid stimulating hormone, the homologies are as low as 38 and 39%, respectively.	Thyrotropin	120-147	follitropin subunit beta	Pelodiscus sinensis	32-39
15861273-14	2005	CONCLUSION: The upper reference limit for TSH based on a reference population according to NACB criteria came down to 3.35 mIU/L, but not to approximately 2.5 mIU/L.	Thyrotropin	42-45	basic transcription factor 3	Homo sapiens	91-95
15652513-4	2005	BMP-2, -4, -6, -7, and TGF-beta1 suppressed TSH receptor mRNA expression on thyrocytes, which was consistent with their suppressive effect on TSH-induced cAMP synthesis and TSH-induced insulin-like growth factor-1 expression.	Thyrotropin	44-47	bone morphogenetic protein 2	Homo sapiens	0-9
15826921-7	2005	TSHR-Abs can be detected by competition assays of TSHR-Abs for labeled TSH, or monoclonal TSHR-Ab binding to solubilized TSHRs, or by bioassays using thyroid cells or mammalian cells expressing recombinant TSHRs.	Thyrotropin	0-3	thyroid stimulating hormone receptor	Homo sapiens	50-54
15826921-7	2005	TSHR-Abs can be detected by competition assays of TSHR-Abs for labeled TSH, or monoclonal TSHR-Ab binding to solubilized TSHRs, or by bioassays using thyroid cells or mammalian cells expressing recombinant TSHRs.	Thyrotropin	0-3	thyroid stimulating hormone receptor	Homo sapiens	50-54
15865205-1	2005	It was previously reported that the up-regulation of ERp29 mRNA depends on the levels of thyroid stimulating hormone (TSH) in the thyrocytes of FRTL-5 cells.	Thyrotropin	89-116	endoplasmic reticulum protein 29	Rattus norvegicus	53-58
15865205-1	2005	It was previously reported that the up-regulation of ERp29 mRNA depends on the levels of thyroid stimulating hormone (TSH) in the thyrocytes of FRTL-5 cells.	Thyrotropin	118-121	endoplasmic reticulum protein 29	Rattus norvegicus	53-58
15757850-7	2005	In multivariate analysis, baseline OPG was significantly associated with baseline levels of TSH (r = 0.280, P = 0.0162) and vWF (r = 0.626, P &lt; 0.0001).	Thyrotropin	92-95	TNF receptor superfamily member 11b	Homo sapiens	35-38
15652513-4	2005	BMP-2, -4, -6, -7, and TGF-beta1 suppressed TSH receptor mRNA expression on thyrocytes, which was consistent with their suppressive effect on TSH-induced cAMP synthesis and TSH-induced insulin-like growth factor-1 expression.	Thyrotropin	142-145	bone morphogenetic protein 2	Homo sapiens	0-9
15652513-4	2005	BMP-2, -4, -6, -7, and TGF-beta1 suppressed TSH receptor mRNA expression on thyrocytes, which was consistent with their suppressive effect on TSH-induced cAMP synthesis and TSH-induced insulin-like growth factor-1 expression.	Thyrotropin	142-145	transforming growth factor beta 1	Homo sapiens	23-32
15652513-4	2005	BMP-2, -4, -6, -7, and TGF-beta1 suppressed TSH receptor mRNA expression on thyrocytes, which was consistent with their suppressive effect on TSH-induced cAMP synthesis and TSH-induced insulin-like growth factor-1 expression.	Thyrotropin	142-145	thyroid stimulating hormone receptor	Homo sapiens	44-56
15652513-4	2005	BMP-2, -4, -6, -7, and TGF-beta1 suppressed TSH receptor mRNA expression on thyrocytes, which was consistent with their suppressive effect on TSH-induced cAMP synthesis and TSH-induced insulin-like growth factor-1 expression.	Thyrotropin	44-47	transforming growth factor beta 1	Homo sapiens	23-32
15652513-8	2005	This diverged regulation of thyroid BMP system by TSH is most likely due to the reduction of ALK-6 expression caused by TSH.	Thyrotropin	50-53	bone morphogenetic protein 1	Homo sapiens	36-39
15745925-2	2005	The aim of the present study was to determine the nature and frequency of TPO gene mutations in patients with CH, characterised by elevated TSH levels and orthotopic thyroid gland, identified in the Portuguese National Neonatal Screening Programme.	Thyrotropin	140-143	thyroid peroxidase	Homo sapiens	74-77
15652513-8	2005	This diverged regulation of thyroid BMP system by TSH is most likely due to the reduction of ALK-6 expression caused by TSH.	Thyrotropin	50-53	bone morphogenetic protein receptor type 1B	Homo sapiens	93-98
15691888-5	2005	Introduction of the V143A mutant p53 allele, which abolishes the p53 DNA-binding function, leads to loss of differentiation markers as well as TSH dependency for growth.	Thyrotropin	143-146	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	33-36
15691888-5	2005	Introduction of the V143A mutant p53 allele, which abolishes the p53 DNA-binding function, leads to loss of differentiation markers as well as TSH dependency for growth.	Thyrotropin	143-146	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	65-68
15691888-6	2005	Conversely, PC Cl3 cells transfected with the S392A mutant p53 allele, presenting the mutation located outside the DNA-binding domain, show only loss of TSH dependency for growth.	Thyrotropin	153-156	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	59-62
15691889-11	2005	The mutant expressing FRTL-5 cells have increased proliferation when chronically exposed to TSH, and this is associated with a reduction in phosphorylated (p) CREB levels.	Thyrotropin	92-95	cAMP responsive element binding protein 1	Rattus norvegicus	159-163
15866284-2	2005	Primary cultures without TSH addition prior to experiments demonstrated a TSH-dependent increase in G6PD activity.	Thyrotropin	25-28	glucose-6-phosphate dehydrogenase	Homo sapiens	100-104
15866284-2	2005	Primary cultures without TSH addition prior to experiments demonstrated a TSH-dependent increase in G6PD activity.	Thyrotropin	74-77	glucose-6-phosphate dehydrogenase	Homo sapiens	100-104
15866284-5	2005	In the serum-free physiological medium, G6PD activity was comparable to that found in primary cultures and a response to high concentrations of TSH was maintained.	Thyrotropin	144-147	glucose-6-phosphate dehydrogenase	Homo sapiens	40-44
16232090-10	2005	TSH levels were associated with gestational age and TPO-Ab status, and with maternal age in TPO-Ab-negative women.	Thyrotropin	0-3	thyroid peroxidase	Homo sapiens	52-55
15459116-7	2005	In contrast, TSHR antibodies, measured by TSH-binding inhibition, thyroid-stimulating activity, and TSH-blocking activity, were induced in the majority of animals immunized with TSHR (but not control) adenovirus and were unaffected by dietary iodide.	Thyrotropin	13-16	thyroid stimulating hormone receptor	Mus musculus	178-182
15860921-2	2005	IFN-induced DT is characterized by suppressed serum TSH levels, normal or elevated FT4 and FT3 concentrations, with the presence or absence of thyroid peroxidase antibodies and antithyroglobulin antibodies, the absence of thyroid receptor antibodies and radioactive iodine uptake suppressed or &lt;5%.	Thyrotropin	52-55	interferon alpha 1	Homo sapiens	0-3
15601836-4	2005	TRbeta(PV/PV) mice lost the negative feedback regulation with highly elevated TSH levels associated with increased thyroid hormone levels (3,3",5-triiodo-l-thyronine [T3]).	Thyrotropin	78-81	apoptosis antagonizing transcription factor	Mus musculus	0-6
15662590-9	2005	Moreover, TSH induced STAT5a and TGFbeta2 expression.	Thyrotropin	10-13	signal transducer and activator of transcription 5A	Mus musculus	22-28
15662590-9	2005	Moreover, TSH induced STAT5a and TGFbeta2 expression.	Thyrotropin	10-13	transforming growth factor, beta 2	Mus musculus	33-41
15509645-4	2005	By inference, hypercortisolism as present in patients with Cushing"s syndrome or major depression may contribute to lower serum TSH or symptoms of depression by lowering hypothalamic TRH expression.	Thyrotropin	128-131	thyrotropin releasing hormone	Homo sapiens	183-186
16299411-0	2005	Exaggerated TSH responses to TRH in patients with goiter and "normal" basal TSH levels.	Thyrotropin	12-15	thyrotropin releasing hormone	Homo sapiens	29-32
16299411-0	2005	Exaggerated TSH responses to TRH in patients with goiter and "normal" basal TSH levels.	Thyrotropin	76-79	thyrotropin releasing hormone	Homo sapiens	29-32
16299411-2	2005	In this study we aimed to evaluate the relation between basal and stimulated serum TSH levels on TRH-ST and to determine the prevalence of patients with normal basal serum TSH and exaggerated TSH responses.	Thyrotropin	83-86	thyrotropin releasing hormone	Homo sapiens	97-100
16299411-4	2005	At TRH-ST, a peak serum TSH level &gt;25 mIU/l was considered as an exaggerated response.	Thyrotropin	24-27	thyrotropin releasing hormone	Homo sapiens	3-6
16299411-7	2005	A positive correlation between basal and TRH-stimulated TSH levels was determined (r = 0.536, p &lt; 0.01).	Thyrotropin	56-59	thyrotropin releasing hormone	Homo sapiens	41-44
16299411-11	2005	Stimulated TSH levels on TRH-ST are valuable, especially when serum TSH concentrations are in the upper half of the normal range.	Thyrotropin	11-14	thyrotropin releasing hormone	Homo sapiens	25-28
16299411-11	2005	Stimulated TSH levels on TRH-ST are valuable, especially when serum TSH concentrations are in the upper half of the normal range.	Thyrotropin	68-71	thyrotropin releasing hormone	Homo sapiens	25-28
15742091-10	2005	The increased TSH levels had a statistically positive relationship with anti-TPO (p = 0.02), but not with gender, abnormal ultrasound or scintigraphy findings.	Thyrotropin	14-17	thyroid peroxidase	Homo sapiens	77-80